,Unnamed: 0.1,Unnamed: 0,ascender,size,text,font,flags,descender,color,page,blocks,lines,umls_entity,mesh_entity,rxnorm_entity,go_entity,hpo_entity,epid_ner,med_ner,keywords_of_interest
0,0,0,0.9169999957084656,97.0,When a different  ,ConduitITC-Bold,20,-0.2349999994039535,16777215,0,1,0,{},{},{},{},{},"  entity_group      value    score
0    Lab_value  different  0.99952",[],"{'keyword': {}, 'score': {}}"
1,1,1,0.9169999957084656,97.0,direction is vital ,ConduitITC-Bold,20,-0.2349999994039535,16777215,0,1,1,"{'concept_id': {0: 'C1550715'}, 'canonical_name': {0: 'direction - AddressPartType'}, 'aliases': {0: ['direction']}, 'types': {0: ['T078']}, 'definition': {0: '<p>Direction (e.g., N, S, W, E)</p>'}, 'entity': {0: 'direction'}, 'text': {0: 'direction is\xa0vital '}}","{'concept_id': {0: 'C0700158'}, 'canonical_name': {0: 'Direction'}, 'aliases': {0: ['Direction compound']}, 'types': {0: ['T122']}, 'definition': {0: None}, 'entity': {0: 'direction'}, 'text': {0: 'direction is\xa0vital '}}",{},{},{},"           entity_group      value     score
0  Diagnostic_procedure  direction  0.999789
1             Lab_value      vital  0.996564",[],"{'keyword': {0: 'direction vital'}, 'score': {0: 0.8764}}"
2,2,2,0.9169999957084656,40.0,A step forward for patients with residual ,ConduitITC-Bold,20,-0.2349999994039535,16777215,0,2,0,"{'concept_id': {0: 'C4684759'}, 'canonical_name': {0: 'Residual Risk'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Risk that remains after risk control measures have been taken.'}, 'entity': {0: 'residual'}, 'text': {0: 'A step forward for patients with residual '}}","{'concept_id': {0: 'C0242740'}, 'canonical_name': {0: 'Gastric Stump'}, 'aliases': {0: ['Remnant Stomachs', 'Stomachs, Remnant', 'Remnant, Gastric', 'Gastric Stumps', 'Gastric Remnant', 'Residual Stomach', 'Residual Stomachs', 'Stomachs, Residual', 'Stomach, Residual', 'Stump, Gastric', 'Stumps, Gastric', 'Remnants, Gastric', 'Gastric Remnants', 'Stomach, Remnant', 'Remnant Stomach']}, 'types': {0: ['T023']}, 'definition': {0: 'That portion of the stomach remaining after gastric surgery, usually gastrectomy or gastroenterostomy for cancer of the stomach or peptic ulcer. It is a common site of cancer referred to as stump cancer or carcinoma of the gastric stump.'}, 'entity': {0: 'residual'}, 'text': {0: 'A step forward for patients with residual '}}",{},{},{},"           entity_group     value     score
0  Detailed_description  residual  0.999819",[],"{'keyword': {0: 'forward patients residual', 1: 'patients residual', 2: 'step forward', 3: 'step forward patients', 4: 'forward patients'}, 'score': {0: 0.888, 1: 0.88, 2: 0.8732, 3: 0.8498, 4: 0.8328}}"
3,3,3,0.9169999957084656,40.0,invasive disease,ConduitITC-Bold,20,-0.2349999994039535,16777215,0,2,1,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'invasive disease'}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'invasive disease'}}",{},{},{},"           entity_group     value     score
0  Detailed_description  invasive  0.615009
1      Disease_disorder   disease  0.795776",[],"{'keyword': {0: 'invasive disease'}, 'score': {0: 1.0}}"
4,4,4,0.8830000162124634,23.0,"Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult ",MyriadPro-Light,4,-0.25,16777215,0,3,0,"{'concept_id': {0: 'C0683572'}, 'canonical_name': {0: 'Adult Children'}, 'aliases': {0: ['Adult children', 'Offspring, Adult', 'Adult Sons', 'Sons, Adult', 'Adult Daughters', 'Adult Offspring', 'Daughter, Adult', 'Children, Adult', 'Daughters, Adult', 'adults children', 'children adult', 'adult child', 'Son, Adult', 'Adult Son', 'Adult Daughter', 'adult children', 'adult offspring']}, 'types': {0: ['T099']}, 'definition': {0: 'Children who have reached maturity or the legal age of majority.'}, 'entity': {0: 'adult'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult '}}","{'concept_id': {0: 'C0043119'}, 'canonical_name': {0: 'Werner Syndrome'}, 'aliases': {0: ['Progeria, Adult', ""Syndrome, Werner's"", 'Syndrome, Werner', ""Werner's Syndrome"", 'Syndrome, Werners', 'Werners Syndrome', 'Adult Progeria', 'Adult Premature Aging Syndrome']}, 'types': {0: ['T047']}, 'definition': {0: 'An autosomal recessive disorder that causes premature aging in adults, characterized by sclerodermal skin changes, cataracts, subcutaneous calcification, muscular atrophy, a tendency to diabetes mellitus, aged appearance of the face, baldness, and a high incidence of neoplastic disease.'}, 'entity': {0: 'adult'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult '}}",{},"{'concept_id': {0: 'C1853562'}, 'canonical_name': {0: 'Adult onset'}, 'aliases': {0: ['Symptoms begin in adulthood', 'Onset in early adulthood', 'Onset in adulthood']}, 'types': {0: ['T033']}, 'definition': {0: 'Onset of disease manifestations in adulthood, defined here as at the age of 16 years or later. [HPO:probinson]'}, 'entity': {0: 'adult'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult '}}","           entity_group  value    score
0  Detailed_description  adult  0.99088","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla single agent', 1: 'treatment adult', 2: 'kadcyla single', 3: 'adjuvant treatment', 4: 'single agent indicated'}, 'score': {0: 0.7787, 1: 0.7573, 2: 0.742, 3: 0.6448, 4: 0.5924}}"
5,5,5,0.8830000162124634,23.0,"patients with HER2-positive eBC who have residual invasive disease, in ",MyriadPro-Light,4,-0.25,16777215,0,3,1,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'patients with HER2-positive eBC who have residual invasive disease, in '}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'patients with HER2-positive eBC who have residual invasive disease, in '}}",{},{},{},"           entity_group                                              value  \
0  Detailed_description                                      HER2-positive   
1             Lab_value                                      HER2-positive   
2      Disease_disorder  patients HER2-positive eBC have residual invas...   
3      Disease_disorder                                                eBC   
4  Detailed_description                                           residual   
5  Detailed_description                                           invasive   

      score  
0  0.859198  
1  0.965879  
2  0.983565  
3  0.993297  
4  0.999768  
5  0.995739  ",[],"{'keyword': {0: 'ebc residual invasive', 1: 'her2 positive ebc', 2: 'patients her2', 3: 'residual invasive disease', 4: 'her2 positive'}, 'score': {0: 0.8802, 1: 0.8746, 2: 0.8033, 3: 0.7645, 4: 0.688}}"
6,6,6,0.8830000162124634,23.0,"the breast and/or lymph nodes, after neoadjuvant taxane-based and ",MyriadPro-Light,4,-0.25,16777215,0,3,2,"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Neoadjuvant Therapy'}, 'aliases': {0: ['Preoperative Therapy', 'Therapy, Neoadjuvant', 'neoadjuvant treatment', 'Neoadjuvant Treatment', 'Neoadjuvant Treatments', 'Neoadjuvant Therapies', 'Neoadjuvant', 'Induction Therapy', 'Neoadjuvant Therapy', 'induction therapy', 'Treatment, Neoadjuvant', 'neoadjuvant therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant taxane-based'}, 'text': {0: 'the breast and/or lymph nodes, after neoadjuvant taxane-based and '}}","{'concept_id': {0: 'C1522495'}, 'canonical_name': {0: 'Sentinal Node'}, 'aliases': {0: ['Nodes, Sentinal', 'Sentinel Lymph Node', 'Node, Sentinal', 'Lymph Node, Sentinel', 'Sentinel Lymph Nodes', 'Sentinal Nodes', 'Lymph Nodes, Sentinel']}, 'types': {0: ['T023']}, 'definition': {0: 'First lymph node to receive drainage from the primary tumor. SENTINEL LYMPH NODE BIOPSY is performed to determine early METASTASIS status because cancer cells may appear first in the sentinel node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'the breast and/or lymph nodes, after neoadjuvant taxane-based and '}}",{},{},"{'concept_id': {0: 'C0024205'}, 'canonical_name': {0: 'Lymphadenitis'}, 'aliases': {0: ['Inflammation of the lymph nodes']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the lymph nodes.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'the breast and/or lymph nodes, after neoadjuvant taxane-based and '}}","           entity_group                     value     score
0  Biological_structure                    breast  0.999862
1  Biological_structure                     lymph  0.716545
2  Detailed_description               neoadjuvant  0.982459
3  Detailed_description  neoadjuvant taxane-based  0.836145","[('taxane', 'DRUG')]","{'keyword': {0: 'neoadjuvant taxane based', 1: 'taxane based', 2: 'nodes neoadjuvant taxane', 3: 'lymph nodes', 4: 'breast lymph'}, 'score': {0: 0.8074, 1: 0.7793, 2: 0.7734, 3: 0.7653, 4: 0.7461}}"
7,7,7,0.8830000162124634,23.0,HER2-targeted therapy.,MyriadPro-Light,4,-0.25,16777215,0,3,3,"{'concept_id': {0: 'C2985566'}, 'canonical_name': {0: 'Targeted Therapy'}, 'aliases': {0: ['targeted therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.'}, 'entity': {0: 'HER2-targeted therapy'}, 'text': {0: 'HER2-targeted therapy.'}}",{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'her2 targeted therapy', 1: 'targeted therapy', 2: 'her2 targeted'}, 'score': {0: 0.9598, 1: 0.9205, 2: 0.9057}}"
8,8,8,0.9520000219345092,19.0,Reporting suspected adverse reactions after authorisation of the medicinal ,MyriadPro-Regular,4,-0.25,16777215,0,4,0,"{'concept_id': {0: 'C0013227'}, 'canonical_name': {0: 'Pharmaceutical Preparations'}, 'aliases': {0: ['Drug/agent', 'drugs', 'Preparations, Pharmaceutic', 'Medicinal product (product)', 'Medication, NOS', 'Drug preparation, NOS', 'Drug Product', 'Drug or medicament', 'medication', 'Medicine', 'drug', 'medicinal product', 'Drug, NOS', 'Pharmaceutical / biologic product', 'Pharmaceutical Product', 'drug/agent', 'Pharmaceutic Preparations', 'Preparation, Pharmaceutical', 'Medicine, NOS', 'Preparations, Pharmaceutical', 'Pharmaceutical Preparation', 'Products, Pharmaceutical', 'Medicinal product', 'Medications', 'medications', 'pharmaceutical preparation', 'pharmaceutical preparations', 'Product, Pharmaceutical', 'Pharmaceutical / biologic product (product)', 'Drugs', 'Pharmaceutical', 'medicinal products', 'Pharmaceutical Preparations', 'Drug', 'Medication', 'Drug or medicament (substance)', 'Pharmaceuticals', 'Pharmaceutical Products', 'Medicines']}, 'types': {0: ['T121']}, 'definition': {0: 'Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.'}, 'entity': {0: 'medicinal'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the medicinal '}}","{'concept_id': {0: 'C0032100'}, 'canonical_name': {0: 'Plants, Medicinal'}, 'aliases': {0: ['Medicinal Plants', 'Medicinal Plant', 'Plant, Medicinal']}, 'types': {0: ['T002']}, 'definition': {0: 'Plants whose roots, leaves, seeds, bark, or other constituent parts possess therapeutic, tonic, purgative, curative or other pharmacologic attributes, when administered to man or animals.'}, 'entity': {0: 'medicinal'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the medicinal '}}",{},{},"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the medicinal '}}","           entity_group              value     score
0          Sign_symptom  adverse reactions  0.999846
1  Detailed_description          medicinal  0.996957",[],"{'keyword': {0: 'reporting suspected adverse', 1: 'reporting suspected', 2: 'adverse reactions', 3: 'authorisation medicinal', 4: 'adverse reactions authorisation'}, 'score': {0: 0.9229, 1: 0.7857, 2: 0.7853, 3: 0.7763, 4: 0.7135}}"
9,9,9,0.9520000219345092,19.0,product is important. It allows continued monitoring of the benefit/risk balance ,MyriadPro-Regular,4,-0.25,16777215,0,4,1,"{'concept_id': {0: 'C0005517'}, 'canonical_name': {0: 'Biological Monitoring'}, 'aliases': {0: ['biological monitoring', 'Bio Monitoring', 'Bio-Monitoring', 'Biomonitoring', 'Biologic Monitoring', 'Monitoring, Biologic', 'Biological monitoring', 'Monitoring, Biological']}, 'types': {0: ['T057']}, 'definition': {0: 'Monitoring of the level of toxins, chemical pollutants, microbial contaminants, or other harmful substances in the bodies of living organisms, by DIAGNOSTIC IMAGING or by analyzing BLOOD; URINE; BREAST MILK; SALIVA, etc.'}, 'entity': {0: 'monitoring'}, 'text': {0: 'product is important. It allows continued monitoring of the benefit/risk balance '}}","{'concept_id': {0: 'C0015945'}, 'canonical_name': {0: 'Monitoring, Fetal'}, 'aliases': {0: ['Fetal Monitoring', 'Fetal Monitorings', 'Monitorings, Fetal']}, 'types': {0: ['T060']}, 'definition': {0: 'Physiologic or biochemical monitoring of the fetus. It is usually done during LABOR, OBSTETRIC and may be performed in conjunction with the monitoring of uterine activity. It may also be performed prenatally as when the mother is undergoing surgery.'}, 'entity': {0: 'monitoring'}, 'text': {0: 'product is important. It allows continued monitoring of the benefit/risk balance '}}",{},{},{},"           entity_group                 value     score
0  Diagnostic_procedure            monitoring  0.750545
1  Diagnostic_procedure  benefit/risk balance  0.999297",[],"{'keyword': {0: 'allows continued monitoring', 1: 'important allows continued', 2: 'product important', 3: 'monitoring benefit risk', 4: 'benefit risk'}, 'score': {0: 0.906, 1: 0.8506, 2: 0.849, 3: 0.7524, 4: 0.6086}}"
10,10,10,0.9520000219345092,19.0,of the medicinal product.,MyriadPro-Regular,4,-0.25,16777215,0,4,2,"{'concept_id': {0: 'C4684711'}, 'canonical_name': {0: 'Medicinal Product Name'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'The name assigned to a medicinal product as approved by a regulatory authority of the country of authorization.'}, 'entity': {0: 'medicinal product'}, 'text': {0: 'of the medicinal product.'}}",{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'medicinal product'}, 'score': {0: 0.8473}}"
11,11,11,0.9520000219345092,19.0,Adverse events should be reported. Reporting forms and information can be ,MyriadPro-Regular,4,-0.25,16777215,0,4,3,"{'concept_id': {0: 'C1561527'}, 'canonical_name': {0: 'Error severity - Information'}, 'aliases': {0: ['Information']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'information'}, 'text': {0: 'Adverse events should be reported. Reporting forms and information can be '}}","{'concept_id': {0: 'C0021428'}, 'canonical_name': {0: 'Information Systems'}, 'aliases': {0: ['Information System']}, 'types': {0: ['T170']}, 'definition': {0: 'Integrated set of files, procedures, and equipment for the storage, manipulation, and retrieval of information.'}, 'entity': {0: 'information'}, 'text': {0: 'Adverse events should be reported. Reporting forms and information can be '}}",{},{},{},"           entity_group           value     score
0          Sign_symptom  Adverse events  0.999894
1  Diagnostic_procedure       Reporting  0.546498",[],"{'keyword': {0: 'events reported', 1: 'reporting forms', 2: 'reported reporting', 3: 'adverse events', 4: 'forms information'}, 'score': {0: 0.8612, 1: 0.8548, 2: 0.7427, 3: 0.7251, 4: 0.5787}}"
12,12,12,0.9520000219345092,19.0,found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the ,MyriadPro-Regular,4,-0.25,16777215,0,4,4,{},{},{},{},"{'concept_id': {0: 'C0240962'}, 'canonical_name': {0: 'Conjunctival icterus'}, 'aliases': {0: ['Yellow sclera', 'Scleral icterus', 'Yellow conjunctiva', 'Yellowing of the whites of the eyes']}, 'types': {0: ['T033']}, 'definition': {0: 'Yellowing of the white part of the eyes, often due to a rise in bilirubin levels.'}, 'entity': {0: 'MHRA Yellow'}, 'text': {0: 'found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the '}}","           entity_group                       value     score
0      Disease_disorder  www.mhra.gov.uk/yellowcard  0.337320
1      Disease_disorder                        MHRA  0.758203
2           Coreference                        MHRA  0.556020
3  Diagnostic_procedure                      Yellow  0.439090
4           Coreference                        Card  0.502206",[],"{'keyword': {0: 'search mhra', 1: 'yellowcard search', 2: 'yellow card', 3: 'www mhra', 4: 'gov uk'}, 'score': {0: 0.5939, 1: 0.3851, 2: 0.3362, 3: 0.3062, 4: 0.244}}"
13,13,13,0.9520000219345092,19.0,Google Play or Apple App Store.,MyriadPro-Regular,4,-0.25,16777215,0,4,5,"{'concept_id': {0: 'C4684566'}, 'canonical_name': {0: 'Applet'}, 'aliases': {0: ['App', 'Applet']}, 'types': {0: ['T170']}, 'definition': {0: 'A small application designed to perform a specific function within another application.'}, 'entity': {0: 'Apple App Store'}, 'text': {0: 'Google Play or Apple App Store.'}}",{},{},{},{},"           entity_group   value     score
0  Detailed_description  Google  0.950251",[],"{'keyword': {0: 'google play apple', 1: 'play apple', 2: 'app store', 3: 'apple app', 4: 'google play'}, 'score': {0: 0.8259, 1: 0.8206, 2: 0.8094, 3: 0.7974, 4: 0.7917}}"
14,14,14,0.9520000219345092,19.0,Adverse events should also be reported to Roche Products Ltd.  ,MyriadPro-Regular,4,-0.25,16777215,0,4,6,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should also be reported to Roche Products Ltd.  '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should also be reported to Roche Products Ltd.  '}}",{},{},{},"   entity_group           value     score
0  Sign_symptom  Adverse events  0.999906
1    Medication           Roche  0.977449",[],"{'keyword': {0: 'adverse events', 1: 'events reported roche', 2: 'reported roche', 3: 'events reported', 4: 'roche products'}, 'score': {0: 0.7217, 1: 0.714, 2: 0.6768, 3: 0.6516, 4: 0.5478}}"
15,15,15,0.9520000219345092,19.0,Please contact Roche Drug Safety Centre by emailing  ,MyriadPro-Regular,4,-0.25,16777215,0,4,7,"{'concept_id': {0: 'C0036043'}, 'canonical_name': {0: 'Safety'}, 'aliases': {0: ['Safeties', 'Safety', 'safety']}, 'types': {0: ['T068']}, 'definition': {0: 'Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.'}, 'entity': {0: 'Drug Safety Centre'}, 'text': {0: 'Please contact Roche Drug Safety Centre by emailing  '}}",{},{},{},{},"             entity_group          value     score
0  Nonbiological_location          Roche  0.929434
1  Nonbiological_location  Safety Centre  0.987673
2          Clinical_event       emailing  0.983830",[],"{'keyword': {0: 'contact roche', 1: 'centre emailing', 2: 'contact roche drug', 3: 'roche drug', 4: 'safety centre'}, 'score': {0: 0.7441, 1: 0.7026, 2: 0.6475, 3: 0.6049, 4: 0.6011}}"
16,16,16,0.9520000219345092,19.0,welwyn.uk_dsc@roche.com or calling +44(0)1707 367554. ,MyriadPro-Regular,4,-0.25,16777215,0,4,8,"{'concept_id': {0: 'C0034770'}, 'canonical_name': {0: 'Mental Recall'}, 'aliases': {0: ['mental recall', 'Mental Recall', 'remember', 'recalling', 'recall', 'remembers', 'Recall, Mental', 'Recall', 'Recollect', 'remembering']}, 'types': {0: ['T041']}, 'definition': {0: 'The process whereby a representation of past experience is elicited.'}, 'entity': {0: 'calling'}, 'text': {0: 'welwyn.uk_dsc@roche.com or calling +44(0)1707 367554. '}}",{},{},{},{},"           entity_group          value     score
0  Diagnostic_procedure  welwyn.uk_dsc  0.992376",[],"{'keyword': {0: '1707 367554', 1: 'welwyn uk_dsc roche', 2: 'uk_dsc roche com', 3: 'calling 44', 4: 'roche com'}, 'score': {0: 0.8708, 1: 0.8137, 2: 0.794, 3: 0.7771, 4: 0.7524}}"
17,17,17,0.9520000219345092,19.0,"As Kadcyla is a biological medicine, healthcare professionals should report ",MyriadPro-Regular,4,-0.25,16777215,0,4,9,"{'concept_id': {0: 'C5554773'}, 'canonical_name': {0: 'Healthcare Professional Visit'}, 'aliases': {0: []}, 'types': {0: ['T058']}, 'definition': {0: 'The subject or patient has interacted with a healthcare professional at a healthcare facility.'}, 'entity': {0: 'healthcare professionals'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should report '}}","{'concept_id': {0: 'C0018722'}, 'canonical_name': {0: 'Health Occupations'}, 'aliases': {0: ['Profession, Health', 'Health Professions', 'Health Occupation', 'Health Profession', 'Professions, Health']}, 'types': {0: ['T091']}, 'definition': {0: 'Professions or other business activities directed to the cure and prevention of disease. For occupations of medical personnel who are not physicians but who are working in the fields of medical technology, physical therapy, etc., ALLIED HEALTH OCCUPATIONS is available.'}, 'entity': {0: 'healthcare professionals'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should report '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should report '}}","{'concept_id': {0: 'C3714634'}, 'canonical_name': {0: 'biological_process'}, 'aliases': {0: ['biological process']}, 'types': {0: ['T038']}, 'definition': {0: 'A biological process represents a specific objective that the organism is genetically programmed to achieve. Biological processes are often described by their outcome or ending state, e.g., the biological process of cell division results in the creation of two daughter cells (a divided cell) from a single parent cell. A biological process is accomplished by a particular set of molecular functions carried out by specific gene products (or macromolecular complexes), often in a highly regulated manner and in a particular temporal sequence. [GOC:pdt]'}, 'entity': {0: 'biological medicine'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should report '}}",{},"     entity_group   value     score
0  Clinical_event  report  0.994782","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'healthcare professionals report', 1: 'healthcare professionals', 2: 'medicine healthcare', 3: 'kadcyla biological', 4: 'biological medicine'}, 'score': {0: 0.8443, 1: 0.8272, 2: 0.7654, 3: 0.7493, 4: 0.6328}}"
18,18,18,0.9520000219345092,19.0,adverse reactions by brand name and batch number.,MyriadPro-Regular,4,-0.25,16777215,0,4,10,"{'concept_id': {0: 'C1948031'}, 'canonical_name': {0: 'Batch (group)'}, 'aliases': {0: ['Batch']}, 'types': {0: ['T081']}, 'definition': {0: 'A quantity of people or things treated or regarded as a group, especially when subdivided from a larger group.'}, 'entity': {0: 'batch number'}, 'text': {0: 'adverse reactions by brand name and batch number.'}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'adverse reactions by brand name and batch number.'}}",{},{},"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'adverse reactions by brand name and batch number.'}}","  entity_group    value     score
0    Lab_value  adverse  0.540336",[],"{'keyword': {0: 'reactions brand batch', 1: 'reactions brand', 2: 'brand batch number', 3: 'batch number', 4: 'adverse reactions'}, 'score': {0: 0.8809, 1: 0.8512, 2: 0.8499, 3: 0.8213, 4: 0.7499}}"
19,19,19,0.8830000162124634,19.0,"eBC, early breast cancer. ",MyriadPro-Light,4,-0.25,16777215,0,5,0,"{'concept_id': {0: 'C0598034'}, 'canonical_name': {0: 'BRCA2 gene'}, 'aliases': {0: ['BRCA2, DNA Repair Associated Gene', 'brca2', 'brca 2 gene', 'FACD', 'breast cancer 2', 'BRCA2 Genes', 'XRCC11', 'BRCA2 DNA repair associated', 'breast cancer 2, early onset', 'BRCC2', 'Fanconi anemia, complementation group D1', 'FANCD1 GENE', 'FAD1', 'BRCA1/BRCA2-containing complex, subunit 2', 'BRCA2 gene', 'FANCD1', 'brca2 gene', 'BRCA2 GENE', 'Breast Cancer 2, Early Onset Gene', 'FANCD', 'Genes, BRCA2', 'BRCA2', 'BRCA2 Gene', 'BRCA2 DNA REPAIR-ASSOCIATED PROTEIN', 'FAD', 'brca2 genes', 'Gene, BRCA2']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}","{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}","           entity_group   value     score
0  Biological_structure  breast  0.991112",[],"{'keyword': {0: 'ebc early breast', 1: 'early breast', 2: 'early breast cancer', 3: 'breast cancer', 4: 'ebc early'}, 'score': {0: 0.9046, 1: 0.8815, 2: 0.8637, 3: 0.744, 4: 0.7344}}"
20,20,20,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,0,7,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
21,21,21,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,0,7,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
22,22,22,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,0,7,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
23,23,23,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,0,7,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
24,24,24,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,0,8,0,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
25,25,25,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,0,8,1,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
26,26,26,0.8830000162124634,19.0,M-GB-00010642. January 2023. ,MyriadPro-Light,4,-0.25,5723991,0,9,0,{},{},{},{},{},"           entity_group          value     score
0  Detailed_description  M-GB-00010642  0.851839",[],"{'keyword': {0: '00010642 january 2023', 1: 'january 2023', 2: '00010642 january', 3: 'gb 00010642 january', 4: 'gb 00010642'}, 'score': {0: 0.9324, 1: 0.872, 2: 0.8664, 3: 0.8105, 4: 0.8002}}"
27,27,27,0.9169999957084656,98.0,A complete response is always ,ConduitITC-Bold,20,-0.2349999994039535,8194925,1,1,0,{},{},{},{},{},"           entity_group     value     score
0  Diagnostic_procedure  complete  0.546737
1             Lab_value  response  0.476576
2             Lab_value    always  0.873711",[],"{'keyword': {0: 'complete response'}, 'score': {0: 0.9008}}"
28,28,28,0.9169999957084656,98.0,"the goal of treatment, but some ",ConduitITC-Bold,20,-0.2349999994039535,8194925,1,1,1,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'the goal of treatment, but some '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'the goal of treatment, but some '}}",{},{},{},"  entity_group value     score
0    Lab_value  some  0.976105",[],"{'keyword': {0: 'goal treatment'}, 'score': {0: 0.3873}}"
29,29,29,0.9169999957084656,98.0,patients don’t quite reach it,ConduitITC-Bold,20,-0.2349999994039535,8194925,1,1,2,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'patients don’t quite reach it'}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'patients don’t quite reach it'}}",{},{},{},"           entity_group                                       value     score
0  Biological_structure                                    patients  0.474887
1          Sign_symptom                                         don  0.943945
2  Detailed_description  ’ patients t quite it quite reach quite it  0.804760",[],"{'keyword': {0: 'don quite reach', 1: 'quite reach', 2: 'patients don quite', 3: 'don quite', 4: 'patients don'}, 'score': {0: 0.8834, 1: 0.8473, 2: 0.8383, 3: 0.7731, 4: 0.7529}}"
30,30,30,0.8830000162124634,32.0,39.3–63.6% of patients achieved a pCR with neoadjuvant PERJETA,MyriadPro-Light,4,-0.25,3355443,1,2,0,"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Neoadjuvant Therapy'}, 'aliases': {0: ['Preoperative Therapy', 'Therapy, Neoadjuvant', 'neoadjuvant treatment', 'Neoadjuvant Treatment', 'Neoadjuvant Treatments', 'Neoadjuvant Therapies', 'Neoadjuvant', 'Induction Therapy', 'Neoadjuvant Therapy', 'induction therapy', 'Treatment, Neoadjuvant', 'neoadjuvant therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant PERJETA'}, 'text': {0: '39.3–63.6% of patients achieved a pCR with neoadjuvant PERJETA'}}","{'concept_id': {0: 'C1709846'}, 'canonical_name': {0: 'Real-Time Polymerase Chain Reaction'}, 'aliases': {0: ['Real Time PCR', 'Real-Time PCRs', 'PCRs, Real-Time', 'PCR, Real-Time', 'Real Time Polymerase Chain Reaction', 'Real-Time PCR']}, 'types': {0: ['T063']}, 'definition': {0: 'An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.'}, 'entity': {0: 'pCR'}, 'text': {0: '39.3–63.6% of patients achieved a pCR with neoadjuvant PERJETA'}}",{},{},{},"           entity_group        value     score
0             Lab_value    39.3–63.6  0.969299
1             Lab_value  39.3–63.6 %  0.972756
2  Diagnostic_procedure          pCR  0.938773
3  Detailed_description  neoadjuvant  0.999933
4          Sign_symptom      PERJETA  0.821127
5  Detailed_description      PERJETA  0.931245",[],"{'keyword': {0: 'achieved pcr neoadjuvant', 1: '63 patients achieved', 2: 'neoadjuvant perjeta', 3: '63 patients', 4: '39 63'}, 'score': {0: 0.8456, 1: 0.8049, 2: 0.6717, 3: 0.6421, 4: 0.5311}}"
31,31,31,0.8830000162124634,32.0,(pertuzumab)-trastuzumab plus chemotherapy*,MyriadPro-Light,4,-0.25,3355443,1,2,1,"{'concept_id': {0: 'C0392920'}, 'canonical_name': {0: 'Chemotherapy Regimen'}, 'aliases': {0: ['chemotherapy regimen', 'Antineoplastic chemotherapy regimen', 'chemotherapies', 'Antineoplastic chemotherapy regimen (regime/therapy)', 'chemotherapy regimens', 'neoplasm chemotherapy', 'neoplasm pharmacotherapy', 'chemotherapy', 'chemo', 'Cancer chemotherapy', 'neoplasm/cancer chemotherapy', 'cancer chemotherapy', 'cancer pharmacotherapy', 'neoplasm/cancer pharmacotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'application of the beneficial effects of drugs to control or cure neoplastic growth.'}, 'entity': {0: 'chemotherapy*'}, 'text': {0: '(pertuzumab)-trastuzumab plus chemotherapy*'}}","{'concept_id': {0: 'C1868801'}, 'canonical_name': {0: 'Hyperthermic Intraperitoneal Chemotherapy'}, 'aliases': {0: ['Hot Chemotherapy', 'Chemotherapy, Intraperitoneal Hyperthermic', 'Chemotherapy, Hyperthermic Intraperitoneal', 'Chemotherapy, Hot', 'Intraperitoneal Hyperthermic Chemotherapies', 'Intraperitoneal Chemotherapy, Hyperthermic', 'Hyperthermic Chemotherapy, Intraperitoneal', 'HIPEC', 'Intraperitoneal Hyperthermic Chemotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.'}, 'entity': {0: 'chemotherapy*'}, 'text': {0: '(pertuzumab)-trastuzumab plus chemotherapy*'}}","{'concept_id': {0: 'C5390937'}, 'canonical_name': {0: 'hyaluronidase / pertuzumab / trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A ready-to-use fixed-dose combination of pertuzumab and trastuzumab, both recombinant humanized monoclonal antibodies directed against the tyrosine kinase receptor (TKR) human epidermal growth factor receptor 2 (HER2; HER-2; receptor tyrosine-protein kinase erbB-2), and hyaluronidase-zzxf, a biosimilar of the recombinant form of the naturally occurring endoglycosidase hyaluronidase, with antineoplastic activity that can be used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration, hyaluronidase-zzxf temporarily breaks down the hyaluronan barrier, which decreases viscosity of, and allows both pertuzumab and trastuzumab to spread rapidly through the interstitial space. This improves access to lymphatic and capillary vessels and facilitates the absorption of both antibodies into the bloodstream. Pertuzumab targets and binds to the extracellular dimerization domain (subdomain II) of HER2 and blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3 and HER4. This inhibits ligand-initiated intracellular signaling and prevents the activation of the mitogen-activated protein (MAP) kinase and the phosphoinositide 3-kinase (PI3K) signaling pathways, leading to growth arrest and apoptosis in HER2-overexpressing tumor cells, respectively. Trastuzumab targets and binds to subdomain IV of HER2 and inhibits ligand-independent, HER2 mediated cell proliferation and inhibits the PI3K signaling pathway in HER2-overexpressing tumor cells. Both antibodies induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. HER2 is overexpressed in many adenocarcinomas, particularly breast adenocarcinomas.'}, 'entity': {0: '(pertuzumab)-trastuzumab'}, 'text': {0: '(pertuzumab)-trastuzumab plus chemotherapy*'}}",{},{},"           entity_group                    value     score
0            Medication               pertuzumab  0.999776
1            Medication  pertuzumab -trastuzumab  0.999478
2            Medication             -trastuzumab  0.999862
3            Medication             chemotherapy  0.999874
4  Detailed_description                        *  0.412626","[('pertuzumab)-trastuzumab', 'DRUG'), ('chemotherapy', 'DRUG')]","{'keyword': {0: 'pertuzumab trastuzumab plus', 1: 'trastuzumab plus chemotherapy', 2: 'trastuzumab plus', 3: 'plus chemotherapy', 4: 'pertuzumab trastuzumab'}, 'score': {0: 0.8233, 1: 0.8197, 2: 0.7893, 3: 0.6917, 4: 0.6127}}"
32,32,32,0.8830000162124634,32.0,36.4–60.7% of patients had residual invasive disease,MyriadPro-Light,4,-0.25,3355443,1,3,0,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: '36.4–60.7% of patients had residual invasive disease'}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: '36.4–60.7% of patients had residual invasive disease'}}",{},{},{},"           entity_group             value     score
0             Lab_value       36.4–60.7 %  0.965148
1  Detailed_description          residual  0.999973
2      Disease_disorder  invasive disease  0.999527",[],"{'keyword': {0: 'residual invasive disease', 1: 'patients residual invasive', 2: 'invasive disease', 3: '60 patients residual', 4: '36 60'}, 'score': {0: 0.871, 1: 0.8041, 2: 0.755, 3: 0.7537, 4: 0.4909}}"
33,33,33,0.8830000162124634,19.0,Adapted from Gianni et al. 2012 and Schneeweiss et al. 2013.,MyriadPro-Light,4,-0.25,3355443,1,4,0,{},{},{},{},{},"  entity_group value     score
0         Date  2012  0.367385",[],"{'keyword': {0: 'adapted gianni et', 1: 'gianni et al', 2: 'et al 2012', 3: 'al 2012 schneeweiss', 4: 'al 2013'}, 'score': {0: 0.8921, 1: 0.8309, 2: 0.7687, 3: 0.7506, 4: 0.6066}}"
34,34,34,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,1,5,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
35,35,35,0.8830000162124634,32.0,arrive at a pCR following anti-HER2 therapy,MyriadPro-Light,4,-0.25,3355443,1,5,1,"{'concept_id': {0: 'C4329777'}, 'canonical_name': {0: 'ERBB2 Antibody'}, 'aliases': {0: ['NEU Antibody', 'c-erbB2 Antibody', 'Anti-Receptor Tyrosine-Protein Kinase erbB-2 Antibody', 'HER2/Neu Antibody', 'Anti-HER2 Antibody', 'Receptor Tyrosine-Protein Kinase erbB-2 Antibody', 'Anti-Tyrosine Kinase-Type Cell Surface Receptor HER2 Antibody', 'Anti-HER-2 Antibody', 'Anti-Proto-Oncogene Neu Antibody', 'Anti-HER2/Neu Antibody', 'HER-2 Antibody', 'Tyrosine Kinase-Type Cell Surface Receptor HER2 Antibody', 'Anti-c-erbB2 Antibody', 'Anti-NEU Antibody', 'HER2 Antibody']}, 'types': {0: ['T116', 'T129']}, 'definition': {0: 'Any immunoglobulin that recognizes receptor tyrosine-protein kinase erbB-2 protein.'}, 'entity': {0: 'anti-HER2 therapy'}, 'text': {0: 'arrive at a pCR following anti-HER2 therapy'}}","{'concept_id': {0: 'C1709846'}, 'canonical_name': {0: 'Real-Time Polymerase Chain Reaction'}, 'aliases': {0: ['Real Time PCR', 'Real-Time PCRs', 'PCRs, Real-Time', 'PCR, Real-Time', 'Real Time Polymerase Chain Reaction', 'Real-Time PCR']}, 'types': {0: ['T063']}, 'definition': {0: 'An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.'}, 'entity': {0: 'pCR'}, 'text': {0: 'arrive at a pCR following anti-HER2 therapy'}}",{},{},{},"           entity_group              value     score
0  Diagnostic_procedure                pCR  0.998102
1            Medication          anti-HER2  0.960210
2           Coreference          anti-HER2  0.639993
3            Medication  anti-HER2 therapy  0.864901",[],"{'keyword': {0: 'arrive pcr following', 1: 'following anti', 2: 'following anti her2', 3: 'her2 therapy', 4: 'anti her2'}, 'score': {0: 0.8703, 1: 0.8576, 2: 0.7276, 3: 0.6964, 4: 0.6757}}"
36,36,36,0.8830000162124634,19.0,"*Absence of invasive tumour residues in the breast and lymph nodes, irrespective of ductal carcinoma in situ.",MyriadPro-Light,4,-0.25,3355443,1,6,0,"{'concept_id': {0: 'C1301536'}, 'canonical_name': {0: 'Device in situ'}, 'aliases': {0: ['Device in situ (finding)']}, 'types': {0: ['T033']}, 'definition': {0: 'Device in the natural or original position or place.'}, 'entity': {0: 'in situ'}, 'text': {0: '*Absence of invasive tumour residues in the breast and lymph nodes, irrespective of ductal carcinoma in situ.'}}","{'concept_id': {0: 'C0007099'}, 'canonical_name': {0: 'Carcinoma, Preinvasive'}, 'aliases': {0: ['Carcinoma in Situ', 'Intraepithelial Carcinoma', 'Carcinoma, Intraepithelial', 'Preinvasive Carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.'}, 'entity': {0: 'in situ'}, 'text': {0: '*Absence of invasive tumour residues in the breast and lymph nodes, irrespective of ductal carcinoma in situ.'}}",{},{},"{'concept_id': {0: 'C0007097'}, 'canonical_name': {0: 'Carcinoma'}, 'aliases': {0: []}, 'types': {0: ['T191']}, 'definition': {0: 'A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for ""cancer.""'}, 'entity': {0: 'ductal carcinoma'}, 'text': {0: '*Absence of invasive tumour residues in the breast and lymph nodes, irrespective of ductal carcinoma in situ.'}}","           entity_group             value     score
0  Detailed_description          invasive  0.556921
1          Sign_symptom            tumour  0.770865
2  Biological_structure            breast  0.999595
3      Disease_disorder  ductal carcinoma  0.999661",[],"{'keyword': {0: 'tumour residues breast', 1: 'absence invasive tumour', 2: 'invasive tumour', 3: 'nodes irrespective ductal', 4: 'carcinoma situ'}, 'score': {0: 0.8037, 1: 0.7663, 2: 0.7164, 3: 0.6591, 4: 0.5055}}"
37,37,37,0.8830000162124634,19.0,"pCR, pathological complete response.",MyriadPro-Light,4,-0.25,3355443,1,6,1,"{'concept_id': {0: 'C4054467'}, 'canonical_name': {0: 'Morphologic Complete Response'}, 'aliases': {0: ['Morphologic CR']}, 'types': {0: ['T033']}, 'definition': {0: 'The disappearance of all signs of cancer, supported by morphological analysis.'}, 'entity': {0: 'pathological complete response'}, 'text': {0: 'pCR, pathological complete response.'}}","{'concept_id': {0: 'C1709846'}, 'canonical_name': {0: 'Real-Time Polymerase Chain Reaction'}, 'aliases': {0: ['Real Time PCR', 'Real-Time PCRs', 'PCRs, Real-Time', 'PCR, Real-Time', 'Real Time Polymerase Chain Reaction', 'Real-Time PCR']}, 'types': {0: ['T063']}, 'definition': {0: 'An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.'}, 'entity': {0: 'pCR'}, 'text': {0: 'pCR, pathological complete response.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'pcr pathological', 1: 'pcr pathological complete', 2: 'pathological complete response', 3: 'pathological complete', 4: 'complete response'}, 'score': {0: 0.714, 1: 0.7119, 2: 0.6896, 3: 0.688, 4: 0.4804}}"
38,38,38,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,1,7,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
39,39,39,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,1,7,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
40,40,40,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,1,7,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
41,41,41,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,1,7,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
42,42,42,0.9169999957084656,98.0,A different direction for patients ,ConduitITC-Bold,20,-0.2349999994039535,8194925,2,1,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'A different direction for patients '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'A different direction for patients '}}",{},{},{},"           entity_group                value     score
0             Lab_value  different direction  0.996501
1  Biological_structure             patients  0.175571",[],"{'keyword': {0: 'different direction patients', 1: 'different direction', 2: 'direction patients'}, 'score': {0: 0.9368, 1: 0.8199, 2: 0.8171}}"
43,43,43,0.9169999957084656,98.0,with residual invasive disease,ConduitITC-Bold,20,-0.2349999994039535,8194925,2,1,1,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'with residual invasive disease'}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'with residual invasive disease'}}",{},{},{},"           entity_group             value     score
0  Detailed_description          residual  0.999918
1  Detailed_description  invasive disease  0.762322",[],"{'keyword': {0: 'residual invasive', 1: 'residual invasive disease', 2: 'invasive disease'}, 'score': {0: 0.9223, 1: 0.907, 2: 0.8886}}"
44,44,44,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,2,2,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
45,45,45,0.8830000162124634,32.0,"by NICE and accepted by the SMC, within its marketing authorisation for the ",MyriadPro-Light,4,-0.25,3355443,2,2,1,"{'concept_id': {0: 'C3888088'}, 'canonical_name': {0: 'SMITH-MCCORT DYSPLASIA 1'}, 'aliases': {0: ['SMC', 'SMITH-McCORT DYSPLASIA 1', 'SMITH-MCCORT DYSPLASIA 1', 'SMC1']}, 'types': {0: ['T047']}, 'definition': {0: None}, 'entity': {0: 'SMC'}, 'text': {0: 'by NICE and accepted by the SMC, within its marketing authorisation for the '}}",{},{},"{'concept_id': {0: 'C2612492'}, 'canonical_name': {0: 'smooth muscle cell apoptotic process'}, 'aliases': {0: ['smooth muscle cell programmed cell death by apoptosis', 'apoptosis of smooth muscle cells', 'smooth muscle cell apoptosis', 'SMC apoptosis', 'programmed cell death of smooth muscle cells by apoptosis', 'programmed cell death, smooth muscle cells']}, 'types': {0: ['T043']}, 'definition': {0: 'Any apoptotic process in a smooth muscle cell. Smooth muscle consists of non-striated, elongated, spindle-shaped cell found lining the digestive tract, uterus, and blood vessels. [CL:0000192, GOC:BHF, GOC:mah, GOC:mtg_apoptosis, GOC:rl]'}, 'entity': {0: 'SMC'}, 'text': {0: 'by NICE and accepted by the SMC, within its marketing authorisation for the '}}",{},"           entity_group value     score
0  Detailed_description  NICE  0.840521",[],"{'keyword': {0: 'nice accepted', 1: 'accepted smc', 2: 'accepted smc marketing', 3: 'smc marketing', 4: 'smc marketing authorisation'}, 'score': {0: 0.7915, 1: 0.7379, 2: 0.6838, 3: 0.6086, 4: 0.3505}}"
46,46,46,0.8830000162124634,32.0,adjuvant treatment of adult patients with HER2-positive eBC who have residual ,MyriadPro-Light,4,-0.25,3355443,2,2,2,"{'concept_id': {0: 'C4684759'}, 'canonical_name': {0: 'Residual Risk'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Risk that remains after risk control measures have been taken.'}, 'entity': {0: 'residual'}, 'text': {0: 'adjuvant treatment of adult patients with HER2-positive eBC who have residual '}}","{'concept_id': {0: 'C0242740'}, 'canonical_name': {0: 'Gastric Stump'}, 'aliases': {0: ['Remnant Stomachs', 'Stomachs, Remnant', 'Remnant, Gastric', 'Gastric Stumps', 'Gastric Remnant', 'Residual Stomach', 'Residual Stomachs', 'Stomachs, Residual', 'Stomach, Residual', 'Stump, Gastric', 'Stumps, Gastric', 'Remnants, Gastric', 'Gastric Remnants', 'Stomach, Remnant', 'Remnant Stomach']}, 'types': {0: ['T023']}, 'definition': {0: 'That portion of the stomach remaining after gastric surgery, usually gastrectomy or gastroenterostomy for cancer of the stomach or peptic ulcer. It is a common site of cancer referred to as stump cancer or carcinoma of the gastric stump.'}, 'entity': {0: 'residual'}, 'text': {0: 'adjuvant treatment of adult patients with HER2-positive eBC who have residual '}}",{},{},"{'concept_id': {0: 'C1853562'}, 'canonical_name': {0: 'Adult onset'}, 'aliases': {0: ['Symptoms begin in adulthood', 'Onset in early adulthood', 'Onset in adulthood']}, 'types': {0: ['T033']}, 'definition': {0: 'Onset of disease manifestations in adulthood, defined here as at the age of 16 years or later. [HPO:probinson]'}, 'entity': {0: 'adult'}, 'text': {0: 'adjuvant treatment of adult patients with HER2-positive eBC who have residual '}}","           entity_group                                              value  \
0            Medication                                 adjuvant treatment   
1  Detailed_description                                      HER2-positive   
2             Lab_value                                      HER2-positive   
3      Disease_disorder  treatment patients HER2-positive eBC have resi...   
4      Disease_disorder                                                eBC   
5  Detailed_description                                           residual   

      score  
0  0.686893  
1  0.995616  
2  0.566300  
3  0.955795  
4  0.812029  
5  0.999888  ",[],"{'keyword': {0: 'adjuvant treatment', 1: 'her2 positive ebc', 2: 'treatment adult', 3: 'adult patients her2', 4: 'her2 positive'}, 'score': {0: 0.8474, 1: 0.8305, 2: 0.7924, 3: 0.7658, 4: 0.7224}}"
47,47,47,0.8830000162124634,32.0,invasive disease in the breast or lymph nodes after neoadjuvant taxane-based ,MyriadPro-Light,4,-0.25,3355443,2,2,3,"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Neoadjuvant Therapy'}, 'aliases': {0: ['Preoperative Therapy', 'Therapy, Neoadjuvant', 'neoadjuvant treatment', 'Neoadjuvant Treatment', 'Neoadjuvant Treatments', 'Neoadjuvant Therapies', 'Neoadjuvant', 'Induction Therapy', 'Neoadjuvant Therapy', 'induction therapy', 'Treatment, Neoadjuvant', 'neoadjuvant therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant taxane-based'}, 'text': {0: 'invasive disease in the breast or lymph nodes after neoadjuvant taxane-based '}}","{'concept_id': {0: 'C1522495'}, 'canonical_name': {0: 'Sentinal Node'}, 'aliases': {0: ['Nodes, Sentinal', 'Sentinel Lymph Node', 'Node, Sentinal', 'Lymph Node, Sentinel', 'Sentinel Lymph Nodes', 'Sentinal Nodes', 'Lymph Nodes, Sentinel']}, 'types': {0: ['T023']}, 'definition': {0: 'First lymph node to receive drainage from the primary tumor. SENTINEL LYMPH NODE BIOPSY is performed to determine early METASTASIS status because cancer cells may appear first in the sentinel node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'invasive disease in the breast or lymph nodes after neoadjuvant taxane-based '}}",{},{},"{'concept_id': {0: 'C0024205'}, 'canonical_name': {0: 'Lymphadenitis'}, 'aliases': {0: ['Inflammation of the lymph nodes']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the lymph nodes.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'invasive disease in the breast or lymph nodes after neoadjuvant taxane-based '}}","           entity_group         value     score
0  Detailed_description      invasive  0.997974
1      Disease_disorder       disease  0.435645
2  Biological_structure        breast  0.999864
3  Biological_structure         lymph  0.999828
4  Biological_structure   lymph nodes  0.996716
5  Detailed_description   neoadjuvant  0.999960
6  Detailed_description  taxane-based  0.981346","[('taxane', 'DRUG')]","{'keyword': {0: 'neoadjuvant taxane based', 1: 'nodes neoadjuvant taxane', 2: 'disease breast', 3: 'breast lymph nodes', 4: 'invasive disease'}, 'score': {0: 0.8861, 1: 0.8782, 2: 0.8419, 3: 0.808, 4: 0.7172}}"
48,48,48,0.8830000162124634,32.0,and HER2-targeted therapy*,MyriadPro-Light,4,-0.25,3355443,2,2,4,"{'concept_id': {0: 'C5235659'}, 'canonical_name': {0: 'HER2-targeting Agent'}, 'aliases': {0: ['ERBB2-Targeting Agent']}, 'types': {0: ['T121']}, 'definition': {0: 'Any agent that targets the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2/neu; HER-2; erbB-2).'}, 'entity': {0: 'HER2-targeted therapy*'}, 'text': {0: 'and HER2-targeted therapy*'}}",{},{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  therapy  0.999469",[],"{'keyword': {0: 'her2 targeted therapy', 1: 'targeted therapy', 2: 'her2 targeted'}, 'score': {0: 0.8687, 1: 0.8654, 2: 0.8155}}"
49,49,49,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,2,3,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
50,50,50,0.8830000162124634,32.0,of trastuzumab,MyriadPro-Light,4,-0.25,3355443,2,3,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  trastuzumab  0.999818","[('trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
51,51,51,0.9890000224113464,36.0,Cytotoxic microtubule  ,MyriadPro-Bold,20,-0.25,16777215,2,4,0,"{'concept_id': {0: 'C4316807'}, 'canonical_name': {0: 'Cytoplasmic microtubule'}, 'aliases': {0: ['Cytoplasmic microtubule', 'Cytoplasmic microtubule (cell structure)', 'cytoplasmic microtubule', 'Cytoplasmic microtubule, NOS']}, 'types': {0: ['T026']}, 'definition': {0: 'Any microtubule in the cytoplasm of a cell. [GOC:mah]'}, 'entity': {0: 'Cytotoxic microtubule'}, 'text': {0: 'Cytotoxic microtubule  '}}","{'concept_id': {0: 'C0026046'}, 'canonical_name': {0: 'Microtubule'}, 'aliases': {0: ['Microtubules']}, 'types': {0: ['T026']}, 'definition': {0: 'Slender, cylindrical filaments found in the cytoskeleton of plant and animal cells. They are composed of the protein TUBULIN and are influenced by TUBULIN MODULATORS.'}, 'entity': {0: 'Cytotoxic microtubule'}, 'text': {0: 'Cytotoxic microtubule  '}}",{},"{'concept_id': {0: 'C4236014'}, 'canonical_name': {0: 'cytoplasmic microtubule plus-end'}, 'aliases': {0: ['growing microtubule plus end of cytoplasmic microtubule', 'microtubule plus-end of cytoplasmic microtubule', 'microtubule plus end of cytoplasmic microtubule']}, 'types': {0: ['T026']}, 'definition': {0: 'Any microtubule plus-end that is part of a cytoplasmic microtubule. [GO_REF:0000064, GOC:TermGenie, PMID:15772152]'}, 'entity': {0: 'Cytotoxic microtubule'}, 'text': {0: 'Cytotoxic microtubule  '}}",{},"           entity_group                              value     score
0  Diagnostic_procedure                          Cytotoxic  0.644969
1             Lab_value  Cytotoxic microtubule microtubule  0.512873
2  Diagnostic_procedure                        microtubule  0.791435",[],"{'keyword': {0: 'cytotoxic microtubule'}, 'score': {0: 1.0}}"
52,52,52,0.9890000224113464,36.0,inhibition,MyriadPro-Bold,20,-0.25,16777215,2,4,1,"{'concept_id': {0: 'C3463820'}, 'canonical_name': {0: 'Inhibition'}, 'aliases': {0: ['Inhibition', 'Inhibiting', 'Response Inhibition', 'physical inhibition', 'inhibition', 'Inhibitory']}, 'types': {0: ['T052']}, 'definition': {0: 'The interference with or prevention of an action or response even though the stimulus for that action or response is present.'}, 'entity': {0: 'inhibition'}, 'text': {0: 'inhibition'}}","{'concept_id': {0: 'C0029968'}, 'canonical_name': {0: 'Ovulation Inhibition'}, 'aliases': {0: ['Inhibition, Ovulation', 'Suppression, Ovulation', 'Ovulation Suppression']}, 'types': {0: ['T061']}, 'definition': {0: 'Blocking the process leading to OVULATION. Various factors are known to inhibit ovulation, such as neuroendocrine, psychological, and pharmacological agents.'}, 'entity': {0: 'inhibition'}, 'text': {0: 'inhibition'}}",{},"{'concept_id': {0: 'C3544778'}, 'canonical_name': {0: 'negative regulation of superoxide dismutase activity'}, 'aliases': {0: ['down regulation of SODS', 'inhibition of superoxide dismutase activity', 'inhibition of SODS', 'down-regulation of superoxide:superoxide oxidoreductase activity', 'negative regulation of superoxide:superoxide oxidoreductase activity', 'downregulation of superoxide:superoxide oxidoreductase activity', 'inhibition of SOD', 'down-regulation of SODS', 'inhibition of superoxide:superoxide oxidoreductase activity', 'negative regulation of SODS', 'down regulation of SOD', 'down-regulation of SOD', 'down regulation of superoxide:superoxide oxidoreductase activity', 'downregulation of superoxide dismutase activity', 'down-regulation of superoxide dismutase activity', 'negative regulation of SOD', 'downregulation of SODS', 'downregulation of SOD', 'down regulation of superoxide dismutase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Any process that stops, prevents or reduces the frequency, rate or extent of superoxide dismutase activity. [GOC:TermGenie]'}, 'entity': {0: 'inhibition'}, 'text': {0: 'inhibition'}}","{'concept_id': {0: 'C0424296'}, 'canonical_name': {0: 'Disinhibition'}, 'aliases': {0: []}, 'types': {0: ['T048']}, 'definition': {0: 'Unrestrained behavior, often at odds with social norms.'}, 'entity': {0: 'inhibition'}, 'text': {0: 'inhibition'}}","   entity_group       value     score
0  Sign_symptom  inhibition  0.849479",[],"{'keyword': {}, 'score': {}}"
53,53,53,0.8830000162124634,36.0,DM1 component,MyriadPro-Light,4,-0.25,16777215,2,4,2,"{'concept_id': {0: 'C3250443'}, 'canonical_name': {0: 'MYOTONIC DYSTROPHY 1'}, 'aliases': {0: ['STEINERT DISEASE', 'DYSTROPHIA MYOTONICA', 'Steinert myotonic dystrophy syndrome (disorder)', 'Steinert syndrome', 'MYOTONIC DYSTROPHY 1', 'Steinert disease', 'Steinert myotonic dystrophy', 'DM1', 'DYSTROPHIA MYOTONICA 1', 'DM', 'Dystrophia Myotonica 1', 'Myotonic dystrophy type 1', 'Steinert myotonic dystrophy syndrome']}, 'types': {0: ['T047']}, 'definition': {0: 'A rare autosomal dominant disorder caused by mutations in the DMPK gene. It is characterized by myotonia, muscular dystrophy, hypogonadism, heart conduction defects and cataracts.'}, 'entity': {0: 'DM1 component'}, 'text': {0: 'DM1 component'}}",{},{},{},{},"           entity_group          value     score
0  Diagnostic_procedure  DM1 component  0.998499",[],"{'keyword': {0: 'dm1 component'}, 'score': {0: 1.0}}"
54,54,54,0.9890000224113464,36.0,Anti-HER2 ,MyriadPro-Bold,20,-0.25,16777215,2,5,0,"{'concept_id': {0: 'C4722434'}, 'canonical_name': {0: 'Anti-HER2 Monoclonal Antibody'}, 'aliases': {0: ['Anti-HER2 Monoclonal Antibody', 'Anti-HER-2 Monoclonal Antibody', 'Anti-ErbB2 Monoclonal Antibody']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'Any monoclonal antibody that is directed against human epidermal growth factor receptor 2 (HER2; HER-2; ERBB2).'}, 'entity': {0: 'Anti-HER2'}, 'text': {0: 'Anti-HER2 '}}",{},{},{},{},"           entity_group      value     score
0  Diagnostic_procedure  Anti-HER2  0.900894",[],"{'keyword': {0: 'anti her2'}, 'score': {0: 0.978}}"
55,55,55,0.9890000224113464,36.0,activity,MyriadPro-Bold,20,-0.25,16777215,2,5,1,"{'concept_id': {0: 'C0441655'}, 'canonical_name': {0: 'Activities'}, 'aliases': {0: ['Activity (observable entity)', 'activities', 'ACTIVITY', 'Activities', 'Activity', 'activity']}, 'types': {0: ['T052']}, 'definition': {0: 'An active process; excludes processes and mechanisms which fulfill biological functions.'}, 'entity': {0: 'activity'}, 'text': {0: 'activity'}}","{'concept_id': {0: 'C0001289'}, 'canonical_name': {0: 'Activity Cycles'}, 'aliases': {0: ['Cycles, Activity', 'Cycle, Activity', 'Activity Cycle']}, 'types': {0: ['T079']}, 'definition': {0: 'Bouts of physical irritability or movement alternating with periods of quiescence. It includes biochemical activity and hormonal activity which may be cellular. These cycles are shorter than 24 hours and include sleep-wakefulness cycles and the periodic activation of the digestive system.'}, 'entity': {0: 'activity'}, 'text': {0: 'activity'}}",{},"{'concept_id': {0: 'C1151329'}, 'canonical_name': {0: 'chlorophyll a oxygenase activity'}, 'aliases': {0: ['chlorophyllide-a oxygenase activity', 'CAO activity', 'chlorophyllide a oxygenase activity', 'chlorophyllide a:oxygen 7-oxidoreductase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: chlorophyllide a + NADPH + O2 + 2 H+ = 7-hydroxychlorophyllide a + NADP+ + H2O. [EC:1.13.12.14, MetaCyc:RXN-7676]'}, 'entity': {0: 'activity'}, 'text': {0: 'activity'}}","{'concept_id': {0: 'C0424295'}, 'canonical_name': {0: 'Hyperactivity'}, 'aliases': {0: ['Hyperactive behavior', 'More active than typical', 'Hyperactive behaviour']}, 'types': {0: ['T048']}, 'definition': {0: 'Increased motor activity that is not goal directed.'}, 'entity': {0: 'activity'}, 'text': {0: 'activity'}}","           entity_group     value    score
0  Detailed_description  activity  0.69726",[],"{'keyword': {}, 'score': {}}"
56,56,56,0.8830000162124634,36.0,Trastuzumab component,MyriadPro-Light,4,-0.25,16777215,2,5,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab component'}, 'text': {0: 'Trastuzumab component'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'Trastuzumab DM1 Conjugate'}, 'aliases': {0: ['Trastuzumab-DM1', 'Ado-Trastuzumab Emtansine', 'Trastuzumab-DM1 Conjugate', 'Trastuzumab DM1', 'Ado Trastuzumab Emtansine', 'Trastuzumab Emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab component'}, 'text': {0: 'Trastuzumab component'}}","{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'Trastuzumab component'}, 'text': {0: 'Trastuzumab component'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.994186","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab component'}, 'score': {0: 1.0}}"
57,57,57,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,2,8,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
58,58,58,0.8830000162124634,32.0,does not fully respond to neoadjuvant HER2-targeted therapy,MyriadPro-Light,4,-0.25,3355443,2,8,1,"{'concept_id': {0: 'C2985566'}, 'canonical_name': {0: 'Targeted Therapy'}, 'aliases': {0: ['targeted therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.'}, 'entity': {0: 'HER2-targeted therapy'}, 'text': {0: 'does not fully respond to neoadjuvant HER2-targeted therapy'}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'does not fully respond to neoadjuvant HER2-targeted therapy'}}",{},{},{},"            entity_group          value     score
0   Detailed_description    neoadjuvant  0.999918
1             Medication  HER2-targeted  0.607919
2   Detailed_description  HER2-targeted  0.996401
3  Therapeutic_procedure        therapy  0.989111",[],"{'keyword': {0: 'fully respond', 1: 'respond neoadjuvant', 2: 'does fully', 3: 'neoadjuvant her2 targeted', 4: 'does fully respond'}, 'score': {0: 0.7973, 1: 0.7652, 2: 0.7073, 3: 0.5667, 4: 0.5608}}"
59,59,59,0.8830000162124634,19.0,*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the ,MyriadPro-Light,4,-0.25,3355443,2,9,0,"{'concept_id': {0: 'C1554146'}, 'canonical_name': {0: 'Receiver responsibility'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: '<p>This property holds the identifier of the follow-on interaction, when the receiving application role for an interaction has the responsibility to initiate a follow-on interaction.</p>'}, 'entity': {0: 'no responsibility'}, 'text': {0: '*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the '}}","{'concept_id': {0: 'C0037433'}, 'canonical_name': {0: 'Social Responsibility'}, 'aliases': {0: ['Responsibility, Social', 'Responsibilities, Social', 'Social Responsibilities']}, 'types': {0: ['T078']}, 'definition': {0: 'The obligations and accountability assumed in carrying out actions or ideas on behalf of others.'}, 'entity': {0: 'no responsibility'}, 'text': {0: '*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the '}}",{},"{'concept_id': {0: 'C2754086'}, 'canonical_name': {0: 'dendrite guidance'}, 'aliases': {0: ['dendritic guidance']}, 'types': {0: ['T043']}, 'definition': {0: 'The process in which the migration of a dendrite is directed to a specific target site in response to a combination of attractive and repulsive cues. [GOC:sart, PMID:15046878]'}, 'entity': {0: 'guidance'}, 'text': {0: '*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the '}}",{},"     entity_group     value     score
0  Clinical_event  guidance  0.947969",[],"{'keyword': {0: 'withdrawn nice accepts', 1: 'accepts responsibility', 2: 'nhs england', 3: 'subject regular review', 4: 'withdrawn nice'}, 'score': {0: 0.8072, 1: 0.5458, 2: 0.1452, 3: 0.1044, 4: -0.0839}}"
60,60,60,0.8830000162124634,19.0,use of its content in this material.,MyriadPro-Light,4,-0.25,3355443,2,9,1,"{'concept_id': {0: 'C1880278'}, 'canonical_name': {0: 'Dent in Material'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Problem associated with a undesired change in shape, characterized by the presence of a slight hollow (dent) in the device surface.'}, 'entity': {0: 'material'}, 'text': {0: 'use of its content in this material.'}}","{'concept_id': {0: 'C0011379'}, 'canonical_name': {0: 'Dental Materials'}, 'aliases': {0: ['Dental Material', 'Material, Dental', 'Materials, Dental']}, 'types': {0: ['T122']}, 'definition': {0: 'Materials used in the production of dental bases, restorations, impressions, prostheses, etc.'}, 'entity': {0: 'material'}, 'text': {0: 'use of its content in this material.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'use content material', 1: 'content material', 2: 'use content'}, 'score': {0: 0.7981, 1: 0.7975, 2: 0.7835}}"
61,61,61,0.8830000162124634,19.0,†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab emtansine ,MyriadPro-Light,4,-0.25,3355443,2,9,2,"{'concept_id': {0: 'C4505403'}, 'canonical_name': {0: 'Maytansinoid DM1'}, 'aliases': {0: ['Emtansine', 'DM1, Maytansinoid', 'Mertansine']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'emtansine'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab emtansine '}}","{'concept_id': {0: 'C4505403'}, 'canonical_name': {0: 'Maytansinoid DM1'}, 'aliases': {0: ['Emtansine', 'Mertansine', 'DM1, Maytansinoid']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'emtansine'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab emtansine '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab emtansine '}}","{'concept_id': {0: 'C2612492'}, 'canonical_name': {0: 'smooth muscle cell apoptotic process'}, 'aliases': {0: ['smooth muscle cell programmed cell death by apoptosis', 'apoptosis of smooth muscle cells', 'smooth muscle cell apoptosis', 'SMC apoptosis', 'programmed cell death of smooth muscle cells by apoptosis', 'programmed cell death, smooth muscle cells']}, 'types': {0: ['T043']}, 'definition': {0: 'Any apoptotic process in a smooth muscle cell. Smooth muscle consists of non-striated, elongated, spindle-shaped cell found lining the digestive tract, uterus, and blood vessels. [CL:0000192, GOC:BHF, GOC:mah, GOC:mtg_apoptosis, GOC:rl]'}, 'entity': {0: 'SMC'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab emtansine '}}",{},"            entity_group        value     score
0  Therapeutic_procedure          SMC  0.619393
1  Therapeutic_procedure      Kadcyla  0.488142
2             Medication      Kadcyla  0.785738
3             Medication  trastuzumab  0.999857
4             Medication    emtansine  0.999645","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG'), ('emtansine', 'FORM')]","{'keyword': {0: 'nice recommends kadcyla', 1: 'kadcyla company', 2: 'recommendation nice', 3: 'provides trastuzumab', 4: 'nice acceptance'}, 'score': {0: 0.6297, 1: 0.5788, 2: 0.5311, 3: 0.4913, 4: 0.388}}"
62,62,62,0.8830000162124634,19.0,according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of ,MyriadPro-Light,4,-0.25,3355443,2,9,3,"{'concept_id': {0: 'C4281677'}, 'canonical_name': {0: 'Application Context'}, 'aliases': {0: ['Context', 'Application Context']}, 'types': {0: ['T170']}, 'definition': {0: 'A designation or description of the application environment or discipline in which a name is applied or from which it originates.'}, 'entity': {0: 'context'}, 'text': {0: 'according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of '}}","{'concept_id': {0: 'C0037414'}, 'canonical_name': {0: 'Social Environment'}, 'aliases': {0: ['Social Environments', 'Environments, Social', 'Social Contexts', 'Environment, Social', 'Context, Social', 'Social Context', 'Contexts, Social']}, 'types': {0: ['T078']}, 'definition': {0: 'The aggregate of social and cultural institutions, forms, patterns, and processes that influence the life of an individual or community.'}, 'entity': {0: 'context'}, 'text': {0: 'according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of '}}","{'concept_id': {0: 'C2612492'}, 'canonical_name': {0: 'smooth muscle cell apoptotic process'}, 'aliases': {0: ['smooth muscle cell programmed cell death by apoptosis', 'apoptosis of smooth muscle cells', 'smooth muscle cell apoptosis', 'SMC apoptosis', 'programmed cell death of smooth muscle cells by apoptosis', 'programmed cell death, smooth muscle cells']}, 'types': {0: ['T043']}, 'definition': {0: 'Any apoptotic process in a smooth muscle cell. Smooth muscle consists of non-striated, elongated, spindle-shaped cell found lining the digestive tract, uterus, and blood vessels. [CL:0000192, GOC:BHF, GOC:mah, GOC:mtg_apoptosis, GOC:rl]'}, 'entity': {0: 'SMC'}, 'text': {0: 'according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of '}}","{'concept_id': {0: 'C2959688'}, 'canonical_name': {0: 'Abnormal location of heart atrium'}, 'aliases': {0: ['Abnormal atrial arrangement']}, 'types': {0: ['T019']}, 'definition': {0: 'Abnormality of the spatial relationship of the atria to other components of the heart. [DDD:dbrown]'}, 'entity': {0: 'arrangement'}, 'text': {0: 'according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of '}}","           entity_group        value     score
0  Detailed_description       simple  0.857207
1  Detailed_description     discount  0.995976
2            Medication  trastuzumab  0.999069
3            Medication    emtansine  0.503035
4        Clinical_event   Acceptance  0.356895
5           Coreference          SMC  0.865350","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'acceptance smc applies', 1: 'trastuzumab emtansine acceptance', 2: 'simple discount patient', 3: 'scheme trastuzumab emtansine', 4: 'applies context'}, 'score': {0: 0.2875, 1: 0.277, 2: 0.2321, 3: 0.2306, 4: 0.1714}}"
63,63,63,0.8830000162124634,19.0,"an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.",MyriadPro-Light,4,-0.25,3355443,2,9,4,"{'concept_id': {0: 'C2003888'}, 'canonical_name': {0: 'Lower (action)'}, 'aliases': {0: ['Lower', 'Lowering', 'Lowered']}, 'types': {0: ['T052']}, 'definition': {0: 'To become lower, grow less, or diminish, as in amount, intensity, degree, or value.'}, 'entity': {0: 'lower'}, 'text': {0: 'an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.'}}","{'concept_id': {0: 'C0226875'}, 'canonical_name': {0: 'Gastrointestinal Tract, Lower'}, 'aliases': {0: ['Lower GI Tract', 'Lower Gastrointestinal Tract']}, 'types': {0: ['T029']}, 'definition': {0: 'The segment of GASTROINTESTINAL TRACT that includes the small intestine below the DUODENUM, and the LARGE INTESTINE.'}, 'entity': {0: 'lower'}, 'text': {0: 'an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.'}}",{},"{'concept_id': {0: 'C1160518'}, 'canonical_name': {0: 'oocyte construction'}, 'aliases': {0: ['oocyte arrangement']}, 'types': {0: ['T043']}, 'definition': {0: 'The synthesis, deposition, and organization of the materials in a cell of an ovary; where the cell can then undergo meiosis and form an ovum. An example of this is found in Drosophila melanogaster. [GOC:dph, GOC:ems, GOC:mtg_sensu, GOC:tb, ISBN:0198506732]'}, 'entity': {0: 'arrangement'}, 'text': {0: 'an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.'}}","{'concept_id': {0: 'C2959688'}, 'canonical_name': {0: 'Abnormal location of heart atrium'}, 'aliases': {0: ['Abnormal atrial arrangement']}, 'types': {0: ['T019']}, 'definition': {0: 'Abnormality of the spatial relationship of the atria to other components of the heart. [DDD:dbrown]'}, 'entity': {0: 'arrangement'}, 'text': {0: 'an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'effectiveness results', 1: 'equivalent lower', 2: 'pas arrangement', 3: 'approved nhs', 4: 'list price'}, 'score': {0: 0.7775, 1: 0.7001, 2: 0.6635, 3: 0.6557, 4: 0.4442}}"
64,64,64,0.8830000162124634,19.0,"eBC, early breast cancer; DM1, derivative of maytansine; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme;  ",MyriadPro-Light,4,-0.25,3355443,2,9,5,"{'concept_id': {0: 'C4728271'}, 'canonical_name': {0: 'access control scheme'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: '<p>An access control policy specific to the type of access control scheme, which is used to enforce one or more authorization policies.</p><i>Usage Note:</i>Access control schemes are the type of access control policy, which is comprised of access control policy rules concerning the provision of the access control service.<p>There are two categories of access control policies, rule-based and identity-based, which are identified in CCITT Rec. X.800 aka ISO 7498-2. Rule-based access control policies are intended to apply to all access requests by any initiator on any target in a security domain. Identity-based access control policies are based on rules specific to an individual initiator, a group of initiators, entities acting on behalf of initiators, or originators acting in a specific role. Context can modify rule-based or identity-based access control policies. Context rules may define the entire policy in effect. Real systems will usually employ a combination of these policy types; if a rule-based policy is used, then an identity-based policy is usually in effect also.</p><p>An access control scheme may be based on access control lists, capabilities, labels, and context or a combination of these. An access control scheme is a component of an access control mechanism or ""service"") along with the supporting mechanisms required by that scheme to provide access control decision information (ADI) supplied by the scheme to the access decision facility (ADF also known as a PDP). (Based on ISO/IEC 10181-3:1996)</p><b>Examples:</b><p>* Attribute Based Access Control (ABAC) * Discretionary Access Control (DAC) * History Based Access Control (HBAC) * Identity Based Access Control (IBAC) * Mandatory Access Control (MAC) * Organization Based Access Control (OrBAC) * Relationship Based Access Control (RelBac) * Responsibility Based Access Control (RespBAC) * Risk Adaptable Access Control (RAdAC)</p><p>></p>'}, 'entity': {0: 'Patient Access Scheme'}, 'text': {0: 'eBC, early breast cancer; DM1, derivative of maytansine; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme;  '}}","{'concept_id': {0: 'C4505404'}, 'canonical_name': {0: 'Maytansinoid DM4'}, 'aliases': {0: ['DM4, Maytansinoid', 'Ravtansine', 'DMMO-Maytansine', 'DMMO Maytansine', ""N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine"", 'Soravtansine']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'A tubulin-binding maytansinoid. Ravtansine binds to tubulin at the maytansine-binding site, which disrupts microtubule assembly/disassembly dynamics and inhibits mitosis.'}, 'entity': {0: 'maytansine'}, 'text': {0: 'eBC, early breast cancer; DM1, derivative of maytansine; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme;  '}}",{},"{'concept_id': {0: 'C2753849'}, 'canonical_name': {0: 'PAS complex'}, 'aliases': {0: ['PAS complex location']}, 'types': {0: ['T026']}, 'definition': {0: 'A class III phosphatidylinositol 3-kinase complex that contains a phosphatidylinositol-3-phosphate 5-kinase subunit (Fab1p in yeast; PIKfyve in mammals), a kinase activator, and a phosphatase, and may also contain additional proteins; it is involved in regulating the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate. In mammals the complex is composed of PIKFYVE, FIG4 and VAC14. In yeast it is composed of Atg18p, Fig4p, Fab1p, Vac14p and Vac7p. [PMID:18950639, PMID:19037259, PMID:19158662]'}, 'entity': {0: 'PAS'}, 'text': {0: 'eBC, early breast cancer; DM1, derivative of maytansine; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme;  '}}","{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer; DM1, derivative of maytansine; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme;  '}}","  entity_group       value     score
0   Medication  maytansine  0.999862","[('maytansine', 'DRUG')]","{'keyword': {0: 'dm1 derivative maytansine', 1: 'institute health', 2: 'breast cancer', 3: 'national institute', 4: 'excellence pas'}, 'score': {0: 0.8138, 1: 0.7445, 2: 0.6758, 3: 0.5866, 4: 0.411}}"
65,65,65,0.8830000162124634,19.0,"SMC, Scottish Medicines Consortium. ",MyriadPro-Light,4,-0.25,3355443,2,9,6,"{'concept_id': {0: 'C3888088'}, 'canonical_name': {0: 'SMITH-MCCORT DYSPLASIA 1'}, 'aliases': {0: ['SMC', 'SMITH-McCORT DYSPLASIA 1', 'SMITH-MCCORT DYSPLASIA 1', 'SMC1']}, 'types': {0: ['T047']}, 'definition': {0: None}, 'entity': {0: 'SMC'}, 'text': {0: 'SMC, Scottish Medicines Consortium. '}}",{},{},"{'concept_id': {0: 'C2612492'}, 'canonical_name': {0: 'smooth muscle cell apoptotic process'}, 'aliases': {0: ['smooth muscle cell programmed cell death by apoptosis', 'apoptosis of smooth muscle cells', 'smooth muscle cell apoptosis', 'SMC apoptosis', 'programmed cell death of smooth muscle cells by apoptosis', 'programmed cell death, smooth muscle cells']}, 'types': {0: ['T043']}, 'definition': {0: 'Any apoptotic process in a smooth muscle cell. Smooth muscle consists of non-striated, elongated, spindle-shaped cell found lining the digestive tract, uterus, and blood vessels. [CL:0000192, GOC:BHF, GOC:mah, GOC:mtg_apoptosis, GOC:rl]'}, 'entity': {0: 'SMC'}, 'text': {0: 'SMC, Scottish Medicines Consortium. '}}",{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'smc scottish medicines', 1: 'scottish medicines consortium', 2: 'scottish medicines', 3: 'medicines consortium', 4: 'smc scottish'}, 'score': {0: 0.9135, 1: 0.8985, 2: 0.8679, 3: 0.8579, 4: 0.7958}}"
66,66,66,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,2,10,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
67,67,67,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,2,10,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
68,68,68,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,2,10,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
69,69,69,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,2,10,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
70,70,70,0.9169999957084656,98.0,Kadcyla can give patients the ,ConduitITC-Bold,20,-0.2349999994039535,8194925,3,1,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla can give patients the '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla can give patients the '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla can give patients the '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.578758
1   Medication  Kadcyla  0.754423","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla patients'}, 'score': {0: 0.737}}"
71,71,71,0.9169999957084656,98.0,hope to make plans again,ConduitITC-Bold,20,-0.2349999994039535,8194925,3,1,1,"{'concept_id': {0: 'C0178916'}, 'canonical_name': {0: 'Care plan'}, 'aliases': {0: ['care plans', 'Care plan (record artifact)', 'care planning', 'care plan', 'Plan of care', 'Care plan']}, 'types': {0: ['T170']}, 'definition': {0: '<p>List of acts representing a care plan. The acts can be in a varierty of moods including event (EVN) to record acts that have been carried out as part of the care plan.</p>'}, 'entity': {0: 'plans'}, 'text': {0: 'hope to make plans again'}}",{},{},{},{},"  entity_group value     score
0    Lab_value  hope  0.239175",[],"{'keyword': {0: 'hope make plans', 1: 'make plans', 2: 'hope make'}, 'score': {0: 0.9278, 1: 0.8636, 2: 0.8351}}"
72,72,72,0.8830000162124634,32.0,The effect of Kadcyla was ,MyriadPro-Light,4,-0.25,16777215,3,2,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was '}}","{'concept_id': {0: 'C1158774'}, 'canonical_name': {0: 'carbon catabolite repression of transcription by glucose'}, 'aliases': {0: ['down regulation of transcription by glucose', 'glucose effect', 'glucose repression', 'down-regulation of transcription by glucose', 'downregulation of transcription by glucose']}, 'types': {0: ['T045']}, 'definition': {0: 'A transcription regulation process in which the presence of glucose leads to a decrease in the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other carbon sources. Carbon catabolite repression is a mechanism of genetic regulation which the accumulation of catabolites of one substance in the cell represses the formation of enzymes that contribute to the catabolism of other substances. [ISBN:0198506732, PMID:11018147]'}, 'entity': {0: 'effect'}, 'text': {0: 'The effect of Kadcyla was '}}",{},"  entity_group    value    score
0  Coreference  Kadcyla  0.99961","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'effect kadcyla'}, 'score': {0: 0.8962}}"
73,73,73,0.8830000162124634,32.0,consistent across most ,MyriadPro-Light,4,-0.25,16777215,3,2,1,{},{},{},{},{},"           entity_group       value     score
0  Detailed_description  consistent  0.953771",[],"{'keyword': {}, 'score': {}}"
74,74,74,0.8830000162124634,32.0,patient subgroups,MyriadPro-Light,4,-0.25,16777215,3,2,2,"{'concept_id': {0: 'C0751987'}, 'canonical_name': {0: 'Betaproteobacteria'}, 'aliases': {0: ['Purple bacteria, beta subdivision', 'Proteobacteria beta subdivision', 'Betaproteobacteria', 'beta subgroup', 'beta Proteobacteria', 'Class Betaproteobacteria', 'beta subdivision', 'beta proteobacteria', 'Class Betaproteobacteria (organism)', 'Proteobacteria beta']}, 'types': {0: ['T007']}, 'definition': {0: 'A class in the phylum PROTEOBACTERIA comprised of chemoheterotrophs and chemoautotrophs which derive nutrients from decomposition of organic material.'}, 'entity': {0: 'subgroups'}, 'text': {0: 'patient subgroups'}}","{'concept_id': {0: 'C4277550'}, 'canonical_name': {0: 'Patient Portals'}, 'aliases': {0: ['Patient Internet Portals', 'Web Portals, Patient', 'Web Portal, Patient', 'Patient Internet Portal', 'Portals, Patient Web', 'Portal, Patient Web', 'Portal, Patient Internet', 'Patient Web Portals', 'Internet Portal, Patient', 'Internet Portals, Patient', 'Patient Portal', 'Patient Web Portal', 'Portals, Patient Internet', 'Portal, Patient']}, 'types': {0: ['T170']}, 'definition': {0: 'A secure online website that provides patients convenient 24-hour access to personal health information via an Internet connection.'}, 'entity': {0: 'patient'}, 'text': {0: 'patient subgroups'}}",{},{},{},"           entity_group              value     score
0  Diagnostic_procedure  patient subgroups  0.808303",[],"{'keyword': {0: 'patient subgroups'}, 'score': {0: 1.0}}"
75,75,75,0.8830000162124634,32.0,Kadcyla reduced  ,MyriadPro-Light,4,-0.25,16777215,3,3,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla reduced  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla reduced  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla reduced  '}}",{},{},"           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.999328
1             Lab_value  reduced  0.998519","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla reduced'}, 'score': {0: 1.0}}"
76,76,76,0.8830000162124634,32.0,the risk of recurrence by ,MyriadPro-Light,4,-0.25,16777215,3,3,1,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'the risk of recurrence by '}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'the risk of recurrence by '}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'the risk of recurrence by '}}","   entity_group       value     score
0  Sign_symptom  recurrence  0.999894",[],"{'keyword': {0: 'risk recurrence'}, 'score': {0: 0.9304}}"
77,77,77,0.8830000162124634,32.0,50% vs trastuzumab (11.3% ,MyriadPro-Light,4,-0.25,16777215,3,3,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: '50% vs trastuzumab (11.3% '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: '50% vs trastuzumab (11.3% '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: '50% vs trastuzumab (11.3% '}}",{},{},"  entity_group        value     score
0    Lab_value       50 % %  0.998706
1   Medication  trastuzumab  0.999815
2    Lab_value     11.3 % %  0.998061","[('trastuzumab', 'DRUG'), ('11.3', 'STRENGTH')]","{'keyword': {0: '50 vs', 1: '50 vs trastuzumab', 2: 'vs trastuzumab', 3: 'vs trastuzumab 11', 4: 'trastuzumab 11'}, 'score': {0: 0.6907, 1: 0.6704, 2: 0.6262, 3: 0.623, 4: 0.5732}}"
78,78,78,0.8830000162124634,32.0,absolute reduction; hazard ,MyriadPro-Light,4,-0.25,16777215,3,3,3,"{'concept_id': {0: 'C1550593'}, 'canonical_name': {0: 'injury hazard - EntityRisk'}, 'aliases': {0: ['injury hazard']}, 'types': {0: ['T078']}, 'definition': {0: '<p>Material is solid and sharp (e.g., cannulas). Dispose in hard container.</p>'}, 'entity': {0: 'hazard'}, 'text': {0: 'absolute reduction; hazard '}}","{'concept_id': {0: 'C0679771'}, 'canonical_name': {0: 'Harm Reduction'}, 'aliases': {0: ['Minimization, Harm', 'Reduction, Harm', 'Harm Minimization']}, 'types': {0: ['T061']}, 'definition': {0: 'The application of methods designed to reduce the risk of harm associated with certain behaviors without reduction in frequency of those behaviors. The risk-associated behaviors include ongoing and active addictive behaviors.'}, 'entity': {0: 'reduction'}, 'text': {0: 'absolute reduction; hazard '}}",{},"{'concept_id': {0: 'C1522821'}, 'canonical_name': {0: 'acidification'}, 'aliases': {0: ['pH reduction']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that reduces the internal pH of an organism, part of an organism or a cell, measured by the concentration of the hydrogen ion. [GOC:go_curators]'}, 'entity': {0: 'reduction'}, 'text': {0: 'absolute reduction; hazard '}}",{},"       entity_group     value     score
0         Lab_value  absolute  0.968440
1  Disease_disorder    hazard  0.846385",[],"{'keyword': {0: 'absolute reduction hazard', 1: 'reduction hazard', 2: 'absolute reduction'}, 'score': {0: 0.8856, 1: 0.8244, 2: 0.819}}"
79,79,79,0.8830000162124634,32.0,ratio 0.50; 95% Cl 0.39–0.64; ,MyriadPro-Light,4,-0.25,16777215,3,3,4,"{'concept_id': {0: 'C0475212'}, 'canonical_name': {0: 'centiliter'}, 'aliases': {0: ['Centiliter (qualifier value)', 'centiliter (cL)', 'Centiliter', 'centilitre', 'cL', 'cl']}, 'types': {0: ['T081']}, 'definition': {0: 'The unit of volume equal to one hundredth of a liter or 10 milliliters. One centiliter is equivalent to 0.6102 cubic inch, or 0.338 U.S. fluid ounce.'}, 'entity': {0: 'Cl'}, 'text': {0: 'ratio 0.50; 95% Cl 0.39–0.64; '}}","{'concept_id': {0: 'C0036893'}, 'canonical_name': {0: 'Sex Ratio'}, 'aliases': {0: ['Ratios, Sex', 'Sex Ratios', 'Ratio, Sex']}, 'types': {0: ['T081']}, 'definition': {0: 'The number of males per 100 females.'}, 'entity': {0: 'ratio'}, 'text': {0: 'ratio 0.50; 95% Cl 0.39–0.64; '}}",{},"{'concept_id': {0: 'C1150758'}, 'canonical_name': {0: '4-coumarate-CoA synthetase activity'}, 'aliases': {0: ['hydroxycinnamoyl CoA synthetase activity', '4-coumarate:CoA ligase activity', '4CL', 'p-hydroxycinnamic acid:CoA ligase activity', '4-coumaroyl-CoA synthetase activity', 'caffeolyl coenzyme A synthetase activity', '4-coumaroyl-CoA synthase activity', 'sinapoyl coenzyme A synthetase activity', 'feruloyl CoA ligase activity', '4-coumarate:coenzyme A ligase activity', 'hydroxycinnamate:CoA ligase activity', 'p-coumaryl coenzyme A synthetase activity', 'feruloyl coenzyme A synthetase activity', 'p-coumaryl-CoA ligase activity', '4-coumarate-CoA ligase activity', 'p-coumaryl-CoA synthetase activity', '4-coumaryl-CoA synthetase activity', '4-coumarate:CoA ligase (AMP-forming)', 'p-hydroxycinnamoyl coenzyme A synthetase activity', 'p-coumaroyl CoA ligase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + 4-coumarate + CoA = AMP + diphosphate + 4-coumaroyl-CoA. [EC:6.2.1.12]'}, 'entity': {0: 'Cl'}, 'text': {0: 'ratio 0.50; 95% Cl 0.39–0.64; '}}","{'concept_id': {0: 'C5539803'}, 'canonical_name': {0: 'Abnormal RV/TLC ratio'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Any deviation from the normal ratio of residual volume (RV) to total lung capacity (TLC) on pulmonary function testing. RV is the amount of air remaining aftermaximal expiration and TLC is the total amount of air in theungs at full inspiration. These volumes cannot be determined by spirometry, but can be measured by inert gas dilution, nitrogen washout, and body plethysmography. [PMID:12934788]'}, 'entity': {0: 'ratio'}, 'text': {0: 'ratio 0.50; 95% Cl 0.39–0.64; '}}","           entity_group           value     score
0  Diagnostic_procedure           ratio  0.998719
1             Lab_value            0.50  0.977213
2             Lab_value            95 %  0.826655
3  Diagnostic_procedure              Cl  0.997318
4             Lab_value  0.50 0.39–0.64  0.903098
5             Lab_value       0.39–0.64  0.866811",[],"{'keyword': {0: 'ratio 50 95', 1: '95 cl 39', 2: '39 64', 3: 'cl 39', 4: '95 cl'}, 'score': {0: 0.8019, 1: 0.767, 2: 0.6972, 3: 0.6432, 4: 0.6431}}"
80,80,80,0.8830000162124634,32.0,p<0.001),MyriadPro-Light,4,-0.25,16777215,3,3,5,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
81,81,81,0.8830000162124634,32.0,The risk of distant ,MyriadPro-Light,4,-0.25,16777215,3,4,0,"{'concept_id': {0: 'C5441917'}, 'canonical_name': {0: 'Distant Metastasis'}, 'aliases': {0: ['Distant Cancer', 'Distant Metastasis', 'Distant metastasis']}, 'types': {0: ['T046']}, 'definition': {0: 'A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.'}, 'entity': {0: 'distant'}, 'text': {0: 'The risk of distant '}}","{'concept_id': {0: 'C0028873'}, 'canonical_name': {0: 'Odds Ratio'}, 'aliases': {0: ['Ratio, Cross-Product', 'Odds, Relative', 'Risk Ratio', 'Risk Ratios', 'Relative Odds', 'Cross Product Ratio', 'Odds Ratios', 'Ratios, Risk', 'Ratio, Risk', 'Ratios, Cross-Product', 'Cross-Product Ratio', 'Cross-Product Ratios']}, 'types': {0: ['T081']}, 'definition': {0: 'The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.'}, 'entity': {0: 'risk'}, 'text': {0: 'The risk of distant '}}",{},{},{},"           entity_group    value     score
0  Detailed_description  distant  0.999642",[],"{'keyword': {0: 'risk distant'}, 'score': {0: 0.821}}"
82,82,82,0.8830000162124634,32.0,recurrence was lower with ,MyriadPro-Light,4,-0.25,16777215,3,4,1,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence was lower with '}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence was lower with '}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence was lower with '}}","   entity_group       value     score
0  Sign_symptom  recurrence  0.999937
1     Lab_value       lower  0.999266",[],"{'keyword': {0: 'recurrence lower'}, 'score': {0: 0.8576}}"
83,83,83,0.8830000162124634,32.0,Kadcyla vs trastuzumab ,MyriadPro-Light,4,-0.25,16777215,3,4,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'Kadcyla vs trastuzumab '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'Kadcyla vs trastuzumab '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'Kadcyla vs trastuzumab '}}",{},{},"  entity_group        value     score
0   Medication      Kadcyla  0.746639
1   Medication  trastuzumab  0.999615","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'kadcyla vs trastuzumab', 1: 'vs trastuzumab', 2: 'kadcyla vs'}, 'score': {0: 1.0, 1: 0.8448, 2: 0.8395}}"
84,84,84,0.8830000162124634,32.0,(unstratified hazard ratio ,MyriadPro-Light,4,-0.25,16777215,3,4,3,"{'concept_id': {0: 'C0597342'}, 'canonical_name': {0: 'radiation hazard'}, 'aliases': {0: ['hazards radiation', 'radiation hazard']}, 'types': {0: ['T038']}, 'definition': {0: 'health hazard arising from exposure to ionizing radiation.'}, 'entity': {0: 'hazard ratio'}, 'text': {0: '(unstratified hazard ratio '}}",{},{},{},{},"           entity_group         value     score
0  Diagnostic_procedure  unstratified  0.905946
1  Diagnostic_procedure  hazard ratio  0.856030",[],"{'keyword': {0: 'unstratified hazard ratio', 1: 'unstratified hazard', 2: 'hazard ratio'}, 'score': {0: 0.9385, 1: 0.9042, 2: 0.7231}}"
85,85,85,0.8830000162124634,32.0,0.60;  ,MyriadPro-Light,4,-0.25,16777215,3,4,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  0.60  0.996137",[],"{'keyword': {}, 'score': {}}"
86,86,86,0.8830000162124634,32.0,95% Cl 0.45–0.79),MyriadPro-Light,4,-0.25,16777215,3,4,5,{},{},{},{},{},"           entity_group value     score
0             Lab_value    95  0.999804
1  Diagnostic_procedure    Cl  0.993519",[],"{'keyword': {0: '95 cl 45', 1: 'cl 45 79', 2: '95 cl', 3: '45 79', 4: 'cl 45'}, 'score': {0: 0.7718, 1: 0.7615, 2: 0.7463, 3: 0.7409, 4: 0.7296}}"
87,87,87,0.8830000162124634,19.0,"CI, confidence interval.",MyriadPro-Light,4,-0.25,3355443,3,11,0,"{'concept_id': {0: 'C1704725'}, 'canonical_name': {0: 'Statistical Confidence'}, 'aliases': {0: ['Confidence', 'Statistical Confidence']}, 'types': {0: ['T080']}, 'definition': {0: 'The statistical calculation of the percentage likelihood for a given set of data to have a given statistical value.'}, 'entity': {0: 'confidence interval'}, 'text': {0: 'CI, confidence interval.'}}","{'concept_id': {0: 'C0009667'}, 'canonical_name': {0: 'Confidence Intervals'}, 'aliases': {0: ['Confidence Interval', 'Intervals, Confidence', 'Interval, Confidence']}, 'types': {0: ['T081']}, 'definition': {0: 'A range of values for a variable of interest, e.g., a rate, constructed so that this range has a specified probability of including the true value of the variable.'}, 'entity': {0: 'confidence interval'}, 'text': {0: 'CI, confidence interval.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'confidence interval', 1: 'ci confidence interval', 2: 'ci confidence'}, 'score': {0: 0.7259, 1: 0.6489, 2: 0.6356}}"
88,88,88,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,3,12,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
89,89,89,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,3,12,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
90,90,90,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,3,12,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
91,91,91,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,3,12,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
92,92,92,0.9169999957084656,98.0,Knowing what may lie ahead  ,ConduitITC-Bold,20,-0.2349999994039535,8194925,4,1,0,{},{},{},{},{},"  entity_group  value     score
0         Date  ahead  0.362999",[],"{'keyword': {0: 'knowing lie', 1: 'knowing lie ahead', 2: 'lie ahead'}, 'score': {0: 0.8569, 1: 0.8339, 2: 0.7784}}"
93,93,93,0.9169999957084656,98.0,can give your patients a sense  ,ConduitITC-Bold,20,-0.2349999994039535,8194925,4,1,1,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'can give your patients a sense  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'can give your patients a sense  '}}",{},{},{},"           entity_group  value     score
0  Diagnostic_procedure  sense  0.836095",[],"{'keyword': {0: 'patients sense'}, 'score': {0: 0.8771}}"
94,94,94,0.9169999957084656,98.0,of control,ConduitITC-Bold,20,-0.2349999994039535,8194925,4,1,2,"{'concept_id': {0: 'C0308718'}, 'canonical_name': {0: 'CONTROL veterinary product'}, 'aliases': {0: ['CONTROL [brand name]', 'CONTROL']}, 'types': {0: ['T121']}, 'definition': {0: 'brand of veterinary product'}, 'entity': {0: 'control'}, 'text': {0: 'of control'}}","{'concept_id': {0: 'C0031249'}, 'canonical_name': {0: 'Control, Pest'}, 'aliases': {0: ['Pest Management', 'Management, Pest', 'Pest Control']}, 'types': {0: ['T057']}, 'definition': {0: 'The reduction or regulation of the population of noxious, destructive, or dangerous plants, insects, or other animals. This includes control of plants that serve as habitats or food sources for animal pests.'}, 'entity': {0: 'control'}, 'text': {0: 'of control'}}",{},"{'concept_id': {0: 'C3544486'}, 'canonical_name': {0: 'cell cycle control'}, 'aliases': {0: ['regulation of cell cycle phase transition', 'regulation of cell cycle transition']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that modulates the frequency, rate or extent of cell cycle phase transition. [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:22841721]'}, 'entity': {0: 'control'}, 'text': {0: 'of control'}}",{},"           entity_group       value     score
0  Detailed_description  of control  0.495689",[],"{'keyword': {}, 'score': {}}"
95,95,95,0.8830000162124634,32.0,The safety profile of adjuvant Kadcyla was consistent with previous studies,MyriadPro-Light,4,-0.25,3355443,4,2,0,"{'concept_id': {0: 'C0036745'}, 'canonical_name': {0: 'Study of serum'}, 'aliases': {0: ['serum studies', 'serology', 'serologies', 'Serology', 'study of serum']}, 'types': {0: ['T091']}, 'definition': {0: 'The study of serum, especially of antigen-antibody reactions in vitro.'}, 'entity': {0: 'studies'}, 'text': {0: 'The safety profile of adjuvant Kadcyla was consistent with previous studies'}}","{'concept_id': {0: 'C0023981'}, 'canonical_name': {0: 'Study, Longitudinal'}, 'aliases': {0: ['Longitudinal Studies', 'Studies, Longitudinal', 'Longitudinal Study']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which variables relating to an individual or group of individuals are assessed over a period of time.'}, 'entity': {0: 'studies'}, 'text': {0: 'The safety profile of adjuvant Kadcyla was consistent with previous studies'}}",{},{},{},"           entity_group             value     score
0  Detailed_description  adjuvant Kadcyla  0.904942
1           Coreference           Kadcyla  0.902791
2           Coreference           studies  0.382323","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'safety profile adjuvant', 1: 'consistent previous studies', 2: 'kadcyla consistent previous', 3: 'consistent previous', 4: 'previous studies'}, 'score': {0: 0.5878, 1: 0.5045, 2: 0.4769, 3: 0.4331, 4: 0.2592}}"
96,96,96,0.8830000162124634,32.0,17.9% of patients discontinued  ,MyriadPro-Light,4,-0.25,16777215,4,3,0,"{'concept_id': {0: 'C0549178'}, 'canonical_name': {0: 'Continuous'}, 'aliases': {0: ['Continuous', 'Continuing', 'Continuous (qualifier value)', 'Continued', 'Continual', 'continuous', 'All of the time', 'Ongoing', 'Continue']}, 'types': {0: ['T078']}, 'definition': {0: 'Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.'}, 'entity': {0: 'discontinued'}, 'text': {0: '17.9% of patients discontinued  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: '17.9% of patients discontinued  '}}",{},{},{},"  entity_group         value     score
0    Lab_value        17.9 %  0.997940
1      History  discontinued  0.754478",[],"{'keyword': {0: '17 patients discontinued', 1: 'patients discontinued', 2: '17 patients'}, 'score': {0: 0.9369, 1: 0.8781, 2: 0.6724}}"
97,97,97,0.8830000162124634,32.0,Kadcyla due to adverse events,MyriadPro-Light,4,-0.25,16777215,4,3,1,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'Kadcyla due to adverse events'}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'Kadcyla due to adverse events'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla due to adverse events'}}",{},{},"   entity_group           value     score
0   Coreference         Kadcyla  0.536706
1  Sign_symptom  adverse events  0.877486","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'adverse events', 1: 'kadcyla adverse events', 2: 'kadcyla adverse'}, 'score': {0: 0.8705, 1: 0.8159, 2: 0.7552}}"
98,98,98,0.8830000162124634,32.0,98.8% of patients experienced  ,MyriadPro-Light,4,-0.25,16777215,4,4,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: '98.8% of patients experienced  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: '98.8% of patients experienced  '}}",{},{},{},"  entity_group   value     score
0    Lab_value  98.8 %  0.999506",[],"{'keyword': {0: '98 patients experienced', 1: '98 patients', 2: 'patients experienced'}, 'score': {0: 0.9446, 1: 0.8177, 2: 0.7901}}"
99,99,99,0.8830000162124634,32.0,adverse events with Kadcyla vs 93.3% with ,MyriadPro-Light,4,-0.25,16777215,4,4,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'adverse events with Kadcyla vs 93.3% with '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'adverse events with Kadcyla vs 93.3% with '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'adverse events with Kadcyla vs 93.3% with '}}",{},{},"   entity_group           value     score
0  Sign_symptom  adverse events  0.999671
1   Coreference         Kadcyla  0.763301
2     Lab_value          93.3 %  0.999893","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'adverse events kadcyla', 1: 'adverse events', 2: 'kadcyla vs', 3: 'events kadcyla', 4: 'vs 93'}, 'score': {0: 0.759, 1: 0.7156, 2: 0.7127, 3: 0.6656, 4: 0.647}}"
100,100,100,0.8830000162124634,32.0,trastuzumab,MyriadPro-Light,4,-0.25,16777215,4,4,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  trastuzumab  0.999798","[('trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
101,101,101,0.8830000162124634,32.0,Serious adverse events occurred in 12.7% of ,MyriadPro-Light,4,-0.25,16777215,4,9,0,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'Serious adverse events occurred in 12.7% of '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'Serious adverse events occurred in 12.7% of '}}",{},{},{},"   entity_group           value     score
0      Severity         Serious  0.999846
1  Sign_symptom  adverse events  0.999908
2     Lab_value          12.7 %  0.996551",[],"{'keyword': {0: 'adverse events', 1: 'adverse events occurred', 2: 'occurred 12', 3: 'events occurred 12', 4: 'events occurred'}, 'score': {0: 0.7243, 1: 0.6976, 2: 0.6883, 3: 0.6805, 4: 0.6696}}"
102,102,102,0.8830000162124634,32.0,patients treated with Kadcyla and 8.1% of ,MyriadPro-Light,4,-0.25,16777215,4,9,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'patients treated with Kadcyla and 8.1% of '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'patients treated with Kadcyla and 8.1% of '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'patients treated with Kadcyla and 8.1% of '}}",{},{},"  entity_group    value     score
0   Medication  Kadcyla  0.996453
1    Lab_value    8.1 %  0.988283","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'treated kadcyla', 1: 'patients treated kadcyla', 2: 'patients treated'}, 'score': {0: 0.7437, 1: 0.7331, 2: 0.7012}}"
103,103,103,0.8830000162124634,32.0,patients treated with trastuzumab,MyriadPro-Light,4,-0.25,16777215,4,9,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'patients treated with trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'patients treated with trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'patients treated with trastuzumab'}}",{},{},"  entity_group                value     score
0   Medication  treated trastuzumab  0.999843
1   Medication          trastuzumab  0.958853","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'patients treated trastuzumab', 1: 'treated trastuzumab', 2: 'patients treated'}, 'score': {0: 0.798, 1: 0.7871, 2: 0.7455}}"
104,104,104,0.8830000162124634,32.0,There was one grade 5  ,MyriadPro-Light,4,-0.25,16777215,4,10,0,{},{},{},{},{},"  entity_group    value     score
0    Lab_value      one  0.998139
1    Lab_value  grade 5  0.998042",[],"{'keyword': {}, 'score': {}}"
105,105,105,0.8830000162124634,32.0,adverse event in a patient  ,MyriadPro-Light,4,-0.25,16777215,4,10,1,"{'concept_id': {0: 'C1578481'}, 'canonical_name': {0: 'Mail Claim Party - Patient'}, 'aliases': {0: ['Patient']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'patient'}, 'text': {0: 'adverse event in a patient  '}}","{'concept_id': {0: 'C4277550'}, 'canonical_name': {0: 'Patient Portals'}, 'aliases': {0: ['Patient Internet Portals', 'Web Portals, Patient', 'Web Portal, Patient', 'Patient Internet Portal', 'Portals, Patient Web', 'Portal, Patient Web', 'Portal, Patient Internet', 'Patient Web Portals', 'Internet Portal, Patient', 'Internet Portals, Patient', 'Patient Portal', 'Patient Web Portal', 'Portals, Patient Internet', 'Portal, Patient']}, 'types': {0: ['T170']}, 'definition': {0: 'A secure online website that provides patients convenient 24-hour access to personal health information via an Internet connection.'}, 'entity': {0: 'patient'}, 'text': {0: 'adverse event in a patient  '}}",{},{},{},"   entity_group          value     score
0  Sign_symptom  adverse event  0.998107",[],"{'keyword': {0: 'adverse event', 1: 'adverse event patient', 2: 'event patient'}, 'score': {0: 0.942, 1: 0.8598, 2: 0.7284}}"
106,106,106,0.8830000162124634,32.0,treated with Kadcyla*,MyriadPro-Light,4,-0.25,16777215,4,10,2,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla*'}, 'text': {0: 'treated with Kadcyla*'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla*'}, 'text': {0: 'treated with Kadcyla*'}}",{},{},{},"           entity_group    value     score
0           Coreference  Kadcyla  0.934317
1  Detailed_description        *  0.725161","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'treated kadcyla'}, 'score': {0: 0.8732}}"
107,107,107,0.8830000162124634,19.0,"*One patient with a platelet count of 55,000 mm",MyriadPro-Light,4,-0.25,3355443,4,13,0,"{'concept_id': {0: 'C5201036'}, 'canonical_name': {0: 'Low Platelet Count'}, 'aliases': {0: ['low platelet', 'low count platelet', 'low platelets', 'platelet count low', 'Low Platelet Count', 'low platelet count', 'platelet low', 'platelets low', 'Low platelet count']}, 'types': {0: ['T034']}, 'definition': {0: 'A lower than average level of platelets in a sample.'}, 'entity': {0: 'platelet count'}, 'text': {0: '*One patient with a platelet count of 55,000 mm'}}","{'concept_id': {0: 'C0005821'}, 'canonical_name': {0: 'Platelet'}, 'aliases': {0: ['Platelets', 'Platelets, Blood', 'Thrombocyte', 'Thrombocytes', 'Blood Platelet', 'Platelet, Blood', 'Blood Platelets']}, 'types': {0: ['T025']}, 'definition': {0: 'Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.'}, 'entity': {0: 'platelet count'}, 'text': {0: '*One patient with a platelet count of 55,000 mm'}}",{},{},"{'concept_id': {0: 'C0857460'}, 'canonical_name': {0: 'Increased platelet count'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'A higher than average level of platelets in a sample.'}, 'entity': {0: 'platelet count'}, 'text': {0: '*One patient with a platelet count of 55,000 mm'}}","           entity_group           value     score
0  Diagnostic_procedure  platelet count  0.999791
1             Lab_value       55,000 mm  0.999824",[],"{'keyword': {0: 'count 55 000', 1: 'patient platelet', 2: 'count 55', 3: 'platelet count', 4: '000 mm'}, 'score': {0: 0.6874, 1: 0.6818, 2: 0.6782, 3: 0.616, 4: 0.6147}}"
108,108,108,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,4,14,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
109,109,109,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,4,14,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
110,110,110,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,4,14,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
111,111,111,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,4,14,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
112,112,112,0.9169999957084656,98.0,When a different direction ,ConduitITC-Bold,20,-0.2349999994039535,8194925,5,1,0,"{'concept_id': {0: 'C1550715'}, 'canonical_name': {0: 'direction - AddressPartType'}, 'aliases': {0: ['direction']}, 'types': {0: ['T078']}, 'definition': {0: '<p>Direction (e.g., N, S, W, E)</p>'}, 'entity': {0: 'direction'}, 'text': {0: 'When a different direction '}}","{'concept_id': {0: 'C0700158'}, 'canonical_name': {0: 'Direction'}, 'aliases': {0: ['Direction compound']}, 'types': {0: ['T122']}, 'definition': {0: None}, 'entity': {0: 'direction'}, 'text': {0: 'When a different direction '}}",{},{},{},"  entity_group                value     score
0    Lab_value                    a  0.640453
1    Lab_value  different direction  0.997081",[],"{'keyword': {0: 'different direction'}, 'score': {0: 0.8296}}"
113,113,113,0.9169999957084656,98.0,"is vital, give them Kadcyla",ConduitITC-Bold,20,-0.2349999994039535,8194925,5,1,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'is\xa0vital, give them Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'is\xa0vital, give them Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'is\xa0vital, give them Kadcyla'}}",{},{},"           entity_group    value     score
0           Coreference     them  0.623846
1  Diagnostic_procedure  Kadcyla  0.918343","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'vital kadcyla'}, 'score': {0: 0.8823}}"
114,114,114,0.8830000162124634,32.0, ,MyriadPro-Light,4,-0.25,16162586,5,2,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
115,115,115,0.8830000162124634,32.0,trastuzumab-based neoadjuvant therapy:,MyriadPro-Light,4,-0.25,3355443,5,2,1,{},"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'trastuzumab-based neoadjuvant therapy'}, 'text': {0: 'trastuzumab-based neoadjuvant therapy:'}}",{},{},{},"            entity_group              value     score
0             Medication  trastuzumab-based  0.999859
1  Therapeutic_procedure        neoadjuvant  0.975939","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab based neoadjuvant', 1: 'based neoadjuvant therapy', 2: 'neoadjuvant therapy', 3: 'trastuzumab based', 4: 'based neoadjuvant'}, 'score': {0: 0.9472, 1: 0.8995, 2: 0.8847, 3: 0.8794, 4: 0.8683}}"
116,116,116,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,5,3,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
117,117,117,0.8830000162124634,32.0,reduction; hazard ratio 0.50; 95% Cl 0.39–0.64; p<0.001),MyriadPro-Light,4,-0.25,3355443,5,3,1,"{'concept_id': {0: 'C0475212'}, 'canonical_name': {0: 'centiliter'}, 'aliases': {0: ['Centiliter (qualifier value)', 'centiliter (cL)', 'Centiliter', 'centilitre', 'cL', 'cl']}, 'types': {0: ['T081']}, 'definition': {0: 'The unit of volume equal to one hundredth of a liter or 10 milliliters. One centiliter is equivalent to 0.6102 cubic inch, or 0.338 U.S. fluid ounce.'}, 'entity': {0: 'Cl'}, 'text': {0: 'reduction; hazard ratio 0.50; 95% Cl 0.39–0.64; p<0.001)'}}","{'concept_id': {0: 'C0679771'}, 'canonical_name': {0: 'Harm Reduction'}, 'aliases': {0: ['Minimization, Harm', 'Reduction, Harm', 'Harm Minimization']}, 'types': {0: ['T061']}, 'definition': {0: 'The application of methods designed to reduce the risk of harm associated with certain behaviors without reduction in frequency of those behaviors. The risk-associated behaviors include ongoing and active addictive behaviors.'}, 'entity': {0: 'reduction'}, 'text': {0: 'reduction; hazard ratio 0.50; 95% Cl 0.39–0.64; p<0.001)'}}",{},"{'concept_id': {0: 'C1150758'}, 'canonical_name': {0: '4-coumarate-CoA synthetase activity'}, 'aliases': {0: ['hydroxycinnamoyl CoA synthetase activity', '4-coumarate:CoA ligase activity', '4CL', 'p-hydroxycinnamic acid:CoA ligase activity', '4-coumaroyl-CoA synthetase activity', 'caffeolyl coenzyme A synthetase activity', '4-coumaroyl-CoA synthase activity', 'sinapoyl coenzyme A synthetase activity', 'feruloyl CoA ligase activity', '4-coumarate:coenzyme A ligase activity', 'hydroxycinnamate:CoA ligase activity', 'p-coumaryl coenzyme A synthetase activity', 'feruloyl coenzyme A synthetase activity', 'p-coumaryl-CoA ligase activity', '4-coumarate-CoA ligase activity', 'p-coumaryl-CoA synthetase activity', '4-coumaryl-CoA synthetase activity', '4-coumarate:CoA ligase (AMP-forming)', 'p-hydroxycinnamoyl coenzyme A synthetase activity', 'p-coumaroyl CoA ligase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + 4-coumarate + CoA = AMP + diphosphate + 4-coumaroyl-CoA. [EC:6.2.1.12]'}, 'entity': {0: 'Cl'}, 'text': {0: 'reduction; hazard ratio 0.50; 95% Cl 0.39–0.64; p<0.001)'}}",{},"           entity_group                 value     score
0  Diagnostic_procedure          hazard ratio  0.999808
1             Lab_value  0.50 0.39–0.64 0.001  0.993856
2             Lab_value                    95  0.999496
3  Diagnostic_procedure                    Cl  0.999522",[],"{'keyword': {0: 'reduction hazard ratio', 1: '95 cl', 2: 'hazard ratio 50', 3: '39 64', 4: 'ratio 50'}, 'score': {0: 0.7375, 1: 0.657, 2: 0.6426, 3: 0.6322, 4: 0.6297}}"
118,118,118,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,5,4,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
119,119,119,0.8830000162124634,32.0,(unstratified hazard ratio 0.60; 95% Cl 0.45–0.79),MyriadPro-Light,4,-0.25,3355443,5,4,1,"{'concept_id': {0: 'C0597342'}, 'canonical_name': {0: 'radiation hazard'}, 'aliases': {0: ['hazards radiation', 'radiation hazard']}, 'types': {0: ['T038']}, 'definition': {0: 'health hazard arising from exposure to ionizing radiation.'}, 'entity': {0: 'hazard ratio'}, 'text': {0: '(unstratified hazard ratio 0.60; 95% Cl 0.45–0.79)'}}",{},{},{},{},"           entity_group                      value     score
0  Diagnostic_procedure               unstratified  0.999883
1  Diagnostic_procedure  unstratified hazard ratio  0.885978
2             Lab_value             0.60 0.45–0.79  0.999824
3             Lab_value                         95  0.999810
4  Diagnostic_procedure                         Cl  0.999488",[],"{'keyword': {0: 'unstratified hazard ratio', 1: 'ratio 60', 2: '60 95 cl', 3: '45 79', 4: 'hazard ratio'}, 'score': {0: 0.8029, 1: 0.7088, 2: 0.6799, 3: 0.5835, 4: 0.4992}}"
120,120,120,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,5,5,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
121,121,121,0.8830000162124634,32.0,but this was consistent with its safety profile from previous studies,MyriadPro-Light,4,-0.25,3355443,5,5,1,"{'concept_id': {0: 'C0036745'}, 'canonical_name': {0: 'Study of serum'}, 'aliases': {0: ['serum studies', 'serology', 'serologies', 'Serology', 'study of serum']}, 'types': {0: ['T091']}, 'definition': {0: 'The study of serum, especially of antigen-antibody reactions in vitro.'}, 'entity': {0: 'studies'}, 'text': {0: 'but this was consistent with its safety profile from previous studies'}}","{'concept_id': {0: 'C0023981'}, 'canonical_name': {0: 'Study, Longitudinal'}, 'aliases': {0: ['Longitudinal Studies', 'Studies, Longitudinal', 'Longitudinal Study']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which variables relating to an individual or group of individuals are assessed over a period of time.'}, 'entity': {0: 'studies'}, 'text': {0: 'but this was consistent with its safety profile from previous studies'}}",{},{},{},"  entity_group    value     score
0    Lab_value  profile  0.429332",[],"{'keyword': {0: 'consistent safety profile', 1: 'consistent safety', 2: 'safety profile', 3: 'safety profile previous', 4: 'previous studies'}, 'score': {0: 0.8271, 1: 0.8026, 2: 0.798, 3: 0.7921, 4: 0.6755}}"
122,122,122,0.8830000162124634,19.0,"CI, confidence interval; eBC, early breast cancer. ",MyriadPro-Light,4,-0.25,3355443,5,6,0,"{'concept_id': {0: 'C0598034'}, 'canonical_name': {0: 'BRCA2 gene'}, 'aliases': {0: ['BRCA2, DNA Repair Associated Gene', 'brca2', 'brca 2 gene', 'FACD', 'breast cancer 2', 'BRCA2 Genes', 'XRCC11', 'BRCA2 DNA repair associated', 'breast cancer 2, early onset', 'BRCC2', 'Fanconi anemia, complementation group D1', 'FANCD1 GENE', 'FAD1', 'BRCA1/BRCA2-containing complex, subunit 2', 'BRCA2 gene', 'FANCD1', 'brca2 gene', 'BRCA2 GENE', 'Breast Cancer 2, Early Onset Gene', 'FANCD', 'Genes, BRCA2', 'BRCA2', 'BRCA2 Gene', 'BRCA2 DNA REPAIR-ASSOCIATED PROTEIN', 'FAD', 'brca2 genes', 'Gene, BRCA2']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'CI, confidence interval; eBC, early breast cancer. '}}","{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'CI, confidence interval; eBC, early breast cancer. '}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'CI, confidence interval; eBC, early breast cancer. '}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'ebc early breast', 1: 'breast cancer', 2: 'ebc early', 3: 'interval ebc', 4: 'ci confidence interval'}, 'score': {0: 0.8357, 1: 0.7051, 2: 0.6649, 3: 0.6073, 4: 0.3895}}"
123,123,123,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,5,7,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
124,124,124,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,5,7,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
125,125,125,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,5,7,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
126,126,126,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,5,7,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
127,127,127,0.9169999957084656,98.0,Consider the whole HER2-positive eBC treatment ,ConduitITC-Bold,20,-0.2349999994039535,8194925,6,1,0,"{'concept_id': {0: 'C1960398'}, 'canonical_name': {0: 'HER2-positive carcinoma of breast'}, 'aliases': {0: ['HER2+ breast cancer', 'HER2 Overexpressing Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast (disorder)', 'HER2-Positive Breast Carcinoma', 'HER2 Overexpressing Subtype of Breast Carcinoma', 'HER2-positive breast cancer', 'HER2/neu-positive breast cancer', 'ERBB2 Overexpressing Subtype of Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast', 'HER2 Positive Breast Carcinoma', 'HER2 Positive Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).'}, 'entity': {0: 'HER2-positive'}, 'text': {0: 'Consider the whole HER2-positive eBC treatment '}}","{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Treatments'}, 'aliases': {0: ['Therapy', 'Treatment', 'Therapeutics', 'Therapeutic', 'Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'eBC treatment'}, 'text': {0: 'Consider the whole HER2-positive eBC treatment '}}",{},{},{},"            entity_group                                           value  \
0              Lab_value                                   HER2-positive   
1  Therapeutic_procedure  Consider the whole HER2-positive eBC treatment   
2  Therapeutic_procedure                                       treatment   

      score  
0  0.803031  
1  0.537932  
2  0.767745  ",[],"{'keyword': {0: 'ebc treatment', 1: 'her2 positive ebc', 2: 'consider her2', 3: 'positive ebc treatment', 4: 'her2 positive'}, 'score': {0: 0.8257, 1: 0.8138, 2: 0.792, 3: 0.768, 4: 0.6419}}"
128,128,128,0.9169999957084656,98.0,journey today to optimise your patients’ outcomes,ConduitITC-Bold,20,-0.2349999994039535,8194925,6,1,1,"{'concept_id': {0: 'C0086749'}, 'canonical_name': {0: 'Outcome Measures'}, 'aliases': {0: ['measure outcomes', 'measures outcome', 'Measures, Outcome', 'outcome measures', 'outcome measure', 'Outcome Measure', 'Outcome Measures', 'Measure, Outcome', 'measures outcomes']}, 'types': {0: ['T081']}, 'definition': {0: '<p>**Description:**Operational activities conducted for the purposes of assessing the results of an activity, product, or service</p>'}, 'entity': {0: 'outcomes'}, 'text': {0: 'journey today to optimise your patients’ outcomes'}}","{'concept_id': {0: 'C0032972'}, 'canonical_name': {0: 'Pregnancy Outcome'}, 'aliases': {0: ['Pregnancy Outcomes', 'Outcome, Pregnancy', 'Outcomes, Pregnancy']}, 'types': {0: ['T033']}, 'definition': {0: 'Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO.'}, 'entity': {0: 'outcomes'}, 'text': {0: 'journey today to optimise your patients’ outcomes'}}",{},{},{},"           entity_group          value     score
0  Detailed_description  journey today  0.940791
1  Diagnostic_procedure       outcomes  0.483345",[],"{'keyword': {0: 'journey today', 1: 'today optimise patients', 2: 'patients outcomes', 3: 'today optimise', 4: 'optimise patients outcomes'}, 'score': {0: 0.9195, 1: 0.8752, 2: 0.8457, 3: 0.8444, 4: 0.8423}}"
129,129,129,0.9520000219345092,24.0,Disease characteristics,MyriadPro-Regular,4,-0.25,0,6,2,0,"{'concept_id': {0: 'C1705348'}, 'canonical_name': {0: 'Disease Characteristics Domain'}, 'aliases': {0: ['Disease Characteristics Domain']}, 'types': {0: ['T077']}, 'definition': {0: 'A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to disease characteristics.'}, 'entity': {0: 'Disease characteristics'}, 'text': {0: 'Disease characteristics'}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'Disease characteristics'}, 'text': {0: 'Disease characteristics'}}",{},{},{},"           entity_group                    value     score
0  Diagnostic_procedure  Disease characteristics  0.896728",[],"{'keyword': {0: 'disease characteristics'}, 'score': {0: 1.0}}"
130,130,130,0.8830000162124634,24.0,Tumour stage ≥2 ,MyriadPro-Light,4,-0.25,0,6,3,0,"{'concept_id': {0: 'C0475455'}, 'canonical_name': {0: 'T - Tumor stage'}, 'aliases': {0: ['T stage', 'T Category', 'T Classification', 'T - Tumour stage', 'T - Tumor stage', 'T - Tumor stage (attribute)', 'Tumour stages', 'Tumor stages', 'T - Tumor stages', 'tumor stages', 'T category (observable entity)', 'T - Tumour stages', 'T category']}, 'types': {0: ['T170']}, 'definition': {0: 'One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).'}, 'entity': {0: 'Tumour stage'}, 'text': {0: 'Tumour stage ≥2 '}}",{},{},{},"{'concept_id': {0: 'C0027651'}, 'canonical_name': {0: 'Oncology'}, 'aliases': {0: ['Oncological abnormality', 'Neoplasia', 'Tumour', 'Neoplasm', 'Tumor']}, 'types': {0: ['T191']}, 'definition': {0: 'New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.'}, 'entity': {0: 'Tumour stage'}, 'text': {0: 'Tumour stage ≥2 '}}","           entity_group   value     score
0          Sign_symptom  Tumour  0.943413
1  Diagnostic_procedure   stage  0.978196
2             Lab_value      ≥2  0.999662",[],"{'keyword': {0: 'tumour stage'}, 'score': {0: 0.7765}}"
131,131,131,0.9520000219345092,24.0,Neoadjuvant,MyriadPro-Regular,4,-0.25,0,6,4,0,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'Neoadjuvant'}, 'text': {0: 'Neoadjuvant'}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'Neoadjuvant'}, 'text': {0: 'Neoadjuvant'}}",{},{},{},"           entity_group        value     score
0  Detailed_description  Neoadjuvant  0.956138
1          Sign_symptom  Neoadjuvant  0.386592
2               History  Neoadjuvant  0.344678",[],"{'keyword': {}, 'score': {}}"
132,132,132,0.8830000162124634,24.0,PHESGO,MyriadPro-Light,4,-0.25,0,6,4,1,"{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: ['Phesgo']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: 'PHESGO'}}",{},"{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: 'PHESGO'}}",{},{},"   entity_group   value     score
0  Sign_symptom  PHESGO  0.506898
1   Coreference  PHESGO  0.299037","[('PHESGO', 'DRUG')]","{'keyword': {}, 'score': {}}"
133,133,133,0.8830000162124634,24.0, (pertuzumab/trastuzumab) SC plus chemotherapy (3–6 cycles),MyriadPro-Light,4,-0.25,0,6,4,2,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: ' (pertuzumab/trastuzumab) SC plus chemotherapy (3–6 cycles)'}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: ' (pertuzumab/trastuzumab) SC plus chemotherapy (3–6 cycles)'}}",{},{},{},"       entity_group                   value     score
0        Medication  pertuzumab/trastuzumab  0.999829
1  Disease_disorder                      SC  0.863019
2        Medication            chemotherapy  0.999876
3         Lab_value                     3–6  0.464376","[('trastuzumab', 'DRUG'), ('SC', 'ROUTE'), ('chemotherapy', 'DRUG'), ('3–6 cycles', 'DURATION')]","{'keyword': {0: 'plus chemotherapy cycles', 1: 'trastuzumab sc plus', 2: 'chemotherapy cycles', 3: 'trastuzumab sc', 4: 'pertuzumab trastuzumab'}, 'score': {0: 0.8387, 1: 0.8298, 2: 0.712, 3: 0.6578, 4: 0.3754}}"
134,134,134,0.9169999957084656,53.0,Kadcyla allows you to ,ConduitITC-Bold,20,-0.2349999994039535,16777215,6,5,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla allows you to '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla allows you to '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla allows you to '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.475378
1   Medication  Kadcyla  0.717254","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla allows'}, 'score': {0: 0.9278}}"
135,135,135,0.9169999957084656,53.0,adapt adjuvant therapy ,ConduitITC-Bold,20,-0.2349999994039535,16777215,6,5,1,"{'concept_id': {0: 'C0085533'}, 'canonical_name': {0: 'Chemotherapy, Adjuvant'}, 'aliases': {0: ['Adjuvant Drug Therapy', 'Adjuvant Chemotherapy', 'adjuvant chemotherapy', 'Drug Therapy, Adjuvant']}, 'types': {0: ['T061']}, 'definition': {0: 'Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.'}, 'entity': {0: 'adjuvant therapy'}, 'text': {0: 'adapt adjuvant therapy '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'adjuvant therapy'}, 'text': {0: 'adapt adjuvant therapy '}}",{},{},{},"            entity_group             value     score
0   Detailed_description             adapt  0.999687
1  Therapeutic_procedure  adjuvant therapy  0.969879",[],"{'keyword': {0: 'adapt adjuvant therapy', 1: 'adapt adjuvant', 2: 'adjuvant therapy'}, 'score': {0: 1.0, 1: 0.9287, 2: 0.8928}}"
136,136,136,0.9169999957084656,53.0,based on patients’ ,ConduitITC-Bold,20,-0.2349999994039535,16777215,6,5,2,"{'concept_id': {0: 'C1705908'}, 'canonical_name': {0: 'Veterinary Patient'}, 'aliases': {0: ['Veterinary Patient', 'Patient']}, 'types': {0: ['T001']}, 'definition': {0: 'A non-human animal that is a subject in a study.'}, 'entity': {0: 'patients’'}, 'text': {0: 'based on patients’ '}}","{'concept_id': {0: 'C0025360'}, 'canonical_name': {0: 'Mentally Ill Persons'}, 'aliases': {0: ['Mental Patients', 'Person, Mentally Ill', 'Ill, Mentally', 'Mentally Ill Person', 'Persons, Mentally Ill', 'Mentally Ill']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.'}, 'entity': {0: 'patients’'}, 'text': {0: 'based on patients’ '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'based patients'}, 'score': {0: 0.8565}}"
137,137,137,0.9169999957084656,53.0,neoadjuvant response,ConduitITC-Bold,20,-0.2349999994039535,16777215,6,5,3,"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Neoadjuvant Therapy'}, 'aliases': {0: ['Preoperative Therapy', 'Therapy, Neoadjuvant', 'neoadjuvant treatment', 'Neoadjuvant Treatment', 'Neoadjuvant Treatments', 'Neoadjuvant Therapies', 'Neoadjuvant', 'Induction Therapy', 'Neoadjuvant Therapy', 'induction therapy', 'Treatment, Neoadjuvant', 'neoadjuvant therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant response'}, 'text': {0: 'neoadjuvant response'}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant response'}, 'text': {0: 'neoadjuvant response'}}",{},{},{},"   entity_group                 value     score
0  Sign_symptom           neoadjuvant  0.998864
1  Sign_symptom  neoadjuvant response  0.993135",[],"{'keyword': {0: 'neoadjuvant response'}, 'score': {0: 1.0}}"
138,138,138,0.9520000219345092,24.0,Surgery,MyriadPro-Regular,4,-0.25,0,6,6,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  Surgery  0.998798",[],"{'keyword': {}, 'score': {}}"
139,139,139,0.8830000162124634,24.0,Clinically,MyriadPro-Light,4,-0.25,0,6,8,0,"{'concept_id': {0: 'C0205210'}, 'canonical_name': {0: 'Clinical'}, 'aliases': {0: ['Clinical (qualifier value)', 'clinical', 'Clinical']}, 'types': {0: ['T080']}, 'definition': {0: 'Relating to the examination and treatment of patients dependent on direct observation. The term may also refer to the institution (clinic) providing this activity.'}, 'entity': {0: 'Clinically'}, 'text': {0: 'Clinically'}}",{},{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  Clinically  0.966238",[],"{'keyword': {}, 'score': {}}"
140,140,140,0.8830000162124634,24.0,Clinically,MyriadPro-Light,4,-0.25,0,6,9,0,"{'concept_id': {0: 'C0205210'}, 'canonical_name': {0: 'Clinical'}, 'aliases': {0: ['Clinical (qualifier value)', 'clinical', 'Clinical']}, 'types': {0: ['T080']}, 'definition': {0: 'Relating to the examination and treatment of patients dependent on direct observation. The term may also refer to the institution (clinic) providing this activity.'}, 'entity': {0: 'Clinically'}, 'text': {0: 'Clinically'}}",{},{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  Clinically  0.966238",[],"{'keyword': {}, 'score': {}}"
141,141,141,0.9520000219345092,26.0,or,MyriadPro-Regular,4,-0.25,0,6,10,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
142,142,142,0.9520000219345092,22.0,and,MyriadPro-Regular,4,-0.25,0,6,10,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
143,143,143,0.9520000219345092,24.0,No evidence of nodal metastases at surgery,MyriadPro-Regular,4,-0.25,0,6,11,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'surgery'}, 'text': {0: 'No evidence of nodal metastases at surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'surgery'}, 'text': {0: 'No evidence of nodal metastases at surgery'}}",{},{},{},"           entity_group       value     score
0  Biological_structure       nodal  0.999686
1      Disease_disorder  metastases  0.975436
2           Coreference     surgery  0.547385",[],"{'keyword': {0: 'evidence nodal', 1: 'evidence nodal metastases', 2: 'nodal metastases', 3: 'nodal metastases surgery', 4: 'metastases surgery'}, 'score': {0: 0.7023, 1: 0.6408, 2: 0.6274, 3: 0.5605, 4: 0.5356}}"
144,144,144,0.9520000219345092,24.0,Evidence of nodal metastases at surgery,MyriadPro-Regular,4,-0.25,0,6,12,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'surgery'}, 'text': {0: 'Evidence of nodal metastases at surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'surgery'}, 'text': {0: 'Evidence of nodal metastases at surgery'}}",{},{},{},"           entity_group       value     score
0  Biological_structure       nodal  0.999766
1      Disease_disorder  metastases  0.927845
2           Coreference     surgery  0.592903",[],"{'keyword': {0: 'evidence nodal metastases', 1: 'evidence nodal', 2: 'nodal metastases', 3: 'nodal metastases surgery', 4: 'metastases surgery'}, 'score': {0: 0.9448, 1: 0.7767, 2: 0.6829, 3: 0.4733, 4: 0.4429}}"
145,145,145,0.8830000162124634,22.894540786743164,pCR in breast and axilla,MyriadPro-Light,4,-0.25,0,6,13,0,"{'concept_id': {0: 'C0238729'}, 'canonical_name': {0: 'Mass of axilla'}, 'aliases': {0: ['Lump of axilla', 'Axillary Mass', 'Mass of axilla (finding)', 'axillary lumps', 'axillary lump', 'axilla mass', 'AXILLARY MASS', 'axilla lump', 'mass axilla', 'axillary mass']}, 'types': {0: ['T033']}, 'definition': {0: 'An abnormal growth in the axilla.'}, 'entity': {0: 'axilla'}, 'text': {0: 'pCR in breast and axilla'}}","{'concept_id': {0: 'C0024947'}, 'canonical_name': {0: 'Bone, Maxillary'}, 'aliases': {0: ['Bones, Maxillary', 'Maxillary Bones', 'Maxillae', 'Maxillas', 'Maxilla', 'Maxillary Bone']}, 'types': {0: ['T023']}, 'definition': {0: 'One of a pair of irregularly shaped bones that form the upper jaw. A maxillary bone provides tooth sockets for the superior teeth, forms part of the ORBIT, and contains the MAXILLARY SINUS.'}, 'entity': {0: 'axilla'}, 'text': {0: 'pCR in breast and axilla'}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast'}, 'text': {0: 'pCR in breast and axilla'}}","           entity_group   value     score
0  Diagnostic_procedure     pCR  0.999817
1  Biological_structure  breast  0.999936
2  Biological_structure  axilla  0.999896",[],"{'keyword': {0: 'pcr breast', 1: 'pcr breast axilla', 2: 'breast axilla'}, 'score': {0: 0.8547, 1: 0.8147, 2: 0.698}}"
146,146,146,0.8830000162124634,22.894540786743164,Residual invasive disease in breast ,MyriadPro-Light,4,-0.25,0,6,13,1,"{'concept_id': {0: 'C0038293'}, 'canonical_name': {0: 'Sternum'}, 'aliases': {0: ['Bone structure of sternum (body structure)', 'sternums', 'Sternum', 'Sternum/Sternal', 'Breast bone', 'Chest>Sternum', 'Sternal', 'breast bone', 'sternum', 'Sternum, NOS', 'Bone structure of sternum']}, 'types': {0: ['T023']}, 'definition': {0: 'A long, narrow, and flat bone commonly known as BREASTBONE occurring in the midsection of the anterior thoracic segment or chest region, which stabilizes the rib cage and serves as the point of origin for several muscles that move the arms, head, and neck.'}, 'entity': {0: 'breast'}, 'text': {0: 'Residual invasive disease in breast '}}","{'concept_id': {0: 'C0024902'}, 'canonical_name': {0: 'Breast Pain'}, 'aliases': {0: ['Mastodynias', 'Mammalgias', 'Mastodynia', 'Mastalgias', 'Mammalgia', 'Pain, Breast', 'Mastalgia', 'Breast Pains', 'Pains, Breast']}, 'types': {0: ['T184']}, 'definition': {0: 'Painful sensation in the breast region.'}, 'entity': {0: 'breast'}, 'text': {0: 'Residual invasive disease in breast '}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast'}, 'text': {0: 'Residual invasive disease in breast '}}","           entity_group     value     score
0  Detailed_description  Residual  0.999941
1  Detailed_description  invasive  0.494565
2  Biological_structure    breast  0.999839",[],"{'keyword': {0: 'residual invasive disease', 1: 'residual invasive', 2: 'invasive disease breast', 3: 'disease breast', 4: 'invasive disease'}, 'score': {0: 0.9347, 1: 0.904, 2: 0.8579, 3: 0.8441, 4: 0.8014}}"
147,147,147,0.8830000162124634,22.894540786743164,(or axilla),MyriadPro-Light,4,-0.25,0,6,13,2,"{'concept_id': {0: 'C0238729'}, 'canonical_name': {0: 'Mass of axilla'}, 'aliases': {0: ['Lump of axilla', 'Axillary Mass', 'Mass of axilla (finding)', 'axillary lumps', 'axillary lump', 'axilla mass', 'AXILLARY MASS', 'axilla lump', 'mass axilla', 'axillary mass']}, 'types': {0: ['T033']}, 'definition': {0: 'An abnormal growth in the axilla.'}, 'entity': {0: 'axilla'}, 'text': {0: '(or axilla)'}}","{'concept_id': {0: 'C0024947'}, 'canonical_name': {0: 'Bone, Maxillary'}, 'aliases': {0: ['Bones, Maxillary', 'Maxillary Bones', 'Maxillae', 'Maxillas', 'Maxilla', 'Maxillary Bone']}, 'types': {0: ['T023']}, 'definition': {0: 'One of a pair of irregularly shaped bones that form the upper jaw. A maxillary bone provides tooth sockets for the superior teeth, forms part of the ORBIT, and contains the MAXILLARY SINUS.'}, 'entity': {0: 'axilla'}, 'text': {0: '(or axilla)'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
148,148,148,0.8830000162124634,24.0,pCR in breast,MyriadPro-Light,4,-0.25,0,6,13,3,"{'concept_id': {0: 'C4050242'}, 'canonical_name': {0: 'Pathologic Complete Response'}, 'aliases': {0: ['Pathologic Complete Response', 'Pathological Complete Remission', 'pCR']}, 'types': {0: ['T033']}, 'definition': {0: 'The disappearance of all signs of cancer, supported by pathological examination.'}, 'entity': {0: 'pCR'}, 'text': {0: 'pCR in breast'}}","{'concept_id': {0: 'C1709846'}, 'canonical_name': {0: 'Real-Time Polymerase Chain Reaction'}, 'aliases': {0: ['Real Time PCR', 'Real-Time PCRs', 'PCRs, Real-Time', 'PCR, Real-Time', 'Real Time Polymerase Chain Reaction', 'Real-Time PCR']}, 'types': {0: ['T063']}, 'definition': {0: 'An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.'}, 'entity': {0: 'pCR'}, 'text': {0: 'pCR in breast'}}",{},{},{},"           entity_group   value     score
0  Diagnostic_procedure     pCR  0.999828
1  Biological_structure  breast  0.999899",[],"{'keyword': {0: 'pcr breast'}, 'score': {0: 0.906}}"
149,149,149,0.9520000219345092,19.0,Other treatment options are available. ,MyriadPro-Regular,4,-0.25,3355443,6,14,0,"{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Therapeutic procedure'}, 'aliases': {0: ['TX', 'therapies', 'treatments', 'Therapeutic', 'Therapeutic procedure', 'Therapeutic procedure, NOS', 'methods treatment', 'Therapies', 'therapeutic method', 'Therapy', 'Therapeutics', 'treatment', 'Treatment', 'Therapeutic Interventions', 'Therapy (regime/therapy)', 'Treatments', 'Therapeutic Technique', 'Therapeutic Procedure', 'Therapeutic procedure (procedure)', 'therapy', 'therapeutic procedure', 'Therapy, NOS', 'method treatment', 'treatment method', 'Therapeutic Method', 'therapeutics']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'treatment options'}, 'text': {0: 'Other treatment options are available. '}}","{'concept_id': {0: 'C0871549'}, 'canonical_name': {0: 'Withholding Treatment'}, 'aliases': {0: ['Treatment, Withholding', 'Treatment Cessations', 'Withholding Treatments', 'Cessation of Treatment', 'Treatment Cessation', 'Treatments, Withholding']}, 'types': {0: ['T058']}, 'definition': {0: ""Withholding or withdrawal of a particular treatment or treatments, often (but not necessarily) life-prolonging treatment, from a patient or from a research subject as part of a research protocol. The concept is differentiated from REFUSAL TO TREAT, where the emphasis is on the health professional's or health facility's refusal to treat a patient or group of patients when the patient or the patient's representative requests treatment. Withholding of life-prolonging treatment is usually indexed only with EUTHANASIA, PASSIVE, unless the distinction between withholding and withdrawing treatment, or the issue of withholding palliative rather than curative treatment, is discussed.""}, 'entity': {0: 'treatment options'}, 'text': {0: 'Other treatment options are available. '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'options available', 1: 'treatment options', 2: 'treatment options available'}, 'score': {0: 0.8093, 1: 0.8063, 2: 0.805}}"
150,150,150,0.8830000162124634,19.0,"*In the adjuvant setting, PHESGO should be administered for a total of one year (up ",MyriadPro-Light,4,-0.25,3355443,6,14,1,"{'concept_id': {0: 'C1561544'}, 'canonical_name': {0: 'Precision - year'}, 'aliases': {0: ['year']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'year'}, 'text': {0: '*In the adjuvant setting, PHESGO should be administered for a total of one year (up '}}",{},"{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: '*In the adjuvant setting, PHESGO should be administered for a total of one year (up '}}",{},{},"  entity_group              value     score
0   Medication             PHESGO  0.990105
1     Duration  total of one year  0.899023
2    Lab_value                 up  0.999710","[('PHESGO', 'DRUG')]","{'keyword': {0: 'phesgo administered', 1: 'setting phesgo', 2: 'total year', 3: 'administered total', 4: 'adjuvant setting'}, 'score': {0: 0.5142, 1: 0.4975, 2: 0.4786, 3: 0.4675, 4: 0.4304}}"
151,151,151,0.8830000162124634,19.0,"to 18 cycles or until disease recurrence, or unmanageable toxicity, whichever occurs ",MyriadPro-Light,4,-0.25,3355443,6,14,2,"{'concept_id': {0: 'C0242890'}, 'canonical_name': {0: 'Toxicity Tests'}, 'aliases': {0: ['toxicity tests', 'testing toxicity', 'Test, Toxicity', 'Toxicity testing', 'Toxicity Testing', 'toxicity test', 'Toxicity Test', 'Tests, Toxicity']}, 'types': {0: ['T060']}, 'definition': {0: 'An array of tests used to determine the toxicity of a substance to living systems. These include tests on clinical drugs, foods, and environmental pollutants.'}, 'entity': {0: 'toxicity'}, 'text': {0: 'to 18 cycles or until disease recurrence, or unmanageable toxicity, whichever occurs '}}","{'concept_id': {0: 'C0013221'}, 'canonical_name': {0: 'Toxicity, Drug'}, 'aliases': {0: ['Drug Toxicities', 'Drug Toxicity', 'Toxicities, Drug']}, 'types': {0: ['T037']}, 'definition': {0: 'An adverse effect of a drug used therapeutically or diagnostically.'}, 'entity': {0: 'toxicity'}, 'text': {0: 'to 18 cycles or until disease recurrence, or unmanageable toxicity, whichever occurs '}}",{},{},{},"           entity_group             value     score
0  Quantitative_concept         18 cycles  0.442979
1  Detailed_description  whichever occurs  0.794513","[('18 cycles', 'DURATION')]","{'keyword': {0: 'unmanageable toxicity whichever', 1: '18 cycles', 2: 'cycles disease', 3: 'whichever occurs', 4: 'toxicity whichever occurs'}, 'score': {0: 0.8195, 1: 0.7131, 2: 0.7023, 3: 0.6882, 4: 0.6297}}"
152,152,152,0.8830000162124634,19.0,"first), as part of a complete regimen for early breast cancer and regardless of the ",MyriadPro-Light,4,-0.25,3355443,6,14,3,"{'concept_id': {0: 'C0598034'}, 'canonical_name': {0: 'BRCA2 gene'}, 'aliases': {0: ['BRCA2, DNA Repair Associated Gene', 'brca2', 'brca 2 gene', 'FACD', 'breast cancer 2', 'BRCA2 Genes', 'XRCC11', 'BRCA2 DNA repair associated', 'breast cancer 2, early onset', 'BRCC2', 'Fanconi anemia, complementation group D1', 'FANCD1 GENE', 'FAD1', 'BRCA1/BRCA2-containing complex, subunit 2', 'BRCA2 gene', 'FANCD1', 'brca2 gene', 'BRCA2 GENE', 'Breast Cancer 2, Early Onset Gene', 'FANCD', 'Genes, BRCA2', 'BRCA2', 'BRCA2 Gene', 'BRCA2 DNA REPAIR-ASSOCIATED PROTEIN', 'FAD', 'brca2 genes', 'Gene, BRCA2']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'first), as part of a complete regimen for early breast cancer and regardless of the '}}","{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'first), as part of a complete regimen for early breast cancer and regardless of the '}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'first), as part of a complete regimen for early breast cancer and regardless of the '}}","           entity_group   value     score
0  Biological_structure  breast  0.991814",[],"{'keyword': {0: 'cancer regardless', 1: 'complete regimen', 2: 'complete regimen early', 3: 'early breast', 4: 'breast cancer'}, 'score': {0: 0.5375, 1: 0.4612, 2: 0.4107, 3: 0.2574, 4: 0.2116}}"
153,153,153,0.8830000162124634,19.0,timing of surgery. Treatment should include standard anthracycline- and/or taxane-,MyriadPro-Light,4,-0.25,3355443,6,14,4,"{'concept_id': {0: 'C2828392'}, 'canonical_name': {0: 'Standard (document)'}, 'aliases': {0: ['Standard']}, 'types': {0: ['T170']}, 'definition': {0: 'A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.'}, 'entity': {0: 'standard'}, 'text': {0: 'timing of surgery. Treatment should include standard anthracycline- and/or taxane-'}}","{'concept_id': {0: 'C0038137'}, 'canonical_name': {0: 'standards'}, 'aliases': {0: []}, 'types': {0: ['T169']}, 'definition': {0: 'Used with facilities, personnel, and program headings for the development, testing, and application of standards of adequacy or acceptable performance and with chemicals and drugs for standards of identification, quality, and potency. It includes health or safety standards in industries and occupations.'}, 'entity': {0: 'standard'}, 'text': {0: 'timing of surgery. Treatment should include standard anthracycline- and/or taxane-'}}",{},{},{},"           entity_group                   value     score
0  Detailed_description                 taxane-  0.913338
1  Detailed_description  anthracycline- taxane-  0.480963","[('anthracycline-', 'DRUG')]","{'keyword': {0: 'treatment include standard', 1: 'include standard anthracycline', 2: 'surgery treatment', 3: 'timing surgery', 4: 'standard anthracycline taxane'}, 'score': {0: 0.8611, 1: 0.7927, 2: 0.723, 3: 0.687, 4: 0.5211}}"
154,154,154,0.8830000162124634,19.0,based chemotherapy.,MyriadPro-Light,4,-0.25,3355443,6,14,5,"{'concept_id': {0: 'C0392920'}, 'canonical_name': {0: 'Chemotherapy Regimen'}, 'aliases': {0: ['chemotherapy regimen', 'Antineoplastic chemotherapy regimen', 'chemotherapies', 'Antineoplastic chemotherapy regimen (regime/therapy)', 'chemotherapy regimens', 'neoplasm chemotherapy', 'neoplasm pharmacotherapy', 'chemotherapy', 'chemo', 'Cancer chemotherapy', 'neoplasm/cancer chemotherapy', 'cancer chemotherapy', 'cancer pharmacotherapy', 'neoplasm/cancer pharmacotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'application of the beneficial effects of drugs to control or cure neoplastic growth.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'based chemotherapy.'}}","{'concept_id': {0: 'C1868801'}, 'canonical_name': {0: 'Hyperthermic Intraperitoneal Chemotherapy'}, 'aliases': {0: ['Hot Chemotherapy', 'Chemotherapy, Intraperitoneal Hyperthermic', 'Chemotherapy, Hyperthermic Intraperitoneal', 'Chemotherapy, Hot', 'Intraperitoneal Hyperthermic Chemotherapies', 'Intraperitoneal Chemotherapy, Hyperthermic', 'Hyperthermic Chemotherapy, Intraperitoneal', 'HIPEC', 'Intraperitoneal Hyperthermic Chemotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'based chemotherapy.'}}",{},{},{},"            entity_group         value    score
0  Therapeutic_procedure  chemotherapy  0.66147","[('chemotherapy', 'DRUG')]","{'keyword': {0: 'based chemotherapy'}, 'score': {0: 0.9665}}"
155,155,155,0.9520000219345092,24.0,Adjuvant* ,MyriadPro-Regular,4,-0.25,0,6,15,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'Adjuvant*'}, 'text': {0: 'Adjuvant* '}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'Adjuvant*'}, 'text': {0: 'Adjuvant* '}}",{},{},{},"           entity_group     value     score
0  Diagnostic_procedure  Adjuvant  0.582094
1  Detailed_description         *  0.614326",[],"{'keyword': {}, 'score': {}}"
156,156,156,0.8830000162124634,22.894540786743164,PHESGO SC based regimen,MyriadPro-Light,4,-0.25,0,6,15,1,"{'concept_id': {0: 'C0392970'}, 'canonical_name': {0: 'Doxorubicin/Docetaxel Regimen'}, 'aliases': {0: ['Docetaxel/Doxorubicin', 'Doxorubicin-Docetaxel', 'Doxorubicin/Docetaxel Regimen', 'Docetaxel/Doxorubicin Regimen', 'Adriamycin-Taxotere Regimen', 'AT Regimen', 'Doxorubicin/Docetaxel', 'Adriamycin/Taxotere', 'DOX/TXT', 'docetaxel/doxorubicin', 'Docetaxel-Doxorubicin']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemotherapy regimen consisting of doxorubicin and docetaxel that may be used in the treatment of breast cancer.'}, 'entity': {0: 'regimen'}, 'text': {0: 'PHESGO SC based regimen'}}","{'concept_id': {0: 'C0912478'}, 'canonical_name': {0: 'TIC protocol'}, 'aliases': {0: ['TIC regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A regimen consisting of paclitaxel, ifosfamide, mesna and carboplatin used as salvage therapy for the treatment of advanced-stage testicular cancer; also used for the treatment of unresectable and recurrent squamous cell head and neck cancer.'}, 'entity': {0: 'regimen'}, 'text': {0: 'PHESGO SC based regimen'}}","{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: 'PHESGO SC based regimen'}}",{},{},"            entity_group   value     score
0  Therapeutic_procedure  PHESGO  0.801073","[('PHESGO', 'DRUG'), ('SC', 'ROUTE')]","{'keyword': {0: 'phesgo sc based', 1: 'phesgo sc', 2: 'sc based', 3: 'based regimen', 4: 'sc based regimen'}, 'score': {0: 0.9229, 1: 0.8759, 2: 0.8432, 3: 0.8229, 4: 0.7852}}"
157,157,157,0.9520000219345092,24.0,Adjuvant,MyriadPro-Regular,4,-0.25,0,6,16,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}",{},{},{},"           entity_group     value     score
0  Detailed_description  Adjuvant  0.584447
1               History  Adjuvant  0.588875",[],"{'keyword': {}, 'score': {}}"
158,158,158,0.8830000162124634,22.894540786743164,Kadcyla (14 cycles),MyriadPro-Light,4,-0.25,0,6,16,1,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Kadcyla (14 cycles)'}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Kadcyla (14 cycles)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (14 cycles)'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.741233
1    Lab_value       14  0.586142","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla 14 cycles', 1: '14 cycles', 2: 'kadcyla 14'}, 'score': {0: 0.9513, 1: 0.8869, 2: 0.8491}}"
159,159,159,0.9520000219345092,24.0,Adjuvant,MyriadPro-Regular,4,-0.25,0,6,17,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}",{},{},{},"           entity_group     value     score
0  Detailed_description  Adjuvant  0.584447
1               History  Adjuvant  0.588875",[],"{'keyword': {}, 'score': {}}"
160,160,160,0.8830000162124634,22.894540786743164,Herceptin,MyriadPro-Light,4,-0.25,0,6,17,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Herceptin'}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Herceptin'}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Herceptin'}}",{},{},"           entity_group      value     score
0  Diagnostic_procedure  Herceptin  0.985167","[('Herceptin', 'DRUG')]","{'keyword': {}, 'score': {}}"
161,161,161,0.8830000162124634,22.894540786743164,   (up to 18 cycles),MyriadPro-Light,4,-0.25,0,6,17,2,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: '   (up to 18 cycles)'}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: '   (up to 18 cycles)'}}",{},{},{},"           entity_group value     score
0  Detailed_description    18  0.406117",[],"{'keyword': {0: '18 cycles'}, 'score': {0: 0.8319}}"
162,162,162,0.8830000162124634,11.07699966430664,†,MyriadPro-Light,4,-0.25,3355443,6,18,0,{},{},{},{},{},"           entity_group value     score
0  Detailed_description     †  0.176692",[],"{'keyword': {}, 'score': {}}"
163,163,163,0.8830000162124634,19.0,be node-positive at diagnosis or node-negative at diagnosis and upstaged following ,MyriadPro-Light,4,-0.25,3355443,6,18,1,"{'concept_id': {0: 'C1546899'}, 'canonical_name': {0: 'Diagnosis Classification - Diagnosis'}, 'aliases': {0: ['Diagnosis']}, 'types': {0: ['T185']}, 'definition': {0: None}, 'entity': {0: 'diagnosis'}, 'text': {0: 'be node-positive at diagnosis or node-negative at diagnosis and upstaged following '}}","{'concept_id': {0: 'C2718037'}, 'canonical_name': {0: 'Late Diagnosis'}, 'aliases': {0: ['Diagnosis, Late', 'Late Diagnoses']}, 'types': {0: ['T080']}, 'definition': {0: 'Excessive period of time between onset of disease and identification.'}, 'entity': {0: 'diagnosis'}, 'text': {0: 'be node-positive at diagnosis or node-negative at diagnosis and upstaged following '}}",{},{},"{'concept_id': {0: 'C0001816'}, 'canonical_name': {0: 'Agnosia'}, 'aliases': {0: []}, 'types': {0: ['T048']}, 'definition': {0: 'Loss of the ability to comprehend the meaning or recognize the importance of various forms of stimulation that cannot be attributed to impairment of a primary sensory modality. Tactile agnosia is characterized by an inability to perceive the shape and nature of an object by touch alone, despite unimpaired sensation to light touch, position, and other primary sensory modalities.'}, 'entity': {0: 'diagnosis'}, 'text': {0: 'be node-positive at diagnosis or node-negative at diagnosis and upstaged following '}}","  entity_group                        value     score
0    Lab_value                node-positive  0.820700
1    Lab_value  node-positive node-negative  0.906166
2    Lab_value                node-negative  0.991914",[],"{'keyword': {0: 'node negative diagnosis', 1: 'diagnosis node', 2: 'negative diagnosis', 3: 'diagnosis upstaged following', 4: 'positive diagnosis'}, 'score': {0: 0.833, 1: 0.7297, 2: 0.7216, 3: 0.7118, 4: 0.5131}}"
164,164,164,0.8830000162124634,19.0,surgery.,MyriadPro-Light,4,-0.25,3355443,6,18,2,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'surgery'}, 'text': {0: 'surgery.'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'surgery'}, 'text': {0: 'surgery.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
165,165,165,0.8830000162124634,19.0,"eBC, early breast cancer; pCR, pathological complete response;  ",MyriadPro-Light,4,-0.25,3355443,6,18,3,"{'concept_id': {0: 'C4054467'}, 'canonical_name': {0: 'Morphologic Complete Response'}, 'aliases': {0: ['Morphologic CR']}, 'types': {0: ['T033']}, 'definition': {0: 'The disappearance of all signs of cancer, supported by morphological analysis.'}, 'entity': {0: 'pathological complete response'}, 'text': {0: 'eBC, early breast cancer; pCR, pathological complete response;  '}}","{'concept_id': {0: 'C1709846'}, 'canonical_name': {0: 'Real-Time Polymerase Chain Reaction'}, 'aliases': {0: ['Real Time PCR', 'Real-Time PCRs', 'PCRs, Real-Time', 'PCR, Real-Time', 'Real Time Polymerase Chain Reaction', 'Real-Time PCR']}, 'types': {0: ['T063']}, 'definition': {0: 'An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.'}, 'entity': {0: 'pCR'}, 'text': {0: 'eBC, early breast cancer; pCR, pathological complete response;  '}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer; pCR, pathological complete response;  '}}","           entity_group   value     score
0  Biological_structure  breast  0.998095",[],"{'keyword': {0: 'ebc early breast', 1: 'breast cancer', 2: 'breast cancer pcr', 3: 'pathological complete', 4: 'pathological complete response'}, 'score': {0: 0.852, 1: 0.7259, 2: 0.7254, 3: 0.6977, 4: 0.6234}}"
166,166,166,0.8830000162124634,19.0,"SC, subcutaneous.",MyriadPro-Light,4,-0.25,3355443,6,18,4,"{'concept_id': {0: 'C0222331'}, 'canonical_name': {0: 'Subcutaneous Fat'}, 'aliases': {0: ['subcutaneous adipose tissue', 'Subcutaneous Fats', 'Subcutaneous adipose tissue', 'Panniculus adiposus', 'Panniculus adiposus telae subcutaneae', 'Subcutaneous fatty tissue', 'paniculus adiposus', 'Structure of subcutaneous fatty tissue', 'Fat, Subcutaneous', 'Subcutaneous fat', 'Paniculus adiposus', 'subcutaneous fat', 'Subcutaneous Fat', 'Subcutaneous Tissue', 'Structure of subcutaneous fatty tissue (body structure)', 'Panniculus adiposus (Tela subcutanea)', 'fat subcutaneous', 'Fatty layer of subcutaneous tissue', 'Subcutis', 'Fats, Subcutaneous', 'Subcutaneous Adipose Tissue', 'Fatty layer of superficial fascia', 'Adipose Tissue, Subcutaneous']}, 'types': {0: ['T024']}, 'definition': {0: 'Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'SC, subcutaneous.'}}","{'concept_id': {0: 'C0278403'}, 'canonical_name': {0: 'Tissues, Subcutaneous'}, 'aliases': {0: ['Subcutaneous Tissue', 'Fascia, Superficial', 'Superficial Fascia', 'Tela Subcutanea', 'Tissue, Subcutaneous', 'Subcutaneous Tissues', 'Hypodermis']}, 'types': {0: ['T024']}, 'definition': {0: 'Loose connective tissue lying under the DERMIS, which binds SKIN loosely to subjacent tissues. It may contain a pad of ADIPOCYTES, which vary in number according to the area of the body and vary in size according to the nutritional state.'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'SC, subcutaneous.'}}",{},{},"{'concept_id': {0: 'C1857657'}, 'canonical_name': {0: 'Reduced subcutaneous fat'}, 'aliases': {0: ['Reduced fat tissue below the skin', 'Reduced subcutaneous adipose tissue', 'Decreased subcutaneous fat', 'Decreased subcutaneous adipose tissue', 'Scanty adipose tissue']}, 'types': {0: ['T033']}, 'definition': {0: 'A reduced amount of fat tissue in the lowest layer of the integument. This feature can be appreciated by a reduced skinfold thickness. []'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'SC, subcutaneous.'}}","Empty DataFrame
Columns: []
Index: []","[('SC', 'ROUTE'), ('subcutaneous', 'ROUTE')]","{'keyword': {0: 'sc subcutaneous'}, 'score': {0: 0.8459}}"
167,167,167,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,6,19,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
168,168,168,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,6,19,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
169,169,169,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,6,19,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
170,170,170,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,6,19,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
171,171,171,0.9169999957084656,98.0,Kadcyla offers dual antitumour activity  ,ConduitITC-Bold,20,-0.2349999994039535,8194925,7,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla offers dual antitumour activity  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla offers dual antitumour activity  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla offers dual antitumour activity  '}}",{},{},"           entity_group                value     score
0            Medication              Kadcyla  0.522079
1           Coreference              Kadcyla  0.340912
2  Detailed_description                 dual  0.995293
3  Diagnostic_procedure  antitumour activity  0.790299","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'dual antitumour activity', 1: 'offers dual antitumour', 2: 'antitumour activity', 3: 'kadcyla offers', 4: 'kadcyla offers dual'}, 'score': {0: 0.962, 1: 0.949, 2: 0.9012, 3: 0.8869, 4: 0.8405}}"
172,172,172,0.9169999957084656,98.0,with HER2 suppression and the release  ,ConduitITC-Bold,20,-0.2349999994039535,8194925,7,1,1,"{'concept_id': {0: 'C0680255'}, 'canonical_name': {0: 'Discharge (release)'}, 'aliases': {0: ['release', 'discharge (release)']}, 'types': {0: ['T058']}, 'definition': {0: None}, 'entity': {0: 'release'}, 'text': {0: 'with HER2 suppression and the release  '}}","{'concept_id': {0: 'C3850077'}, 'canonical_name': {0: 'Drug Liberation'}, 'aliases': {0: ['Release, Drug', 'Dissolution, Drug', 'Drug Dissolution', 'Liberation, Drug', 'Drug Release']}, 'types': {0: ['T070']}, 'definition': {0: 'Release of drugs from DOSAGE FORMS into solution.'}, 'entity': {0: 'release'}, 'text': {0: 'with HER2 suppression and the release  '}}",{},"{'concept_id': {0: 'C1160693'}, 'canonical_name': {0: 'virus exit from host cell'}, 'aliases': {0: ['viral exit', 'viral release', 'viral shedding', 'viral release from host cell', 'release of virus from host']}, 'types': {0: ['T043']}, 'definition': {0: 'The dissemination of mature viral particles from the host cell, e.g. by cell lysis or the budding of virus particles from the cell membrane. [GOC:jl]'}, 'entity': {0: 'release'}, 'text': {0: 'with HER2 suppression and the release  '}}",{},"  entity_group        value     score
0   Medication         HER2  0.852387
1  Coreference  suppression  0.554873
2   Medication      release  0.383429",[],"{'keyword': {0: 'her2 suppression release', 1: 'suppression release', 2: 'her2 suppression'}, 'score': {0: 0.9031, 1: 0.8856, 2: 0.7413}}"
173,173,173,0.9169999957084656,98.0,of DM1 inside HER2-targeted cells,ConduitITC-Bold,20,-0.2349999994039535,8194925,7,1,2,"{'concept_id': {0: 'C5235659'}, 'canonical_name': {0: 'HER2-targeting Agent'}, 'aliases': {0: ['ERBB2-Targeting Agent']}, 'types': {0: ['T121']}, 'definition': {0: 'Any agent that targets the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2/neu; HER-2; erbB-2).'}, 'entity': {0: 'HER2-targeted cells'}, 'text': {0: 'of DM1 inside HER2-targeted cells'}}",{},{},{},"{'concept_id': {0: 'C0221284'}, 'canonical_name': {0: 'Codocytes'}, 'aliases': {0: ['Target cells']}, 'types': {0: ['T025']}, 'definition': {0: 'Target cells (codocytes) have a centrally located disk of hemoglobin surrounded by an area of pallor with an outer rim of hemoglobin adjacent to the cell membrane giving the cell the appearance of a target. [PMID:27372866, PMID:32965812]'}, 'entity': {0: 'HER2-targeted cells'}, 'text': {0: 'of DM1 inside HER2-targeted cells'}}","           entity_group                value     score
0  Diagnostic_procedure                  DM1  0.999445
1  Biological_structure        HER2-targeted  0.751804
2  Detailed_description  HER2-targeted cells  0.822867",[],"{'keyword': {0: 'targeted cells', 1: 'inside her2', 2: 'dm1 inside her2', 3: 'dm1 inside', 4: 'her2 targeted'}, 'score': {0: 0.817, 1: 0.7905, 2: 0.7811, 3: 0.7668, 4: 0.7056}}"
174,174,174,0.8830000162124634,32.0,This dual mechanism of action expands on the activity of trastuzumab,MyriadPro-Light,4,-0.25,3355443,7,2,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'This dual mechanism of action expands on the activity of trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'This dual mechanism of action expands on the activity of trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'This dual mechanism of action expands on the activity of trastuzumab'}}","{'concept_id': {0: 'C1151329'}, 'canonical_name': {0: 'chlorophyll a oxygenase activity'}, 'aliases': {0: ['chlorophyllide-a oxygenase activity', 'CAO activity', 'chlorophyllide a oxygenase activity', 'chlorophyllide a:oxygen 7-oxidoreductase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: chlorophyllide a + NADPH + O2 + 2 H+ = 7-hydroxychlorophyllide a + NADP+ + H2O. [EC:1.13.12.14, MetaCyc:RXN-7676]'}, 'entity': {0: 'activity'}, 'text': {0: 'This dual mechanism of action expands on the activity of trastuzumab'}}","{'concept_id': {0: 'C0424295'}, 'canonical_name': {0: 'Hyperactivity'}, 'aliases': {0: ['Hyperactive behavior', 'More active than typical', 'Hyperactive behaviour']}, 'types': {0: ['T048']}, 'definition': {0: 'Increased motor activity that is not goal directed.'}, 'entity': {0: 'activity'}, 'text': {0: 'This dual mechanism of action expands on the activity of trastuzumab'}}","  entity_group        value     score
0   Medication  trastuzumab  0.999828","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'dual mechanism action', 1: 'expands activity', 2: 'activity trastuzumab', 3: 'mechanism action', 4: 'action expands'}, 'score': {0: 0.858, 1: 0.8561, 2: 0.8354, 3: 0.8204, 4: 0.7866}}"
175,175,175,0.9520000219345092,28.0,HER2+ antitumour activities,MyriadPro-Regular,4,-0.25,3355443,7,2,1,"{'concept_id': {0: 'C1960398'}, 'canonical_name': {0: 'HER2-positive carcinoma of breast'}, 'aliases': {0: ['HER2+ breast cancer', 'HER2 Overexpressing Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast (disorder)', 'HER2-Positive Breast Carcinoma', 'HER2 Overexpressing Subtype of Breast Carcinoma', 'HER2-positive breast cancer', 'HER2/neu-positive breast cancer', 'ERBB2 Overexpressing Subtype of Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast', 'HER2 Positive Breast Carcinoma', 'HER2 Positive Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).'}, 'entity': {0: 'HER2+'}, 'text': {0: 'HER2+ antitumour activities'}}",{},{},{},{},"           entity_group                  value     score
0  Diagnostic_procedure             antitumour  0.444132
1            Medication             antitumour  0.358042
2  Diagnostic_procedure  antitumour activities  0.608017",[],"{'keyword': {0: 'her2 antitumour activities', 1: 'antitumour activities', 2: 'her2 antitumour'}, 'score': {0: 0.9807, 1: 0.9304, 2: 0.9011}}"
176,176,176,0.9520000219345092,28.0,1.  ,MyriadPro-Regular,4,-0.25,16233287,7,3,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
177,177,177,0.8830000162124634,28.0,receptor at subdomain IV,MyriadPro-Light,4,-0.25,3355443,7,3,1,{},{},{},{},{},"           entity_group      value     score
0  Diagnostic_procedure   receptor  0.988074
1  Detailed_description  subdomain  0.588519
2  Biological_structure  subdomain  0.562773
3  Detailed_description         IV  0.569774",[],"{'keyword': {0: 'receptor subdomain iv', 1: 'receptor subdomain', 2: 'subdomain iv'}, 'score': {0: 0.9109, 1: 0.8745, 2: 0.8374}}"
178,178,178,0.944000005722046,33.023399353027344,1,UniversSB-Medium,4,-0.2349999994039535,16777215,7,4,0,{},{},{},{},{},"  entity_group value     score
0       Dosage     1  0.686147",[],"{'keyword': {}, 'score': {}}"
179,179,179,0.9520000219345092,28.0,2. ,MyriadPro-Regular,4,-0.25,16233287,7,7,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
180,180,180,0.944000005722046,33.023399353027344,2,UniversSB-Medium,4,-0.2349999994039535,16777215,7,11,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.982709",[],"{'keyword': {}, 'score': {}}"
181,181,181,0.8830000162124634,28.0,•,MyriadPro-Light,4,-0.25,16162586,7,15,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
182,182,182,0.8830000162124634,28.0,(antiproliferative and apoptotic effects),MyriadPro-Light,4,-0.25,3355443,7,15,1,"{'concept_id': {0: 'C1280500'}, 'canonical_name': {0: 'Effect'}, 'aliases': {0: ['effects', 'Effect', 'Effect (qualifier value)', 'effect']}, 'types': {0: ['T080']}, 'definition': {0: 'A phenomenon that follows and is caused by some previous phenomenon.'}, 'entity': {0: 'apoptotic effects'}, 'text': {0: '(antiproliferative and apoptotic effects)'}}",{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'apoptotic effects', 1: 'antiproliferative apoptotic effects', 2: 'antiproliferative apoptotic'}, 'score': {0: 0.8326, 1: 0.8263, 2: 0.8136}}"
183,183,183,0.944000005722046,33.023399353027344,3,UniversSB-Medium,4,-0.2349999994039535,16777215,7,18,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     3  0.991883",[],"{'keyword': {}, 'score': {}}"
184,184,184,0.8830000162124634,28.0,•,MyriadPro-Light,4,-0.25,16162586,7,19,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
185,185,185,0.8830000162124634,28.0,•,MyriadPro-Light,4,-0.25,16162586,7,22,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
186,186,186,0.944000005722046,33.023399353027344,4,UniversSB-Medium,4,-0.2349999994039535,16777215,7,23,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     4  0.999388",[],"{'keyword': {}, 'score': {}}"
187,187,187,0.9520000219345092,28.0,DM1 cytotoxic activity*,MyriadPro-Regular,4,-0.25,3355443,7,29,0,"{'concept_id': {0: 'C3250443'}, 'canonical_name': {0: 'MYOTONIC DYSTROPHY 1'}, 'aliases': {0: ['STEINERT DISEASE', 'DYSTROPHIA MYOTONICA', 'Steinert myotonic dystrophy syndrome (disorder)', 'Steinert syndrome', 'MYOTONIC DYSTROPHY 1', 'Steinert disease', 'Steinert myotonic dystrophy', 'DM1', 'DYSTROPHIA MYOTONICA 1', 'DM', 'Dystrophia Myotonica 1', 'Myotonic dystrophy type 1', 'Steinert myotonic dystrophy syndrome']}, 'types': {0: ['T047']}, 'definition': {0: 'A rare autosomal dominant disorder caused by mutations in the DMPK gene. It is characterized by myotonia, muscular dystrophy, hypogonadism, heart conduction defects and cataracts.'}, 'entity': {0: 'DM1\xa0'}, 'text': {0: 'DM1\xa0cytotoxic activity*'}}",{},{},{},{},"           entity_group               value     score
0  Diagnostic_procedure                 DM1  0.995482
1  Diagnostic_procedure  cytotoxic activity  0.994031",[],"{'keyword': {0: 'dm1 cytotoxic activity', 1: 'dm1 cytotoxic', 2: 'cytotoxic activity'}, 'score': {0: 0.9739, 1: 0.8992, 2: 0.8551}}"
188,188,188,0.944000005722046,33.023399353027344,5,UniversSB-Medium,4,-0.2349999994039535,16777215,7,32,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     5  0.998987",[],"{'keyword': {}, 'score': {}}"
189,189,189,0.9520000219345092,28.0,3.  ,MyriadPro-Regular,4,-0.25,16233287,7,34,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
190,190,190,0.8830000162124634,28.0,receptor complex is internalised via endocytosis,MyriadPro-Light,4,-0.25,3355443,7,34,1,"{'concept_id': {0: 'C1159767'}, 'canonical_name': {0: 'regulation of endocytosis'}, 'aliases': {0: []}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that modulates the frequency, rate or extent of endocytosis. [GOC:go_curators]'}, 'entity': {0: 'endocytosis'}, 'text': {0: 'receptor complex is internalised via endocytosis'}}","{'concept_id': {0: 'C0014139'}, 'canonical_name': {0: 'Endocytoses'}, 'aliases': {0: ['Endocytosis']}, 'types': {0: ['T043']}, 'definition': {0: 'Cellular uptake of extracellular materials within membrane-limited vacuoles or microvesicles. ENDOSOMES play a central role in endocytosis.'}, 'entity': {0: 'endocytosis'}, 'text': {0: 'receptor complex is internalised via endocytosis'}}",{},"{'concept_id': {0: 'C1159769'}, 'canonical_name': {0: 'positive regulation of endocytosis'}, 'aliases': {0: ['up-regulation of endocytosis', 'upregulation of endocytosis', 'up regulation of endocytosis']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that activates or increases the frequency, rate or extent of endocytosis. [GOC:go_curators]'}, 'entity': {0: 'endocytosis'}, 'text': {0: 'receptor complex is internalised via endocytosis'}}",{},"           entity_group             value     score
0  Diagnostic_procedure  receptor complex  0.999658
1  Detailed_description       endocytosis  0.973203",[],"{'keyword': {0: 'complex internalised endocytosis', 1: 'internalised endocytosis', 2: 'receptor complex internalised', 3: 'complex internalised', 4: 'receptor complex'}, 'score': {0: 0.8428, 1: 0.8251, 2: 0.8135, 3: 0.7085, 4: 0.4795}}"
191,191,191,0.9520000219345092,28.0,4.  ,MyriadPro-Regular,4,-0.25,16233287,7,49,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
192,192,192,0.8830000162124634,28.0,degradation inside the target cell and releases the ,MyriadPro-Light,4,-0.25,3355443,7,49,1,"{'concept_id': {0: 'C0391871'}, 'canonical_name': {0: 'Released (action)'}, 'aliases': {0: ['release', 'Release, NOS', 'Release', 'Released', 'Released (qualifier value)']}, 'types': {0: ['T169']}, 'definition': {0: '<p>Change the status of an object representing an Act so it is no longer ""held"", i.e., allow action to occur. For an HL7 Act, the state transitions per the HL7 Reference Information Model.</p>'}, 'entity': {0: 'releases'}, 'text': {0: 'degradation inside the target cell and releases the '}}","{'concept_id': {0: 'C0019595'}, 'canonical_name': {0: 'Histamine Release'}, 'aliases': {0: ['Histamine Releases', 'Histamine Liberation', 'Histamine Liberations']}, 'types': {0: ['T043']}, 'definition': {0: ""The secretion of histamine from mast cell and basophil granules by exocytosis. This can be initiated by a number of factors, all of which involve binding of IgE, cross-linked by antigen, to the mast cell or basophil's Fc receptors. Once released, histamine binds to a number of different target cell receptors and exerts a wide variety of effects.""}, 'entity': {0: 'releases'}, 'text': {0: 'degradation inside the target cell and releases the '}}",{},"{'concept_id': {0: 'C1257756'}, 'canonical_name': {0: 'RNA catabolic process'}, 'aliases': {0: ['RNA catabolism', 'RNA breakdown', 'RNA degradation']}, 'types': {0: ['T045']}, 'definition': {0: ""The chemical reactions and pathways resulting in the breakdown of RNA, ribonucleic acid, one of the two main type of nucleic acid, consisting of a long, unbranched macromolecule formed from ribonucleotides joined in 3',5'-phosphodiester linkage. [ISBN:0198506732]""}, 'entity': {0: 'degradation'}, 'text': {0: 'degradation inside the target cell and releases the '}}","{'concept_id': {0: 'C0221284'}, 'canonical_name': {0: 'Codocytes'}, 'aliases': {0: ['Target cells']}, 'types': {0: ['T025']}, 'definition': {0: 'Target cells (codocytes) have a centrally located disk of hemoglobin surrounded by an area of pallor with an outer rim of hemoglobin adjacent to the cell membrane giving the cell the appearance of a target. [PMID:27372866, PMID:32965812]'}, 'entity': {0: 'target cell'}, 'text': {0: 'degradation inside the target cell and releases the '}}","   entity_group        value     score
0  Sign_symptom  degradation  0.795822",[],"{'keyword': {0: 'cell releases', 1: 'degradation inside', 2: 'inside target cell', 3: 'target cell', 4: 'inside target'}, 'score': {0: 0.9015, 1: 0.8798, 2: 0.8585, 3: 0.8536, 4: 0.8174}}"
193,193,193,0.8830000162124634,28.0,"active chemotherapy, DM1",MyriadPro-Light,4,-0.25,3355443,7,49,2,"{'concept_id': {0: 'C3250443'}, 'canonical_name': {0: 'MYOTONIC DYSTROPHY 1'}, 'aliases': {0: ['STEINERT DISEASE', 'DYSTROPHIA MYOTONICA', 'Steinert myotonic dystrophy syndrome (disorder)', 'Steinert syndrome', 'MYOTONIC DYSTROPHY 1', 'Steinert disease', 'Steinert myotonic dystrophy', 'DM1', 'DYSTROPHIA MYOTONICA 1', 'DM', 'Dystrophia Myotonica 1', 'Myotonic dystrophy type 1', 'Steinert myotonic dystrophy syndrome']}, 'types': {0: ['T047']}, 'definition': {0: 'A rare autosomal dominant disorder caused by mutations in the DMPK gene. It is characterized by myotonia, muscular dystrophy, hypogonadism, heart conduction defects and cataracts.'}, 'entity': {0: 'DM1'}, 'text': {0: 'active chemotherapy, DM1'}}","{'concept_id': {0: 'C1868801'}, 'canonical_name': {0: 'Hyperthermic Intraperitoneal Chemotherapy'}, 'aliases': {0: ['Hot Chemotherapy', 'Chemotherapy, Intraperitoneal Hyperthermic', 'Chemotherapy, Hyperthermic Intraperitoneal', 'Chemotherapy, Hot', 'Intraperitoneal Hyperthermic Chemotherapies', 'Intraperitoneal Chemotherapy, Hyperthermic', 'Hyperthermic Chemotherapy, Intraperitoneal', 'HIPEC', 'Intraperitoneal Hyperthermic Chemotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.'}, 'entity': {0: 'active chemotherapy'}, 'text': {0: 'active chemotherapy, DM1'}}",{},{},{},"           entity_group         value     score
0  Detailed_description        active  0.991542
1            Medication  chemotherapy  0.999001
2            Medication           DM1  0.950382
3  Diagnostic_procedure           DM1  0.723564","[('chemotherapy', 'DRUG')]","{'keyword': {0: 'active chemotherapy dm1', 1: 'active chemotherapy', 2: 'chemotherapy dm1'}, 'score': {0: 0.9373, 1: 0.9289, 2: 0.732}}"
194,194,194,0.944000005722046,24.76759910583496,Downstream ,UniversSB-Medium,4,-0.2349999994039535,0,7,55,0,"{'concept_id': {0: 'C1333245'}, 'canonical_name': {0: 'DOCK1 gene'}, 'aliases': {0: ['dedicator of cyto-kinesis 1', 'DOWNSTREAM OF CRK, 180-KD', 'DOCK1', 'DOCK180', 'DEDICATOR OF CYTOKINESIS 1', 'DOWNSTREAM OF CRK', 'DOCK1 Gene', 'CED5, C. ELEGANS, HOMOLOG OF', 'DOCK1 gene', 'ced5', 'DOwnstream of CrK', 'DOCK', 'dedicator of cytokinesis 1', 'Dedicator of Cytokinesis 1 Gene']}, 'types': {0: ['T028']}, 'definition': {0: 'This gene is involved in apoptosis, cell motility/migration and phagocytosis.'}, 'entity': {0: 'Downstream'}, 'text': {0: 'Downstream '}}",{},{},{},{},"           entity_group       value     score
0  Detailed_description  Downstream  0.999402",[],"{'keyword': {}, 'score': {}}"
195,195,195,0.944000005722046,24.76759910583496,signalling pathways,UniversSB-Medium,4,-0.2349999994039535,0,7,55,1,"{'concept_id': {0: 'C4236748'}, 'canonical_name': {0: 'receptor signaling pathway via STAT'}, 'aliases': {0: ['kinase activated-STAT cascade', 'STAT signalling pathway', 'kinase-STAT cascade']}, 'types': {0: ['T044']}, 'definition': {0: 'An intracellular signal transduction process in which STAT proteins (Signal Transducers and Activators of Transcription) convey a signal to trigger a change in the activity or state of a cell. The STAT cascade begins with receptor activation followed by activation of STAT proteins by kinases. It proceeds through STA dimerization and subsequent nuclear translocation of STAT proteins, and ends with regulation of target gene expression by STAT proteins. [GOC:rjd, PMID:21534947, PMID:24587195]'}, 'entity': {0: 'signalling pathways'}, 'text': {0: 'signalling pathways'}}","{'concept_id': {0: 'C0086982'}, 'canonical_name': {0: 'Pathway, Signal Transduction'}, 'aliases': {0: ['Pathways, Signal Transduction', 'Signal Transduction Pathways', 'Signal Transduction Pathway']}, 'types': {0: ['T044']}, 'definition': {0: 'An elaboration of the known or inferred interactions involved in a signal transduction pathway.'}, 'entity': {0: 'signalling pathways'}, 'text': {0: 'signalling pathways'}}",{},"{'concept_id': {0: 'C1155452'}, 'canonical_name': {0: 'Notch-receptor signaling pathway'}, 'aliases': {0: ['Notch signalling pathway', 'N signaling pathway', 'N signalling pathway', 'Notch-receptor signalling pathway', 'Notch receptor signaling pathway', 'Notch signaling pathway', 'Notch receptor signalling pathway']}, 'types': {0: ['T044']}, 'definition': {0: 'The series of molecular signals initiated by an extracellular ligand binding to the receptor Notch on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:go_curators, GOC:signaling]'}, 'entity': {0: 'signalling pathways'}, 'text': {0: 'signalling pathways'}}",{},"           entity_group                value     score
0  Diagnostic_procedure  signalling pathways  0.999775",[],"{'keyword': {0: 'signalling pathways'}, 'score': {0: 1.0}}"
196,196,196,0.9520000219345092,28.0,5.  ,MyriadPro-Regular,4,-0.25,16233287,7,58,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
197,197,197,0.8830000162124634,28.0,"inhibits their polymerisation, causing cell-cycle ",MyriadPro-Light,4,-0.25,3355443,7,58,1,"{'concept_id': {0: 'C0243021'}, 'canonical_name': {0: 'Cell Cycle Proteins'}, 'aliases': {0: ['cdc Proteins', 'Cell-Cycle Regulatory Proteins', 'Cell Cycle Protein', 'Cell Division Cycle Proteins', 'cell cycle protein', 'Cell Cycle Regulatory Proteins']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'Proteins that control the CELL DIVISION CYCLE. This family of proteins includes a wide variety of classes, including CYCLIN-DEPENDENT KINASES, mitogen-activated kinases, CYCLINS, and PHOSPHOPROTEIN PHOSPHATASES as well as their putative substrates such as chromatin-associated proteins, CYTOSKELETAL PROTEINS, and TRANSCRIPTION FACTORS.'}, 'entity': {0: 'cell-cycle'}, 'text': {0: 'inhibits their polymerisation, causing cell-cycle '}}",{},{},"{'concept_id': {0: 'C1519613'}, 'canonical_name': {0: 'biopolymerization'}, 'aliases': {0: ['biopolymerisation', 'translation initiation', 'translational initiation']}, 'types': {0: ['T045']}, 'definition': {0: 'The process preceding formation of the peptide bond between the first two amino acids of a protein. This includes the formation of a complex of the ribosome, mRNA or circRNA, and an initiation complex that contains the first aminoacyl-tRNA. [ISBN:019879276X]'}, 'entity': {0: 'polymerisation'}, 'text': {0: 'inhibits their polymerisation, causing cell-cycle '}}","{'concept_id': {0: 'C0424296'}, 'canonical_name': {0: 'Disinhibition'}, 'aliases': {0: []}, 'types': {0: ['T048']}, 'definition': {0: 'Unrestrained behavior, often at odds with social norms.'}, 'entity': {0: 'inhibits'}, 'text': {0: 'inhibits their polymerisation, causing cell-cycle '}}","           entity_group       value     score
0  Detailed_description  cell-cycle  0.988535",[],"{'keyword': {0: 'polymerisation causing cell', 1: 'causing cell cycle', 2: 'inhibits polymerisation', 3: 'causing cell', 4: 'cell cycle'}, 'score': {0: 0.8852, 1: 0.8406, 2: 0.8325, 3: 0.8206, 4: 0.8112}}"
198,198,198,0.8830000162124634,28.0,arrest and cell death,MyriadPro-Light,4,-0.25,3355443,7,58,2,"{'concept_id': {0: 'C2754100'}, 'canonical_name': {0: 'neuron death'}, 'aliases': {0: ['neuron cell death', 'neuronal cell death']}, 'types': {0: ['T043']}, 'definition': {0: 'The process of cell death in a neuron. [GOC:BHF, GOC:mah]'}, 'entity': {0: 'cell death'}, 'text': {0: 'arrest and cell death'}}","{'concept_id': {0: 'C3546446'}, 'canonical_name': {0: 'Regulated Cell Death'}, 'aliases': {0: ['Cell Death, Regulated']}, 'types': {0: ['T043']}, 'definition': {0: 'Genetically encoded mechanisms in multicellular and unicellular eukaryotes that function to eliminate cells that are superfluous either during development, or to maintain tissue and organism homeostasis; and cells that are irreversibly damaged, abnormal, and/or potentially harmful.'}, 'entity': {0: 'cell death'}, 'text': {0: 'arrest and cell death'}}",{},"{'concept_id': {0: 'C3546446'}, 'canonical_name': {0: 'regulated cell death'}, 'aliases': {0: []}, 'types': {0: ['T043']}, 'definition': {0: 'Genetically encoded mechanisms in multicellular and unicellular eukaryotes that function to eliminate cells that are superfluous either during development, or to maintain tissue and organism homeostasis; and cells that are irreversibly damaged, abnormal, and/or potentially harmful.'}, 'entity': {0: 'cell death'}, 'text': {0: 'arrest and cell death'}}",{},"           entity_group   value     score
0  Diagnostic_procedure  arrest  0.257914
1  Biological_structure    cell  0.261412
2  Diagnostic_procedure   death  0.686128",[],"{'keyword': {0: 'arrest cell death', 1: 'arrest cell', 2: 'cell death'}, 'score': {0: 0.8747, 1: 0.8438, 2: 0.7801}}"
199,199,199,0.8830000162124634,19.0,*Cytotoxic DM1-containing catabolites (primarily lysine-bound emtansine).,MyriadPro-Light,4,-0.25,3355443,7,59,0,"{'concept_id': {0: 'C4505403'}, 'canonical_name': {0: 'Maytansinoid DM1'}, 'aliases': {0: ['Emtansine', 'DM1, Maytansinoid', 'Mertansine']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'emtansine'}, 'text': {0: '*Cytotoxic DM1-containing catabolites (primarily lysine-bound emtansine).'}}","{'concept_id': {0: 'C4505403'}, 'canonical_name': {0: 'Maytansinoid DM1'}, 'aliases': {0: ['Emtansine', 'Mertansine', 'DM1, Maytansinoid']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'emtansine'}, 'text': {0: '*Cytotoxic DM1-containing catabolites (primarily lysine-bound emtansine).'}}",{},{},{},"           entity_group                               value     score
0  Diagnostic_procedure                           Cytotoxic  0.425934
1  Detailed_description                      DM1-containing  0.907907
2  Detailed_description  catabolites primarily lysine-bound  0.563882
3  Detailed_description              lysine-bound emtansine  0.697296","[('emtansine', 'DRUG')]","{'keyword': {0: 'dm1 containing catabolites', 1: 'cytotoxic dm1 containing', 2: 'primarily lysine', 3: 'cytotoxic dm1', 4: 'dm1 containing'}, 'score': {0: 0.9177, 1: 0.8341, 2: 0.758, 3: 0.7538, 4: 0.7417}}"
200,200,200,0.8830000162124634,19.0,"DM1, derivative of maytansine; IV, intravenous.",MyriadPro-Light,4,-0.25,3355443,7,60,0,"{'concept_id': {0: 'C0455142'}, 'canonical_name': {0: 'Intravenous therapy'}, 'aliases': {0: ['care intravenous', 'Intravenous Care', 'Intravenous therapy (regime/therapy)', 'Intravenous (IV) Therapy', 'Intravenous therapy', 'intravenous therapy', 'Intravenous care']}, 'types': {0: ['T061']}, 'definition': {0: 'Actions performed to support the use of infusion equipment'}, 'entity': {0: 'intravenous'}, 'text': {0: 'DM1, derivative of maytansine; IV, intravenous.'}}","{'concept_id': {0: 'C0021440'}, 'canonical_name': {0: 'Infusion, Intravenous'}, 'aliases': {0: ['Intravenous Infusion', 'Intravenous Infusions', 'Infusions, Intravenous']}, 'types': {0: ['T061']}, 'definition': {0: 'The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.'}, 'entity': {0: 'intravenous'}, 'text': {0: 'DM1, derivative of maytansine; IV, intravenous.'}}",{},{},{},"     entity_group        value     score
0      Medication   maytansine  0.999303
1  Administration  intravenous  0.999469","[('maytansine', 'DRUG'), ('IV', 'ROUTE'), ('intravenous', 'ROUTE')]","{'keyword': {0: 'dm1 derivative maytansine', 1: 'maytansine iv', 2: 'maytansine iv intravenous', 3: 'dm1 derivative', 4: 'iv intravenous'}, 'score': {0: 0.8663, 1: 0.8395, 2: 0.8073, 3: 0.7113, 4: 0.6078}}"
201,201,201,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,7,61,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
202,202,202,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,7,61,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
203,203,203,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,7,61,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
204,204,204,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,16777215,7,61,3,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
205,205,205,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,8,2,0,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
206,206,206,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,8,2,1,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
207,207,207,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,8,2,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
208,208,208,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,16777215,8,2,3,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
209,209,209,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,9,6,0,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
210,210,210,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,9,6,1,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
211,211,211,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,9,6,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
212,212,212,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,16777215,9,6,3,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
213,213,213,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,10,1,0,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
214,214,214,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,10,1,1,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
215,215,215,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,10,1,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
216,216,216,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,16777215,10,1,3,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
217,217,217,0.8830000162124634,16.0,Reporting suspected adverse reactions after authorisation of the medicinal product is ,MyriadPro-Light,4,-0.25,3355443,11,1,0,"{'concept_id': {0: 'C4684711'}, 'canonical_name': {0: 'Medicinal Product Name'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'The name assigned to a medicinal product as approved by a regulatory authority of the country of authorization.'}, 'entity': {0: 'medicinal product'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the medicinal product is '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the medicinal product is '}}",{},{},"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the medicinal product is '}}","   entity_group              value     score
0  Sign_symptom  adverse reactions  0.999916",[],"{'keyword': {0: 'reporting suspected adverse', 1: 'medicinal product', 2: 'adverse reactions', 3: 'authorisation medicinal', 4: 'adverse reactions authorisation'}, 'score': {0: 0.9063, 1: 0.8039, 2: 0.7794, 3: 0.77, 4: 0.6922}}"
218,218,218,0.8830000162124634,16.0,important. It allows continued monitoring of the benefit/risk balance of the medicinal ,MyriadPro-Light,4,-0.25,3355443,11,1,1,"{'concept_id': {0: 'C0013227'}, 'canonical_name': {0: 'Pharmaceutical Preparations'}, 'aliases': {0: ['Drug/agent', 'drugs', 'Preparations, Pharmaceutic', 'Medicinal product (product)', 'Medication, NOS', 'Drug preparation, NOS', 'Drug Product', 'Drug or medicament', 'medication', 'Medicine', 'drug', 'medicinal product', 'Drug, NOS', 'Pharmaceutical / biologic product', 'Pharmaceutical Product', 'drug/agent', 'Pharmaceutic Preparations', 'Preparation, Pharmaceutical', 'Medicine, NOS', 'Preparations, Pharmaceutical', 'Pharmaceutical Preparation', 'Products, Pharmaceutical', 'Medicinal product', 'Medications', 'medications', 'pharmaceutical preparation', 'pharmaceutical preparations', 'Product, Pharmaceutical', 'Pharmaceutical / biologic product (product)', 'Drugs', 'Pharmaceutical', 'medicinal products', 'Pharmaceutical Preparations', 'Drug', 'Medication', 'Drug or medicament (substance)', 'Pharmaceuticals', 'Pharmaceutical Products', 'Medicines']}, 'types': {0: ['T121']}, 'definition': {0: 'Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.'}, 'entity': {0: 'medicinal'}, 'text': {0: 'important. It allows continued monitoring of the benefit/risk balance of the medicinal '}}","{'concept_id': {0: 'C0032100'}, 'canonical_name': {0: 'Plants, Medicinal'}, 'aliases': {0: ['Medicinal Plants', 'Medicinal Plant', 'Plant, Medicinal']}, 'types': {0: ['T002']}, 'definition': {0: 'Plants whose roots, leaves, seeds, bark, or other constituent parts possess therapeutic, tonic, purgative, curative or other pharmacologic attributes, when administered to man or animals.'}, 'entity': {0: 'medicinal'}, 'text': {0: 'important. It allows continued monitoring of the benefit/risk balance of the medicinal '}}",{},{},{},"           entity_group      value     score
0  Detailed_description  medicinal  0.704737",[],"{'keyword': {0: 'allows continued monitoring', 1: 'important allows continued', 2: 'monitoring benefit', 3: 'balance medicinal', 4: 'benefit risk'}, 'score': {0: 0.8892, 1: 0.8427, 2: 0.813, 3: 0.7552, 4: 0.5912}}"
219,219,219,0.8830000162124634,16.0,product. Adverse events should be reported. Reporting forms and information can be ,MyriadPro-Light,4,-0.25,3355443,11,1,2,"{'concept_id': {0: 'C1561527'}, 'canonical_name': {0: 'Error severity - Information'}, 'aliases': {0: ['Information']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'information'}, 'text': {0: 'product. Adverse events should be reported. Reporting forms and information can be '}}","{'concept_id': {0: 'C0021428'}, 'canonical_name': {0: 'Information Systems'}, 'aliases': {0: ['Information System']}, 'types': {0: ['T170']}, 'definition': {0: 'Integrated set of files, procedures, and equipment for the storage, manipulation, and retrieval of information.'}, 'entity': {0: 'information'}, 'text': {0: 'product. Adverse events should be reported. Reporting forms and information can be '}}",{},{},{},"           entity_group           value     score
0          Sign_symptom  Adverse events  0.999894
1  Diagnostic_procedure       Reporting  0.546498",[],"{'keyword': {0: 'events reported', 1: 'reporting forms', 2: 'adverse events', 3: 'reporting forms information', 4: 'product adverse'}, 'score': {0: 0.8518, 1: 0.845, 2: 0.7215, 3: 0.6657, 4: 0.442}}"
220,220,220,0.8830000162124634,16.0,found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play ,MyriadPro-Light,4,-0.25,3355443,11,1,3,{},{},{},{},{},"           entity_group                       value     score
0           Coreference  www.mhra.gov.uk/yellowcard  0.268889
1  Detailed_description  www.mhra.gov.uk/yellowcard  0.976540
2      Disease_disorder                        MHRA  0.537804
3           Coreference                        MHRA  0.581580
4  Detailed_description                      Yellow  0.645877
5  Detailed_description                 Google Play  0.998340",[],"{'keyword': {0: 'search mhra yellow', 1: 'card google play', 2: 'uk yellowcard', 3: 'www mhra', 4: 'gov uk'}, 'score': {0: 0.8966, 1: 0.8388, 2: 0.8184, 3: 0.8142, 4: 0.7242}}"
221,221,221,0.8830000162124634,16.0,or Apple App Store.,MyriadPro-Light,4,-0.25,3355443,11,1,4,"{'concept_id': {0: 'C4684566'}, 'canonical_name': {0: 'Applet'}, 'aliases': {0: ['App', 'Applet']}, 'types': {0: ['T170']}, 'definition': {0: 'A small application designed to perform a specific function within another application.'}, 'entity': {0: 'Apple App Store'}, 'text': {0: 'or Apple App Store.'}}",{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'apple app store', 1: 'app store', 2: 'apple app'}, 'score': {0: 0.9069, 1: 0.8902, 2: 0.8445}}"
222,222,222,0.8830000162124634,16.0,Adverse events should also be reported to Roche Products Ltd. Please contact Roche ,MyriadPro-Light,4,-0.25,3355443,11,1,5,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should also be reported to Roche Products Ltd. Please contact Roche '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should also be reported to Roche Products Ltd. Please contact Roche '}}",{},{},{},"           entity_group           value     score
0          Sign_symptom  Adverse events  0.999906
1            Medication           Roche  0.977449
2  Detailed_description           Roche  0.377658",[],"{'keyword': {0: 'events reported roche', 1: 'products contact', 2: 'reported roche products', 3: 'contact roche', 4: 'roche products'}, 'score': {0: 0.7272, 1: 0.5991, 2: 0.536, 3: 0.4962, 4: 0.3808}}"
223,223,223,0.8830000162124634,16.0,Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44(0)1707 367554. ,MyriadPro-Light,4,-0.25,3355443,11,1,6,"{'concept_id': {0: 'C0034770'}, 'canonical_name': {0: 'Mental Recall'}, 'aliases': {0: ['mental recall', 'Mental Recall', 'remember', 'recalling', 'recall', 'remembers', 'Recall, Mental', 'Recall', 'Recollect', 'remembering']}, 'types': {0: ['T041']}, 'definition': {0: 'The process whereby a representation of past experience is elicited.'}, 'entity': {0: 'calling'}, 'text': {0: 'Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44(0)1707 367554. '}}",{},{},{},{},"     entity_group     value     score
0  Clinical_event  emailing  0.984051",[],"{'keyword': {0: 'welwyn uk_dsc roche', 1: '1707 367554', 2: 'emailing welwyn uk_dsc', 3: 'centre emailing', 4: 'safety centre'}, 'score': {0: 0.8298, 1: 0.8143, 2: 0.8043, 3: 0.7887, 4: 0.6858}}"
224,224,224,0.8830000162124634,16.0,"As Herceptin is a biological medicine, healthcare professionals should report adverse ",MyriadPro-Light,4,-0.25,3355443,11,1,7,"{'concept_id': {0: 'C5554773'}, 'canonical_name': {0: 'Healthcare Professional Visit'}, 'aliases': {0: []}, 'types': {0: ['T058']}, 'definition': {0: 'The subject or patient has interacted with a healthcare professional at a healthcare facility.'}, 'entity': {0: 'healthcare professionals'}, 'text': {0: 'As Herceptin is a biological medicine, healthcare professionals should report adverse '}}","{'concept_id': {0: 'C0018722'}, 'canonical_name': {0: 'Health Occupations'}, 'aliases': {0: ['Profession, Health', 'Health Professions', 'Health Occupation', 'Health Profession', 'Professions, Health']}, 'types': {0: ['T091']}, 'definition': {0: 'Professions or other business activities directed to the cure and prevention of disease. For occupations of medical personnel who are not physicians but who are working in the fields of medical technology, physical therapy, etc., ALLIED HEALTH OCCUPATIONS is available.'}, 'entity': {0: 'healthcare professionals'}, 'text': {0: 'As Herceptin is a biological medicine, healthcare professionals should report adverse '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'As Herceptin is a biological medicine, healthcare professionals should report adverse '}}","{'concept_id': {0: 'C3714634'}, 'canonical_name': {0: 'biological_process'}, 'aliases': {0: ['biological process']}, 'types': {0: ['T038']}, 'definition': {0: 'A biological process represents a specific objective that the organism is genetically programmed to achieve. Biological processes are often described by their outcome or ending state, e.g., the biological process of cell division results in the creation of two daughter cells (a divided cell) from a single parent cell. A biological process is accomplished by a particular set of molecular functions carried out by specific gene products (or macromolecular complexes), often in a highly regulated manner and in a particular temporal sequence. [GOC:pdt]'}, 'entity': {0: 'biological medicine'}, 'text': {0: 'As Herceptin is a biological medicine, healthcare professionals should report adverse '}}",{},"  entity_group      value     score
0   Medication  Herceptin  0.849327
1    Lab_value    adverse  0.543240","[('Herceptin', 'DRUG')]","{'keyword': {0: 'report adverse', 1: 'professionals report adverse', 2: 'healthcare professionals', 3: 'healthcare professionals report', 4: 'herceptin biological'}, 'score': {0: 0.8638, 1: 0.8617, 2: 0.7178, 3: 0.663, 4: 0.3036}}"
225,225,225,0.8830000162124634,16.0,reactions by brand name and batch number.,MyriadPro-Light,4,-0.25,3355443,11,1,8,"{'concept_id': {0: 'C1948031'}, 'canonical_name': {0: 'Batch (group)'}, 'aliases': {0: ['Batch']}, 'types': {0: ['T081']}, 'definition': {0: 'A quantity of people or things treated or regarded as a group, especially when subdivided from a larger group.'}, 'entity': {0: 'batch number'}, 'text': {0: 'reactions by brand name and batch number.'}}","{'concept_id': {0: 'C0600485'}, 'canonical_name': {0: 'Acrosome Reaction'}, 'aliases': {0: ['Reaction, Acrosome', 'Acrosome Reactions', 'Reactions, Acrosome']}, 'types': {0: ['T043']}, 'definition': {0: ""The discharge, by sperm, of a single, anterior secretory granule following the sperm's attachment to the zona pellucida of the oocyte. The process begins with the fusion of the outer acrosomal membrane with the sperm plasma membrane and ends with the exocytosis of the acrosomal contents into the zona pellucida. [GOC:dph, PMID:11175768, PMID:21042299, PMID:3886029]""}, 'entity': {0: 'reactions'}, 'text': {0: 'reactions by brand name and batch number.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'reactions brand batch', 1: 'brand batch', 2: 'brand batch number', 3: 'reactions brand', 4: 'batch number'}, 'score': {0: 0.9138, 1: 0.9068, 2: 0.8822, 3: 0.8519, 4: 0.8409}}"
226,226,226,0.9890000224113464,16.0,Enhanced Safety Reporting for Potential Herceptin-Exposed Pregnancies,MyriadPro-Bold,20,-0.25,3355443,11,2,0,"{'concept_id': {0: 'C0036043'}, 'canonical_name': {0: 'Safety'}, 'aliases': {0: ['Safeties', 'Safety', 'safety']}, 'types': {0: ['T068']}, 'definition': {0: 'Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.'}, 'entity': {0: 'Safety Reporting'}, 'text': {0: 'Enhanced Safety Reporting for Potential Herceptin-Exposed Pregnancies'}}","{'concept_id': {0: 'C0036043'}, 'canonical_name': {0: 'Safeties'}, 'aliases': {0: ['Safety']}, 'types': {0: ['T068']}, 'definition': {0: 'Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.'}, 'entity': {0: 'Safety Reporting'}, 'text': {0: 'Enhanced Safety Reporting for Potential Herceptin-Exposed Pregnancies'}}",{},{},{},"           entity_group              value     score
0  Diagnostic_procedure   Safety Reporting  0.982271
1  Detailed_description  Herceptin-Exposed  0.584369
2      Disease_disorder        Pregnancies  0.819017","[('Herceptin', 'DRUG')]","{'keyword': {0: 'enhanced safety reporting', 1: 'safety reporting', 2: 'reporting potential', 3: 'herceptin exposed', 4: 'herceptin exposed pregnancies'}, 'score': {0: 0.9133, 1: 0.8916, 2: 0.8826, 3: 0.7957, 4: 0.7478}}"
227,227,227,0.8830000162124634,16.0,•  Herceptin should be avoided during pregnancy unless the potential benefit for the ,MyriadPro-Light,4,-0.25,3355443,11,2,1,"{'concept_id': {0: 'C3242014'}, 'canonical_name': {0: 'benefit policy'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: '<p>**Description:**A mandate, obligation, requirement, rule, or expectation unilaterally imposed on benefit coverage under a policy or program by a sponsor, underwriter or payor on:</p><p>* The activity of another party * The behavior of another party * The manner in which an act is executed</p><p>**Examples:**A clinical protocol imposed by a payer to which a provider must adhere in order to be paid for providing the service. A formulary from which a provider must select prescribed drugs in order for the patient to incur a lower copay.</p>'}, 'entity': {0: 'benefit'}, 'text': {0: '•  Herceptin should be avoided during pregnancy unless the potential benefit for the '}}","{'concept_id': {0: 'C0021674'}, 'canonical_name': {0: 'Insurance Benefits'}, 'aliases': {0: ['Benefits, Insurance', 'Insurance Benefit', 'Benefit, Insurance']}, 'types': {0: ['T081']}, 'definition': {0: 'Payments or services provided under stated circumstances under the terms of an insurance policy. In prepayment programs, benefits are the services the programs will provide at defined locations and to the extent needed.'}, 'entity': {0: 'benefit'}, 'text': {0: '•  Herceptin should be avoided during pregnancy unless the potential benefit for the '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: '•  Herceptin should be avoided during pregnancy unless the potential benefit for the '}}","{'concept_id': {0: 'C0032961'}, 'canonical_name': {0: 'female pregnancy'}, 'aliases': {0: ['gestation']}, 'types': {0: ['T040']}, 'definition': {0: 'The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.'}, 'entity': {0: 'pregnancy'}, 'text': {0: '•  Herceptin should be avoided during pregnancy unless the potential benefit for the '}}","{'concept_id': {0: 'C4551893'}, 'canonical_name': {0: 'Toxaemia of pregnancy'}, 'aliases': {0: ['Hypertensive disorder of pregnancy', 'Toxemia of pregnancy']}, 'types': {0: ['T047']}, 'definition': {0: 'A pregnancy induced hypertensive state that occurs after 20 weeks of gestation characterized by an increase in blood pressure, along with body swelling and proteinuria.'}, 'entity': {0: 'pregnancy'}, 'text': {0: '•  Herceptin should be avoided during pregnancy unless the potential benefit for the '}}","           entity_group             value     score
0  Diagnostic_procedure         Herceptin  0.603096
1            Medication  Herceptin during  0.992071","[('Herceptin', 'DRUG')]","{'keyword': {0: 'potential benefit', 1: 'avoided pregnancy unless', 2: 'avoided pregnancy', 3: 'pregnancy unless', 4: 'herceptin avoided pregnancy'}, 'score': {0: 0.7128, 1: 0.6967, 2: 0.5376, 3: 0.4537, 4: 0.2229}}"
228,228,228,0.8830000162124634,16.0,mother outweighs the potential risk to the foetus. There is a limited amount of data ,MyriadPro-Light,4,-0.25,3355443,11,2,2,"{'concept_id': {0: 'C3714741'}, 'canonical_name': {0: 'Data (eukaryote)'}, 'aliases': {0: ['Data']}, 'types': {0: ['T204']}, 'definition': {0: None}, 'entity': {0: 'data'}, 'text': {0: 'mother outweighs the potential risk to the foetus. There is a limited amount of data '}}","{'concept_id': {0: 'C1328866'}, 'canonical_name': {0: 'Data Mining'}, 'aliases': {0: ['Mining, Data']}, 'types': {0: ['T066']}, 'definition': {0: 'Use of sophisticated analysis tools to sort through, organize, examine, and combine large sets of information.'}, 'entity': {0: 'data'}, 'text': {0: 'mother outweighs the potential risk to the foetus. There is a limited amount of data '}}",{},"{'concept_id': {0: 'C1154426'}, 'canonical_name': {0: 'positive regulation of action potential'}, 'aliases': {0: ['upregulation of action potential', 'up regulation of action potential', 'up-regulation of action potential']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that activates or increases the frequency, rate or extent of action potential creation, propagation or termination. This typically occurs via modulation of the activity or expression of voltage-gated ion channels. [GOC:go_curators]'}, 'entity': {0: 'potential'}, 'text': {0: 'mother outweighs the potential risk to the foetus. There is a limited amount of data '}}",{},"           entity_group                   value     score
0  Detailed_description  limited amount of data  0.959287",[],"{'keyword': {0: 'limited data', 1: 'potential risk', 2: 'foetus limited data', 3: 'outweighs potential risk', 4: 'risk foetus'}, 'score': {0: 0.7922, 1: 0.7419, 2: 0.7355, 3: 0.7209, 4: 0.5105}}"
229,229,229,0.8830000162124634,16.0,"from the use of Herceptin in pregnant women, and the safe use of Herceptin during ",MyriadPro-Light,4,-0.25,3355443,11,2,3,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Herceptin'}, 'text': {0: 'from the use of Herceptin in pregnant women, and the safe use of Herceptin during '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'from the use of Herceptin in pregnant women, and the safe use of Herceptin during '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'from the use of Herceptin in pregnant women, and the safe use of Herceptin during '}}",{},{},"           entity_group                value     score
0            Medication  Herceptin Herceptin  0.927837
1  Detailed_description             pregnant  0.477659","[('Herceptin', 'DRUG'), ('Herceptin', 'DRUG')]","{'keyword': {0: 'pregnant women', 1: 'safe use', 2: 'pregnant women safe', 3: 'use herceptin', 4: 'safe use herceptin'}, 'score': {0: 0.6581, 1: 0.5599, 2: 0.5459, 3: 0.4864, 4: 0.4793}}"
230,230,230,0.8830000162124634,16.0,pregnancy and lactation has not been established. ,MyriadPro-Light,4,-0.25,3355443,11,2,4,"{'concept_id': {0: 'C2828358'}, 'canonical_name': {0: 'Lactating (finding)'}, 'aliases': {0: ['Lactating']}, 'types': {0: ['T033']}, 'definition': {0: 'An indication that the subject is currently producing milk.'}, 'entity': {0: 'lactation'}, 'text': {0: 'pregnancy and lactation has not been established. '}}","{'concept_id': {0: 'C0376261'}, 'canonical_name': {0: 'Lactate'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'name of an organic chemical'}, 'entity': {0: 'lactation'}, 'text': {0: 'pregnancy and lactation has not been established. '}}","{'concept_id': {0: 'C0376261'}, 'canonical_name': {0: 'lactate'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'name of an organic chemical'}, 'entity': {0: 'lactation'}, 'text': {0: 'pregnancy and lactation has not been established. '}}","{'concept_id': {0: 'C3894549'}, 'canonical_name': {0: 'positive regulation of lactation'}, 'aliases': {0: ['up regulation of lactation', 'upregulation of lactation', 'up-regulation of lactation']}, 'types': {0: ['T039']}, 'definition': {0: 'Any process that activates or increases the frequency, rate or extent of lactation. [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:19563620]'}, 'entity': {0: 'lactation'}, 'text': {0: 'pregnancy and lactation has not been established. '}}","{'concept_id': {0: 'C4551893'}, 'canonical_name': {0: 'Toxaemia of pregnancy'}, 'aliases': {0: ['Hypertensive disorder of pregnancy', 'Toxemia of pregnancy']}, 'types': {0: ['T047']}, 'definition': {0: 'A pregnancy induced hypertensive state that occurs after 20 weeks of gestation characterized by an increase in blood pressure, along with body swelling and proteinuria.'}, 'entity': {0: 'pregnancy'}, 'text': {0: 'pregnancy and lactation has not been established. '}}","            entity_group      value     score
0   Detailed_description  pregnancy  0.324810
1  Therapeutic_procedure  lactation  0.551528
2           Sign_symptom  lactation  0.893866",[],"{'keyword': {0: 'lactation established', 1: 'pregnancy lactation established', 2: 'pregnancy lactation'}, 'score': {0: 0.7245, 1: 0.6076, 2: 0.4362}}"
231,231,231,0.8830000162124634,16.0,•  Verify pregnancy status prior to the initiation of Herceptin. Women of child bearing ,MyriadPro-Light,4,-0.25,3355443,11,2,5,"{'concept_id': {0: 'C1546495'}, 'canonical_name': {0: 'Relationship - Child'}, 'aliases': {0: ['Child']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'child'}, 'text': {0: '•  Verify pregnancy status prior to the initiation of Herceptin. Women of child bearing '}}","{'concept_id': {0: 'C0008091'}, 'canonical_name': {0: 'Child Rearing'}, 'aliases': {0: ['Childrearing', 'Rearing, Child']}, 'types': {0: ['T054']}, 'definition': {0: 'The training or bringing-up of children by parents or parent-substitutes. It is used also for child rearing practices in different societies, at different economic levels, in different ethnic groups, etc. It differs from PARENTING in that in child rearing the emphasis is on the act of training or bringing up the child and the interaction between the parent and child, while parenting emphasizes the responsibility and qualities of exemplary behavior of the parent.'}, 'entity': {0: 'child'}, 'text': {0: '•  Verify pregnancy status prior to the initiation of Herceptin. Women of child bearing '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: '•  Verify pregnancy status prior to the initiation of Herceptin. Women of child bearing '}}","{'concept_id': {0: 'C4236548'}, 'canonical_name': {0: 'action potential initiation'}, 'aliases': {0: ['action potential firing', 'action potential triggering']}, 'types': {0: ['T043']}, 'definition': {0: 'The initiating cycle of an action potential. In vertebrate neurons this typically occurs at an axon hillock. Not all initiated axon potentials propagate. [ISBN:978-0071390118, PMID:19439602]'}, 'entity': {0: 'initiation'}, 'text': {0: '•  Verify pregnancy status prior to the initiation of Herceptin. Women of child bearing '}}",{},"           entity_group             value     score
0  Diagnostic_procedure  pregnancy status  0.861261
1                   Sex             Women  0.429149
2        Family_history     child bearing  0.928172","[('Herceptin', 'DRUG')]","{'keyword': {0: 'women child', 1: 'verify pregnancy status', 2: 'status prior', 3: 'initiation herceptin women', 4: 'prior initiation'}, 'score': {0: 0.8411, 1: 0.7354, 2: 0.7199, 3: 0.6725, 4: 0.6082}}"
232,232,232,0.8830000162124634,16.0,potential should use effective contraception while receiving Herceptin and for 7 months ,MyriadPro-Light,4,-0.25,3355443,11,2,6,"{'concept_id': {0: 'C4745111'}, 'canonical_name': {0: '24 Months'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'A period of time of twenty-four months.'}, 'entity': {0: 'months'}, 'text': {0: 'potential should use effective contraception while receiving Herceptin and for 7 months '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'potential should use effective contraception while receiving Herceptin and for 7 months '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'potential should use effective contraception while receiving Herceptin and for 7 months '}}","{'concept_id': {0: 'C1154426'}, 'canonical_name': {0: 'positive regulation of action potential'}, 'aliases': {0: ['upregulation of action potential', 'up regulation of action potential', 'up-regulation of action potential']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that activates or increases the frequency, rate or extent of action potential creation, propagation or termination. This typically occurs via modulation of the activity or expression of voltage-gated ion channels. [GOC:go_curators]'}, 'entity': {0: 'potential'}, 'text': {0: 'potential should use effective contraception while receiving Herceptin and for 7 months '}}",{},"            entity_group                              value     score
0  Therapeutic_procedure                      contraception  0.703507
1             Medication                          Herceptin  0.999688
2             Medication  contraception receiving Herceptin  0.998080
3             Medication            contraception Herceptin  0.993953
4               Duration                           7 months  0.967110","[('Herceptin', 'DRUG'), ('for 7 months', 'DURATION')]","{'keyword': {0: 'contraception receiving', 1: 'potential use effective', 2: 'contraception receiving herceptin', 3: 'receiving herceptin', 4: 'herceptin months'}, 'score': {0: 0.8971, 1: 0.8582, 2: 0.8277, 3: 0.8126, 4: 0.6699}}"
233,233,233,0.8830000162124634,16.0,following the last dose of Herceptin.,MyriadPro-Light,4,-0.25,3355443,11,2,7,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Herceptin'}, 'text': {0: 'following the last dose of Herceptin.'}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'following the last dose of Herceptin.'}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'following the last dose of Herceptin.'}}",{},{},"  entity_group      value     score
0  Coreference  Herceptin  0.493574","[('Herceptin', 'DRUG')]","{'keyword': {0: 'following dose herceptin', 1: 'following dose', 2: 'dose herceptin'}, 'score': {0: 0.8929, 1: 0.8857, 2: 0.6973}}"
234,234,234,0.8830000162124634,16.0,"•  If a pregnant woman is treated with Herceptin, or if a patient becomes pregnant ",MyriadPro-Light,4,-0.25,3355443,11,2,8,"{'concept_id': {0: 'C1514389'}, 'canonical_name': {0: 'Pregnant Uterus'}, 'aliases': {0: []}, 'types': {0: ['T023']}, 'definition': {0: 'A uterus containing one or more viable embryos or fetuses.'}, 'entity': {0: 'pregnant'}, 'text': {0: '•  If a pregnant woman is treated with Herceptin, or if a patient becomes pregnant '}}","{'concept_id': {0: 'C0032961'}, 'canonical_name': {0: 'Pregnancies'}, 'aliases': {0: ['Pregnancy', 'Gestation']}, 'types': {0: ['T040']}, 'definition': {0: 'The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.'}, 'entity': {0: 'pregnant'}, 'text': {0: '•  If a pregnant woman is treated with Herceptin, or if a patient becomes pregnant '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: '•  If a pregnant woman is treated with Herceptin, or if a patient becomes pregnant '}}",{},{},"  entity_group              value     score
0      Subject  pregnant pregnant  0.602032
1          Sex              woman  0.586891
2      History  pregnant pregnant  0.569482","[('Herceptin', 'DRUG')]","{'keyword': {0: 'pregnant woman', 1: 'patient pregnant', 2: 'pregnant woman treated', 3: 'woman treated', 4: 'treated herceptin'}, 'score': {0: 0.8736, 1: 0.8584, 2: 0.8373, 3: 0.7716, 4: 0.3417}}"
235,235,235,0.8830000162124634,16.0,"while receiving Herceptin or within 7 months following last dose of Herceptin, close ",MyriadPro-Light,4,-0.25,3355443,11,2,9,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Herceptin'}, 'text': {0: 'while receiving Herceptin or within 7 months following last dose of Herceptin, close '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'while receiving Herceptin or within 7 months following last dose of Herceptin, close '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'while receiving Herceptin or within 7 months following last dose of Herceptin, close '}}",{},{},"           entity_group                          value     score
0            Medication            Herceptin Herceptin  0.999554
1            Medication  receiving Herceptin Herceptin  0.998678
2                  Date                within 7 months  0.999586
3  Detailed_description                          close  0.988780","[('Herceptin', 'DRUG'), ('Herceptin', 'DRUG')]","{'keyword': {0: 'following dose', 1: 'months following', 2: 'herceptin close', 3: 'receiving herceptin months', 4: 'dose herceptin'}, 'score': {0: 0.7995, 1: 0.7409, 2: 0.7033, 3: 0.7026, 4: 0.5487}}"
236,236,236,0.8830000162124634,16.0,monitoring by a multidisciplinary team is desirable.,MyriadPro-Light,4,-0.25,3355443,11,2,10,"{'concept_id': {0: 'C0030679'}, 'canonical_name': {0: 'Patient Care Team'}, 'aliases': {0: ['patient care team', 'Care Teams, Patient', 'Multidisciplinary Care Teams', 'Patient Care Teams', 'Multidisciplinary Care Team', 'Team, Multidisciplinary Care', 'Care Team, Multidisciplinary', 'Care Team, Patient', 'Team, Patient Care']}, 'types': {0: ['T058']}, 'definition': {0: 'Care of patients by a multidisciplinary team usually organized under the leadership of a physician; each member of the team has specific responsibilities and the whole team contributes to the care of the patient.'}, 'entity': {0: 'multidisciplinary'}, 'text': {0: 'monitoring by a multidisciplinary team is desirable.'}}","{'concept_id': {0: 'C0079631'}, 'canonical_name': {0: 'Interdisciplinary Communication'}, 'aliases': {0: ['Cross-Disciplinary Communications', 'Multidisciplinary Communication', 'Communications, Interdisciplinary', 'Communications, Cross-Disciplinary', 'Communication, Cross-Disciplinary', 'Communication, Multidisciplinary', 'Multidisciplinary Communications', 'Cross Disciplinary Communication', 'Communication, Interdisciplinary', 'Communications, Multidisciplinary', 'Interdisciplinary Communications', 'Cross-Disciplinary Communication']}, 'types': {0: ['T054']}, 'definition': {0: 'Communication, in the sense of cross-fertilization of ideas, involving two or more academic disciplines (such as the disciplines that comprise the cross-disciplinary field of bioethics, including the health and biological sciences, the humanities, and the social sciences and law). Also includes differences in patterns of language usage in different academic or medical disciplines.'}, 'entity': {0: 'multidisciplinary'}, 'text': {0: 'monitoring by a multidisciplinary team is desirable.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'monitoring multidisciplinary', 1: 'multidisciplinary team desirable', 2: 'multidisciplinary team', 3: 'monitoring multidisciplinary team', 4: 'team desirable'}, 'score': {0: 0.8618, 1: 0.8585, 2: 0.8544, 3: 0.8325, 4: 0.8286}}"
237,237,237,0.8830000162124634,16.0,•  If a pregnancy occurs while using Herceptin or within 7 months following the last dose of ,MyriadPro-Light,4,-0.25,3355443,11,2,11,"{'concept_id': {0: 'C1512044'}, 'canonical_name': {0: 'Dose Rate'}, 'aliases': {0: ['doses rate', 'dose-rate', 'dose rate', 'Dose-Rate']}, 'types': {0: ['T081']}, 'definition': {0: 'The amount of any substance administered over a specific period of time.'}, 'entity': {0: 'dose'}, 'text': {0: '•  If a pregnancy occurs while using Herceptin or within 7 months following the last dose of '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: '•  If a pregnancy occurs while using Herceptin or within 7 months following the last dose of '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: '•  If a pregnancy occurs while using Herceptin or within 7 months following the last dose of '}}","{'concept_id': {0: 'C0032961'}, 'canonical_name': {0: 'female pregnancy'}, 'aliases': {0: ['gestation']}, 'types': {0: ['T040']}, 'definition': {0: 'The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.'}, 'entity': {0: 'pregnancy'}, 'text': {0: '•  If a pregnancy occurs while using Herceptin or within 7 months following the last dose of '}}","{'concept_id': {0: 'C4551893'}, 'canonical_name': {0: 'Toxaemia of pregnancy'}, 'aliases': {0: ['Hypertensive disorder of pregnancy', 'Toxemia of pregnancy']}, 'types': {0: ['T047']}, 'definition': {0: 'A pregnancy induced hypertensive state that occurs after 20 weeks of gestation characterized by an increase in blood pressure, along with body swelling and proteinuria.'}, 'entity': {0: 'pregnancy'}, 'text': {0: '•  If a pregnancy occurs while using Herceptin or within 7 months following the last dose of '}}","       entity_group            value     score
0  Disease_disorder        pregnancy  0.995583
1        Medication        Herceptin  0.999788
2              Date  within 7 months  0.831939","[('Herceptin', 'DRUG')]","{'keyword': {0: 'following dose', 1: 'pregnancy occurs', 2: 'months following', 3: 'pregnancy occurs using', 4: 'herceptin months'}, 'score': {0: 0.7877, 1: 0.7566, 2: 0.7487, 3: 0.7352, 4: 0.5499}}"
238,238,238,0.8830000162124634,16.0,"Herceptin, please immediately report the pregnancy to the Roche Drug Safety Centre by ",MyriadPro-Light,4,-0.25,3355443,11,2,12,"{'concept_id': {0: 'C0678800'}, 'canonical_name': {0: 'drug safety'}, 'aliases': {0: ['Drug Safety', 'drugs safety', 'drug safety']}, 'types': {0: ['T080']}, 'definition': {0: '<p>In the U.S., the government\'s Food and Drug Administration (FDA) must approve any drug before it can be sold. This is true whether it\'s a prescription or an over-the-counter drug. The FDA evaluates the safety of a drug by looking at</p> <ul> <li><a href=""https://medlineplus.gov/drugreactions.html"">Side effects</a></li> <li>How it\'s manufactured</li> <li>Results of animal testing and clinical trials</li> </ul> <p>The FDA also monitors a drug\'s safety after approval.</p> <p>For you, drug safety means buying online from only legitimate pharmacies and <a href=""https://medlineplus.gov/medicationerrors.html"">taking your medicines correctly</a>.</p>'}, 'entity': {0: 'Roche Drug Safety Centre'}, 'text': {0: 'Herceptin, please immediately report the pregnancy to the Roche Drug Safety Centre by '}}","{'concept_id': {0: 'C0032974'}, 'canonical_name': {0: 'Pregnancy Proteins'}, 'aliases': {0: ['Placental Proteins', 'Proteins, Pregnancy', 'Proteins, Placental']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'Proteins produced by organs of the mother or the PLACENTA during PREGNANCY. These proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.)'}, 'entity': {0: 'pregnancy'}, 'text': {0: 'Herceptin, please immediately report the pregnancy to the Roche Drug Safety Centre by '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Herceptin, please immediately report the pregnancy to the Roche Drug Safety Centre by '}}","{'concept_id': {0: 'C0032961'}, 'canonical_name': {0: 'female pregnancy'}, 'aliases': {0: ['gestation']}, 'types': {0: ['T040']}, 'definition': {0: 'The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.'}, 'entity': {0: 'pregnancy'}, 'text': {0: 'Herceptin, please immediately report the pregnancy to the Roche Drug Safety Centre by '}}","{'concept_id': {0: 'C4551893'}, 'canonical_name': {0: 'Toxaemia of pregnancy'}, 'aliases': {0: ['Hypertensive disorder of pregnancy', 'Toxemia of pregnancy']}, 'types': {0: ['T047']}, 'definition': {0: 'A pregnancy induced hypertensive state that occurs after 20 weeks of gestation characterized by an increase in blood pressure, along with body swelling and proteinuria.'}, 'entity': {0: 'pregnancy'}, 'text': {0: 'Herceptin, please immediately report the pregnancy to the Roche Drug Safety Centre by '}}","             entity_group                     value     score
0          Clinical_event                    report  0.998687
1  Nonbiological_location  Roche Drug Safety Centre  0.988810","[('Herceptin', 'DRUG')]","{'keyword': {0: 'immediately report', 1: 'herceptin immediately', 2: 'drug safety', 3: 'roche drug', 4: 'report pregnancy'}, 'score': {0: 0.5674, 1: 0.5494, 2: 0.5179, 3: 0.421, 4: 0.2983}}"
239,239,239,0.8830000162124634,16.0,emailing welwyn.uk_dsc@roche.com or calling +44(0)1707 367554.,MyriadPro-Light,4,-0.25,3355443,11,2,13,"{'concept_id': {0: 'C0034770'}, 'canonical_name': {0: 'Mental Recall'}, 'aliases': {0: ['mental recall', 'Mental Recall', 'remember', 'recalling', 'recall', 'remembers', 'Recall, Mental', 'Recall', 'Recollect', 'remembering']}, 'types': {0: ['T041']}, 'definition': {0: 'The process whereby a representation of past experience is elicited.'}, 'entity': {0: 'calling'}, 'text': {0: 'emailing welwyn.uk_dsc@roche.com or calling +44(0)1707 367554.'}}",{},{},{},{},"           entity_group     value     score
0  Detailed_description  emailing  0.901394
1  Detailed_description   calling  0.895427",[],"{'keyword': {0: '44 1707 367554', 1: 'uk_dsc roche', 2: 'emailing welwyn uk_dsc', 3: 'roche com calling', 4: 'calling 44'}, 'score': {0: 0.8114, 1: 0.7784, 2: 0.7669, 3: 0.7442, 4: 0.711}}"
240,240,240,0.8830000162124634,16.0,•  Additional information will be requested during a Herceptin-exposed pregnancy and ,MyriadPro-Light,4,-0.25,3355443,11,2,14,"{'concept_id': {0: 'C1561527'}, 'canonical_name': {0: 'Error severity - Information'}, 'aliases': {0: ['Information']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'information'}, 'text': {0: '•  Additional information will be requested during a Herceptin-exposed pregnancy and '}}","{'concept_id': {0: 'C0021428'}, 'canonical_name': {0: 'Information Systems'}, 'aliases': {0: ['Information System']}, 'types': {0: ['T170']}, 'definition': {0: 'Integrated set of files, procedures, and equipment for the storage, manipulation, and retrieval of information.'}, 'entity': {0: 'information'}, 'text': {0: '•  Additional information will be requested during a Herceptin-exposed pregnancy and '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []","[('Herceptin', 'DRUG')]","{'keyword': {0: 'information requested', 1: 'requested herceptin', 2: 'additional information', 3: 'herceptin exposed', 4: 'herceptin exposed pregnancy'}, 'score': {0: 0.8802, 1: 0.8214, 2: 0.7578, 3: 0.7185, 4: 0.6887}}"
241,241,241,0.8830000162124634,16.0,the first year of the infant’s life. This will enable Roche to better understand the safety ,MyriadPro-Light,4,-0.25,3355443,11,2,15,"{'concept_id': {0: 'C1456533'}, 'canonical_name': {0: 'Fire Safety'}, 'aliases': {0: []}, 'types': {0: ['T089']}, 'definition': {0: ""<p>Preventing fires is an important part of fire safety. In the United States, cooking is the main cause of home fires. Cigarettes are a big risk too - they are the leading cause of fire deaths. Here are some fire prevention tips:</p> <ul> <li>Don't leave the stove or oven unattended when they are on</li> <li>Don't let children use kitchen appliances unsupervised</li> <li>Don't smoke in bed</li> <li>Make sure your electrical appliances and cords are in good condition</li> </ul> <p>It is also important to be prepared in case there is a fire. Make sure that you have working smoke detectors on every floor and in every bedroom. You should also have fire extinguishers on every floor and in your kitchen. Make and practice an escape plan in case the main exit is blocked.</p>""}, 'entity': {0: 'safety'}, 'text': {0: 'the first year of the infant’s life. This will enable Roche to better understand the safety '}}","{'concept_id': {0: 'C1456535'}, 'canonical_name': {0: 'Food Safety'}, 'aliases': {0: ['Safety, Food']}, 'types': {0: ['T057']}, 'definition': {0: 'Activities involved in ensuring the safety of FOOD including avoidance of bacterial and other contamination.'}, 'entity': {0: 'safety'}, 'text': {0: 'the first year of the infant’s life. This will enable Roche to better understand the safety '}}","{'concept_id': {0: 'C0991564'}, 'canonical_name': {0: 'Oral Troche'}, 'aliases': {0: ['Oral Lozenge']}, 'types': {0: ['T122']}, 'definition': {0: 'A solid composed of active and/or inert ingredient(s), sweeteners, other flavorings and mucilage, intended for oral administration.'}, 'entity': {0: 'Roche'}, 'text': {0: 'the first year of the infant’s life. This will enable Roche to better understand the safety '}}",{},{},"  entity_group       value     score
0         Date  first year  0.993277",[],"{'keyword': {0: 'understand safety', 1: 'life enable', 2: 'infant life', 3: 'enable roche', 4: 'year infant'}, 'score': {0: 0.7802, 1: 0.7429, 2: 0.7119, 3: 0.637, 4: 0.4667}}"
242,242,242,0.8830000162124634,16.0,"of Herceptin and to provide appropriate information to Health Authorities, Healthcare ",MyriadPro-Light,4,-0.25,3355443,11,2,16,"{'concept_id': {0: 'C0085552'}, 'canonical_name': {0: 'Health Care Costs'}, 'aliases': {0: ['Cost, Healthcare', 'Healthcare Costs', 'Healthcare Cost', 'Health Care Cost', 'Costs, Health', 'Costs, Healthcare', 'Costs, Health Care', 'Cost, Health Care', 'health care cost', 'Health Cost', 'health care costs', 'Cost, Health', 'health costs', 'Health Costs']}, 'types': {0: ['T081']}, 'definition': {0: 'The actual costs of providing services related to the delivery of health care, including the costs of procedures, therapies, and medications. It is differentiated from HEALTH EXPENDITURES, which refers to the amount of money paid for the services, and from fees, which refers to the amount charged, regardless of cost.'}, 'entity': {0: 'Healthcare'}, 'text': {0: 'of Herceptin and to provide appropriate information to Health Authorities, Healthcare '}}","{'concept_id': {0: 'C0525053'}, 'canonical_name': {0: 'Health Care Sector'}, 'aliases': {0: ['Sectors, Healthcare', 'Health Care Sectors', 'Healthcare Sectors', 'Sector, Health Care', 'Healthcare Sector', 'Sector, Healthcare', 'Sectors, Health Care']}, 'types': {0: ['T078']}, 'definition': {0: 'Economic sector concerned with the provision, distribution, and consumption of health care services and related products.'}, 'entity': {0: 'Healthcare'}, 'text': {0: 'of Herceptin and to provide appropriate information to Health Authorities, Healthcare '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'of Herceptin and to provide appropriate information to Health Authorities, Healthcare '}}",{},"{'concept_id': {0: 'C3898900'}, 'canonical_name': {0: 'Healthy'}, 'aliases': {0: []}, 'types': {0: ['T080']}, 'definition': {0: 'Having no significant health-related issues.'}, 'entity': {0: 'Healthcare'}, 'text': {0: 'of Herceptin and to provide appropriate information to Health Authorities, Healthcare '}}","             entity_group       value     score
0    Diagnostic_procedure   Herceptin  0.932412
1  Nonbiological_location  Healthcare  0.990043","[('Herceptin', 'DRUG')]","{'keyword': {0: 'appropriate information health', 1: 'herceptin provide appropriate', 2: 'herceptin provide', 3: 'provide appropriate information', 4: 'health authorities'}, 'score': {0: 0.8507, 1: 0.8044, 2: 0.7596, 3: 0.6929, 4: 0.6817}}"
243,243,243,0.8830000162124634,16.0,Providers and patients.,MyriadPro-Light,4,-0.25,3355443,11,2,17,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'Providers and patients.'}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'Providers and patients.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'providers patients'}, 'score': {0: 0.6701}}"
244,244,244,0.9520000219345092,15.0,with anthracyclines refer to the SmPC. ARRs are known to occur with Herceptin subcutaneous ,MyriadPro-Regular,4,-0.25,3355443,11,3,0,"{'concept_id': {0: 'C1522438'}, 'canonical_name': {0: 'Subcutaneous Route of Drug Administration'}, 'aliases': {0: ['subcutaneous drug administration', 'Subcutaneous Route of Administration', 'SubcutaneousRoute', 'Subcutaneous route', 'Subcutaneous route (qualifier value)', 'SC use', 'Subcutaneous (intended site)', 'SC route', 'Subcutaneous use', 'Subcutaneous', 'Subdermal route']}, 'types': {0: ['T169']}, 'definition': {0: 'Drug administration beneath the skin. It provides for relatively slow, sustained release of the drug. The rate of absorption into the blood is perfusion-limited, proportional to the amount of drug at the site and can be enhanced by chemical or physical stimulation of blood flow. Subcutaneous administration minimizes the risks associated with intravascular injection: for subcutaneous infusions, external and implantable pumps are used.'}, 'entity': {0: 'Herceptin subcutaneous'}, 'text': {0: 'with anthracyclines refer to the SmPC. ARRs are known to occur with Herceptin subcutaneous '}}","{'concept_id': {0: 'C0222331'}, 'canonical_name': {0: 'Subcutaneous Adipose Tissue'}, 'aliases': {0: ['Subcutaneous Fat', 'Fats, Subcutaneous', 'Subcutaneous Fats', 'Adipose Tissue, Subcutaneous', 'Fat, Subcutaneous']}, 'types': {0: ['T024']}, 'definition': {0: 'Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.'}, 'entity': {0: 'Herceptin subcutaneous'}, 'text': {0: 'with anthracyclines refer to the SmPC. ARRs are known to occur with Herceptin subcutaneous '}}",{},{},{},"           entity_group           value     score
0  Detailed_description  anthracyclines  0.898059
1           Coreference            SmPC  0.990215
2      Disease_disorder            ARRs  0.999882
3            Medication       Herceptin  0.999223
4  Biological_structure    subcutaneous  0.992418","[('anthracyclines', 'DRUG'), ('Herceptin', 'DRUG'), ('subcutaneous', 'ROUTE')]","{'keyword': {0: 'herceptin subcutaneous', 1: 'anthracyclines refer', 2: 'occur herceptin', 3: 'smpc arrs known', 4: 'known occur'}, 'score': {0: 0.7257, 1: 0.7017, 2: 0.63, 3: 0.5995, 4: 0.392}}"
245,245,245,0.9520000219345092,15.0,formulation. Pre-medication may be used to reduce risk of occurrence of ARRs. Although serious ,MyriadPro-Regular,4,-0.25,3355443,11,3,1,"{'concept_id': {0: 'C1842073'}, 'canonical_name': {0: 'Prolonged Electroretinal Response Suppression'}, 'aliases': {0: ['Prolonged electroretinal response suppression', 'Bradyopsia (disorder)', 'Difficulty seeing moving objects', 'BRADYOPSIA', 'Bradyopsia', 'PROLONGED ELECTRORETINAL RESPONSE SUPPRESSION', 'Prolonged Electroretinal Response Suppression', 'PERRS']}, 'types': {0: ['T033']}, 'definition': {0: 'Difficulty in seeing moving objects. [PMID:25770143]'}, 'entity': {0: 'ARRs'}, 'text': {0: 'formulation. Pre-medication may be used to reduce risk of occurrence of ARRs. Although serious '}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'occurrence'}, 'text': {0: 'formulation. Pre-medication may be used to reduce risk of occurrence of ARRs. Although serious '}}",{},{},{},"       entity_group           value     score
0        Medication  Pre-medication  0.999324
1  Disease_disorder            ARRs  0.735231
2          Severity         serious  0.997043",[],"{'keyword': {0: 'used reduce risk', 1: 'risk occurrence', 2: 'medication used', 3: 'occurrence arrs', 4: 'formulation pre'}, 'score': {0: 0.7111, 1: 0.6906, 2: 0.6557, 3: 0.584, 4: 0.5034}}"
246,246,246,0.9520000219345092,15.0,"ARRs, including dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen ",MyriadPro-Regular,4,-0.25,3355443,11,3,2,"{'concept_id': {0: 'C0184633'}, 'canonical_name': {0: 'Oxygen Therapy Care'}, 'aliases': {0: ['oxygen administration', 'Therapy, Oxygen Inhalation', 'oxygen therapies', 'oxygen therapy', 'Oxygen Inhalation Therapy', 'O2 therapy', 'oxygenation therapy', 'Oxygen therapy', 'Oxygen Therapy', 'Oxygen therapy (procedure)', 'Oxygen therapy, NOS', 'o2 therapy', 'Oxygen Therapy Care', 'Inhalation Therapies, Oxygen', 'Inhalation Therapy, Oxygen', 'Oxygen Inhalation Therapies', 'Oxygen therapy care', 'Therapies, Oxygen Inhalation', 'On oxygen', 'oxygen inhalation therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'Inhalation of oxygen aimed at restoring toward normal any pathophysiologic alterations of gas exchange in the cardiopulmonary system, as by the use of a respirator, nasal catheter, tent, chamber, or mask. (From Dorland, 27th ed & Stedman, 25th ed)'}, 'entity': {0: 'oxygen'}, 'text': {0: 'ARRs, including dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen '}}","{'concept_id': {0: 'C0162772'}, 'canonical_name': {0: 'Active Oxygen Species'}, 'aliases': {0: ['Pro Oxidant', 'Oxygen Radicals', 'Radical, Oxygen', 'Pro-Oxidants', 'Pro-Oxidant', 'Reactive Oxygen Species', 'Oxygen Species, Reactive', 'Reactive Oxygen Intermediates', 'Pro Oxidants', 'Active Oxygen', 'Oxygen, Active', 'Oxygen Radical']}, 'types': {0: ['T123', 'T196']}, 'definition': {0: 'Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of SIGNAL TRANSDUCTION and GENE EXPRESSION, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS.'}, 'entity': {0: 'oxygen'}, 'text': {0: 'ARRs, including dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen '}}","{'concept_id': {0: 'C0030054'}, 'canonical_name': {0: 'oxygen'}, 'aliases': {0: []}, 'types': {0: ['T121', 'T123', 'T196']}, 'definition': {0: 'An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration.'}, 'entity': {0: 'oxygen'}, 'text': {0: 'ARRs, including dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen '}}","{'concept_id': {0: 'C3156653'}, 'canonical_name': {0: 'oxygen metabolic process'}, 'aliases': {0: ['oxygen metabolism', 'diatomic oxygen metabolic process']}, 'types': {0: ['T043']}, 'definition': {0: 'The chemical reactions and pathways involving diatomic oxygen (O2). [GOC:mah]'}, 'entity': {0: 'oxygen'}, 'text': {0: 'ARRs, including dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen '}}","{'concept_id': {0: 'C4476774'}, 'canonical_name': {0: 'Reduced hemolytic complement activity'}, 'aliases': {0: ['Reduced CH50']}, 'types': {0: ['T033']}, 'definition': {0: 'A diminished activity of the classical complement pathway as measured by the assay for 50% haemolytic complement (CH50) activity of serum. [PMID:20351687]'}, 'entity': {0: 'reduced'}, 'text': {0: 'ARRs, including dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen '}}","           entity_group                                          value  \
0          Sign_symptom         including dyspnoea tachycardia reduced   
1          Sign_symptom                                       dyspnoea   
2          Sign_symptom  hypotension wheezing bronchospasm tachycardia   
3          Sign_symptom                                    hypotension   
4          Sign_symptom                                       wheezing   
5          Sign_symptom                                    tachycardia   
6          Sign_symptom                                        reduced   
7  Diagnostic_procedure                                         oxygen   

      score  
0  0.998932  
1  0.908840  
2  0.999161  
3  0.970414  
4  0.546790  
5  0.994039  
6  0.933563  
7  0.433572  ",[],"{'keyword': {0: 'arrs including dyspnoea', 1: 'bronchospasm tachycardia reduced', 2: 'hypotension wheezing', 3: 'tachycardia reduced oxygen', 4: 'bronchospasm tachycardia'}, 'score': {0: 0.9483, 1: 0.8409, 2: 0.8237, 3: 0.798, 4: 0.7168}}"
247,247,247,0.9520000219345092,15.0,"saturation and respiratory distress, were not reported in the clinical trial with the Herceptin ",MyriadPro-Regular,4,-0.25,3355443,11,3,3,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Herceptin'}, 'text': {0: 'saturation and respiratory distress, were not reported in the clinical trial with the Herceptin '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'saturation and respiratory distress, were not reported in the clinical trial with the Herceptin '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'saturation and respiratory distress, were not reported in the clinical trial with the Herceptin '}}",{},"{'concept_id': {0: 'C2887484'}, 'canonical_name': {0: 'Acute respiratory distress syndrome'}, 'aliases': {0: ['ARDS']}, 'types': {0: ['T047']}, 'definition': {0: ""Acute respiratory distress syndrome (ARDS) is defined as an acute disorder that starts within seven days of the inciting event and is characterized by bilateral lung infiltrates and severe progressive hypoxemia in the absence of any evidence of cardiogenic pulmonary edema. ARDS is defined by the patient's oxygen in arterial blood (PaO2) to the fraction of the oxygen in the inspired air (FiO2). These patients have a PaO2/FiO2 ratio of less than 300. [PMID:28613773]""}, 'entity': {0: 'respiratory distress'}, 'text': {0: 'saturation and respiratory distress, were not reported in the clinical trial with the Herceptin '}}","  entity_group      value     score
0   Medication  Herceptin  0.988083","[('Herceptin', 'DRUG')]","{'keyword': {0: 'respiratory distress reported', 1: 'respiratory distress', 2: 'reported clinical', 3: 'saturation respiratory', 4: 'clinical trial herceptin'}, 'score': {0: 0.7319, 1: 0.686, 2: 0.6071, 3: 0.5589, 4: 0.285}}"
248,248,248,0.9520000219345092,15.0,"subcutaneous formulation, caution should be exercised as these have been associated with the ",MyriadPro-Regular,4,-0.25,3355443,11,3,4,"{'concept_id': {0: 'C1428063'}, 'canonical_name': {0: 'MYCBP2 gene'}, 'aliases': {0: ['MYCBP2', 'PROTEIN ASSOCIATED WITH MYC', 'MYCBP2 gene', 'KIAA0916', 'FLJ10106', 'PHR1', 'MYCBP2 Gene', 'PAM/Highwire/RPM-1 protein 1', 'MYC binding protein 2, E3 ubiquitin protein ligase', 'MYC-BINDING PROTEIN 2', 'MYC binding protein 2', 'MYC Binding Protein 2 Gene', 'PAM']}, 'types': {0: ['T028']}, 'definition': {0: 'This gene may play a role in both ubiquitination and transcriptional regulation.'}, 'entity': {0: 'associated with'}, 'text': {0: 'subcutaneous formulation, caution should be exercised as these have been associated with the '}}","{'concept_id': {0: 'C0222331'}, 'canonical_name': {0: 'Subcutaneous Adipose Tissue'}, 'aliases': {0: ['Subcutaneous Fat', 'Fats, Subcutaneous', 'Subcutaneous Fats', 'Adipose Tissue, Subcutaneous', 'Fat, Subcutaneous']}, 'types': {0: ['T024']}, 'definition': {0: 'Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.'}, 'entity': {0: 'subcutaneous formulation'}, 'text': {0: 'subcutaneous formulation, caution should be exercised as these have been associated with the '}}",{},"{'concept_id': {0: 'C0699040'}, 'canonical_name': {0: 'cell bound'}, 'aliases': {0: ['cell surface', 'cell associated']}, 'types': {0: ['T026']}, 'definition': {0: 'The external part of the cell wall and/or plasma membrane. [GOC:jl, GOC:mtg_sensu, GOC:sm]'}, 'entity': {0: 'associated with'}, 'text': {0: 'subcutaneous formulation, caution should be exercised as these have been associated with the '}}",{},"Empty DataFrame
Columns: []
Index: []","[('subcutaneous', 'ROUTE')]","{'keyword': {0: 'exercised associated', 1: 'caution exercised', 2: 'caution exercised associated', 3: 'subcutaneous formulation', 4: 'subcutaneous formulation caution'}, 'score': {0: 0.6493, 1: 0.4373, 2: 0.3916, 3: 0.3905, 4: 0.331}}"
249,249,249,0.9520000219345092,15.0,intravenous formulation. Refer to SmPC for more detailed information. ,MyriadPro-Regular,4,-0.25,3355443,11,3,5,"{'concept_id': {0: 'C1561527'}, 'canonical_name': {0: 'Error severity - Information'}, 'aliases': {0: ['Information']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'information'}, 'text': {0: 'intravenous formulation. Refer to SmPC for more detailed information. '}}","{'concept_id': {0: 'C0021428'}, 'canonical_name': {0: 'Information Systems'}, 'aliases': {0: ['Information System']}, 'types': {0: ['T170']}, 'definition': {0: 'Integrated set of files, procedures, and equipment for the storage, manipulation, and retrieval of information.'}, 'entity': {0: 'information'}, 'text': {0: 'intravenous formulation. Refer to SmPC for more detailed information. '}}",{},{},{},"     entity_group        value     score
0  Administration  intravenous  0.999572
1     Coreference         SmPC  0.821039","[('intravenous', 'ROUTE')]","{'keyword': {0: 'formulation refer smpc', 1: 'refer smpc', 2: 'smpc detailed', 3: 'intravenous formulation', 4: 'detailed information'}, 'score': {0: 0.8289, 1: 0.8006, 2: 0.7454, 3: 0.6316, 4: 0.5179}}"
250,250,250,0.9520000219345092,15.0,Adverse Reactions: For full information and listings please refer to the Herceptin SmPC. Most ,MyriadPro-Regular,4,-0.25,3355443,11,3,6,"{'concept_id': {0: 'C3829994'}, 'canonical_name': {0: 'Generally Satisfied or Pleased'}, 'aliases': {0: ['Generally Satisfied, Pleased', 'Pleased', 'Generally satisfied, pleased', 'Generally Satisfied or Pleased']}, 'types': {0: ['T033']}, 'definition': {0: 'A response indicating that an individual is or has been generally satisfied or pleased.'}, 'entity': {0: 'please'}, 'text': {0: 'Adverse Reactions: For full information and listings please refer to the Herceptin SmPC. Most '}}","{'concept_id': {0: 'C0021428'}, 'canonical_name': {0: 'Information Systems'}, 'aliases': {0: ['Information System']}, 'types': {0: ['T170']}, 'definition': {0: 'Integrated set of files, procedures, and equipment for the storage, manipulation, and retrieval of information.'}, 'entity': {0: 'information'}, 'text': {0: 'Adverse Reactions: For full information and listings please refer to the Herceptin SmPC. Most '}}",{},{},"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse Reactions'}, 'text': {0: 'Adverse Reactions: For full information and listings please refer to the Herceptin SmPC. Most '}}","   entity_group              value     score
0  Sign_symptom  Adverse Reactions  0.695711
1   Coreference          Herceptin  0.484058
2     Lab_value               Most  0.911895","[('Herceptin', 'DRUG')]","{'keyword': {0: 'adverse reactions information', 1: 'adverse reactions', 2: 'herceptin smpc', 3: 'information listings refer', 4: 'refer herceptin'}, 'score': {0: 0.7033, 1: 0.6726, 2: 0.6516, 3: 0.6502, 4: 0.5976}}"
251,251,251,0.9520000219345092,15.0,"common reactions: Infection, nasopharyngitis, febrile neutropenia, anaemia, neutropenia, ",MyriadPro-Regular,4,-0.25,3355443,11,3,7,"{'concept_id': {0: 'C0853697'}, 'canonical_name': {0: 'Neutrophil count decreased'}, 'aliases': {0: ['Neutrophil count below reference range', 'Neutropenia', 'Neutrophil Count Decreased', 'Neutropoenia', 'Low neutrophil count', 'Peripheral neutropenia', 'Low blood neutrophil count', 'Decreased neutrophils', 'Neutropenia (finding)', 'Neutrophils decreased']}, 'types': {0: ['T033']}, 'definition': {0: 'A decrease in the number of neutrophils in the peripheral blood.'}, 'entity': {0: 'neutropenia'}, 'text': {0: 'common reactions: Infection, nasopharyngitis, febrile neutropenia, anaemia, neutropenia, '}}","{'concept_id': {0: 'C0340970'}, 'canonical_name': {0: 'Congenital Neutropenia'}, 'aliases': {0: ['Congenital Agranulocytosis', 'Autosomal dominant or sporadic congenital neutropenia', 'Severe congenital neutropenia']}, 'types': {0: ['T019']}, 'definition': {0: 'A rare congenital disorder characterized by mild or severe reduction of neutrophils in the peripheral blood and recurrent infantile infections.'}, 'entity': {0: 'neutropenia'}, 'text': {0: 'common reactions: Infection, nasopharyngitis, febrile neutropenia, anaemia, neutropenia, '}}",{},"{'concept_id': {0: 'C0042769'}, 'canonical_name': {0: 'viral infection'}, 'aliases': {0: []}, 'types': {0: ['T047']}, 'definition': {0: 'A general term for diseases caused by viruses.'}, 'entity': {0: 'Infection'}, 'text': {0: 'common reactions: Infection, nasopharyngitis, febrile neutropenia, anaemia, neutropenia, '}}","{'concept_id': {0: 'C5139431'}, 'canonical_name': {0: 'Transient neutropenia'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'A transient reduction in the number of neutrophils in the peripheral blood. Transient neutropenia is most commonly associated with viral infections, but other causes include drugs and autoimmunity. [PMID:23953336]'}, 'entity': {0: 'neutropenia'}, 'text': {0: 'common reactions: Infection, nasopharyngitis, febrile neutropenia, anaemia, neutropenia, '}}","           entity_group    value     score
0  Detailed_description  febrile  0.705834",[],"{'keyword': {0: 'common reactions', 1: 'infection nasopharyngitis febrile', 2: 'febrile neutropenia', 3: 'reactions infection', 4: 'anaemia neutropenia'}, 'score': {0: 0.8406, 1: 0.776, 2: 0.7622, 3: 0.7477, 4: 0.388}}"
252,252,252,0.9520000219345092,15.0,"leukopenia, thrombocytopenia, weight loss, anorexia, insomnia, tremor",MyriadPro-Regular,4,-0.25,3355443,11,3,8,"{'concept_id': {0: 'C0234376'}, 'canonical_name': {0: 'Action Tremor'}, 'aliases': {0: ['intention tremor', 'Action Tremor', 'cerebellar tremors', 'action tremors', 'Action Tremors', 'Intention Tremor', 'intention tremors', 'Tremor, Intention', 'Tremor Action', 'action tremor', 'cerebellar tremor', 'volitional tremor', 'kinetic tremor', 'Action tremor', 'Tremor, action', 'intentioned tremors', 'Tremor, Action', 'Intention Tremors']}, 'types': {0: ['T184']}, 'definition': {0: 'A tremor that occurs with the voluntary movement of a muscle. Subcategories include postural, kinetic, and isometric tremors.'}, 'entity': {0: 'tremor'}, 'text': {0: 'leukopenia, thrombocytopenia, weight loss, anorexia, insomnia, tremor'}}","{'concept_id': {0: 'C0234376'}, 'canonical_name': {0: 'Intention Tremors'}, 'aliases': {0: ['Tremor, Action', 'Tremor, Intention', 'Intention Tremor', 'Action Tremors', 'Action Tremor']}, 'types': {0: ['T184']}, 'definition': {0: 'A tremor that occurs with the voluntary movement of a muscle. Subcategories include postural, kinetic, and isometric tremors.'}, 'entity': {0: 'tremor'}, 'text': {0: 'leukopenia, thrombocytopenia, weight loss, anorexia, insomnia, tremor'}}",{},{},"{'concept_id': {0: 'C0239842'}, 'canonical_name': {0: 'tremors in hands'}, 'aliases': {0: ['Tremor of hands', 'Tremor of hand', 'Hand tremor']}, 'types': {0: ['T184']}, 'definition': {0: 'An unintentional, oscillating to-and-fro muscle movement affecting the hand. []'}, 'entity': {0: 'tremor'}, 'text': {0: 'leukopenia, thrombocytopenia, weight loss, anorexia, insomnia, tremor'}}","   entity_group                      value     score
0       History                   anorexia  0.645514
1       History  thrombocytopenia insomnia  0.831237
2  Sign_symptom                     tremor  0.628104",[],"{'keyword': {0: 'loss anorexia insomnia', 1: 'weight loss', 2: 'thrombocytopenia weight', 3: 'leukopenia thrombocytopenia', 4: 'thrombocytopenia weight loss'}, 'score': {0: 0.8111, 1: 0.7604, 2: 0.7566, 3: 0.7108, 4: 0.7014}}"
253,253,253,0.9520000219345092,15.0,"paraesthesia, dysgeusia, conjunctivitis, increased lacrimation, change in blood pressure",MyriadPro-Regular,4,-0.25,3355443,11,3,9,"{'concept_id': {0: 'C1271104'}, 'canonical_name': {0: 'Blood pressure finding'}, 'aliases': {0: ['Blood Pressure', 'Blood Pressure Finding', 'Blood pressure finding', 'Blood Pressure Result', 'Blood pressure measurements', 'Blood pressure finding (finding)', 'Blood pressure']}, 'types': {0: ['T033']}, 'definition': {0: 'A test result that reports the diastolic and systolic pressure of the blood.'}, 'entity': {0: 'blood pressure'}, 'text': {0: 'paraesthesia, dysgeusia, conjunctivitis, increased lacrimation, change in blood pressure'}}","{'concept_id': {0: 'C0005825'}, 'canonical_name': {0: 'Continuous Sphygmomanometers'}, 'aliases': {0: ['Blood Pressure Monitors', 'Blood Pressure Monitor', 'Continuous Sphygmomanometer', 'Sphygmomanometers, Continuous', 'Pressure Monitor, Blood', 'Monitors, Blood Pressure', 'Pressure Monitors, Blood', 'Sphygmomanometer, Continuous', 'Monitor, Blood Pressure']}, 'types': {0: ['T074']}, 'definition': {0: 'Devices for continuously measuring and displaying the arterial blood pressure.'}, 'entity': {0: 'blood pressure'}, 'text': {0: 'paraesthesia, dysgeusia, conjunctivitis, increased lacrimation, change in blood pressure'}}",{},"{'concept_id': {0: 'C1160590'}, 'canonical_name': {0: 'negative regulation of blood pressure'}, 'aliases': {0: ['down-regulation of blood pressure', 'downregulation of blood pressure', 'down regulation of blood pressure']}, 'types': {0: ['T040']}, 'definition': {0: 'Any process in which the force of blood traveling through the circulatory system is decreased. [GOC:go_curators, GOC:mtg_cardio]'}, 'entity': {0: 'blood pressure'}, 'text': {0: 'paraesthesia, dysgeusia, conjunctivitis, increased lacrimation, change in blood pressure'}}","{'concept_id': {0: 'C0020538'}, 'canonical_name': {0: 'High blood pressure'}, 'aliases': {0: ['Arterial hypertension', 'Hypertension', 'Systemic hypertension']}, 'types': {0: ['T047']}, 'definition': {0: 'Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.'}, 'entity': {0: 'blood pressure'}, 'text': {0: 'paraesthesia, dysgeusia, conjunctivitis, increased lacrimation, change in blood pressure'}}","           entity_group                      value     score
0          Sign_symptom  dysgeusia increased blood  0.994040
1      Disease_disorder             conjunctivitis  0.965263
2             Lab_value                  increased  0.995193
3          Sign_symptom  change increased in blood  0.803529
4  Diagnostic_procedure                   pressure  0.656477",[],"{'keyword': {0: 'lacrimation change blood', 1: 'paraesthesia dysgeusia conjunctivitis', 2: 'conjunctivitis increased lacrimation', 3: 'blood pressure', 4: 'change blood pressure'}, 'score': {0: 0.882, 1: 0.8667, 2: 0.8349, 3: 0.7786, 4: 0.7517}}"
254,254,254,0.9520000219345092,15.0,irregular heart beat,MyriadPro-Regular,4,-0.25,3355443,11,3,10,"{'concept_id': {0: 'C2256369'}, 'canonical_name': {0: 'heart process'}, 'aliases': {0: ['cardiac process', 'Heart beating', 'heart process', 'Cardiac process (qualifier value)', 'Heart beating process', 'Cardiac process']}, 'types': {0: ['T039']}, 'definition': {0: 'A circulatory system process carried out by the heart. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood. [GOC:mtg_cardio]'}, 'entity': {0: 'heart beat'}, 'text': {0: 'irregular heart beat'}}","{'concept_id': {0: 'C0018787'}, 'canonical_name': {0: 'Hearts'}, 'aliases': {0: ['Heart']}, 'types': {0: ['T023']}, 'definition': {0: 'The hollow, muscular organ that maintains the circulation of the blood.'}, 'entity': {0: 'heart beat'}, 'text': {0: 'irregular heart beat'}}",{},"{'concept_id': {0: 'C0027045'}, 'canonical_name': {0: 'heart beating'}, 'aliases': {0: ['heart contraction', 'cardiac contraction']}, 'types': {0: ['T042']}, 'definition': {0: 'Contractile activity of the MYOCARDIUM.'}, 'entity': {0: 'heart beat'}, 'text': {0: 'irregular heart beat'}}","{'concept_id': {0: 'C0039231'}, 'canonical_name': {0: 'Fast heart rate'}, 'aliases': {0: ['Racing heart', 'Tachycardia', 'Heart racing', 'Rapid heart beat', 'Increased heart rate']}, 'types': {0: ['T033']}, 'definition': {0: 'Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.'}, 'entity': {0: 'heart beat'}, 'text': {0: 'irregular heart beat'}}","           entity_group       value     score
0             Lab_value   irregular  0.904771
1  Diagnostic_procedure  heart beat  0.999178",[],"{'keyword': {0: 'irregular heart beat', 1: 'irregular heart', 2: 'heart beat'}, 'score': {0: 1.0, 1: 0.9464, 2: 0.8552}}"
255,255,255,0.9520000219345092,15.0,dyspnoea,MyriadPro-Regular,4,-0.25,3355443,11,3,11,"{'concept_id': {0: 'C0231807'}, 'canonical_name': {0: 'Dyspnea on exertion'}, 'aliases': {0: ['Shortness of breathing upon physical activity', 'Dyspnea on exertion', 'exertional dyspnoea', 'Dyspnea on effort', 'Dyspnoea on exertion', 'exertional dyspnea', 'Breathlessness on exertion', 'SOBOE - Shortness of breath on exertion', 'Exertional dyspnoea', 'doe', 'DYSPNEA, EXERTIONAL', 'Exertional breathlessness', 'exertion dyspnea', 'SHORTNESS OF BREATH (ON EXERTION)', 'Short of breath on exertion', 'DOE', 'Dyspnea on exertion (finding)', 'dyspnea on exertion', 'shortness of breath on exertion', 'shortness of breath during exercise', 'Dyspnea Exertional', 'dyspnea on exertion (DOE)', 'dyspnea exertional', 'Exertional dyspnea', 'Dyspnoea on effort', 'Dyspnea, exertional', 'short of breath on exertion', 'DYSPNEA (ON EXERTION)']}, 'types': {0: ['T184']}, 'definition': {0: 'Perceived difficulty to breathe that occurs with exercise or exertion and improves with rest. [PMID:29763022]'}, 'entity': {0: 'dyspnoea'}, 'text': {0: 'dyspnoea'}}",{},{},{},"{'concept_id': {0: 'C0231807'}, 'canonical_name': {0: 'Exertional dyspnoea'}, 'aliases': {0: ['Exertional dyspnea', 'Shortness of breathing upon physical activity', 'Exertional breathlessness']}, 'types': {0: ['T184']}, 'definition': {0: 'Perceived difficulty to breathe that occurs with exercise or exertion and improves with rest. [PMID:29763022]'}, 'entity': {0: 'dyspnoea'}, 'text': {0: 'dyspnoea'}}","   entity_group     value     score
0  Sign_symptom  dyspnoea  0.997353",[],"{'keyword': {}, 'score': {}}"
256,256,256,0.9520000219345092,15.0,"pain, dyspepsia, constipation, stomatitis, erythema, rash, swelling face",MyriadPro-Regular,4,-0.25,3355443,11,3,12,"{'concept_id': {0: 'C0038999'}, 'canonical_name': {0: 'Swelling'}, 'aliases': {0: ['Swelling', 'Bulging', 'Swelling (finding)', 'Swollen', 'Part of body puffy', 'Tumefaction', 'swellings', 'bulge', 'Swelling, NOS', 'swelling', 'Bulge', 'Bulge, NOS', 'bulging', 'Swelling (excluding K07)', 'tumefaction', 'Tumescence', 'Observation of swelling', 'tumescence', 'Swelling (morphologic abnormality)', 'swell', 'SWELLING', 'swelled', 'swells', 'tumefactions', 'swollen', 'Part of body swollen', 'Bulging (morphologic abnormality)']}, 'types': {0: ['T033']}, 'definition': {0: 'Enlargement; expansion in size; sign of inflammation'}, 'entity': {0: 'swelling face'}, 'text': {0: 'pain, dyspepsia, constipation, stomatitis, erythema, rash, swelling face'}}","{'concept_id': {0: 'C1527311'}, 'canonical_name': {0: 'Brain Edema'}, 'aliases': {0: ['Edema, Brain', 'Intracranial Edema', 'Brain Swelling', 'Swelling, Brain', 'Brain Swellings', 'Edema, Intracranial']}, 'types': {0: ['T046']}, 'definition': {0: 'Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)'}, 'entity': {0: 'swelling face'}, 'text': {0: 'pain, dyspepsia, constipation, stomatitis, erythema, rash, swelling face'}}",{},{},"{'concept_id': {0: 'C0239598'}, 'canonical_name': {0: 'Swollen finger'}, 'aliases': {0: ['Swelling of fingers', 'Finger swelling', 'Swollen fingers']}, 'types': {0: ['T033']}, 'definition': {0: 'Enlargement of the soft tissues of one or more fingers. [PMID:16269085, PMID:19946526, PMID:24758199, PMID:9715244]'}, 'entity': {0: 'swelling face'}, 'text': {0: 'pain, dyspepsia, constipation, stomatitis, erythema, rash, swelling face'}}","           entity_group                    value     score
0          Sign_symptom                dyspepsia  0.999922
1          Sign_symptom             constipation  0.999826
2      Disease_disorder  constipation stomatitis  0.934123
3          Sign_symptom                 swelling  0.999780
4  Biological_structure                     face  0.999199",[],"{'keyword': {0: 'stomatitis erythema rash', 1: 'dyspepsia constipation stomatitis', 2: 'constipation stomatitis erythema', 3: 'constipation stomatitis', 4: 'swelling face'}, 'score': {0: 0.8714, 1: 0.8683, 2: 0.8458, 3: 0.8155, 4: 0.7855}}"
257,257,257,0.9520000219345092,15.0,"hand-foot syndrome, arthralgia, muscle tightness",MyriadPro-Regular,4,-0.25,3355443,11,3,13,"{'concept_id': {0: 'C4318613'}, 'canonical_name': {0: 'Have Skin Tightness'}, 'aliases': {0: ['Have Skin Tightness', 'Skin Tightness']}, 'types': {0: ['T170']}, 'definition': {0: ""A question about whether an individual's skin feels or felt tight.""}, 'entity': {0: 'muscle tightness'}, 'text': {0: 'hand-foot syndrome, arthralgia, muscle tightness'}}","{'concept_id': {0: 'C0026841'}, 'canonical_name': {0: 'Tension, Muscular'}, 'aliases': {0: ['Muscle Tension', 'Tonus, Muscle', 'Muscle Tightness', 'Tension, Muscle', 'Muscular Tension', 'Tightness, Muscle', 'Muscle Tonus']}, 'types': {0: ['T042']}, 'definition': {0: 'The state of activity or tension of a muscle beyond that related to its physical properties, that is, its active resistance to stretch. In skeletal muscle, tonus is dependent upon efferent innervation. (Stedman, 25th ed)'}, 'entity': {0: 'muscle tightness'}, 'text': {0: 'hand-foot syndrome, arthralgia, muscle tightness'}}",{},{},"{'concept_id': {0: 'C0019559'}, 'canonical_name': {0: 'Hip joint pain'}, 'aliases': {0: ['Hip arthralgia', 'Arthralgia of the hip', 'Coxalgia']}, 'types': {0: ['T184']}, 'definition': {0: 'A sensation of discomfort emanating from the pelvis, its supporting structures, or its articulation with the femur (acetabulofemoral or femoroacetabular joint).'}, 'entity': {0: 'arthralgia'}, 'text': {0: 'hand-foot syndrome, arthralgia, muscle tightness'}}","   entity_group             value     score
0  Sign_symptom        arthralgia  0.718758
1  Sign_symptom  muscle tightness  0.838398",[],"{'keyword': {0: 'arthralgia muscle tightness', 1: 'syndrome arthralgia', 2: 'muscle tightness', 3: 'foot syndrome', 4: 'hand foot'}, 'score': {0: 0.9183, 1: 0.8455, 2: 0.8271, 3: 0.7971, 4: 0.4824}}"
258,258,258,0.9520000219345092,15.0,"influenza-like symptoms, infusion related reactions, pain, pyrexia, mucosal inflammation, ",MyriadPro-Regular,4,-0.25,3355443,11,3,14,"{'concept_id': {0: 'C0021368'}, 'canonical_name': {0: 'Inflammation'}, 'aliases': {0: ['Inflammatory reaction', 'inflammations', 'Inflammation', 'Inflammations', 'Inflammatory Finding', 'Inflammation (qualifier value)', 'Inflammatory reaction, NOS', 'inflammation', 'Inflammation, NOS']}, 'types': {0: ['T046']}, 'definition': {0: 'A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.'}, 'entity': {0: 'mucosal inflammation'}, 'text': {0: 'influenza-like symptoms, infusion related reactions, pain, pyrexia, mucosal inflammation, '}}","{'concept_id': {0: 'C0021368'}, 'canonical_name': {0: 'Inflammations'}, 'aliases': {0: ['Inflammation']}, 'types': {0: ['T046']}, 'definition': {0: 'A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.'}, 'entity': {0: 'mucosal inflammation'}, 'text': {0: 'influenza-like symptoms, infusion related reactions, pain, pyrexia, mucosal inflammation, '}}","{'concept_id': {0: 'C0030346'}, 'canonical_name': {0: 'papain'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T126']}, 'definition': {0: 'A proteolytic enzyme obtained from Carica papaya. It is also the name used for a purified mixture of papain and CHYMOPAPAIN that is used as a topical enzymatic debriding agent. EC 3.4.22.2.'}, 'entity': {0: 'pain'}, 'text': {0: 'influenza-like symptoms, infusion related reactions, pain, pyrexia, mucosal inflammation, '}}","{'concept_id': {0: 'C0021368'}, 'canonical_name': {0: 'inflammation'}, 'aliases': {0: []}, 'types': {0: ['T046']}, 'definition': {0: 'A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.'}, 'entity': {0: 'mucosal inflammation'}, 'text': {0: 'influenza-like symptoms, infusion related reactions, pain, pyrexia, mucosal inflammation, '}}","{'concept_id': {0: 'C0392676'}, 'canonical_name': {0: 'Hyperpyrexia'}, 'aliases': {0: []}, 'types': {0: ['T046']}, 'definition': {0: 'Body temperature of 106 degrees Fahrenheit (41.1 degrees Celsius) or higher.'}, 'entity': {0: 'pyrexia'}, 'text': {0: 'influenza-like symptoms, infusion related reactions, pain, pyrexia, mucosal inflammation, '}}","     entity_group                                      value     score
0  Administration  influenza-like infusion pain inflammation  0.963365
1  Administration                                   infusion  0.475298",[],"{'keyword': {0: 'pyrexia mucosal inflammation', 1: 'reactions pain pyrexia', 2: 'symptoms infusion related', 3: 'related reactions', 4: 'influenza like'}, 'score': {0: 0.861, 1: 0.8599, 2: 0.7943, 3: 0.6879, 4: 0.6816}}"
259,259,259,0.9520000219345092,15.0,"peripheral oedema, neutropenic sepsis, cystitis, influenza, sinusitis, skin infection, rhinitis, URTI, ",MyriadPro-Regular,4,-0.25,3355443,11,3,15,"{'concept_id': {0: 'C0002103'}, 'canonical_name': {0: 'Atopic rhinitis'}, 'aliases': {0: ['Atopic rhinitis', 'RHINITIS, ATOPIC', 'RHINITIS ALLERGIC ATOPIC', 'Atopic Rhinitis']}, 'types': {0: ['T047']}, 'definition': {0: 'Allergic rhinitis with a positive skin prick test (SPT equal or greater than 3 mm) to any allergen.'}, 'entity': {0: 'rhinitis'}, 'text': {0: 'peripheral oedema, neutropenic sepsis, cystitis, influenza, sinusitis, skin infection, rhinitis, URTI, '}}","{'concept_id': {0: 'C2607914'}, 'canonical_name': {0: 'Rhinitides, Allergic'}, 'aliases': {0: ['Rhinitis, Allergic', 'Allergic Rhinitides', 'Allergic Rhinitis']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea, and itching. It may lead to fatigue, drowsiness, and malaise thus causing impairment of the quality of life.'}, 'entity': {0: 'rhinitis'}, 'text': {0: 'peripheral oedema, neutropenic sepsis, cystitis, influenza, sinusitis, skin infection, rhinitis, URTI, '}}","{'concept_id': {0: 'C0029348'}, 'canonical_name': {0: 'influenza B virus whole'}, 'aliases': {0: ['influenza B virus']}, 'types': {0: ['T005']}, 'definition': {0: 'A negative-strand linear single-strand RNA virus with an 8 segment genome. Virions are enveloped and usually spherical or pleomorphic, 50-120 nm in diameter. Influenza B viruses are usually found only in humans. Unlike influenza A viruses, these viruses are not classified according to subtype.'}, 'entity': {0: 'influenza'}, 'text': {0: 'peripheral oedema, neutropenic sepsis, cystitis, influenza, sinusitis, skin infection, rhinitis, URTI, '}}",{},"{'concept_id': {0: 'C0264272'}, 'canonical_name': {0: 'Purulent rhinitis'}, 'aliases': {0: []}, 'types': {0: ['T184']}, 'definition': {0: 'Chronic rhinitis accompanied by pus formation. []'}, 'entity': {0: 'rhinitis'}, 'text': {0: 'peripheral oedema, neutropenic sepsis, cystitis, influenza, sinusitis, skin infection, rhinitis, URTI, '}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'neutropenic sepsis cystitis', 1: 'rhinitis urti', 2: 'cystitis influenza sinusitis', 3: 'skin infection', 4: 'peripheral oedema'}, 'score': {0: 0.8742, 1: 0.8008, 2: 0.7954, 3: 0.7934, 4: 0.6501}}"
260,260,260,0.9520000219345092,15.0,"UTI, pharyngitis,  hypersensitivity, anxiety, depression, peripheral neuropathy, hypertonia, ",MyriadPro-Regular,4,-0.25,3355443,11,3,16,"{'concept_id': {0: 'C4021898'}, 'canonical_name': {0: 'Upper limb hypertonia'}, 'aliases': {0: []}, 'types': {0: ['T190']}, 'definition': {0: 'Increased muscle tone observed in the arms of the affected person. [ORCID:0000-0002-6670-9157, PMID:21642056]'}, 'entity': {0: 'hypertonia'}, 'text': {0: 'UTI, pharyngitis,  hypersensitivity, anxiety, depression, peripheral neuropathy, hypertonia, '}}","{'concept_id': {0: 'C0026826'}, 'canonical_name': {0: 'Hypermyotonia'}, 'aliases': {0: ['Muscle Hypertonia', 'Muscle Hypertonias', 'Hypermyotonias', 'Muscle Tone Increased', 'Muscular Hypertonicity', 'Muscular Hypertonicities', 'Hypertonicities, Muscular', 'Hypertonia, Muscle', 'Increased, Muscle Tone', 'Tone Increased, Muscle', 'Hypertonicity, Muscular', 'Hypertonias, Muscle']}, 'types': {0: ['T033']}, 'definition': {0: 'Abnormal increase in skeletal or smooth muscle tone. Skeletal muscle hypertonicity may be associated with PYRAMIDAL TRACT lesions or BASAL GANGLIA DISEASES.'}, 'entity': {0: 'hypertonia'}, 'text': {0: 'UTI, pharyngitis,  hypersensitivity, anxiety, depression, peripheral neuropathy, hypertonia, '}}",{},"{'concept_id': {0: 'C1154951'}, 'canonical_name': {0: 'hyperosmotic response'}, 'aliases': {0: ['hypertonic response', 'HOG response', 'response to hypertonicity']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a hyperosmotic environment, i.e. an environment with a higher concentration of solutes than the organism or cell. [GOC:jl, PMID:12142009]'}, 'entity': {0: 'hypertonia'}, 'text': {0: 'UTI, pharyngitis,  hypersensitivity, anxiety, depression, peripheral neuropathy, hypertonia, '}}","{'concept_id': {0: 'C4021898'}, 'canonical_name': {0: 'Upper limb hypertonia'}, 'aliases': {0: []}, 'types': {0: ['T190']}, 'definition': {0: 'Increased muscle tone observed in the arms of the affected person. [ORCID:0000-0002-6670-9157, PMID:21642056]'}, 'entity': {0: 'hypertonia'}, 'text': {0: 'UTI, pharyngitis,  hypersensitivity, anxiety, depression, peripheral neuropathy, hypertonia, '}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'pharyngitis hypersensitivity anxiety', 1: 'uti pharyngitis', 2: 'anxiety depression peripheral', 3: 'anxiety depression', 4: 'peripheral neuropathy'}, 'score': {0: 0.8675, 1: 0.8608, 2: 0.8294, 3: 0.789, 4: 0.7601}}"
261,261,261,0.9520000219345092,15.0,"somnolence, dry eye, congestive cardiac failure",MyriadPro-Regular,4,-0.25,3355443,11,3,17,"{'concept_id': {0: 'C0023212'}, 'canonical_name': {0: 'Left-Sided Heart Failure'}, 'aliases': {0: ['Left ventricular failure', 'failure left ventricular', 'PULMONARY OEDEMA CARDIAC CAUSE', 'CARDIAC FAILURE LEFT', 'Left heart failure', 'LEFT HEART FAILURE', 'FAILURE HEART LEFT', 'FAILURE LEFT HEART', 'left ventricular failure', 'failure heart left sided', 'Heart Failure, Left Sided', 'Left Ventricular Failure', 'left heart failure', 'Left-sided heart failure', 'Left Sided Heart Failure', 'Heart failure, left-sided', 'Left heart failure (disorder)', 'failure heart left side', 'left side heart failure', 'lvf', 'Left-Sided Heart Failure', 'left-sided heart failure', 'Heart Failure, Left-Sided', 'heart failure left', 'LVF - Left ventricular failure', 'Left-sided heart failure syndrome', 'PULMONARY EDEMA CARDIAC CAUSE']}, 'types': {0: ['T047']}, 'definition': {0: 'Failure of adequate output by the left ventricle despite an increase in distending pressure and in end-diastolic volume, with dyspnea, orthopnea, and other signs and symptoms of pulmonary congestion and edema.'}, 'entity': {0: 'congestive cardiac failure'}, 'text': {0: 'somnolence, dry eye, congestive cardiac failure'}}","{'concept_id': {0: 'C0018802'}, 'canonical_name': {0: 'Heart Failure, Congestive'}, 'aliases': {0: ['Congestive Heart Failure']}, 'types': {0: ['T047']}, 'definition': {0: 'Heart failure accompanied by EDEMA, such as swelling of the legs and ankles and congestion in the lungs.'}, 'entity': {0: 'congestive cardiac failure'}, 'text': {0: 'somnolence, dry eye, congestive cardiac failure'}}",{},{},"{'concept_id': {0: 'C0018802'}, 'canonical_name': {0: 'CHF'}, 'aliases': {0: ['Cardiac failures', 'Congestive heart failure', 'Cardiac failure', 'Heart failure']}, 'types': {0: ['T047']}, 'definition': {0: 'Heart failure accompanied by EDEMA, such as swelling of the legs and ankles and congestion in the lungs.'}, 'entity': {0: 'congestive cardiac failure'}, 'text': {0: 'somnolence, dry eye, congestive cardiac failure'}}","           entity_group            value     score
0          Sign_symptom              dry  0.982351
1  Detailed_description       congestive  0.806438
2      Disease_disorder  cardiac failure  0.999874",[],"{'keyword': {0: 'somnolence dry eye', 1: 'eye congestive', 2: 'somnolence dry', 3: 'dry eye congestive', 4: 'cardiac failure'}, 'score': {0: 0.9224, 1: 0.8512, 2: 0.8432, 3: 0.8089, 4: 0.7512}}"
262,262,262,0.9520000219345092,15.0,"cardiomyopathy, hypotension",MyriadPro-Regular,4,-0.25,3355443,11,3,18,"{'concept_id': {0: 'C0028841'}, 'canonical_name': {0: 'Ocular Hypotension'}, 'aliases': {0: ['Hypotony, Ocular', 'decreased intraocular pressure', 'INTRAOCULAR PRESSURE DECREASE', 'hypotony ocular', 'Lowered intraocular pressure', 'Low intraocular pressure', 'ocular hypotony', 'low intraocular pressure', 'decrease intraocular pressure', 'Ocular hypotony', 'Hypotony of eye, NOS', 'Globe hypotension', 'Hypotony of eye (disorder)', 'Hypotony of eye, unspecified', 'decreased iop', 'Intraocular Pressure Decreased', 'Decreased intraocular pressure', 'Decreased intraocular pressure (finding)', 'ocular hypotension', 'Hypotony of eye', 'Ocular Hypotony', 'Hypotension, Ocular']}, 'types': {0: ['T047']}, 'definition': {0: 'Abnormally low intraocular pressure often related to chronic inflammation (uveitis).'}, 'entity': {0: 'hypotension'}, 'text': {0: 'cardiomyopathy, hypotension'}}","{'concept_id': {0: 'C0020650'}, 'canonical_name': {0: 'Hypotension, Controlled'}, 'aliases': {0: ['Controlled Hypotension', 'Induced Hypotension', 'Hypotension, Induced']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedure in which arterial blood pressure is intentionally reduced in order to control blood loss during surgery. This procedure is performed either pharmacologically or by pre-surgical removal of blood.'}, 'entity': {0: 'hypotension'}, 'text': {0: 'cardiomyopathy, hypotension'}}",{},{},"{'concept_id': {0: 'C0020651'}, 'canonical_name': {0: 'Postural hypotension'}, 'aliases': {0: ['Decrease in blood pressure upon standing up', 'Orthostatic hypotension']}, 'types': {0: ['T047']}, 'definition': {0: 'A significant drop in BLOOD PRESSURE after assuming a standing position. Orthostatic hypotension is a finding, and defined as a 20-mm Hg decrease in systolic pressure or a 10-mm Hg decrease in diastolic pressure 3 minutes after the person has risen from supine to standing. Symptoms generally include DIZZINESS, blurred vision, and SYNCOPE.'}, 'entity': {0: 'hypotension'}, 'text': {0: 'cardiomyopathy, hypotension'}}","   entity_group                       value     score
0  Sign_symptom  cardiomyopathy hypotension  0.999948
1  Sign_symptom                 hypotension  0.997607",[],"{'keyword': {0: 'cardiomyopathy hypotension'}, 'score': {0: 0.876}}"
263,263,263,0.9520000219345092,15.0,effusion,MyriadPro-Regular,4,-0.25,3355443,11,3,19,"{'concept_id': {0: 'C2317432'}, 'canonical_name': {0: 'Effusion (substance)'}, 'aliases': {0: ['Effusion', 'Effusion (substance)']}, 'types': {0: ['T031']}, 'definition': {0: None}, 'entity': {0: 'effusion'}, 'text': {0: 'effusion'}}","{'concept_id': {0: 'C0031039'}, 'canonical_name': {0: 'Effusions, Pericardial'}, 'aliases': {0: ['Pericardial Effusion', 'Effusion, Pericardial', 'Pericardial Effusions']}, 'types': {0: ['T047']}, 'definition': {0: 'Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.'}, 'entity': {0: 'effusion'}, 'text': {0: 'effusion'}}",{},{},"{'concept_id': {0: 'C5441966'}, 'canonical_name': {0: 'Peritoneal effusion'}, 'aliases': {0: []}, 'types': {0: ['T046']}, 'definition': {0: 'The abnormal collection of fluid in the peritoneal cavity resulting in ascites.'}, 'entity': {0: 'effusion'}, 'text': {0: 'effusion'}}","       entity_group     value     score
0  Disease_disorder  effusion  0.952411",[],"{'keyword': {}, 'score': {}}"
264,264,264,0.9520000219345092,15.0,"skin, ecchymosis, hyperhydrosis, maculopapular rash, pruritus, onychoclasis, dermatitis, arthritis, ",MyriadPro-Regular,4,-0.25,3355443,11,3,20,"{'concept_id': {0: 'C0949690'}, 'canonical_name': {0: 'Spondylarthritis'}, 'aliases': {0: ['spine arthritis', 'arthritis of spine', 'Spondylitis', 'spondarthritis', 'Inflammatory spondylopathy', 'Spinal Arthritides', 'Arthritis of spine (disorder)', 'Arthritis, Spinal', 'Spinal Arthritis', 'Spondyloarthritis', 'spinal osteoarthritis', 'osteoarthritis spinal', 'Spondylarthritides', 'Arthritis of spine', 'spondylarthritis', 'spondylarthritides', 'spinal arthritis', 'osteoarthritis of spine', 'Spondylarthritis', 'Spondyloarthritis syndrome', 'spondyloarthritis', 'arthritis spine', 'spine osteoarthritis', 'osteoarthritis spine', 'Spondarthritis', 'Spondyloarthritis (disorder)', 'arthritis spinal']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the joints of the SPINE, the intervertebral articulations.'}, 'entity': {0: 'arthritis'}, 'text': {0: 'skin, ecchymosis, hyperhydrosis, maculopapular rash, pruritus, onychoclasis, dermatitis, arthritis, '}}","{'concept_id': {0: 'C1692886'}, 'canonical_name': {0: 'Arthritis, Septic'}, 'aliases': {0: ['Arthritides, Bacterial', 'Bacterial Arthritides', 'Septic Arthritis', 'Arthritis, Bacterial', 'Bacterial Arthritis']}, 'types': {0: ['T047']}, 'definition': {0: 'The inflammation of one or more joints caused by a bacterial infection within the joint space. Symptoms include pain, stiffness, and decreased range of motion in the affected joint.'}, 'entity': {0: 'arthritis'}, 'text': {0: 'skin, ecchymosis, hyperhydrosis, maculopapular rash, pruritus, onychoclasis, dermatitis, arthritis, '}}","{'concept_id': {0: 'C0035100'}, 'canonical_name': {0: 'chymosin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T126']}, 'definition': {0: 'The predominant milk-clotting enzyme from the true stomach or abomasum of the suckling calf. It is secreted as an inactive precursor called prorennin and converted in the acid environment of the stomach to the active enzyme. EC 3.4.23.4.'}, 'entity': {0: 'ecchymosis'}, 'text': {0: 'skin, ecchymosis, hyperhydrosis, maculopapular rash, pruritus, onychoclasis, dermatitis, arthritis, '}}","{'concept_id': {0: 'C4321528'}, 'canonical_name': {0: 'pruritus'}, 'aliases': {0: ['sensory perception of itch']}, 'types': {0: ['T080']}, 'definition': {0: 'A sensory perception which causes the desire or reflex to scratch. [PMID:26015312, PMID:29723501, PMID:30734045, Wikipedia:Itch]'}, 'entity': {0: 'pruritus'}, 'text': {0: 'skin, ecchymosis, hyperhydrosis, maculopapular rash, pruritus, onychoclasis, dermatitis, arthritis, '}}","{'concept_id': {0: 'C0003869'}, 'canonical_name': {0: 'Septic arthritis'}, 'aliases': {0: []}, 'types': {0: ['T047']}, 'definition': {0: 'Arthritis caused by BACTERIA; RICKETTSIA; MYCOPLASMA; VIRUSES; FUNGI; or PARASITES.'}, 'entity': {0: 'arthritis'}, 'text': {0: 'skin, ecchymosis, hyperhydrosis, maculopapular rash, pruritus, onychoclasis, dermatitis, arthritis, '}}","           entity_group                     value     score
0      Disease_disorder  ecchymosis hyperhydrosis  0.835798
1  Detailed_description             maculopapular  0.979323
2      Disease_disorder             maculopapular  0.411943
3      Disease_disorder              onychoclasis  0.525489
4               History              onychoclasis  0.749299",[],"{'keyword': {0: 'skin ecchymosis hyperhydrosis', 1: 'ecchymosis hyperhydrosis maculopapular', 2: 'rash pruritus onychoclasis', 3: 'maculopapular rash', 4: 'dermatitis arthritis'}, 'score': {0: 0.2755, 1: 0.2628, 2: 0.2282, 3: 0.2029, 4: 0.1128}}"
265,265,265,0.9520000219345092,15.0,"back pain, bone pain, muscle spasms, neck pain, pain in the extremity, renal disorder, breast ",MyriadPro-Regular,4,-0.25,3355443,11,3,21,"{'concept_id': {0: 'C0038293'}, 'canonical_name': {0: 'Sternum'}, 'aliases': {0: ['Bone structure of sternum (body structure)', 'sternums', 'Sternum', 'Sternum/Sternal', 'Breast bone', 'Chest>Sternum', 'Sternal', 'breast bone', 'sternum', 'Sternum, NOS', 'Bone structure of sternum']}, 'types': {0: ['T023']}, 'definition': {0: 'A long, narrow, and flat bone commonly known as BREASTBONE occurring in the midsection of the anterior thoracic segment or chest region, which stabilizes the rib cage and serves as the point of origin for several muscles that move the arms, head, and neck.'}, 'entity': {0: 'breast'}, 'text': {0: 'back pain, bone pain, muscle spasms, neck pain, pain in the extremity, renal disorder, breast '}}","{'concept_id': {0: 'C0024902'}, 'canonical_name': {0: 'Breast Pain'}, 'aliases': {0: ['Mastodynias', 'Mammalgias', 'Mastodynia', 'Mastalgias', 'Mammalgia', 'Pain, Breast', 'Mastalgia', 'Breast Pains', 'Pains, Breast']}, 'types': {0: ['T184']}, 'definition': {0: 'Painful sensation in the breast region.'}, 'entity': {0: 'breast'}, 'text': {0: 'back pain, bone pain, muscle spasms, neck pain, pain in the extremity, renal disorder, breast '}}","{'concept_id': {0: 'C0030346'}, 'canonical_name': {0: 'papain'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T126']}, 'definition': {0: 'A proteolytic enzyme obtained from Carica papaya. It is also the name used for a purified mixture of papain and CHYMOPAPAIN that is used as a topical enzymatic debriding agent. EC 3.4.22.2.'}, 'entity': {0: 'pain'}, 'text': {0: 'back pain, bone pain, muscle spasms, neck pain, pain in the extremity, renal disorder, breast '}}","{'concept_id': {0: 'C3159206'}, 'canonical_name': {0: 'pedicle'}, 'aliases': {0: ['dendritic spine neck', 'spine neck', 'neck']}, 'types': {0: ['T026']}, 'definition': {0: 'Part of the dendritic spine that connects the dendritic shaft to the head of the dendritic spine. [GOC:nln]'}, 'entity': {0: 'neck pain'}, 'text': {0: 'back pain, bone pain, muscle spasms, neck pain, pain in the extremity, renal disorder, breast '}}","{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast'}, 'text': {0: 'back pain, bone pain, muscle spasms, neck pain, pain in the extremity, renal disorder, breast '}}","           entity_group                value     score
0  Biological_structure                 back  0.999925
1  Biological_structure                 bone  0.999922
2  Biological_structure               muscle  0.999903
3  Biological_structure                 neck  0.999920
4          Sign_symptom  pain pain pain pain  0.752524
5  Biological_structure               breast  0.999897",[],"{'keyword': {0: 'pain pain', 1: 'renal disorder', 2: 'pain muscle spasms', 3: 'neck pain', 4: 'renal disorder breast'}, 'score': {0: 0.4863, 1: 0.428, 2: 0.4, 3: 0.3935, 4: 0.3036}}"
266,266,266,0.9520000219345092,15.0,"inflammation, malaise, oedema, contusion. Serious adverse reactions: associated with a fatal ",MyriadPro-Regular,4,-0.25,3355443,11,3,22,"{'concept_id': {0: 'C1705232'}, 'canonical_name': {0: 'Death Related to Adverse Event'}, 'aliases': {0: ['Standard Toxicity Grade 5', 'Fatal', 'Common terminology criteria for adverse events grade 5 (finding)', 'CTCAE grade 5', 'Grade 5 Death Related to Adverse Event', 'Death Related to Adverse Event', 'Common terminology criteria for adverse events grade 5']}, 'types': {0: ['T033']}, 'definition': {0: 'The termination of life associated with an adverse event.'}, 'entity': {0: 'fatal'}, 'text': {0: 'inflammation, malaise, oedema, contusion. Serious adverse reactions: associated with a fatal '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'inflammation, malaise, oedema, contusion. Serious adverse reactions: associated with a fatal '}}",{},"{'concept_id': {0: 'C0699040'}, 'canonical_name': {0: 'cell bound'}, 'aliases': {0: ['cell surface', 'cell associated']}, 'types': {0: ['T026']}, 'definition': {0: 'The external part of the cell wall and/or plasma membrane. [GOC:jl, GOC:mtg_sensu, GOC:sm]'}, 'entity': {0: 'associated with'}, 'text': {0: 'inflammation, malaise, oedema, contusion. Serious adverse reactions: associated with a fatal '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'inflammation, malaise, oedema, contusion. Serious adverse reactions: associated with a fatal '}}","   entity_group              value     score
0      Severity            Serious  0.999731
1  Sign_symptom  adverse reactions  0.991347
2      Severity              fatal  0.995399",[],"{'keyword': {0: 'reactions associated fatal', 1: 'adverse reactions', 2: 'contusion adverse reactions', 3: 'reactions associated', 4: 'oedema contusion'}, 'score': {0: 0.8657, 1: 0.8599, 2: 0.7725, 3: 0.7379, 4: 0.6226}}"
267,267,267,0.9520000219345092,15.0,"outcome (frequency rare) anaphylactic reaction/shock, (frequency uncommon) wheezing",MyriadPro-Regular,4,-0.25,3355443,11,3,23,"{'concept_id': {0: 'C0871396'}, 'canonical_name': {0: 'Spatial Frequency'}, 'aliases': {0: ['spatial frequency', 'Frequency', 'Spatial Frequency']}, 'types': {0: ['T081']}, 'definition': {0: 'The number of occurrences of something within a given spatial interval.'}, 'entity': {0: 'frequency'}, 'text': {0: 'outcome (frequency rare) anaphylactic reaction/shock, (frequency uncommon) wheezing'}}","{'concept_id': {0: 'C3178846'}, 'canonical_name': {0: 'Mutation Rate'}, 'aliases': {0: ['Frequency, Mutation', 'Mutation Frequencies', 'Mutation Frequency', 'Rates, Mutation', 'Mutation Rates', 'Frequencies, Mutation', 'Rate, Mutation']}, 'types': {0: ['T033']}, 'definition': {0: 'The number of mutations that occur in a specific sequence, GENE, or GENOME over a specified period of time such as years, CELL DIVISIONS, or generations.'}, 'entity': {0: 'frequency'}, 'text': {0: 'outcome (frequency rare) anaphylactic reaction/shock, (frequency uncommon) wheezing'}}",{},"{'concept_id': {0: 'C2753752'}, 'canonical_name': {0: 'regulation of cilium beat frequency'}, 'aliases': {0: ['regulation of microtubule-based flagellum beat frequency']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that modulates the frequency of cilium movement, the directed, self-propelled movement of a cilium. [GOC:dph]'}, 'entity': {0: 'frequency'}, 'text': {0: 'outcome (frequency rare) anaphylactic reaction/shock, (frequency uncommon) wheezing'}}","{'concept_id': {0: 'C0239998'}, 'canonical_name': {0: 'Frequent, severe infections'}, 'aliases': {0: ['Recurrent infections', 'Frequent infections', 'Predisposition to infections', 'Increased frequency of infection', 'infections, recurrent']}, 'types': {0: ['T033']}, 'definition': {0: 'Increased susceptibility to infections. [HPO:probinson, HPO:skoehler]'}, 'entity': {0: 'frequency'}, 'text': {0: 'outcome (frequency rare) anaphylactic reaction/shock, (frequency uncommon) wheezing'}}","   entity_group         value     score
0  Sign_symptom  anaphylactic  0.788952
1  Sign_symptom      wheezing  0.999928",[],"{'keyword': {0: 'rare anaphylactic reaction', 1: 'frequency uncommon wheezing', 2: 'shock frequency', 3: 'anaphylactic reaction shock', 4: 'frequency rare anaphylactic'}, 'score': {0: 0.8367, 1: 0.807, 2: 0.7952, 3: 0.7701, 4: 0.6724}}"
268,268,268,0.9520000219345092,15.0,"(reaction frequency cannot be estimated) pulmonary fibrosis, respiratory distress/failure, lung ",MyriadPro-Regular,4,-0.25,3355443,11,3,24,"{'concept_id': {0: 'C0225730'}, 'canonical_name': {0: 'Left lung'}, 'aliases': {0: ['Pulmo sinister', 'Left lung, NOS', 'Left Lung', 'Left lung structure', 'left lung', 'left lungs', 'Left lung structure (body structure)', 'Lung.left', 'Lung Left', 'Left lung']}, 'types': {0: ['T023']}, 'definition': {0: 'The 2-lobed lung located on the left side of the body.'}, 'entity': {0: 'lung'}, 'text': {0: '(reaction frequency cannot be estimated) pulmonary fibrosis, respiratory distress/failure, lung '}}","{'concept_id': {0: 'C0242379'}, 'canonical_name': {0: 'Cancer, Lung'}, 'aliases': {0: ['Pulmonary Cancers', 'Cancers, Pulmonary', 'Lung Cancer', 'Cancers, Lung', 'Cancer of the Lung', 'Cancer of Lung', 'Cancer, Pulmonary', 'Pulmonary Cancer', 'Lung Cancers']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the lung.'}, 'entity': {0: 'lung'}, 'text': {0: '(reaction frequency cannot be estimated) pulmonary fibrosis, respiratory distress/failure, lung '}}",{},"{'concept_id': {0: 'C2610587'}, 'canonical_name': {0: 'lung growth'}, 'aliases': {0: []}, 'types': {0: ['T040']}, 'definition': {0: 'The increase in size or mass of a lung. In all air-breathing vertebrates the lungs are developed from the ventral wall of the oesophagus as a pouch which divides into two sacs. In amphibians and many reptiles the lungs retain very nearly this primitive sac-like character, but in the higher forms the connection with the esophagus becomes elongated into the windpipe and the inner walls of the sacs become more and more divided, until, in the mammals, the air spaces become minutely divided into tubes ending in small air cells, in the walls of which the blood circulates in a fine network of capillaries. In mammals the lungs are more or less divided into lobes, and each lung occupies a separate cavity in the thorax. [GOC:dph]'}, 'entity': {0: 'lung'}, 'text': {0: '(reaction frequency cannot be estimated) pulmonary fibrosis, respiratory distress/failure, lung '}}","{'concept_id': {0: 'C0546483'}, 'canonical_name': {0: 'Lung cyst'}, 'aliases': {0: ['Pulmonary cyst']}, 'types': {0: ['T190']}, 'definition': {0: 'A round, usually thin-walled, abnormal space located in the lung.'}, 'entity': {0: 'lung'}, 'text': {0: '(reaction frequency cannot be estimated) pulmonary fibrosis, respiratory distress/failure, lung '}}","           entity_group      value     score
0  Biological_structure  pulmonary  0.984217
1  Biological_structure       lung  0.999950",[],"{'keyword': {0: 'pulmonary fibrosis respiratory', 1: 'fibrosis respiratory distress', 2: 'estimated pulmonary', 3: 'respiratory distress', 4: 'frequency estimated'}, 'score': {0: 0.9104, 1: 0.8813, 2: 0.8555, 3: 0.8221, 4: 0.8196}}"
269,269,269,0.9520000219345092,15.0,"infiltration, acute pulmonary oedema, acute respiratory distress syndrome, bronchospasm, ",MyriadPro-Regular,4,-0.25,3355443,11,3,25,"{'concept_id': {0: 'C0006266'}, 'canonical_name': {0: 'Bronchospasm'}, 'aliases': {0: ['Bronchial spasm', 'bronchial spasms', 'Spasms, Bronchial', 'Bronchospasms', 'BRONCHOSPASM', 'bronchospasms', 'Bronchial Spasm', 'bronchial spasm', 'Spasm, Bronchial', 'Bronchial Spasms', 'Bronchospasm (finding)', 'SPASM BRONCHIAL', 'bronchospasm', 'Bronchospasm NOS', 'Bronchospasm']}, 'types': {0: ['T047']}, 'definition': {0: 'Spasmodic contraction of the smooth muscle of the bronchi.'}, 'entity': {0: 'bronchospasm'}, 'text': {0: 'infiltration, acute pulmonary oedema, acute respiratory distress syndrome, bronchospasm, '}}","{'concept_id': {0: 'C0006266'}, 'canonical_name': {0: 'Bronchial Spasms'}, 'aliases': {0: ['Bronchospasm', 'Bronchospasms', 'Bronchial Spasm', 'Spasm, Bronchial', 'Spasms, Bronchial']}, 'types': {0: ['T047']}, 'definition': {0: 'Spasmodic contraction of the smooth muscle of the bronchi.'}, 'entity': {0: 'bronchospasm'}, 'text': {0: 'infiltration, acute pulmonary oedema, acute respiratory distress syndrome, bronchospasm, '}}",{},"{'concept_id': {0: 'C3269157'}, 'canonical_name': {0: 'renal filtration'}, 'aliases': {0: []}, 'types': {0: ['T039']}, 'definition': {0: 'A renal system process in which fluid circulating through the body is filtered through a barrier system. [GOC:pr, GOC:sart]'}, 'entity': {0: 'infiltration'}, 'text': {0: 'infiltration, acute pulmonary oedema, acute respiratory distress syndrome, bronchospasm, '}}","{'concept_id': {0: 'C0006266'}, 'canonical_name': {0: 'Bronchospasm'}, 'aliases': {0: []}, 'types': {0: ['T047']}, 'definition': {0: 'Spasmodic contraction of the smooth muscle of the bronchi.'}, 'entity': {0: 'bronchospasm'}, 'text': {0: 'infiltration, acute pulmonary oedema, acute respiratory distress syndrome, bronchospasm, '}}","           entity_group        value     score
0  Detailed_description  acute acute  0.498178",[],"{'keyword': {0: 'infiltration acute pulmonary', 1: 'pulmonary oedema', 2: 'distress syndrome', 3: 'oedema acute', 4: 'acute respiratory distress'}, 'score': {0: 0.846, 1: 0.8005, 2: 0.762, 3: 0.7471, 4: 0.7072}}"
270,270,270,0.9520000219345092,15.0,"hypoxia, oxygen saturation decreased. Other serious adverse reactions (frequency uncommon) ",MyriadPro-Regular,4,-0.25,3355443,11,3,26,"{'concept_id': {0: 'C0871396'}, 'canonical_name': {0: 'Spatial Frequency'}, 'aliases': {0: ['spatial frequency', 'Frequency', 'Spatial Frequency']}, 'types': {0: ['T081']}, 'definition': {0: 'The number of occurrences of something within a given spatial interval.'}, 'entity': {0: 'frequency'}, 'text': {0: 'hypoxia, oxygen saturation decreased. Other serious adverse reactions (frequency uncommon) '}}","{'concept_id': {0: 'C3178846'}, 'canonical_name': {0: 'Mutation Rate'}, 'aliases': {0: ['Frequency, Mutation', 'Mutation Frequencies', 'Mutation Frequency', 'Rates, Mutation', 'Mutation Rates', 'Frequencies, Mutation', 'Rate, Mutation']}, 'types': {0: ['T033']}, 'definition': {0: 'The number of mutations that occur in a specific sequence, GENE, or GENOME over a specified period of time such as years, CELL DIVISIONS, or generations.'}, 'entity': {0: 'frequency'}, 'text': {0: 'hypoxia, oxygen saturation decreased. Other serious adverse reactions (frequency uncommon) '}}",{},"{'concept_id': {0: 'C2753752'}, 'canonical_name': {0: 'regulation of cilium beat frequency'}, 'aliases': {0: ['regulation of microtubule-based flagellum beat frequency']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that modulates the frequency of cilium movement, the directed, self-propelled movement of a cilium. [GOC:dph]'}, 'entity': {0: 'frequency'}, 'text': {0: 'hypoxia, oxygen saturation decreased. Other serious adverse reactions (frequency uncommon) '}}","{'concept_id': {0: 'C0239998'}, 'canonical_name': {0: 'Frequent, severe infections'}, 'aliases': {0: ['Recurrent infections', 'Frequent infections', 'Predisposition to infections', 'Increased frequency of infection', 'infections, recurrent']}, 'types': {0: ['T033']}, 'definition': {0: 'Increased susceptibility to infections. [HPO:probinson, HPO:skoehler]'}, 'entity': {0: 'frequency'}, 'text': {0: 'hypoxia, oxygen saturation decreased. Other serious adverse reactions (frequency uncommon) '}}","           entity_group              value     score
0  Diagnostic_procedure  oxygen saturation  0.999942
1              Severity            serious  0.999724
2          Sign_symptom  adverse reactions  0.999915",[],"{'keyword': {0: 'adverse reactions', 1: 'oxygen saturation decreased', 2: 'reactions frequency', 3: 'saturation decreased adverse', 4: 'oxygen saturation'}, 'score': {0: 0.8244, 1: 0.8144, 2: 0.8112, 3: 0.734, 4: 0.5676}}"
271,271,271,0.9520000219345092,15.0,pericardial effusion and deafness (frequency rare) jaundice. Other serious adverse reactions ,MyriadPro-Regular,4,-0.25,3355443,11,3,27,"{'concept_id': {0: 'C1368999'}, 'canonical_name': {0: 'Late effect of medical intervention'}, 'aliases': {0: ['Late Adverse Reaction', 'Late effect of', 'Aftereffect', 'Late effect', 'Adverse Late Effects', 'Late Adverse Effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Any symptom or condition which is a result of a medical intervention but arises months or years after it.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'pericardial effusion and deafness (frequency rare) jaundice. Other serious adverse reactions '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'pericardial effusion and deafness (frequency rare) jaundice. Other serious adverse reactions '}}",{},{},"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'pericardial effusion and deafness (frequency rare) jaundice. Other serious adverse reactions '}}","       entity_group                                              value  \
0  Disease_disorder                                        pericardial   
1      Sign_symptom                                        pericardial   
2  Disease_disorder  pericardial effusion deafness frequency rare j...   
3      Sign_symptom                                           effusion   
4  Disease_disorder                                           effusion   
5      Sign_symptom                                           deafness   
6          Severity                                            serious   
7      Sign_symptom                                  adverse reactions   

      score  
0  0.595672  
1  0.731679  
2  0.617260  
3  0.771923  
4  0.535855  
5  0.939725  
6  0.999617  
7  0.999923  ",[],"{'keyword': {0: 'deafness frequency', 1: 'adverse reactions', 2: 'rare jaundice', 3: 'pericardial effusion', 4: 'frequency rare'}, 'score': {0: 0.673, 1: 0.6253, 2: 0.5938, 3: 0.4195, 4: 0.2605}}"
272,272,272,0.9520000219345092,15.0,"(frequency not known); interstitial lung disease, renal hypoplasia of the foetus, pulmonary ",MyriadPro-Regular,4,-0.25,3355443,11,3,28,"{'concept_id': {0: 'C2709248'}, 'canonical_name': {0: 'Pulmonary (qualifier value)'}, 'aliases': {0: ['Pulmonary (qualifier value)', 'Pulmonary', 'Pulmono-']}, 'types': {0: ['T080']}, 'definition': {0: 'Relating to the lungs as the intended site of administration, where the pharmaceutical product is administered, usually by inhalation, for local action in the lower respiratory tract or for systemic action after absorption via the lower respiratory tract.'}, 'entity': {0: 'pulmonary'}, 'text': {0: '(frequency not known); interstitial lung disease, renal hypoplasia of the foetus, pulmonary '}}","{'concept_id': {0: 'C0242379'}, 'canonical_name': {0: 'Cancer, Lung'}, 'aliases': {0: ['Pulmonary Cancers', 'Cancers, Pulmonary', 'Lung Cancer', 'Cancers, Lung', 'Cancer of the Lung', 'Cancer of Lung', 'Cancer, Pulmonary', 'Pulmonary Cancer', 'Lung Cancers']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the lung.'}, 'entity': {0: 'pulmonary'}, 'text': {0: '(frequency not known); interstitial lung disease, renal hypoplasia of the foetus, pulmonary '}}",{},"{'concept_id': {0: 'C2753575'}, 'canonical_name': {0: 'pulmonary valve development'}, 'aliases': {0: []}, 'types': {0: ['T042']}, 'definition': {0: 'The progression of the pulmonary valve over time, from its formation to the mature structure. [GOC:mtg_heart]'}, 'entity': {0: 'pulmonary'}, 'text': {0: '(frequency not known); interstitial lung disease, renal hypoplasia of the foetus, pulmonary '}}","{'concept_id': {0: 'C1857434'}, 'canonical_name': {0: 'Pulmonary bleb'}, 'aliases': {0: []}, 'types': {0: ['T047']}, 'definition': {0: 'A bleb is a small gas-containing space within the visceral pleura or in the subpleural lung, not larger than 1 cm in diameter. CT findings show a bleb as a thin-walled cystic air space contiguous with the pleura. [PMID:12934786, PMID:18195376, PMID:20028879]'}, 'entity': {0: 'pulmonary'}, 'text': {0: '(frequency not known); interstitial lung disease, renal hypoplasia of the foetus, pulmonary '}}","           entity_group       value     score
0  Biological_structure        lung  0.999887
1  Biological_structure       renal  0.987559
2      Disease_disorder  hypoplasia  0.737671
3  Biological_structure      foetus  0.979098
4  Biological_structure   pulmonary  0.999959",[],"{'keyword': {0: 'frequency known', 1: 'known interstitial lung', 2: 'disease renal', 3: 'interstitial lung', 4: 'renal hypoplasia'}, 'score': {0: 0.4938, 1: 0.3898, 2: 0.3377, 3: 0.3346, 4: 0.2535}}"
273,273,273,0.9520000219345092,15.0,"hypoplasia of the foetus, oligohydramnios of the foetus, renal failure, glomerulonephropathy, ",MyriadPro-Regular,4,-0.25,3355443,11,3,29,"{'concept_id': {0: 'C0017658'}, 'canonical_name': {0: 'Glomerulonephritis'}, 'aliases': {0: ['glomerulonephritis', 'Kidney Scarring', 'GLOMERULONEPHRITIS', 'GN - Glomerulonephritis', 'Scarring, Kidney', 'Glomerulonephritis, NOS', 'glomerulonephritides', 'Glomerulonephritis', 'Glomerulonephritis NOS', 'Glomerulonephritis (disorder)', 'Glomerular nephritis', 'Glomerulonephritides']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.'}, 'entity': {0: 'glomerulonephropathy'}, 'text': {0: 'hypoplasia of the foetus, oligohydramnios of the foetus, renal failure, glomerulonephropathy, '}}","{'concept_id': {0: 'C0017658'}, 'canonical_name': {0: 'Glomerulonephritis'}, 'aliases': {0: ['Kidney Scarring', 'Glomerulonephritides', 'Scarring, Kidney']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.'}, 'entity': {0: 'glomerulonephropathy'}, 'text': {0: 'hypoplasia of the foetus, oligohydramnios of the foetus, renal failure, glomerulonephropathy, '}}",{},{},"{'concept_id': {0: 'C0017658'}, 'canonical_name': {0: 'Glomerulonephritis'}, 'aliases': {0: ['Glomerular nephritis']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.'}, 'entity': {0: 'glomerulonephropathy'}, 'text': {0: 'hypoplasia of the foetus, oligohydramnios of the foetus, renal failure, glomerulonephropathy, '}}","           entity_group                                              value  \
0      Disease_disorder  hypoplasia the oligohydramnios the glomerulone...   
1               History                                         hypoplasia   
2      Disease_disorder                                         hypoplasia   
3          Sign_symptom                                    oligohydramnios   
4  Biological_structure                                      foetus foetus   
5      Disease_disorder                                              renal   
6      Disease_disorder               oligohydramnios glomerulonephropathy   
7               History                               glomerulonephropathy   

      score  
0  0.977141  
1  0.561553  
2  0.592584  
3  0.927326  
4  0.990463  
5  0.686441  
6  0.799002  
7  0.417537  ",[],"{'keyword': {0: 'renal failure', 1: 'renal failure glomerulonephropathy', 2: 'foetus renal', 3: 'hypoplasia foetus', 4: 'foetus oligohydramnios foetus'}, 'score': {0: 0.5639, 1: 0.367, 2: 0.2783, 3: 0.2617, 4: 0.1725}}"
274,274,274,0.9520000219345092,15.0,"glomerulonephritis membranous, angioedema, cardiogenic shock, retinal haemorrhage, ",MyriadPro-Regular,4,-0.25,3355443,11,3,30,"{'concept_id': {0: 'C0271049'}, 'canonical_name': {0: 'Subretinal hemorrhage'}, 'aliases': {0: ['Hemorrhage, subretinal', 'subretinal hemorrhage', 'hemorrhages subretinal', 'Subretinal haemorrhage', 'Subretinal hemorrhage', 'Subretinal heme', 'Subretinal hemorrhage (disorder)']}, 'types': {0: ['T046']}, 'definition': {0: 'Accumulation of blood located beneath the neurosensory retina in the space between the neurosensory retina and the retinal pigment epithelium. []'}, 'entity': {0: 'retinal haemorrhage'}, 'text': {0: 'glomerulonephritis membranous, angioedema, cardiogenic shock, retinal haemorrhage, '}}","{'concept_id': {0: 'C0035317'}, 'canonical_name': {0: 'Retinal Hemorrhage'}, 'aliases': {0: ['Hemorrhage, Retinal', 'Retinal Hemorrhages']}, 'types': {0: ['T046']}, 'definition': {0: 'Bleeding from the vessels of the retina.'}, 'entity': {0: 'retinal haemorrhage'}, 'text': {0: 'glomerulonephritis membranous, angioedema, cardiogenic shock, retinal haemorrhage, '}}",{},{},"{'concept_id': {0: 'C4551659'}, 'canonical_name': {0: 'Intraretinal hemorrhage'}, 'aliases': {0: ['Intraretinal haemorrhage']}, 'types': {0: ['T047']}, 'definition': {0: ""A subtype of fundus hemorrhage occurring within the neurosensory retina. Intraretinal haemorrhages may be 'dot' or' blot' shaped or flame shaped depending upon their depth within the retina. [UManchester:psergouniotis]""}, 'entity': {0: 'retinal haemorrhage'}, 'text': {0: 'glomerulonephritis membranous, angioedema, cardiogenic shock, retinal haemorrhage, '}}","           entity_group               value     score
0      Disease_disorder  glomerulonephritis  0.989732
1          Sign_symptom          angioedema  0.536726
2  Biological_structure             retinal  0.815146",[],"{'keyword': {0: 'glomerulonephritis membranous angioedema', 1: 'angioedema cardiogenic', 2: 'cardiogenic shock', 3: 'shock retinal haemorrhage', 4: 'retinal haemorrhage'}, 'score': {0: 0.8402, 1: 0.8258, 2: 0.785, 3: 0.7824, 4: 0.6277}}"
275,275,275,0.9520000219345092,15.0,"papilloedema, hyperkalaemia, tumour lysis syndrome. ",MyriadPro-Regular,4,-0.25,3355443,11,3,31,"{'concept_id': {0: 'C1882062'}, 'canonical_name': {0: 'Neoplastic disease'}, 'aliases': {0: ['Neoplastic syndrome, NOS', 'neoplastic disease', 'Neoplastic disease (disorder)', 'Neoplasia', 'Neoplastic disease', 'Neoplasm', 'Neoplastic syndrome', 'neoplastic syndrome', 'Neoplastic Syndrome', 'New growth', 'Neoplastic growth', 'NG - Neoplastic growth', 'Tumor Syndrome', 'Neoplastic disease, NOS', 'NG - New growth']}, 'types': {0: ['T191']}, 'definition': {0: 'A broad classification for disorders in which the development of neoplasms typically occur in association with a characteristic set of signs or symptoms. These disorders may be inherited or acquired.'}, 'entity': {0: 'tumour lysis syndrome'}, 'text': {0: 'papilloedema, hyperkalaemia, tumour lysis syndrome. '}}","{'concept_id': {0: 'C0041364'}, 'canonical_name': {0: 'Syndromes, Tumour Lysis'}, 'aliases': {0: ['Tumor Lysis Syndromes', 'Tumour Lysis Syndrome', 'Syndrome, Tumor Lysis', 'Syndromes, Tumor Lysis', 'Tumor Lysis Syndrome', 'Syndrome, Tumour Lysis', 'Tumour Lysis Syndromes']}, 'types': {0: ['T047']}, 'definition': {0: 'A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.'}, 'entity': {0: 'tumour lysis syndrome'}, 'text': {0: 'papilloedema, hyperkalaemia, tumour lysis syndrome. '}}",{},{},"{'concept_id': {0: 'C0020461'}, 'canonical_name': {0: 'Elevated serum potassium levels'}, 'aliases': {0: ['Hyperkalemia']}, 'types': {0: ['T033']}, 'definition': {0: 'Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)'}, 'entity': {0: 'hyperkalaemia'}, 'text': {0: 'papilloedema, hyperkalaemia, tumour lysis syndrome. '}}","   entity_group          value     score
0  Sign_symptom  hyperkalaemia  0.968600
1  Sign_symptom         tumour  0.999392",[],"{'keyword': {0: 'papilloedema hyperkalaemia', 1: 'hyperkalaemia tumour lysis', 2: 'hyperkalaemia tumour', 3: 'lysis syndrome', 4: 'tumour lysis'}, 'score': {0: 0.9034, 1: 0.8793, 2: 0.8352, 3: 0.7749, 4: 0.7672}}"
276,276,276,0.9520000219345092,15.0,outcome. ,MyriadPro-Regular,4,-0.25,3355443,11,3,32,"{'concept_id': {0: 'C0206277'}, 'canonical_name': {0: 'Fatal Outcome'}, 'aliases': {0: ['Fatal Outcomes', 'Outcomes, Fatal', 'Outcome, Fatal']}, 'types': {0: ['T046']}, 'definition': {0: 'Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.'}, 'entity': {0: 'outcome'}, 'text': {0: 'outcome. '}}","{'concept_id': {0: 'C0032972'}, 'canonical_name': {0: 'Pregnancy Outcome'}, 'aliases': {0: ['Pregnancy Outcomes', 'Outcome, Pregnancy', 'Outcomes, Pregnancy']}, 'types': {0: ['T033']}, 'definition': {0: 'Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO.'}, 'entity': {0: 'outcome'}, 'text': {0: 'outcome. '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
277,277,277,0.9520000219345092,15.0,available. *Observed in combination therapy following anthracyclines and combined with ,MyriadPro-Regular,4,-0.25,3355443,11,3,33,"{'concept_id': {0: 'C0282564'}, 'canonical_name': {0: 'Anthracyclines'}, 'aliases': {0: ['anthracyclines', 'anthracycline', 'Anthracyclines', 'Anthracycline']}, 'types': {0: ['T109']}, 'definition': {0: 'Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.'}, 'entity': {0: 'anthracyclines'}, 'text': {0: 'available. *Observed in combination therapy following anthracyclines and combined with '}}","{'concept_id': {0: 'C0282564'}, 'canonical_name': {0: 'Anthracyclines'}, 'aliases': {0: ['Anthracycline']}, 'types': {0: ['T109']}, 'definition': {0: 'Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.'}, 'entity': {0: 'anthracyclines'}, 'text': {0: 'available. *Observed in combination therapy following anthracyclines and combined with '}}",{},{},{},"            entity_group                value     score
0  Therapeutic_procedure  combination therapy  0.995705
1             Medication       anthracyclines  0.944492
2   Detailed_description       anthracyclines  0.921661","[('anthracyclines', 'DRUG')]","{'keyword': {0: 'observed combination therapy', 1: 'therapy following anthracyclines', 2: 'following anthracyclines combined', 3: 'available observed', 4: 'observed combination'}, 'score': {0: 0.9042, 1: 0.8796, 2: 0.8632, 3: 0.8273, 4: 0.7893}}"
278,278,278,0.9520000219345092,15.0,taxanes. ,MyriadPro-Regular,4,-0.25,3355443,11,3,34,"{'concept_id': {0: 'C1100802'}, 'canonical_name': {0: 'Rotaxanes'}, 'aliases': {0: ['Rotaxane', 'Rotaxanes']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'Complex compounds in which a dumbbell shaped molecule is encircled by a macrocycle. They are named after rota (wheel) and axis (axle). Notation with a prefix is used to indicate the number of interlocked components. They have potential use in NANOTECHNOLOGY. Rotaxanes have been made with CYCLODEXTRINS and CYCLIC ETHERS.'}, 'entity': {0: 'taxanes'}, 'text': {0: 'taxanes. '}}","{'concept_id': {0: 'C1100802'}, 'canonical_name': {0: 'Rotaxanes'}, 'aliases': {0: ['Rotaxane']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'Complex compounds in which a dumbbell shaped molecule is encircled by a macrocycle. They are named after rota (wheel) and axis (axle). Notation with a prefix is used to indicate the number of interlocked components. They have potential use in NANOTECHNOLOGY. Rotaxanes have been made with CYCLODEXTRINS and CYCLIC ETHERS.'}, 'entity': {0: 'taxanes'}, 'text': {0: 'taxanes. '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
279,279,279,0.9520000219345092,15.0,Legal Category: POM ,MyriadPro-Regular,4,-0.25,3355443,11,3,35,"{'concept_id': {0: 'C0475455'}, 'canonical_name': {0: 'T - Tumor stage'}, 'aliases': {0: ['T stage', 'T Category', 'T Classification', 'T - Tumour stage', 'T - Tumor stage', 'T - Tumor stage (attribute)', 'Tumour stages', 'Tumor stages', 'T - Tumor stages', 'tumor stages', 'T category (observable entity)', 'T - Tumour stages', 'T category']}, 'types': {0: ['T170']}, 'definition': {0: 'One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).'}, 'entity': {0: 'Legal Category'}, 'text': {0: 'Legal Category: POM '}}",{},{},{},{},"           entity_group value     score
0      Disease_disorder   POM  0.942097
1  Diagnostic_procedure   POM  0.215521",[],"{'keyword': {0: 'legal category pom', 1: 'legal category', 2: 'category pom'}, 'score': {0: 0.9384, 1: 0.873, 2: 0.8584}}"
280,280,280,0.9520000219345092,15.0,Presentation and Basic NHS Cost: Pack of one 6mL vial containing 5mL of solution (600mg of ,MyriadPro-Regular,4,-0.25,3355443,11,3,36,"{'concept_id': {0: 'C1382100'}, 'canonical_name': {0: 'Solution Dosage Form'}, 'aliases': {0: ['SolutionDrugForm', 'Solution (basic dose form)', 'Solution', 'Solution Dosage Form', 'Solution Dose Form']}, 'types': {0: ['T122']}, 'definition': {0: 'A clear, homogeneous liquid composed of one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.'}, 'entity': {0: 'solution'}, 'text': {0: 'Presentation and Basic NHS Cost: Pack of one 6mL vial containing 5mL of solution (600mg of '}}","{'concept_id': {0: 'C0620561'}, 'canonical_name': {0: 'Orth solution'}, 'aliases': {0: [""Orth's solution""]}, 'types': {0: ['T130']}, 'definition': {0: 'A general purpose reagent is a chemical reagent that has general laboratory application, that is used to collect, prepare, and examine specimens from the human body for diagnostic histopathology, cytology, and hematology, and that is not labeled or otherwise intended for a specific diagnostic application. General purpose reagents include cytological preservatives, decalcifying reagents, fixatives and adhesives, tissue processing reagents, isotonic solutions, and pH buffers.'}, 'entity': {0: 'solution'}, 'text': {0: 'Presentation and Basic NHS Cost: Pack of one 6mL vial containing 5mL of solution (600mg of '}}","{'concept_id': {0: 'C0991555'}, 'canonical_name': {0: 'Topical Solution'}, 'aliases': {0: []}, 'types': {0: ['T122']}, 'definition': {0: 'A solution intended for administration to a body surface.'}, 'entity': {0: 'solution'}, 'text': {0: 'Presentation and Basic NHS Cost: Pack of one 6mL vial containing 5mL of solution (600mg of '}}","{'concept_id': {0: 'C0206431'}, 'canonical_name': {0: 'antigen processing and presentation'}, 'aliases': {0: ['antigen processing', 'antigen presentation']}, 'types': {0: ['T043']}, 'definition': {0: 'The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)'}, 'entity': {0: 'Presentation'}, 'text': {0: 'Presentation and Basic NHS Cost: Pack of one 6mL vial containing 5mL of solution (600mg of '}}",{},"  entity_group         value     score
0       Dosage  one 6mL vial  0.891233
1       Dosage           5mL  0.941630
2   Medication      solution  0.996775
3       Dosage         600mg  0.822075","[('5mL', 'DOSAGE'), ('600mg', 'STRENGTH')]","{'keyword': {0: 'vial containing', 1: 'containing 5ml', 2: 'nhs cost', 3: 'basic nhs', 4: 'presentation basic'}, 'score': {0: 0.6932, 1: 0.5495, 2: 0.5422, 3: 0.317, 4: 0.3058}}"
281,281,281,0.9520000219345092,15.0,"trastuzumab) - £1,222.20 per vial excluding VAT ",MyriadPro-Regular,4,-0.25,3355443,11,3,37,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab) - £1,222.20 per vial excluding VAT '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab) - £1,222.20 per vial excluding VAT '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab) - £1,222.20 per vial excluding VAT '}}",{},{},"           entity_group               value     score
0            Medication         trastuzumab  0.999763
1                Dosage  £1,222.20 per vial  0.921785
2  Diagnostic_procedure                 VAT  0.947230","[('trastuzumab', 'DRUG')]","{'keyword': {0: '222 20 vial', 1: 'trastuzumab 222 20', 2: '222 20', 3: 'vial excluding', 4: 'excluding vat'}, 'score': {0: 0.8068, 1: 0.8004, 2: 0.7899, 3: 0.5945, 4: 0.2524}}"
282,282,282,0.9520000219345092,15.0,Marketing Authorisation Number: EU/1/00/145/002 PLGB 00031/0860 ,MyriadPro-Regular,4,-0.25,3355443,11,3,38,{},{},{},{},"{'concept_id': {0: 'C0265931'}, 'canonical_name': {0: 'PLSVC'}, 'aliases': {0: ['Persistent left superior vena cava']}, 'types': {0: ['T019']}, 'definition': {0: 'Finding of the SUPERIOR VENA CAVA on the left instead of the usual right side of the ASCENDING AORTA. In bilateral superior vena cava it is found on both sides.'}, 'entity': {0: 'PLGB\xa000031/0860'}, 'text': {0: 'Marketing Authorisation Number: EU/1/00/145/002 PLGB\xa000031/0860 '}}","           entity_group            value     score
0             Lab_value  EU/1/00/145/002  0.870108
1  Diagnostic_procedure             PLGB  0.503661
2             Lab_value       00031/0860  0.998348",[],"{'keyword': {0: 'plgb 00031 0860', 1: 'marketing authorisation', 2: 'eu 00', 3: 'number eu', 4: 'authorisation number'}, 'score': {0: 0.8159, 1: 0.765, 2: 0.7316, 3: 0.7225, 4: 0.6621}}"
283,283,283,0.9520000219345092,15.0,"Supplied by: Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, ",MyriadPro-Regular,4,-0.25,3355443,11,3,39,"{'concept_id': {0: 'C0999244'}, 'canonical_name': {0: 'Falco'}, 'aliases': {0: ['Genus Falco (organism)', 'falco', 'Genus Falco', 'falcon', 'Falco', 'Falcon, NOS', 'Falcons', 'Falcon', 'Falcon (organism)']}, 'types': {0: ['T012']}, 'definition': {0: None}, 'entity': {0: 'Falcon'}, 'text': {0: 'Supplied by: Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, '}}",{},{},{},{},"           entity_group  value     score
0            Medication  Roche  0.537361
1  Detailed_description    AL7  0.987487
2             Lab_value    AL7  0.882593
3  Detailed_description    1TW  0.849547",[],"{'keyword': {0: 'limited falcon way', 1: 'roche products limited', 2: 'al7 1tw', 3: 'roche products', 4: 'supplied roche'}, 'score': {0: 0.8373, 1: 0.7756, 2: 0.7474, 3: 0.7336, 4: 0.7268}}"
284,284,284,0.9520000219345092,15.0,United Kingdom Herceptin,MyriadPro-Regular,4,-0.25,3355443,11,3,40,"{'concept_id': {0: 'C0041700'}, 'canonical_name': {0: 'United Kingdom'}, 'aliases': {0: ['united kingdom', 'United Kingdom', 'UK - United Kingdom of Great Britain and Northern Ireland', 'United Kingdom of Great Britain and Northern Ireland (geographic location)', 'United Kingdom of Great Britain and Northern Ireland', 'kingdom united']}, 'types': {0: ['T083']}, 'definition': {0: 'Country in northwestern Europe including Great Britain and the northern one-sixth of the island of Ireland, located between the North Sea and north Atlantic Ocean. The capital is London.'}, 'entity': {0: 'United Kingdom Herceptin'}, 'text': {0: 'United Kingdom Herceptin'}}","{'concept_id': {0: 'C0041700'}, 'canonical_name': {0: 'United Kingdom'}, 'aliases': {0: []}, 'types': {0: ['T083']}, 'definition': {0: 'Country in northwestern Europe including Great Britain and the northern one-sixth of the island of Ireland, located between the North Sea and north Atlantic Ocean. The capital is London.'}, 'entity': {0: 'United Kingdom Herceptin'}, 'text': {0: 'United Kingdom Herceptin'}}",{},{},{},"           entity_group      value     score
0  Detailed_description     United  0.485646
1             Lab_value    Kingdom  0.095276
2            Medication  Herceptin  0.931192","[('Herceptin', 'DRUG')]","{'keyword': {0: 'united kingdom herceptin', 1: 'kingdom herceptin', 2: 'united kingdom'}, 'score': {0: 1.0, 1: 0.9313, 2: 0.8531}}"
285,285,285,0.9520000219345092,15.0,M-GB-00003953 ,MyriadPro-Regular,4,-0.25,3355443,11,3,41,{},{},{},{},{},"           entity_group          value     score
0  Diagnostic_procedure  M-GB-00003953  0.637559
1  Detailed_description  M-GB-00003953  0.443480
2             Lab_value  M-GB-00003953  0.737372",[],"{'keyword': {0: 'gb 00003953'}, 'score': {0: 0.9082}}"
286,286,286,0.9520000219345092,15.0,Date of Preparation: July 2021,MyriadPro-Regular,4,-0.25,3355443,11,3,42,"{'concept_id': {0: 'C0039315'}, 'canonical_name': {0: 'Tars'}, 'aliases': {0: ['Tars', 'Tar', 'Tar-containing product', 'Tar preparation', 'tar', 'Tar preparation, NOS', 'Product containing tar (product)', 'tars', 'Tar (substance)']}, 'types': {0: ['T109']}, 'definition': {0: 'Viscous materials composed of complex, high-molecular-weight compounds derived from the distillation of petroleum or the destructive distillation of wood or coal. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)'}, 'entity': {0: 'Preparation'}, 'text': {0: 'Date of Preparation: July 2021'}}","{'concept_id': {0: 'C0018503'}, 'canonical_name': {0: 'Hair Preparations'}, 'aliases': {0: ['Preparation, Hair', 'Preparations, Hair', 'Hair Cosmetics', 'Hair Cosmetic', 'Cosmetics, Hair', 'Cosmetic, Hair', 'Hair Preparation']}, 'types': {0: ['T073']}, 'definition': {0: 'Hair grooming, cleansing and modifying products meant for topical application to hair, usually human. They include sprays, bleaches, dyes, conditioners, rinses, shampoos, nutrient lotions, etc.'}, 'entity': {0: 'Preparation'}, 'text': {0: 'Date of Preparation: July 2021'}}",{},{},{},"  entity_group      value     score
0         Date  July 2021  0.996167",[],"{'keyword': {0: 'preparation july 2021', 1: 'july 2021', 2: 'date preparation july', 3: 'preparation july', 4: 'date preparation'}, 'score': {0: 0.9162, 1: 0.8854, 2: 0.8745, 3: 0.8692, 4: 0.8375}}"
287,287,287,0.9520000219345092,15.0,PRESCRIBING INFORMATION ,MyriadPro-Regular,4,-0.25,3355443,11,4,0,"{'concept_id': {0: 'C1561527'}, 'canonical_name': {0: 'Error severity - Information'}, 'aliases': {0: ['Information']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'INFORMATION'}, 'text': {0: 'PRESCRIBING INFORMATION '}}","{'concept_id': {0: 'C0021428'}, 'canonical_name': {0: 'Information Systems'}, 'aliases': {0: ['Information System']}, 'types': {0: ['T170']}, 'definition': {0: 'Integrated set of files, procedures, and equipment for the storage, manipulation, and retrieval of information.'}, 'entity': {0: 'INFORMATION'}, 'text': {0: 'PRESCRIBING INFORMATION '}}",{},{},{},"           entity_group                    value     score
0  Diagnostic_procedure  PRESCRIBING INFORMATION  0.954923",[],"{'keyword': {0: 'prescribing information'}, 'score': {0: 1.0}}"
288,288,288,0.9520000219345092,15.0,HERCEPTIN,MyriadPro-Regular,4,-0.25,3355443,11,4,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'HERCEPTIN'}, 'text': {0: 'HERCEPTIN'}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'HERCEPTIN'}, 'text': {0: 'HERCEPTIN'}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'HERCEPTIN'}, 'text': {0: 'HERCEPTIN'}}",{},{},"           entity_group      value     score
0  Diagnostic_procedure  HERCEPTIN  0.985167","[('HERCEPTIN', 'DRUG')]","{'keyword': {}, 'score': {}}"
289,289,289,0.9520000219345092,15.0,"Indications: Treatment of HER2-positive early breast cancer (eBC): (i)  following surgery, ",MyriadPro-Regular,4,-0.25,3355443,11,4,2,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'surgery'}, 'text': {0: 'Indications: Treatment of HER2-positive early breast cancer (eBC): (i)\xa0 following surgery, '}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'surgery'}, 'text': {0: 'Indications: Treatment of HER2-positive early breast cancer (eBC): (i)\xa0 following surgery, '}}",{},{},{},"           entity_group          value     score
0             Lab_value  HER2-positive  0.983616
1  Detailed_description          early  0.900401
2  Biological_structure         breast  0.629052",[],"{'keyword': {0: 'ebc following surgery', 1: 'early breast', 2: 'treatment her2', 3: 'indications treatment', 4: 'breast cancer'}, 'score': {0: 0.852, 1: 0.847, 2: 0.7846, 3: 0.7624, 4: 0.6905}}"
290,290,290,0.9520000219345092,15.0,chemotherapy (CT) (neoadjuvant or adjuvant) and radiotherapy  (if applicable) (ii)  following ,MyriadPro-Regular,4,-0.25,3355443,11,4,3,"{'concept_id': {0: 'C1522449'}, 'canonical_name': {0: 'Therapeutic radiology procedure'}, 'aliases': {0: ['irradiation', 'Irradiated', 'Radiotherapeutics', 'RT - Radiotherapy', 'Irradiation', 'Treatment, Radiation', 'Cancer Radiotherapy', 'Therapies, Radiation', 'Radiotherapies', 'Radiation oncology AND/OR radiotherapy (procedure)', 'RADIATION AND RADIONUCLIDE THERAPEUTIC PROCEDURES', 'therapy, radiation', 'Radiotherapy', 'Radiation Therapy', 'Radiation Treatment', 'Radiation', 'Radiotherapy, NOS', 'Radiation Therapy (Procedure)', 'RADIATION THERAPY', 'therapy radiation', 'Radiation oncology AND/OR radiotherapy', 'Therapeutic radiology for cancer treatment', 'radiation therapy', 'Radiation Therapies', 'radiation therapies', 'Therapeutic radiology', 'Radiation therapy, NOS', 'Therapy, Radiation', 'RADIATION ONCOLOGY AND RADIOTHERAPY', 'Radiation therapy procedure or service, NOS', 'radiotherapy', 'Irradiate', 'Radiation Treatments', 'radiations therapy', 'Radiation Therapy Procedures and Services', 'Radiation therapy procedure or service', 'Radiation treatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.'}, 'entity': {0: 'radiotherapy'}, 'text': {0: 'chemotherapy (CT) (neoadjuvant or adjuvant) and radiotherapy  (if applicable) (ii)\xa0 following '}}","{'concept_id': {0: 'C0436307'}, 'canonical_name': {0: 'Radiochemotherapy'}, 'aliases': {0: ['Chemoradiotherapies', 'Chemoradiotherapy', 'Radiochemotherapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Treatment that combines chemotherapy with radiotherapy.'}, 'entity': {0: 'radiotherapy'}, 'text': {0: 'chemotherapy (CT) (neoadjuvant or adjuvant) and radiotherapy  (if applicable) (ii)\xa0 following '}}",{},{},{},"            entity_group                      value     score
0             Medication               chemotherapy  0.999829
1  Therapeutic_procedure               radiotherapy  0.999944
2  Therapeutic_procedure  chemotherapy radiotherapy  0.950773","[('chemotherapy', 'DRUG')]","{'keyword': {0: 'adjuvant radiotherapy applicable', 1: 'ct neoadjuvant', 2: 'ii following', 3: 'applicable ii', 4: 'neoadjuvant adjuvant'}, 'score': {0: 0.7785, 1: 0.7455, 2: 0.7257, 3: 0.708, 4: 0.6163}}"
291,291,291,0.9520000219345092,15.0,"adjuvant CT with doxorubicin and cyclophosphamide, in combination with paclitaxel or ",MyriadPro-Regular,4,-0.25,3355443,11,4,4,"{'concept_id': {0: 'C1541201'}, 'canonical_name': {0: 'Pegylated Paclitaxel'}, 'aliases': {0: ['PEG Paclitaxel', 'pegylated paclitaxel', 'PEG-paclitaxel']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'A formulation of polyethylene glycol (PEG) conjugated paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia, with antineoplastic activity. Paclitaxel binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly and resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2). Compared to paclitaxel alone, pegylated paclitaxel has an enhanced water solubility leading to an increase in bioavailability, and decreases its toxicity profile. Therefore, the pegylated formulation potentially supports delivery of higher doses of paclitaxel to the specific site.'}, 'entity': {0: 'paclitaxel'}, 'text': {0: 'adjuvant CT with doxorubicin and cyclophosphamide, in combination with paclitaxel or '}}","{'concept_id': {0: 'C1134470'}, 'canonical_name': {0: 'docosahexaenoyl-paclitaxel'}, 'aliases': {0: ['DHA-paclitaxel', 'docosahexaenoic acid-paclitaxel']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'A prodrug comprised of the naturally occurring omega-3 fatty acid docosahexaenoic acid (DHA) covalently conjugated to the anti-microtubule agent paclitaxel. Because tumor cells take up DHA, DHA-paclitaxel is delivered directly to tumor tissue, where the paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Paclitaxel also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). DHA-paclitaxel exhibits improved pharmacokinetic and toxicity profiles when compared to conventional paclitaxel and has demonstrated antineoplastic activity in animal models of cancer. (NCI04)'}, 'entity': {0: 'paclitaxel'}, 'text': {0: 'adjuvant CT with doxorubicin and cyclophosphamide, in combination with paclitaxel or '}}","{'concept_id': {0: 'C1702776'}, 'canonical_name': {0: 'paclitaxel poliglumex'}, 'aliases': {0: ['PACLitaxel poliglumex']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'The agent paclitaxel linked to a biodegradable, water-soluble polyglutamate polymer with antineoplastic properties. The polyglutamate residue increases the water solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone. Paclitaxel promotes microtubule assembly and prevents microtubule depolymerization, thus interfering with normal mitosis.'}, 'entity': {0: 'paclitaxel'}, 'text': {0: 'adjuvant CT with doxorubicin and cyclophosphamide, in combination with paclitaxel or '}}","{'concept_id': {0: 'C3547190'}, 'canonical_name': {0: 'response to paclitaxel'}, 'aliases': {0: []}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a paclitaxel stimulus. [GOC:TermGenie]'}, 'entity': {0: 'paclitaxel'}, 'text': {0: 'adjuvant CT with doxorubicin and cyclophosphamide, in combination with paclitaxel or '}}",{},"           entity_group                   value     score
0  Detailed_description                adjuvant  0.999953
1  Diagnostic_procedure                      CT  0.999912
2            Medication             doxorubicin  0.999884
3            Medication  doxorubicin paclitaxel  0.999137
4            Medication          doxorubicin or  0.998823
5            Medication        cyclophosphamide  0.997114
6            Medication              paclitaxel  0.999851","[('doxorubicin', 'DRUG'), ('cyclophosphamide', 'DRUG'), ('paclitaxel', 'DRUG')]","{'keyword': {0: 'doxorubicin cyclophosphamide combination', 1: 'combination paclitaxel', 2: 'adjuvant ct', 3: 'ct doxorubicin cyclophosphamide', 4: 'doxorubicin cyclophosphamide'}, 'score': {0: 0.7452, 1: 0.7122, 2: 0.6501, 3: 0.6329, 4: 0.5977}}"
292,292,292,0.9520000219345092,15.0,docetaxel (iii) in combination with adjuvant CT consisting of docetaxel and carboplatin (iv) in ,MyriadPro-Regular,4,-0.25,3355443,11,4,5,"{'concept_id': {0: 'C3899706'}, 'canonical_name': {0: 'Carbon C14-labeled Carboplatin'}, 'aliases': {0: ['14C Carboplatin', 'Carbon-14-labeled Carboplatin']}, 'types': {0: ['T130', 'T197']}, 'definition': {0: 'A radioconjugate composed of the platinum compound carboplatin conjugated to the isotope carbon C 14 (14C-carboplatin), which can potentially be used to predict chemoresistance to carboplatin using accelerator mass spectrometry (AMS). Upon administration of a microdose of 14C-carboplatin, the carboplatin moiety covalently binds to DNA and forms carboplatin-DNA monoadducts. Using AMS, the 14C-carboplatin-DNA monoadducts can be detected and measured. The levels of microdose-induced carboplatin-DNA monoadducts can be used to assess the degree of chemoresistance to carboplatin and can predict cancer response to carboplatin-based chemotherapy. The carboplatin microdose is defined as 1/100 of the pharmacologically effective concentration of carboplatin. Low levels of carboplatin monoadduct formation and increased DNA repair, measured by a decrease in the detection of carboplatin-DNA monoadducts over a given time period, are correlated with increased resistance to platinum-based chemotherapeutics.'}, 'entity': {0: 'carboplatin'}, 'text': {0: 'docetaxel (iii)\xa0in combination with adjuvant CT consisting of docetaxel and carboplatin (iv)\xa0in '}}","{'concept_id': {0: 'C0079083'}, 'canonical_name': {0: 'cis-Diammine(cyclobutanedicarboxylato)platinum II'}, 'aliases': {0: ['Carboplatin', 'Platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)-', 'CBDCA']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'An organoplatinum compound that possesses antineoplastic activity.'}, 'entity': {0: 'carboplatin'}, 'text': {0: 'docetaxel (iii)\xa0in combination with adjuvant CT consisting of docetaxel and carboplatin (iv)\xa0in '}}","{'concept_id': {0: 'C0079083'}, 'canonical_name': {0: 'carboplatin'}, 'aliases': {0: ['CARBOplatin']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'An organoplatinum compound that possesses antineoplastic activity.'}, 'entity': {0: 'carboplatin'}, 'text': {0: 'docetaxel (iii)\xa0in combination with adjuvant CT consisting of docetaxel and carboplatin (iv)\xa0in '}}","{'concept_id': {0: 'C3548509'}, 'canonical_name': {0: 'response to carboplatin'}, 'aliases': {0: []}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carboplatin stimulus. [GOC:pr]'}, 'entity': {0: 'carboplatin'}, 'text': {0: 'docetaxel (iii)\xa0in combination with adjuvant CT consisting of docetaxel and carboplatin (iv)\xa0in '}}",{},"           entity_group                value     score
0            Medication  docetaxel docetaxel  0.996630
1  Detailed_description             adjuvant  0.999646
2  Diagnostic_procedure                   CT  0.999833
3            Medication          carboplatin  0.999522","[('docetaxel', 'DRUG'), ('docetaxel', 'DRUG'), ('carboplatin', 'DRUG')]","{'keyword': {0: 'combination adjuvant ct', 1: 'consisting docetaxel carboplatin', 2: 'carboplatin iv', 3: 'docetaxel iii', 4: 'iii combination'}, 'score': {0: 0.8706, 1: 0.8307, 2: 0.8301, 3: 0.7974, 4: 0.685}}"
293,293,293,0.9520000219345092,15.0,combination with neoadjuvant CT followed by adjuvant trastuzumab for locally advanced ,MyriadPro-Regular,4,-0.25,3355443,11,4,6,"{'concept_id': {0: 'C4727005'}, 'canonical_name': {0: 'Locally Advanced Sarcoma'}, 'aliases': {0: []}, 'types': {0: ['T191']}, 'definition': {0: 'Sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.'}, 'entity': {0: 'locally advanced'}, 'text': {0: 'combination with neoadjuvant CT followed by adjuvant trastuzumab for locally advanced '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant CT'}, 'text': {0: 'combination with neoadjuvant CT followed by adjuvant trastuzumab for locally advanced '}}","{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'adjuvant trastuzumab'}, 'text': {0: 'combination with neoadjuvant CT followed by adjuvant trastuzumab for locally advanced '}}","{'concept_id': {0: 'C0034865'}, 'canonical_name': {0: 'DNA recombination'}, 'aliases': {0: []}, 'types': {0: ['T045']}, 'definition': {0: 'Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses.'}, 'entity': {0: 'combination'}, 'text': {0: 'combination with neoadjuvant CT followed by adjuvant trastuzumab for locally advanced '}}",{},"           entity_group                          value     score
0  Detailed_description                    neoadjuvant  0.999973
1  Detailed_description           neoadjuvant adjuvant  0.963308
2  Diagnostic_procedure                             CT  0.980321
3  Detailed_description  neoadjuvant adjuvant advanced  0.999971
4            Medication                    trastuzumab  0.995329
5  Detailed_description               locally advanced  0.998912","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'ct followed adjuvant', 1: 'trastuzumab locally advanced', 2: 'neoadjuvant ct', 3: 'trastuzumab locally', 4: 'locally advanced'}, 'score': {0: 0.9288, 1: 0.838, 2: 0.8295, 3: 0.7598, 4: 0.685}}"
294,294,294,0.9520000219345092,15.0,(including inflammatory) disease or tumours > 2cm in diameter. Treatment of HER2-positive ,MyriadPro-Regular,4,-0.25,3355443,11,4,7,"{'concept_id': {0: 'C1960398'}, 'canonical_name': {0: 'HER2-positive carcinoma of breast'}, 'aliases': {0: ['HER2+ breast cancer', 'HER2 Overexpressing Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast (disorder)', 'HER2-Positive Breast Carcinoma', 'HER2 Overexpressing Subtype of Breast Carcinoma', 'HER2-positive breast cancer', 'HER2/neu-positive breast cancer', 'ERBB2 Overexpressing Subtype of Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast', 'HER2 Positive Breast Carcinoma', 'HER2 Positive Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).'}, 'entity': {0: 'HER2-positive'}, 'text': {0: '(including inflammatory) disease or tumours > 2cm in diameter. Treatment of HER2-positive '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'Treatment'}, 'text': {0: '(including inflammatory) disease or tumours > 2cm in diameter. Treatment of HER2-positive '}}",{},"{'concept_id': {0: 'C1621986'}, 'canonical_name': {0: 'regulation of axon diameter'}, 'aliases': {0: []}, 'types': {0: ['T042']}, 'definition': {0: 'Any process that modulates the rate, direction or extent of axon growth such that the correct diameter is attained and maintained. [GOC:dph, GOC:mah, GOC:tb]'}, 'entity': {0: 'diameter'}, 'text': {0: '(including inflammatory) disease or tumours > 2cm in diameter. Treatment of HER2-positive '}}","{'concept_id': {0: 'C0037939'}, 'canonical_name': {0: 'Spinal tumours'}, 'aliases': {0: ['Spinal tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'New abnormal growth of tissue in the SPINE.'}, 'entity': {0: 'tumours'}, 'text': {0: '(including inflammatory) disease or tumours > 2cm in diameter. Treatment of HER2-positive '}}","       entity_group          value     score
0  Disease_disorder        disease  0.913378
1      Sign_symptom        tumours  0.998422
2          Distance          > 2cm  0.829058
3         Lab_value  HER2-positive  0.998376",[],"{'keyword': {0: 'treatment her2', 1: 'disease tumours', 2: '2cm diameter treatment', 3: 'tumours 2cm', 4: 'including inflammatory'}, 'score': {0: 0.7722, 1: 0.6049, 2: 0.5953, 3: 0.4077, 4: 0.4006}}"
295,295,295,0.9520000219345092,15.0,metastatic breast cancer (mBC): (i) as monotherapy following at least 2 CT regimens for mBC. ,MyriadPro-Regular,4,-0.25,3355443,11,4,8,"{'concept_id': {0: 'C0040808'}, 'canonical_name': {0: 'Treatment Protocols'}, 'aliases': {0: ['protocols treatment', 'Treatment Protocol', 'treatment protocol', 'regimens', 'Treatment Schedule', 'Treatment Protocols', 'treatment protocols', 'protocol treatment', 'regimen', 'Treatment Regimen', 'Protocols, Treatment', 'Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A treatment plan that specifies the dosage, the schedule, and the duration of treatment.'}, 'entity': {0: 'CT regimens'}, 'text': {0: 'metastatic breast cancer (mBC): (i)\xa0as monotherapy following at least 2 CT regimens for mBC. '}}","{'concept_id': {0: 'C0020311'}, 'canonical_name': {0: 'Hydrotherapy'}, 'aliases': {0: []}, 'types': {0: ['T061']}, 'definition': {0: 'External application of water for therapeutic purposes, such as whirlpool baths or water shiatsu.'}, 'entity': {0: 'monotherapy'}, 'text': {0: 'metastatic breast cancer (mBC): (i)\xa0as monotherapy following at least 2 CT regimens for mBC. '}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'metastatic breast cancer'}, 'text': {0: 'metastatic breast cancer (mBC): (i)\xa0as monotherapy following at least 2 CT regimens for mBC. '}}","            entity_group          value     score
0   Detailed_description     metastatic  0.999488
1       Disease_disorder  breast cancer  0.851113
2       Disease_disorder        mBC mBC  0.996427
3  Therapeutic_procedure    monotherapy  0.993673
4   Diagnostic_procedure             CT  0.999956",[],"{'keyword': {0: 'cancer mbc monotherapy', 1: 'mbc monotherapy following', 2: 'following ct', 3: 'breast cancer', 4: 'ct regimens'}, 'score': {0: 0.863, 1: 0.8361, 2: 0.6351, 3: 0.5639, 4: 0.5434}}"
296,296,296,0.9520000219345092,15.0,"Prior CT to have included at least an anthracycline and a taxane, unless unsuitable. Hormone-",MyriadPro-Regular,4,-0.25,3355443,11,4,9,"{'concept_id': {0: 'C1100802'}, 'canonical_name': {0: 'Rotaxanes'}, 'aliases': {0: ['Rotaxane', 'Rotaxanes']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'Complex compounds in which a dumbbell shaped molecule is encircled by a macrocycle. They are named after rota (wheel) and axis (axle). Notation with a prefix is used to indicate the number of interlocked components. They have potential use in NANOTECHNOLOGY. Rotaxanes have been made with CYCLODEXTRINS and CYCLIC ETHERS.'}, 'entity': {0: 'taxane'}, 'text': {0: 'Prior CT to have included at least an anthracycline and a taxane, unless unsuitable. Hormone-'}}","{'concept_id': {0: 'C1100802'}, 'canonical_name': {0: 'Rotaxanes'}, 'aliases': {0: ['Rotaxane']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'Complex compounds in which a dumbbell shaped molecule is encircled by a macrocycle. They are named after rota (wheel) and axis (axle). Notation with a prefix is used to indicate the number of interlocked components. They have potential use in NANOTECHNOLOGY. Rotaxanes have been made with CYCLODEXTRINS and CYCLIC ETHERS.'}, 'entity': {0: 'taxane'}, 'text': {0: 'Prior CT to have included at least an anthracycline and a taxane, unless unsuitable. Hormone-'}}",{},{},{},"           entity_group     value     score
0  Diagnostic_procedure        CT  0.989768
1            Medication  Hormone-  0.473915","[('anthracycline', 'DRUG'), ('taxane', 'DRUG')]","{'keyword': {0: 'prior ct', 1: 'included anthracycline taxane', 2: 'unless unsuitable', 3: 'ct included', 4: 'anthracycline taxane'}, 'score': {0: 0.3319, 1: 0.1788, 2: 0.1384, 3: 0.1276, 4: 0.0974}}"
297,297,297,0.9520000219345092,15.0,"receptor positive patients must have failed hormonal therapy, unless unsuitable (ii)  in ",MyriadPro-Regular,4,-0.25,3355443,11,4,10,"{'concept_id': {0: 'C1514460'}, 'canonical_name': {0: 'Prior Hormone Therapy'}, 'aliases': {0: ['prior hormonal therapy']}, 'types': {0: ['T201']}, 'definition': {0: 'An indication that an individual has been previously treated with hormonal therapy.'}, 'entity': {0: 'hormonal therapy'}, 'text': {0: 'receptor positive patients must have failed hormonal therapy, unless unsuitable (ii)\xa0 in '}}","{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Treatments'}, 'aliases': {0: ['Therapy', 'Treatment', 'Therapeutics', 'Therapeutic', 'Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'hormonal therapy'}, 'text': {0: 'receptor positive patients must have failed hormonal therapy, unless unsuitable (ii)\xa0 in '}}",{},"{'concept_id': {0: 'C4235600'}, 'canonical_name': {0: 'positive regulation of establishment of protein localization'}, 'aliases': {0: ['upregulation of protein recruitment', 'positive regulation of establishment of protein localisation', 'up regulation of protein positioning', 'up-regulation of protein positioning', 'upregulation of establishment of protein localisation', 'positive regulation of protein positioning', 'positive regulation of protein recruitment', 'up-regulation of establishment of protein localization', 'upregulation of protein positioning', 'up-regulation of protein recruitment', 'upregulation of establishment of protein localization', 'up regulation of establishment of protein localisation', 'up-regulation of establishment of protein localisation', 'up regulation of establishment of protein localization', 'up regulation of protein recruitment']}, 'types': {0: ['T039']}, 'definition': {0: 'Any process that activates or increases the frequency, rate or extent of establishment of protein localization. [GO_REF:0000058, GOC:TermGenie, PMID:22761445]'}, 'entity': {0: 'positive'}, 'text': {0: 'receptor positive patients must have failed hormonal therapy, unless unsuitable (ii)\xa0 in '}}","{'concept_id': {0: 'C4703609'}, 'canonical_name': {0: 'Anti-mitochondrial M2 antibody positivity'}, 'aliases': {0: ['AMA-M2 positive']}, 'types': {0: ['T034']}, 'definition': {0: 'The presence of M2 anti-mitochondrial antibody (immunoglobulins) in the serum. [LMU:mgriese, PMID:30579751]'}, 'entity': {0: 'positive'}, 'text': {0: 'receptor positive patients must have failed hormonal therapy, unless unsuitable (ii)\xa0 in '}}","           entity_group     value     score
0  Detailed_description  receptor  0.839683
1             Lab_value  positive  0.364990",[],"{'keyword': {0: 'therapy unless unsuitable', 1: 'patients failed hormonal', 2: 'unsuitable ii', 3: 'positive patients failed', 4: 'receptor positive'}, 'score': {0: 0.8804, 1: 0.8616, 2: 0.8465, 3: 0.8142, 4: 0.6257}}"
298,298,298,0.9520000219345092,15.0,combination with paclitaxel for patients who have not received CT for mBC and where ,MyriadPro-Regular,4,-0.25,3355443,11,4,11,"{'concept_id': {0: 'C1367551'}, 'canonical_name': {0: 'CALCA gene'}, 'aliases': {0: ['CGRP', 'calcitonin', 'calcitonin related polypeptide alpha', 'calcitonin 1', 'CALCITONIN/CALCITONIN-RELATED POLYPEPTIDE, ALPHA', 'CALCA gene', 'CT', 'CALCA', 'Calcitonin Related Polypeptide Alpha Gene', 'CALC1', 'KATACALCIN', 'CALCITONIN', 'CALCITONIN GENE-RELATED PEPTIDE', 'CALCA Gene', 'CGRP-alpha']}, 'types': {0: ['T028']}, 'definition': {0: 'This gene is involved in the regulation of bone incorporation and blood calcium and phosphate levels.'}, 'entity': {0: 'CT'}, 'text': {0: 'combination with paclitaxel for patients who have not received CT for mBC and where '}}","{'concept_id': {0: 'C3472245'}, 'canonical_name': {0: 'Single Photon Emission Computed Tomography Computed Tomography'}, 'aliases': {0: ['SPECT CT Scans', 'Scans, CT SPECT', 'Scans, SPECT CT', 'CT SPECT', 'Scan, CT SPECT', 'SPECT CT Scan', 'SPECT, CT', 'Scan, SPECT CT', 'SPECTs, CT', 'SPECT CT', 'CT Scans, SPECT', 'CT SPECTs', 'CT SPECT Scans', 'SPECT Scan, CT', 'SPECT Scans, CT', 'CT SPECT Scan', 'CT Scan, SPECT']}, 'types': {0: ['T060']}, 'definition': {0: 'An imaging technique using a device which combines TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON and TOMOGRAPHY, X-RAY COMPUTED in the same session.'}, 'entity': {0: 'CT'}, 'text': {0: 'combination with paclitaxel for patients who have not received CT for mBC and where '}}","{'concept_id': {0: 'C1702776'}, 'canonical_name': {0: 'paclitaxel poliglumex'}, 'aliases': {0: ['PACLitaxel poliglumex']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'The agent paclitaxel linked to a biodegradable, water-soluble polyglutamate polymer with antineoplastic properties. The polyglutamate residue increases the water solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone. Paclitaxel promotes microtubule assembly and prevents microtubule depolymerization, thus interfering with normal mitosis.'}, 'entity': {0: 'paclitaxel'}, 'text': {0: 'combination with paclitaxel for patients who have not received CT for mBC and where '}}","{'concept_id': {0: 'C3547190'}, 'canonical_name': {0: 'response to paclitaxel'}, 'aliases': {0: []}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a paclitaxel stimulus. [GOC:TermGenie]'}, 'entity': {0: 'paclitaxel'}, 'text': {0: 'combination with paclitaxel for patients who have not received CT for mBC and where '}}",{},"           entity_group       value     score
0            Medication  paclitaxel  0.999869
1  Diagnostic_procedure          CT  0.999867
2      Disease_disorder         mBC  0.999851","[('paclitaxel', 'DRUG')]","{'keyword': {0: 'paclitaxel patients received', 1: 'combination paclitaxel', 2: 'paclitaxel patients', 3: 'received ct', 4: 'ct mbc'}, 'score': {0: 0.7513, 1: 0.7368, 2: 0.7099, 3: 0.6946, 4: 0.6279}}"
299,299,299,0.9520000219345092,15.0,anthracyclines are not suitable. (iii) in combination with docetaxel for patients who have not ,MyriadPro-Regular,4,-0.25,3355443,11,4,12,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'anthracyclines are not suitable. (iii)\xa0in combination with docetaxel for patients who have not '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'anthracyclines are not suitable. (iii)\xa0in combination with docetaxel for patients who have not '}}","{'concept_id': {0: 'C0246415'}, 'canonical_name': {0: 'docetaxel'}, 'aliases': {0: ['DOCEtaxel']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.'}, 'entity': {0: 'docetaxel'}, 'text': {0: 'anthracyclines are not suitable. (iii)\xa0in combination with docetaxel for patients who have not '}}","{'concept_id': {0: 'C0034865'}, 'canonical_name': {0: 'DNA recombination'}, 'aliases': {0: []}, 'types': {0: ['T045']}, 'definition': {0: 'Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses.'}, 'entity': {0: 'combination'}, 'text': {0: 'anthracyclines are not suitable. (iii)\xa0in combination with docetaxel for patients who have not '}}",{},"            entity_group           value     score
0  Therapeutic_procedure  anthracyclines  0.885410
1             Medication       docetaxel  0.999898
2                History             not  0.427446","[('anthracyclines', 'DRUG'), ('docetaxel', 'DRUG')]","{'keyword': {0: 'iii combination docetaxel', 1: 'combination docetaxel', 2: 'anthracyclines suitable', 3: 'docetaxel patients', 4: 'suitable iii combination'}, 'score': {0: 0.7396, 1: 0.7291, 2: 0.7097, 3: 0.707, 4: 0.5679}}"
300,300,300,0.9520000219345092,15.0,received CT for mBC (iv)  in combination with an aromatase inhibitor for the treatment of ,MyriadPro-Regular,4,-0.25,3355443,11,4,13,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'received CT for mBC (iv)\xa0 in combination with an aromatase inhibitor for the treatment of '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'received CT for mBC (iv)\xa0 in combination with an aromatase inhibitor for the treatment of '}}",{},"{'concept_id': {0: 'C3548805'}, 'canonical_name': {0: 'response to aromatase inhibitor'}, 'aliases': {0: []}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an aromatase inhibitor stimulus. [GOC:dph]'}, 'entity': {0: 'aromatase inhibitor'}, 'text': {0: 'received CT for mBC (iv)\xa0 in combination with an aromatase inhibitor for the treatment of '}}",{},"           entity_group                value     score
0  Diagnostic_procedure                   CT  0.999792
1            Medication                  mBC  0.514393
2            Medication  aromatase inhibitor  0.998818","[('aromatase inhibitor', 'DRUG')]","{'keyword': {0: 'aromatase inhibitor treatment', 1: 'iv combination', 2: 'mbc iv', 3: 'received ct', 4: 'ct mbc'}, 'score': {0: 0.8475, 1: 0.8175, 2: 0.8058, 3: 0.7789, 4: 0.7144}}"
301,301,301,0.9520000219345092,15.0,"postmenopausal patients with hormone-receptor positive mBC, not previously treated with ",MyriadPro-Regular,4,-0.25,3355443,11,4,14,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treated with'}, 'text': {0: 'postmenopausal patients with hormone-receptor positive mBC, not previously treated with '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'postmenopausal patients with hormone-receptor positive mBC, not previously treated with '}}",{},{},"{'concept_id': {0: 'C0032776'}, 'canonical_name': {0: 'Postmenopausal bleeding'}, 'aliases': {0: []}, 'types': {0: ['T046']}, 'definition': {0: 'Uterine bleeding occurring after menopause.'}, 'entity': {0: 'postmenopausal'}, 'text': {0: 'postmenopausal patients with hormone-receptor positive mBC, not previously treated with '}}","            entity_group             value     score
0   Detailed_description    postmenopausal  0.991750
1                History    postmenopausal  0.424837
2  Therapeutic_procedure    postmenopausal  0.552071
3               Activity    postmenopausal  0.194182
4   Detailed_description  hormone-receptor  0.998174",[],"{'keyword': {0: 'patients hormone receptor', 1: 'receptor positive mbc', 2: 'postmenopausal patients', 3: 'mbc previously', 4: 'positive mbc'}, 'score': {0: 0.6987, 1: 0.6567, 2: 0.6538, 3: 0.4915, 4: 0.4096}}"
302,302,302,0.9520000219345092,15.0,trastuzumab. ,MyriadPro-Regular,4,-0.25,3355443,11,4,15,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab. '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab. '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab. '}}",{},{},"  entity_group        value     score
0   Medication  trastuzumab  0.954843","[('trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
303,303,303,0.9520000219345092,15.0,Dosage and Administration: Refer to Herceptin solution for injection Summary of Product ,MyriadPro-Regular,4,-0.25,3355443,11,4,16,"{'concept_id': {0: 'C1533685'}, 'canonical_name': {0: 'Injection procedure'}, 'aliases': {0: ['Injection - action', 'Injection (procedure)', 'Injection', 'Injection, NOS', 'INJECTIONS', 'Injection Administration', 'Injection - action (qualifier value)', 'Injections', 'injection']}, 'types': {0: ['T061']}, 'definition': {0: 'Administration using positive pressure and a needle or other equipment to drive a substance into the body.'}, 'entity': {0: 'injection'}, 'text': {0: 'Dosage and Administration: Refer to Herceptin solution for injection Summary of Product '}}","{'concept_id': {0: 'C0021498'}, 'canonical_name': {0: 'Injections, Spinal'}, 'aliases': {0: ['Injection, Spinal', 'Spinal Injection', 'Intraspinal Injection', 'Injections, Intraspinal', 'Injection, Intraspinal', 'Intraspinal Injections', 'Spinal Injections']}, 'types': {0: ['T169']}, 'definition': {0: 'Introduction of therapeutic agents into the spinal region using a needle and syringe.'}, 'entity': {0: 'injection'}, 'text': {0: 'Dosage and Administration: Refer to Herceptin solution for injection Summary of Product '}}","{'concept_id': {0: 'C1272883'}, 'canonical_name': {0: 'Injection'}, 'aliases': {0: []}, 'types': {0: ['T122']}, 'definition': {0: 'A substance intended for injection.'}, 'entity': {0: 'injection'}, 'text': {0: 'Dosage and Administration: Refer to Herceptin solution for injection Summary of Product '}}",{},{},"  entity_group               value     score
0   Medication           Herceptin  0.999835
1   Medication  Herceptin solution  0.981173","[('Herceptin', 'DRUG'), ('solution', 'FORM'), ('injection', 'FORM')]","{'keyword': {0: 'administration refer herceptin', 1: 'solution injection summary', 2: 'herceptin solution', 3: 'solution injection', 4: 'summary product'}, 'score': {0: 0.8963, 1: 0.8742, 2: 0.8546, 3: 0.7887, 4: 0.7693}}"
304,304,304,0.9520000219345092,15.0,Characteristics (SmPC) for full guidance. To prevent medication errors check vial labels to ensure ,MyriadPro-Regular,4,-0.25,3355443,11,4,17,"{'concept_id': {0: 'C0037914'}, 'canonical_name': {0: 'Spin Labels'}, 'aliases': {0: ['spin label', 'labeling spin', 'Spin Label', 'Spin labels', 'Label, Spin', 'spin labels', 'Labels, Spin']}, 'types': {0: ['T130']}, 'definition': {0: 'Molecules which contain an atom or a group of atoms exhibiting an unpaired electron spin that can be detected by electron spin resonance spectroscopy and can be bonded to another molecule. (McGraw-Hill Dictionary of Chemical and Technical Terms, 4th ed)'}, 'entity': {0: 'vial labels'}, 'text': {0: 'Characteristics (SmPC) for full guidance. To prevent medication errors check vial labels to ensure '}}","{'concept_id': {0: 'C0376531'}, 'canonical_name': {0: 'Medical Errors'}, 'aliases': {0: ['Errors, Medical', 'Medical Mistakes', 'Error, Medical', 'Mistakes, Medical', 'Medical Error', 'Medical Mistake', 'Mistake, Medical']}, 'types': {0: ['T080']}, 'definition': {0: 'Errors or mistakes committed by health professionals which result in harm to the patient. They include errors in diagnosis (DIAGNOSTIC ERRORS), errors in the administration of drugs and other medications (MEDICATION ERRORS), errors in the performance of surgical procedures, in the use of other types of therapy, in the use of equipment, and in the interpretation of laboratory findings. Medical errors are differentiated from MALPRACTICE in that the former are regarded as honest mistakes or accidents while the latter is the result of negligence, reprehensible ignorance, or criminal intent.'}, 'entity': {0: 'medication errors'}, 'text': {0: 'Characteristics (SmPC) for full guidance. To prevent medication errors check vial labels to ensure '}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'Characteristics'}, 'text': {0: 'Characteristics (SmPC) for full guidance. To prevent medication errors check vial labels to ensure '}}","           entity_group              value     score
0  Diagnostic_procedure               SmPC  0.989217
1          Sign_symptom  medication errors  0.979888
2          Other_entity             labels  0.791441",[],"{'keyword': {0: 'vial labels ensure', 1: 'guidance prevent', 2: 'characteristics smpc guidance', 3: 'medication errors', 4: 'prevent medication errors'}, 'score': {0: 0.5212, 1: 0.4301, 2: 0.3659, 3: 0.3612, 4: 0.3202}}"
305,305,305,0.9520000219345092,15.0,the drug being prepared and administered is Herceptin (trastuzumab) and not another ,MyriadPro-Regular,4,-0.25,3355443,11,4,18,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'the drug being prepared and administered is Herceptin (trastuzumab) and not another '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'the drug being prepared and administered is Herceptin (trastuzumab) and not another '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'the drug being prepared and administered is Herceptin (trastuzumab) and not another '}}","{'concept_id': {0: 'C3270708'}, 'canonical_name': {0: 'regulation of response to drug'}, 'aliases': {0: []}, 'types': {0: ['T039']}, 'definition': {0: 'Any process that modulates the frequency, rate or extent of response to drug. [GOC:obol]'}, 'entity': {0: 'drug being'}, 'text': {0: 'the drug being prepared and administered is Herceptin (trastuzumab) and not another '}}",{},"           entity_group                value     score
0            Medication            Herceptin  0.999882
1            Medication          trastuzumab  0.999831
2  Detailed_description  not another another  0.743914","[('Herceptin', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'drug prepared administered', 1: 'drug prepared', 2: 'prepared administered herceptin', 3: 'herceptin trastuzumab', 4: 'administered herceptin'}, 'score': {0: 0.8041, 1: 0.7673, 2: 0.7657, 3: 0.7421, 4: 0.7066}}"
306,306,306,0.9520000219345092,15.0,trastuzumab-containing product (e.g. trastuzumab emtansine or trastuzumab deruxtecan). ,MyriadPro-Regular,4,-0.25,3355443,11,4,19,"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: ['anti-HER2/c-erbB2 monoclonal antibody', 'anti-ERB-2', 'Anti-HER2/c-erbB2 Monoclonal Antibody', 'Trastuzumab (substance)', 'rhuMAb HER2', 'anti-c-erbB2 monoclonal antibody', 'Monoclonal Antibody c-erb-2', 'Trastuzumab-containing product', 'Product containing trastuzumab (medicinal product)', 'anti-p185-HER2', 'beta, Trastuzumab', 'c-erb-2 Monoclonal Antibody', 'Trastuzumab Biosimilar SIBP-01', 'Anti-erbB2 Monoclonal Antibody', 'HER2 monoclonal antibody', 'anti-erbB2 monoclonal antibody', 'RHUMAB HER2', 'anti-erbB-2', 'Anti-erbB-2', 'Trastuzumab', 'monoclonal antibody HER2', 'anti-c-erB-2', 'Anti-p185-HER2', 'Anti-c-ERB-2', 'Trastuzumab beta', 'TRASTUZUMAB', 'Monoclonal Antibody HER2', 'MOAB HER2', 'monoclonal antibody c-erb-2', 'Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer', 'HER2 Monoclonal Antibody', 'Anti-c-erbB2 Monoclonal Antibody', 'Anti-ERB-2', 'MoAb HER2', 'trastuzumab']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab deruxtecan'}, 'text': {0: 'trastuzumab-containing product (e.g. trastuzumab emtansine or trastuzumab deruxtecan). '}}","{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'beta, Trastuzumab'}, 'aliases': {0: ['Trastuzumab beta', 'Trastuzumab']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab deruxtecan'}, 'text': {0: 'trastuzumab-containing product (e.g. trastuzumab emtansine or trastuzumab deruxtecan). '}}","{'concept_id': {0: 'C4726900'}, 'canonical_name': {0: 'trastuzumab deruxtecan'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon administration of trastuzumab deruxtecan, trastuzumab targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect.'}, 'entity': {0: 'trastuzumab deruxtecan'}, 'text': {0: 'trastuzumab-containing product (e.g. trastuzumab emtansine or trastuzumab deruxtecan). '}}",{},{},"  entity_group                           value     score
0   Medication  trastuzumab-containing product  0.838533
1   Medication         trastuzumab trastuzumab  0.999717
2   Medication                       emtansine  0.919705
3   Medication                      deruxtecan  0.669594","[('trastuzumab', 'DRUG'), ('trastuzumab', 'DRUG'), ('emtansine', 'DRUG'), ('trastuzumab', 'DRUG'), ('deruxtecan', 'DRUG')]","{'keyword': {0: 'trastuzumab containing product', 1: 'trastuzumab containing', 2: 'containing product', 3: 'trastuzumab deruxtecan', 4: 'product trastuzumab emtansine'}, 'score': {0: 0.8578, 1: 0.7996, 2: 0.7731, 3: 0.6737, 4: 0.6636}}"
307,307,307,0.9520000219345092,15.0,Check product labels to ensure correct Herceptin formulation (intravenous or subcutaneous ,MyriadPro-Regular,4,-0.25,3355443,11,4,20,"{'concept_id': {0: 'C0222331'}, 'canonical_name': {0: 'Subcutaneous Fat'}, 'aliases': {0: ['subcutaneous adipose tissue', 'Subcutaneous Fats', 'Subcutaneous adipose tissue', 'Panniculus adiposus', 'Panniculus adiposus telae subcutaneae', 'Subcutaneous fatty tissue', 'paniculus adiposus', 'Structure of subcutaneous fatty tissue', 'Fat, Subcutaneous', 'Subcutaneous fat', 'Paniculus adiposus', 'subcutaneous fat', 'Subcutaneous Fat', 'Subcutaneous Tissue', 'Structure of subcutaneous fatty tissue (body structure)', 'Panniculus adiposus (Tela subcutanea)', 'fat subcutaneous', 'Fatty layer of subcutaneous tissue', 'Subcutis', 'Fats, Subcutaneous', 'Subcutaneous Adipose Tissue', 'Fatty layer of superficial fascia', 'Adipose Tissue, Subcutaneous']}, 'types': {0: ['T024']}, 'definition': {0: 'Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'Check product labels to ensure correct Herceptin formulation (intravenous or subcutaneous '}}","{'concept_id': {0: 'C0278403'}, 'canonical_name': {0: 'Tissues, Subcutaneous'}, 'aliases': {0: ['Subcutaneous Tissue', 'Fascia, Superficial', 'Superficial Fascia', 'Tela Subcutanea', 'Tissue, Subcutaneous', 'Subcutaneous Tissues', 'Hypodermis']}, 'types': {0: ['T024']}, 'definition': {0: 'Loose connective tissue lying under the DERMIS, which binds SKIN loosely to subjacent tissues. It may contain a pad of ADIPOCYTES, which vary in number according to the area of the body and vary in size according to the nutritional state.'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'Check product labels to ensure correct Herceptin formulation (intravenous or subcutaneous '}}",{},{},"{'concept_id': {0: 'C1857657'}, 'canonical_name': {0: 'Reduced subcutaneous fat'}, 'aliases': {0: ['Reduced fat tissue below the skin', 'Reduced subcutaneous adipose tissue', 'Decreased subcutaneous fat', 'Decreased subcutaneous adipose tissue', 'Scanty adipose tissue']}, 'types': {0: ['T033']}, 'definition': {0: 'A reduced amount of fat tissue in the lowest layer of the integument. This feature can be appreciated by a reduced skinfold thickness. []'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'Check product labels to ensure correct Herceptin formulation (intravenous or subcutaneous '}}","           entity_group                     value     score
0  Diagnostic_procedure                     Check  0.526734
1  Diagnostic_procedure                    labels  0.993674
2            Medication                 Herceptin  0.999733
3        Administration               intravenous  0.999514
4        Administration  intravenous subcutaneous  0.997115
5        Administration              subcutaneous  0.998859","[('Herceptin', 'DRUG'), ('intravenous', 'ROUTE'), ('subcutaneous', 'ROUTE')]","{'keyword': {0: 'ensure correct', 1: 'check product labels', 2: 'correct herceptin', 3: 'herceptin formulation', 4: 'formulation intravenous subcutaneous'}, 'score': {0: 0.6111, 1: 0.5339, 2: 0.5066, 3: 0.3942, 4: 0.37}}"
308,308,308,0.9520000219345092,15.0,fixed dose) is being administered. Herceptin subcutaneous formulation is not intended for ,MyriadPro-Regular,4,-0.25,3355443,11,4,21,"{'concept_id': {0: 'C1621583'}, 'canonical_name': {0: 'Administer - dosing instruction imperative'}, 'aliases': {0: ['Administer - dosing instruction imperative', 'Administer', 'Administer - dosing instruction imperative (qualifier value)']}, 'types': {0: ['T169']}, 'definition': {0: 'To dispense, apply, or tender something to another, such as administering a medicine.'}, 'entity': {0: 'administered'}, 'text': {0: 'fixed dose) is being administered. Herceptin subcutaneous formulation is not intended for '}}",{},{},{},{},"     entity_group         value     score
0      Medication     Herceptin  0.999871
1  Administration  subcutaneous  0.987084","[('Herceptin', 'DRUG'), ('subcutaneous', 'ROUTE')]","{'keyword': {0: 'subcutaneous formulation', 1: 'formulation intended', 2: 'dose administered', 3: 'fixed dose administered', 4: 'administered herceptin'}, 'score': {0: 0.5015, 1: 0.4002, 2: 0.3663, 3: 0.3632, 4: 0.3177}}"
309,309,309,0.9520000219345092,15.0,intravenous administration and should be administered via a subcutaneous injection only. ,MyriadPro-Regular,4,-0.25,3355443,11,4,22,"{'concept_id': {0: 'C0181984'}, 'canonical_name': {0: 'Subcutaneous injection/infusion port needle'}, 'aliases': {0: ['Huber Needles', 'Needles, Huber', 'huber needles', 'Needles, Subcutaneous Injection/Infusion Port', 'Subcutaneous injection/infusion port needle (physical object)', 'Subcutaneous Port Injection Needles', 'Needles, Injection, Subcutaneous Port', 'huber needle']}, 'types': {0: ['T074']}, 'definition': {0: 'Needles designed for injection or infusion of fluids through a subcutaneous implanted injection/infusion port. These devices typically consist of hollow, blunt-tip needles that inject the fluids through side holes near their tip, avoiding coring (i.e., noncoring needles).'}, 'entity': {0: 'subcutaneous injection'}, 'text': {0: 'intravenous administration and should be administered via a subcutaneous injection only. '}}","{'concept_id': {0: 'C0222331'}, 'canonical_name': {0: 'Subcutaneous Adipose Tissue'}, 'aliases': {0: ['Subcutaneous Fat', 'Fats, Subcutaneous', 'Subcutaneous Fats', 'Adipose Tissue, Subcutaneous', 'Fat, Subcutaneous']}, 'types': {0: ['T024']}, 'definition': {0: 'Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.'}, 'entity': {0: 'subcutaneous injection'}, 'text': {0: 'intravenous administration and should be administered via a subcutaneous injection only. '}}",{},{},{},"     entity_group         value     score
0  Administration   intravenous  0.999607
1  Administration  subcutaneous  0.998807
2  Administration     injection  0.975760","[('intravenous', 'ROUTE'), ('subcutaneous', 'ROUTE'), ('injection', 'FORM')]","{'keyword': {0: 'administered subcutaneous injection', 1: 'administration administered subcutaneous', 2: 'subcutaneous injection', 3: 'intravenous administration', 4: 'administration administered'}, 'score': {0: 0.7685, 1: 0.7521, 2: 0.7199, 3: 0.5517, 4: 0.5061}}"
310,310,310,0.9520000219345092,15.0,"Patients treated with Herceptin must have HER2-positive breast cancer, (IHC 3+ and/or ISH ≥2.0 ",MyriadPro-Regular,4,-0.25,3355443,11,4,23,"{'concept_id': {0: 'C5202586'}, 'canonical_name': {0: 'Dual-probe in Situ Hybridization'}, 'aliases': {0: ['DISH', 'Dual-probe in Situ Hybridization']}, 'types': {0: ['T063']}, 'definition': {0: 'An in situ hybridization assay for HER2/Neu that uses probes for both HER2 and chromosome 17.'}, 'entity': {0: 'ISH'}, 'text': {0: 'Patients treated with Herceptin must have HER2-positive breast cancer, (IHC 3+ and/or ISH ≥2.0 '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Patients treated with Herceptin must have HER2-positive breast cancer, (IHC 3+ and/or ISH ≥2.0 '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Patients treated with Herceptin must have HER2-positive breast cancer, (IHC 3+ and/or ISH ≥2.0 '}}","{'concept_id': {0: 'C1151558'}, 'canonical_name': {0: '2,3-dihydroxybiphenyl-1,2-dioxygenase activity'}, 'aliases': {0: ['biphenyl-2,3-diol:oxygen 1,2-oxidoreductase (decyclizing)', '2,3-dihydroxybiphenyl 1,2-dioxygenase activity', 'biphenyl-2,3-diol dioxygenase activity', 'BphC', 'biphenyl-2,3-diol 1,2-dioxygenase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: biphenyl-2,3-diol + O2 = 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate + H2O. [EC:1.13.11.39]'}, 'entity': {0: 'IHC'}, 'text': {0: 'Patients treated with Herceptin must have HER2-positive breast cancer, (IHC 3+ and/or ISH ≥2.0 '}}","{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'HER2-positive breast cancer'}, 'text': {0: 'Patients treated with Herceptin must have HER2-positive breast cancer, (IHC 3+ and/or ISH ≥2.0 '}}","           entity_group      value     score
0            Medication  Herceptin  0.995766
1  Biological_structure     breast  0.997123
2  Diagnostic_procedure    IHC ISH  0.999471
3  Diagnostic_procedure        IHC  0.998350
4             Lab_value         3+  0.520852
5  Diagnostic_procedure        ISH  0.909312
6             Lab_value       ≥2.0  0.993041","[('Herceptin', 'DRUG')]","{'keyword': {0: 'her2 positive breast', 1: 'patients treated', 2: 'patients treated herceptin', 3: 'breast cancer', 4: 'ihc ish'}, 'score': {0: 0.8399, 1: 0.7214, 2: 0.6619, 3: 0.6599, 4: 0.5121}}"
311,311,311,0.9520000219345092,15.0,using a validated test). Herceptin should only be initiated by a physician experienced in the ,MyriadPro-Regular,4,-0.25,3355443,11,4,24,"{'concept_id': {0: 'C0031829'}, 'canonical_name': {0: ""Physician's Role""}, 'aliases': {0: [""Physicians' Roles"", 'physician roles', 'Physician Role', ""Roles, Physician's"", 'Physicians Role', 'physicians role', 'physician role', ""Roles, Physicians'"", ""physicians' role"", ""Role, Physicians'"", ""Physician's Roles"", ""Physicians' Role"", ""Role, Physician's"", ""physician's role""]}, 'types': {0: ['T054']}, 'definition': {0: 'The expected function of a member of the medical profession.'}, 'entity': {0: 'physician'}, 'text': {0: 'using a validated test). Herceptin should only be initiated by a physician experienced in the '}}","{'concept_id': {0: 'C1704221'}, 'canonical_name': {0: 'Physicians, Family'}, 'aliases': {0: ['Physician, Family', 'Family Physicians', 'Family Physician']}, 'types': {0: ['T097']}, 'definition': {0: 'Those physicians who have completed the education requirements specified by the American Academy of Family Physicians.'}, 'entity': {0: 'physician'}, 'text': {0: 'using a validated test). Herceptin should only be initiated by a physician experienced in the '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'using a validated test). Herceptin should only be initiated by a physician experienced in the '}}",{},{},"           entity_group                  value     score
0            Medication              Herceptin  0.823444
1  Diagnostic_procedure  Herceptin experienced  0.370873","[('Herceptin', 'DRUG')]","{'keyword': {0: 'initiated physician experienced', 1: 'using validated test', 2: 'initiated physician', 3: 'herceptin initiated', 4: 'test herceptin'}, 'score': {0: 0.5189, 1: 0.5082, 2: 0.5053, 3: 0.4772, 4: 0.4144}}"
312,312,312,0.9520000219345092,15.0,administration of cytotoxic CT. The recommended dose for Herceptin subcutaneous formulation ,MyriadPro-Regular,4,-0.25,3355443,11,4,25,"{'concept_id': {0: 'C0034866'}, 'canonical_name': {0: 'Recommendation'}, 'aliases': {0: ['Recommendation', 'recommends', 'recommend', 'Recommended (qualifier value)', 'Recommended', 'recommendation', 'recommended', 'recommendations']}, 'types': {0: ['T078']}, 'definition': {0: 'Advice telling someone what the best thing to do is.'}, 'entity': {0: 'recommended dose'}, 'text': {0: 'administration of cytotoxic CT. The recommended dose for Herceptin subcutaneous formulation '}}","{'concept_id': {0: 'C0010868'}, 'canonical_name': {0: 'Cytotoxic Agent'}, 'aliases': {0: ['Cytotoxins', 'Agent, Cytotoxic', 'Cytotoxin', 'Cytotoxic Agents']}, 'types': {0: ['T123', 'T131']}, 'definition': {0: 'Substances that are toxic to cells; they may be involved in immunity or may be contained in venoms. These are distinguished from CYTOSTATIC AGENTS in degree of effect. Some of them are used as CYTOTOXIC ANTIBIOTICS. The mechanism of action of many of these are as ALKYLATING AGENTS or MITOSIS MODULATORS.'}, 'entity': {0: 'cytotoxic CT'}, 'text': {0: 'administration of cytotoxic CT. The recommended dose for Herceptin subcutaneous formulation '}}",{},{},{},"           entity_group                     value     score
0  Detailed_description                 cytotoxic  0.990598
1            Medication                 Herceptin  0.999865
2        Administration              subcutaneous  0.689168
3            Medication  subcutaneous formulation  0.448460","[('cytotoxic CT', 'DRUG'), ('Herceptin', 'DRUG'), ('subcutaneous', 'ROUTE'), ('formulation', 'FORM')]","{'keyword': {0: 'recommended dose herceptin', 1: 'ct recommended', 2: 'subcutaneous formulation', 3: 'cytotoxic ct', 4: 'administration cytotoxic ct'}, 'score': {0: 0.8448, 1: 0.7742, 2: 0.773, 3: 0.7643, 4: 0.6517}}"
313,313,313,0.9520000219345092,15.0,is 600 mg irrespective of the patient’s body weight. No loading dose is required. This dose ,MyriadPro-Regular,4,-0.25,3355443,11,4,26,"{'concept_id': {0: 'C1512044'}, 'canonical_name': {0: 'Dose Rate'}, 'aliases': {0: ['doses rate', 'dose-rate', 'dose rate', 'Dose-Rate']}, 'types': {0: ['T081']}, 'definition': {0: 'The amount of any substance administered over a specific period of time.'}, 'entity': {0: 'dose'}, 'text': {0: 'is 600 mg irrespective of the patient’s body weight. No loading dose is required. This dose '}}","{'concept_id': {0: 'C0421272'}, 'canonical_name': {0: 'Body Weight, Ideal'}, 'aliases': {0: ['Body Weights, Ideal', 'Ideal Body Weight', 'Ideal Body Masses', 'Body Masses, Ideal', 'Normal Body Weight', 'Weight, Normal Body', 'Masses, Ideal Body', 'Ideal Body Weights', 'Weights, Normal Body', 'Ideal Body Mass', 'Normal Body Weights', 'Body Weight, Normal', 'Mass, Ideal Body', 'Weights, Ideal Body', 'Weight, Ideal Body', 'Body Weights, Normal', 'Body Mass, Ideal']}, 'types': {0: ['T201']}, 'definition': {0: 'Expected weight of a healthy normal individual based on age, sex, and height. Thus, a malnourished person would weigh less than their ideal body weight.'}, 'entity': {0: 'patient’s body weight'}, 'text': {0: 'is 600 mg irrespective of the patient’s body weight. No loading dose is required. This dose '}}",{},{},"{'concept_id': {0: 'C4025357'}, 'canonical_name': {0: 'Abnormality of body weight'}, 'aliases': {0: ['Abnormality of body weight']}, 'types': {0: ['T033']}, 'definition': {0: 'An abnormal increase or decrease of weight or an abnormal distribution of mass in the body. [HPO:probinson]'}, 'entity': {0: 'patient’s body weight'}, 'text': {0: 'is 600 mg irrespective of the patient’s body weight. No loading dose is required. This dose '}}","            entity_group         value     score
0              Lab_value        600 mg  0.990252
1  Therapeutic_procedure  loading dose  0.841559
2                 Dosage     This dose  0.819614","[('600 mg', 'STRENGTH')]","{'keyword': {0: 'dose required', 1: 'required dose', 2: '600 mg', 3: 'patient body weight', 4: 'irrespective patient body'}, 'score': {0: 0.7845, 1: 0.7077, 2: 0.5926, 3: 0.4233, 4: 0.3465}}"
314,314,314,0.9520000219345092,15.0,should be administered subcutaneously over 2-5 minutes every three weeks. Patients with eBC ,MyriadPro-Regular,4,-0.25,3355443,11,4,27,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'Patients'}, 'text': {0: 'should be administered subcutaneously over 2-5 minutes every three weeks. Patients with eBC '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'Patients'}, 'text': {0: 'should be administered subcutaneously over 2-5 minutes every three weeks. Patients with eBC '}}",{},{},"{'concept_id': {0: 'C1857657'}, 'canonical_name': {0: 'Reduced subcutaneous fat'}, 'aliases': {0: ['Reduced fat tissue below the skin', 'Reduced subcutaneous adipose tissue', 'Decreased subcutaneous fat', 'Decreased subcutaneous adipose tissue', 'Scanty adipose tissue']}, 'types': {0: ['T033']}, 'definition': {0: 'A reduced amount of fat tissue in the lowest layer of the integument. This feature can be appreciated by a reduced skinfold thickness. []'}, 'entity': {0: 'subcutaneously'}, 'text': {0: 'should be administered subcutaneously over 2-5 minutes every three weeks. Patients with eBC '}}","       entity_group           value     score
0    Administration  subcutaneously  0.984526
1            Dosage             2-5  0.963822
2         Frequency             2-5  0.523611
3         Frequency         minutes  0.599438
4         Frequency     every three  0.969420
5  Disease_disorder             eBC  0.976574","[('subcutaneously', 'ROUTE'), ('every three weeks', 'FREQUENCY')]","{'keyword': {0: 'patients ebc', 1: 'weeks patients ebc', 2: 'administered subcutaneously', 3: 'subcutaneously minutes', 4: 'minutes weeks'}, 'score': {0: 0.8359, 1: 0.8046, 2: 0.7706, 3: 0.7317, 4: 0.7122}}"
315,315,315,0.9520000219345092,15.0,"should be treated with Herceptin for 1 year or until disease recurrence, whichever occurs first. ",MyriadPro-Regular,4,-0.25,3355443,11,4,28,"{'concept_id': {0: 'C5447866'}, 'canonical_name': {0: 'Disease Recurrence Evidence'}, 'aliases': {0: ['Disease Recurrence Evidence']}, 'types': {0: ['T033']}, 'definition': {0: 'Clinical or laboratory test results that are the basis for a recurrent disease finding.'}, 'entity': {0: 'disease recurrence'}, 'text': {0: 'should be treated with Herceptin for 1 year or until disease recurrence, whichever occurs first. '}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'disease recurrence'}, 'text': {0: 'should be treated with Herceptin for 1 year or until disease recurrence, whichever occurs first. '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'should be treated with Herceptin for 1 year or until disease recurrence, whichever occurs first. '}}",{},{},"  entity_group                 value     score
0   Medication             Herceptin  0.999839
1   Medication  Herceptin recurrence  0.999621
2     Duration                1 year  0.999462","[('Herceptin', 'DRUG'), ('for 1 year', 'DURATION')]","{'keyword': {0: 'herceptin year disease', 1: 'treated herceptin', 2: 'year disease recurrence', 3: 'whichever occurs', 4: 'recurrence whichever occurs'}, 'score': {0: 0.8364, 1: 0.802, 2: 0.7361, 3: 0.6904, 4: 0.6063}}"
316,316,316,0.9520000219345092,15.0,Patients with mBC should be treated with Herceptin until progression of disease. Observe the ,MyriadPro-Regular,4,-0.25,3355443,11,4,29,"{'concept_id': {0: 'C5446366'}, 'canonical_name': {0: 'Upon Progression'}, 'aliases': {0: ['At Progression']}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring after a subject experienced disease progression.'}, 'entity': {0: 'progression'}, 'text': {0: 'Patients with mBC should be treated with Herceptin until progression of disease. Observe the '}}","{'concept_id': {0: 'C0449259'}, 'canonical_name': {0: 'Clinical Course'}, 'aliases': {0: ['Progression, Clinical', 'Clinical Progression']}, 'types': {0: ['T079']}, 'definition': {0: 'A term that refers to the nature and/or clinical outcome of a disease (e.g., acute or chronic disease, aggressive or indolent disease, recurrent disease, etc.).'}, 'entity': {0: 'progression'}, 'text': {0: 'Patients with mBC should be treated with Herceptin until progression of disease. Observe the '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Patients with mBC should be treated with Herceptin until progression of disease. Observe the '}}","{'concept_id': {0: 'C1155872'}, 'canonical_name': {0: 'regulation of progression through cell cycle'}, 'aliases': {0: ['regulation of cell cycle', 'regulation of cell cycle progression', 'regulation of cell cycle process', 'modulation of cell cycle progression', 'control of cell cycle progression', 'cell cycle regulation', 'cell cycle modulation']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that modulates the rate or extent of progression through the cell cycle. [GOC:ai, GOC:dph, GOC:tb]'}, 'entity': {0: 'progression'}, 'text': {0: 'Patients with mBC should be treated with Herceptin until progression of disease. Observe the '}}","{'concept_id': {0: 'C1838681'}, 'canonical_name': {0: 'Rapidly progressive'}, 'aliases': {0: ['Worsening quickly', 'Rapid progression']}, 'types': {0: ['T033']}, 'definition': {0: 'Applies to a disease manifestation that quickly increases in scope or severity over the course of time. []'}, 'entity': {0: 'progression'}, 'text': {0: 'Patients with mBC should be treated with Herceptin until progression of disease. Observe the '}}","           entity_group        value     score
0      Disease_disorder          mBC  0.999917
1            Medication    Herceptin  0.999711
2  Detailed_description  Observe the  0.816124","[('Herceptin', 'DRUG')]","{'keyword': {0: 'disease observe', 1: 'treated herceptin progression', 2: 'treated herceptin', 3: 'patients mbc', 4: 'mbc treated'}, 'score': {0: 0.6558, 1: 0.6082, 2: 0.5709, 3: 0.5176, 4: 0.4107}}"
317,317,317,0.9520000219345092,15.0,patient for administration related reactions (ARRs) for 30 minutes after the first injection and for ,MyriadPro-Regular,4,-0.25,3355443,11,4,30,"{'concept_id': {0: 'C1533685'}, 'canonical_name': {0: 'Injection procedure'}, 'aliases': {0: ['Injection - action', 'Injection (procedure)', 'Injection', 'Injection, NOS', 'INJECTIONS', 'Injection Administration', 'Injection - action (qualifier value)', 'Injections', 'injection']}, 'types': {0: ['T061']}, 'definition': {0: 'Administration using positive pressure and a needle or other equipment to drive a substance into the body.'}, 'entity': {0: 'injection'}, 'text': {0: 'patient for administration related reactions (ARRs) for 30 minutes after the first injection and for '}}","{'concept_id': {0: 'C0021498'}, 'canonical_name': {0: 'Injections, Spinal'}, 'aliases': {0: ['Injection, Spinal', 'Spinal Injection', 'Intraspinal Injection', 'Injections, Intraspinal', 'Injection, Intraspinal', 'Intraspinal Injections', 'Spinal Injections']}, 'types': {0: ['T169']}, 'definition': {0: 'Introduction of therapeutic agents into the spinal region using a needle and syringe.'}, 'entity': {0: 'injection'}, 'text': {0: 'patient for administration related reactions (ARRs) for 30 minutes after the first injection and for '}}","{'concept_id': {0: 'C1272883'}, 'canonical_name': {0: 'Injection'}, 'aliases': {0: []}, 'types': {0: ['T122']}, 'definition': {0: 'A substance intended for injection.'}, 'entity': {0: 'injection'}, 'text': {0: 'patient for administration related reactions (ARRs) for 30 minutes after the first injection and for '}}",{},{},"           entity_group       value     score
0  Detailed_description   reactions  0.588500
1      Disease_disorder        ARRs  0.965397
2              Duration  30 minutes  0.797264
3        Administration   injection  0.984909",[],"{'keyword': {0: 'related reactions', 1: 'reactions arrs 30', 2: 'arrs 30', 3: 'patient administration related', 4: 'minutes injection'}, 'score': {0: 0.7009, 1: 0.5438, 2: 0.4125, 3: 0.3363, 4: 0.1711}}"
318,318,318,0.9520000219345092,15.0,15 minutes after subsequent injections. If the patient misses a dose of Herceptin subcutaneous ,MyriadPro-Regular,4,-0.25,3355443,11,4,31,"{'concept_id': {0: 'C1522438'}, 'canonical_name': {0: 'Subcutaneous Route of Drug Administration'}, 'aliases': {0: ['subcutaneous drug administration', 'Subcutaneous Route of Administration', 'SubcutaneousRoute', 'Subcutaneous route', 'Subcutaneous route (qualifier value)', 'SC use', 'Subcutaneous (intended site)', 'SC route', 'Subcutaneous use', 'Subcutaneous', 'Subdermal route']}, 'types': {0: ['T169']}, 'definition': {0: 'Drug administration beneath the skin. It provides for relatively slow, sustained release of the drug. The rate of absorption into the blood is perfusion-limited, proportional to the amount of drug at the site and can be enhanced by chemical or physical stimulation of blood flow. Subcutaneous administration minimizes the risks associated with intravascular injection: for subcutaneous infusions, external and implantable pumps are used.'}, 'entity': {0: 'Herceptin subcutaneous'}, 'text': {0: '15 minutes after subsequent injections. If the patient misses a dose of Herceptin subcutaneous '}}","{'concept_id': {0: 'C0222331'}, 'canonical_name': {0: 'Subcutaneous Adipose Tissue'}, 'aliases': {0: ['Subcutaneous Fat', 'Fats, Subcutaneous', 'Subcutaneous Fats', 'Adipose Tissue, Subcutaneous', 'Fat, Subcutaneous']}, 'types': {0: ['T024']}, 'definition': {0: 'Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.'}, 'entity': {0: 'Herceptin subcutaneous'}, 'text': {0: '15 minutes after subsequent injections. If the patient misses a dose of Herceptin subcutaneous '}}",{},{},{},"           entity_group             value     score
0                  Time  15 minutes after  0.998231
1        Administration        injections  0.751337
2            Medication         Herceptin  0.999794
3        Administration      subcutaneous  0.985902
4  Detailed_description      subcutaneous  0.664407","[('Herceptin', 'DRUG'), ('subcutaneous', 'ROUTE')]","{'keyword': {0: '15 minutes subsequent', 1: '15 minutes', 2: 'misses dose', 3: 'herceptin subcutaneous', 4: 'dose herceptin'}, 'score': {0: 0.4547, 1: 0.4221, 2: 0.4045, 3: 0.3145, 4: 0.2546}}"
319,319,319,0.9520000219345092,15.0,"formulation, it is recommended to administer the next dose as soon as possible. The interval ",MyriadPro-Regular,4,-0.25,3355443,11,4,32,"{'concept_id': {0: 'C0872291'}, 'canonical_name': {0: 'Time Interval'}, 'aliases': {0: ['time interval', 'Time Frame', 'Time Interval', 'Timespan']}, 'types': {0: ['T079']}, 'definition': {0: 'The period of time between two dates or events or between the beginning and end of something.'}, 'entity': {0: 'interval'}, 'text': {0: 'formulation, it is recommended to administer the next dose as soon as possible. The interval '}}","{'concept_id': {0: 'C0005605'}, 'canonical_name': {0: 'Birth Intervals'}, 'aliases': {0: ['Birth Spacing', 'Birth Interval', 'Birth Spacings']}, 'types': {0: ['T079']}, 'definition': {0: 'The lengths of intervals between births to women in the population.'}, 'entity': {0: 'interval'}, 'text': {0: 'formulation, it is recommended to administer the next dose as soon as possible. The interval '}}",{},{},"{'concept_id': {0: 'C4703431'}, 'canonical_name': {0: 'Abnormal PR interval'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'An anomaly of the PR interval, which is the portion of the ECG from the onset of the P wave to the beginning of the QRS complex. A normal PR interval in adults is 0.12-0.2 seconds. [PMID:23677846]'}, 'entity': {0: 'interval'}, 'text': {0: 'formulation, it is recommended to administer the next dose as soon as possible. The interval '}}","           entity_group     value     score
0  Detailed_description  interval  0.997335",[],"{'keyword': {0: 'possible interval', 1: 'soon possible', 2: 'administer dose soon', 3: 'soon possible interval', 4: 'recommended administer dose'}, 'score': {0: 0.7662, 1: 0.7488, 2: 0.713, 3: 0.6681, 4: 0.5604}}"
320,320,320,0.9520000219345092,15.0,between consecutive Herceptin subcutaneous formulation administrations should not be less ,MyriadPro-Regular,4,-0.25,3355443,11,4,33,"{'concept_id': {0: 'C1533734'}, 'canonical_name': {0: 'Administration procedure'}, 'aliases': {0: ['Treatment', 'Administering', 'Administration (Procedure)', 'Administration', 'administration procedures']}, 'types': {0: ['T061']}, 'definition': {0: 'The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.'}, 'entity': {0: 'administrations'}, 'text': {0: 'between consecutive Herceptin subcutaneous formulation administrations should not be less '}}","{'concept_id': {0: 'C1527425'}, 'canonical_name': {0: 'Administrations, Rectal'}, 'aliases': {0: ['Rectal Administration', 'Administrations, Anal Drug', 'Rectal Administrations', 'Drug Administrations, Rectal', 'Administration, Rectal', 'Drug Administration, Rectal', 'Anal Drug Administrations', 'Rectal Drug Administrations', 'Rectal Drug Administration', 'Administration, Rectal Drug', 'Instillations, Rectal', 'Rectal Instillations', 'Drug Administration, Anal', 'Administrations, Rectal Drug', 'Rectal Instillation', 'Anal Drug Administration', 'Administration, Anal Drug', 'Instillation, Rectal', 'Drug Administrations, Anal']}, 'types': {0: ['T169']}, 'definition': {0: 'The insertion of drugs into the rectum, usually for confused or incompetent patients, like children, infants, and the very old or comatose.'}, 'entity': {0: 'administrations'}, 'text': {0: 'between consecutive Herceptin subcutaneous formulation administrations should not be less '}}",{},{},"{'concept_id': {0: 'C0339637'}, 'canonical_name': {0: 'Consecutive exotropia'}, 'aliases': {0: []}, 'types': {0: ['T047']}, 'definition': {0: 'Exotropia in an individual who has previously had esotropia or esophoria. [ORCID:0000-0003-0986-4123]'}, 'entity': {0: 'consecutive'}, 'text': {0: 'between consecutive Herceptin subcutaneous formulation administrations should not be less '}}","            entity_group         value     score
0   Detailed_description       between  0.591595
1   Detailed_description   consecutive  0.821005
2             Medication     Herceptin  0.996948
3         Administration  subcutaneous  0.990636
4  Therapeutic_procedure  subcutaneous  0.549813
5              Lab_value          less  0.980998","[('Herceptin', 'DRUG'), ('subcutaneous', 'ROUTE'), ('formulation', 'FORM')]","{'keyword': {0: 'subcutaneous formulation administrations', 1: 'herceptin subcutaneous', 2: 'consecutive herceptin', 3: 'consecutive herceptin subcutaneous', 4: 'formulation administrations'}, 'score': {0: 0.8016, 1: 0.771, 2: 0.7519, 3: 0.7361, 4: 0.697}}"
321,321,321,0.9520000219345092,15.0,than three weeks. ,MyriadPro-Regular,4,-0.25,3355443,11,4,34,"{'concept_id': {0: 'C4288440'}, 'canonical_name': {0: 'Past 2 Weeks'}, 'aliases': {0: ['Last 2 Weeks', 'Past Two Weeks', 'Last Two Weeks']}, 'types': {0: ['T079']}, 'definition': {0: 'A period of time consisting of the 14 days before the present.'}, 'entity': {0: 'weeks'}, 'text': {0: 'than three weeks. '}}","{'concept_id': {0: 'C0331595'}, 'canonical_name': {0: 'Leeks'}, 'aliases': {0: ['Leek']}, 'types': {0: ['T168']}, 'definition': {0: 'Onion like roots from Allium porrum.'}, 'entity': {0: 'weeks'}, 'text': {0: 'than three weeks. '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []","[('three weeks', 'DURATION')]","{'keyword': {}, 'score': {}}"
322,322,322,0.9520000219345092,15.0,"Contraindications:  Hypersensitivity to trastuzumab, murine proteins, hyaluronidase or any ",MyriadPro-Regular,4,-0.25,3355443,11,4,35,"{'concept_id': {0: 'C1415825'}, 'canonical_name': {0: 'HYAL1 gene'}, 'aliases': {0: ['hyaluronoglucosaminidase 1', 'HYAL1', 'hyaluronidase 1', 'LUCA1', 'HYAL1 gene', 'HYAL-1', 'HYALURONOGLUCOSAMINIDASE 1', 'HYALURONIDASE 1']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'hyaluronidase'}, 'text': {0: 'Contraindications:  Hypersensitivity to trastuzumab, murine proteins, hyaluronidase or any '}}","{'concept_id': {0: 'C0020196'}, 'canonical_name': {0: 'Hyaluronic Acid'}, 'aliases': {0: ['Hyaluronic acid', 'Acid, Hyaluronic', 'Hyaluronan']}, 'types': {0: ['T109', 'T121', 'T123']}, 'definition': {0: 'A natural high-viscosity mucopolysaccharide with alternating beta (1-3) glucuronide and beta (1-4) glucosaminidic bonds. It is found in the UMBILICAL CORD, in VITREOUS BODY and in SYNOVIAL FLUID. A high urinary level is found in PROGERIA.'}, 'entity': {0: 'hyaluronidase'}, 'text': {0: 'Contraindications:  Hypersensitivity to trastuzumab, murine proteins, hyaluronidase or any '}}","{'concept_id': {0: 'C4490298'}, 'canonical_name': {0: 'hyaluronidase / rituximab'}, 'aliases': {0: ['hyaluronidase / riTUXimab']}, 'types': {0: ['T121']}, 'definition': {0: 'A combination preparation of rituximab, a genetically engineered chimeric murine/human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the CD20 antigen, and the recombinant form of the human enzyme hyaluronidase, with antineoplastic activity. Upon subcutaneous administration of rituximab and hyaluronidase human, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of rituximab into the systemic circulation. In turn, rituximab targets and binds to CD20 expressed on tumor cells, and induces tumor cell lysis primarily through the induction of complement dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC). When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs. CD20 is expressed on the surface of pre-B and mature B-lymphocytes, and is overexpressed in a variety of B-cell malignancies.'}, 'entity': {0: 'hyaluronidase'}, 'text': {0: 'Contraindications:  Hypersensitivity to trastuzumab, murine proteins, hyaluronidase or any '}}","{'concept_id': {0: 'C1150072'}, 'canonical_name': {0: 'hyaluronoglucosidase activity'}, 'aliases': {0: ['hyalurononglucosaminidase activity', 'hyaluronate 4-glycanohydrolase activity', 'chondroitinase I activity', 'hyaluronoglucosaminidase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the random hydrolysis of (1->4) linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. [EC:3.2.1.35]'}, 'entity': {0: 'hyaluronidase'}, 'text': {0: 'Contraindications:  Hypersensitivity to trastuzumab, murine proteins, hyaluronidase or any '}}","{'concept_id': {0: 'C0151206'}, 'canonical_name': {0: 'Scalp tenderness'}, 'aliases': {0: ['Scalp hypersensitivity']}, 'types': {0: ['T184']}, 'definition': {0: 'Pain or discomfort of the scalp elicited by palpation. [HPO:probinson]'}, 'entity': {0: 'Hypersensitivity'}, 'text': {0: 'Contraindications:  Hypersensitivity to trastuzumab, murine proteins, hyaluronidase or any '}}","           entity_group             value     score
0             Lab_value  Hypersensitivity  0.497586
1  Diagnostic_procedure            murine  0.999413
2  Diagnostic_procedure     hyaluronidase  0.960121","[('trastuzumab', 'DRUG'), ('murine proteins', 'DRUG'), ('hyaluronidase', 'DRUG')]","{'keyword': {0: 'contraindications hypersensitivity', 1: 'contraindications hypersensitivity trastuzumab', 2: 'murine proteins hyaluronidase', 3: 'hypersensitivity trastuzumab', 4: 'trastuzumab murine'}, 'score': {0: 0.6282, 1: 0.5972, 2: 0.2968, 3: 0.278, 4: 0.2091}}"
323,323,323,0.9520000219345092,15.0,excipients. Severe dyspnoea at rest due to complications of advanced malignancy or requiring ,MyriadPro-Regular,4,-0.25,3355443,11,4,36,"{'concept_id': {0: 'C0877373'}, 'canonical_name': {0: 'Advanced Malignant Neoplasm'}, 'aliases': {0: ['cancer advanced', 'Advanced Cancer', 'advanced cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A malignant neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.'}, 'entity': {0: 'advanced malignancy'}, 'text': {0: 'excipients. Severe dyspnoea at rest due to complications of advanced malignancy or requiring '}}","{'concept_id': {0: 'C0006826'}, 'canonical_name': {0: 'Neoplasms, Malignant'}, 'aliases': {0: ['Malignancies', 'Malignant Neoplasm', 'Malignancy', 'Cancer', 'Cancers', 'Malignant Neoplasms', 'Neoplasm, Malignant']}, 'types': {0: ['T191']}, 'definition': {0: 'A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.'}, 'entity': {0: 'advanced malignancy'}, 'text': {0: 'excipients. Severe dyspnoea at rest due to complications of advanced malignancy or requiring '}}",{},{},"{'concept_id': {0: 'C0231807'}, 'canonical_name': {0: 'Exertional dyspnoea'}, 'aliases': {0: ['Exertional dyspnea', 'Shortness of breathing upon physical activity', 'Exertional breathlessness']}, 'types': {0: ['T184']}, 'definition': {0: 'Perceived difficulty to breathe that occurs with exercise or exertion and improves with rest. [PMID:29763022]'}, 'entity': {0: 'dyspnoea'}, 'text': {0: 'excipients. Severe dyspnoea at rest due to complications of advanced malignancy or requiring '}}","           entity_group                  value     score
0              Severity                 Severe  0.999808
1          Sign_symptom  dyspnoea due advanced  0.999943
2          Sign_symptom               dyspnoea  0.999578
3      Disease_disorder          complications  0.581353
4  Detailed_description    advanced malignancy  0.792677
5  Detailed_description              requiring  0.496546",[],"{'keyword': {0: 'malignancy requiring', 1: 'complications advanced', 2: 'severe dyspnoea rest', 3: 'rest complications advanced', 4: 'excipients severe'}, 'score': {0: 0.8898, 1: 0.8504, 2: 0.7821, 3: 0.7581, 4: 0.5708}}"
324,324,324,0.9520000219345092,15.0,oxygen therapy. ,MyriadPro-Regular,4,-0.25,3355443,11,4,37,"{'concept_id': {0: 'C3665674'}, 'canonical_name': {0: 'Warburg Therapy'}, 'aliases': {0: ['Oxygen Therapy', 'Warburg Therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'The cornerstone of oxygenation therapy is the presumption that human disease, including cancer, is caused by a deficit of tissue oxygen. According to proponents, hypoxia results in anaerobic fermentation, a loss of capacity for oxidative detoxification of toxins and metabolic products, and failure of immune killing of invading bacteria and viruses. To restore ability to carry out these functions, oxygenation promoters propose using chemicals they claim will release oxygen in tissue or act as germicides in vivo.'}, 'entity': {0: 'oxygen therapy'}, 'text': {0: 'oxygen therapy. '}}","{'concept_id': {0: 'C0039798'}, 'canonical_name': {0: 'disease management'}, 'aliases': {0: ['therapy', 'treatment']}, 'types': {0: ['T169']}, 'definition': {0: 'Used with diseases for therapeutic interventions except drug therapy, diet therapy, radiotherapy, and surgery, for which specific subheadings exist. The concept is also used for articles and books dealing with multiple therapies.'}, 'entity': {0: 'oxygen therapy'}, 'text': {0: 'oxygen therapy. '}}",{},{},{},"            entity_group   value     score
0  Therapeutic_procedure  oxygen  0.926585","[('oxygen', 'DRUG')]","{'keyword': {0: 'oxygen therapy'}, 'score': {0: 0.9274}}"
325,325,325,0.9520000219345092,15.0,"Precautions: Refer to the SmPC for further information. To improve traceability, clearly record ",MyriadPro-Regular,4,-0.25,3355443,11,4,38,"{'concept_id': {0: 'C0011412'}, 'canonical_name': {0: 'Dental Records'}, 'aliases': {0: ['Dental Record', 'Dental records', 'dental records', 'Records, Dental', 'Record, Dental', 'dental record']}, 'types': {0: ['T170']}, 'definition': {0: 'Data collected during dental examination for the purpose of study, diagnosis, or treatment planning.'}, 'entity': {0: 'record'}, 'text': {0: 'Precautions: Refer to the SmPC for further information. To improve traceability, clearly record '}}","{'concept_id': {0: 'C0012157'}, 'canonical_name': {0: 'Diet Records'}, 'aliases': {0: ['Dietary Records', 'Records, Diet', 'Food Diaries', 'Diary, Food', 'Diaries, Food', 'Diet Record', 'Record, Dietary', 'Dietary Record', 'Record, Diet', 'Records, Dietary', 'Food Diary']}, 'types': {0: ['T170']}, 'definition': {0: 'Records of nutrient intake over a specific period of time, usually kept by the patient.'}, 'entity': {0: 'record'}, 'text': {0: 'Precautions: Refer to the SmPC for further information. To improve traceability, clearly record '}}",{},{},{},"             entity_group    value     score
0  Nonbiological_location     SmPC  0.946507
1    Detailed_description  clearly  0.998995
2    Diagnostic_procedure   record  0.613756",[],"{'keyword': {0: 'traceability clearly record', 1: 'information improve', 2: 'smpc information', 3: 'precautions refer', 4: 'refer smpc'}, 'score': {0: 0.8955, 1: 0.8159, 2: 0.7862, 3: 0.7329, 4: 0.6526}}"
326,326,326,0.9520000219345092,15.0,name and batch number of administered product. Congestive heart failure (CHF): Patients ,MyriadPro-Regular,4,-0.25,3355443,11,4,39,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'Patients'}, 'text': {0: 'name and batch number of administered product. Congestive heart failure (CHF): Patients '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'Patients'}, 'text': {0: 'name and batch number of administered product. Congestive heart failure (CHF): Patients '}}",{},{},"{'concept_id': {0: 'C0018802'}, 'canonical_name': {0: 'CHF'}, 'aliases': {0: ['Cardiac failures', 'Congestive heart failure', 'Cardiac failure', 'Heart failure']}, 'types': {0: ['T047']}, 'definition': {0: 'Heart failure accompanied by EDEMA, such as swelling of the legs and ankles and congestion in the lungs.'}, 'entity': {0: 'CHF'}, 'text': {0: 'name and batch number of administered product. Congestive heart failure (CHF): Patients '}}","           entity_group                     value     score
0  Detailed_description                Congestive  0.970514
1      Disease_disorder  Congestive heart failure  0.956123
2      Disease_disorder                       CHF  0.999886",[],"{'keyword': {0: 'chf patients', 1: 'administered product', 2: 'number administered', 3: 'heart failure chf', 4: 'batch number administered'}, 'score': {0: 0.8501, 1: 0.8261, 2: 0.7943, 3: 0.7742, 4: 0.6338}}"
327,327,327,0.9520000219345092,15.0,treated with Herceptin are at increased risk for developing CHF or asymptomatic cardiac ,MyriadPro-Regular,4,-0.25,3355443,11,4,40,"{'concept_id': {0: 'C1522601'}, 'canonical_name': {0: 'Cardiac - anatomy qualifier'}, 'aliases': {0: ['Cardiac']}, 'types': {0: ['T080']}, 'definition': {0: None}, 'entity': {0: 'cardiac'}, 'text': {0: 'treated with Herceptin are at increased risk for developing CHF or asymptomatic cardiac '}}","{'concept_id': {0: 'C0018799'}, 'canonical_name': {0: 'Heart Disorders'}, 'aliases': {0: ['Cardiac Diseases', 'Heart Disease', 'Heart Diseases', 'Cardiac Disease', 'Cardiac Disorder', 'Heart Disorder', 'Cardiac Disorders']}, 'types': {0: ['T047']}, 'definition': {0: 'Pathological conditions involving the HEART including its structural and functional abnormalities.'}, 'entity': {0: 'cardiac'}, 'text': {0: 'treated with Herceptin are at increased risk for developing CHF or asymptomatic cardiac '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'treated with Herceptin are at increased risk for developing CHF or asymptomatic cardiac '}}","{'concept_id': {0: 'C0232217'}, 'canonical_name': {0: 'cardiac conduction'}, 'aliases': {0: []}, 'types': {0: ['T042']}, 'definition': {0: 'Transfer of an organized electrical impulse across the heart to coordinate the contraction of cardiac muscles. The process begins with generation of an action potential (in the sinoatrial node (SA) in humans) and ends with a change in the rate, frequency, or extent of the contraction of the heart muscles. [GOC:dph]'}, 'entity': {0: 'cardiac'}, 'text': {0: 'treated with Herceptin are at increased risk for developing CHF or asymptomatic cardiac '}}","{'concept_id': {0: 'C0018790'}, 'canonical_name': {0: 'Heart stops beating'}, 'aliases': {0: ['Cardiac arrest']}, 'types': {0: ['T047']}, 'definition': {0: 'Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.'}, 'entity': {0: 'cardiac'}, 'text': {0: 'treated with Herceptin are at increased risk for developing CHF or asymptomatic cardiac '}}","           entity_group                   value     score
0           Coreference               Herceptin  0.685500
1      Disease_disorder                     CHF  0.999873
2          Sign_symptom  increased asymptomatic  0.996570
3          Sign_symptom            asymptomatic  0.988449
4          Sign_symptom  Herceptin asymptomatic  0.988657
5  Biological_structure                 cardiac  0.999822","[('Herceptin', 'DRUG')]","{'keyword': {0: 'increased risk developing', 1: 'herceptin increased risk', 2: 'treated herceptin increased', 3: 'asymptomatic cardiac', 4: 'treated herceptin'}, 'score': {0: 0.9075, 1: 0.7234, 2: 0.6602, 3: 0.6385, 4: 0.3764}}"
328,328,328,0.9520000219345092,15.0,dysfunction. These events have been observed in patients receiving Herceptin therapy alone or ,MyriadPro-Regular,4,-0.25,3355443,11,4,41,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'Herceptin therapy'}, 'text': {0: 'dysfunction. These events have been observed in patients receiving Herceptin therapy alone or '}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'Herceptin therapy'}, 'text': {0: 'dysfunction. These events have been observed in patients receiving Herceptin therapy alone or '}}",{},{},"{'concept_id': {0: 'C0086565'}, 'canonical_name': {0: 'Liver dysfunction'}, 'aliases': {0: ['Abnormal liver function']}, 'types': {0: ['T033']}, 'definition': {0: 'A finding that indicates abnormal liver function.'}, 'entity': {0: 'dysfunction'}, 'text': {0: 'dysfunction. These events have been observed in patients receiving Herceptin therapy alone or '}}","  entity_group                value     score
0   Medication            Herceptin  0.999894
1   Medication  receiving Herceptin  0.604990
2   Medication    Herceptin therapy  0.999465","[('Herceptin', 'DRUG')]","{'keyword': {0: 'events observed patients', 1: 'patients receiving', 2: 'observed patients', 3: 'dysfunction events observed', 4: 'herceptin therapy'}, 'score': {0: 0.786, 1: 0.7249, 2: 0.7102, 3: 0.6958, 4: 0.641}}"
329,329,329,0.9520000219345092,15.0,"in combination with paclitaxel or docetaxel, particularly following anthracycline (doxorubicin or ",MyriadPro-Regular,4,-0.25,3355443,11,4,42,"{'concept_id': {0: 'C0546861'}, 'canonical_name': {0: 'doxorubicin hydrochloride'}, 'aliases': {0: ['Doxorubicin hydrochloride', 'Hydroxydaunomycin hydrochloride', 'hydroxydaunorubicin', '3-hydroxyacetyldaunorubicin hydrochloride', 'DOXORUBICIN HYDROCHLORIDE', 'Hydroxydaunorubicin', 'DOXOrubicin hydrochloride', 'doxorubicin hydrochloride', 'Hydroxydaunomycin', 'Chloridrato de Doxorrubicina', 'Hydrochloride, Doxorubicin', 'L-Lyxo-hexopyranoside, 3b-glycol-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-, hydrochloride', 'Hydroxydaunorubicin hydrochloride', 'doxorubicin.HCl', 'DOXOrubicin Hydrochloride', '3-Hydroxyacetyldaunorubicin Hydrochloride', 'chloridrato de doxorrubicina', 'Doxorubicin Hydrochloride', 'doxorubicin hcl', '14-Hydroxydaunorubicin Hydrochloride', '5,12-naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-(9CI)', 'Doxorubicin hydrochloride (substance)', 'Doxorubicin HCl', '14-hydroxydaunorubicin hydrochloride', '5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-(9CI)', 'L-lyxo-hexopyranoside, 3b-glycol-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-.alpha.-, hydrochloride']}, 'types': {0: ['T109', 'T195']}, 'definition': {0: 'The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.'}, 'entity': {0: 'doxorubicin'}, 'text': {0: 'in combination with paclitaxel or docetaxel, particularly following anthracycline (doxorubicin or '}}","{'concept_id': {0: 'C0058725'}, 'canonical_name': {0: 'doxorubicin-DNA'}, 'aliases': {0: ['adriamycin-DNA', 'DNA-adriamycin complex']}, 'types': {0: ['T114', 'T121']}, 'definition': {0: 'A complex comprised of Doxorubicin linked to DNA to enhance the topoisomerase II-mediated interaction with the DNA base pairs and reduce cardiotoxicity associated with anthracyclines. (NCI)'}, 'entity': {0: 'doxorubicin'}, 'text': {0: 'in combination with paclitaxel or docetaxel, particularly following anthracycline (doxorubicin or '}}","{'concept_id': {0: 'C0546861'}, 'canonical_name': {0: 'doxorubicin hydrochloride'}, 'aliases': {0: ['DOXOrubicin hydrochloride']}, 'types': {0: ['T109', 'T195']}, 'definition': {0: 'The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.'}, 'entity': {0: 'doxorubicin'}, 'text': {0: 'in combination with paclitaxel or docetaxel, particularly following anthracycline (doxorubicin or '}}","{'concept_id': {0: 'C3549011'}, 'canonical_name': {0: 'doxorubicin metabolic process'}, 'aliases': {0: []}, 'types': {0: ['T044']}, 'definition': {0: 'The chemical reactions and pathways involving doxorubicin, an anthracycline antibiotic, used in cancer chemotherapy. [PMID:10200167]'}, 'entity': {0: 'doxorubicin'}, 'text': {0: 'in combination with paclitaxel or docetaxel, particularly following anthracycline (doxorubicin or '}}",{},"  entity_group                             value     score
0   Medication                        paclitaxel  0.999886
1   Medication              paclitaxel docetaxel  0.801809
2   Medication                         docetaxel  0.999879
3   Medication  paclitaxel docetaxel doxorubicin  0.961664
4   Medication                     anthracycline  0.939904
5   Medication             docetaxel doxorubicin  0.999756
6   Medication                       doxorubicin  0.943927","[('paclitaxel', 'DRUG'), ('docetaxel', 'DRUG'), ('anthracycline', 'DRUG'), ('doxorubicin', 'DRUG')]","{'keyword': {0: 'particularly following', 1: 'combination paclitaxel', 2: 'following anthracycline doxorubicin', 3: 'docetaxel particularly', 4: 'paclitaxel docetaxel'}, 'score': {0: 0.6988, 1: 0.5875, 2: 0.4513, 3: 0.4277, 4: 0.1993}}"
330,330,330,0.9520000219345092,15.0,epirubicin)–containing chemotherapy. These may be moderate to severe and have been ,MyriadPro-Regular,4,-0.25,3355443,11,4,43,"{'concept_id': {0: 'C1547231'}, 'canonical_name': {0: 'Severe - Triage Code'}, 'aliases': {0: ['Severe']}, 'types': {0: ['T170']}, 'definition': {0: None}, 'entity': {0: 'severe'}, 'text': {0: 'epirubicin)–containing chemotherapy. These may be moderate to severe and have been '}}","{'concept_id': {0: 'C1719672'}, 'canonical_name': {0: 'Severe Sepsis'}, 'aliases': {0: ['Sepsis, Severe']}, 'types': {0: ['T047']}, 'definition': {0: 'Clinical syndrome defined by the presence of both infection and a systemic inflammatory response that progresses to multi-organ failure.'}, 'entity': {0: 'severe'}, 'text': {0: 'epirubicin)–containing chemotherapy. These may be moderate to severe and have been '}}",{},{},"{'concept_id': {0: 'C0205082'}, 'canonical_name': {0: 'Severe'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Intensely bad or unpleasant in degree, quality or extent.'}, 'entity': {0: 'severe'}, 'text': {0: 'epirubicin)–containing chemotherapy. These may be moderate to severe and have been '}}","           entity_group       value     score
0            Medication  epirubicin  0.999795
1           Coreference       These  0.993745
2              Severity    moderate  0.992396
3  Detailed_description        have  0.669139
4  Detailed_description        been  0.653500","[('chemotherapy', 'DRUG')]","{'keyword': {0: 'containing chemotherapy moderate', 1: 'containing chemotherapy', 2: 'chemotherapy moderate severe', 3: 'epirubicin containing chemotherapy', 4: 'moderate severe'}, 'score': {0: 0.7617, 1: 0.7208, 2: 0.6531, 3: 0.4728, 4: 0.4639}}"
331,331,331,0.9520000219345092,15.0,"associated with death. In addition, caution should be exercised in treating patients with ",MyriadPro-Regular,4,-0.25,3355443,11,4,44,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'associated with death. In addition, caution should be exercised in treating patients with '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'associated with death. In addition, caution should be exercised in treating patients with '}}",{},"{'concept_id': {0: 'C2754100'}, 'canonical_name': {0: 'neuron death'}, 'aliases': {0: ['neuronal cell death', 'neuron cell death']}, 'types': {0: ['T043']}, 'definition': {0: 'The process of cell death in a neuron. [GOC:BHF, GOC:mah]'}, 'entity': {0: 'death'}, 'text': {0: 'associated with death. In addition, caution should be exercised in treating patients with '}}","{'concept_id': {0: 'C0015927'}, 'canonical_name': {0: 'Foetal death'}, 'aliases': {0: ['Fetal demise', 'Prenatal death', 'Fetal death', 'Intrauterine death']}, 'types': {0: ['T046']}, 'definition': {0: 'Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.'}, 'entity': {0: 'death'}, 'text': {0: 'associated with death. In addition, caution should be exercised in treating patients with '}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'associated death', 1: 'caution exercised treating', 2: 'associated death addition', 3: 'treating patients', 4: 'exercised treating'}, 'score': {0: 0.7553, 1: 0.6914, 2: 0.6621, 3: 0.6352, 4: 0.5649}}"
332,332,332,0.9520000219345092,15.0,"increased cardiac risk, e.g. hypertension, documented coronary artery disease, CHF, LVEF of ",MyriadPro-Regular,4,-0.25,3355443,11,4,45,"{'concept_id': {0: 'C0019099'}, 'canonical_name': {0: 'Hemorrhagic Fever, Crimean'}, 'aliases': {0: ['Crimean-Congo haemorrhagic fever', 'Haemorrhagic Fever, Crimean-Congo', 'Hemorrhagic Fever, Crimean-Congo', 'Crimean-Congo Hemorrhagic Fever', 'Crimean hemorrhagic fever [CHF Congo virus]', 'Congo-Crimean hemorrhagic fever', 'CHF Congo virus', 'Fever, Congo-Crimean Hemorrhagic', 'Fever, Crimean Hemorrhagic', 'CCHF - Crimean-Congo hemorrhagic fever', 'Viral haemorrhagic fever, Crimean-Congo', 'CCHF - Crimean-Congo haemorrhagic fever', 'Congo Virus Infection', 'Hemorrhagic Fever, Congo-Crimean', 'Congo-Crimean haemorrhagic fever', 'Crimean-Congo Haemorrhagic Fever', 'crimean hemorrhagic fever', 'Congo Crimean Hemorrhagic Fever', 'Infection, Congo Virus', 'Fever, Crimean-Congo Hemorrhagic', 'Hemorrhagic Fever, Crimean', 'crimean congo haemorrhagic fever', 'Crimean Hemorrhagic Fever', 'Central Asian haemorrhagic fever', 'Crimean Congo Haemorrhagic Fever', 'Crimean-Congo hemorrhagic fever', 'Crimean haemorrhagic fever', 'Congo fever', 'congo fever', 'Fever, Crimean-Congo Haemorrhagic', 'crimean-congo haemorrhagic fever', 'Congo-Crimean hemorrhagic fever (disorder)', 'Central Asian hemorrhagic fever', 'CHF - Crimean hemorrhagic fever', 'Congo-Crimean Hemorrhagic Fever', 'crimean-congo hemorrhagic fever', 'Crimean hemorrhagic fever', 'Viral hemorrhagic fever, Crimean-Congo', 'CHF - Crimean haemorrhagic fever', 'CCHF', 'Congo hemorrhagic fever', 'crimean congo hemorrhagic fever', 'Crimean Congo Hemorrhagic Fever', 'HEMORRHAGIC FEVER, CRIMEAN-CONGO']}, 'types': {0: ['T047']}, 'definition': {0: 'A severe, often fatal disease in humans caused by the Crimean-Congo hemorrhagic fever virus (HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO).'}, 'entity': {0: 'CHF'}, 'text': {0: 'increased cardiac risk, e.g. hypertension, documented coronary artery disease, CHF, LVEF of '}}","{'concept_id': {0: 'C0010068'}, 'canonical_name': {0: 'Diseases, Coronary'}, 'aliases': {0: ['Coronary Heart Disease', 'Coronary Diseases', 'Heart Disease, Coronary', 'Coronary Heart Diseases', 'Diseases, Coronary Heart', 'Disease, Coronary Heart', 'Coronary Disease', 'Disease, Coronary', 'Heart Diseases, Coronary']}, 'types': {0: ['T047']}, 'definition': {0: 'An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.'}, 'entity': {0: 'coronary artery disease'}, 'text': {0: 'increased cardiac risk, e.g. hypertension, documented coronary artery disease, CHF, LVEF of '}}",{},{},"{'concept_id': {0: 'C0018802'}, 'canonical_name': {0: 'CHF'}, 'aliases': {0: ['Cardiac failures', 'Congestive heart failure', 'Cardiac failure', 'Heart failure']}, 'types': {0: ['T047']}, 'definition': {0: 'Heart failure accompanied by EDEMA, such as swelling of the legs and ankles and congestion in the lungs.'}, 'entity': {0: 'CHF'}, 'text': {0: 'increased cardiac risk, e.g. hypertension, documented coronary artery disease, CHF, LVEF of '}}","  entity_group                               value     score
0    Lab_value                           increased  0.987601
1      History                        hypertension  0.866704
2      History  documented coronary artery disease  0.894785
3      History                                 CHF  0.981203
4      History                                LVEF  0.825729",[],"{'keyword': {0: 'chf lvef', 1: 'coronary artery', 2: 'increased cardiac', 3: 'documented coronary', 4: 'disease chf'}, 'score': {0: 0.388, 1: 0.3837, 2: 0.359, 3: 0.2872, 4: 0.2239}}"
333,333,333,0.9520000219345092,15.0,"<55%, older age. For further information on cardiac monitoring and Herceptin in combination ",MyriadPro-Regular,4,-0.25,3355443,11,4,46,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Herceptin'}, 'text': {0: '<55%, older age. For further information on cardiac monitoring and Herceptin in combination '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: '<55%, older age. For further information on cardiac monitoring and Herceptin in combination '}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: '<55%, older age. For further information on cardiac monitoring and Herceptin in combination '}}",{},{},"           entity_group      value     score
0  Detailed_description      older  0.419874
1  Diagnostic_procedure  Herceptin  0.907598","[('Herceptin', 'DRUG')]","{'keyword': {0: 'information cardiac', 1: '55 older', 2: 'cardiac monitoring', 3: 'monitoring herceptin', 4: 'age information'}, 'score': {0: 0.7531, 1: 0.7298, 2: 0.7177, 3: 0.6514, 4: 0.5928}}"
334,334,334,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,11,5,0,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
335,335,335,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,11,5,1,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
336,336,336,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,11,5,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
337,337,337,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,16777215,11,5,3,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
338,338,338,0.75,110.0,When a different  ,ConduitITC-Bold,20,-0.1700000017881393,16777215,13,1,0,{},{},{},{},{},"  entity_group      value    score
0    Lab_value  different  0.99952",[],"{'keyword': {}, 'score': {}}"
339,339,339,0.75,110.0,direction is vital ,ConduitITC-Bold,20,-0.1700000017881393,16777215,13,1,1,"{'concept_id': {0: 'C1550715'}, 'canonical_name': {0: 'direction - AddressPartType'}, 'aliases': {0: ['direction']}, 'types': {0: ['T078']}, 'definition': {0: '<p>Direction (e.g., N, S, W, E)</p>'}, 'entity': {0: 'direction'}, 'text': {0: 'direction is vital '}}","{'concept_id': {0: 'C0700158'}, 'canonical_name': {0: 'Direction'}, 'aliases': {0: ['Direction compound']}, 'types': {0: ['T122']}, 'definition': {0: None}, 'entity': {0: 'direction'}, 'text': {0: 'direction is vital '}}",{},{},{},"           entity_group      value     score
0  Diagnostic_procedure  direction  0.999789
1             Lab_value      vital  0.996564",[],"{'keyword': {0: 'direction vital'}, 'score': {0: 0.8764}}"
340,340,340,0.75,48.0,A step forward for patients with ,ConduitITC-Bold,20,-0.1700000017881393,16777215,13,2,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'A step forward for patients with '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'A step forward for patients with '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'step forward', 1: 'step forward patients', 2: 'forward patients'}, 'score': {0: 0.8969, 1: 0.8443, 2: 0.8292}}"
341,341,341,0.75,48.0,residual invasive disease,ConduitITC-Bold,20,-0.1700000017881393,16777215,13,2,1,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'residual invasive disease'}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'residual invasive disease'}}",{},{},{},"           entity_group              value     score
0  Detailed_description  residual invasive  0.722441
1      Disease_disorder            disease  0.738652",[],"{'keyword': {0: 'residual invasive disease', 1: 'residual invasive', 2: 'invasive disease'}, 'score': {0: 1.0, 1: 0.9438, 2: 0.8031}}"
342,342,342,0.9470000267028807,23.0,"Kadcyla, as a single agent, is indicated for the adjuvant ",UniversSB-Light,4,-0.2329999953508377,16777215,13,3,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant '}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant '}}",{},{},"  entity_group             value     score
0   Medication  Kadcyla adjuvant  0.913006
1   Medication          adjuvant  0.915010","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla single agent', 1: 'kadcyla single', 2: 'single agent', 3: 'single agent indicated', 4: 'agent indicated'}, 'score': {0: 0.6756, 1: 0.6359, 2: 0.5335, 3: 0.4616, 4: 0.4001}}"
343,343,343,0.9470000267028807,23.0,treatment of adult patients with HER2-positive eBC who have ,UniversSB-Light,4,-0.2329999953508377,16777215,13,3,1,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'treatment of adult patients with HER2-positive eBC who have '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'treatment of adult patients with HER2-positive eBC who have '}}",{},{},"{'concept_id': {0: 'C1853562'}, 'canonical_name': {0: 'Adult onset'}, 'aliases': {0: ['Symptoms begin in adulthood', 'Onset in early adulthood', 'Onset in adulthood']}, 'types': {0: ['T033']}, 'definition': {0: 'Onset of disease manifestations in adulthood, defined here as at the age of 16 years or later. [HPO:probinson]'}, 'entity': {0: 'adult'}, 'text': {0: 'treatment of adult patients with HER2-positive eBC who have '}}","           entity_group                                      value     score
0  Detailed_description                              HER2-positive  0.989120
1             Lab_value                              HER2-positive  0.988010
2      Disease_disorder  treatment patients HER2-positive eBC have  0.985162
3      Disease_disorder                                        eBC  0.938856",[],"{'keyword': {0: 'her2 positive ebc', 1: 'treatment adult patients', 2: 'adult patients', 3: 'patients her2', 4: 'her2 positive'}, 'score': {0: 0.794, 1: 0.7385, 2: 0.7364, 3: 0.7343, 4: 0.6985}}"
344,344,344,0.9470000267028807,23.0,"residual invasive disease, in the breast and/or lymph nodes, ",UniversSB-Light,4,-0.2329999953508377,16777215,13,3,2,"{'concept_id': {0: 'C0578050'}, 'canonical_name': {0: 'Pain of lymph node'}, 'aliases': {0: ['lymph nodes pain', 'Pain of lymph node (finding)', 'glands lymph pain', 'lymph nodes painful', 'pain lymph glands', 'Pain of lymph node', 'gland lymph pain', 'lymph gland pain', 'Lymph Node Pain', 'painful lymph node', 'Painful lymph node', 'lymph glands pain', 'lymph node painful', 'lymph node pain']}, 'types': {0: ['T184']}, 'definition': {0: 'A painful sensation in a lymph node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'residual invasive disease, in the breast and/or lymph nodes, '}}","{'concept_id': {0: 'C1522495'}, 'canonical_name': {0: 'Sentinal Node'}, 'aliases': {0: ['Nodes, Sentinal', 'Sentinel Lymph Node', 'Node, Sentinal', 'Lymph Node, Sentinel', 'Sentinel Lymph Nodes', 'Sentinal Nodes', 'Lymph Nodes, Sentinel']}, 'types': {0: ['T023']}, 'definition': {0: 'First lymph node to receive drainage from the primary tumor. SENTINEL LYMPH NODE BIOPSY is performed to determine early METASTASIS status because cancer cells may appear first in the sentinel node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'residual invasive disease, in the breast and/or lymph nodes, '}}",{},{},"{'concept_id': {0: 'C0024205'}, 'canonical_name': {0: 'Lymphadenitis'}, 'aliases': {0: ['Inflammation of the lymph nodes']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the lymph nodes.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'residual invasive disease, in the breast and/or lymph nodes, '}}","           entity_group     value     score
0  Detailed_description  residual  0.646063
1  Biological_structure    breast  0.999617",[],"{'keyword': {0: 'residual invasive disease', 1: 'disease breast', 2: 'invasive disease', 3: 'lymph nodes', 4: 'breast lymph'}, 'score': {0: 0.9104, 1: 0.8342, 2: 0.8331, 3: 0.813, 4: 0.76}}"
345,345,345,0.9470000267028807,23.0,after neoadjuvant taxane-based and HER2-targeted therapy.,UniversSB-Light,4,-0.2329999953508377,16777215,13,3,3,"{'concept_id': {0: 'C2985566'}, 'canonical_name': {0: 'Targeted Therapy'}, 'aliases': {0: ['targeted therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.'}, 'entity': {0: 'HER2-targeted therapy'}, 'text': {0: 'after neoadjuvant taxane-based and HER2-targeted therapy.'}}",{},{},{},{},"           entity_group         value     score
0  Detailed_description   neoadjuvant  0.999715
1  Detailed_description  taxane-based  0.995623","[('taxane', 'DRUG')]","{'keyword': {0: 'taxane based her2', 1: 'neoadjuvant taxane based', 2: 'taxane based', 3: 'based her2', 4: 'her2 targeted'}, 'score': {0: 0.8503, 1: 0.8213, 2: 0.821, 3: 0.7663, 4: 0.7652}}"
346,346,346,0.9169999957084656,30.0,Reference:,ConduitITC-Bold,20,-0.2349999994039535,8194925,13,4,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
347,347,347,0.8830000162124634,22.0,1.  Kadcyla Summary of Product Characteristics.,MyriadPro-Light,4,-0.25,3355443,13,4,1,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'Characteristics'}, 'text': {0: '1.  Kadcyla Summary of Product Characteristics.'}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1.  Kadcyla Summary of Product Characteristics.'}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1.  Kadcyla Summary of Product Characteristics.'}}","           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.796608","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla summary', 1: 'kadcyla summary product', 2: 'summary product', 3: 'summary product characteristics', 4: 'product characteristics'}, 'score': {0: 0.8868, 1: 0.8835, 2: 0.8533, 3: 0.7331, 4: 0.7046}}"
348,348,348,0.944000005722046,19.0,Reporting suspected adverse reactions after authorisation of the ,UniversSB-Medium,4,-0.2349999994039535,16777215,13,5,0,"{'concept_id': {0: 'C1368999'}, 'canonical_name': {0: 'Late effect of medical intervention'}, 'aliases': {0: ['Late Adverse Reaction', 'Late effect of', 'Aftereffect', 'Late effect', 'Adverse Late Effects', 'Late Adverse Effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Any symptom or condition which is a result of a medical intervention but arises months or years after it.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the '}}",{},{},"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the '}}","   entity_group              value     score
0  Sign_symptom  adverse reactions  0.999826",[],"{'keyword': {0: 'reporting suspected adverse', 1: 'suspected adverse reactions', 2: 'reporting suspected', 3: 'adverse reactions', 4: 'adverse reactions authorisation'}, 'score': {0: 0.921, 1: 0.8343, 2: 0.8335, 3: 0.7955, 4: 0.6816}}"
349,349,349,0.944000005722046,19.0,medicinal product is important. It allows continued monitoring of ,UniversSB-Medium,4,-0.2349999994039535,16777215,13,5,1,"{'concept_id': {0: 'C0005517'}, 'canonical_name': {0: 'Biological Monitoring'}, 'aliases': {0: ['biological monitoring', 'Bio Monitoring', 'Bio-Monitoring', 'Biomonitoring', 'Biologic Monitoring', 'Monitoring, Biologic', 'Biological monitoring', 'Monitoring, Biological']}, 'types': {0: ['T057']}, 'definition': {0: 'Monitoring of the level of toxins, chemical pollutants, microbial contaminants, or other harmful substances in the bodies of living organisms, by DIAGNOSTIC IMAGING or by analyzing BLOOD; URINE; BREAST MILK; SALIVA, etc.'}, 'entity': {0: 'monitoring'}, 'text': {0: 'medicinal product is important. It allows continued monitoring of '}}","{'concept_id': {0: 'C0015945'}, 'canonical_name': {0: 'Monitoring, Fetal'}, 'aliases': {0: ['Fetal Monitoring', 'Fetal Monitorings', 'Monitorings, Fetal']}, 'types': {0: ['T060']}, 'definition': {0: 'Physiologic or biochemical monitoring of the fetus. It is usually done during LABOR, OBSTETRIC and may be performed in conjunction with the monitoring of uterine activity. It may also be performed prenatally as when the mother is undergoing surgery.'}, 'entity': {0: 'monitoring'}, 'text': {0: 'medicinal product is important. It allows continued monitoring of '}}",{},{},{},"           entity_group       value     score
0  Diagnostic_procedure   medicinal  0.862680
1  Diagnostic_procedure  monitoring  0.996455",[],"{'keyword': {0: 'allows continued monitoring', 1: 'product important', 2: 'important allows continued', 3: 'medicinal product', 4: 'continued monitoring'}, 'score': {0: 0.909, 1: 0.8711, 2: 0.8252, 3: 0.8155, 4: 0.7951}}"
350,350,350,0.944000005722046,19.0,the benefit/risk balance of the medicinal product.,UniversSB-Medium,4,-0.2349999994039535,16777215,13,5,2,"{'concept_id': {0: 'C4684711'}, 'canonical_name': {0: 'Medicinal Product Name'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'The name assigned to a medicinal product as approved by a regulatory authority of the country of authorization.'}, 'entity': {0: 'medicinal product'}, 'text': {0: 'the benefit/risk balance of the medicinal product.'}}",{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'balance medicinal product', 1: 'risk balance medicinal', 2: 'benefit risk balance', 3: 'medicinal product', 4: 'benefit risk'}, 'score': {0: 0.9077, 1: 0.8857, 2: 0.8782, 3: 0.8101, 4: 0.7799}}"
351,351,351,0.944000005722046,19.0,Adverse events should be reported. Reporting forms and ,UniversSB-Medium,4,-0.2349999994039535,16777215,13,5,3,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should be reported. Reporting forms and '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should be reported. Reporting forms and '}}",{},{},{},"     entity_group           value     score
0    Sign_symptom  Adverse events  0.999894
1  Clinical_event       Reporting  0.978902",[],"{'keyword': {0: 'reporting forms', 1: 'events reported', 2: 'reported reporting', 3: 'adverse events', 4: 'events reported reporting'}, 'score': {0: 0.8998, 1: 0.875, 2: 0.8205, 3: 0.7868, 4: 0.7718}}"
352,352,352,0.944000005722046,19.0,information can be found at www.mhra.gov.uk/yellowcard or search ,UniversSB-Medium,4,-0.2349999994039535,16777215,13,5,4,"{'concept_id': {0: 'C4289829'}, 'canonical_name': {0: 'Case Search'}, 'aliases': {0: []}, 'types': {0: ['T062']}, 'definition': {0: 'The activity of looking for individuals with a shared characteristic such as a disease.'}, 'entity': {0: 'search'}, 'text': {0: 'information can be found at www.mhra.gov.uk/yellowcard or search '}}","{'concept_id': {0: 'C2348167'}, 'canonical_name': {0: 'Search Engine'}, 'aliases': {0: ['Engine, Search', 'Search Engines']}, 'types': {0: ['T170']}, 'definition': {0: 'A computer program that retrieves documents or files or data from a database or from a computer network.'}, 'entity': {0: 'search'}, 'text': {0: 'information can be found at www.mhra.gov.uk/yellowcard or search '}}",{},"{'concept_id': {0: 'C4690920'}, 'canonical_name': {0: 'T cell meandering migration'}, 'aliases': {0: ['T cell meandering search']}, 'types': {0: ['T043']}, 'definition': {0: 'The random-like motility observed for T cells in lymph nodes which enhances surveillance of antigens presented by major histocompatibility complex (MHC) molecules on antigen presenting cells (APCs). [GOC:add, GOC:krc, PMID:25083865]'}, 'entity': {0: 'search'}, 'text': {0: 'information can be found at www.mhra.gov.uk/yellowcard or search '}}",{},"           entity_group   value     score
0  Detailed_description  search  0.504256",[],"{'keyword': {0: 'information www mhra', 1: 'yellowcard search', 2: 'mhra gov', 3: 'gov uk yellowcard', 4: 'gov uk'}, 'score': {0: 0.8294, 1: 0.7855, 2: 0.7495, 3: 0.7295, 4: 0.6662}}"
353,353,353,0.944000005722046,19.0,for MHRA Yellow Card in the Google Play or Apple App Store.,UniversSB-Medium,4,-0.2349999994039535,16777215,13,5,5,"{'concept_id': {0: 'C4684566'}, 'canonical_name': {0: 'Applet'}, 'aliases': {0: ['App', 'Applet']}, 'types': {0: ['T170']}, 'definition': {0: 'A small application designed to perform a specific function within another application.'}, 'entity': {0: 'Apple App Store'}, 'text': {0: 'for MHRA Yellow Card in the Google Play or Apple App Store.'}}",{},{},{},"{'concept_id': {0: 'C0240962'}, 'canonical_name': {0: 'Conjunctival icterus'}, 'aliases': {0: ['Yellow sclera', 'Scleral icterus', 'Yellow conjunctiva', 'Yellowing of the whites of the eyes']}, 'types': {0: ['T033']}, 'definition': {0: 'Yellowing of the white part of the eyes, often due to a rise in bilirubin levels.'}, 'entity': {0: 'MHRA Yellow'}, 'text': {0: 'for MHRA Yellow Card in the Google Play or Apple App Store.'}}","           entity_group   value     score
0  Detailed_description  Google  0.998453
1  Detailed_description   Apple  0.958338",[],"{'keyword': {0: 'mhra yellow card', 1: 'play apple', 2: 'card google', 3: 'google play', 4: 'apple app'}, 'score': {0: 0.8936, 1: 0.8418, 2: 0.8411, 3: 0.8193, 4: 0.808}}"
354,354,354,0.944000005722046,19.0,Adverse events should also be reported to Roche Products Ltd.  ,UniversSB-Medium,4,-0.2349999994039535,16777215,13,5,6,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should also be reported to Roche Products Ltd.  '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should also be reported to Roche Products Ltd.  '}}",{},{},{},"   entity_group           value     score
0  Sign_symptom  Adverse events  0.999906
1    Medication           Roche  0.977449",[],"{'keyword': {0: 'adverse events', 1: 'events reported roche', 2: 'reported roche', 3: 'events reported', 4: 'roche products'}, 'score': {0: 0.7217, 1: 0.714, 2: 0.6768, 3: 0.6516, 4: 0.5478}}"
355,355,355,0.944000005722046,19.0,Please contact Roche Drug Safety Centre by emailing  ,UniversSB-Medium,4,-0.2349999994039535,16777215,13,5,7,"{'concept_id': {0: 'C0036043'}, 'canonical_name': {0: 'Safety'}, 'aliases': {0: ['Safeties', 'Safety', 'safety']}, 'types': {0: ['T068']}, 'definition': {0: 'Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.'}, 'entity': {0: 'Drug Safety Centre'}, 'text': {0: 'Please contact Roche Drug Safety Centre by emailing  '}}",{},{},{},{},"             entity_group          value     score
0  Nonbiological_location          Roche  0.929434
1  Nonbiological_location  Safety Centre  0.987673
2          Clinical_event       emailing  0.983830",[],"{'keyword': {0: 'contact roche', 1: 'centre emailing', 2: 'contact roche drug', 3: 'roche drug', 4: 'safety centre'}, 'score': {0: 0.7441, 1: 0.7026, 2: 0.6475, 3: 0.6049, 4: 0.6011}}"
356,356,356,0.944000005722046,19.0,welwyn.uk_dsc@roche.com or calling +44(0)1707 367554. ,UniversSB-Medium,4,-0.2349999994039535,16777215,13,5,8,"{'concept_id': {0: 'C0034770'}, 'canonical_name': {0: 'Mental Recall'}, 'aliases': {0: ['mental recall', 'Mental Recall', 'remember', 'recalling', 'recall', 'remembers', 'Recall, Mental', 'Recall', 'Recollect', 'remembering']}, 'types': {0: ['T041']}, 'definition': {0: 'The process whereby a representation of past experience is elicited.'}, 'entity': {0: 'calling'}, 'text': {0: 'welwyn.uk_dsc@roche.com or calling +44(0)1707 367554. '}}",{},{},{},{},"           entity_group          value     score
0  Diagnostic_procedure  welwyn.uk_dsc  0.992376",[],"{'keyword': {0: '1707 367554', 1: 'welwyn uk_dsc roche', 2: 'uk_dsc roche com', 3: 'calling 44', 4: 'roche com'}, 'score': {0: 0.8708, 1: 0.8137, 2: 0.794, 3: 0.7771, 4: 0.7524}}"
357,357,357,0.944000005722046,19.0,"As Kadcyla is a biological medicine, healthcare professionals should ",UniversSB-Medium,4,-0.2349999994039535,16777215,13,5,9,"{'concept_id': {0: 'C5554773'}, 'canonical_name': {0: 'Healthcare Professional Visit'}, 'aliases': {0: []}, 'types': {0: ['T058']}, 'definition': {0: 'The subject or patient has interacted with a healthcare professional at a healthcare facility.'}, 'entity': {0: 'healthcare professionals'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}","{'concept_id': {0: 'C0018722'}, 'canonical_name': {0: 'Health Occupations'}, 'aliases': {0: ['Profession, Health', 'Health Professions', 'Health Occupation', 'Health Profession', 'Professions, Health']}, 'types': {0: ['T091']}, 'definition': {0: 'Professions or other business activities directed to the cure and prevention of disease. For occupations of medical personnel who are not physicians but who are working in the fields of medical technology, physical therapy, etc., ALLIED HEALTH OCCUPATIONS is available.'}, 'entity': {0: 'healthcare professionals'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}","{'concept_id': {0: 'C3714634'}, 'canonical_name': {0: 'biological_process'}, 'aliases': {0: ['biological process']}, 'types': {0: ['T038']}, 'definition': {0: 'A biological process represents a specific objective that the organism is genetically programmed to achieve. Biological processes are often described by their outcome or ending state, e.g., the biological process of cell division results in the creation of two daughter cells (a divided cell) from a single parent cell. A biological process is accomplished by a particular set of molecular functions carried out by specific gene products (or macromolecular complexes), often in a highly regulated manner and in a particular temporal sequence. [GOC:pdt]'}, 'entity': {0: 'biological medicine'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}",{},"Empty DataFrame
Columns: []
Index: []","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla biological medicine', 1: 'medicine healthcare professionals', 2: 'kadcyla biological', 3: 'medicine healthcare', 4: 'healthcare professionals'}, 'score': {0: 0.8437, 1: 0.827, 2: 0.824, 3: 0.8164, 4: 0.7824}}"
358,358,358,0.944000005722046,19.0,report adverse reactions by brand name and batch number.,UniversSB-Medium,4,-0.2349999994039535,16777215,13,5,10,"{'concept_id': {0: 'C1948031'}, 'canonical_name': {0: 'Batch (group)'}, 'aliases': {0: ['Batch']}, 'types': {0: ['T081']}, 'definition': {0: 'A quantity of people or things treated or regarded as a group, especially when subdivided from a larger group.'}, 'entity': {0: 'batch number'}, 'text': {0: 'report adverse reactions by brand name and batch number.'}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'report adverse reactions by brand name and batch number.'}}",{},{},"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'report adverse reactions by brand name and batch number.'}}","   entity_group              value     score
0  Sign_symptom  adverse reactions  0.744242",[],"{'keyword': {0: 'reactions brand batch', 1: 'reactions brand', 2: 'batch number', 3: 'adverse reactions', 4: 'report adverse reactions'}, 'score': {0: 0.8437, 1: 0.8276, 2: 0.7816, 3: 0.7576, 4: 0.6528}}"
359,359,359,0.9470000267028807,19.0,"eBC, early breast cancer. ",UniversSB-Light,4,-0.2329999953508377,16777215,13,6,0,"{'concept_id': {0: 'C0598034'}, 'canonical_name': {0: 'BRCA2 gene'}, 'aliases': {0: ['BRCA2, DNA Repair Associated Gene', 'brca2', 'brca 2 gene', 'FACD', 'breast cancer 2', 'BRCA2 Genes', 'XRCC11', 'BRCA2 DNA repair associated', 'breast cancer 2, early onset', 'BRCC2', 'Fanconi anemia, complementation group D1', 'FANCD1 GENE', 'FAD1', 'BRCA1/BRCA2-containing complex, subunit 2', 'BRCA2 gene', 'FANCD1', 'brca2 gene', 'BRCA2 GENE', 'Breast Cancer 2, Early Onset Gene', 'FANCD', 'Genes, BRCA2', 'BRCA2', 'BRCA2 Gene', 'BRCA2 DNA REPAIR-ASSOCIATED PROTEIN', 'FAD', 'brca2 genes', 'Gene, BRCA2']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}","{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}","           entity_group   value     score
0  Biological_structure  breast  0.991112",[],"{'keyword': {0: 'ebc early breast', 1: 'early breast', 2: 'early breast cancer', 3: 'breast cancer', 4: 'ebc early'}, 'score': {0: 0.9046, 1: 0.8815, 2: 0.8637, 3: 0.744, 4: 0.7344}}"
360,360,360,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,13,8,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
361,361,361,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,13,8,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
362,362,362,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,13,8,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
363,363,363,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,13,8,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
364,364,364,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,13,9,0,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
365,365,365,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,13,9,1,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
366,366,366,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,13,10,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
367,367,367,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,13,10,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
368,368,368,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,13,10,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
369,369,369,0.9470000267028807,19.0,M-GB-00004511. September 2021. ,UniversSB-Light,4,-0.2329999953508377,5723991,13,11,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '00004511 september 2021', 1: 'september 2021', 2: '00004511 september', 3: 'gb 00004511 september', 4: 'gb 00004511'}, 'score': {0: 0.9362, 1: 0.9072, 2: 0.9023, 3: 0.8713, 4: 0.8382}}"
370,370,370,0.9169999957084656,98.0,Kadcyla,ConduitITC-Bold,20,-0.2349999994039535,8194925,14,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
371,371,371,0.9890000224113464,34.0,Adjuvant treatment of eBC,MyriadPro-Bold,20,-0.25,3355443,14,2,0,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'Adjuvant treatment'}, 'text': {0: 'Adjuvant treatment of eBC'}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'Adjuvant treatment'}, 'text': {0: 'Adjuvant treatment of eBC'}}",{},{},{},"       entity_group     value     score
0        Medication  Adjuvant  0.783787
1  Disease_disorder       eBC  0.915630",[],"{'keyword': {0: 'adjuvant treatment', 1: 'adjuvant treatment ebc', 2: 'treatment ebc'}, 'score': {0: 0.9304, 1: 0.9177, 2: 0.8707}}"
372,372,372,0.8830000162124634,34.0,"Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive eBC who have residual ",MyriadPro-Light,4,-0.25,3355443,14,3,0,"{'concept_id': {0: 'C4684759'}, 'canonical_name': {0: 'Residual Risk'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Risk that remains after risk control measures have been taken.'}, 'entity': {0: 'residual'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive eBC who have residual '}}","{'concept_id': {0: 'C0242740'}, 'canonical_name': {0: 'Gastric Stump'}, 'aliases': {0: ['Remnant Stomachs', 'Stomachs, Remnant', 'Remnant, Gastric', 'Gastric Stumps', 'Gastric Remnant', 'Residual Stomach', 'Residual Stomachs', 'Stomachs, Residual', 'Stomach, Residual', 'Stump, Gastric', 'Stumps, Gastric', 'Remnants, Gastric', 'Gastric Remnants', 'Stomach, Remnant', 'Remnant Stomach']}, 'types': {0: ['T023']}, 'definition': {0: 'That portion of the stomach remaining after gastric surgery, usually gastrectomy or gastroenterostomy for cancer of the stomach or peptic ulcer. It is a common site of cancer referred to as stump cancer or carcinoma of the gastric stump.'}, 'entity': {0: 'residual'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive eBC who have residual '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive eBC who have residual '}}",{},"{'concept_id': {0: 'C1853562'}, 'canonical_name': {0: 'Adult onset'}, 'aliases': {0: ['Symptoms begin in adulthood', 'Onset in early adulthood', 'Onset in adulthood']}, 'types': {0: ['T033']}, 'definition': {0: 'Onset of disease manifestations in adulthood, defined here as at the age of 16 years or later. [HPO:probinson]'}, 'entity': {0: 'adult'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive eBC who have residual '}}","           entity_group                                              value  \
0             Lab_value                                      HER2-positive   
1  Detailed_description                                      HER2-positive   
2      Disease_disorder  single agent indicated the treatment patients ...   
3      Disease_disorder                                                eBC   
4  Detailed_description                                           residual   

      score  
0  0.735842  
1  0.393418  
2  0.978383  
3  0.820240  
4  0.999943  ","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'ebc residual', 1: 'her2 positive ebc', 2: 'single agent', 3: 'indicated adjuvant', 4: 'treatment adult patients'}, 'score': {0: 0.6179, 1: 0.521, 2: 0.4948, 3: 0.4357, 4: 0.3733}}"
373,373,373,0.8830000162124634,34.0,"invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.",MyriadPro-Light,4,-0.25,3355443,14,3,1,"{'concept_id': {0: 'C2985566'}, 'canonical_name': {0: 'Targeted Therapy'}, 'aliases': {0: ['targeted therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.'}, 'entity': {0: 'HER2-targeted therapy'}, 'text': {0: 'invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.'}}","{'concept_id': {0: 'C1522495'}, 'canonical_name': {0: 'Sentinal Node'}, 'aliases': {0: ['Nodes, Sentinal', 'Sentinel Lymph Node', 'Node, Sentinal', 'Lymph Node, Sentinel', 'Sentinel Lymph Nodes', 'Sentinal Nodes', 'Lymph Nodes, Sentinel']}, 'types': {0: ['T023']}, 'definition': {0: 'First lymph node to receive drainage from the primary tumor. SENTINEL LYMPH NODE BIOPSY is performed to determine early METASTASIS status because cancer cells may appear first in the sentinel node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.'}}",{},{},"{'concept_id': {0: 'C0024205'}, 'canonical_name': {0: 'Lymphadenitis'}, 'aliases': {0: ['Inflammation of the lymph nodes']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the lymph nodes.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.'}}","           entity_group         value     score
0  Biological_structure        breast  0.999555
1  Detailed_description   neoadjuvant  0.995614
2  Detailed_description  taxane-based  0.921506","[('taxane', 'DRUG')]","{'keyword': {0: 'taxane based', 1: 'nodes neoadjuvant taxane', 2: 'her2 targeted therapy', 3: 'lymph nodes', 4: 'invasive disease'}, 'score': {0: 0.8855, 1: 0.8809, 2: 0.8266, 3: 0.8003, 4: 0.6513}}"
374,374,374,0.75,110.0,When a different  ,ConduitITC-Bold,20,-0.1700000017881393,16777215,14,4,0,{},{},{},{},{},"  entity_group      value    score
0    Lab_value  different  0.99952",[],"{'keyword': {}, 'score': {}}"
375,375,375,0.75,110.0,direction is vital ,ConduitITC-Bold,20,-0.1700000017881393,16777215,14,4,1,"{'concept_id': {0: 'C1550715'}, 'canonical_name': {0: 'direction - AddressPartType'}, 'aliases': {0: ['direction']}, 'types': {0: ['T078']}, 'definition': {0: '<p>Direction (e.g., N, S, W, E)</p>'}, 'entity': {0: 'direction'}, 'text': {0: 'direction is vital '}}","{'concept_id': {0: 'C0700158'}, 'canonical_name': {0: 'Direction'}, 'aliases': {0: ['Direction compound']}, 'types': {0: ['T122']}, 'definition': {0: None}, 'entity': {0: 'direction'}, 'text': {0: 'direction is vital '}}",{},{},{},"           entity_group      value     score
0  Diagnostic_procedure  direction  0.999789
1             Lab_value      vital  0.996564",[],"{'keyword': {0: 'direction vital'}, 'score': {0: 0.8764}}"
376,376,376,0.9890000224113464,34.0,Kadcyla is recommended by NICE and accepted by the SMC*,MyriadPro-Bold,20,-0.25,3355443,14,5,0,"{'concept_id': {0: 'C1420578'}, 'canonical_name': {0: 'TAGLN gene'}, 'aliases': {0: ['WS3-10', 'SM22-alpha', 'TAGLN gene', 'TRANSGELIN', 'SMCC', 'TAGLN', 'TAGLN1', 'SM22-ALPHA', 'TAGLN Gene', 'DKFZp686P11128', 'transgelin', 'Transgelin Gene', 'SM22']}, 'types': {0: ['T028']}, 'definition': {0: 'This gene is involved in actin crosslinking.'}, 'entity': {0: 'SMC*'}, 'text': {0: 'Kadcyla is recommended by NICE and accepted by the SMC*'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla is recommended by NICE and accepted by the SMC*'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla is recommended by NICE and accepted by the SMC*'}}","{'concept_id': {0: 'C1167267'}, 'canonical_name': {0: 'submicrovillar cisterna'}, 'aliases': {0: ['SMC', 'subrhabdomeral cisterna']}, 'types': {0: ['T026']}, 'definition': {0: 'A membrane-bounded compartment that is found at the base of the rhabdomere and contains stored calcium, InsP3 receptors and smooth endoplasmic reticulum Ca2+-ATPase. [PMID:11707492, PMID:8646774]'}, 'entity': {0: 'SMC*'}, 'text': {0: 'Kadcyla is recommended by NICE and accepted by the SMC*'}}",{},"             entity_group    value     score
0             Coreference  Kadcyla  0.491492
1              Medication  Kadcyla  0.614310
2  Nonbiological_location     NICE  0.275274
3   Therapeutic_procedure      SMC  0.437523
4               Lab_value        *  0.283684","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla recommended nice', 1: 'nice accepted smc', 2: 'kadcyla recommended', 3: 'recommended nice accepted', 4: 'nice accepted'}, 'score': {0: 0.7995, 1: 0.7421, 2: 0.7247, 3: 0.708, 4: 0.4878}}"
377,377,377,0.75,48.0,A step forward for patients with ,ConduitITC-Bold,20,-0.1700000017881393,16777215,14,6,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'A step forward for patients with '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'A step forward for patients with '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'step forward', 1: 'step forward patients', 2: 'forward patients'}, 'score': {0: 0.8969, 1: 0.8443, 2: 0.8292}}"
378,378,378,0.75,48.0,residual invasive disease,ConduitITC-Bold,20,-0.1700000017881393,16777215,14,6,1,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'residual invasive disease'}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'residual invasive disease'}}",{},{},{},"           entity_group              value     score
0  Detailed_description  residual invasive  0.722441
1      Disease_disorder            disease  0.738652",[],"{'keyword': {0: 'residual invasive disease', 1: 'residual invasive', 2: 'invasive disease'}, 'score': {0: 1.0, 1: 0.9438, 2: 0.8031}}"
379,379,379,0.8830000162124634,34.0,"Kadcyla, as an alternative option to trastuzumab, is recommended by NICE and accepted by the SMC, within its marketing ",MyriadPro-Light,4,-0.25,3355443,14,7,0,"{'concept_id': {0: 'C3888088'}, 'canonical_name': {0: 'SMITH-MCCORT DYSPLASIA 1'}, 'aliases': {0: ['SMC', 'SMITH-McCORT DYSPLASIA 1', 'SMITH-MCCORT DYSPLASIA 1', 'SMC1']}, 'types': {0: ['T047']}, 'definition': {0: None}, 'entity': {0: 'SMC'}, 'text': {0: 'Kadcyla, as an alternative option to trastuzumab, is recommended by NICE and accepted by the SMC, within its marketing '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'Kadcyla, as an alternative option to trastuzumab, is recommended by NICE and accepted by the SMC, within its marketing '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'Kadcyla, as an alternative option to trastuzumab, is recommended by NICE and accepted by the SMC, within its marketing '}}","{'concept_id': {0: 'C2612492'}, 'canonical_name': {0: 'smooth muscle cell apoptotic process'}, 'aliases': {0: ['smooth muscle cell programmed cell death by apoptosis', 'apoptosis of smooth muscle cells', 'smooth muscle cell apoptosis', 'SMC apoptosis', 'programmed cell death of smooth muscle cells by apoptosis', 'programmed cell death, smooth muscle cells']}, 'types': {0: ['T043']}, 'definition': {0: 'Any apoptotic process in a smooth muscle cell. Smooth muscle consists of non-striated, elongated, spindle-shaped cell found lining the digestive tract, uterus, and blood vessels. [CL:0000192, GOC:BHF, GOC:mah, GOC:mtg_apoptosis, GOC:rl]'}, 'entity': {0: 'SMC'}, 'text': {0: 'Kadcyla, as an alternative option to trastuzumab, is recommended by NICE and accepted by the SMC, within its marketing '}}",{},"  entity_group        value     score
0   Medication      Kadcyla  0.996245
1   Medication  trastuzumab  0.987061","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'nice accepted smc', 1: 'option trastuzumab recommended', 2: 'alternative option', 3: 'alternative option trastuzumab', 4: 'trastuzumab recommended nice'}, 'score': {0: 0.85, 1: 0.8339, 2: 0.8068, 3: 0.7638, 4: 0.5826}}"
380,380,380,0.8830000162124634,34.0,authorisation for the adjuvant treatment of adult patients with HER2-positive eBC who have residual invasive disease in the ,MyriadPro-Light,4,-0.25,3355443,14,7,1,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'authorisation for the adjuvant treatment of adult patients with HER2-positive eBC who have residual invasive disease in the '}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'authorisation for the adjuvant treatment of adult patients with HER2-positive eBC who have residual invasive disease in the '}}",{},{},"{'concept_id': {0: 'C1853562'}, 'canonical_name': {0: 'Adult onset'}, 'aliases': {0: ['Symptoms begin in adulthood', 'Onset in early adulthood', 'Onset in adulthood']}, 'types': {0: ['T033']}, 'definition': {0: 'Onset of disease manifestations in adulthood, defined here as at the age of 16 years or later. [HPO:probinson]'}, 'entity': {0: 'adult'}, 'text': {0: 'authorisation for the adjuvant treatment of adult patients with HER2-positive eBC who have residual invasive disease in the '}}","            entity_group                                              value  \
0             Medication                                           adjuvant   
1  Therapeutic_procedure                                          treatment   
2                Subject                                              adult   
3   Detailed_description                                      HER2-positive   
4       Disease_disorder  the treatment patients HER2-positive eBC have ...   
5       Disease_disorder                                                eBC   
6   Detailed_description                                           residual   
7       Disease_disorder                                   invasive disease   

      score  
0  0.933404  
1  0.787508  
2  0.573259  
3  0.635303  
4  0.986707  
5  0.943063  
6  0.999948  
7  0.923347  ",[],"{'keyword': {0: 'ebc residual', 1: 'her2 positive ebc', 2: 'authorisation adjuvant', 3: 'adult patients', 4: 'treatment adult patients'}, 'score': {0: 0.7938, 1: 0.7244, 2: 0.6784, 3: 0.6672, 4: 0.5019}}"
381,381,381,0.8830000162124634,34.0,breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.,MyriadPro-Light,4,-0.25,3355443,14,7,2,"{'concept_id': {0: 'C2985566'}, 'canonical_name': {0: 'Targeted Therapy'}, 'aliases': {0: ['targeted therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.'}, 'entity': {0: 'HER2-targeted therapy'}, 'text': {0: 'breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.'}}","{'concept_id': {0: 'C1522495'}, 'canonical_name': {0: 'Sentinal Node'}, 'aliases': {0: ['Nodes, Sentinal', 'Sentinel Lymph Node', 'Node, Sentinal', 'Lymph Node, Sentinel', 'Sentinel Lymph Nodes', 'Sentinal Nodes', 'Lymph Nodes, Sentinel']}, 'types': {0: ['T023']}, 'definition': {0: 'First lymph node to receive drainage from the primary tumor. SENTINEL LYMPH NODE BIOPSY is performed to determine early METASTASIS status because cancer cells may appear first in the sentinel node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.'}}",{},{},"{'concept_id': {0: 'C0024205'}, 'canonical_name': {0: 'Lymphadenitis'}, 'aliases': {0: ['Inflammation of the lymph nodes']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the lymph nodes.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.'}}","           entity_group         value     score
0  Biological_structure        breast  0.999883
1  Biological_structure   lymph nodes  0.999878
2  Detailed_description   neoadjuvant  0.996868
3  Detailed_description  taxane-based  0.999814","[('taxane', 'DRUG')]","{'keyword': {0: 'nodes neoadjuvant taxane', 1: 'taxane based', 2: 'targeted therapy', 3: 'based her2', 4: 'lymph nodes'}, 'score': {0: 0.8936, 1: 0.8805, 2: 0.8271, 3: 0.8202, 4: 0.8081}}"
382,382,382,0.9470000267028807,23.0,"Kadcyla, as a single agent, is indicated for the adjuvant ",UniversSB-Light,4,-0.2329999953508377,16777215,14,8,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant '}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant '}}",{},{},"  entity_group             value     score
0   Medication  Kadcyla adjuvant  0.913006
1   Medication          adjuvant  0.915010","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla single agent', 1: 'kadcyla single', 2: 'single agent', 3: 'single agent indicated', 4: 'agent indicated'}, 'score': {0: 0.6756, 1: 0.6359, 2: 0.5335, 3: 0.4616, 4: 0.4001}}"
383,383,383,0.9470000267028807,23.0,treatment of adult patients with HER2-positive eBC who have ,UniversSB-Light,4,-0.2329999953508377,16777215,14,8,1,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'treatment of adult patients with HER2-positive eBC who have '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'treatment of adult patients with HER2-positive eBC who have '}}",{},{},"{'concept_id': {0: 'C1853562'}, 'canonical_name': {0: 'Adult onset'}, 'aliases': {0: ['Symptoms begin in adulthood', 'Onset in early adulthood', 'Onset in adulthood']}, 'types': {0: ['T033']}, 'definition': {0: 'Onset of disease manifestations in adulthood, defined here as at the age of 16 years or later. [HPO:probinson]'}, 'entity': {0: 'adult'}, 'text': {0: 'treatment of adult patients with HER2-positive eBC who have '}}","           entity_group                                      value     score
0  Detailed_description                              HER2-positive  0.989120
1             Lab_value                              HER2-positive  0.988010
2      Disease_disorder  treatment patients HER2-positive eBC have  0.985162
3      Disease_disorder                                        eBC  0.938856",[],"{'keyword': {0: 'her2 positive ebc', 1: 'treatment adult patients', 2: 'adult patients', 3: 'patients her2', 4: 'her2 positive'}, 'score': {0: 0.794, 1: 0.7385, 2: 0.7364, 3: 0.7343, 4: 0.6985}}"
384,384,384,0.9470000267028807,23.0,"residual invasive disease, in the breast and/or lymph nodes, ",UniversSB-Light,4,-0.2329999953508377,16777215,14,8,2,"{'concept_id': {0: 'C0578050'}, 'canonical_name': {0: 'Pain of lymph node'}, 'aliases': {0: ['lymph nodes pain', 'Pain of lymph node (finding)', 'glands lymph pain', 'lymph nodes painful', 'pain lymph glands', 'Pain of lymph node', 'gland lymph pain', 'lymph gland pain', 'Lymph Node Pain', 'painful lymph node', 'Painful lymph node', 'lymph glands pain', 'lymph node painful', 'lymph node pain']}, 'types': {0: ['T184']}, 'definition': {0: 'A painful sensation in a lymph node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'residual invasive disease, in the breast and/or lymph nodes, '}}","{'concept_id': {0: 'C1522495'}, 'canonical_name': {0: 'Sentinal Node'}, 'aliases': {0: ['Nodes, Sentinal', 'Sentinel Lymph Node', 'Node, Sentinal', 'Lymph Node, Sentinel', 'Sentinel Lymph Nodes', 'Sentinal Nodes', 'Lymph Nodes, Sentinel']}, 'types': {0: ['T023']}, 'definition': {0: 'First lymph node to receive drainage from the primary tumor. SENTINEL LYMPH NODE BIOPSY is performed to determine early METASTASIS status because cancer cells may appear first in the sentinel node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'residual invasive disease, in the breast and/or lymph nodes, '}}",{},{},"{'concept_id': {0: 'C0024205'}, 'canonical_name': {0: 'Lymphadenitis'}, 'aliases': {0: ['Inflammation of the lymph nodes']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the lymph nodes.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'residual invasive disease, in the breast and/or lymph nodes, '}}","           entity_group     value     score
0  Detailed_description  residual  0.646063
1  Biological_structure    breast  0.999617",[],"{'keyword': {0: 'residual invasive disease', 1: 'disease breast', 2: 'invasive disease', 3: 'lymph nodes', 4: 'breast lymph'}, 'score': {0: 0.9104, 1: 0.8342, 2: 0.8331, 3: 0.813, 4: 0.76}}"
385,385,385,0.9470000267028807,23.0,after neoadjuvant taxane-based and HER2-targeted therapy.,UniversSB-Light,4,-0.2329999953508377,16777215,14,8,3,"{'concept_id': {0: 'C2985566'}, 'canonical_name': {0: 'Targeted Therapy'}, 'aliases': {0: ['targeted therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.'}, 'entity': {0: 'HER2-targeted therapy'}, 'text': {0: 'after neoadjuvant taxane-based and HER2-targeted therapy.'}}",{},{},{},{},"           entity_group         value     score
0  Detailed_description   neoadjuvant  0.999715
1  Detailed_description  taxane-based  0.995623","[('taxane', 'DRUG')]","{'keyword': {0: 'taxane based her2', 1: 'neoadjuvant taxane based', 2: 'taxane based', 3: 'based her2', 4: 'her2 targeted'}, 'score': {0: 0.8503, 1: 0.8213, 2: 0.821, 3: 0.7663, 4: 0.7652}}"
386,386,386,0.944000005722046,19.0,Reporting suspected adverse reactions after authorisation of the ,UniversSB-Medium,4,-0.2349999994039535,16777215,14,9,0,"{'concept_id': {0: 'C1368999'}, 'canonical_name': {0: 'Late effect of medical intervention'}, 'aliases': {0: ['Late Adverse Reaction', 'Late effect of', 'Aftereffect', 'Late effect', 'Adverse Late Effects', 'Late Adverse Effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Any symptom or condition which is a result of a medical intervention but arises months or years after it.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the '}}",{},{},"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the '}}","   entity_group              value     score
0  Sign_symptom  adverse reactions  0.999826",[],"{'keyword': {0: 'reporting suspected adverse', 1: 'suspected adverse reactions', 2: 'reporting suspected', 3: 'adverse reactions', 4: 'adverse reactions authorisation'}, 'score': {0: 0.921, 1: 0.8343, 2: 0.8335, 3: 0.7955, 4: 0.6816}}"
387,387,387,0.944000005722046,19.0,medicinal product is important. It allows continued monitoring of ,UniversSB-Medium,4,-0.2349999994039535,16777215,14,9,1,"{'concept_id': {0: 'C0005517'}, 'canonical_name': {0: 'Biological Monitoring'}, 'aliases': {0: ['biological monitoring', 'Bio Monitoring', 'Bio-Monitoring', 'Biomonitoring', 'Biologic Monitoring', 'Monitoring, Biologic', 'Biological monitoring', 'Monitoring, Biological']}, 'types': {0: ['T057']}, 'definition': {0: 'Monitoring of the level of toxins, chemical pollutants, microbial contaminants, or other harmful substances in the bodies of living organisms, by DIAGNOSTIC IMAGING or by analyzing BLOOD; URINE; BREAST MILK; SALIVA, etc.'}, 'entity': {0: 'monitoring'}, 'text': {0: 'medicinal product is important. It allows continued monitoring of '}}","{'concept_id': {0: 'C0015945'}, 'canonical_name': {0: 'Monitoring, Fetal'}, 'aliases': {0: ['Fetal Monitoring', 'Fetal Monitorings', 'Monitorings, Fetal']}, 'types': {0: ['T060']}, 'definition': {0: 'Physiologic or biochemical monitoring of the fetus. It is usually done during LABOR, OBSTETRIC and may be performed in conjunction with the monitoring of uterine activity. It may also be performed prenatally as when the mother is undergoing surgery.'}, 'entity': {0: 'monitoring'}, 'text': {0: 'medicinal product is important. It allows continued monitoring of '}}",{},{},{},"           entity_group       value     score
0  Diagnostic_procedure   medicinal  0.862680
1  Diagnostic_procedure  monitoring  0.996455",[],"{'keyword': {0: 'allows continued monitoring', 1: 'product important', 2: 'important allows continued', 3: 'medicinal product', 4: 'continued monitoring'}, 'score': {0: 0.909, 1: 0.8711, 2: 0.8252, 3: 0.8155, 4: 0.7951}}"
388,388,388,0.944000005722046,19.0,the benefit/risk balance of the medicinal product.,UniversSB-Medium,4,-0.2349999994039535,16777215,14,9,2,"{'concept_id': {0: 'C4684711'}, 'canonical_name': {0: 'Medicinal Product Name'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'The name assigned to a medicinal product as approved by a regulatory authority of the country of authorization.'}, 'entity': {0: 'medicinal product'}, 'text': {0: 'the benefit/risk balance of the medicinal product.'}}",{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'balance medicinal product', 1: 'risk balance medicinal', 2: 'benefit risk balance', 3: 'medicinal product', 4: 'benefit risk'}, 'score': {0: 0.9077, 1: 0.8857, 2: 0.8782, 3: 0.8101, 4: 0.7799}}"
389,389,389,0.944000005722046,19.0,Adverse events should be reported. Reporting forms and ,UniversSB-Medium,4,-0.2349999994039535,16777215,14,9,3,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should be reported. Reporting forms and '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should be reported. Reporting forms and '}}",{},{},{},"     entity_group           value     score
0    Sign_symptom  Adverse events  0.999894
1  Clinical_event       Reporting  0.978902",[],"{'keyword': {0: 'reporting forms', 1: 'events reported', 2: 'reported reporting', 3: 'adverse events', 4: 'events reported reporting'}, 'score': {0: 0.8998, 1: 0.875, 2: 0.8205, 3: 0.7868, 4: 0.7718}}"
390,390,390,0.944000005722046,19.0,information can be found at www.mhra.gov.uk/yellowcard or search ,UniversSB-Medium,4,-0.2349999994039535,16777215,14,9,4,"{'concept_id': {0: 'C4289829'}, 'canonical_name': {0: 'Case Search'}, 'aliases': {0: []}, 'types': {0: ['T062']}, 'definition': {0: 'The activity of looking for individuals with a shared characteristic such as a disease.'}, 'entity': {0: 'search'}, 'text': {0: 'information can be found at www.mhra.gov.uk/yellowcard or search '}}","{'concept_id': {0: 'C2348167'}, 'canonical_name': {0: 'Search Engine'}, 'aliases': {0: ['Engine, Search', 'Search Engines']}, 'types': {0: ['T170']}, 'definition': {0: 'A computer program that retrieves documents or files or data from a database or from a computer network.'}, 'entity': {0: 'search'}, 'text': {0: 'information can be found at www.mhra.gov.uk/yellowcard or search '}}",{},"{'concept_id': {0: 'C4690920'}, 'canonical_name': {0: 'T cell meandering migration'}, 'aliases': {0: ['T cell meandering search']}, 'types': {0: ['T043']}, 'definition': {0: 'The random-like motility observed for T cells in lymph nodes which enhances surveillance of antigens presented by major histocompatibility complex (MHC) molecules on antigen presenting cells (APCs). [GOC:add, GOC:krc, PMID:25083865]'}, 'entity': {0: 'search'}, 'text': {0: 'information can be found at www.mhra.gov.uk/yellowcard or search '}}",{},"           entity_group   value     score
0  Detailed_description  search  0.504256",[],"{'keyword': {0: 'information www mhra', 1: 'yellowcard search', 2: 'mhra gov', 3: 'gov uk yellowcard', 4: 'gov uk'}, 'score': {0: 0.8294, 1: 0.7855, 2: 0.7495, 3: 0.7295, 4: 0.6662}}"
391,391,391,0.944000005722046,19.0,for MHRA Yellow Card in the Google Play or Apple App Store.,UniversSB-Medium,4,-0.2349999994039535,16777215,14,9,5,"{'concept_id': {0: 'C4684566'}, 'canonical_name': {0: 'Applet'}, 'aliases': {0: ['App', 'Applet']}, 'types': {0: ['T170']}, 'definition': {0: 'A small application designed to perform a specific function within another application.'}, 'entity': {0: 'Apple App Store'}, 'text': {0: 'for MHRA Yellow Card in the Google Play or Apple App Store.'}}",{},{},{},"{'concept_id': {0: 'C0240962'}, 'canonical_name': {0: 'Conjunctival icterus'}, 'aliases': {0: ['Yellow sclera', 'Scleral icterus', 'Yellow conjunctiva', 'Yellowing of the whites of the eyes']}, 'types': {0: ['T033']}, 'definition': {0: 'Yellowing of the white part of the eyes, often due to a rise in bilirubin levels.'}, 'entity': {0: 'MHRA Yellow'}, 'text': {0: 'for MHRA Yellow Card in the Google Play or Apple App Store.'}}","           entity_group   value     score
0  Detailed_description  Google  0.998453
1  Detailed_description   Apple  0.958338",[],"{'keyword': {0: 'mhra yellow card', 1: 'play apple', 2: 'card google', 3: 'google play', 4: 'apple app'}, 'score': {0: 0.8936, 1: 0.8418, 2: 0.8411, 3: 0.8193, 4: 0.808}}"
392,392,392,0.944000005722046,19.0,Adverse events should also be reported to Roche Products Ltd.  ,UniversSB-Medium,4,-0.2349999994039535,16777215,14,9,6,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should also be reported to Roche Products Ltd.  '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should also be reported to Roche Products Ltd.  '}}",{},{},{},"   entity_group           value     score
0  Sign_symptom  Adverse events  0.999906
1    Medication           Roche  0.977449",[],"{'keyword': {0: 'adverse events', 1: 'events reported roche', 2: 'reported roche', 3: 'events reported', 4: 'roche products'}, 'score': {0: 0.7217, 1: 0.714, 2: 0.6768, 3: 0.6516, 4: 0.5478}}"
393,393,393,0.944000005722046,19.0,Please contact Roche Drug Safety Centre by emailing  ,UniversSB-Medium,4,-0.2349999994039535,16777215,14,9,7,"{'concept_id': {0: 'C0036043'}, 'canonical_name': {0: 'Safety'}, 'aliases': {0: ['Safeties', 'Safety', 'safety']}, 'types': {0: ['T068']}, 'definition': {0: 'Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.'}, 'entity': {0: 'Drug Safety Centre'}, 'text': {0: 'Please contact Roche Drug Safety Centre by emailing  '}}",{},{},{},{},"             entity_group          value     score
0  Nonbiological_location          Roche  0.929434
1  Nonbiological_location  Safety Centre  0.987673
2          Clinical_event       emailing  0.983830",[],"{'keyword': {0: 'contact roche', 1: 'centre emailing', 2: 'contact roche drug', 3: 'roche drug', 4: 'safety centre'}, 'score': {0: 0.7441, 1: 0.7026, 2: 0.6475, 3: 0.6049, 4: 0.6011}}"
394,394,394,0.944000005722046,19.0,welwyn.uk_dsc@roche.com or calling +44(0)1707 367554. ,UniversSB-Medium,4,-0.2349999994039535,16777215,14,9,8,"{'concept_id': {0: 'C0034770'}, 'canonical_name': {0: 'Mental Recall'}, 'aliases': {0: ['mental recall', 'Mental Recall', 'remember', 'recalling', 'recall', 'remembers', 'Recall, Mental', 'Recall', 'Recollect', 'remembering']}, 'types': {0: ['T041']}, 'definition': {0: 'The process whereby a representation of past experience is elicited.'}, 'entity': {0: 'calling'}, 'text': {0: 'welwyn.uk_dsc@roche.com or calling +44(0)1707 367554. '}}",{},{},{},{},"           entity_group          value     score
0  Diagnostic_procedure  welwyn.uk_dsc  0.992376",[],"{'keyword': {0: '1707 367554', 1: 'welwyn uk_dsc roche', 2: 'uk_dsc roche com', 3: 'calling 44', 4: 'roche com'}, 'score': {0: 0.8708, 1: 0.8137, 2: 0.794, 3: 0.7771, 4: 0.7524}}"
395,395,395,0.944000005722046,19.0,"As Kadcyla is a biological medicine, healthcare professionals should ",UniversSB-Medium,4,-0.2349999994039535,16777215,14,9,9,"{'concept_id': {0: 'C5554773'}, 'canonical_name': {0: 'Healthcare Professional Visit'}, 'aliases': {0: []}, 'types': {0: ['T058']}, 'definition': {0: 'The subject or patient has interacted with a healthcare professional at a healthcare facility.'}, 'entity': {0: 'healthcare professionals'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}","{'concept_id': {0: 'C0018722'}, 'canonical_name': {0: 'Health Occupations'}, 'aliases': {0: ['Profession, Health', 'Health Professions', 'Health Occupation', 'Health Profession', 'Professions, Health']}, 'types': {0: ['T091']}, 'definition': {0: 'Professions or other business activities directed to the cure and prevention of disease. For occupations of medical personnel who are not physicians but who are working in the fields of medical technology, physical therapy, etc., ALLIED HEALTH OCCUPATIONS is available.'}, 'entity': {0: 'healthcare professionals'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}","{'concept_id': {0: 'C3714634'}, 'canonical_name': {0: 'biological_process'}, 'aliases': {0: ['biological process']}, 'types': {0: ['T038']}, 'definition': {0: 'A biological process represents a specific objective that the organism is genetically programmed to achieve. Biological processes are often described by their outcome or ending state, e.g., the biological process of cell division results in the creation of two daughter cells (a divided cell) from a single parent cell. A biological process is accomplished by a particular set of molecular functions carried out by specific gene products (or macromolecular complexes), often in a highly regulated manner and in a particular temporal sequence. [GOC:pdt]'}, 'entity': {0: 'biological medicine'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}",{},"Empty DataFrame
Columns: []
Index: []","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla biological medicine', 1: 'medicine healthcare professionals', 2: 'kadcyla biological', 3: 'medicine healthcare', 4: 'healthcare professionals'}, 'score': {0: 0.8437, 1: 0.827, 2: 0.824, 3: 0.8164, 4: 0.7824}}"
396,396,396,0.944000005722046,19.0,report adverse reactions by brand name and batch number.,UniversSB-Medium,4,-0.2349999994039535,16777215,14,9,10,"{'concept_id': {0: 'C1948031'}, 'canonical_name': {0: 'Batch (group)'}, 'aliases': {0: ['Batch']}, 'types': {0: ['T081']}, 'definition': {0: 'A quantity of people or things treated or regarded as a group, especially when subdivided from a larger group.'}, 'entity': {0: 'batch number'}, 'text': {0: 'report adverse reactions by brand name and batch number.'}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'report adverse reactions by brand name and batch number.'}}",{},{},"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'report adverse reactions by brand name and batch number.'}}","   entity_group              value     score
0  Sign_symptom  adverse reactions  0.744242",[],"{'keyword': {0: 'reactions brand batch', 1: 'reactions brand', 2: 'batch number', 3: 'adverse reactions', 4: 'report adverse reactions'}, 'score': {0: 0.8437, 1: 0.8276, 2: 0.7816, 3: 0.7576, 4: 0.6528}}"
397,397,397,0.9470000267028807,19.0,"eBC, early breast cancer. ",UniversSB-Light,4,-0.2329999953508377,16777215,14,10,0,"{'concept_id': {0: 'C0598034'}, 'canonical_name': {0: 'BRCA2 gene'}, 'aliases': {0: ['BRCA2, DNA Repair Associated Gene', 'brca2', 'brca 2 gene', 'FACD', 'breast cancer 2', 'BRCA2 Genes', 'XRCC11', 'BRCA2 DNA repair associated', 'breast cancer 2, early onset', 'BRCC2', 'Fanconi anemia, complementation group D1', 'FANCD1 GENE', 'FAD1', 'BRCA1/BRCA2-containing complex, subunit 2', 'BRCA2 gene', 'FANCD1', 'brca2 gene', 'BRCA2 GENE', 'Breast Cancer 2, Early Onset Gene', 'FANCD', 'Genes, BRCA2', 'BRCA2', 'BRCA2 Gene', 'BRCA2 DNA REPAIR-ASSOCIATED PROTEIN', 'FAD', 'brca2 genes', 'Gene, BRCA2']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}","{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}","           entity_group   value     score
0  Biological_structure  breast  0.991112",[],"{'keyword': {0: 'ebc early breast', 1: 'early breast', 2: 'early breast cancer', 3: 'breast cancer', 4: 'ebc early'}, 'score': {0: 0.9046, 1: 0.8815, 2: 0.8637, 3: 0.744, 4: 0.7344}}"
398,398,398,0.8830000162124634,19.0,*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this material.,MyriadPro-Light,4,-0.25,3355443,14,12,0,"{'concept_id': {0: 'C1880278'}, 'canonical_name': {0: 'Dent in Material'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Problem associated with a undesired change in shape, characterized by the presence of a slight hollow (dent) in the device surface.'}, 'entity': {0: 'material'}, 'text': {0: '*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this material.'}}","{'concept_id': {0: 'C0011379'}, 'canonical_name': {0: 'Dental Materials'}, 'aliases': {0: ['Dental Material', 'Material, Dental', 'Materials, Dental']}, 'types': {0: ['T122']}, 'definition': {0: 'Materials used in the production of dental bases, restorations, impressions, prostheses, etc.'}, 'entity': {0: 'material'}, 'text': {0: '*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this material.'}}",{},"{'concept_id': {0: 'C2754086'}, 'canonical_name': {0: 'dendrite guidance'}, 'aliases': {0: ['dendritic guidance']}, 'types': {0: ['T043']}, 'definition': {0: 'The process in which the migration of a dendrite is directed to a specific target site in response to a combination of attractive and repulsive cues. [GOC:sart, PMID:15046878]'}, 'entity': {0: 'guidance'}, 'text': {0: '*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this material.'}}",{},"     entity_group     value     score
0  Clinical_event  guidance  0.947969",[],"{'keyword': {0: 'withdrawn nice accepts', 1: 'accepts responsibility', 2: 'subject regular review', 3: 'nhs england', 4: 'withdrawn nice'}, 'score': {0: 0.7391, 1: 0.7163, 2: 0.5167, 3: 0.4619, 4: 0.3586}}"
399,399,399,0.8830000162124634,19.0,†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab emtansine according to the commercial arrangement. There is a simple discount patient ,MyriadPro-Light,4,-0.25,3355443,14,12,1,"{'concept_id': {0: 'C1578481'}, 'canonical_name': {0: 'Mail Claim Party - Patient'}, 'aliases': {0: ['Patient']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'patient'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab emtansine according to the commercial arrangement. There is a simple discount patient '}}","{'concept_id': {0: 'C4277550'}, 'canonical_name': {0: 'Patient Portals'}, 'aliases': {0: ['Patient Internet Portals', 'Web Portals, Patient', 'Web Portal, Patient', 'Patient Internet Portal', 'Portals, Patient Web', 'Portal, Patient Web', 'Portal, Patient Internet', 'Patient Web Portals', 'Internet Portal, Patient', 'Internet Portals, Patient', 'Patient Portal', 'Patient Web Portal', 'Portals, Patient Internet', 'Portal, Patient']}, 'types': {0: ['T170']}, 'definition': {0: 'A secure online website that provides patients convenient 24-hour access to personal health information via an Internet connection.'}, 'entity': {0: 'patient'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab emtansine according to the commercial arrangement. There is a simple discount patient '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab emtansine according to the commercial arrangement. There is a simple discount patient '}}","{'concept_id': {0: 'C1160518'}, 'canonical_name': {0: 'oocyte construction'}, 'aliases': {0: ['oocyte arrangement']}, 'types': {0: ['T043']}, 'definition': {0: 'The synthesis, deposition, and organization of the materials in a cell of an ovary; where the cell can then undergo meiosis and form an ovum. An example of this is found in Drosophila melanogaster. [GOC:dph, GOC:ems, GOC:mtg_sensu, GOC:tb, ISBN:0198506732]'}, 'entity': {0: 'arrangement'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab emtansine according to the commercial arrangement. There is a simple discount patient '}}","{'concept_id': {0: 'C2959688'}, 'canonical_name': {0: 'Abnormal location of heart atrium'}, 'aliases': {0: ['Abnormal atrial arrangement']}, 'types': {0: ['T019']}, 'definition': {0: 'Abnormality of the spatial relationship of the atria to other components of the heart. [DDD:dbrown]'}, 'entity': {0: 'arrangement'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab emtansine according to the commercial arrangement. There is a simple discount patient '}}","            entity_group                  value     score
0  Therapeutic_procedure                    SMC  0.619393
1             Medication                Kadcyla  0.991403
2             Medication            trastuzumab  0.999803
3             Medication  emtansine arrangement  0.998263
4             Medication              emtansine  0.965123
5   Detailed_description                 simple  0.999914
6   Detailed_description       discount patient  0.644307","[('Kadcyla', 'DRUG'), ('emtansine', 'FORM')]","{'keyword': {0: 'nice recommends kadcyla', 1: 'simple discount patient', 2: 'trastuzumab emtansine', 3: 'recommendation nice', 4: 'nice acceptance'}, 'score': {0: 0.6351, 1: 0.6123, 2: 0.5031, 3: 0.4859, 4: 0.2005}}"
400,400,400,0.8830000162124634,19.0,"access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is ",MyriadPro-Light,4,-0.25,3355443,14,12,2,"{'concept_id': {0: 'C0011115'}, 'canonical_name': {0: 'Decision Trees'}, 'aliases': {0: ['Trees, Decision', 'decision trees', 'Decision trees', 'decision tree', 'Tree, Decision', 'Decision Tree']}, 'types': {0: ['T170']}, 'definition': {0: 'A graphic device used in decision analysis, series of decision options are represented as branches (hierarchical).'}, 'entity': {0: 'decision'}, 'text': {0: 'access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is '}}","{'concept_id': {0: 'C0011109'}, 'canonical_name': {0: 'Decision Making'}, 'aliases': {0: []}, 'types': {0: ['T041']}, 'definition': {0: 'The process of making a selective intellectual judgment when presented with several complex alternatives consisting of several variables, and usually defining a course of action or an idea.'}, 'entity': {0: 'decision'}, 'text': {0: 'access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is '}}","{'concept_id': {0: 'C1160518'}, 'canonical_name': {0: 'oocyte construction'}, 'aliases': {0: ['oocyte arrangement']}, 'types': {0: ['T043']}, 'definition': {0: 'The synthesis, deposition, and organization of the materials in a cell of an ovary; where the cell can then undergo meiosis and form an ovum. An example of this is found in Drosophila melanogaster. [GOC:dph, GOC:ems, GOC:mtg_sensu, GOC:tb, ISBN:0198506732]'}, 'entity': {0: 'arrangement'}, 'text': {0: 'access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is '}}","{'concept_id': {0: 'C2959688'}, 'canonical_name': {0: 'Abnormal location of heart atrium'}, 'aliases': {0: ['Abnormal atrial arrangement']}, 'types': {0: ['T019']}, 'definition': {0: 'Abnormality of the spatial relationship of the atria to other components of the heart. [DDD:dbrown]'}, 'entity': {0: 'arrangement'}, 'text': {0: 'access scheme for trastuzumab emtansine. Acceptance by the SMC applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is '}}","           entity_group        value     score
0            Medication  trastuzumab  0.999758
1            Medication    emtansine  0.666624
2           Coreference          SMC  0.713714
3  Diagnostic_procedure     PAS PAS/  0.939536","[('trastuzumab', 'DRUG'), ('emtansine', 'DRUG')]","{'keyword': {0: 'applies context', 1: 'effectiveness results', 2: 'pas arrangement', 3: 'approved nhs', 4: 'cost effectiveness'}, 'score': {0: 0.6886, 1: 0.5688, 2: 0.446, 3: 0.4051, 4: 0.2215}}"
401,401,401,0.8830000162124634,19.0,equivalent or lower.,MyriadPro-Light,4,-0.25,3355443,14,12,3,"{'concept_id': {0: 'C2003888'}, 'canonical_name': {0: 'Lower (action)'}, 'aliases': {0: ['Lower', 'Lowering', 'Lowered']}, 'types': {0: ['T052']}, 'definition': {0: 'To become lower, grow less, or diminish, as in amount, intensity, degree, or value.'}, 'entity': {0: 'lower'}, 'text': {0: 'equivalent or lower.'}}","{'concept_id': {0: 'C0226875'}, 'canonical_name': {0: 'Gastrointestinal Tract, Lower'}, 'aliases': {0: ['Lower GI Tract', 'Lower Gastrointestinal Tract']}, 'types': {0: ['T029']}, 'definition': {0: 'The segment of GASTROINTESTINAL TRACT that includes the small intestine below the DUODENUM, and the LARGE INTESTINE.'}, 'entity': {0: 'lower'}, 'text': {0: 'equivalent or lower.'}}",{},{},{},"           entity_group       value     score
0  Detailed_description  equivalent  0.947257",[],"{'keyword': {0: 'equivalent lower'}, 'score': {0: 0.8363}}"
402,402,402,0.8830000162124634,19.0,"eBC, early breast cancer; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme; SMC, Scottish Medicines Consortium.",MyriadPro-Light,4,-0.25,3355443,14,12,4,"{'concept_id': {0: 'C3888088'}, 'canonical_name': {0: 'SMITH-MCCORT DYSPLASIA 1'}, 'aliases': {0: ['SMC', 'SMITH-McCORT DYSPLASIA 1', 'SMITH-MCCORT DYSPLASIA 1', 'SMC1']}, 'types': {0: ['T047']}, 'definition': {0: None}, 'entity': {0: 'SMC'}, 'text': {0: 'eBC, early breast cancer; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme; SMC, Scottish Medicines Consortium.'}}","{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme; SMC, Scottish Medicines Consortium.'}}",{},"{'concept_id': {0: 'C2612492'}, 'canonical_name': {0: 'smooth muscle cell apoptotic process'}, 'aliases': {0: ['smooth muscle cell programmed cell death by apoptosis', 'apoptosis of smooth muscle cells', 'smooth muscle cell apoptosis', 'SMC apoptosis', 'programmed cell death of smooth muscle cells by apoptosis', 'programmed cell death, smooth muscle cells']}, 'types': {0: ['T043']}, 'definition': {0: 'Any apoptotic process in a smooth muscle cell. Smooth muscle consists of non-striated, elongated, spindle-shaped cell found lining the digestive tract, uterus, and blood vessels. [CL:0000192, GOC:BHF, GOC:mah, GOC:mtg_apoptosis, GOC:rl]'}, 'entity': {0: 'SMC'}, 'text': {0: 'eBC, early breast cancer; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme; SMC, Scottish Medicines Consortium.'}}","{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme; SMC, Scottish Medicines Consortium.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'smc scottish medicines', 1: 'breast cancer', 2: 'ebc early', 3: 'national institute', 4: 'excellence pas'}, 'score': {0: 0.8401, 1: 0.6905, 2: 0.6279, 3: 0.5662, 4: 0.4206}}"
403,403,403,0.8830000162124634,19.0,"eBC, early breast cancer.",MyriadPro-Light,4,-0.25,3355443,14,13,0,"{'concept_id': {0: 'C0598034'}, 'canonical_name': {0: 'BRCA2 gene'}, 'aliases': {0: ['BRCA2, DNA Repair Associated Gene', 'brca2', 'brca 2 gene', 'FACD', 'breast cancer 2', 'BRCA2 Genes', 'XRCC11', 'BRCA2 DNA repair associated', 'breast cancer 2, early onset', 'BRCC2', 'Fanconi anemia, complementation group D1', 'FANCD1 GENE', 'FAD1', 'BRCA1/BRCA2-containing complex, subunit 2', 'BRCA2 gene', 'FANCD1', 'brca2 gene', 'BRCA2 GENE', 'Breast Cancer 2, Early Onset Gene', 'FANCD', 'Genes, BRCA2', 'BRCA2', 'BRCA2 Gene', 'BRCA2 DNA REPAIR-ASSOCIATED PROTEIN', 'FAD', 'brca2 genes', 'Gene, BRCA2']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer.'}}","{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer.'}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer.'}}","           entity_group   value     score
0  Biological_structure  breast  0.991112",[],"{'keyword': {0: 'ebc early breast', 1: 'early breast', 2: 'early breast cancer', 3: 'breast cancer', 4: 'ebc early'}, 'score': {0: 0.9046, 1: 0.8815, 2: 0.8637, 3: 0.744, 4: 0.7344}}"
404,404,404,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,14,15,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
405,405,405,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,14,15,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
406,406,406,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,14,15,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
407,407,407,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,14,15,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
408,408,408,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,14,16,0,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
409,409,409,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,14,16,1,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
410,410,410,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,14,17,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
411,411,411,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,14,17,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
412,412,412,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,14,17,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
413,413,413,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,14,17,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
414,414,414,0.9470000267028807,19.0,M-GB-00004511. September 2021. ,UniversSB-Light,4,-0.2329999953508377,5723991,14,18,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '00004511 september 2021', 1: 'september 2021', 2: '00004511 september', 3: 'gb 00004511 september', 4: 'gb 00004511'}, 'score': {0: 0.9362, 1: 0.9072, 2: 0.9023, 3: 0.8713, 4: 0.8382}}"
415,415,415,0.75,110.0,When a different  ,ConduitITC-Bold,20,-0.1700000017881393,16777215,15,1,0,{},{},{},{},{},"  entity_group      value    score
0    Lab_value  different  0.99952",[],"{'keyword': {}, 'score': {}}"
416,416,416,0.75,110.0,direction is vital ,ConduitITC-Bold,20,-0.1700000017881393,16777215,15,1,1,"{'concept_id': {0: 'C1550715'}, 'canonical_name': {0: 'direction - AddressPartType'}, 'aliases': {0: ['direction']}, 'types': {0: ['T078']}, 'definition': {0: '<p>Direction (e.g., N, S, W, E)</p>'}, 'entity': {0: 'direction'}, 'text': {0: 'direction is vital '}}","{'concept_id': {0: 'C0700158'}, 'canonical_name': {0: 'Direction'}, 'aliases': {0: ['Direction compound']}, 'types': {0: ['T122']}, 'definition': {0: None}, 'entity': {0: 'direction'}, 'text': {0: 'direction is vital '}}",{},{},{},"           entity_group      value     score
0  Diagnostic_procedure  direction  0.999789
1             Lab_value      vital  0.996564",[],"{'keyword': {0: 'direction vital'}, 'score': {0: 0.8764}}"
417,417,417,0.75,48.0,A step forward for patients with ,ConduitITC-Bold,20,-0.1700000017881393,16777215,15,2,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'A step forward for patients with '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'A step forward for patients with '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'step forward', 1: 'step forward patients', 2: 'forward patients'}, 'score': {0: 0.8969, 1: 0.8443, 2: 0.8292}}"
418,418,418,0.75,48.0,residual invasive disease,ConduitITC-Bold,20,-0.1700000017881393,16777215,15,2,1,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'residual invasive disease'}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'residual invasive disease'}}",{},{},{},"           entity_group              value     score
0  Detailed_description  residual invasive  0.722441
1      Disease_disorder            disease  0.738652",[],"{'keyword': {0: 'residual invasive disease', 1: 'residual invasive', 2: 'invasive disease'}, 'score': {0: 1.0, 1: 0.9438, 2: 0.8031}}"
419,419,419,0.9470000267028807,23.0,"Kadcyla, as a single agent, is indicated for the adjuvant ",UniversSB-Light,4,-0.2329999953508377,16777215,15,3,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant '}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla, as a single agent, is indicated for the adjuvant '}}",{},{},"  entity_group             value     score
0   Medication  Kadcyla adjuvant  0.913006
1   Medication          adjuvant  0.915010","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla single agent', 1: 'kadcyla single', 2: 'single agent', 3: 'single agent indicated', 4: 'agent indicated'}, 'score': {0: 0.6756, 1: 0.6359, 2: 0.5335, 3: 0.4616, 4: 0.4001}}"
420,420,420,0.9470000267028807,23.0,treatment of adult patients with HER2-positive eBC who have ,UniversSB-Light,4,-0.2329999953508377,16777215,15,3,1,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'treatment of adult patients with HER2-positive eBC who have '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'treatment of adult patients with HER2-positive eBC who have '}}",{},{},"{'concept_id': {0: 'C1853562'}, 'canonical_name': {0: 'Adult onset'}, 'aliases': {0: ['Symptoms begin in adulthood', 'Onset in early adulthood', 'Onset in adulthood']}, 'types': {0: ['T033']}, 'definition': {0: 'Onset of disease manifestations in adulthood, defined here as at the age of 16 years or later. [HPO:probinson]'}, 'entity': {0: 'adult'}, 'text': {0: 'treatment of adult patients with HER2-positive eBC who have '}}","           entity_group                                      value     score
0  Detailed_description                              HER2-positive  0.989120
1             Lab_value                              HER2-positive  0.988010
2      Disease_disorder  treatment patients HER2-positive eBC have  0.985162
3      Disease_disorder                                        eBC  0.938856",[],"{'keyword': {0: 'her2 positive ebc', 1: 'treatment adult patients', 2: 'adult patients', 3: 'patients her2', 4: 'her2 positive'}, 'score': {0: 0.794, 1: 0.7385, 2: 0.7364, 3: 0.7343, 4: 0.6985}}"
421,421,421,0.9470000267028807,23.0,"residual invasive disease, in the breast and/or lymph nodes, ",UniversSB-Light,4,-0.2329999953508377,16777215,15,3,2,"{'concept_id': {0: 'C0578050'}, 'canonical_name': {0: 'Pain of lymph node'}, 'aliases': {0: ['lymph nodes pain', 'Pain of lymph node (finding)', 'glands lymph pain', 'lymph nodes painful', 'pain lymph glands', 'Pain of lymph node', 'gland lymph pain', 'lymph gland pain', 'Lymph Node Pain', 'painful lymph node', 'Painful lymph node', 'lymph glands pain', 'lymph node painful', 'lymph node pain']}, 'types': {0: ['T184']}, 'definition': {0: 'A painful sensation in a lymph node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'residual invasive disease, in the breast and/or lymph nodes, '}}","{'concept_id': {0: 'C1522495'}, 'canonical_name': {0: 'Sentinal Node'}, 'aliases': {0: ['Nodes, Sentinal', 'Sentinel Lymph Node', 'Node, Sentinal', 'Lymph Node, Sentinel', 'Sentinel Lymph Nodes', 'Sentinal Nodes', 'Lymph Nodes, Sentinel']}, 'types': {0: ['T023']}, 'definition': {0: 'First lymph node to receive drainage from the primary tumor. SENTINEL LYMPH NODE BIOPSY is performed to determine early METASTASIS status because cancer cells may appear first in the sentinel node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'residual invasive disease, in the breast and/or lymph nodes, '}}",{},{},"{'concept_id': {0: 'C0024205'}, 'canonical_name': {0: 'Lymphadenitis'}, 'aliases': {0: ['Inflammation of the lymph nodes']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the lymph nodes.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'residual invasive disease, in the breast and/or lymph nodes, '}}","           entity_group     value     score
0  Detailed_description  residual  0.646063
1  Biological_structure    breast  0.999617",[],"{'keyword': {0: 'residual invasive disease', 1: 'disease breast', 2: 'invasive disease', 3: 'lymph nodes', 4: 'breast lymph'}, 'score': {0: 0.9104, 1: 0.8342, 2: 0.8331, 3: 0.813, 4: 0.76}}"
422,422,422,0.9470000267028807,23.0,after neoadjuvant taxane-based and HER2-targeted therapy.,UniversSB-Light,4,-0.2329999953508377,16777215,15,3,3,"{'concept_id': {0: 'C2985566'}, 'canonical_name': {0: 'Targeted Therapy'}, 'aliases': {0: ['targeted therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.'}, 'entity': {0: 'HER2-targeted therapy'}, 'text': {0: 'after neoadjuvant taxane-based and HER2-targeted therapy.'}}",{},{},{},{},"           entity_group         value     score
0  Detailed_description   neoadjuvant  0.999715
1  Detailed_description  taxane-based  0.995623","[('taxane', 'DRUG')]","{'keyword': {0: 'taxane based her2', 1: 'neoadjuvant taxane based', 2: 'taxane based', 3: 'based her2', 4: 'her2 targeted'}, 'score': {0: 0.8503, 1: 0.8213, 2: 0.821, 3: 0.7663, 4: 0.7652}}"
423,423,423,0.944000005722046,19.0,Reporting suspected adverse reactions after authorisation of the ,UniversSB-Medium,4,-0.2349999994039535,16777215,15,4,0,"{'concept_id': {0: 'C1368999'}, 'canonical_name': {0: 'Late effect of medical intervention'}, 'aliases': {0: ['Late Adverse Reaction', 'Late effect of', 'Aftereffect', 'Late effect', 'Adverse Late Effects', 'Late Adverse Effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Any symptom or condition which is a result of a medical intervention but arises months or years after it.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the '}}",{},{},"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'Reporting suspected adverse reactions after authorisation of the '}}","   entity_group              value     score
0  Sign_symptom  adverse reactions  0.999826",[],"{'keyword': {0: 'reporting suspected adverse', 1: 'suspected adverse reactions', 2: 'reporting suspected', 3: 'adverse reactions', 4: 'adverse reactions authorisation'}, 'score': {0: 0.921, 1: 0.8343, 2: 0.8335, 3: 0.7955, 4: 0.6816}}"
424,424,424,0.944000005722046,19.0,medicinal product is important. It allows continued monitoring of ,UniversSB-Medium,4,-0.2349999994039535,16777215,15,4,1,"{'concept_id': {0: 'C0005517'}, 'canonical_name': {0: 'Biological Monitoring'}, 'aliases': {0: ['biological monitoring', 'Bio Monitoring', 'Bio-Monitoring', 'Biomonitoring', 'Biologic Monitoring', 'Monitoring, Biologic', 'Biological monitoring', 'Monitoring, Biological']}, 'types': {0: ['T057']}, 'definition': {0: 'Monitoring of the level of toxins, chemical pollutants, microbial contaminants, or other harmful substances in the bodies of living organisms, by DIAGNOSTIC IMAGING or by analyzing BLOOD; URINE; BREAST MILK; SALIVA, etc.'}, 'entity': {0: 'monitoring'}, 'text': {0: 'medicinal product is important. It allows continued monitoring of '}}","{'concept_id': {0: 'C0015945'}, 'canonical_name': {0: 'Monitoring, Fetal'}, 'aliases': {0: ['Fetal Monitoring', 'Fetal Monitorings', 'Monitorings, Fetal']}, 'types': {0: ['T060']}, 'definition': {0: 'Physiologic or biochemical monitoring of the fetus. It is usually done during LABOR, OBSTETRIC and may be performed in conjunction with the monitoring of uterine activity. It may also be performed prenatally as when the mother is undergoing surgery.'}, 'entity': {0: 'monitoring'}, 'text': {0: 'medicinal product is important. It allows continued monitoring of '}}",{},{},{},"           entity_group       value     score
0  Diagnostic_procedure   medicinal  0.862680
1  Diagnostic_procedure  monitoring  0.996455",[],"{'keyword': {0: 'allows continued monitoring', 1: 'product important', 2: 'important allows continued', 3: 'medicinal product', 4: 'continued monitoring'}, 'score': {0: 0.909, 1: 0.8711, 2: 0.8252, 3: 0.8155, 4: 0.7951}}"
425,425,425,0.944000005722046,19.0,the benefit/risk balance of the medicinal product.,UniversSB-Medium,4,-0.2349999994039535,16777215,15,4,2,"{'concept_id': {0: 'C4684711'}, 'canonical_name': {0: 'Medicinal Product Name'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'The name assigned to a medicinal product as approved by a regulatory authority of the country of authorization.'}, 'entity': {0: 'medicinal product'}, 'text': {0: 'the benefit/risk balance of the medicinal product.'}}",{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'balance medicinal product', 1: 'risk balance medicinal', 2: 'benefit risk balance', 3: 'medicinal product', 4: 'benefit risk'}, 'score': {0: 0.9077, 1: 0.8857, 2: 0.8782, 3: 0.8101, 4: 0.7799}}"
426,426,426,0.944000005722046,19.0,Adverse events should be reported. Reporting forms and ,UniversSB-Medium,4,-0.2349999994039535,16777215,15,4,3,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should be reported. Reporting forms and '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should be reported. Reporting forms and '}}",{},{},{},"     entity_group           value     score
0    Sign_symptom  Adverse events  0.999894
1  Clinical_event       Reporting  0.978902",[],"{'keyword': {0: 'reporting forms', 1: 'events reported', 2: 'reported reporting', 3: 'adverse events', 4: 'events reported reporting'}, 'score': {0: 0.8998, 1: 0.875, 2: 0.8205, 3: 0.7868, 4: 0.7718}}"
427,427,427,0.944000005722046,19.0,information can be found at www.mhra.gov.uk/yellowcard or search ,UniversSB-Medium,4,-0.2349999994039535,16777215,15,4,4,"{'concept_id': {0: 'C4289829'}, 'canonical_name': {0: 'Case Search'}, 'aliases': {0: []}, 'types': {0: ['T062']}, 'definition': {0: 'The activity of looking for individuals with a shared characteristic such as a disease.'}, 'entity': {0: 'search'}, 'text': {0: 'information can be found at www.mhra.gov.uk/yellowcard or search '}}","{'concept_id': {0: 'C2348167'}, 'canonical_name': {0: 'Search Engine'}, 'aliases': {0: ['Engine, Search', 'Search Engines']}, 'types': {0: ['T170']}, 'definition': {0: 'A computer program that retrieves documents or files or data from a database or from a computer network.'}, 'entity': {0: 'search'}, 'text': {0: 'information can be found at www.mhra.gov.uk/yellowcard or search '}}",{},"{'concept_id': {0: 'C4690920'}, 'canonical_name': {0: 'T cell meandering migration'}, 'aliases': {0: ['T cell meandering search']}, 'types': {0: ['T043']}, 'definition': {0: 'The random-like motility observed for T cells in lymph nodes which enhances surveillance of antigens presented by major histocompatibility complex (MHC) molecules on antigen presenting cells (APCs). [GOC:add, GOC:krc, PMID:25083865]'}, 'entity': {0: 'search'}, 'text': {0: 'information can be found at www.mhra.gov.uk/yellowcard or search '}}",{},"           entity_group   value     score
0  Detailed_description  search  0.504256",[],"{'keyword': {0: 'information www mhra', 1: 'yellowcard search', 2: 'mhra gov', 3: 'gov uk yellowcard', 4: 'gov uk'}, 'score': {0: 0.8294, 1: 0.7855, 2: 0.7495, 3: 0.7295, 4: 0.6662}}"
428,428,428,0.944000005722046,19.0,for MHRA Yellow Card in the Google Play or Apple App Store.,UniversSB-Medium,4,-0.2349999994039535,16777215,15,4,5,"{'concept_id': {0: 'C4684566'}, 'canonical_name': {0: 'Applet'}, 'aliases': {0: ['App', 'Applet']}, 'types': {0: ['T170']}, 'definition': {0: 'A small application designed to perform a specific function within another application.'}, 'entity': {0: 'Apple App Store'}, 'text': {0: 'for MHRA Yellow Card in the Google Play or Apple App Store.'}}",{},{},{},"{'concept_id': {0: 'C0240962'}, 'canonical_name': {0: 'Conjunctival icterus'}, 'aliases': {0: ['Yellow sclera', 'Scleral icterus', 'Yellow conjunctiva', 'Yellowing of the whites of the eyes']}, 'types': {0: ['T033']}, 'definition': {0: 'Yellowing of the white part of the eyes, often due to a rise in bilirubin levels.'}, 'entity': {0: 'MHRA Yellow'}, 'text': {0: 'for MHRA Yellow Card in the Google Play or Apple App Store.'}}","           entity_group   value     score
0  Detailed_description  Google  0.998453
1  Detailed_description   Apple  0.958338",[],"{'keyword': {0: 'mhra yellow card', 1: 'play apple', 2: 'card google', 3: 'google play', 4: 'apple app'}, 'score': {0: 0.8936, 1: 0.8418, 2: 0.8411, 3: 0.8193, 4: 0.808}}"
429,429,429,0.944000005722046,19.0,Adverse events should also be reported to Roche Products Ltd.  ,UniversSB-Medium,4,-0.2349999994039535,16777215,15,4,6,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should also be reported to Roche Products Ltd.  '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'Adverse events'}, 'text': {0: 'Adverse events should also be reported to Roche Products Ltd.  '}}",{},{},{},"   entity_group           value     score
0  Sign_symptom  Adverse events  0.999906
1    Medication           Roche  0.977449",[],"{'keyword': {0: 'adverse events', 1: 'events reported roche', 2: 'reported roche', 3: 'events reported', 4: 'roche products'}, 'score': {0: 0.7217, 1: 0.714, 2: 0.6768, 3: 0.6516, 4: 0.5478}}"
430,430,430,0.944000005722046,19.0,Please contact Roche Drug Safety Centre by emailing  ,UniversSB-Medium,4,-0.2349999994039535,16777215,15,4,7,"{'concept_id': {0: 'C0036043'}, 'canonical_name': {0: 'Safety'}, 'aliases': {0: ['Safeties', 'Safety', 'safety']}, 'types': {0: ['T068']}, 'definition': {0: 'Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.'}, 'entity': {0: 'Drug Safety Centre'}, 'text': {0: 'Please contact Roche Drug Safety Centre by emailing  '}}",{},{},{},{},"             entity_group          value     score
0  Nonbiological_location          Roche  0.929434
1  Nonbiological_location  Safety Centre  0.987673
2          Clinical_event       emailing  0.983830",[],"{'keyword': {0: 'contact roche', 1: 'centre emailing', 2: 'contact roche drug', 3: 'roche drug', 4: 'safety centre'}, 'score': {0: 0.7441, 1: 0.7026, 2: 0.6475, 3: 0.6049, 4: 0.6011}}"
431,431,431,0.944000005722046,19.0,welwyn.uk_dsc@roche.com or calling +44(0)1707 367554. ,UniversSB-Medium,4,-0.2349999994039535,16777215,15,4,8,"{'concept_id': {0: 'C0034770'}, 'canonical_name': {0: 'Mental Recall'}, 'aliases': {0: ['mental recall', 'Mental Recall', 'remember', 'recalling', 'recall', 'remembers', 'Recall, Mental', 'Recall', 'Recollect', 'remembering']}, 'types': {0: ['T041']}, 'definition': {0: 'The process whereby a representation of past experience is elicited.'}, 'entity': {0: 'calling'}, 'text': {0: 'welwyn.uk_dsc@roche.com or calling +44(0)1707 367554. '}}",{},{},{},{},"           entity_group          value     score
0  Diagnostic_procedure  welwyn.uk_dsc  0.992376",[],"{'keyword': {0: '1707 367554', 1: 'welwyn uk_dsc roche', 2: 'uk_dsc roche com', 3: 'calling 44', 4: 'roche com'}, 'score': {0: 0.8708, 1: 0.8137, 2: 0.794, 3: 0.7771, 4: 0.7524}}"
432,432,432,0.944000005722046,19.0,"As Kadcyla is a biological medicine, healthcare professionals should ",UniversSB-Medium,4,-0.2349999994039535,16777215,15,4,9,"{'concept_id': {0: 'C5554773'}, 'canonical_name': {0: 'Healthcare Professional Visit'}, 'aliases': {0: []}, 'types': {0: ['T058']}, 'definition': {0: 'The subject or patient has interacted with a healthcare professional at a healthcare facility.'}, 'entity': {0: 'healthcare professionals'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}","{'concept_id': {0: 'C0018722'}, 'canonical_name': {0: 'Health Occupations'}, 'aliases': {0: ['Profession, Health', 'Health Professions', 'Health Occupation', 'Health Profession', 'Professions, Health']}, 'types': {0: ['T091']}, 'definition': {0: 'Professions or other business activities directed to the cure and prevention of disease. For occupations of medical personnel who are not physicians but who are working in the fields of medical technology, physical therapy, etc., ALLIED HEALTH OCCUPATIONS is available.'}, 'entity': {0: 'healthcare professionals'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}","{'concept_id': {0: 'C3714634'}, 'canonical_name': {0: 'biological_process'}, 'aliases': {0: ['biological process']}, 'types': {0: ['T038']}, 'definition': {0: 'A biological process represents a specific objective that the organism is genetically programmed to achieve. Biological processes are often described by their outcome or ending state, e.g., the biological process of cell division results in the creation of two daughter cells (a divided cell) from a single parent cell. A biological process is accomplished by a particular set of molecular functions carried out by specific gene products (or macromolecular complexes), often in a highly regulated manner and in a particular temporal sequence. [GOC:pdt]'}, 'entity': {0: 'biological medicine'}, 'text': {0: 'As Kadcyla is a biological medicine, healthcare professionals should '}}",{},"Empty DataFrame
Columns: []
Index: []","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla biological medicine', 1: 'medicine healthcare professionals', 2: 'kadcyla biological', 3: 'medicine healthcare', 4: 'healthcare professionals'}, 'score': {0: 0.8437, 1: 0.827, 2: 0.824, 3: 0.8164, 4: 0.7824}}"
433,433,433,0.944000005722046,19.0,report adverse reactions by brand name and batch number.,UniversSB-Medium,4,-0.2349999994039535,16777215,15,4,10,"{'concept_id': {0: 'C1948031'}, 'canonical_name': {0: 'Batch (group)'}, 'aliases': {0: ['Batch']}, 'types': {0: ['T081']}, 'definition': {0: 'A quantity of people or things treated or regarded as a group, especially when subdivided from a larger group.'}, 'entity': {0: 'batch number'}, 'text': {0: 'report adverse reactions by brand name and batch number.'}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'report adverse reactions by brand name and batch number.'}}",{},{},"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse drug reaction'}, 'aliases': {0: ['Adverse drug response', 'Toxic drug response', 'Drug-induced reaction', 'Drug-induced response']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse reactions'}, 'text': {0: 'report adverse reactions by brand name and batch number.'}}","   entity_group              value     score
0  Sign_symptom  adverse reactions  0.744242",[],"{'keyword': {0: 'reactions brand batch', 1: 'reactions brand', 2: 'batch number', 3: 'adverse reactions', 4: 'report adverse reactions'}, 'score': {0: 0.8437, 1: 0.8276, 2: 0.7816, 3: 0.7576, 4: 0.6528}}"
434,434,434,0.9169999957084656,30.0,References:,ConduitITC-Bold,20,-0.2349999994039535,8194925,15,5,0,"{'concept_id': {0: 'C1561577'}, 'canonical_name': {0: 'Reference - MdfHmdMetSourceType'}, 'aliases': {0: ['Reference']}, 'types': {0: ['T170']}, 'definition': {0: '<p>This row represents a reference to a previously defined type. Such a reference means that, in a given message, the message element instance for the current row is identical to the message element instance that instantiates the referred row.</p>'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}","{'concept_id': {0: 'C0016483'}, 'canonical_name': {0: 'Food Preferences'}, 'aliases': {0: ['Food Preference', 'Preferences, Food', 'Preference, Food']}, 'types': {0: ['T080']}, 'definition': {0: 'The selection of one food over another.'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
435,435,435,0.8830000162124634,22.0,1. Kadcyla Summary of Product Characteristics.,MyriadPro-Light,4,-0.25,3355443,15,5,1,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics.'}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics.'}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics.'}}","           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.796608","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla summary', 1: 'kadcyla summary product', 2: 'summary product', 3: 'summary product characteristics', 4: 'product characteristics'}, 'score': {0: 0.8868, 1: 0.8835, 2: 0.8533, 3: 0.7331, 4: 0.7046}}"
436,436,436,0.8830000162124634,22.0,2. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020.,MyriadPro-Light,4,-0.25,3355443,15,5,2,"{'concept_id': {0: 'C1960398'}, 'canonical_name': {0: 'HER2-positive carcinoma of breast'}, 'aliases': {0: ['HER2+ breast cancer', 'HER2 Overexpressing Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast (disorder)', 'HER2-Positive Breast Carcinoma', 'HER2 Overexpressing Subtype of Breast Carcinoma', 'HER2-positive breast cancer', 'HER2/neu-positive breast cancer', 'ERBB2 Overexpressing Subtype of Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast', 'HER2 Positive Breast Carcinoma', 'HER2 Positive Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).'}, 'entity': {0: 'HER2-positive'}, 'text': {0: '2. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020.'}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: '2. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020.'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: '2. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020.'}}",{},{},"           entity_group                value     score
0            Medication          Trastuzumab  0.999841
1            Medication            emtansine  0.995490
2  Detailed_description             adjuvant  0.609343
3             Lab_value  HER2-positive TA632  0.996677
4             Lab_value        HER2-positive  0.734865
5  Detailed_description                early  0.694268
6  Biological_structure               breast  0.949489","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'emtansine adjuvant treatment', 1: 'health care excellence', 2: 'breast cancer', 3: 'national institute', 4: 'positive early'}, 'score': {0: 0.8466, 1: 0.7894, 2: 0.6906, 3: 0.6491, 4: 0.5441}}"
437,437,437,0.8830000162124634,22.0,3. Scottish Medicines Consortium. SMC2298. November 2020.,MyriadPro-Light,4,-0.25,3355443,15,5,3,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'medicines consortium smc2298', 1: 'consortium smc2298 november', 2: 'scottish medicines', 3: 'smc2298 november', 4: 'november 2020'}, 'score': {0: 0.9007, 1: 0.8849, 2: 0.8669, 3: 0.8379, 4: 0.8054}}"
438,438,438,0.9470000267028807,19.0,"eBC, early breast cancer. ",UniversSB-Light,4,-0.2329999953508377,16777215,15,6,0,"{'concept_id': {0: 'C0598034'}, 'canonical_name': {0: 'BRCA2 gene'}, 'aliases': {0: ['BRCA2, DNA Repair Associated Gene', 'brca2', 'brca 2 gene', 'FACD', 'breast cancer 2', 'BRCA2 Genes', 'XRCC11', 'BRCA2 DNA repair associated', 'breast cancer 2, early onset', 'BRCC2', 'Fanconi anemia, complementation group D1', 'FANCD1 GENE', 'FAD1', 'BRCA1/BRCA2-containing complex, subunit 2', 'BRCA2 gene', 'FANCD1', 'brca2 gene', 'BRCA2 GENE', 'Breast Cancer 2, Early Onset Gene', 'FANCD', 'Genes, BRCA2', 'BRCA2', 'BRCA2 Gene', 'BRCA2 DNA REPAIR-ASSOCIATED PROTEIN', 'FAD', 'brca2 genes', 'Gene, BRCA2']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}","{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer. '}}","           entity_group   value     score
0  Biological_structure  breast  0.991112",[],"{'keyword': {0: 'ebc early breast', 1: 'early breast', 2: 'early breast cancer', 3: 'breast cancer', 4: 'ebc early'}, 'score': {0: 0.9046, 1: 0.8815, 2: 0.8637, 3: 0.744, 4: 0.7344}}"
439,439,439,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,15,8,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
440,440,440,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,15,8,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
441,441,441,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,15,8,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
442,442,442,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,15,8,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
443,443,443,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,15,9,0,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
444,444,444,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,15,9,1,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
445,445,445,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,15,10,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
446,446,446,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,15,10,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
447,447,447,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,15,10,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
448,448,448,0.9470000267028807,19.0,M-GB-00004511. September 2021. ,UniversSB-Light,4,-0.2329999953508377,5723991,15,11,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '00004511 september 2021', 1: 'september 2021', 2: '00004511 september', 3: 'gb 00004511 september', 4: 'gb 00004511'}, 'score': {0: 0.9362, 1: 0.9072, 2: 0.9023, 3: 0.8713, 4: 0.8382}}"
449,449,449,0.75,98.0,A complete response is always ,ConduitITC-Bold,20,-0.1700000017881393,8194925,16,1,0,{},{},{},{},{},"           entity_group     value     score
0  Diagnostic_procedure  complete  0.546737
1             Lab_value  response  0.476576
2             Lab_value    always  0.873711",[],"{'keyword': {0: 'complete response'}, 'score': {0: 0.9008}}"
450,450,450,0.75,98.0,"the goal of treatment, but some ",ConduitITC-Bold,20,-0.1700000017881393,8194925,16,1,1,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'the goal of treatment, but some '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'the goal of treatment, but some '}}",{},{},{},"  entity_group value     score
0    Lab_value  some  0.976105",[],"{'keyword': {0: 'goal treatment'}, 'score': {0: 0.3873}}"
451,451,451,0.75,98.0,patients don’t quite reach it,ConduitITC-Bold,20,-0.1700000017881393,8194925,16,1,2,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'patients don’t quite reach it'}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'patients don’t quite reach it'}}",{},{},{},"           entity_group                                       value     score
0  Biological_structure                                    patients  0.474887
1          Sign_symptom                                         don  0.943945
2  Detailed_description  ’ patients t quite it quite reach quite it  0.804760",[],"{'keyword': {0: 'don quite reach', 1: 'quite reach', 2: 'patients don quite', 3: 'don quite', 4: 'patients don'}, 'score': {0: 0.8834, 1: 0.8473, 2: 0.8383, 3: 0.7731, 4: 0.7529}}"
452,452,452,0.9470000267028807,32.0,39.3–63.6% of patients achieved a pCR with neoadjuvant ,UniversSB-Light,4,-0.2329999953508377,3355443,16,2,0,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: '39.3–63.6% of patients achieved a pCR with neoadjuvant '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: '39.3–63.6% of patients achieved a pCR with neoadjuvant '}}",{},{},{},"           entity_group        value     score
0             Lab_value    39.3–63.6  0.927733
1             Lab_value  39.3–63.6 %  0.980455
2  Diagnostic_procedure          pCR  0.989988
3  Detailed_description  neoadjuvant  0.999915",[],"{'keyword': {0: 'achieved pcr neoadjuvant', 1: '63 patients achieved', 2: 'achieved pcr', 3: 'pcr neoadjuvant', 4: '39 63 patients'}, 'score': {0: 0.8898, 1: 0.8465, 2: 0.8328, 3: 0.7879, 4: 0.4429}}"
453,453,453,0.9470000267028807,32.0,PERJETA,UniversSB-Light,4,-0.2329999953508377,3355443,16,2,1,"{'concept_id': {0: 'C4527348'}, 'canonical_name': {0: 'Pertuzumab/Trastuzumab Regimen'}, 'aliases': {0: ['Pertuzumab Plus Trastuzumab', 'Pertuzumab + Trastuzumab', 'Pertuzumab-Trastuzumab Regimen', 'Pertuzumab/Trastuzumab', 'Herceptin-Perjeta']}, 'types': {0: ['T061']}, 'definition': {0: 'A regimen consisting of pertuzumab and trastuzumab that may be used as a treatment for recurrent and metastatic HER-2/neu-positive breast and colorectal cancers.'}, 'entity': {0: 'PERJETA'}, 'text': {0: 'PERJETA'}}","{'concept_id': {0: 'C3473371'}, 'canonical_name': {0: 'Perjeta'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121']}, 'definition': {0: None}, 'entity': {0: 'PERJETA'}, 'text': {0: 'PERJETA'}}","{'concept_id': {0: 'C3473371'}, 'canonical_name': {0: 'Perjeta'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121']}, 'definition': {0: None}, 'entity': {0: 'PERJETA'}, 'text': {0: 'PERJETA'}}",{},{},"           entity_group    value     score
0  Detailed_description  PERJETA  0.340269
1            Medication  PERJETA  0.239947","[('PERJETA', 'DRUG')]","{'keyword': {}, 'score': {}}"
454,454,454,0.9470000267028807,32.0,36.4–60.7% of patients had residual invasive disease,UniversSB-Light,4,-0.2329999953508377,3355443,16,3,0,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: '36.4–60.7% of patients had residual invasive disease'}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: '36.4–60.7% of patients had residual invasive disease'}}",{},{},{},"           entity_group             value     score
0             Lab_value       36.4–60.7 %  0.965148
1  Detailed_description          residual  0.999973
2      Disease_disorder  invasive disease  0.999527",[],"{'keyword': {0: 'residual invasive disease', 1: 'patients residual invasive', 2: 'invasive disease', 3: '60 patients residual', 4: '36 60'}, 'score': {0: 0.871, 1: 0.8041, 2: 0.755, 3: 0.7537, 4: 0.4909}}"
455,455,455,0.9470000267028807,19.0,Adapted from Gianni et al. 2012 and Schneeweiss et al. 2013.,UniversSB-Light,4,-0.2329999953508377,3355443,16,4,0,{},{},{},{},{},"  entity_group value     score
0         Date  2012  0.367385",[],"{'keyword': {0: 'adapted gianni et', 1: 'gianni et al', 2: 'et al 2012', 3: 'al 2012 schneeweiss', 4: 'al 2013'}, 'score': {0: 0.8921, 1: 0.8309, 2: 0.7687, 3: 0.7506, 4: 0.6066}}"
456,456,456,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,16,5,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
457,457,457,0.9470000267028807,32.0,whether patients arrive at a pCR following anti-HER2 therapy,UniversSB-Light,4,-0.2329999953508377,3355443,16,5,1,"{'concept_id': {0: 'C4329777'}, 'canonical_name': {0: 'ERBB2 Antibody'}, 'aliases': {0: ['NEU Antibody', 'c-erbB2 Antibody', 'Anti-Receptor Tyrosine-Protein Kinase erbB-2 Antibody', 'HER2/Neu Antibody', 'Anti-HER2 Antibody', 'Receptor Tyrosine-Protein Kinase erbB-2 Antibody', 'Anti-Tyrosine Kinase-Type Cell Surface Receptor HER2 Antibody', 'Anti-HER-2 Antibody', 'Anti-Proto-Oncogene Neu Antibody', 'Anti-HER2/Neu Antibody', 'HER-2 Antibody', 'Tyrosine Kinase-Type Cell Surface Receptor HER2 Antibody', 'Anti-c-erbB2 Antibody', 'Anti-NEU Antibody', 'HER2 Antibody']}, 'types': {0: ['T116', 'T129']}, 'definition': {0: 'Any immunoglobulin that recognizes receptor tyrosine-protein kinase erbB-2 protein.'}, 'entity': {0: 'anti-HER2 therapy'}, 'text': {0: 'whether patients arrive at a pCR following anti-HER2 therapy'}}","{'concept_id': {0: 'C1709846'}, 'canonical_name': {0: 'Real-Time Polymerase Chain Reaction'}, 'aliases': {0: ['Real Time PCR', 'Real-Time PCRs', 'PCRs, Real-Time', 'PCR, Real-Time', 'Real Time Polymerase Chain Reaction', 'Real-Time PCR']}, 'types': {0: ['T063']}, 'definition': {0: 'An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.'}, 'entity': {0: 'pCR'}, 'text': {0: 'whether patients arrive at a pCR following anti-HER2 therapy'}}",{},{},{},"            entity_group              value     score
0   Diagnostic_procedure                pCR  0.923542
1  Therapeutic_procedure      pCR anti-HER2  0.673528
2             Medication          anti-HER2  0.980083
3            Coreference          anti-HER2  0.778609
4             Medication  anti-HER2 therapy  0.903626",[],"{'keyword': {0: 'arrive pcr following', 1: 'patients arrive', 2: 'following anti', 3: 'anti her2 therapy', 4: 'anti her2'}, 'score': {0: 0.7834, 1: 0.7668, 2: 0.7628, 3: 0.6614, 4: 0.6468}}"
458,458,458,0.9169999957084656,30.0,References:,ConduitITC-Bold,20,-0.2349999994039535,8194925,16,6,0,"{'concept_id': {0: 'C1561577'}, 'canonical_name': {0: 'Reference - MdfHmdMetSourceType'}, 'aliases': {0: ['Reference']}, 'types': {0: ['T170']}, 'definition': {0: '<p>This row represents a reference to a previously defined type. Such a reference means that, in a given message, the message element instance for the current row is identical to the message element instance that instantiates the referred row.</p>'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}","{'concept_id': {0: 'C0016483'}, 'canonical_name': {0: 'Food Preferences'}, 'aliases': {0: ['Food Preference', 'Preferences, Food', 'Preference, Food']}, 'types': {0: ['T080']}, 'definition': {0: 'The selection of one food over another.'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
459,459,459,0.8830000162124634,22.0,1. Gianni L et al. Lancet Oncol. 2012;13(1):25–32. ,MyriadPro-Light,4,-0.25,3355443,16,6,1,{},{},{},{},{},"           entity_group   value     score
0  Detailed_description  Gianni  0.505333",[],"{'keyword': {0: '13 25 32', 1: 'gianni et al', 2: 'oncol 2012', 3: 'al lancet', 4: 'et al'}, 'score': {0: 0.8726, 1: 0.8242, 2: 0.7961, 3: 0.7379, 4: 0.7348}}"
460,460,460,0.8830000162124634,22.0,2. Schneeweiss A et al. Ann Oncol. 2013;24(9):2278–2284.,MyriadPro-Light,4,-0.25,3355443,16,6,2,{},{},{},"{'concept_id': {0: 'C1709317'}, 'canonical_name': {0: 'oncosis'}, 'aliases': {0: []}, 'types': {0: ['T043']}, 'definition': {0: 'A cellular process characteristic of necrotic cell death, resulting in swelling of the cell body.'}, 'entity': {0: 'Oncol'}, 'text': {0: '2. Schneeweiss A et al. Ann Oncol. 2013;24(9):2278–2284.'}}",{},"           entity_group        value     score
0  Detailed_description  Schneeweiss  0.539144",[],"{'keyword': {0: '2278 2284', 1: '2013 24 2278', 2: 'schneeweiss et', 3: 'al ann oncol', 4: '2013 24'}, 'score': {0: 0.8333, 1: 0.8154, 2: 0.7929, 3: 0.7546, 4: 0.6922}}"
461,461,461,0.8830000162124634,22.0,3. Katayama A et al. Mod Pathol. 2021;34(7):1271–1281.,MyriadPro-Light,4,-0.25,3355443,16,6,3,"{'concept_id': {0: 'C4264324'}, 'canonical_name': {0: 'AR mod'}, 'aliases': {0: []}, 'types': {0: ['T074']}, 'definition': {0: 'Amplatz right modified'}, 'entity': {0: 'Mod'}, 'text': {0: '3. Katayama A et al. Mod Pathol. 2021;34(7):1271–1281.'}}","{'concept_id': {0: 'C0036323'}, 'canonical_name': {0: 'Schistoma Infection'}, 'aliases': {0: ['Infection, Schistoma', 'Infections, Schistoma', 'Schistoma Infections', 'Fever, Katayama', 'Bilharziases', 'Schistosomiasis', 'Schistosomiases', 'Katayama Fever', 'Bilharziasis']}, 'types': {0: ['T047']}, 'definition': {0: 'Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States.'}, 'entity': {0: 'Katayama A'}, 'text': {0: '3. Katayama A et al. Mod Pathol. 2021;34(7):1271–1281.'}}",{},{},{},"           entity_group       value     score
0  Detailed_description    Katayama  0.878531
1  Detailed_description        2021  0.919773
2             Lab_value  :1271–1281  0.976890",[],"{'keyword': {0: '1271 1281', 1: 'pathol 2021', 2: '2021 34', 3: 'katayama et al', 4: 'et al'}, 'score': {0: 0.8355, 1: 0.7944, 2: 0.7724, 3: 0.76, 4: 0.657}}"
462,462,462,0.9470000267028807,19.0,"*Absence of invasive tumour residues in the breast and lymph nodes, irrespective of ductal carcinoma in situ.",UniversSB-Light,4,-0.2329999953508377,3355443,16,7,0,"{'concept_id': {0: 'C1301536'}, 'canonical_name': {0: 'Device in situ'}, 'aliases': {0: ['Device in situ (finding)']}, 'types': {0: ['T033']}, 'definition': {0: 'Device in the natural or original position or place.'}, 'entity': {0: 'in situ'}, 'text': {0: '*Absence of invasive tumour residues in the breast and lymph nodes, irrespective of ductal carcinoma in situ.'}}","{'concept_id': {0: 'C0007099'}, 'canonical_name': {0: 'Carcinoma, Preinvasive'}, 'aliases': {0: ['Carcinoma in Situ', 'Intraepithelial Carcinoma', 'Carcinoma, Intraepithelial', 'Preinvasive Carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.'}, 'entity': {0: 'in situ'}, 'text': {0: '*Absence of invasive tumour residues in the breast and lymph nodes, irrespective of ductal carcinoma in situ.'}}",{},{},"{'concept_id': {0: 'C0007097'}, 'canonical_name': {0: 'Carcinoma'}, 'aliases': {0: []}, 'types': {0: ['T191']}, 'definition': {0: 'A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for ""cancer.""'}, 'entity': {0: 'ductal carcinoma'}, 'text': {0: '*Absence of invasive tumour residues in the breast and lymph nodes, irrespective of ductal carcinoma in situ.'}}","           entity_group             value     score
0  Detailed_description          invasive  0.556921
1          Sign_symptom            tumour  0.770865
2  Biological_structure            breast  0.999595
3      Disease_disorder  ductal carcinoma  0.999661",[],"{'keyword': {0: 'tumour residues breast', 1: 'absence invasive tumour', 2: 'invasive tumour', 3: 'nodes irrespective ductal', 4: 'carcinoma situ'}, 'score': {0: 0.8037, 1: 0.7663, 2: 0.7164, 3: 0.6591, 4: 0.5055}}"
463,463,463,0.9470000267028807,19.0,"pCR, pathological complete response.",UniversSB-Light,4,-0.2329999953508377,3355443,16,7,1,"{'concept_id': {0: 'C4054467'}, 'canonical_name': {0: 'Morphologic Complete Response'}, 'aliases': {0: ['Morphologic CR']}, 'types': {0: ['T033']}, 'definition': {0: 'The disappearance of all signs of cancer, supported by morphological analysis.'}, 'entity': {0: 'pathological complete response'}, 'text': {0: 'pCR, pathological complete response.'}}","{'concept_id': {0: 'C1709846'}, 'canonical_name': {0: 'Real-Time Polymerase Chain Reaction'}, 'aliases': {0: ['Real Time PCR', 'Real-Time PCRs', 'PCRs, Real-Time', 'PCR, Real-Time', 'Real Time Polymerase Chain Reaction', 'Real-Time PCR']}, 'types': {0: ['T063']}, 'definition': {0: 'An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.'}, 'entity': {0: 'pCR'}, 'text': {0: 'pCR, pathological complete response.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'pcr pathological', 1: 'pcr pathological complete', 2: 'pathological complete response', 3: 'pathological complete', 4: 'complete response'}, 'score': {0: 0.714, 1: 0.7119, 2: 0.6896, 3: 0.688, 4: 0.4804}}"
464,464,464,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,16,8,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
465,465,465,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,16,8,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
466,466,466,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,16,8,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
467,467,467,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,16,8,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
468,468,468,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,16,9,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
469,469,469,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,16,9,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
470,470,470,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,16,9,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
471,471,471,0.75,98.0,A different direction for patients ,ConduitITC-Bold,20,-0.1700000017881393,8194925,17,1,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'A different direction for patients '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'A different direction for patients '}}",{},{},{},"           entity_group                value     score
0             Lab_value  different direction  0.996501
1  Biological_structure             patients  0.175571",[],"{'keyword': {0: 'different direction patients', 1: 'different direction', 2: 'direction patients'}, 'score': {0: 0.9368, 1: 0.8199, 2: 0.8171}}"
472,472,472,0.75,98.0,with residual invasive disease,ConduitITC-Bold,20,-0.1700000017881393,8194925,17,1,1,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'with residual invasive disease'}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'with residual invasive disease'}}",{},{},{},"           entity_group             value     score
0  Detailed_description          residual  0.999918
1  Detailed_description  invasive disease  0.762322",[],"{'keyword': {0: 'residual invasive', 1: 'residual invasive disease', 2: 'invasive disease'}, 'score': {0: 0.9223, 1: 0.907, 2: 0.8886}}"
473,473,473,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,17,2,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
474,474,474,0.9470000267028807,32.0,"by NICE and accepted by the SMC, within its marketing authorisation ",UniversSB-Light,4,-0.2329999953508377,3355443,17,2,1,"{'concept_id': {0: 'C3888088'}, 'canonical_name': {0: 'SMITH-MCCORT DYSPLASIA 1'}, 'aliases': {0: ['SMC', 'SMITH-McCORT DYSPLASIA 1', 'SMITH-MCCORT DYSPLASIA 1', 'SMC1']}, 'types': {0: ['T047']}, 'definition': {0: None}, 'entity': {0: 'SMC'}, 'text': {0: 'by NICE and accepted by the SMC, within its marketing authorisation '}}",{},{},"{'concept_id': {0: 'C2612492'}, 'canonical_name': {0: 'smooth muscle cell apoptotic process'}, 'aliases': {0: ['smooth muscle cell programmed cell death by apoptosis', 'apoptosis of smooth muscle cells', 'smooth muscle cell apoptosis', 'SMC apoptosis', 'programmed cell death of smooth muscle cells by apoptosis', 'programmed cell death, smooth muscle cells']}, 'types': {0: ['T043']}, 'definition': {0: 'Any apoptotic process in a smooth muscle cell. Smooth muscle consists of non-striated, elongated, spindle-shaped cell found lining the digestive tract, uterus, and blood vessels. [CL:0000192, GOC:BHF, GOC:mah, GOC:mtg_apoptosis, GOC:rl]'}, 'entity': {0: 'SMC'}, 'text': {0: 'by NICE and accepted by the SMC, within its marketing authorisation '}}",{},"           entity_group value     score
0  Detailed_description  NICE  0.880457",[],"{'keyword': {0: 'nice accepted smc', 1: 'accepted smc marketing', 2: 'smc marketing', 3: 'nice accepted', 4: 'smc marketing authorisation'}, 'score': {0: 0.8918, 1: 0.8719, 2: 0.7515, 3: 0.7371, 4: 0.6703}}"
475,475,475,0.9470000267028807,32.0,for the adjuvant treatment of adult patients with HER2-positive eBC ,UniversSB-Light,4,-0.2329999953508377,3355443,17,2,2,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'for the adjuvant treatment of adult patients with HER2-positive eBC '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'for the adjuvant treatment of adult patients with HER2-positive eBC '}}",{},{},"{'concept_id': {0: 'C1853562'}, 'canonical_name': {0: 'Adult onset'}, 'aliases': {0: ['Symptoms begin in adulthood', 'Onset in early adulthood', 'Onset in adulthood']}, 'types': {0: ['T033']}, 'definition': {0: 'Onset of disease manifestations in adulthood, defined here as at the age of 16 years or later. [HPO:probinson]'}, 'entity': {0: 'adult'}, 'text': {0: 'for the adjuvant treatment of adult patients with HER2-positive eBC '}}","            entity_group           value     score
0           Sign_symptom  adjuvant adult  0.555520
1  Therapeutic_procedure       treatment  0.489698
2   Detailed_description   HER2-positive  0.617876
3              Lab_value   HER2-positive  0.925583
4       Disease_disorder             eBC  0.946575",[],"{'keyword': {0: 'adjuvant treatment', 1: 'her2 positive ebc', 2: 'adult patients her2', 3: 'treatment adult patients', 4: 'her2 positive'}, 'score': {0: 0.8331, 1: 0.8259, 2: 0.7833, 3: 0.7771, 4: 0.6666}}"
476,476,476,0.9470000267028807,32.0,who have residual invasive disease in the breast or lymph nodes ,UniversSB-Light,4,-0.2329999953508377,3355443,17,2,3,"{'concept_id': {0: 'C0578050'}, 'canonical_name': {0: 'Pain of lymph node'}, 'aliases': {0: ['lymph nodes pain', 'Pain of lymph node (finding)', 'glands lymph pain', 'lymph nodes painful', 'pain lymph glands', 'Pain of lymph node', 'gland lymph pain', 'lymph gland pain', 'Lymph Node Pain', 'painful lymph node', 'Painful lymph node', 'lymph glands pain', 'lymph node painful', 'lymph node pain']}, 'types': {0: ['T184']}, 'definition': {0: 'A painful sensation in a lymph node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'who have residual invasive disease in the breast or lymph nodes '}}","{'concept_id': {0: 'C1522495'}, 'canonical_name': {0: 'Sentinal Node'}, 'aliases': {0: ['Nodes, Sentinal', 'Sentinel Lymph Node', 'Node, Sentinal', 'Lymph Node, Sentinel', 'Sentinel Lymph Nodes', 'Sentinal Nodes', 'Lymph Nodes, Sentinel']}, 'types': {0: ['T023']}, 'definition': {0: 'First lymph node to receive drainage from the primary tumor. SENTINEL LYMPH NODE BIOPSY is performed to determine early METASTASIS status because cancer cells may appear first in the sentinel node.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'who have residual invasive disease in the breast or lymph nodes '}}",{},{},"{'concept_id': {0: 'C0024205'}, 'canonical_name': {0: 'Lymphadenitis'}, 'aliases': {0: ['Inflammation of the lymph nodes']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the lymph nodes.'}, 'entity': {0: 'lymph nodes'}, 'text': {0: 'who have residual invasive disease in the breast or lymph nodes '}}","           entity_group             value     score
0  Detailed_description          residual  0.999903
1      Disease_disorder  invasive disease  0.862857
2  Biological_structure            breast  0.999892
3  Biological_structure    residual lymph  0.999920
4  Biological_structure       lymph nodes  0.939990",[],"{'keyword': {0: 'residual invasive disease', 1: 'invasive disease', 2: 'disease breast', 3: 'lymph nodes', 4: 'breast lymph'}, 'score': {0: 0.8443, 1: 0.816, 2: 0.8119, 3: 0.801, 4: 0.7521}}"
477,477,477,0.9470000267028807,32.0,after neoadjuvant taxane-based and HER2-targeted therapy*,UniversSB-Light,4,-0.2329999953508377,3355443,17,2,4,"{'concept_id': {0: 'C5235659'}, 'canonical_name': {0: 'HER2-targeting Agent'}, 'aliases': {0: ['ERBB2-Targeting Agent']}, 'types': {0: ['T121']}, 'definition': {0: 'Any agent that targets the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2/neu; HER-2; erbB-2).'}, 'entity': {0: 'HER2-targeted therapy*'}, 'text': {0: 'after neoadjuvant taxane-based and HER2-targeted therapy*'}}",{},{},{},{},"            entity_group         value     score
0   Detailed_description   neoadjuvant  0.999899
1   Detailed_description  taxane-based  0.998750
2  Therapeutic_procedure       therapy  0.999659
3              Lab_value             *  0.895167","[('taxane', 'DRUG')]","{'keyword': {0: 'neoadjuvant taxane based', 1: 'taxane based her2', 2: 'based her2 targeted', 3: 'targeted therapy', 4: 'based her2'}, 'score': {0: 0.8682, 1: 0.8419, 2: 0.8276, 3: 0.809, 4: 0.787}}"
478,478,478,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,17,3,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
479,479,479,0.9470000267028807,32.0,of trastuzumab,UniversSB-Light,4,-0.2329999953508377,3355443,17,3,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  trastuzumab  0.999818","[('trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
480,480,480,0.944000005722046,36.0,Anti-HER2 ,UniversSB-Bold,20,-0.2469999939203262,16777215,17,4,0,"{'concept_id': {0: 'C4722434'}, 'canonical_name': {0: 'Anti-HER2 Monoclonal Antibody'}, 'aliases': {0: ['Anti-HER2 Monoclonal Antibody', 'Anti-HER-2 Monoclonal Antibody', 'Anti-ErbB2 Monoclonal Antibody']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'Any monoclonal antibody that is directed against human epidermal growth factor receptor 2 (HER2; HER-2; ERBB2).'}, 'entity': {0: 'Anti-HER2'}, 'text': {0: 'Anti-HER2 '}}",{},{},{},{},"           entity_group      value     score
0  Diagnostic_procedure  Anti-HER2  0.900894",[],"{'keyword': {0: 'anti her2'}, 'score': {0: 0.978}}"
481,481,481,0.944000005722046,36.0,activity,UniversSB-Bold,20,-0.2469999939203262,16777215,17,4,1,"{'concept_id': {0: 'C0441655'}, 'canonical_name': {0: 'Activities'}, 'aliases': {0: ['Activity (observable entity)', 'activities', 'ACTIVITY', 'Activities', 'Activity', 'activity']}, 'types': {0: ['T052']}, 'definition': {0: 'An active process; excludes processes and mechanisms which fulfill biological functions.'}, 'entity': {0: 'activity'}, 'text': {0: 'activity'}}","{'concept_id': {0: 'C0001289'}, 'canonical_name': {0: 'Activity Cycles'}, 'aliases': {0: ['Cycles, Activity', 'Cycle, Activity', 'Activity Cycle']}, 'types': {0: ['T079']}, 'definition': {0: 'Bouts of physical irritability or movement alternating with periods of quiescence. It includes biochemical activity and hormonal activity which may be cellular. These cycles are shorter than 24 hours and include sleep-wakefulness cycles and the periodic activation of the digestive system.'}, 'entity': {0: 'activity'}, 'text': {0: 'activity'}}",{},"{'concept_id': {0: 'C1151329'}, 'canonical_name': {0: 'chlorophyll a oxygenase activity'}, 'aliases': {0: ['chlorophyllide-a oxygenase activity', 'CAO activity', 'chlorophyllide a oxygenase activity', 'chlorophyllide a:oxygen 7-oxidoreductase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: chlorophyllide a + NADPH + O2 + 2 H+ = 7-hydroxychlorophyllide a + NADP+ + H2O. [EC:1.13.12.14, MetaCyc:RXN-7676]'}, 'entity': {0: 'activity'}, 'text': {0: 'activity'}}","{'concept_id': {0: 'C0424295'}, 'canonical_name': {0: 'Hyperactivity'}, 'aliases': {0: ['Hyperactive behavior', 'More active than typical', 'Hyperactive behaviour']}, 'types': {0: ['T048']}, 'definition': {0: 'Increased motor activity that is not goal directed.'}, 'entity': {0: 'activity'}, 'text': {0: 'activity'}}","           entity_group     value    score
0  Detailed_description  activity  0.69726",[],"{'keyword': {}, 'score': {}}"
482,482,482,0.9470000267028807,36.0,Trastuzumab component,UniversSB-Light,4,-0.2329999953508377,16777215,17,4,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab component'}, 'text': {0: 'Trastuzumab component'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'Trastuzumab DM1 Conjugate'}, 'aliases': {0: ['Trastuzumab-DM1', 'Ado-Trastuzumab Emtansine', 'Trastuzumab-DM1 Conjugate', 'Trastuzumab DM1', 'Ado Trastuzumab Emtansine', 'Trastuzumab Emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab component'}, 'text': {0: 'Trastuzumab component'}}","{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'Trastuzumab component'}, 'text': {0: 'Trastuzumab component'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.994186","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab component'}, 'score': {0: 1.0}}"
483,483,483,0.944000005722046,36.0,Cytotoxic microtubule  ,UniversSB-Bold,20,-0.2469999939203262,16777215,17,5,0,"{'concept_id': {0: 'C4316807'}, 'canonical_name': {0: 'Cytoplasmic microtubule'}, 'aliases': {0: ['Cytoplasmic microtubule', 'Cytoplasmic microtubule (cell structure)', 'cytoplasmic microtubule', 'Cytoplasmic microtubule, NOS']}, 'types': {0: ['T026']}, 'definition': {0: 'Any microtubule in the cytoplasm of a cell. [GOC:mah]'}, 'entity': {0: 'Cytotoxic microtubule'}, 'text': {0: 'Cytotoxic microtubule  '}}","{'concept_id': {0: 'C0026046'}, 'canonical_name': {0: 'Microtubule'}, 'aliases': {0: ['Microtubules']}, 'types': {0: ['T026']}, 'definition': {0: 'Slender, cylindrical filaments found in the cytoskeleton of plant and animal cells. They are composed of the protein TUBULIN and are influenced by TUBULIN MODULATORS.'}, 'entity': {0: 'Cytotoxic microtubule'}, 'text': {0: 'Cytotoxic microtubule  '}}",{},"{'concept_id': {0: 'C4236014'}, 'canonical_name': {0: 'cytoplasmic microtubule plus-end'}, 'aliases': {0: ['growing microtubule plus end of cytoplasmic microtubule', 'microtubule plus-end of cytoplasmic microtubule', 'microtubule plus end of cytoplasmic microtubule']}, 'types': {0: ['T026']}, 'definition': {0: 'Any microtubule plus-end that is part of a cytoplasmic microtubule. [GO_REF:0000064, GOC:TermGenie, PMID:15772152]'}, 'entity': {0: 'Cytotoxic microtubule'}, 'text': {0: 'Cytotoxic microtubule  '}}",{},"           entity_group                              value     score
0  Diagnostic_procedure                          Cytotoxic  0.644969
1             Lab_value  Cytotoxic microtubule microtubule  0.512873
2  Diagnostic_procedure                        microtubule  0.791435",[],"{'keyword': {0: 'cytotoxic microtubule'}, 'score': {0: 1.0}}"
484,484,484,0.944000005722046,36.0,inhibition,UniversSB-Bold,20,-0.2469999939203262,16777215,17,5,1,"{'concept_id': {0: 'C3463820'}, 'canonical_name': {0: 'Inhibition'}, 'aliases': {0: ['Inhibition', 'Inhibiting', 'Response Inhibition', 'physical inhibition', 'inhibition', 'Inhibitory']}, 'types': {0: ['T052']}, 'definition': {0: 'The interference with or prevention of an action or response even though the stimulus for that action or response is present.'}, 'entity': {0: 'inhibition'}, 'text': {0: 'inhibition'}}","{'concept_id': {0: 'C0029968'}, 'canonical_name': {0: 'Ovulation Inhibition'}, 'aliases': {0: ['Inhibition, Ovulation', 'Suppression, Ovulation', 'Ovulation Suppression']}, 'types': {0: ['T061']}, 'definition': {0: 'Blocking the process leading to OVULATION. Various factors are known to inhibit ovulation, such as neuroendocrine, psychological, and pharmacological agents.'}, 'entity': {0: 'inhibition'}, 'text': {0: 'inhibition'}}",{},"{'concept_id': {0: 'C3544778'}, 'canonical_name': {0: 'negative regulation of superoxide dismutase activity'}, 'aliases': {0: ['down regulation of SODS', 'inhibition of superoxide dismutase activity', 'inhibition of SODS', 'down-regulation of superoxide:superoxide oxidoreductase activity', 'negative regulation of superoxide:superoxide oxidoreductase activity', 'downregulation of superoxide:superoxide oxidoreductase activity', 'inhibition of SOD', 'down-regulation of SODS', 'inhibition of superoxide:superoxide oxidoreductase activity', 'negative regulation of SODS', 'down regulation of SOD', 'down-regulation of SOD', 'down regulation of superoxide:superoxide oxidoreductase activity', 'downregulation of superoxide dismutase activity', 'down-regulation of superoxide dismutase activity', 'negative regulation of SOD', 'downregulation of SODS', 'downregulation of SOD', 'down regulation of superoxide dismutase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Any process that stops, prevents or reduces the frequency, rate or extent of superoxide dismutase activity. [GOC:TermGenie]'}, 'entity': {0: 'inhibition'}, 'text': {0: 'inhibition'}}","{'concept_id': {0: 'C0424296'}, 'canonical_name': {0: 'Disinhibition'}, 'aliases': {0: []}, 'types': {0: ['T048']}, 'definition': {0: 'Unrestrained behavior, often at odds with social norms.'}, 'entity': {0: 'inhibition'}, 'text': {0: 'inhibition'}}","   entity_group       value     score
0  Sign_symptom  inhibition  0.849479",[],"{'keyword': {}, 'score': {}}"
485,485,485,0.9470000267028807,36.0,DM1 component,UniversSB-Light,4,-0.2329999953508377,16777215,17,5,2,"{'concept_id': {0: 'C3250443'}, 'canonical_name': {0: 'MYOTONIC DYSTROPHY 1'}, 'aliases': {0: ['STEINERT DISEASE', 'DYSTROPHIA MYOTONICA', 'Steinert myotonic dystrophy syndrome (disorder)', 'Steinert syndrome', 'MYOTONIC DYSTROPHY 1', 'Steinert disease', 'Steinert myotonic dystrophy', 'DM1', 'DYSTROPHIA MYOTONICA 1', 'DM', 'Dystrophia Myotonica 1', 'Myotonic dystrophy type 1', 'Steinert myotonic dystrophy syndrome']}, 'types': {0: ['T047']}, 'definition': {0: 'A rare autosomal dominant disorder caused by mutations in the DMPK gene. It is characterized by myotonia, muscular dystrophy, hypogonadism, heart conduction defects and cataracts.'}, 'entity': {0: 'DM1 component'}, 'text': {0: 'DM1 component'}}",{},{},{},{},"           entity_group          value     score
0  Diagnostic_procedure  DM1 component  0.998499",[],"{'keyword': {0: 'dm1 component'}, 'score': {0: 1.0}}"
486,486,486,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,17,8,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
487,487,487,0.9470000267028807,32.0,disease does not fully respond to neoadjuvant HER2-targeted therapy,UniversSB-Light,4,-0.2329999953508377,3355443,17,8,1,"{'concept_id': {0: 'C2985566'}, 'canonical_name': {0: 'Targeted Therapy'}, 'aliases': {0: ['targeted therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.'}, 'entity': {0: 'HER2-targeted therapy'}, 'text': {0: 'disease does not fully respond to neoadjuvant HER2-targeted therapy'}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'disease does not fully respond to neoadjuvant HER2-targeted therapy'}}",{},{},"{'concept_id': {0: 'C0752347'}, 'canonical_name': {0: 'Lewy body disease'}, 'aliases': {0: []}, 'types': {0: ['T047']}, 'definition': {0: 'A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)'}, 'entity': {0: 'disease'}, 'text': {0: 'disease does not fully respond to neoadjuvant HER2-targeted therapy'}}","            entity_group          value     score
0   Detailed_description    neoadjuvant  0.960975
1  Therapeutic_procedure  HER2-targeted  0.485038
2   Detailed_description  HER2-targeted  0.974843
3  Therapeutic_procedure        therapy  0.985395",[],"{'keyword': {0: 'disease does', 1: 'fully respond', 2: 'neoadjuvant her2', 3: 'her2 targeted', 4: 'does fully respond'}, 'score': {0: 0.8095, 1: 0.7574, 2: 0.7424, 3: 0.5477, 4: 0.5048}}"
488,488,488,0.9169999957084656,30.0,References:,ConduitITC-Bold,20,-0.2349999994039535,8194925,17,9,0,"{'concept_id': {0: 'C1561577'}, 'canonical_name': {0: 'Reference - MdfHmdMetSourceType'}, 'aliases': {0: ['Reference']}, 'types': {0: ['T170']}, 'definition': {0: '<p>This row represents a reference to a previously defined type. Such a reference means that, in a given message, the message element instance for the current row is identical to the message element instance that instantiates the referred row.</p>'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}","{'concept_id': {0: 'C0016483'}, 'canonical_name': {0: 'Food Preferences'}, 'aliases': {0: ['Food Preference', 'Preferences, Food', 'Preference, Food']}, 'types': {0: ['T080']}, 'definition': {0: 'The selection of one food over another.'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
489,489,489,0.8830000162124634,22.0,1. Kadcyla Summary of Product Characteristics. ,MyriadPro-Light,4,-0.25,3355443,17,9,1,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics. '}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics. '}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics. '}}","           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.796608","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla summary', 1: 'kadcyla summary product', 2: 'summary product', 3: 'summary product characteristics', 4: 'product characteristics'}, 'score': {0: 0.8868, 1: 0.8835, 2: 0.8533, 3: 0.7331, 4: 0.7046}}"
490,490,490,0.8830000162124634,22.0,2. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020. ,MyriadPro-Light,4,-0.25,3355443,17,9,2,"{'concept_id': {0: 'C1960398'}, 'canonical_name': {0: 'HER2-positive carcinoma of breast'}, 'aliases': {0: ['HER2+ breast cancer', 'HER2 Overexpressing Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast (disorder)', 'HER2-Positive Breast Carcinoma', 'HER2 Overexpressing Subtype of Breast Carcinoma', 'HER2-positive breast cancer', 'HER2/neu-positive breast cancer', 'ERBB2 Overexpressing Subtype of Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast', 'HER2 Positive Breast Carcinoma', 'HER2 Positive Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).'}, 'entity': {0: 'HER2-positive'}, 'text': {0: '2. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020. '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: '2. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020. '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: '2. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020. '}}",{},{},"           entity_group                value     score
0            Medication          Trastuzumab  0.999841
1            Medication            emtansine  0.995490
2  Detailed_description             adjuvant  0.609343
3             Lab_value  HER2-positive TA632  0.996677
4             Lab_value        HER2-positive  0.734865
5  Detailed_description                early  0.694268
6  Biological_structure               breast  0.949489","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'emtansine adjuvant treatment', 1: 'health care excellence', 2: 'breast cancer', 3: 'national institute', 4: 'positive early'}, 'score': {0: 0.8466, 1: 0.7894, 2: 0.6906, 3: 0.6491, 4: 0.5441}}"
491,491,491,0.8830000162124634,22.0,3. Scottish Medicines Consortium. SMC2298. November 2020. ,MyriadPro-Light,4,-0.25,3355443,17,9,3,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'medicines consortium smc2298', 1: 'consortium smc2298 november', 2: 'scottish medicines', 3: 'smc2298 november', 4: 'november 2020'}, 'score': {0: 0.9007, 1: 0.8849, 2: 0.8669, 3: 0.8379, 4: 0.8054}}"
492,492,492,0.8830000162124634,22.0,4. Herceptin,MyriadPro-Light,4,-0.25,3355443,17,9,4,{},{},{},{},{},"           entity_group      value     score
0  Diagnostic_procedure  Herceptin  0.985167","[('Herceptin', 'DRUG')]","{'keyword': {}, 'score': {}}"
493,493,493,0.8830000162124634,22.0,5. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628.,MyriadPro-Light,4,-0.25,3355443,17,9,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value    5.  0.861246",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'engl med 2019', 4: 'et al'}, 'score': {0: 0.8017, 1: 0.7134, 2: 0.7071, 3: 0.6469, 4: 0.6445}}"
494,494,494,0.9470000267028807,19.0,*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no ,UniversSB-Light,4,-0.2329999953508377,3355443,17,10,0,"{'concept_id': {0: 'C1272684'}, 'canonical_name': {0: 'Accepted'}, 'aliases': {0: ['accepted', 'accepting', 'accepts', 'accept', 'Accepted', 'Accepted (qualifier value)', 'Established']}, 'types': {0: ['T080']}, 'definition': {0: 'Generally approved or used.'}, 'entity': {0: 'accepts'}, 'text': {0: '*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no '}}","{'concept_id': {0: 'C0282443'}, 'canonical_name': {0: 'Review'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'An article or book published after examination of published material on a subject. It may be comprehensive to various degrees and the time range of material scrutinized may be broad or narrow, but the reviews most often desired are reviews of the current literature. The textual material examined may be equally broad and can encompass, in medicine specifically, clinical material as well as experimental research or case reports. State-of-the-art reviews tend to address more current matters. A review of the literature must be differentiated from HISTORICAL ARTICLE on the same subject, but a review of historical literature is also within the scope of this publication type.'}, 'entity': {0: 'regular review'}, 'text': {0: '*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no '}}",{},"{'concept_id': {0: 'C2754086'}, 'canonical_name': {0: 'dendrite guidance'}, 'aliases': {0: ['dendritic guidance']}, 'types': {0: ['T043']}, 'definition': {0: 'The process in which the migration of a dendrite is directed to a specific target site in response to a combination of attractive and repulsive cues. [GOC:sart, PMID:15046878]'}, 'entity': {0: 'guidance'}, 'text': {0: '*NICE guidance is prepared for the NHS in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no '}}",{},"     entity_group     value     score
0  Clinical_event  guidance  0.947969
1       Lab_value      NICE  0.859123
2       Lab_value        no  0.999031",[],"{'keyword': {0: 'withdrawn nice accepts', 1: 'subject regular', 2: 'nhs england', 3: 'nice guidance subject', 4: 'withdrawn nice'}, 'score': {0: 0.7602, 1: 0.0607, 2: 0.0537, 3: 0.0231, 4: -0.1638}}"
495,495,495,0.9470000267028807,19.0,responsibility for the use of its content in this material.,UniversSB-Light,4,-0.2329999953508377,3355443,17,10,1,"{'concept_id': {0: 'C1880278'}, 'canonical_name': {0: 'Dent in Material'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Problem associated with a undesired change in shape, characterized by the presence of a slight hollow (dent) in the device surface.'}, 'entity': {0: 'material'}, 'text': {0: 'responsibility for the use of its content in this material.'}}","{'concept_id': {0: 'C0011379'}, 'canonical_name': {0: 'Dental Materials'}, 'aliases': {0: ['Dental Material', 'Material, Dental', 'Materials, Dental']}, 'types': {0: ['T122']}, 'definition': {0: 'Materials used in the production of dental bases, restorations, impressions, prostheses, etc.'}, 'entity': {0: 'material'}, 'text': {0: 'responsibility for the use of its content in this material.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'responsibility use content', 1: 'responsibility use', 2: 'content material', 3: 'use content material', 4: 'use content'}, 'score': {0: 0.858, 1: 0.8233, 2: 0.7927, 3: 0.7894, 4: 0.7853}}"
496,496,496,0.9470000267028807,19.0,†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab ,UniversSB-Light,4,-0.2329999953508377,3355443,17,10,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab '}}","{'concept_id': {0: 'C2612492'}, 'canonical_name': {0: 'smooth muscle cell apoptotic process'}, 'aliases': {0: ['smooth muscle cell programmed cell death by apoptosis', 'apoptosis of smooth muscle cells', 'smooth muscle cell apoptosis', 'SMC apoptosis', 'programmed cell death of smooth muscle cells by apoptosis', 'programmed cell death, smooth muscle cells']}, 'types': {0: ['T043']}, 'definition': {0: 'Any apoptotic process in a smooth muscle cell. Smooth muscle consists of non-striated, elongated, spindle-shaped cell found lining the digestive tract, uterus, and blood vessels. [CL:0000192, GOC:BHF, GOC:mah, GOC:mtg_apoptosis, GOC:rl]'}, 'entity': {0: 'SMC'}, 'text': {0: '†Recommendation by NICE and acceptance by the SMC is contingent on discount. NICE recommends Kadcyla only if the company provides trastuzumab '}}",{},"            entity_group        value     score
0  Therapeutic_procedure          SMC  0.619393
1  Therapeutic_procedure      Kadcyla  0.657999
2             Medication      Kadcyla  0.586651
3             Medication  trastuzumab  0.999832","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'nice recommends kadcyla', 1: 'kadcyla company', 2: 'recommendation nice', 3: 'provides trastuzumab', 4: 'nice acceptance'}, 'score': {0: 0.6379, 1: 0.574, 2: 0.5452, 3: 0.4799, 4: 0.3122}}"
497,497,497,0.9470000267028807,19.0,emtansine according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the ,UniversSB-Light,4,-0.2329999953508377,3355443,17,10,3,"{'concept_id': {0: 'C4054110'}, 'canonical_name': {0: 'Reduced Acceptance of Extremity'}, 'aliases': {0: ['Reduced Acceptance']}, 'types': {0: ['T170']}, 'definition': {0: ""A response indicating that a person's emotional acceptance of their extremity is at an intermediate level between enthusiastic and satisfied.""}, 'entity': {0: 'Acceptance'}, 'text': {0: 'emtansine according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the '}}","{'concept_id': {0: 'C4505403'}, 'canonical_name': {0: 'Maytansinoid DM1'}, 'aliases': {0: ['Emtansine', 'Mertansine', 'DM1, Maytansinoid']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'emtansine'}, 'text': {0: 'emtansine according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'emtansine according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the '}}","{'concept_id': {0: 'C2610447'}, 'canonical_name': {0: 'acceptance of pollen'}, 'aliases': {0: []}, 'types': {0: ['T043']}, 'definition': {0: 'The recognition and acceptance of pollen by cells in the stigma, mediated by the sharing and interaction of the single locus incompatibility haplotypes. [GOC:dph, GOC:tb]'}, 'entity': {0: 'Acceptance'}, 'text': {0: 'emtansine according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the '}}","{'concept_id': {0: 'C2959688'}, 'canonical_name': {0: 'Abnormal location of heart atrium'}, 'aliases': {0: ['Abnormal atrial arrangement']}, 'types': {0: ['T019']}, 'definition': {0: 'Abnormality of the spatial relationship of the atria to other components of the heart. [DDD:dbrown]'}, 'entity': {0: 'arrangement'}, 'text': {0: 'emtansine according to the commercial arrangement. There is a simple discount patient access scheme for trastuzumab emtansine. Acceptance by the '}}","           entity_group                  value     score
0            Medication  emtansine arrangement  0.997942
1            Medication              emtansine  0.917253
2  Detailed_description                 simple  0.857207
3  Detailed_description               discount  0.995976
4            Medication            trastuzumab  0.999069
5        Clinical_event             Acceptance  0.947355","[('emtansine', 'DRUG'), ('trastuzumab', 'DRUG'), ('emtansine', 'DRUG')]","{'keyword': {0: 'patient access', 1: 'trastuzumab emtansine acceptance', 2: 'arrangement simple', 3: 'commercial arrangement', 4: 'trastuzumab emtansine'}, 'score': {0: 0.7722, 1: 0.6919, 2: 0.6509, 3: 0.646, 4: 0.3712}}"
498,498,498,0.9470000267028807,19.0,SMC applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was ,UniversSB-Light,4,-0.2329999953508377,3355443,17,10,4,"{'concept_id': {0: 'C0011115'}, 'canonical_name': {0: 'Decision Trees'}, 'aliases': {0: ['Trees, Decision', 'decision trees', 'Decision trees', 'decision tree', 'Tree, Decision', 'Decision Tree']}, 'types': {0: ['T170']}, 'definition': {0: 'A graphic device used in decision analysis, series of decision options are represented as branches (hierarchical).'}, 'entity': {0: 'decision'}, 'text': {0: 'SMC applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was '}}","{'concept_id': {0: 'C0011109'}, 'canonical_name': {0: 'Decision Making'}, 'aliases': {0: []}, 'types': {0: ['T041']}, 'definition': {0: 'The process of making a selective intellectual judgment when presented with several complex alternatives consisting of several variables, and usually defining a course of action or an idea.'}, 'entity': {0: 'decision'}, 'text': {0: 'SMC applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was '}}",{},"{'concept_id': {0: 'C1160518'}, 'canonical_name': {0: 'oocyte construction'}, 'aliases': {0: ['oocyte arrangement']}, 'types': {0: ['T043']}, 'definition': {0: 'The synthesis, deposition, and organization of the materials in a cell of an ovary; where the cell can then undergo meiosis and form an ovum. An example of this is found in Drosophila melanogaster. [GOC:dph, GOC:ems, GOC:mtg_sensu, GOC:tb, ISBN:0198506732]'}, 'entity': {0: 'arrangement'}, 'text': {0: 'SMC applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was '}}","{'concept_id': {0: 'C2959688'}, 'canonical_name': {0: 'Abnormal location of heart atrium'}, 'aliases': {0: ['Abnormal atrial arrangement']}, 'types': {0: ['T019']}, 'definition': {0: 'Abnormality of the spatial relationship of the atria to other components of the heart. [DDD:dbrown]'}, 'entity': {0: 'arrangement'}, 'text': {0: 'SMC applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was '}}","       entity_group value     score
0  Disease_disorder   SMC  0.691219",[],"{'keyword': {0: 'arrangement delivering cost', 1: 'cost effectiveness', 2: 'approved nhs scotland', 3: 'cost effectiveness results', 4: 'applies context'}, 'score': {0: 0.8168, 1: 0.7698, 2: 0.7097, 3: 0.6881, 4: 0.4486}}"
499,499,499,0.9470000267028807,19.0,"based, or a PAS/list price that is equivalent or lower.",UniversSB-Light,4,-0.2329999953508377,3355443,17,10,5,"{'concept_id': {0: 'C2003888'}, 'canonical_name': {0: 'Lower (action)'}, 'aliases': {0: ['Lower', 'Lowering', 'Lowered']}, 'types': {0: ['T052']}, 'definition': {0: 'To become lower, grow less, or diminish, as in amount, intensity, degree, or value.'}, 'entity': {0: 'lower'}, 'text': {0: 'based, or a PAS/list price that is equivalent or lower.'}}","{'concept_id': {0: 'C0226875'}, 'canonical_name': {0: 'Gastrointestinal Tract, Lower'}, 'aliases': {0: ['Lower GI Tract', 'Lower Gastrointestinal Tract']}, 'types': {0: ['T029']}, 'definition': {0: 'The segment of GASTROINTESTINAL TRACT that includes the small intestine below the DUODENUM, and the LARGE INTESTINE.'}, 'entity': {0: 'lower'}, 'text': {0: 'based, or a PAS/list price that is equivalent or lower.'}}",{},{},{},"           entity_group     value     score
0  Diagnostic_procedure  PAS/list  0.734749",[],"{'keyword': {0: 'based pas', 1: 'pas list', 2: 'price equivalent', 3: 'equivalent lower', 4: 'list price'}, 'score': {0: 0.8637, 1: 0.8486, 2: 0.8403, 3: 0.7847, 4: 0.6674}}"
500,500,500,0.9470000267028807,19.0,"eBC, early breast cancer; DM1, derivative of maytansine; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme;  ",UniversSB-Light,4,-0.2329999953508377,3355443,17,10,6,"{'concept_id': {0: 'C4728271'}, 'canonical_name': {0: 'access control scheme'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: '<p>An access control policy specific to the type of access control scheme, which is used to enforce one or more authorization policies.</p><i>Usage Note:</i>Access control schemes are the type of access control policy, which is comprised of access control policy rules concerning the provision of the access control service.<p>There are two categories of access control policies, rule-based and identity-based, which are identified in CCITT Rec. X.800 aka ISO 7498-2. Rule-based access control policies are intended to apply to all access requests by any initiator on any target in a security domain. Identity-based access control policies are based on rules specific to an individual initiator, a group of initiators, entities acting on behalf of initiators, or originators acting in a specific role. Context can modify rule-based or identity-based access control policies. Context rules may define the entire policy in effect. Real systems will usually employ a combination of these policy types; if a rule-based policy is used, then an identity-based policy is usually in effect also.</p><p>An access control scheme may be based on access control lists, capabilities, labels, and context or a combination of these. An access control scheme is a component of an access control mechanism or ""service"") along with the supporting mechanisms required by that scheme to provide access control decision information (ADI) supplied by the scheme to the access decision facility (ADF also known as a PDP). (Based on ISO/IEC 10181-3:1996)</p><b>Examples:</b><p>* Attribute Based Access Control (ABAC) * Discretionary Access Control (DAC) * History Based Access Control (HBAC) * Identity Based Access Control (IBAC) * Mandatory Access Control (MAC) * Organization Based Access Control (OrBAC) * Relationship Based Access Control (RelBac) * Responsibility Based Access Control (RespBAC) * Risk Adaptable Access Control (RAdAC)</p><p>></p>'}, 'entity': {0: 'Patient Access Scheme'}, 'text': {0: 'eBC, early breast cancer; DM1, derivative of maytansine; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme;  '}}","{'concept_id': {0: 'C4505404'}, 'canonical_name': {0: 'Maytansinoid DM4'}, 'aliases': {0: ['DM4, Maytansinoid', 'Ravtansine', 'DMMO-Maytansine', 'DMMO Maytansine', ""N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine"", 'Soravtansine']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'A tubulin-binding maytansinoid. Ravtansine binds to tubulin at the maytansine-binding site, which disrupts microtubule assembly/disassembly dynamics and inhibits mitosis.'}, 'entity': {0: 'maytansine'}, 'text': {0: 'eBC, early breast cancer; DM1, derivative of maytansine; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme;  '}}",{},"{'concept_id': {0: 'C2753849'}, 'canonical_name': {0: 'PAS complex'}, 'aliases': {0: ['PAS complex location']}, 'types': {0: ['T026']}, 'definition': {0: 'A class III phosphatidylinositol 3-kinase complex that contains a phosphatidylinositol-3-phosphate 5-kinase subunit (Fab1p in yeast; PIKfyve in mammals), a kinase activator, and a phosphatase, and may also contain additional proteins; it is involved in regulating the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate. In mammals the complex is composed of PIKFYVE, FIG4 and VAC14. In yeast it is composed of Atg18p, Fig4p, Fab1p, Vac14p and Vac7p. [PMID:18950639, PMID:19037259, PMID:19158662]'}, 'entity': {0: 'PAS'}, 'text': {0: 'eBC, early breast cancer; DM1, derivative of maytansine; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme;  '}}","{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer; DM1, derivative of maytansine; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme;  '}}","  entity_group       value     score
0   Medication  maytansine  0.999862","[('maytansine', 'DRUG')]","{'keyword': {0: 'dm1 derivative maytansine', 1: 'institute health', 2: 'breast cancer', 3: 'national institute', 4: 'excellence pas'}, 'score': {0: 0.8138, 1: 0.7445, 2: 0.6758, 3: 0.5866, 4: 0.411}}"
501,501,501,0.9470000267028807,19.0,"SMC, Scottish Medicines Consortium. ",UniversSB-Light,4,-0.2329999953508377,3355443,17,10,7,"{'concept_id': {0: 'C3888088'}, 'canonical_name': {0: 'SMITH-MCCORT DYSPLASIA 1'}, 'aliases': {0: ['SMC', 'SMITH-McCORT DYSPLASIA 1', 'SMITH-MCCORT DYSPLASIA 1', 'SMC1']}, 'types': {0: ['T047']}, 'definition': {0: None}, 'entity': {0: 'SMC'}, 'text': {0: 'SMC, Scottish Medicines Consortium. '}}",{},{},"{'concept_id': {0: 'C2612492'}, 'canonical_name': {0: 'smooth muscle cell apoptotic process'}, 'aliases': {0: ['smooth muscle cell programmed cell death by apoptosis', 'apoptosis of smooth muscle cells', 'smooth muscle cell apoptosis', 'SMC apoptosis', 'programmed cell death of smooth muscle cells by apoptosis', 'programmed cell death, smooth muscle cells']}, 'types': {0: ['T043']}, 'definition': {0: 'Any apoptotic process in a smooth muscle cell. Smooth muscle consists of non-striated, elongated, spindle-shaped cell found lining the digestive tract, uterus, and blood vessels. [CL:0000192, GOC:BHF, GOC:mah, GOC:mtg_apoptosis, GOC:rl]'}, 'entity': {0: 'SMC'}, 'text': {0: 'SMC, Scottish Medicines Consortium. '}}",{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'smc scottish medicines', 1: 'scottish medicines consortium', 2: 'scottish medicines', 3: 'medicines consortium', 4: 'smc scottish'}, 'score': {0: 0.9135, 1: 0.8985, 2: 0.8679, 3: 0.8579, 4: 0.7958}}"
502,502,502,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,17,11,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
503,503,503,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,17,11,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
504,504,504,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,17,11,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
505,505,505,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,17,11,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
506,506,506,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,17,12,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
507,507,507,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,17,12,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
508,508,508,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,17,12,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
509,509,509,0.75,98.0,Kadcyla can give patients the ,ConduitITC-Bold,20,-0.1700000017881393,8194925,18,1,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla can give patients the '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla can give patients the '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla can give patients the '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.578758
1   Medication  Kadcyla  0.754423","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla patients'}, 'score': {0: 0.737}}"
510,510,510,0.75,98.0,hope to make plans again,ConduitITC-Bold,20,-0.1700000017881393,8194925,18,1,1,"{'concept_id': {0: 'C0178916'}, 'canonical_name': {0: 'Care plan'}, 'aliases': {0: ['care plans', 'Care plan (record artifact)', 'care planning', 'care plan', 'Plan of care', 'Care plan']}, 'types': {0: ['T170']}, 'definition': {0: '<p>List of acts representing a care plan. The acts can be in a varierty of moods including event (EVN) to record acts that have been carried out as part of the care plan.</p>'}, 'entity': {0: 'plans'}, 'text': {0: 'hope to make plans again'}}",{},{},{},{},"  entity_group value     score
0    Lab_value  hope  0.239175",[],"{'keyword': {0: 'hope make plans', 1: 'make plans', 2: 'hope make'}, 'score': {0: 0.9278, 1: 0.8636, 2: 0.8351}}"
511,511,511,0.9470000267028807,32.0,The effect of Kadcyla ,UniversSB-Light,4,-0.2329999953508377,16777215,18,2,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla '}}","{'concept_id': {0: 'C1158774'}, 'canonical_name': {0: 'carbon catabolite repression of transcription by glucose'}, 'aliases': {0: ['down regulation of transcription by glucose', 'glucose effect', 'glucose repression', 'down-regulation of transcription by glucose', 'downregulation of transcription by glucose']}, 'types': {0: ['T045']}, 'definition': {0: 'A transcription regulation process in which the presence of glucose leads to a decrease in the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other carbon sources. Carbon catabolite repression is a mechanism of genetic regulation which the accumulation of catabolites of one substance in the cell represses the formation of enzymes that contribute to the catabolism of other substances. [ISBN:0198506732, PMID:11018147]'}, 'entity': {0: 'effect'}, 'text': {0: 'The effect of Kadcyla '}}",{},"  entity_group    value     score
0  Coreference  Kadcyla  0.986918","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'effect kadcyla'}, 'score': {0: 0.9018}}"
512,512,512,0.9470000267028807,32.0,was consistent across ,UniversSB-Light,4,-0.2329999953508377,16777215,18,2,1,{},{},{},{},{},"           entity_group       value     score
0             Lab_value  consistent  0.949195
1  Detailed_description      across  0.964696",[],"{'keyword': {}, 'score': {}}"
513,513,513,0.9470000267028807,32.0,most patient subgroups,UniversSB-Light,4,-0.2329999953508377,16777215,18,2,2,"{'concept_id': {0: 'C0751987'}, 'canonical_name': {0: 'Betaproteobacteria'}, 'aliases': {0: ['Purple bacteria, beta subdivision', 'Proteobacteria beta subdivision', 'Betaproteobacteria', 'beta subgroup', 'beta Proteobacteria', 'Class Betaproteobacteria', 'beta subdivision', 'beta proteobacteria', 'Class Betaproteobacteria (organism)', 'Proteobacteria beta']}, 'types': {0: ['T007']}, 'definition': {0: 'A class in the phylum PROTEOBACTERIA comprised of chemoheterotrophs and chemoautotrophs which derive nutrients from decomposition of organic material.'}, 'entity': {0: 'subgroups'}, 'text': {0: 'most patient subgroups'}}","{'concept_id': {0: 'C4277550'}, 'canonical_name': {0: 'Patient Portals'}, 'aliases': {0: ['Patient Internet Portals', 'Web Portals, Patient', 'Web Portal, Patient', 'Patient Internet Portal', 'Portals, Patient Web', 'Portal, Patient Web', 'Portal, Patient Internet', 'Patient Web Portals', 'Internet Portal, Patient', 'Internet Portals, Patient', 'Patient Portal', 'Patient Web Portal', 'Portals, Patient Internet', 'Portal, Patient']}, 'types': {0: ['T170']}, 'definition': {0: 'A secure online website that provides patients convenient 24-hour access to personal health information via an Internet connection.'}, 'entity': {0: 'patient'}, 'text': {0: 'most patient subgroups'}}",{},{},{},"           entity_group              value     score
0  Diagnostic_procedure  patient subgroups  0.692869",[],"{'keyword': {0: 'patient subgroups'}, 'score': {0: 0.8227}}"
514,514,514,0.9470000267028807,32.0,The risk of distant ,UniversSB-Light,4,-0.2329999953508377,16777215,18,3,0,"{'concept_id': {0: 'C5441917'}, 'canonical_name': {0: 'Distant Metastasis'}, 'aliases': {0: ['Distant Cancer', 'Distant Metastasis', 'Distant metastasis']}, 'types': {0: ['T046']}, 'definition': {0: 'A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.'}, 'entity': {0: 'distant'}, 'text': {0: 'The risk of distant '}}","{'concept_id': {0: 'C0028873'}, 'canonical_name': {0: 'Odds Ratio'}, 'aliases': {0: ['Ratio, Cross-Product', 'Odds, Relative', 'Risk Ratio', 'Risk Ratios', 'Relative Odds', 'Cross Product Ratio', 'Odds Ratios', 'Ratios, Risk', 'Ratio, Risk', 'Ratios, Cross-Product', 'Cross-Product Ratio', 'Cross-Product Ratios']}, 'types': {0: ['T081']}, 'definition': {0: 'The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.'}, 'entity': {0: 'risk'}, 'text': {0: 'The risk of distant '}}",{},{},{},"           entity_group    value     score
0  Detailed_description  distant  0.999642",[],"{'keyword': {0: 'risk distant'}, 'score': {0: 0.821}}"
515,515,515,0.9470000267028807,32.0,recurrence was lower ,UniversSB-Light,4,-0.2329999953508377,16777215,18,3,1,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence was lower '}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence was lower '}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence was lower '}}","   entity_group       value     score
0  Sign_symptom  recurrence  0.999631
1     Lab_value       lower  0.999864",[],"{'keyword': {0: 'recurrence lower'}, 'score': {0: 0.8651}}"
516,516,516,0.9470000267028807,32.0,with Kadcyla vs ,UniversSB-Light,4,-0.2329999953508377,16777215,18,3,2,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'with Kadcyla vs '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'with Kadcyla vs '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'with Kadcyla vs '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.913164","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla vs'}, 'score': {0: 0.9202}}"
517,517,517,0.9470000267028807,32.0,trastuzumab (unstratified ,UniversSB-Light,4,-0.2329999953508377,16777215,18,3,3,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab (unstratified '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab (unstratified '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab (unstratified '}}",{},{},"           entity_group                     value     score
0            Medication  trastuzumab unstratified  0.999804
1            Medication               trastuzumab  0.914716
2  Detailed_description              unstratified  0.974952
3          Sign_symptom              unstratified  0.563836","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab unstratified'}, 'score': {0: 0.8878}}"
518,518,518,0.9470000267028807,32.0,hazard ratio 0.60;  ,UniversSB-Light,4,-0.2329999953508377,16777215,18,3,4,"{'concept_id': {0: 'C0597342'}, 'canonical_name': {0: 'radiation hazard'}, 'aliases': {0: ['hazards radiation', 'radiation hazard']}, 'types': {0: ['T038']}, 'definition': {0: 'health hazard arising from exposure to ionizing radiation.'}, 'entity': {0: 'hazard ratio'}, 'text': {0: 'hazard ratio 0.60;  '}}",{},{},{},{},"           entity_group         value     score
0  Diagnostic_procedure  hazard ratio  0.999913",[],"{'keyword': {0: 'hazard ratio', 1: 'hazard ratio 60', 2: 'ratio 60'}, 'score': {0: 0.6806, 1: 0.652, 2: 0.6169}}"
519,519,519,0.9470000267028807,32.0,95% Cl 0.45–0.79),UniversSB-Light,4,-0.2329999953508377,16777215,18,3,5,{},{},{},{},{},"           entity_group value     score
0             Lab_value    95  0.999804
1  Diagnostic_procedure    Cl  0.993519",[],"{'keyword': {0: '95 cl 45', 1: 'cl 45 79', 2: '95 cl', 3: '45 79', 4: 'cl 45'}, 'score': {0: 0.7718, 1: 0.7615, 2: 0.7463, 3: 0.7409, 4: 0.7296}}"
520,520,520,0.9470000267028807,32.0,Kadcyla reduced  ,UniversSB-Light,4,-0.2329999953508377,16777215,18,4,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla reduced  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla reduced  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla reduced  '}}",{},{},"           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.999328
1             Lab_value  reduced  0.998519","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla reduced'}, 'score': {0: 1.0}}"
521,521,521,0.9470000267028807,32.0,the risk of recurrence ,UniversSB-Light,4,-0.2329999953508377,16777215,18,4,1,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'the risk of recurrence '}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'the risk of recurrence '}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'the risk of recurrence '}}","   entity_group       value     score
0  Sign_symptom  recurrence  0.999955",[],"{'keyword': {0: 'risk recurrence'}, 'score': {0: 0.8694}}"
522,522,522,0.9470000267028807,32.0,by 50% vs trastuzumab ,UniversSB-Light,4,-0.2329999953508377,16777215,18,4,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'by 50% vs trastuzumab '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'by 50% vs trastuzumab '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'by 50% vs trastuzumab '}}",{},{},"  entity_group        value     score
0    Lab_value         50 %  0.977016
1   Medication  trastuzumab  0.999849","[('trastuzumab', 'DRUG')]","{'keyword': {0: '50 vs trastuzumab', 1: '50 vs', 2: 'vs trastuzumab'}, 'score': {0: 0.8863, 1: 0.8215, 2: 0.8142}}"
523,523,523,0.9470000267028807,32.0,(11.3% absolute ,UniversSB-Light,4,-0.2329999953508377,16777215,18,4,3,"{'concept_id': {0: 'C4086990'}, 'canonical_name': {0: 'Absolutely Sure'}, 'aliases': {0: ['Absolutely Certain']}, 'types': {0: ['T170']}, 'definition': {0: 'A subjective answer of strong agreement regarding the certainty of something.'}, 'entity': {0: 'absolute'}, 'text': {0: '(11.3% absolute '}}","{'concept_id': {0: 'C4760601'}, 'canonical_name': {0: 'Poverty, Extreme'}, 'aliases': {0: ['Absolute Poverty', 'Extreme Poverty', 'Poverty, Absolute']}, 'types': {0: ['T102']}, 'definition': {0: 'The inability to meet basic human needs, such as food, shelter, and avoidance of disease.'}, 'entity': {0: 'absolute'}, 'text': {0: '(11.3% absolute '}}",{},{},{},"           entity_group     value     score
0             Lab_value      11.3  0.923740
1  Detailed_description  absolute  0.956758",[],"{'keyword': {0: '11 absolute'}, 'score': {0: 0.7991}}"
524,524,524,0.9470000267028807,32.0,reduction; hazard ratio ,UniversSB-Light,4,-0.2329999953508377,16777215,18,4,4,"{'concept_id': {0: 'C0597342'}, 'canonical_name': {0: 'radiation hazard'}, 'aliases': {0: ['hazards radiation', 'radiation hazard']}, 'types': {0: ['T038']}, 'definition': {0: 'health hazard arising from exposure to ionizing radiation.'}, 'entity': {0: 'hazard ratio'}, 'text': {0: 'reduction; hazard ratio '}}","{'concept_id': {0: 'C0679771'}, 'canonical_name': {0: 'Harm Reduction'}, 'aliases': {0: ['Minimization, Harm', 'Reduction, Harm', 'Harm Minimization']}, 'types': {0: ['T061']}, 'definition': {0: 'The application of methods designed to reduce the risk of harm associated with certain behaviors without reduction in frequency of those behaviors. The risk-associated behaviors include ongoing and active addictive behaviors.'}, 'entity': {0: 'reduction'}, 'text': {0: 'reduction; hazard ratio '}}",{},"{'concept_id': {0: 'C1522821'}, 'canonical_name': {0: 'acidification'}, 'aliases': {0: ['pH reduction']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that reduces the internal pH of an organism, part of an organism or a cell, measured by the concentration of the hydrogen ion. [GOC:go_curators]'}, 'entity': {0: 'reduction'}, 'text': {0: 'reduction; hazard ratio '}}",{},"           entity_group         value     score
0  Diagnostic_procedure  hazard ratio  0.999716",[],"{'keyword': {0: 'reduction hazard ratio', 1: 'reduction hazard', 2: 'hazard ratio'}, 'score': {0: 0.9144, 1: 0.8837, 2: 0.8506}}"
525,525,525,0.9470000267028807,32.0,0.50; 95% Cl 0.39–0.64; ,UniversSB-Light,4,-0.2329999953508377,16777215,18,4,5,"{'concept_id': {0: 'C0475212'}, 'canonical_name': {0: 'centiliter'}, 'aliases': {0: ['Centiliter (qualifier value)', 'centiliter (cL)', 'Centiliter', 'centilitre', 'cL', 'cl']}, 'types': {0: ['T081']}, 'definition': {0: 'The unit of volume equal to one hundredth of a liter or 10 milliliters. One centiliter is equivalent to 0.6102 cubic inch, or 0.338 U.S. fluid ounce.'}, 'entity': {0: 'Cl'}, 'text': {0: '0.50; 95% Cl 0.39–0.64; '}}",{},{},"{'concept_id': {0: 'C1150758'}, 'canonical_name': {0: '4-coumarate-CoA synthetase activity'}, 'aliases': {0: ['hydroxycinnamoyl CoA synthetase activity', '4-coumarate:CoA ligase activity', '4CL', 'p-hydroxycinnamic acid:CoA ligase activity', '4-coumaroyl-CoA synthetase activity', 'caffeolyl coenzyme A synthetase activity', '4-coumaroyl-CoA synthase activity', 'sinapoyl coenzyme A synthetase activity', 'feruloyl CoA ligase activity', '4-coumarate:coenzyme A ligase activity', 'hydroxycinnamate:CoA ligase activity', 'p-coumaryl coenzyme A synthetase activity', 'feruloyl coenzyme A synthetase activity', 'p-coumaryl-CoA ligase activity', '4-coumarate-CoA ligase activity', 'p-coumaryl-CoA synthetase activity', '4-coumaryl-CoA synthetase activity', '4-coumarate:CoA ligase (AMP-forming)', 'p-hydroxycinnamoyl coenzyme A synthetase activity', 'p-coumaroyl CoA ligase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + 4-coumarate + CoA = AMP + diphosphate + 4-coumaroyl-CoA. [EC:6.2.1.12]'}, 'entity': {0: 'Cl'}, 'text': {0: '0.50; 95% Cl 0.39–0.64; '}}",{},"           entity_group           value     score
0             Lab_value            0.50  0.997288
1             Lab_value            95 %  0.773418
2  Diagnostic_procedure              Cl  0.951768
3             Lab_value  0.50 0.39–0.64  0.914815
4             Lab_value       0.39–0.64  0.804375",[],"{'keyword': {0: '95 cl 39', 1: 'cl 39 64', 2: '50 95', 3: '50 95 cl', 4: 'cl 39'}, 'score': {0: 0.7935, 1: 0.7897, 2: 0.756, 3: 0.7237, 4: 0.6794}}"
526,526,526,0.9470000267028807,32.0,p<0.001),UniversSB-Light,4,-0.2329999953508377,16777215,18,4,6,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
527,527,527,0.9169999957084656,30.0,Reference:,ConduitITC-Bold,20,-0.2349999994039535,8194925,18,11,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
528,528,528,0.8830000162124634,22.0,1. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628.,MyriadPro-Light,4,-0.25,3355443,18,11,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'et al', 4: 'engl med 2019'}, 'score': {0: 0.8031, 1: 0.7251, 2: 0.7194, 3: 0.6642, 4: 0.6422}}"
529,529,529,0.9470000267028807,19.0,"CI, confidence interval.",UniversSB-Light,4,-0.2329999953508377,3355443,18,12,0,"{'concept_id': {0: 'C1704725'}, 'canonical_name': {0: 'Statistical Confidence'}, 'aliases': {0: ['Confidence', 'Statistical Confidence']}, 'types': {0: ['T080']}, 'definition': {0: 'The statistical calculation of the percentage likelihood for a given set of data to have a given statistical value.'}, 'entity': {0: 'confidence interval'}, 'text': {0: 'CI, confidence interval.'}}","{'concept_id': {0: 'C0009667'}, 'canonical_name': {0: 'Confidence Intervals'}, 'aliases': {0: ['Confidence Interval', 'Intervals, Confidence', 'Interval, Confidence']}, 'types': {0: ['T081']}, 'definition': {0: 'A range of values for a variable of interest, e.g., a rate, constructed so that this range has a specified probability of including the true value of the variable.'}, 'entity': {0: 'confidence interval'}, 'text': {0: 'CI, confidence interval.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'confidence interval', 1: 'ci confidence interval', 2: 'ci confidence'}, 'score': {0: 0.7259, 1: 0.6489, 2: 0.6356}}"
530,530,530,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,18,13,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
531,531,531,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,18,13,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
532,532,532,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,18,13,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
533,533,533,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,18,13,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
534,534,534,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,18,14,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
535,535,535,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,18,14,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
536,536,536,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,18,14,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
537,537,537,0.9169999957084656,98.0,Kadcyla reduced the risk of recurrence  ,ConduitITC-Bold,20,-0.2349999994039535,8194925,19,1,0,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'Kadcyla reduced the risk of recurrence  '}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'Kadcyla reduced the risk of recurrence  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla reduced the risk of recurrence  '}}",{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'Kadcyla reduced the risk of recurrence  '}}","   entity_group       value     score
0   Coreference     Kadcyla  0.906293
1  Sign_symptom  recurrence  0.993433","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'reduced risk recurrence', 1: 'kadcyla reduced risk', 2: 'reduced risk', 3: 'kadcyla reduced', 4: 'risk recurrence'}, 'score': {0: 0.8653, 1: 0.8547, 2: 0.8412, 3: 0.8357, 4: 0.7091}}"
538,538,538,0.9169999957084656,98.0,by 50% vs trastuzumab,ConduitITC-Bold,20,-0.2349999994039535,8194925,19,1,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'by 50% vs trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'by 50% vs trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'by 50% vs trastuzumab'}}",{},{},"  entity_group        value     score
0    Lab_value         50 %  0.977016
1   Medication  trastuzumab  0.999849","[('trastuzumab', 'DRUG')]","{'keyword': {0: '50 vs trastuzumab', 1: '50 vs', 2: 'vs trastuzumab'}, 'score': {0: 0.8863, 1: 0.8215, 2: 0.8142}}"
539,539,539,0.9890000224113464,32.0,IDFS at 40.9–41.1 months’ median follow-up,MyriadPro-Bold,20,-0.25,3355443,19,2,0,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'IDFS at 40.9–41.1 months’ median follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'IDFS at 40.9–41.1 months’ median follow-up'}}",{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: 'IDFS at 40.9–41.1 months’ median follow-up'}}",{},"           entity_group      value     score
0      Disease_disorder       IDFS  0.656999
1  Diagnostic_procedure       IDFS  0.861576
2             Lab_value  40.9–41.1  0.944411
3              Duration  40.9–41.1  0.978035
4              Duration     months  0.873750
5        Clinical_event  follow-up  0.998250",[],"{'keyword': {0: '41 months median', 1: '40 41 months', 2: 'median follow', 3: '40 41', 4: 'months median follow'}, 'score': {0: 0.8866, 1: 0.8272, 2: 0.7682, 3: 0.7551, 4: 0.6022}}"
540,540,540,0.9470000267028807,21.0,100,UniversSB-Light,4,-0.2329999953508377,5723991,19,3,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   100  0.996131",[],"{'keyword': {}, 'score': {}}"
541,541,541,0.9470000267028807,21.0,80,UniversSB-Light,4,-0.2329999953508377,5723991,19,4,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    80  0.999572",[],"{'keyword': {}, 'score': {}}"
542,542,542,0.9470000267028807,21.0,60,UniversSB-Light,4,-0.2329999953508377,5723991,19,5,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    60  0.999203",[],"{'keyword': {}, 'score': {}}"
543,543,543,0.9399999976158142,24.0,Hazard ratio = 0.50,UniversSB-Roman,4,-0.2339999973773956,8194925,19,6,0,"{'concept_id': {0: 'C0597342'}, 'canonical_name': {0: 'radiation hazard'}, 'aliases': {0: ['hazards radiation', 'radiation hazard']}, 'types': {0: ['T038']}, 'definition': {0: 'health hazard arising from exposure to ionizing radiation.'}, 'entity': {0: 'Hazard ratio'}, 'text': {0: 'Hazard ratio = 0.50'}}",{},{},{},{},"           entity_group         value     score
0  Diagnostic_procedure  Hazard ratio  0.999912
1             Lab_value          0.50  0.999924",[],"{'keyword': {0: 'ratio 50', 1: 'hazard ratio 50', 2: 'hazard ratio'}, 'score': {0: 0.7125, 1: 0.6789, 2: 0.6672}}"
544,544,544,0.9399999976158142,24.0,95% CI 0.39–0.64,UniversSB-Roman,4,-0.2339999973773956,8194925,19,6,1,"{'concept_id': {0: 'C1417638'}, 'canonical_name': {0: 'NDUFB6 gene'}, 'aliases': {0: ['NDUFB6', 'COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, B17 SUBUNIT', 'NADH-ubiquinone oxidoreductase beta subunit, 6', 'NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa', 'CI', 'NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 (17kD, B17)', 'NADH:ubiquinone oxidoreductase subunit B6', 'NADH-ubiquinone oxidoreductase B17 subunit', 'B17', 'complex I, mitochondrial respiratory chain, B17 subunit', 'NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 6', 'NDUFB6 gene']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'CI'}, 'text': {0: '95% CI 0.39–0.64'}}",{},{},{},{},"  entity_group              value     score
0    Lab_value  95 % CI 0.39–0.64  0.940124",[],"{'keyword': {0: 'ci 39 64', 1: '95 ci 39', 2: 'ci 39', 3: '39 64', 4: '95 ci'}, 'score': {0: 0.8169, 1: 0.755, 2: 0.7467, 3: 0.7323, 4: 0.6729}}"
545,545,545,0.9399999976158142,24.0,p<0.001,UniversSB-Roman,4,-0.2339999973773956,8194925,19,6,2,{},{},{},{},{},"  entity_group    value     score
0    Lab_value        p  0.670408
1    Lab_value  < 0.001  0.998420",[],"{'keyword': {}, 'score': {}}"
546,546,546,0.9399999976158142,20.0,3-year IDFS rate,UniversSB-Roman,4,-0.2339999973773956,5723991,19,7,0,{},{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: '3-year IDFS rate'}}",{},"           entity_group      value     score
0              Duration     3-year  0.990561
1  Diagnostic_procedure  IDFS rate  0.999856",[],"{'keyword': {0: 'year idfs rate', 1: 'idfs rate', 2: 'year idfs'}, 'score': {0: 0.8794, 1: 0.8787, 2: 0.7801}}"
547,547,547,0.9399999976158142,20.0,IDFS events at 40.9–41.1 ,UniversSB-Roman,4,-0.2339999973773956,5723991,19,8,0,{},{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: 'IDFS events at 40.9–41.1 '}}",{},"           entity_group      value     score
0      Disease_disorder       IDFS  0.702184
1  Detailed_description  40.9–41.1  0.982732",[],"{'keyword': {0: '40 41', 1: 'events 40 41', 2: 'events 40', 3: 'idfs events 40', 4: 'idfs events'}, 'score': {0: 0.7154, 1: 0.7146, 2: 0.6451, 3: 0.4739, 4: 0.3749}}"
548,548,548,0.9399999976158142,20.0,months’ follow-up,UniversSB-Roman,4,-0.2339999973773956,5723991,19,8,1,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'months’ follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'months’ follow-up'}}",{},{},{},"     entity_group      value     score
0  Clinical_event  follow-up  0.996701",[],"{'keyword': {0: 'months follow'}, 'score': {0: 0.9111}}"
549,549,549,0.9470000267028807,21.0,40,UniversSB-Light,4,-0.2329999953508377,5723991,19,9,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    40  0.998907",[],"{'keyword': {}, 'score': {}}"
550,550,550,0.9470000267028807,25.0,IDFS rate (%),UniversSB-Light,4,-0.2329999953508377,5658197,19,10,0,{},{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: 'IDFS rate (%)'}}",{},"           entity_group      value     score
0  Diagnostic_procedure  IDFS rate  0.999296",[],"{'keyword': {0: 'idfs rate'}, 'score': {0: 0.8831}}"
551,551,551,0.944000005722046,20.0,91 (12.2%) ,UniversSB-Medium,4,-0.2349999994039535,8194925,19,11,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    91  0.999551
1    Lab_value  12.2  0.665941",[],"{'keyword': {0: '91 12'}, 'score': {0: 0.7485}}"
552,552,552,0.944000005722046,20.0,Kadcyla,UniversSB-Medium,4,-0.2349999994039535,8194925,19,12,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
553,553,553,0.944000005722046,20.0,88.3%,UniversSB-Medium,4,-0.2349999994039535,8194925,19,13,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  88.3 %  0.999505",[],"{'keyword': {}, 'score': {}}"
554,554,554,0.944000005722046,20.0,77.0%,UniversSB-Medium,4,-0.2349999994039535,16162586,19,14,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  77.0 %  0.999817",[],"{'keyword': {}, 'score': {}}"
555,555,555,0.944000005722046,20.0,165 (22.2%),UniversSB-Medium,4,-0.2349999994039535,16162586,19,15,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   165  0.999504
1    Lab_value  22.2  0.836550",[],"{'keyword': {0: '165 22'}, 'score': {0: 0.6801}}"
556,556,556,0.944000005722046,20.0,Trastuzumab,UniversSB-Medium,4,-0.2349999994039535,16162586,19,15,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
557,557,557,0.9470000267028807,21.0,20,UniversSB-Light,4,-0.2329999953508377,5723991,19,16,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value    20  0.99851",[],"{'keyword': {}, 'score': {}}"
558,558,558,0.944000005722046,20.0,11.3% ,UniversSB-Medium,4,-0.2349999994039535,9013641,19,17,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  11.3 %  0.999733",[],"{'keyword': {}, 'score': {}}"
559,559,559,0.944000005722046,20.0,difference,UniversSB-Medium,4,-0.2349999994039535,9013641,19,17,1,{},{},{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  difference  0.979387",[],"{'keyword': {}, 'score': {}}"
560,560,560,0.9470000267028807,21.0,0,UniversSB-Light,4,-0.2329999953508377,5723991,19,18,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     0  0.998937",[],"{'keyword': {}, 'score': {}}"
561,561,561,0.9470000267028807,21.0,0,UniversSB-Light,4,-0.2329999953508377,5723991,19,19,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     0  0.998937",[],"{'keyword': {}, 'score': {}}"
562,562,562,0.9470000267028807,21.0,6,UniversSB-Light,4,-0.2329999953508377,5723991,19,19,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value     6  0.981812",[],"{'keyword': {}, 'score': {}}"
563,563,563,0.9470000267028807,21.0,12,UniversSB-Light,4,-0.2329999953508377,5723991,19,19,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    12  0.950751",[],"{'keyword': {}, 'score': {}}"
564,564,564,0.9470000267028807,21.0,18,UniversSB-Light,4,-0.2329999953508377,5723991,19,19,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    18  0.978542",[],"{'keyword': {}, 'score': {}}"
565,565,565,0.9470000267028807,21.0,24,UniversSB-Light,4,-0.2329999953508377,5723991,19,19,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    24  0.807345",[],"{'keyword': {}, 'score': {}}"
566,566,566,0.9470000267028807,21.0,30,UniversSB-Light,4,-0.2329999953508377,5723991,19,19,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value    30  0.998713",[],"{'keyword': {}, 'score': {}}"
567,567,567,0.9470000267028807,21.0,36,UniversSB-Light,4,-0.2329999953508377,5723991,19,20,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    36  0.994924",[],"{'keyword': {}, 'score': {}}"
568,568,568,0.9470000267028807,21.0,42,UniversSB-Light,4,-0.2329999953508377,5723991,19,20,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value    42  0.998523",[],"{'keyword': {}, 'score': {}}"
569,569,569,0.9470000267028807,21.0,48,UniversSB-Light,4,-0.2329999953508377,5723991,19,20,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value    48  0.99335",[],"{'keyword': {}, 'score': {}}"
570,570,570,0.9470000267028807,21.0,60,UniversSB-Light,4,-0.2329999953508377,5723991,19,20,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    60  0.999203",[],"{'keyword': {}, 'score': {}}"
571,571,571,0.9470000267028807,21.0,54,UniversSB-Light,4,-0.2329999953508377,5723991,19,20,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    54  0.996933",[],"{'keyword': {}, 'score': {}}"
572,572,572,0.9470000267028807,21.0,No. at risk,UniversSB-Light,4,-0.2329999953508377,5723991,19,21,0,"{'concept_id': {0: 'C2825539'}, 'canonical_name': {0: 'Cellular Telephone Number'}, 'aliases': {0: ['Cell Phone No.']}, 'types': {0: ['T170']}, 'definition': {0: 'The sequence of numbers or characters, that when dialed, connects to a particular cellular telephone.'}, 'entity': {0: 'No.'}, 'text': {0: 'No. at risk'}}",{},{},{},{},"  entity_group    value     score
0    Lab_value  at risk  0.947494",[],"{'keyword': {}, 'score': {}}"
573,573,573,0.9470000267028807,25.0,Months,UniversSB-Light,4,-0.2329999953508377,5658197,19,22,0,"{'concept_id': {0: 'C4745111'}, 'canonical_name': {0: '24 Months'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'A period of time of twenty-four months.'}, 'entity': {0: 'Months'}, 'text': {0: 'Months'}}",{},{},{},{},"  entity_group   value     score
0     Duration  Months  0.571131",[],"{'keyword': {}, 'score': {}}"
574,574,574,0.9470000267028807,21.0,Kadcyla,UniversSB-Light,4,-0.2329999953508377,5723991,19,23,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
575,575,575,0.9470000267028807,21.0,743,UniversSB-Light,4,-0.2329999953508377,5723991,19,24,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   743  0.949835",[],"{'keyword': {}, 'score': {}}"
576,576,576,0.9470000267028807,21.0,707,UniversSB-Light,4,-0.2329999953508377,5723991,19,25,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   707  0.863332",[],"{'keyword': {}, 'score': {}}"
577,577,577,0.9470000267028807,21.0,681,UniversSB-Light,4,-0.2329999953508377,5723991,19,26,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   681  0.973583",[],"{'keyword': {}, 'score': {}}"
578,578,578,0.9470000267028807,21.0,658,UniversSB-Light,4,-0.2329999953508377,5723991,19,27,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   658  0.982223",[],"{'keyword': {}, 'score': {}}"
579,579,579,0.9470000267028807,21.0,633,UniversSB-Light,4,-0.2329999953508377,5723991,19,28,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   633  0.948349",[],"{'keyword': {}, 'score': {}}"
580,580,580,0.9470000267028807,21.0,561,UniversSB-Light,4,-0.2329999953508377,5723991,19,29,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   561  0.949995",[],"{'keyword': {}, 'score': {}}"
581,581,581,0.9470000267028807,21.0,409,UniversSB-Light,4,-0.2329999953508377,5723991,19,30,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   409  0.954376",[],"{'keyword': {}, 'score': {}}"
582,582,582,0.9470000267028807,21.0,255,UniversSB-Light,4,-0.2329999953508377,5723991,19,31,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   255  0.999666",[],"{'keyword': {}, 'score': {}}"
583,583,583,0.9470000267028807,21.0,142,UniversSB-Light,4,-0.2329999953508377,5723991,19,32,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   142  0.996654",[],"{'keyword': {}, 'score': {}}"
584,584,584,0.9470000267028807,21.0,44,UniversSB-Light,4,-0.2329999953508377,5723991,19,33,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    44  0.991506",[],"{'keyword': {}, 'score': {}}"
585,585,585,0.9470000267028807,21.0,4,UniversSB-Light,4,-0.2329999953508377,5723991,19,34,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     4  0.999388",[],"{'keyword': {}, 'score': {}}"
586,586,586,0.9470000267028807,21.0,743,UniversSB-Light,4,-0.2329999953508377,5723991,19,35,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   743  0.949835",[],"{'keyword': {}, 'score': {}}"
587,587,587,0.9470000267028807,21.0,676,UniversSB-Light,4,-0.2329999953508377,5723991,19,36,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   676  0.968719",[],"{'keyword': {}, 'score': {}}"
588,588,588,0.9470000267028807,21.0,635,UniversSB-Light,4,-0.2329999953508377,5723991,19,37,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   635  0.939994",[],"{'keyword': {}, 'score': {}}"
589,589,589,0.9470000267028807,21.0,594,UniversSB-Light,4,-0.2329999953508377,5723991,19,38,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   594  0.994751",[],"{'keyword': {}, 'score': {}}"
590,590,590,0.9470000267028807,21.0,555,UniversSB-Light,4,-0.2329999953508377,5723991,19,39,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   555  0.997093",[],"{'keyword': {}, 'score': {}}"
591,591,591,0.9470000267028807,21.0,501,UniversSB-Light,4,-0.2329999953508377,5723991,19,40,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   501  0.932264",[],"{'keyword': {}, 'score': {}}"
592,592,592,0.9470000267028807,21.0,342,UniversSB-Light,4,-0.2329999953508377,5723991,19,41,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   342  0.847533",[],"{'keyword': {}, 'score': {}}"
593,593,593,0.9470000267028807,21.0,220,UniversSB-Light,4,-0.2329999953508377,5723991,19,42,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   220  0.999528",[],"{'keyword': {}, 'score': {}}"
594,594,594,0.9470000267028807,21.0,119,UniversSB-Light,4,-0.2329999953508377,5723991,19,43,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value   119  0.99204",[],"{'keyword': {}, 'score': {}}"
595,595,595,0.9470000267028807,21.0,38,UniversSB-Light,4,-0.2329999953508377,5723991,19,44,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    38  0.998779",[],"{'keyword': {}, 'score': {}}"
596,596,596,0.9470000267028807,21.0,4,UniversSB-Light,4,-0.2329999953508377,5723991,19,45,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     4  0.999388",[],"{'keyword': {}, 'score': {}}"
597,597,597,0.9470000267028807,21.0,Trastuzumab,UniversSB-Light,4,-0.2329999953508377,5723991,19,46,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
598,598,598,0.8830000162124634,19.0,Adapted from von Minckwitz et al. 2019.,MyriadPro-Light,4,-0.25,3355443,19,47,0,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
599,599,599,0.8830000162124634,19.0,"CI, confidence interval; IDFS, invasive disease-free survival.",MyriadPro-Light,4,-0.25,3355443,19,47,1,"{'concept_id': {0: 'C5401422'}, 'canonical_name': {0: 'Disease Free'}, 'aliases': {0: ['Disease Free', 'Disease-free']}, 'types': {0: ['T080']}, 'definition': {0: 'An indication that an individual shows no signs of having or carrying a disease.'}, 'entity': {0: 'disease-free survival'}, 'text': {0: 'CI, confidence interval; IDFS, invasive disease-free survival.'}}","{'concept_id': {0: 'C0242793'}, 'canonical_name': {0: 'Disease Free Survival'}, 'aliases': {0: ['Survival, Disease Free', 'Survival, Disease-Free', 'Disease-Free Survival']}, 'types': {0: ['T081']}, 'definition': {0: 'Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.'}, 'entity': {0: 'disease-free survival'}, 'text': {0: 'CI, confidence interval; IDFS, invasive disease-free survival.'}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'CI, confidence interval; IDFS, invasive disease-free survival.'}}",{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'free survival', 1: 'idfs invasive disease', 2: 'interval idfs', 3: 'disease free', 4: 'ci confidence interval'}, 'score': {0: 0.7521, 1: 0.744, 2: 0.7281, 3: 0.4979, 4: 0.3221}}"
600,600,600,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,19,48,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
601,601,601,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,19,48,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
602,602,602,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,19,48,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
603,603,603,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,19,48,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
604,604,604,0.75,98.0,Kadcyla reduced the risk of recurrence  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,20,1,0,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'Kadcyla reduced the risk of recurrence  '}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'Kadcyla reduced the risk of recurrence  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla reduced the risk of recurrence  '}}",{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'Kadcyla reduced the risk of recurrence  '}}","   entity_group       value     score
0   Coreference     Kadcyla  0.906293
1  Sign_symptom  recurrence  0.993433","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'reduced risk recurrence', 1: 'kadcyla reduced risk', 2: 'reduced risk', 3: 'kadcyla reduced', 4: 'risk recurrence'}, 'score': {0: 0.8653, 1: 0.8547, 2: 0.8412, 3: 0.8357, 4: 0.7091}}"
605,605,605,0.75,98.0,by 50% vs trastuzumab,ConduitITC-Bold,20,-0.1700000017881393,8194925,20,1,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'by 50% vs trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'by 50% vs trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'by 50% vs trastuzumab'}}",{},{},"  entity_group        value     score
0    Lab_value         50 %  0.977016
1   Medication  trastuzumab  0.999849","[('trastuzumab', 'DRUG')]","{'keyword': {0: '50 vs trastuzumab', 1: '50 vs', 2: 'vs trastuzumab'}, 'score': {0: 0.8863, 1: 0.8215, 2: 0.8142}}"
606,606,606,0.944000005722046,32.0,IDFS at 40.9–41.1 months’ median follow-up,UniversSB-Bold,20,-0.2469999939203262,3355443,20,2,0,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'IDFS at 40.9–41.1 months’ median follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'IDFS at 40.9–41.1 months’ median follow-up'}}",{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: 'IDFS at 40.9–41.1 months’ median follow-up'}}",{},"           entity_group      value     score
0      Disease_disorder       IDFS  0.656999
1  Diagnostic_procedure       IDFS  0.861576
2             Lab_value  40.9–41.1  0.944411
3              Duration  40.9–41.1  0.978035
4              Duration     months  0.873750
5        Clinical_event  follow-up  0.998250",[],"{'keyword': {0: '41 months median', 1: '40 41 months', 2: 'median follow', 3: '40 41', 4: 'months median follow'}, 'score': {0: 0.8866, 1: 0.8272, 2: 0.7682, 3: 0.7551, 4: 0.6022}}"
607,607,607,0.9470000267028807,21.0,100,UniversSB-Light,4,-0.2329999953508377,5723991,20,3,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   100  0.996131",[],"{'keyword': {}, 'score': {}}"
608,608,608,0.9470000267028807,21.0,80,UniversSB-Light,4,-0.2329999953508377,5723991,20,4,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    80  0.999572",[],"{'keyword': {}, 'score': {}}"
609,609,609,0.9470000267028807,21.0,60,UniversSB-Light,4,-0.2329999953508377,5723991,20,5,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    60  0.999203",[],"{'keyword': {}, 'score': {}}"
610,610,610,0.9399999976158142,24.0,Hazard ratio = 0.50,UniversSB-Roman,4,-0.2339999973773956,8194925,20,6,0,"{'concept_id': {0: 'C0597342'}, 'canonical_name': {0: 'radiation hazard'}, 'aliases': {0: ['hazards radiation', 'radiation hazard']}, 'types': {0: ['T038']}, 'definition': {0: 'health hazard arising from exposure to ionizing radiation.'}, 'entity': {0: 'Hazard ratio'}, 'text': {0: 'Hazard ratio = 0.50'}}",{},{},{},{},"           entity_group         value     score
0  Diagnostic_procedure  Hazard ratio  0.999912
1             Lab_value          0.50  0.999924",[],"{'keyword': {0: 'ratio 50', 1: 'hazard ratio 50', 2: 'hazard ratio'}, 'score': {0: 0.7125, 1: 0.6789, 2: 0.6672}}"
611,611,611,0.9399999976158142,24.0,95% CI 0.39–0.64,UniversSB-Roman,4,-0.2339999973773956,8194925,20,6,1,"{'concept_id': {0: 'C1417638'}, 'canonical_name': {0: 'NDUFB6 gene'}, 'aliases': {0: ['NDUFB6', 'COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, B17 SUBUNIT', 'NADH-ubiquinone oxidoreductase beta subunit, 6', 'NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa', 'CI', 'NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 (17kD, B17)', 'NADH:ubiquinone oxidoreductase subunit B6', 'NADH-ubiquinone oxidoreductase B17 subunit', 'B17', 'complex I, mitochondrial respiratory chain, B17 subunit', 'NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 6', 'NDUFB6 gene']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'CI'}, 'text': {0: '95% CI 0.39–0.64'}}",{},{},{},{},"  entity_group              value     score
0    Lab_value  95 % CI 0.39–0.64  0.940124",[],"{'keyword': {0: 'ci 39 64', 1: '95 ci 39', 2: 'ci 39', 3: '39 64', 4: '95 ci'}, 'score': {0: 0.8169, 1: 0.755, 2: 0.7467, 3: 0.7323, 4: 0.6729}}"
612,612,612,0.9399999976158142,24.0,p<0.001,UniversSB-Roman,4,-0.2339999973773956,8194925,20,6,2,{},{},{},{},{},"  entity_group    value     score
0    Lab_value        p  0.670408
1    Lab_value  < 0.001  0.998420",[],"{'keyword': {}, 'score': {}}"
613,613,613,0.9399999976158142,20.0,3-year IDFS rate,UniversSB-Roman,4,-0.2339999973773956,5723991,20,7,0,{},{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: '3-year IDFS rate'}}",{},"           entity_group      value     score
0              Duration     3-year  0.990561
1  Diagnostic_procedure  IDFS rate  0.999856",[],"{'keyword': {0: 'year idfs rate', 1: 'idfs rate', 2: 'year idfs'}, 'score': {0: 0.8794, 1: 0.8787, 2: 0.7801}}"
614,614,614,0.9399999976158142,20.0,IDFS events at 40.9–41.1 ,UniversSB-Roman,4,-0.2339999973773956,5723991,20,8,0,{},{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: 'IDFS events at 40.9–41.1 '}}",{},"           entity_group      value     score
0      Disease_disorder       IDFS  0.702184
1  Detailed_description  40.9–41.1  0.982732",[],"{'keyword': {0: '40 41', 1: 'events 40 41', 2: 'events 40', 3: 'idfs events 40', 4: 'idfs events'}, 'score': {0: 0.7154, 1: 0.7146, 2: 0.6451, 3: 0.4739, 4: 0.3749}}"
615,615,615,0.9399999976158142,20.0,months’ follow-up,UniversSB-Roman,4,-0.2339999973773956,5723991,20,8,1,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'months’ follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'months’ follow-up'}}",{},{},{},"     entity_group      value     score
0  Clinical_event  follow-up  0.996701",[],"{'keyword': {0: 'months follow'}, 'score': {0: 0.9111}}"
616,616,616,0.9470000267028807,21.0,40,UniversSB-Light,4,-0.2329999953508377,5723991,20,9,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    40  0.998907",[],"{'keyword': {}, 'score': {}}"
617,617,617,0.9470000267028807,25.0,IDFS rate (%),UniversSB-Light,4,-0.2329999953508377,5658197,20,10,0,{},{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: 'IDFS rate (%)'}}",{},"           entity_group      value     score
0  Diagnostic_procedure  IDFS rate  0.999296",[],"{'keyword': {0: 'idfs rate'}, 'score': {0: 0.8831}}"
618,618,618,0.944000005722046,20.0,91 (12.2%) ,UniversSB-Medium,4,-0.2349999994039535,8194925,20,11,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    91  0.999551
1    Lab_value  12.2  0.665941",[],"{'keyword': {0: '91 12'}, 'score': {0: 0.7485}}"
619,619,619,0.944000005722046,20.0,Kadcyla,UniversSB-Medium,4,-0.2349999994039535,8194925,20,12,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
620,620,620,0.944000005722046,20.0,88.3%,UniversSB-Medium,4,-0.2349999994039535,8194925,20,13,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  88.3 %  0.999505",[],"{'keyword': {}, 'score': {}}"
621,621,621,0.944000005722046,20.0,77.0%,UniversSB-Medium,4,-0.2349999994039535,16162586,20,14,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  77.0 %  0.999817",[],"{'keyword': {}, 'score': {}}"
622,622,622,0.944000005722046,20.0,165 (22.2%),UniversSB-Medium,4,-0.2349999994039535,16162586,20,15,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   165  0.999504
1    Lab_value  22.2  0.836550",[],"{'keyword': {0: '165 22'}, 'score': {0: 0.6801}}"
623,623,623,0.944000005722046,20.0,Trastuzumab,UniversSB-Medium,4,-0.2349999994039535,16162586,20,15,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
624,624,624,0.9470000267028807,21.0,20,UniversSB-Light,4,-0.2329999953508377,5723991,20,16,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value    20  0.99851",[],"{'keyword': {}, 'score': {}}"
625,625,625,0.944000005722046,20.0,11.3% ,UniversSB-Medium,4,-0.2349999994039535,9013641,20,17,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  11.3 %  0.999733",[],"{'keyword': {}, 'score': {}}"
626,626,626,0.944000005722046,20.0,difference,UniversSB-Medium,4,-0.2349999994039535,9013641,20,17,1,{},{},{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  difference  0.979387",[],"{'keyword': {}, 'score': {}}"
627,627,627,0.9470000267028807,21.0,0,UniversSB-Light,4,-0.2329999953508377,5723991,20,18,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     0  0.998937",[],"{'keyword': {}, 'score': {}}"
628,628,628,0.9470000267028807,21.0,0,UniversSB-Light,4,-0.2329999953508377,5723991,20,19,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     0  0.998937",[],"{'keyword': {}, 'score': {}}"
629,629,629,0.9470000267028807,21.0,6,UniversSB-Light,4,-0.2329999953508377,5723991,20,19,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value     6  0.981812",[],"{'keyword': {}, 'score': {}}"
630,630,630,0.9470000267028807,21.0,12,UniversSB-Light,4,-0.2329999953508377,5723991,20,19,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    12  0.950751",[],"{'keyword': {}, 'score': {}}"
631,631,631,0.9470000267028807,21.0,18,UniversSB-Light,4,-0.2329999953508377,5723991,20,19,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    18  0.978542",[],"{'keyword': {}, 'score': {}}"
632,632,632,0.9470000267028807,21.0,24,UniversSB-Light,4,-0.2329999953508377,5723991,20,19,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    24  0.807345",[],"{'keyword': {}, 'score': {}}"
633,633,633,0.9470000267028807,21.0,30,UniversSB-Light,4,-0.2329999953508377,5723991,20,19,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value    30  0.998713",[],"{'keyword': {}, 'score': {}}"
634,634,634,0.9470000267028807,21.0,36,UniversSB-Light,4,-0.2329999953508377,5723991,20,20,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    36  0.994924",[],"{'keyword': {}, 'score': {}}"
635,635,635,0.9470000267028807,21.0,42,UniversSB-Light,4,-0.2329999953508377,5723991,20,20,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value    42  0.998523",[],"{'keyword': {}, 'score': {}}"
636,636,636,0.9470000267028807,21.0,48,UniversSB-Light,4,-0.2329999953508377,5723991,20,20,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value    48  0.99335",[],"{'keyword': {}, 'score': {}}"
637,637,637,0.9470000267028807,21.0,60,UniversSB-Light,4,-0.2329999953508377,5723991,20,20,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    60  0.999203",[],"{'keyword': {}, 'score': {}}"
638,638,638,0.9470000267028807,21.0,54,UniversSB-Light,4,-0.2329999953508377,5723991,20,20,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    54  0.996933",[],"{'keyword': {}, 'score': {}}"
639,639,639,0.9169999957084656,30.0,Reference:,ConduitITC-Bold,20,-0.2349999994039535,8194925,20,21,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
640,640,640,0.8830000162124634,22.0,1. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628.,MyriadPro-Light,4,-0.25,3355443,20,21,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'et al', 4: 'engl med 2019'}, 'score': {0: 0.8031, 1: 0.7251, 2: 0.7194, 3: 0.6642, 4: 0.6422}}"
641,641,641,0.9470000267028807,21.0,No. at risk,UniversSB-Light,4,-0.2329999953508377,5723991,20,22,0,"{'concept_id': {0: 'C2825539'}, 'canonical_name': {0: 'Cellular Telephone Number'}, 'aliases': {0: ['Cell Phone No.']}, 'types': {0: ['T170']}, 'definition': {0: 'The sequence of numbers or characters, that when dialed, connects to a particular cellular telephone.'}, 'entity': {0: 'No.'}, 'text': {0: 'No. at risk'}}",{},{},{},{},"  entity_group    value     score
0    Lab_value  at risk  0.947494",[],"{'keyword': {}, 'score': {}}"
642,642,642,0.9470000267028807,25.0,Months,UniversSB-Light,4,-0.2329999953508377,5658197,20,23,0,"{'concept_id': {0: 'C4745111'}, 'canonical_name': {0: '24 Months'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'A period of time of twenty-four months.'}, 'entity': {0: 'Months'}, 'text': {0: 'Months'}}",{},{},{},{},"  entity_group   value     score
0     Duration  Months  0.571131",[],"{'keyword': {}, 'score': {}}"
643,643,643,0.9470000267028807,21.0,Kadcyla,UniversSB-Light,4,-0.2329999953508377,5723991,20,24,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
644,644,644,0.9470000267028807,21.0,743,UniversSB-Light,4,-0.2329999953508377,5723991,20,25,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   743  0.949835",[],"{'keyword': {}, 'score': {}}"
645,645,645,0.9470000267028807,21.0,707,UniversSB-Light,4,-0.2329999953508377,5723991,20,26,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   707  0.863332",[],"{'keyword': {}, 'score': {}}"
646,646,646,0.9470000267028807,21.0,681,UniversSB-Light,4,-0.2329999953508377,5723991,20,27,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   681  0.973583",[],"{'keyword': {}, 'score': {}}"
647,647,647,0.9470000267028807,21.0,658,UniversSB-Light,4,-0.2329999953508377,5723991,20,28,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   658  0.982223",[],"{'keyword': {}, 'score': {}}"
648,648,648,0.9470000267028807,21.0,633,UniversSB-Light,4,-0.2329999953508377,5723991,20,29,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   633  0.948349",[],"{'keyword': {}, 'score': {}}"
649,649,649,0.9470000267028807,21.0,561,UniversSB-Light,4,-0.2329999953508377,5723991,20,30,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   561  0.949995",[],"{'keyword': {}, 'score': {}}"
650,650,650,0.9470000267028807,21.0,409,UniversSB-Light,4,-0.2329999953508377,5723991,20,31,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   409  0.954376",[],"{'keyword': {}, 'score': {}}"
651,651,651,0.9470000267028807,21.0,255,UniversSB-Light,4,-0.2329999953508377,5723991,20,32,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   255  0.999666",[],"{'keyword': {}, 'score': {}}"
652,652,652,0.9470000267028807,21.0,142,UniversSB-Light,4,-0.2329999953508377,5723991,20,33,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   142  0.996654",[],"{'keyword': {}, 'score': {}}"
653,653,653,0.9470000267028807,21.0,44,UniversSB-Light,4,-0.2329999953508377,5723991,20,34,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    44  0.991506",[],"{'keyword': {}, 'score': {}}"
654,654,654,0.9470000267028807,21.0,4,UniversSB-Light,4,-0.2329999953508377,5723991,20,35,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     4  0.999388",[],"{'keyword': {}, 'score': {}}"
655,655,655,0.9470000267028807,21.0,743,UniversSB-Light,4,-0.2329999953508377,5723991,20,36,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   743  0.949835",[],"{'keyword': {}, 'score': {}}"
656,656,656,0.9470000267028807,21.0,676,UniversSB-Light,4,-0.2329999953508377,5723991,20,37,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   676  0.968719",[],"{'keyword': {}, 'score': {}}"
657,657,657,0.9470000267028807,21.0,635,UniversSB-Light,4,-0.2329999953508377,5723991,20,38,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   635  0.939994",[],"{'keyword': {}, 'score': {}}"
658,658,658,0.9470000267028807,21.0,594,UniversSB-Light,4,-0.2329999953508377,5723991,20,39,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   594  0.994751",[],"{'keyword': {}, 'score': {}}"
659,659,659,0.9470000267028807,21.0,555,UniversSB-Light,4,-0.2329999953508377,5723991,20,40,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   555  0.997093",[],"{'keyword': {}, 'score': {}}"
660,660,660,0.9470000267028807,21.0,501,UniversSB-Light,4,-0.2329999953508377,5723991,20,41,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   501  0.932264",[],"{'keyword': {}, 'score': {}}"
661,661,661,0.9470000267028807,21.0,342,UniversSB-Light,4,-0.2329999953508377,5723991,20,42,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   342  0.847533",[],"{'keyword': {}, 'score': {}}"
662,662,662,0.9470000267028807,21.0,220,UniversSB-Light,4,-0.2329999953508377,5723991,20,43,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   220  0.999528",[],"{'keyword': {}, 'score': {}}"
663,663,663,0.9470000267028807,21.0,119,UniversSB-Light,4,-0.2329999953508377,5723991,20,44,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value   119  0.99204",[],"{'keyword': {}, 'score': {}}"
664,664,664,0.9470000267028807,21.0,38,UniversSB-Light,4,-0.2329999953508377,5723991,20,45,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    38  0.998779",[],"{'keyword': {}, 'score': {}}"
665,665,665,0.9470000267028807,21.0,4,UniversSB-Light,4,-0.2329999953508377,5723991,20,46,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     4  0.999388",[],"{'keyword': {}, 'score': {}}"
666,666,666,0.9470000267028807,21.0,Trastuzumab,UniversSB-Light,4,-0.2329999953508377,5723991,20,47,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
667,667,667,0.9470000267028807,19.0,Adapted from von Minckwitz et al. 2019.,UniversSB-Light,4,-0.2329999953508377,3355443,20,48,0,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
668,668,668,0.9470000267028807,19.0,"CI, confidence interval; IDFS, invasive disease-free survival.",UniversSB-Light,4,-0.2329999953508377,3355443,20,48,1,"{'concept_id': {0: 'C5401422'}, 'canonical_name': {0: 'Disease Free'}, 'aliases': {0: ['Disease Free', 'Disease-free']}, 'types': {0: ['T080']}, 'definition': {0: 'An indication that an individual shows no signs of having or carrying a disease.'}, 'entity': {0: 'disease-free survival'}, 'text': {0: 'CI, confidence interval; IDFS, invasive disease-free survival.'}}","{'concept_id': {0: 'C0242793'}, 'canonical_name': {0: 'Disease Free Survival'}, 'aliases': {0: ['Survival, Disease Free', 'Survival, Disease-Free', 'Disease-Free Survival']}, 'types': {0: ['T081']}, 'definition': {0: 'Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.'}, 'entity': {0: 'disease-free survival'}, 'text': {0: 'CI, confidence interval; IDFS, invasive disease-free survival.'}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'CI, confidence interval; IDFS, invasive disease-free survival.'}}",{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'free survival', 1: 'idfs invasive disease', 2: 'interval idfs', 3: 'disease free', 4: 'ci confidence interval'}, 'score': {0: 0.7521, 1: 0.744, 2: 0.7281, 3: 0.4979, 4: 0.3221}}"
669,669,669,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,20,49,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
670,670,670,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,20,49,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
671,671,671,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,20,49,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
672,672,672,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,20,49,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
673,673,673,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,20,50,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
674,674,674,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,20,50,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
675,675,675,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,20,50,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
676,676,676,0.9169999957084656,101.0,The risk of distant recurrence was  ,ConduitITC-Bold,20,-0.2349999994039535,8194925,21,1,0,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'distant recurrence'}, 'text': {0: 'The risk of distant recurrence was  '}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'distant recurrence'}, 'text': {0: 'The risk of distant recurrence was  '}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'distant recurrence'}, 'text': {0: 'The risk of distant recurrence was  '}}","           entity_group       value     score
0  Detailed_description     distant  0.999931
1          Sign_symptom  recurrence  0.999798",[],"{'keyword': {0: 'risk distant', 1: 'risk distant recurrence', 2: 'distant recurrence'}, 'score': {0: 0.8488, 1: 0.8431, 2: 0.809}}"
677,677,677,0.9169999957084656,101.0,lower with Kadcyla vs trastuzumab,ConduitITC-Bold,20,-0.2349999994039535,8194925,21,1,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'lower with Kadcyla vs trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'lower with Kadcyla vs trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'lower with Kadcyla vs trastuzumab'}}",{},{},"           entity_group        value     score
0  Detailed_description        lower  0.458509
1            Medication      Kadcyla  0.934418
2            Medication  trastuzumab  0.999772","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'lower kadcyla vs', 1: 'lower kadcyla', 2: 'kadcyla vs trastuzumab', 3: 'kadcyla vs', 4: 'vs trastuzumab'}, 'score': {0: 0.8629, 1: 0.8419, 2: 0.811, 3: 0.7717, 4: 0.7264}}"
678,678,678,0.9470000267028807,21.0,30,UniversSB-Light,4,-0.2329999953508377,5723991,21,2,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    30  0.998713",[],"{'keyword': {}, 'score': {}}"
679,679,679,0.9890000224113464,32.0,Site of first invasive disease event,MyriadPro-Bold,20,-0.25,3355443,21,3,0,"{'concept_id': {0: 'C1546778'}, 'canonical_name': {0: 'Specimen Source Codes - Site'}, 'aliases': {0: ['Site']}, 'types': {0: ['T170']}, 'definition': {0: None}, 'entity': {0: 'Site'}, 'text': {0: 'Site of first invasive disease event'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  invasive disease  0.615184
1           Coreference             event  0.648659",[],"{'keyword': {0: 'site invasive disease', 1: 'site invasive', 2: 'invasive disease event', 3: 'disease event', 4: 'invasive disease'}, 'score': {0: 0.8054, 1: 0.7506, 2: 0.7207, 3: 0.6548, 4: 0.6186}}"
680,680,680,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,21,3,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
681,681,681,0.8830000162124634,32.0,Kadcyla were free of distant recurrence vs ,MyriadPro-Light,4,-0.25,3355443,21,3,2,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'distant recurrence'}, 'text': {0: 'Kadcyla were free of distant recurrence vs '}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'distant recurrence'}, 'text': {0: 'Kadcyla were free of distant recurrence vs '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla were free of distant recurrence vs '}}",{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'distant recurrence'}, 'text': {0: 'Kadcyla were free of distant recurrence vs '}}","           entity_group       value     score
0  Diagnostic_procedure     Kadcyla  0.957612
1  Detailed_description     distant  0.999973
2          Sign_symptom  recurrence  0.974182
3  Detailed_description          vs  0.920929",[],"{'keyword': {0: 'free distant recurrence', 1: 'kadcyla free distant', 2: 'free distant', 3: 'kadcyla free', 4: 'recurrence vs'}, 'score': {0: 0.8805, 1: 0.8554, 2: 0.8284, 3: 0.7987, 4: 0.6649}}"
682,682,682,0.8830000162124634,32.0,83.0% of patients treated with trastuzumab ,MyriadPro-Light,4,-0.25,3355443,21,3,3,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: '83.0% of patients treated with trastuzumab '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: '83.0% of patients treated with trastuzumab '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: '83.0% of patients treated with trastuzumab '}}",{},{},"  entity_group                value     score
0    Lab_value               83.0 %  0.999578
1   Medication  treated trastuzumab  0.999846
2   Medication          trastuzumab  0.991171","[('trastuzumab', 'DRUG')]","{'keyword': {0: '83 patients', 1: '83 patients treated', 2: 'treated trastuzumab', 3: 'patients treated trastuzumab', 4: 'patients treated'}, 'score': {0: 0.8025, 1: 0.8014, 2: 0.6606, 3: 0.6557, 4: 0.6034}}"
683,683,683,0.8830000162124634,32.0,(unstratified hazard ratio 0.60; 95% Cl 0.45–,MyriadPro-Light,4,-0.25,3355443,21,3,4,"{'concept_id': {0: 'C0475212'}, 'canonical_name': {0: 'centiliter'}, 'aliases': {0: ['Centiliter (qualifier value)', 'centiliter (cL)', 'Centiliter', 'centilitre', 'cL', 'cl']}, 'types': {0: ['T081']}, 'definition': {0: 'The unit of volume equal to one hundredth of a liter or 10 milliliters. One centiliter is equivalent to 0.6102 cubic inch, or 0.338 U.S. fluid ounce.'}, 'entity': {0: 'Cl'}, 'text': {0: '(unstratified hazard ratio 0.60; 95% Cl 0.45–'}}",{},{},"{'concept_id': {0: 'C1150758'}, 'canonical_name': {0: '4-coumarate-CoA synthetase activity'}, 'aliases': {0: ['hydroxycinnamoyl CoA synthetase activity', '4-coumarate:CoA ligase activity', '4CL', 'p-hydroxycinnamic acid:CoA ligase activity', '4-coumaroyl-CoA synthetase activity', 'caffeolyl coenzyme A synthetase activity', '4-coumaroyl-CoA synthase activity', 'sinapoyl coenzyme A synthetase activity', 'feruloyl CoA ligase activity', '4-coumarate:coenzyme A ligase activity', 'hydroxycinnamate:CoA ligase activity', 'p-coumaryl coenzyme A synthetase activity', 'feruloyl coenzyme A synthetase activity', 'p-coumaryl-CoA ligase activity', '4-coumarate-CoA ligase activity', 'p-coumaryl-CoA synthetase activity', '4-coumaryl-CoA synthetase activity', '4-coumarate:CoA ligase (AMP-forming)', 'p-hydroxycinnamoyl coenzyme A synthetase activity', 'p-coumaroyl CoA ligase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + 4-coumarate + CoA = AMP + diphosphate + 4-coumaroyl-CoA. [EC:6.2.1.12]'}, 'entity': {0: 'Cl'}, 'text': {0: '(unstratified hazard ratio 0.60; 95% Cl 0.45–'}}",{},"           entity_group         value     score
0  Diagnostic_procedure  unstratified  0.999717
1  Diagnostic_procedure  hazard ratio  0.998547
2             Lab_value    0.60 0.45–  0.999892
3             Lab_value          0.60  0.880694
4             Lab_value            95  0.999889
5  Diagnostic_procedure            Cl  0.999413
6             Lab_value         0.45–  0.864769",[],"{'keyword': {0: 'unstratified hazard ratio', 1: 'ratio 60', 2: '95 cl 45', 3: 'cl 45', 4: 'hazard ratio'}, 'score': {0: 0.7825, 1: 0.7323, 2: 0.6576, 3: 0.6157, 4: 0.5298}}"
684,684,684,0.8830000162124634,32.0,0.79),MyriadPro-Light,4,-0.25,3355443,21,3,5,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
685,685,685,0.9470000267028807,20.0,22.2%,UniversSB-Light,4,-0.2329999953508377,5723991,21,4,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  22.2 %  0.999039",[],"{'keyword': {}, 'score': {}}"
686,686,686,0.9470000267028807,18.0,Kadcyla (n=743),UniversSB-Light,4,-0.2329999953508377,5723991,21,5,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}",{},{},"           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.969694",[],"{'keyword': {0: 'kadcyla 743'}, 'score': {0: 0.8404}}"
687,687,687,0.9470000267028807,18.0,Trastuzumab (n=743),UniversSB-Light,4,-0.2329999953508377,5723991,21,6,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999833","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab 743'}, 'score': {0: 0.8631}}"
688,688,688,0.9470000267028807,21.0,20,UniversSB-Light,4,-0.2329999953508377,5723991,21,7,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value    20  0.99851",[],"{'keyword': {}, 'score': {}}"
689,689,689,0.9470000267028807,20.0,15.9%,UniversSB-Light,4,-0.2329999953508377,5723991,21,8,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  15.9 %  0.999848",[],"{'keyword': {}, 'score': {}}"
690,690,690,0.9470000267028807,20.0,12.2%,UniversSB-Light,4,-0.2329999953508377,5723991,21,9,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  12.2 %  0.999785",[],"{'keyword': {}, 'score': {}}"
691,691,691,0.9470000267028807,20.0,10.5%,UniversSB-Light,4,-0.2329999953508377,5723991,21,10,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  10.5 %  0.999838",[],"{'keyword': {}, 'score': {}}"
692,692,692,0.9470000267028807,21.0,10,UniversSB-Light,4,-0.2329999953508377,5723991,21,11,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    10  0.987546",[],"{'keyword': {}, 'score': {}}"
693,693,693,0.9470000267028807,25.0,Proportion of patients (%),UniversSB-Light,4,-0.2329999953508377,5658197,21,12,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'Proportion of patients (%)'}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'Proportion of patients (%)'}}",{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  Proportion  0.977215",[],"{'keyword': {0: 'proportion patients'}, 'score': {0: 0.9134}}"
694,694,694,0.9470000267028807,20.0,5.9%,UniversSB-Light,4,-0.2329999953508377,5723991,21,13,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  5.9 %  0.999684",[],"{'keyword': {}, 'score': {}}"
695,695,695,0.9470000267028807,20.0,4.6%,UniversSB-Light,4,-0.2329999953508377,5723991,21,14,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  4.6 %  0.999555",[],"{'keyword': {}, 'score': {}}"
696,696,696,0.9470000267028807,20.0,4.3%,UniversSB-Light,4,-0.2329999953508377,5723991,21,15,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  4.3 %  0.999487",[],"{'keyword': {}, 'score': {}}"
697,697,697,0.9470000267028807,20.0,1.1%,UniversSB-Light,4,-0.2329999953508377,5723991,21,16,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  1.1 %  0.999533",[],"{'keyword': {}, 'score': {}}"
698,698,698,0.9470000267028807,20.0,0.4%,UniversSB-Light,4,-0.2329999953508377,5723991,21,17,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0.4 %  0.999798",[],"{'keyword': {}, 'score': {}}"
699,699,699,0.9470000267028807,20.0,1.3%,UniversSB-Light,4,-0.2329999953508377,5723991,21,17,1,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  1.3 %  0.999539",[],"{'keyword': {}, 'score': {}}"
700,700,700,0.9470000267028807,20.0,0.3%,UniversSB-Light,4,-0.2329999953508377,5723991,21,17,2,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0.3 %  0.999762","[('0.3', 'STRENGTH')]","{'keyword': {}, 'score': {}}"
701,701,701,0.9470000267028807,20.0,0.4%,UniversSB-Light,4,-0.2329999953508377,5723991,21,17,3,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0.4 %  0.999798",[],"{'keyword': {}, 'score': {}}"
702,702,702,0.9470000267028807,21.0,0,UniversSB-Light,4,-0.2329999953508377,5723991,21,18,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     0  0.998937",[],"{'keyword': {}, 'score': {}}"
703,703,703,0.9470000267028807,21.0,0,UniversSB-Light,4,-0.2329999953508377,5723991,21,19,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     0  0.998937",[],"{'keyword': {}, 'score': {}}"
704,704,704,0.9470000267028807,21.0,Any invasive ,UniversSB-Light,4,-0.2329999953508377,5723991,21,20,0,"{'concept_id': {0: 'C1334278'}, 'canonical_name': {0: 'Invasive Lesion'}, 'aliases': {0: ['Invasive Lesion']}, 'types': {0: ['T033']}, 'definition': {0: 'A malignant cellular population that has increased in size and infiltrates the surrounding tissues.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Any invasive '}}","{'concept_id': {0: 'C2936533'}, 'canonical_name': {0: 'Invasive Species'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Non-native species that threaten ecosystems, habitats, or other species and are likely to cause economic or environmental harm or harm to human health.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Any invasive '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'Any invasive '}}",{},"           entity_group     value     score
0  Detailed_description  invasive  0.999601",[],"{'keyword': {}, 'score': {}}"
705,705,705,0.9470000267028807,21.0,disease event,UniversSB-Light,4,-0.2329999953508377,5723991,21,20,1,"{'concept_id': {0: 'C0878681'}, 'canonical_name': {0: ""Dent's disease""}, 'aliases': {0: ['NEPHROLITHIASIS, X-LINKED RECESSIVE', 'Dent disease', 'X-Linked Recessive Hypophosphatemic Rickets', ""Dent's Disease"", 'Disease, Dent', 'X-linked recessive nephrolithiasis', 'Renal Fanconi syndrome with nephrocalcinosis and renal stones', 'Dent syndrome', 'X-linked recessive hypercalciuric hypophosphatemic rickets', 'Dents Disease', 'Low-molecular-weight proteinuria with hypercalciuria and nephrocalcinosis', ""Disease, Dent's"", 'Dent Disease', ""Dent's disease"", 'Disease, Dents', ""Dent's disease (disorder)""]}, 'types': {0: ['T047']}, 'definition': {0: 'X-linked recessive NEPHROLITHIASIS characterized by HYPERCALCIURIA; HYPOPHOSPHATEMIA; NEPHROCALCINOSIS; and PROTEINURIA. It is associated with mutations in the voltage-gated chloride channel, CLC-5 (Dent Disease I). Another group of mutations associated with this disease is in phosphatidylinositol 4,5-bisphosphate-5-phosphatase gene.'}, 'entity': {0: 'disease event'}, 'text': {0: 'disease event'}}","{'concept_id': {0: 'C0029896'}, 'canonical_name': {0: 'Otorhinolaryngologic Diseases'}, 'aliases': {0: ['Diseases, Otorhinolaryngological', 'Otorhinolaryngological Disease', 'ENT Disease', 'Otolaryngological Diseases', 'Diseases, Otolaryngologic', 'Disease, Otorhinolaryngological', 'Otolaryngologic Diseases', 'Disease, Otorhinolaryngologic', 'Otolaryngological Disease', 'Disease, Otolaryngological', 'ENT Diseases', 'Otorhinolaryngologic Disease', 'Otolaryngologic Disease', 'Disease, Otolaryngologic', 'Diseases, Otolaryngological', 'Disease, ENT', 'Diseases, Otorhinolaryngologic', 'Diseases, ENT', 'Otorhinolaryngological Diseases']}, 'types': {0: ['T047']}, 'definition': {0: 'Pathological processes of the ear, the nose, and the throat, also known as the ENT diseases.'}, 'entity': {0: 'disease event'}, 'text': {0: 'disease event'}}",{},{},{},"           entity_group    value     score
0  Detailed_description  disease  0.989883
1           Coreference    event  0.532086",[],"{'keyword': {0: 'disease event'}, 'score': {0: 1.0}}"
706,706,706,0.9470000267028807,21.0,Distant,UniversSB-Light,4,-0.2329999953508377,5723991,21,20,2,"{'concept_id': {0: 'C5441917'}, 'canonical_name': {0: 'Distant Metastasis'}, 'aliases': {0: ['Distant Cancer', 'Distant Metastasis', 'Distant metastasis']}, 'types': {0: ['T046']}, 'definition': {0: 'A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.'}, 'entity': {0: 'Distant'}, 'text': {0: 'Distant'}}",{},{},{},{},"           entity_group    value     score
0  Detailed_description  Distant  0.997582",[],"{'keyword': {}, 'score': {}}"
707,707,707,0.9470000267028807,21.0,recurrence,UniversSB-Light,4,-0.2329999953508377,5723991,21,20,3,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","   entity_group       value     score
0  Sign_symptom  recurrence  0.998374",[],"{'keyword': {}, 'score': {}}"
708,708,708,0.9470000267028807,21.0,CNS,UniversSB-Light,4,-0.2329999953508377,5723991,21,20,4,"{'concept_id': {0: 'C3899750'}, 'canonical_name': {0: 'CNS1 (classification)'}, 'aliases': {0: ['CNS1', 'CNS 1']}, 'types': {0: ['T185']}, 'definition': {0: 'The status of central nervous system leukemia at diagnosis, where there is an absence of blasts on a cerebral spinal fluid cytospin preparation, regardless of the number of white blood cells.'}, 'entity': {0: 'CNS'}, 'text': {0: 'CNS'}}","{'concept_id': {0: 'C0007682'}, 'canonical_name': {0: 'Central Nervous System Disorder'}, 'aliases': {0: ['CNS Disease', 'CNS Diseases', 'Central Nervous System Disease', 'Central Nervous System Disorders', 'Central Nervous System Diseases']}, 'types': {0: ['T047']}, 'definition': {0: 'Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.'}, 'entity': {0: 'CNS'}, 'text': {0: 'CNS'}}",{},{},"{'concept_id': {0: 'C0349606'}, 'canonical_name': {0: 'CNS cyst'}, 'aliases': {0: ['Central nervous system cyst', 'Cyst of the central nervous system']}, 'types': {0: ['T047']}, 'definition': {0: 'Congenital or acquired cysts of the brain, spinal cord, or meninges which may remain stable in size or undergo progressive enlargement.'}, 'entity': {0: 'CNS'}, 'text': {0: 'CNS'}}","           entity_group value   score
0  Biological_structure   CNS  0.9953",[],"{'keyword': {}, 'score': {}}"
709,709,709,0.9470000267028807,21.0,recurrence,UniversSB-Light,4,-0.2329999953508377,5723991,21,20,5,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","   entity_group       value     score
0  Sign_symptom  recurrence  0.998374",[],"{'keyword': {}, 'score': {}}"
710,710,710,0.9470000267028807,21.0,Locoregional,UniversSB-Light,4,-0.2329999953508377,5723991,21,20,6,{},{},{},{},{},"           entity_group         value     score
0  Detailed_description  Locoregional  0.994198",[],"{'keyword': {}, 'score': {}}"
711,711,711,0.9470000267028807,21.0,recurrence,UniversSB-Light,4,-0.2329999953508377,5723991,21,20,7,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","   entity_group       value     score
0  Sign_symptom  recurrence  0.998374",[],"{'keyword': {}, 'score': {}}"
712,712,712,0.9470000267028807,21.0,Contralateral,UniversSB-Light,4,-0.2329999953508377,5723991,21,20,8,"{'concept_id': {0: 'C0441988'}, 'canonical_name': {0: 'Contralateral'}, 'aliases': {0: ['contralateral', 'Contralateral', 'Contralateral (qualifier value)']}, 'types': {0: ['T082']}, 'definition': {0: 'On or relating to the opposite side of the body.'}, 'entity': {0: 'Contralateral'}, 'text': {0: 'Contralateral'}}",{},{},{},{},"           entity_group          value     score
0  Detailed_description  Contralateral  0.999619",[],"{'keyword': {}, 'score': {}}"
713,713,713,0.9470000267028807,21.0,breast cancer,UniversSB-Light,4,-0.2329999953508377,5723991,21,20,9,"{'concept_id': {0: 'C0376571'}, 'canonical_name': {0: 'BRCA1 gene'}, 'aliases': {0: ['BRCA1, DNA Repair Associated Gene', 'brca1', 'Gene, BRCA1', 'FANCS', 'BRCA1 gene', 'BRCA1 Gene', 'BRCA1 DNA REPAIR-ASSOCIATED PROTEIN', 'brca1 gene', 'Fanconi anemia, complementation group S', 'BRCA1/BRCA2-containing complex, subunit 1', 'Genes, BRCA1', 'BRCA1 DNA repair associated', 'RNF53', 'BRCC1', 'BRCA1', 'Breast Cancer 1, Early Onset Gene', 'BREAST CANCER 1 GENE', 'breast cancer 1', 'PPP1R53', 'brca 1 gene', 'breast cancer 1, early onset', 'BRCA1 Genes', 'protein phosphatase 1, regulatory subunit 53']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.'}, 'entity': {0: 'breast cancer'}, 'text': {0: 'breast cancer'}}","{'concept_id': {0: 'C0294028'}, 'canonical_name': {0: 'Breast Cancer 2 Protein'}, 'aliases': {0: ['Fanconi Anemia Complementation Group D1 Protein', 'Fanconi Anemia Group D1 Protein', 'FANCD1 Protein', 'BRCA2 Protein', 'Fanconi Anemia Group D1 Complementing Protein', 'BRCA2 Gene Product', 'Breast Cancer 2 Gene Product']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)'}, 'entity': {0: 'breast cancer'}, 'text': {0: 'breast cancer'}}",{},{},"{'concept_id': {0: 'C0006826'}, 'canonical_name': {0: 'Cancer'}, 'aliases': {0: []}, 'types': {0: ['T191']}, 'definition': {0: 'A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.'}, 'entity': {0: 'breast cancer'}, 'text': {0: 'breast cancer'}}","       entity_group          value     score
0  Disease_disorder  breast cancer  0.981334",[],"{'keyword': {0: 'breast cancer'}, 'score': {0: 1.0}}"
714,714,714,0.9470000267028807,21.0,Death without,UniversSB-Light,4,-0.2329999953508377,5723991,21,21,0,"{'concept_id': {0: 'C1546949'}, 'canonical_name': {0: 'Event Consequence - Death'}, 'aliases': {0: ['Death']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'Death'}, 'text': {0: 'Death without'}}","{'concept_id': {0: 'C0038644'}, 'canonical_name': {0: 'Death, Crib'}, 'aliases': {0: ['Sudden Infant Death Syndrome', 'Death, Sudden Infant', 'Cot Deaths', 'SID', 'Cot Death', 'Sudden Infant Death', 'SIDS', 'Infant Death, Sudden', 'Crib Death', 'Death, Cot']}, 'types': {0: ['T047']}, 'definition': {0: 'The abrupt and unexplained death of an apparently healthy infant under one year of age, remaining unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of the clinical history. (Pediatr Pathol 1991 Sep-Oct;11(5):677-84)'}, 'entity': {0: 'Death'}, 'text': {0: 'Death without'}}",{},"{'concept_id': {0: 'C2754100'}, 'canonical_name': {0: 'neuron death'}, 'aliases': {0: ['neuronal cell death', 'neuron cell death']}, 'types': {0: ['T043']}, 'definition': {0: 'The process of cell death in a neuron. [GOC:BHF, GOC:mah]'}, 'entity': {0: 'Death'}, 'text': {0: 'Death without'}}","{'concept_id': {0: 'C0015927'}, 'canonical_name': {0: 'Foetal death'}, 'aliases': {0: ['Fetal demise', 'Prenatal death', 'Fetal death', 'Intrauterine death']}, 'types': {0: ['T046']}, 'definition': {0: 'Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.'}, 'entity': {0: 'Death'}, 'text': {0: 'Death without'}}","           entity_group    value     score
0               Outcome    Death  0.726540
1  Detailed_description  without  0.966122",[],"{'keyword': {}, 'score': {}}"
715,715,715,0.9470000267028807,21.0,previous event,UniversSB-Light,4,-0.2329999953508377,5723991,21,21,1,"{'concept_id': {0: 'C1708728'}, 'canonical_name': {0: 'Event Log'}, 'aliases': {0: ['Log', 'Event Log']}, 'types': {0: ['T170']}, 'definition': {0: 'A written record of events.'}, 'entity': {0: 'event'}, 'text': {0: 'previous event'}}",{},{},{},{},"           entity_group     value     score
0  Detailed_description  previous  0.511909",[],"{'keyword': {0: 'previous event'}, 'score': {0: 1.0}}"
716,716,716,0.8830000162124634,19.0,Adapted from von Minckwitz et al. 2019.,MyriadPro-Light,4,-0.25,3355443,21,22,0,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
717,717,717,0.8830000162124634,19.0,"CI, confidence interval; CNS, central nervous system.",MyriadPro-Light,4,-0.25,3355443,21,22,1,"{'concept_id': {0: 'C1268141'}, 'canonical_name': {0: 'Central nervous system part'}, 'aliases': {0: ['Central nervous system part (body structure)', 'Central Nervous System Part']}, 'types': {0: ['T023']}, 'definition': {0: 'Any component of the nervous system that consists of the brain, spinal cord, and meninges.'}, 'entity': {0: 'central nervous system'}, 'text': {0: 'CI, confidence interval; CNS, central nervous system.'}}","{'concept_id': {0: 'C0007682'}, 'canonical_name': {0: 'Central Nervous System Disorder'}, 'aliases': {0: ['CNS Disease', 'CNS Diseases', 'Central Nervous System Disease', 'Central Nervous System Disorders', 'Central Nervous System Diseases']}, 'types': {0: ['T047']}, 'definition': {0: 'Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.'}, 'entity': {0: 'central nervous system'}, 'text': {0: 'CI, confidence interval; CNS, central nervous system.'}}",{},"{'concept_id': {0: 'C1160339'}, 'canonical_name': {0: 'central nervous system development'}, 'aliases': {0: ['CNS development']}, 'types': {0: ['T042']}, 'definition': {0: 'The process whose specific outcome is the progression of the central nervous system over time, from its formation to the mature structure. The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain and spinal cord. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord. [GOC:bf, GOC:jid, ISBN:0582227089]'}, 'entity': {0: 'central nervous system'}, 'text': {0: 'CI, confidence interval; CNS, central nervous system.'}}","{'concept_id': {0: 'C4021765'}, 'canonical_name': {0: 'Morphological central nervous system abnormality'}, 'aliases': {0: ['Morphological abnormality of the central nervous system', 'Morphological abnormality of the CNS', 'Abnormality of the central nervous system']}, 'types': {0: ['T190']}, 'definition': {0: 'A structural abnormality of the central nervous system. [HPO:probinson]'}, 'entity': {0: 'central nervous system'}, 'text': {0: 'CI, confidence interval; CNS, central nervous system.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'cns central nervous', 1: 'central nervous', 2: 'confidence interval cns', 3: 'cns central', 4: 'ci confidence interval'}, 'score': {0: 0.7781, 1: 0.7661, 2: 0.7015, 3: 0.587, 4: 0.4333}}"
718,718,718,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,21,23,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
719,719,719,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,21,23,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
720,720,720,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,21,23,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
721,721,721,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,21,23,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
722,722,722,0.75,101.0,The risk of distant recurrence was  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,22,1,0,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'distant recurrence'}, 'text': {0: 'The risk of distant recurrence was  '}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'distant recurrence'}, 'text': {0: 'The risk of distant recurrence was  '}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'distant recurrence'}, 'text': {0: 'The risk of distant recurrence was  '}}","           entity_group       value     score
0  Detailed_description     distant  0.999931
1          Sign_symptom  recurrence  0.999798",[],"{'keyword': {0: 'risk distant', 1: 'risk distant recurrence', 2: 'distant recurrence'}, 'score': {0: 0.8488, 1: 0.8431, 2: 0.809}}"
723,723,723,0.75,101.0,lower with Kadcyla vs trastuzumab,ConduitITC-Bold,20,-0.1700000017881393,8194925,22,1,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'lower with Kadcyla vs trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'lower with Kadcyla vs trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'lower with Kadcyla vs trastuzumab'}}",{},{},"           entity_group        value     score
0  Detailed_description        lower  0.458509
1            Medication      Kadcyla  0.934418
2            Medication  trastuzumab  0.999772","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'lower kadcyla vs', 1: 'lower kadcyla', 2: 'kadcyla vs trastuzumab', 3: 'kadcyla vs', 4: 'vs trastuzumab'}, 'score': {0: 0.8629, 1: 0.8419, 2: 0.811, 3: 0.7717, 4: 0.7264}}"
724,724,724,0.9470000267028807,21.0,30,UniversSB-Light,4,-0.2329999953508377,5723991,22,2,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    30  0.998713",[],"{'keyword': {}, 'score': {}}"
725,725,725,0.944000005722046,32.0,Site of first invasive disease event,UniversSB-Bold,20,-0.2469999939203262,3355443,22,3,0,"{'concept_id': {0: 'C1546778'}, 'canonical_name': {0: 'Specimen Source Codes - Site'}, 'aliases': {0: ['Site']}, 'types': {0: ['T170']}, 'definition': {0: None}, 'entity': {0: 'Site'}, 'text': {0: 'Site of first invasive disease event'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  invasive disease  0.615184
1           Coreference             event  0.648659",[],"{'keyword': {0: 'site invasive disease', 1: 'site invasive', 2: 'invasive disease event', 3: 'disease event', 4: 'invasive disease'}, 'score': {0: 0.8054, 1: 0.7506, 2: 0.7207, 3: 0.6548, 4: 0.6186}}"
726,726,726,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,22,3,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
727,727,727,0.9470000267028807,32.0,with Kadcyla were free of distant ,UniversSB-Light,4,-0.2329999953508377,3355443,22,3,2,"{'concept_id': {0: 'C5441917'}, 'canonical_name': {0: 'Distant Metastasis'}, 'aliases': {0: ['Distant Cancer', 'Distant Metastasis', 'Distant metastasis']}, 'types': {0: ['T046']}, 'definition': {0: 'A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.'}, 'entity': {0: 'distant'}, 'text': {0: 'with Kadcyla were free of distant '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'with Kadcyla were free of distant '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'with Kadcyla were free of distant '}}",{},{},"           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.791369
1  Detailed_description  distant  0.999780","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla free distant', 1: 'kadcyla free', 2: 'free distant'}, 'score': {0: 0.8724, 1: 0.8291, 2: 0.821}}"
728,728,728,0.9470000267028807,32.0,recurrence vs 83.0% of patients treated ,UniversSB-Light,4,-0.2329999953508377,3355443,22,3,3,"{'concept_id': {0: 'C1292734'}, 'canonical_name': {0: 'Treatment intent'}, 'aliases': {0: ['treat', 'Treatment intent (situation)', 'treats', 'Treatment Intent', 'Intent To Treat', 'Treats (attribute)', 'Treats', 'Treatment intent']}, 'types': {0: ['T169']}, 'definition': {0: 'The use of a particular medical device, medication or treatment to treat a pre-existing disease or condition.'}, 'entity': {0: 'treated'}, 'text': {0: 'recurrence vs 83.0% of patients treated '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'recurrence vs 83.0% of patients treated '}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence vs 83.0% of patients treated '}}","     entity_group       value     score
0    Sign_symptom  recurrence  0.999960
1       Lab_value      83.0 %  0.996718
2  Clinical_event     treated  0.826606",[],"{'keyword': {0: 'recurrence vs 83', 1: 'vs 83 patients', 2: 'recurrence vs', 3: '83 patients', 4: 'patients treated'}, 'score': {0: 0.886, 1: 0.7596, 2: 0.7291, 3: 0.6562, 4: 0.6464}}"
729,729,729,0.9470000267028807,32.0,with trastuzumab (unstratified hazard ,UniversSB-Light,4,-0.2329999953508377,3355443,22,3,4,"{'concept_id': {0: 'C1550593'}, 'canonical_name': {0: 'injury hazard - EntityRisk'}, 'aliases': {0: ['injury hazard']}, 'types': {0: ['T078']}, 'definition': {0: '<p>Material is solid and sharp (e.g., cannulas). Dispose in hard container.</p>'}, 'entity': {0: 'hazard'}, 'text': {0: 'with trastuzumab (unstratified hazard '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'with trastuzumab (unstratified hazard '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'with trastuzumab (unstratified hazard '}}",{},{},"           entity_group                     value     score
0            Medication  trastuzumab unstratified  0.999859
1            Medication               trastuzumab  0.981955
2  Detailed_description              unstratified  0.999869
3          Sign_symptom                    hazard  0.992923","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab unstratified hazard', 1: 'trastuzumab unstratified', 2: 'unstratified hazard'}, 'score': {0: 0.8549, 1: 0.7942, 2: 0.6939}}"
730,730,730,0.9470000267028807,32.0,ratio 0.60; 95% Cl 0.45–0.79),UniversSB-Light,4,-0.2329999953508377,3355443,22,3,5,"{'concept_id': {0: 'C1264675'}, 'canonical_name': {0: 'Time ratio'}, 'aliases': {0: ['TRTO', 'Time Ratio', 'Time ratio (property) (qualifier value)', 'Time ratio (property)', 'TRto']}, 'types': {0: ['T081']}, 'definition': {0: 'The ratio of the length of time for one event and the length of time for another event.'}, 'entity': {0: 'ratio'}, 'text': {0: 'ratio 0.60; 95% Cl 0.45–0.79)'}}","{'concept_id': {0: 'C0036893'}, 'canonical_name': {0: 'Sex Ratio'}, 'aliases': {0: ['Ratios, Sex', 'Sex Ratios', 'Ratio, Sex']}, 'types': {0: ['T081']}, 'definition': {0: 'The number of males per 100 females.'}, 'entity': {0: 'ratio'}, 'text': {0: 'ratio 0.60; 95% Cl 0.45–0.79)'}}",{},{},"{'concept_id': {0: 'C5539803'}, 'canonical_name': {0: 'Abnormal RV/TLC ratio'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Any deviation from the normal ratio of residual volume (RV) to total lung capacity (TLC) on pulmonary function testing. RV is the amount of air remaining aftermaximal expiration and TLC is the total amount of air in theungs at full inspiration. These volumes cannot be determined by spirometry, but can be measured by inert gas dilution, nitrogen washout, and body plethysmography. [PMID:12934788]'}, 'entity': {0: 'ratio'}, 'text': {0: 'ratio 0.60; 95% Cl 0.45–0.79)'}}","           entity_group  value     score
0  Diagnostic_procedure  ratio  0.998174
1             Lab_value   0.60  0.984684
2             Lab_value     95  0.996119
3  Diagnostic_procedure     Cl  0.990715",[],"{'keyword': {0: 'ratio 60 95', 1: '60 95', 2: 'ratio 60', 3: '95 cl 45', 4: 'cl 45'}, 'score': {0: 0.7978, 1: 0.7523, 2: 0.7518, 3: 0.707, 4: 0.7026}}"
731,731,731,0.9470000267028807,20.0,22.2%,UniversSB-Light,4,-0.2329999953508377,5723991,22,4,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  22.2 %  0.999039",[],"{'keyword': {}, 'score': {}}"
732,732,732,0.9470000267028807,18.0,Kadcyla (n=743),UniversSB-Light,4,-0.2329999953508377,5723991,22,5,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}",{},{},"           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.969694",[],"{'keyword': {0: 'kadcyla 743'}, 'score': {0: 0.8404}}"
733,733,733,0.9470000267028807,18.0,Trastuzumab (n=743),UniversSB-Light,4,-0.2329999953508377,5723991,22,6,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999833","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab 743'}, 'score': {0: 0.8631}}"
734,734,734,0.9470000267028807,21.0,20,UniversSB-Light,4,-0.2329999953508377,5723991,22,7,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value    20  0.99851",[],"{'keyword': {}, 'score': {}}"
735,735,735,0.9470000267028807,20.0,15.9%,UniversSB-Light,4,-0.2329999953508377,5723991,22,8,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  15.9 %  0.999848",[],"{'keyword': {}, 'score': {}}"
736,736,736,0.9470000267028807,20.0,12.2%,UniversSB-Light,4,-0.2329999953508377,5723991,22,9,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  12.2 %  0.999785",[],"{'keyword': {}, 'score': {}}"
737,737,737,0.9470000267028807,20.0,10.5%,UniversSB-Light,4,-0.2329999953508377,5723991,22,10,0,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  10.5 %  0.999838",[],"{'keyword': {}, 'score': {}}"
738,738,738,0.9470000267028807,21.0,10,UniversSB-Light,4,-0.2329999953508377,5723991,22,11,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value    10  0.987546",[],"{'keyword': {}, 'score': {}}"
739,739,739,0.9470000267028807,25.0,Proportion of patients (%),UniversSB-Light,4,-0.2329999953508377,5658197,22,12,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'Proportion of patients (%)'}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'Proportion of patients (%)'}}",{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  Proportion  0.977215",[],"{'keyword': {0: 'proportion patients'}, 'score': {0: 0.9134}}"
740,740,740,0.9470000267028807,20.0,5.9%,UniversSB-Light,4,-0.2329999953508377,5723991,22,13,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  5.9 %  0.999684",[],"{'keyword': {}, 'score': {}}"
741,741,741,0.9470000267028807,20.0,4.6%,UniversSB-Light,4,-0.2329999953508377,5723991,22,14,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  4.6 %  0.999555",[],"{'keyword': {}, 'score': {}}"
742,742,742,0.9470000267028807,20.0,4.3%,UniversSB-Light,4,-0.2329999953508377,5723991,22,15,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  4.3 %  0.999487",[],"{'keyword': {}, 'score': {}}"
743,743,743,0.9470000267028807,20.0,1.1%,UniversSB-Light,4,-0.2329999953508377,5723991,22,16,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  1.1 %  0.999533",[],"{'keyword': {}, 'score': {}}"
744,744,744,0.9470000267028807,20.0,0.4%,UniversSB-Light,4,-0.2329999953508377,5723991,22,17,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0.4 %  0.999798",[],"{'keyword': {}, 'score': {}}"
745,745,745,0.9470000267028807,20.0,1.3%,UniversSB-Light,4,-0.2329999953508377,5723991,22,17,1,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  1.3 %  0.999539",[],"{'keyword': {}, 'score': {}}"
746,746,746,0.9470000267028807,20.0,0.3%,UniversSB-Light,4,-0.2329999953508377,5723991,22,17,2,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0.3 %  0.999762","[('0.3', 'STRENGTH')]","{'keyword': {}, 'score': {}}"
747,747,747,0.9470000267028807,20.0,0.4%,UniversSB-Light,4,-0.2329999953508377,5723991,22,17,3,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0.4 %  0.999798",[],"{'keyword': {}, 'score': {}}"
748,748,748,0.9169999957084656,30.0,Reference:,ConduitITC-Bold,20,-0.2349999994039535,8194925,22,18,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
749,749,749,0.8830000162124634,22.0,1. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628. ,MyriadPro-Light,4,-0.25,3355443,22,18,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'et al', 4: 'engl med 2019'}, 'score': {0: 0.8031, 1: 0.7251, 2: 0.7194, 3: 0.6642, 4: 0.6422}}"
750,750,750,0.9470000267028807,21.0,0,UniversSB-Light,4,-0.2329999953508377,5723991,22,19,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     0  0.998937",[],"{'keyword': {}, 'score': {}}"
751,751,751,0.9470000267028807,21.0,0,UniversSB-Light,4,-0.2329999953508377,5723991,22,20,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     0  0.998937",[],"{'keyword': {}, 'score': {}}"
752,752,752,0.9470000267028807,21.0,Any invasive ,UniversSB-Light,4,-0.2329999953508377,5723991,22,21,0,"{'concept_id': {0: 'C1334278'}, 'canonical_name': {0: 'Invasive Lesion'}, 'aliases': {0: ['Invasive Lesion']}, 'types': {0: ['T033']}, 'definition': {0: 'A malignant cellular population that has increased in size and infiltrates the surrounding tissues.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Any invasive '}}","{'concept_id': {0: 'C2936533'}, 'canonical_name': {0: 'Invasive Species'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Non-native species that threaten ecosystems, habitats, or other species and are likely to cause economic or environmental harm or harm to human health.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Any invasive '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'Any invasive '}}",{},"           entity_group     value     score
0  Detailed_description  invasive  0.999601",[],"{'keyword': {}, 'score': {}}"
753,753,753,0.9470000267028807,21.0,disease event,UniversSB-Light,4,-0.2329999953508377,5723991,22,21,1,"{'concept_id': {0: 'C0878681'}, 'canonical_name': {0: ""Dent's disease""}, 'aliases': {0: ['NEPHROLITHIASIS, X-LINKED RECESSIVE', 'Dent disease', 'X-Linked Recessive Hypophosphatemic Rickets', ""Dent's Disease"", 'Disease, Dent', 'X-linked recessive nephrolithiasis', 'Renal Fanconi syndrome with nephrocalcinosis and renal stones', 'Dent syndrome', 'X-linked recessive hypercalciuric hypophosphatemic rickets', 'Dents Disease', 'Low-molecular-weight proteinuria with hypercalciuria and nephrocalcinosis', ""Disease, Dent's"", 'Dent Disease', ""Dent's disease"", 'Disease, Dents', ""Dent's disease (disorder)""]}, 'types': {0: ['T047']}, 'definition': {0: 'X-linked recessive NEPHROLITHIASIS characterized by HYPERCALCIURIA; HYPOPHOSPHATEMIA; NEPHROCALCINOSIS; and PROTEINURIA. It is associated with mutations in the voltage-gated chloride channel, CLC-5 (Dent Disease I). Another group of mutations associated with this disease is in phosphatidylinositol 4,5-bisphosphate-5-phosphatase gene.'}, 'entity': {0: 'disease event'}, 'text': {0: 'disease event'}}","{'concept_id': {0: 'C0029896'}, 'canonical_name': {0: 'Otorhinolaryngologic Diseases'}, 'aliases': {0: ['Diseases, Otorhinolaryngological', 'Otorhinolaryngological Disease', 'ENT Disease', 'Otolaryngological Diseases', 'Diseases, Otolaryngologic', 'Disease, Otorhinolaryngological', 'Otolaryngologic Diseases', 'Disease, Otorhinolaryngologic', 'Otolaryngological Disease', 'Disease, Otolaryngological', 'ENT Diseases', 'Otorhinolaryngologic Disease', 'Otolaryngologic Disease', 'Disease, Otolaryngologic', 'Diseases, Otolaryngological', 'Disease, ENT', 'Diseases, Otorhinolaryngologic', 'Diseases, ENT', 'Otorhinolaryngological Diseases']}, 'types': {0: ['T047']}, 'definition': {0: 'Pathological processes of the ear, the nose, and the throat, also known as the ENT diseases.'}, 'entity': {0: 'disease event'}, 'text': {0: 'disease event'}}",{},{},{},"           entity_group    value     score
0  Detailed_description  disease  0.989883
1           Coreference    event  0.532086",[],"{'keyword': {0: 'disease event'}, 'score': {0: 1.0}}"
754,754,754,0.9470000267028807,21.0,Distant,UniversSB-Light,4,-0.2329999953508377,5723991,22,21,2,"{'concept_id': {0: 'C5441917'}, 'canonical_name': {0: 'Distant Metastasis'}, 'aliases': {0: ['Distant Cancer', 'Distant Metastasis', 'Distant metastasis']}, 'types': {0: ['T046']}, 'definition': {0: 'A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.'}, 'entity': {0: 'Distant'}, 'text': {0: 'Distant'}}",{},{},{},{},"           entity_group    value     score
0  Detailed_description  Distant  0.997582",[],"{'keyword': {}, 'score': {}}"
755,755,755,0.9470000267028807,21.0,recurrence,UniversSB-Light,4,-0.2329999953508377,5723991,22,21,3,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","   entity_group       value     score
0  Sign_symptom  recurrence  0.998374",[],"{'keyword': {}, 'score': {}}"
756,756,756,0.9470000267028807,21.0,CNS,UniversSB-Light,4,-0.2329999953508377,5723991,22,21,4,"{'concept_id': {0: 'C3899750'}, 'canonical_name': {0: 'CNS1 (classification)'}, 'aliases': {0: ['CNS1', 'CNS 1']}, 'types': {0: ['T185']}, 'definition': {0: 'The status of central nervous system leukemia at diagnosis, where there is an absence of blasts on a cerebral spinal fluid cytospin preparation, regardless of the number of white blood cells.'}, 'entity': {0: 'CNS'}, 'text': {0: 'CNS'}}","{'concept_id': {0: 'C0007682'}, 'canonical_name': {0: 'Central Nervous System Disorder'}, 'aliases': {0: ['CNS Disease', 'CNS Diseases', 'Central Nervous System Disease', 'Central Nervous System Disorders', 'Central Nervous System Diseases']}, 'types': {0: ['T047']}, 'definition': {0: 'Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.'}, 'entity': {0: 'CNS'}, 'text': {0: 'CNS'}}",{},{},"{'concept_id': {0: 'C0349606'}, 'canonical_name': {0: 'CNS cyst'}, 'aliases': {0: ['Central nervous system cyst', 'Cyst of the central nervous system']}, 'types': {0: ['T047']}, 'definition': {0: 'Congenital or acquired cysts of the brain, spinal cord, or meninges which may remain stable in size or undergo progressive enlargement.'}, 'entity': {0: 'CNS'}, 'text': {0: 'CNS'}}","           entity_group value   score
0  Biological_structure   CNS  0.9953",[],"{'keyword': {}, 'score': {}}"
757,757,757,0.9470000267028807,21.0,recurrence,UniversSB-Light,4,-0.2329999953508377,5723991,22,21,5,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","   entity_group       value     score
0  Sign_symptom  recurrence  0.998374",[],"{'keyword': {}, 'score': {}}"
758,758,758,0.9470000267028807,21.0,Locoregional,UniversSB-Light,4,-0.2329999953508377,5723991,22,21,6,{},{},{},{},{},"           entity_group         value     score
0  Detailed_description  Locoregional  0.994198",[],"{'keyword': {}, 'score': {}}"
759,759,759,0.9470000267028807,21.0,recurrence,UniversSB-Light,4,-0.2329999953508377,5723991,22,21,7,"{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrence (disease attribute)'}, 'aliases': {0: ['recurrence', 'Recurrence', 'recurrences', 'relapse/recurrence', 'Recurrences']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}",{},{},"{'concept_id': {0: 'C2945760'}, 'canonical_name': {0: 'Recurrent'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring again.'}, 'entity': {0: 'recurrence'}, 'text': {0: 'recurrence'}}","   entity_group       value     score
0  Sign_symptom  recurrence  0.998374",[],"{'keyword': {}, 'score': {}}"
760,760,760,0.9470000267028807,21.0,Contralateral,UniversSB-Light,4,-0.2329999953508377,5723991,22,21,8,"{'concept_id': {0: 'C0441988'}, 'canonical_name': {0: 'Contralateral'}, 'aliases': {0: ['contralateral', 'Contralateral', 'Contralateral (qualifier value)']}, 'types': {0: ['T082']}, 'definition': {0: 'On or relating to the opposite side of the body.'}, 'entity': {0: 'Contralateral'}, 'text': {0: 'Contralateral'}}",{},{},{},{},"           entity_group          value     score
0  Detailed_description  Contralateral  0.999619",[],"{'keyword': {}, 'score': {}}"
761,761,761,0.9470000267028807,21.0,breast cancer,UniversSB-Light,4,-0.2329999953508377,5723991,22,21,9,"{'concept_id': {0: 'C0376571'}, 'canonical_name': {0: 'BRCA1 gene'}, 'aliases': {0: ['BRCA1, DNA Repair Associated Gene', 'brca1', 'Gene, BRCA1', 'FANCS', 'BRCA1 gene', 'BRCA1 Gene', 'BRCA1 DNA REPAIR-ASSOCIATED PROTEIN', 'brca1 gene', 'Fanconi anemia, complementation group S', 'BRCA1/BRCA2-containing complex, subunit 1', 'Genes, BRCA1', 'BRCA1 DNA repair associated', 'RNF53', 'BRCC1', 'BRCA1', 'Breast Cancer 1, Early Onset Gene', 'BREAST CANCER 1 GENE', 'breast cancer 1', 'PPP1R53', 'brca 1 gene', 'breast cancer 1, early onset', 'BRCA1 Genes', 'protein phosphatase 1, regulatory subunit 53']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.'}, 'entity': {0: 'breast cancer'}, 'text': {0: 'breast cancer'}}","{'concept_id': {0: 'C0294028'}, 'canonical_name': {0: 'Breast Cancer 2 Protein'}, 'aliases': {0: ['Fanconi Anemia Complementation Group D1 Protein', 'Fanconi Anemia Group D1 Protein', 'FANCD1 Protein', 'BRCA2 Protein', 'Fanconi Anemia Group D1 Complementing Protein', 'BRCA2 Gene Product', 'Breast Cancer 2 Gene Product']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)'}, 'entity': {0: 'breast cancer'}, 'text': {0: 'breast cancer'}}",{},{},"{'concept_id': {0: 'C0006826'}, 'canonical_name': {0: 'Cancer'}, 'aliases': {0: []}, 'types': {0: ['T191']}, 'definition': {0: 'A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.'}, 'entity': {0: 'breast cancer'}, 'text': {0: 'breast cancer'}}","       entity_group          value     score
0  Disease_disorder  breast cancer  0.981334",[],"{'keyword': {0: 'breast cancer'}, 'score': {0: 1.0}}"
762,762,762,0.9470000267028807,21.0,Death without,UniversSB-Light,4,-0.2329999953508377,5723991,22,22,0,"{'concept_id': {0: 'C1546949'}, 'canonical_name': {0: 'Event Consequence - Death'}, 'aliases': {0: ['Death']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'Death'}, 'text': {0: 'Death without'}}","{'concept_id': {0: 'C0038644'}, 'canonical_name': {0: 'Death, Crib'}, 'aliases': {0: ['Sudden Infant Death Syndrome', 'Death, Sudden Infant', 'Cot Deaths', 'SID', 'Cot Death', 'Sudden Infant Death', 'SIDS', 'Infant Death, Sudden', 'Crib Death', 'Death, Cot']}, 'types': {0: ['T047']}, 'definition': {0: 'The abrupt and unexplained death of an apparently healthy infant under one year of age, remaining unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of the clinical history. (Pediatr Pathol 1991 Sep-Oct;11(5):677-84)'}, 'entity': {0: 'Death'}, 'text': {0: 'Death without'}}",{},"{'concept_id': {0: 'C2754100'}, 'canonical_name': {0: 'neuron death'}, 'aliases': {0: ['neuronal cell death', 'neuron cell death']}, 'types': {0: ['T043']}, 'definition': {0: 'The process of cell death in a neuron. [GOC:BHF, GOC:mah]'}, 'entity': {0: 'Death'}, 'text': {0: 'Death without'}}","{'concept_id': {0: 'C0015927'}, 'canonical_name': {0: 'Foetal death'}, 'aliases': {0: ['Fetal demise', 'Prenatal death', 'Fetal death', 'Intrauterine death']}, 'types': {0: ['T046']}, 'definition': {0: 'Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.'}, 'entity': {0: 'Death'}, 'text': {0: 'Death without'}}","           entity_group    value     score
0               Outcome    Death  0.726540
1  Detailed_description  without  0.966122",[],"{'keyword': {}, 'score': {}}"
763,763,763,0.9470000267028807,21.0,previous event,UniversSB-Light,4,-0.2329999953508377,5723991,22,22,1,"{'concept_id': {0: 'C1708728'}, 'canonical_name': {0: 'Event Log'}, 'aliases': {0: ['Log', 'Event Log']}, 'types': {0: ['T170']}, 'definition': {0: 'A written record of events.'}, 'entity': {0: 'event'}, 'text': {0: 'previous event'}}",{},{},{},{},"           entity_group     value     score
0  Detailed_description  previous  0.511909",[],"{'keyword': {0: 'previous event'}, 'score': {0: 1.0}}"
764,764,764,0.9470000267028807,19.0,Adapted from von Minckwitz et al. 2019.,UniversSB-Light,4,-0.2329999953508377,3355443,22,23,0,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
765,765,765,0.9470000267028807,19.0,"CI, confidence interval; CNS, central nervous system.",UniversSB-Light,4,-0.2329999953508377,3355443,22,23,1,"{'concept_id': {0: 'C1268141'}, 'canonical_name': {0: 'Central nervous system part'}, 'aliases': {0: ['Central nervous system part (body structure)', 'Central Nervous System Part']}, 'types': {0: ['T023']}, 'definition': {0: 'Any component of the nervous system that consists of the brain, spinal cord, and meninges.'}, 'entity': {0: 'central nervous system'}, 'text': {0: 'CI, confidence interval; CNS, central nervous system.'}}","{'concept_id': {0: 'C0007682'}, 'canonical_name': {0: 'Central Nervous System Disorder'}, 'aliases': {0: ['CNS Disease', 'CNS Diseases', 'Central Nervous System Disease', 'Central Nervous System Disorders', 'Central Nervous System Diseases']}, 'types': {0: ['T047']}, 'definition': {0: 'Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.'}, 'entity': {0: 'central nervous system'}, 'text': {0: 'CI, confidence interval; CNS, central nervous system.'}}",{},"{'concept_id': {0: 'C1160339'}, 'canonical_name': {0: 'central nervous system development'}, 'aliases': {0: ['CNS development']}, 'types': {0: ['T042']}, 'definition': {0: 'The process whose specific outcome is the progression of the central nervous system over time, from its formation to the mature structure. The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain and spinal cord. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord. [GOC:bf, GOC:jid, ISBN:0582227089]'}, 'entity': {0: 'central nervous system'}, 'text': {0: 'CI, confidence interval; CNS, central nervous system.'}}","{'concept_id': {0: 'C4021765'}, 'canonical_name': {0: 'Morphological central nervous system abnormality'}, 'aliases': {0: ['Morphological abnormality of the central nervous system', 'Morphological abnormality of the CNS', 'Abnormality of the central nervous system']}, 'types': {0: ['T190']}, 'definition': {0: 'A structural abnormality of the central nervous system. [HPO:probinson]'}, 'entity': {0: 'central nervous system'}, 'text': {0: 'CI, confidence interval; CNS, central nervous system.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'cns central nervous', 1: 'central nervous', 2: 'confidence interval cns', 3: 'cns central', 4: 'ci confidence interval'}, 'score': {0: 0.7781, 1: 0.7661, 2: 0.7015, 3: 0.587, 4: 0.4333}}"
766,766,766,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,22,24,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
767,767,767,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,22,24,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
768,768,768,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,22,24,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
769,769,769,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,22,24,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
770,770,770,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,22,25,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
771,771,771,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,22,25,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
772,772,772,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,22,25,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
773,773,773,0.9169999957084656,98.0,The effect of Kadcyla was consistent  ,ConduitITC-Bold,20,-0.2349999994039535,8194925,23,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}","{'concept_id': {0: 'C1158774'}, 'canonical_name': {0: 'carbon catabolite repression of transcription by glucose'}, 'aliases': {0: ['down regulation of transcription by glucose', 'glucose effect', 'glucose repression', 'down-regulation of transcription by glucose', 'downregulation of transcription by glucose']}, 'types': {0: ['T045']}, 'definition': {0: 'A transcription regulation process in which the presence of glucose leads to a decrease in the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other carbon sources. Carbon catabolite repression is a mechanism of genetic regulation which the accumulation of catabolites of one substance in the cell represses the formation of enzymes that contribute to the catabolism of other substances. [ISBN:0198506732, PMID:11018147]'}, 'entity': {0: 'effect'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}",{},"  entity_group       value     score
0  Coreference     Kadcyla  0.981526
1    Lab_value  consistent  0.999529","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla consistent', 1: 'effect kadcyla consistent', 2: 'effect kadcyla'}, 'score': {0: 0.8612, 1: 0.8439, 2: 0.7451}}"
774,774,774,0.9169999957084656,98.0,across most patient subgroups,ConduitITC-Bold,20,-0.2349999994039535,8194925,23,1,1,"{'concept_id': {0: 'C0751987'}, 'canonical_name': {0: 'Betaproteobacteria'}, 'aliases': {0: ['Purple bacteria, beta subdivision', 'Proteobacteria beta subdivision', 'Betaproteobacteria', 'beta subgroup', 'beta Proteobacteria', 'Class Betaproteobacteria', 'beta subdivision', 'beta proteobacteria', 'Class Betaproteobacteria (organism)', 'Proteobacteria beta']}, 'types': {0: ['T007']}, 'definition': {0: 'A class in the phylum PROTEOBACTERIA comprised of chemoheterotrophs and chemoautotrophs which derive nutrients from decomposition of organic material.'}, 'entity': {0: 'subgroups'}, 'text': {0: 'across most patient subgroups'}}","{'concept_id': {0: 'C4277550'}, 'canonical_name': {0: 'Patient Portals'}, 'aliases': {0: ['Patient Internet Portals', 'Web Portals, Patient', 'Web Portal, Patient', 'Patient Internet Portal', 'Portals, Patient Web', 'Portal, Patient Web', 'Portal, Patient Internet', 'Patient Web Portals', 'Internet Portal, Patient', 'Internet Portals, Patient', 'Patient Portal', 'Patient Web Portal', 'Portals, Patient Internet', 'Portal, Patient']}, 'types': {0: ['T170']}, 'definition': {0: 'A secure online website that provides patients convenient 24-hour access to personal health information via an Internet connection.'}, 'entity': {0: 'patient'}, 'text': {0: 'across most patient subgroups'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'patient subgroups'}, 'score': {0: 0.7486}}"
775,775,775,0.9520000219345092,25.0,Subgroup,MyriadPro-Regular,4,-0.25,5723991,23,2,0,"{'concept_id': {0: 'C0751987'}, 'canonical_name': {0: 'Betaproteobacteria'}, 'aliases': {0: ['Purple bacteria, beta subdivision', 'Proteobacteria beta subdivision', 'Betaproteobacteria', 'beta subgroup', 'beta Proteobacteria', 'Class Betaproteobacteria', 'beta subdivision', 'beta proteobacteria', 'Class Betaproteobacteria (organism)', 'Proteobacteria beta']}, 'types': {0: ['T007']}, 'definition': {0: 'A class in the phylum PROTEOBACTERIA comprised of chemoheterotrophs and chemoautotrophs which derive nutrients from decomposition of organic material.'}, 'entity': {0: 'Subgroup'}, 'text': {0: 'Subgroup'}}",{},{},{},{},"           entity_group     value     score
0  Detailed_description  Subgroup  0.984178",[],"{'keyword': {}, 'score': {}}"
776,776,776,0.9520000219345092,25.0,Kadcyla,MyriadPro-Regular,4,-0.25,5723991,23,2,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
777,777,777,0.9520000219345092,25.0,Trastuzumab,MyriadPro-Regular,4,-0.25,5723991,23,2,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
778,778,778,0.9520000219345092,25.0,Hazard ratio for IDFS event (95% CI),MyriadPro-Regular,4,-0.25,5723991,23,2,3,"{'concept_id': {0: 'C1417638'}, 'canonical_name': {0: 'NDUFB6 gene'}, 'aliases': {0: ['NDUFB6', 'COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, B17 SUBUNIT', 'NADH-ubiquinone oxidoreductase beta subunit, 6', 'NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa', 'CI', 'NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 (17kD, B17)', 'NADH:ubiquinone oxidoreductase subunit B6', 'NADH-ubiquinone oxidoreductase B17 subunit', 'B17', 'complex I, mitochondrial respiratory chain, B17 subunit', 'NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 6', 'NDUFB6 gene']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'CI'}, 'text': {0: 'Hazard ratio for IDFS event (95% CI)'}}",{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: 'Hazard ratio for IDFS event (95% CI)'}}",{},"           entity_group         value     score
0  Diagnostic_procedure  Hazard ratio  0.997832",[],"{'keyword': {0: 'hazard ratio', 1: 'event 95 ci', 2: 'idfs event', 3: '95 ci', 4: 'event 95'}, 'score': {0: 0.8621, 1: 0.8066, 2: 0.7644, 3: 0.7367, 4: 0.6039}}"
779,779,779,0.9520000219345092,25.0,3-year IDFS rate (%),MyriadPro-Regular,4,-0.25,5723991,23,2,4,{},{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: '3-year IDFS rate (%)'}}",{},"           entity_group      value     score
0              Duration     3-year  0.817769
1  Diagnostic_procedure  IDFS rate  0.999706",[],"{'keyword': {0: 'idfs rate', 1: 'year idfs rate', 2: 'year idfs'}, 'score': {0: 0.8784, 1: 0.838, 2: 0.7549}}"
780,780,780,0.8830000162124634,25.0,no. of patients with an invasive dis-,MyriadPro-Light,4,-0.25,5723991,23,3,0,"{'concept_id': {0: 'C1334278'}, 'canonical_name': {0: 'Invasive Lesion'}, 'aliases': {0: ['Invasive Lesion']}, 'types': {0: ['T033']}, 'definition': {0: 'A malignant cellular population that has increased in size and infiltrates the surrounding tissues.'}, 'entity': {0: 'invasive'}, 'text': {0: 'no. of patients with an invasive dis-'}}","{'concept_id': {0: 'C2936533'}, 'canonical_name': {0: 'Invasive Species'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Non-native species that threaten ecosystems, habitats, or other species and are likely to cause economic or environmental harm or harm to human health.'}, 'entity': {0: 'invasive'}, 'text': {0: 'no. of patients with an invasive dis-'}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'no. of patients with an invasive dis-'}}",{},"           entity_group     value     score
0  Detailed_description  invasive  0.999970
1  Detailed_description      dis-  0.980101",[],"{'keyword': {0: 'patients invasive dis', 1: 'patients invasive', 2: 'invasive dis'}, 'score': {0: 0.6283, 1: 0.5813, 2: 0.5606}}"
781,781,781,0.8830000162124634,25.0,ease event/total no.,MyriadPro-Light,4,-0.25,5723991,23,3,1,{},{},{},{},{},"           entity_group value     score
0  Detailed_description  ease  0.999821",[],"{'keyword': {0: 'ease event total', 1: 'ease event', 2: 'event total'}, 'score': {0: 0.8999, 1: 0.8672, 2: 0.8524}}"
782,782,782,0.8830000162124634,25.0,Kadcyla,MyriadPro-Light,4,-0.25,5723991,23,3,2,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
783,783,783,0.8830000162124634,25.0,Trastuzumab,MyriadPro-Light,4,-0.25,5723991,23,3,3,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
784,784,784,0.8830000162124634,24.0,All patients,MyriadPro-Light,4,-0.25,5723991,23,4,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'All patients'}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'All patients'}}",{},{},{},"           entity_group         value     score
0  Detailed_description  All patients  0.686864",[],"{'keyword': {}, 'score': {}}"
785,785,785,0.8830000162124634,24.0,91/743,MyriadPro-Light,4,-0.25,5723991,23,4,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  91/743  0.999071",[],"{'keyword': {0: '91 743'}, 'score': {0: 0.9052}}"
786,786,786,0.8830000162124634,24.0,165/743,MyriadPro-Light,4,-0.25,5723991,23,4,2,{},{},{},{},{},"  entity_group    value     score
0    Lab_value  165/743  0.994471",[],"{'keyword': {0: '165 743'}, 'score': {0: 0.9102}}"
787,787,787,0.8830000162124634,24.0,0.50 (0.39–0.64),MyriadPro-Light,4,-0.25,5723991,23,4,3,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.50 (  0.984410
1    Lab_value  0.39–0.64  0.797765",[],"{'keyword': {0: '50 39', 1: '39 64', 2: '50 39 64'}, 'score': {0: 0.7748, 1: 0.6913, 2: 0.6562}}"
788,788,788,0.8830000162124634,24.0,88.3,MyriadPro-Light,4,-0.25,5723991,23,4,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  88.3  0.999122",[],"{'keyword': {}, 'score': {}}"
789,789,789,0.8830000162124634,24.0,77.0,MyriadPro-Light,4,-0.25,5723991,23,4,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  77.0  0.999825",[],"{'keyword': {}, 'score': {}}"
790,790,790,0.8830000162124634,24.0,Age group,MyriadPro-Light,4,-0.25,5723991,23,5,0,"{'concept_id': {0: 'C1830159'}, 'canonical_name': {0: 'Age group:Type:Point in time:^Patient:Ordinal'}, 'aliases': {0: ['Age group', 'Age group:Type:To identify measures at a point in time:^Patient:Ordinal', 'Age group:Type:Pt:^Patient:Ord']}, 'types': {0: ['T201']}, 'definition': {0: None}, 'entity': {0: 'Age group'}, 'text': {0: 'Age group'}}","{'concept_id': {0: 'C0027362'}, 'canonical_name': {0: 'Age Groups'}, 'aliases': {0: ['Age Group', 'Group, Age']}, 'types': {0: ['T100']}, 'definition': {0: 'Persons classified by age from birth (INFANT, NEWBORN) to octogenarians and older (AGED, 80 AND OVER).'}, 'entity': {0: 'Age group'}, 'text': {0: 'Age group'}}",{},{},{},"           entity_group      value     score
0  Diagnostic_procedure  Age group  0.817007",[],"{'keyword': {0: 'age group'}, 'score': {0: 1.0}}"
791,791,791,0.8830000162124634,24.0,<40 years,MyriadPro-Light,4,-0.25,5723991,23,6,0,"{'concept_id': {0: 'C3843646'}, 'canonical_name': {0: 'One to Two Years'}, 'aliases': {0: ['1 to 2 Years', '1-2 years']}, 'types': {0: ['T079']}, 'definition': {0: 'An indication that something has lasted, or occurred during, one to two years.'}, 'entity': {0: 'years'}, 'text': {0: '<40 years'}}",{},{},{},{},"  entity_group       value     score
0     Duration  < 40 years  0.982235",[],"{'keyword': {0: '40 years'}, 'score': {0: 0.7648}}"
792,792,792,0.8830000162124634,24.0,20/143,MyriadPro-Light,4,-0.25,5723991,23,6,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  20/143  0.871735",[],"{'keyword': {0: '20 143'}, 'score': {0: 0.8982}}"
793,793,793,0.8830000162124634,24.0,37/153,MyriadPro-Light,4,-0.25,5723991,23,6,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  37/153  0.993976",[],"{'keyword': {0: '37 153'}, 'score': {0: 0.9094}}"
794,794,794,0.8830000162124634,24.0,0.50 (0.29–0.36),MyriadPro-Light,4,-0.25,5723991,23,6,3,{},{},{},{},{},"  entity_group           value     score
0    Lab_value          0.50 (  0.914456
1    Lab_value  0.50 0.29–0.36  0.774167
2    Lab_value       0.29–0.36  0.708873",[],"{'keyword': {0: '50 29', 1: '50 29 36', 2: '29 36'}, 'score': {0: 0.7309, 1: 0.6744, 2: 0.6039}}"
795,795,795,0.8830000162124634,24.0,86.5,MyriadPro-Light,4,-0.25,5723991,23,6,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  86.5  0.999513",[],"{'keyword': {}, 'score': {}}"
796,796,796,0.8830000162124634,24.0,74.9,MyriadPro-Light,4,-0.25,5723991,23,6,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  74.9  0.999394",[],"{'keyword': {}, 'score': {}}"
797,797,797,0.8830000162124634,24.0,40–64 years,MyriadPro-Light,4,-0.25,5723991,23,7,0,"{'concept_id': {0: 'C3843646'}, 'canonical_name': {0: 'One to Two Years'}, 'aliases': {0: ['1 to 2 Years', '1-2 years']}, 'types': {0: ['T079']}, 'definition': {0: 'An indication that something has lasted, or occurred during, one to two years.'}, 'entity': {0: 'years'}, 'text': {0: '40–64 years'}}",{},{},{},{},"  entity_group        value     score
0     Duration  40–64 years  0.990326",[],"{'keyword': {0: '40 64 years', 1: '64 years', 2: '40 64'}, 'score': {0: 0.9496, 1: 0.904, 2: 0.8886}}"
798,798,798,0.8830000162124634,24.0,64/542,MyriadPro-Light,4,-0.25,5723991,23,7,1,{},{},{},{},{},"  entity_group   value    score
0    Lab_value  64/542  0.99957",[],"{'keyword': {0: '64 542'}, 'score': {0: 0.8752}}"
799,799,799,0.8830000162124634,24.0,113/522,MyriadPro-Light,4,-0.25,5723991,23,7,2,{},{},{},{},{},"  entity_group    value     score
0    Lab_value  113/522  0.999293",[],"{'keyword': {0: '113 522'}, 'score': {0: 0.8476}}"
800,800,800,0.8830000162124634,24.0,0.49 (0.36–0.67),MyriadPro-Light,4,-0.25,5723991,23,7,3,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.49 (  0.978429
1    Lab_value  0.36–0.67  0.832066",[],"{'keyword': {0: '36 67', 1: '49 36', 2: '49 36 67'}, 'score': {0: 0.7391, 1: 0.7297, 2: 0.7293}}"
801,801,801,0.8830000162124634,24.0,88.8,MyriadPro-Light,4,-0.25,5723991,23,7,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  88.8  0.999285",[],"{'keyword': {}, 'score': {}}"
802,802,802,0.8830000162124634,24.0,77.1,MyriadPro-Light,4,-0.25,5723991,23,7,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  77.1  0.997772",[],"{'keyword': {}, 'score': {}}"
803,803,803,0.9319999814033508,24.0,≥,Ubuntu,4,-0.1889999955892563,5723991,23,8,0,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
804,804,804,0.8830000162124634,24.0,7/58,MyriadPro-Light,4,-0.25,5723991,23,8,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value  7/58  0.997541",[],"{'keyword': {}, 'score': {}}"
805,805,805,0.8830000162124634,24.0,15/68,MyriadPro-Light,4,-0.25,5723991,23,8,2,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  15/68  0.999253",[],"{'keyword': {0: '15 68'}, 'score': {0: 0.8441}}"
806,806,806,0.8830000162124634,24.0,0.55 (0.22–1.34),MyriadPro-Light,4,-0.25,5723991,23,8,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value  0.55  0.999334",[],"{'keyword': {0: '55 22 34', 1: '55 22', 2: '22 34'}, 'score': {0: 0.7397, 1: 0.7238, 2: 0.5203}}"
807,807,807,0.8830000162124634,24.0,87.4,MyriadPro-Light,4,-0.25,5723991,23,8,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  87.4  0.998877",[],"{'keyword': {}, 'score': {}}"
808,808,808,0.8830000162124634,24.0,81.1,MyriadPro-Light,4,-0.25,5723991,23,8,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  81.1  0.997878",[],"{'keyword': {}, 'score': {}}"
809,809,809,0.8830000162124634,24.0,Clinical stage at presentation,MyriadPro-Light,4,-0.25,5723991,23,9,0,"{'concept_id': {0: 'C0233302'}, 'canonical_name': {0: 'Funic presentation'}, 'aliases': {0: ['Funic Presentation', 'Funic presentation', 'Funis Presentation', 'Presentation of cord', 'Presentation of cord (disorder)', 'Funic presentation (finding)', 'Cord presentation', 'Cord Presentation']}, 'types': {0: ['T033']}, 'definition': {0: 'The positioning of the umbilical cord before the main presenting part of the fetus.'}, 'entity': {0: 'presentation'}, 'text': {0: 'Clinical stage at presentation'}}","{'concept_id': {0: 'C1257986'}, 'canonical_name': {0: 'Cross-Presentation'}, 'aliases': {0: ['Cross Presentation']}, 'types': {0: ['T043']}, 'definition': {0: 'Transfer of exogenous ANTIGEN to the ANTIGEN-PRESENTING CELLS for presentation to naive CD8-POSITIVE LYMPHOCYTES.'}, 'entity': {0: 'presentation'}, 'text': {0: 'Clinical stage at presentation'}}",{},"{'concept_id': {0: 'C0206431'}, 'canonical_name': {0: 'antigen processing and presentation'}, 'aliases': {0: ['antigen processing', 'antigen presentation']}, 'types': {0: ['T043']}, 'definition': {0: 'The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)'}, 'entity': {0: 'presentation'}, 'text': {0: 'Clinical stage at presentation'}}",{},"           entity_group           value     score
0  Diagnostic_procedure  Clinical stage  0.704720
1        Clinical_event    presentation  0.998513",[],"{'keyword': {0: 'clinical stage', 1: 'stage presentation', 2: 'clinical stage presentation'}, 'score': {0: 0.9438, 1: 0.908, 2: 0.8979}}"
810,810,810,0.8830000162124634,24.0,Inoperable breast cancer,MyriadPro-Light,4,-0.25,5723991,23,10,0,"{'concept_id': {0: 'C0376571'}, 'canonical_name': {0: 'BRCA1 gene'}, 'aliases': {0: ['BRCA1, DNA Repair Associated Gene', 'brca1', 'Gene, BRCA1', 'FANCS', 'BRCA1 gene', 'BRCA1 Gene', 'BRCA1 DNA REPAIR-ASSOCIATED PROTEIN', 'brca1 gene', 'Fanconi anemia, complementation group S', 'BRCA1/BRCA2-containing complex, subunit 1', 'Genes, BRCA1', 'BRCA1 DNA repair associated', 'RNF53', 'BRCC1', 'BRCA1', 'Breast Cancer 1, Early Onset Gene', 'BREAST CANCER 1 GENE', 'breast cancer 1', 'PPP1R53', 'brca 1 gene', 'breast cancer 1, early onset', 'BRCA1 Genes', 'protein phosphatase 1, regulatory subunit 53']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.'}, 'entity': {0: 'Inoperable breast cancer'}, 'text': {0: 'Inoperable breast cancer'}}","{'concept_id': {0: 'C0238033'}, 'canonical_name': {0: 'Breast Carcinoma, Male'}, 'aliases': {0: ['Cancer, Male Breast', 'Breast Cancer, Male', 'Carcinoma, Male Breast', 'Male Breast Carcinoma', 'Male Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A rare malignant tumor of the breast, affecting mostly older men. It accounts for less than 1% of all malignancies in men. The most common histologic type is invasive ductal carcinoma. Most patients are treated with mastectomy.'}, 'entity': {0: 'Inoperable breast cancer'}, 'text': {0: 'Inoperable breast cancer'}}",{},{},{},"           entity_group          value     score
0  Detailed_description     Inoperable  0.999938
1      Disease_disorder  breast cancer  0.969098",[],"{'keyword': {0: 'inoperable breast cancer', 1: 'inoperable breast', 2: 'breast cancer'}, 'score': {0: 1.0, 1: 0.9156, 2: 0.6935}}"
811,811,811,0.8830000162124634,24.0,42/185,MyriadPro-Light,4,-0.25,5723991,23,10,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  42/185  0.948985",[],"{'keyword': {0: '42 185'}, 'score': {0: 0.9429}}"
812,812,812,0.8830000162124634,24.0,70/190,MyriadPro-Light,4,-0.25,5723991,23,10,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  70/190  0.846365",[],"{'keyword': {0: '70 190'}, 'score': {0: 0.9112}}"
813,813,813,0.8830000162124634,24.0,0.54 (0.37–0.80),MyriadPro-Light,4,-0.25,5723991,23,10,3,{},{},{},{},{},"  entity_group           value     score
0    Lab_value          0.54 (  0.969042
1    Lab_value  0.54 0.37–0.80  0.813234
2    Lab_value       0.37–0.80  0.770023",[],"{'keyword': {0: '54 37 80', 1: '54 37', 2: '37 80'}, 'score': {0: 0.7429, 1: 0.7296, 2: 0.7012}}"
814,814,814,0.8830000162124634,24.0,76.0,MyriadPro-Light,4,-0.25,5723991,23,10,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  76.0  0.999726",[],"{'keyword': {}, 'score': {}}"
815,815,815,0.8830000162124634,24.0,60.2,MyriadPro-Light,4,-0.25,5723991,23,10,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  60.2  0.995108",[],"{'keyword': {}, 'score': {}}"
816,816,816,0.8830000162124634,24.0,Operable breast cancer,MyriadPro-Light,4,-0.25,5723991,23,11,0,"{'concept_id': {0: 'C0376571'}, 'canonical_name': {0: 'BRCA1 gene'}, 'aliases': {0: ['BRCA1, DNA Repair Associated Gene', 'brca1', 'Gene, BRCA1', 'FANCS', 'BRCA1 gene', 'BRCA1 Gene', 'BRCA1 DNA REPAIR-ASSOCIATED PROTEIN', 'brca1 gene', 'Fanconi anemia, complementation group S', 'BRCA1/BRCA2-containing complex, subunit 1', 'Genes, BRCA1', 'BRCA1 DNA repair associated', 'RNF53', 'BRCC1', 'BRCA1', 'Breast Cancer 1, Early Onset Gene', 'BREAST CANCER 1 GENE', 'breast cancer 1', 'PPP1R53', 'brca 1 gene', 'breast cancer 1, early onset', 'BRCA1 Genes', 'protein phosphatase 1, regulatory subunit 53']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.'}, 'entity': {0: 'Operable breast cancer'}, 'text': {0: 'Operable breast cancer'}}","{'concept_id': {0: 'C0238033'}, 'canonical_name': {0: 'Breast Carcinoma, Male'}, 'aliases': {0: ['Cancer, Male Breast', 'Breast Cancer, Male', 'Carcinoma, Male Breast', 'Male Breast Carcinoma', 'Male Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A rare malignant tumor of the breast, affecting mostly older men. It accounts for less than 1% of all malignancies in men. The most common histologic type is invasive ductal carcinoma. Most patients are treated with mastectomy.'}, 'entity': {0: 'Operable breast cancer'}, 'text': {0: 'Operable breast cancer'}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'Operable breast cancer'}, 'text': {0: 'Operable breast cancer'}}","           entity_group          value     score
0  Detailed_description       Operable  0.983971
1      Disease_disorder  breast cancer  0.999287",[],"{'keyword': {0: 'operable breast cancer', 1: 'operable breast', 2: 'breast cancer'}, 'score': {0: 1.0, 1: 0.9106, 2: 0.7264}}"
817,817,817,0.8830000162124634,24.0,49/558,MyriadPro-Light,4,-0.25,5723991,23,11,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  49/558  0.999437",[],"{'keyword': {0: '49 558'}, 'score': {0: 0.8766}}"
818,818,818,0.8830000162124634,24.0,95/553,MyriadPro-Light,4,-0.25,5723991,23,11,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  95/553  0.999606",[],"{'keyword': {0: '95 553'}, 'score': {0: 0.8497}}"
819,819,819,0.8830000162124634,24.0,0.47 (0.33–0.66),MyriadPro-Light,4,-0.25,5723991,23,11,3,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.47 (  0.967341
1    Lab_value  0.33–0.66  0.940299",[],"{'keyword': {0: '47 33 66', 1: '33 66', 2: '47 33'}, 'score': {0: 0.6814, 1: 0.6812, 2: 0.6675}}"
820,820,820,0.8830000162124634,24.0,92.3,MyriadPro-Light,4,-0.25,5723991,23,11,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  92.3  0.994991",[],"{'keyword': {}, 'score': {}}"
821,821,821,0.8830000162124634,24.0,82.8,MyriadPro-Light,4,-0.25,5723991,23,11,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  82.8  0.998815",[],"{'keyword': {}, 'score': {}}"
822,822,822,0.8830000162124634,24.0,HR status,MyriadPro-Light,4,-0.25,5723991,23,12,0,"{'concept_id': {0: 'C1415713'}, 'canonical_name': {0: 'HR gene'}, 'aliases': {0: ['HR', 'HAIRLESS, MOUSE, HOMOLOG OF', 'AU', 'HR lysine demethylase and nuclear receptor corepressor', 'hairless homolog (mouse)', 'ALUNC', 'HR LYSINE DEMETHYLASE AND NUCLEAR RECEPTOR COREPRESSOR', 'HR gene', 'hair growth associated']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'HR'}, 'text': {0: 'HR status'}}",{},{},"{'concept_id': {0: 'C2247597'}, 'canonical_name': {0: 'positive regulation of plant-type hypersensitive response'}, 'aliases': {0: ['up-regulation of plant-type hypersensitive response', 'up regulation of plant-type hypersensitive response', 'positive regulation of plant hypersensitive response', 'upregulation of plant-type hypersensitive response', 'positive regulation of HR']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that activates or increases the frequency, rate or extent of the hypersensitive response in a plant. [GOC:pamgo_curators]'}, 'entity': {0: 'HR'}, 'text': {0: 'HR status'}}",{},"           entity_group      value     score
0  Diagnostic_procedure  HR status  0.998637",[],"{'keyword': {0: 'hr status'}, 'score': {0: 1.0}}"
823,823,823,0.8830000162124634,24.0,"Negative (ER-negative and PR-negative, or ",MyriadPro-Light,4,-0.25,5723991,23,13,0,"{'concept_id': {0: 'C3539878'}, 'canonical_name': {0: 'Triple Negative Breast Neoplasms'}, 'aliases': {0: ['Triple Negative Breast Cancer', 'Triple-Negative Breast Neoplasms', 'triple-negative breast cancer', 'TNBC - Triple-negative breast cancer', 'Breast Cancers, Triple-Negative', 'ER-Negative PR-Negative HER2-Negative Breast Cancer', 'Triple-negative breast cancer', 'Breast Cancer, Triple-Negative', 'Triple negative malignant neoplasm of breast (disorder)', 'Triple Negative Breast Neoplasm', 'ER Negative PR Negative HER2 Negative Breast Neoplasms', 'Triple-Negative Breast Cancers', 'Breast Neoplasm, Triple-Negative', 'Triple-Negative Breast Cancer', 'Breast Neoplasms, Triple-Negative', 'ER-Negative PR-Negative HER2-Negative Breast Neoplasms', 'Triple negative malignant neoplasm of breast', 'ER Negative PR Negative HER2 Negative Breast Cancer', 'Triple Negative Breast Neoplasms', 'Triple-Negative Breast Neoplasm']}, 'types': {0: ['T191']}, 'definition': {0: 'Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.'}, 'entity': {0: 'PR-negative'}, 'text': {0: 'Negative (ER-negative and PR-negative, or '}}","{'concept_id': {0: 'C3539878'}, 'canonical_name': {0: 'Triple Negative Breast Neoplasm'}, 'aliases': {0: ['Triple-Negative Breast Neoplasm', 'ER-Negative PR-Negative HER2-Negative Breast Neoplasms', 'ER-Negative PR-Negative HER2-Negative Breast Cancer', 'Triple-Negative Breast Neoplasms', 'Breast Neoplasms, Triple-Negative', 'ER Negative PR Negative HER2 Negative Breast Neoplasms', 'Triple Negative Breast Neoplasms', 'Triple-Negative Breast Cancers', 'Breast Cancers, Triple-Negative', 'Breast Cancer, Triple-Negative', 'Breast Neoplasm, Triple-Negative', 'ER Negative PR Negative HER2 Negative Breast Cancer', 'Triple-Negative Breast Cancer', 'Triple Negative Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.'}, 'entity': {0: 'PR-negative'}, 'text': {0: 'Negative (ER-negative and PR-negative, or '}}",{},"{'concept_id': {0: 'C1327540'}, 'canonical_name': {0: 'negative regulation of negative chemotaxis'}, 'aliases': {0: ['down-regulation of negative chemotaxis', 'down regulation of negative chemotaxis', 'downregulation of negative chemotaxis']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a motile cell or organism towards a lower concentration in a concentration gradient of a specific chemical. [GOC:ai]'}, 'entity': {0: 'Negative'}, 'text': {0: 'Negative (ER-negative and PR-negative, or '}}","{'concept_id': {0: 'C4280805'}, 'canonical_name': {0: 'Impaired oxidative burst'}, 'aliases': {0: ['Negative nitroblue tetrazolium reduction test', 'Negative NBT reduction test']}, 'types': {0: ['T034']}, 'definition': {0: 'In the NBT test, neutrophils change the colorless compound NBT into a compound with a deep blue color. If this test is negative (i.e., no blue color is produced), then this indicates a defect in superoxide-generating NADPH oxidase activity with inability to efficiently kill phagocytized bacteria. [HPO:probinson]'}, 'entity': {0: 'Negative'}, 'text': {0: 'Negative (ER-negative and PR-negative, or '}}","  entity_group     value    score
0    Lab_value  Negative  0.99994",[],"{'keyword': {0: 'er negative', 1: 'negative pr negative', 2: 'er negative pr', 3: 'negative er negative', 4: 'negative pr'}, 'score': {0: 0.9097, 1: 0.9059, 2: 0.8864, 3: 0.8805, 4: 0.8414}}"
824,824,824,0.8830000162124634,24.0,unknown),MyriadPro-Light,4,-0.25,5723991,23,13,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
825,825,825,0.8830000162124634,24.0,38/209,MyriadPro-Light,4,-0.25,5723991,23,13,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  38/209  0.993997",[],"{'keyword': {0: '38 209'}, 'score': {0: 0.9155}}"
826,826,826,0.8830000162124634,24.0,61/203,MyriadPro-Light,4,-0.25,5723991,23,13,3,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  61/203  0.989098",[],"{'keyword': {0: '61 203'}, 'score': {0: 0.9105}}"
827,827,827,0.8830000162124634,24.0,0.50 (0.33–0.74),MyriadPro-Light,4,-0.25,5723991,23,13,4,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.50 (  0.978005
1    Lab_value  0.33–0.74  0.922554",[],"{'keyword': {0: '50 33', 1: '33 74', 2: '50 33 74'}, 'score': {0: 0.7218, 1: 0.68, 2: 0.6494}}"
828,828,828,0.8830000162124634,24.0,82.1,MyriadPro-Light,4,-0.25,5723991,23,13,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  82.1  0.996401",[],"{'keyword': {}, 'score': {}}"
829,829,829,0.8830000162124634,24.0,66.6,MyriadPro-Light,4,-0.25,5723991,23,13,6,{},{},{},{},{},"  entity_group value     score
0    Lab_value  66.6  0.999289",[],"{'keyword': {}, 'score': {}}"
830,830,830,0.8830000162124634,24.0,"Positive (ER-positive and PR-positive,  ",MyriadPro-Light,4,-0.25,5723991,23,14,0,"{'concept_id': {0: 'C2825490'}, 'canonical_name': {0: 'Positive Charge'}, 'aliases': {0: ['Positive Charge', 'Positive']}, 'types': {0: ['T080']}, 'definition': {0: 'Having a deficiency of electrons; having a higher electric potential.'}, 'entity': {0: 'Positive'}, 'text': {0: 'Positive (ER-positive and PR-positive,  '}}",{},{},"{'concept_id': {0: 'C4235600'}, 'canonical_name': {0: 'positive regulation of establishment of protein localization'}, 'aliases': {0: ['upregulation of protein recruitment', 'positive regulation of establishment of protein localisation', 'up regulation of protein positioning', 'up-regulation of protein positioning', 'upregulation of establishment of protein localisation', 'positive regulation of protein positioning', 'positive regulation of protein recruitment', 'up-regulation of establishment of protein localization', 'upregulation of protein positioning', 'up-regulation of protein recruitment', 'upregulation of establishment of protein localization', 'up regulation of establishment of protein localisation', 'up-regulation of establishment of protein localisation', 'up regulation of establishment of protein localization', 'up regulation of protein recruitment']}, 'types': {0: ['T039']}, 'definition': {0: 'Any process that activates or increases the frequency, rate or extent of establishment of protein localization. [GO_REF:0000058, GOC:TermGenie, PMID:22761445]'}, 'entity': {0: 'Positive'}, 'text': {0: 'Positive (ER-positive and PR-positive,  '}}","{'concept_id': {0: 'C4703609'}, 'canonical_name': {0: 'Anti-mitochondrial M2 antibody positivity'}, 'aliases': {0: ['AMA-M2 positive']}, 'types': {0: ['T034']}, 'definition': {0: 'The presence of M2 anti-mitochondrial antibody (immunoglobulins) in the serum. [LMU:mgriese, PMID:30579751]'}, 'entity': {0: 'Positive'}, 'text': {0: 'Positive (ER-positive and PR-positive,  '}}","  entity_group                    value     score
0    Lab_value                 Positive  0.999952
1    Lab_value  ER-positive PR-positive  0.636249",[],"{'keyword': {0: 'er positive', 1: 'positive er positive', 2: 'positive pr', 3: 'positive er', 4: 'er positive pr'}, 'score': {0: 0.9342, 1: 0.9304, 2: 0.9268, 3: 0.9236, 4: 0.8878}}"
831,831,831,0.8830000162124634,24.0,or both),MyriadPro-Light,4,-0.25,5723991,23,14,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value  both  0.545316",[],"{'keyword': {}, 'score': {}}"
832,832,832,0.8830000162124634,24.0,53/534,MyriadPro-Light,4,-0.25,5723991,23,14,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  53/534  0.998756",[],"{'keyword': {0: '53 534'}, 'score': {0: 0.9098}}"
833,833,833,0.8830000162124634,24.0,104/540,MyriadPro-Light,4,-0.25,5723991,23,14,3,{},{},{},{},{},"  entity_group    value     score
0    Lab_value  104/540  0.998175",[],"{'keyword': {0: '104 540'}, 'score': {0: 0.9335}}"
834,834,834,0.8830000162124634,24.0,0.48 (0.35–0.67),MyriadPro-Light,4,-0.25,5723991,23,14,4,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.48 (  0.976063
1    Lab_value  0.35–0.67  0.801017",[],"{'keyword': {0: '48 35', 1: '48 35 67', 2: '35 67'}, 'score': {0: 0.7295, 1: 0.6517, 2: 0.6361}}"
835,835,835,0.8830000162124634,24.0,90.7,MyriadPro-Light,4,-0.25,5723991,23,14,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  90.7  0.951443",[],"{'keyword': {}, 'score': {}}"
836,836,836,0.8830000162124634,24.0,80.7,MyriadPro-Light,4,-0.25,5723991,23,14,6,{},{},{},{},{},"  entity_group value     score
0    Lab_value  80.7  0.999448",[],"{'keyword': {}, 'score': {}}"
837,837,837,0.8830000162124634,24.0,Preoperative HER2-directed therapy,MyriadPro-Light,4,-0.25,5723991,23,15,0,"{'concept_id': {0: 'C0178808'}, 'canonical_name': {0: 'Preoperative state'}, 'aliases': {0: ['preoperative state', 'Preoperative state', 'Preoperative state (finding)']}, 'types': {0: ['T033']}, 'definition': {0: 'condition of the patient preceding surgery.'}, 'entity': {0: 'Preoperative'}, 'text': {0: 'Preoperative HER2-directed therapy'}}","{'concept_id': {0: 'C5392083'}, 'canonical_name': {0: 'Preoperative Exercise'}, 'aliases': {0: ['Pre-operative Conditionings', 'Pre-operative Conditioning', 'Preoperative Conditionings', 'Pre operative Exercise', 'Rehabilitation, Pre-operative', 'Pre-operative Rehabilitations', 'Pre operative Rehabilitation', 'Preoperative Conditioning', 'Preoperative Rehabilitations', 'Conditioning, Preoperative', 'Exercise, Preoperative', 'Pre-operative Exercises', 'Exercise, Pre-operative', 'Pre operative Conditioning', 'Pre-operative Exercise', 'Preoperative Rehabilitation', 'Conditioning, Pre-operative', 'Preoperative Exercises', 'Rehabilitation, Preoperative', 'Pre-operative Rehabilitation']}, 'types': {0: ['T061']}, 'definition': {0: 'Various physical exercises implemented before a surgery designed for better TREATMENT OUTCOME.'}, 'entity': {0: 'Preoperative'}, 'text': {0: 'Preoperative HER2-directed therapy'}}",{},{},{},"            entity_group                  value     score
0  Therapeutic_procedure          HER2-directed  0.929885
1  Therapeutic_procedure  HER2-directed therapy  0.850966",[],"{'keyword': {0: 'preoperative her2 directed', 1: 'preoperative her2', 2: 'her2 directed therapy', 3: 'directed therapy', 4: 'her2 directed'}, 'score': {0: 0.8902, 1: 0.8061, 2: 0.8019, 3: 0.7403, 4: 0.6978}}"
838,838,838,0.8830000162124634,24.0,Trastuzumab alone,MyriadPro-Light,4,-0.25,5723991,23,16,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab alone'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab alone'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab alone'}}",{},{},"           entity_group        value     score
0            Medication  Trastuzumab  0.999842
1  Detailed_description        alone  0.629467","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
839,839,839,0.8830000162124634,24.0,78/600,MyriadPro-Light,4,-0.25,5723991,23,16,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  78/600  0.999577",[],"{'keyword': {0: '78 600'}, 'score': {0: 0.8883}}"
840,840,840,0.8830000162124634,24.0,141/596,MyriadPro-Light,4,-0.25,5723991,23,16,2,{},{},{},{},{},"  entity_group    value     score
0    Lab_value  141/596  0.999635",[],"{'keyword': {0: '141 596'}, 'score': {0: 0.9094}}"
841,841,841,0.8830000162124634,24.0,0.49 (0.37–0.65),MyriadPro-Light,4,-0.25,5723991,23,16,3,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.49 (  0.967708
1    Lab_value  0.37–0.65  0.736413",[],"{'keyword': {0: '49 37', 1: '49 37 65', 2: '37 65'}, 'score': {0: 0.7745, 1: 0.7657, 2: 0.7363}}"
842,842,842,0.8830000162124634,24.0,87.7,MyriadPro-Light,4,-0.25,5723991,23,16,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  87.7  0.998607",[],"{'keyword': {}, 'score': {}}"
843,843,843,0.8830000162124634,24.0,75.9,MyriadPro-Light,4,-0.25,5723991,23,16,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  75.9  0.999323",[],"{'keyword': {}, 'score': {}}"
844,844,844,0.8830000162124634,24.0,Trastuzumab plus additional  ,MyriadPro-Light,4,-0.25,5723991,23,17,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab plus additional  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab plus additional  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab plus additional  '}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999878","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab plus additional', 1: 'trastuzumab plus', 2: 'plus additional'}, 'score': {0: 1.0, 1: 0.9551, 2: 0.9061}}"
845,845,845,0.8830000162124634,24.0,HER2-directed agent or agents,MyriadPro-Light,4,-0.25,5723991,23,17,1,"{'concept_id': {0: 'C1710439'}, 'canonical_name': {0: 'Topical Dosage Form'}, 'aliases': {0: ['Topical', 'Topical agents', 'Topical Dosage Form', 'Topical Dose Form']}, 'types': {0: ['T122']}, 'definition': {0: 'A substance intended for administration to a body surface.'}, 'entity': {0: 'agents'}, 'text': {0: 'HER2-directed agent or agents'}}","{'concept_id': {0: 'C0013973'}, 'canonical_name': {0: 'Emetics'}, 'aliases': {0: ['Drug, Emetic', 'Agents, Emetic', 'Emetic Agents', 'Emetic Agent', 'Emetic Drugs', 'Drugs, Emetic', 'Emetic Drug', 'Emetic', 'Agent, Emetic']}, 'types': {0: ['T121']}, 'definition': {0: 'Agents that cause vomiting. They may act directly on the gastrointestinal tract, bringing about emesis through local irritant effects, or indirectly, through their effects on the chemoreceptor trigger zone in the postremal area near the medulla.'}, 'entity': {0: 'agents'}, 'text': {0: 'HER2-directed agent or agents'}}",{},{},{},"           entity_group                       value     score
0  Detailed_description               HER2-directed  0.885715
1  Detailed_description  HER2-directed agent agents  0.996651
2  Detailed_description                      agents  0.504430",[],"{'keyword': {0: 'agent agents', 1: 'her2 directed agent', 2: 'her2 directed', 3: 'directed agent', 4: 'directed agent agents'}, 'score': {0: 0.8199, 1: 0.812, 2: 0.7663, 3: 0.7543, 4: 0.7278}}"
846,846,846,0.8830000162124634,24.0,13/143,MyriadPro-Light,4,-0.25,5723991,23,17,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  13/143  0.978334",[],"{'keyword': {0: '13 143'}, 'score': {0: 0.8964}}"
847,847,847,0.8830000162124634,24.0,24/147,MyriadPro-Light,4,-0.25,5723991,23,17,3,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  24/147  0.890299",[],"{'keyword': {0: '24 147'}, 'score': {0: 0.8901}}"
848,848,848,0.8830000162124634,24.0,0.54 (0.27–1.06),MyriadPro-Light,4,-0.25,5723991,23,17,4,{},{},{},{},{},"  entity_group value    score
0    Lab_value  0.54  0.99934",[],"{'keyword': {0: '54 27', 1: '54 27 06', 2: '27 06'}, 'score': {0: 0.7083, 1: 0.6951, 2: 0.6258}}"
849,849,849,0.8830000162124634,24.0,90.9,MyriadPro-Light,4,-0.25,5723991,23,17,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  90.9  0.994503",[],"{'keyword': {}, 'score': {}}"
850,850,850,0.8830000162124634,24.0,81.8,MyriadPro-Light,4,-0.25,5723991,23,17,6,{},{},{},{},{},"  entity_group value     score
0    Lab_value  81.8  0.999384",[],"{'keyword': {}, 'score': {}}"
851,851,851,0.8830000162124634,24.688661575317383,0.15,MyriadPro-Light,4,-0.25,5723991,23,18,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value  0.15  0.996109",[],"{'keyword': {}, 'score': {}}"
852,852,852,0.8830000162124634,24.688661575317383,0.5,MyriadPro-Light,4,-0.25,5723991,23,18,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   0.5  0.999093","[('0.5', 'STRENGTH')]","{'keyword': {}, 'score': {}}"
853,853,853,0.8830000162124634,24.688661575317383,1.0,MyriadPro-Light,4,-0.25,5723991,23,18,2,{},{},{},{},{},"           entity_group value     score
0  Detailed_description   1.0  0.501226
1             Lab_value   1.0  0.710047",[],"{'keyword': {}, 'score': {}}"
854,854,854,0.8830000162124634,24.688661575317383,2.0,MyriadPro-Light,4,-0.25,5723991,23,18,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   2.0  0.883895",[],"{'keyword': {}, 'score': {}}"
855,855,855,0.8830000162124634,24.688661575317383,5.0,MyriadPro-Light,4,-0.25,5723991,23,18,4,{},{},{},{},{},"  entity_group value    score
0    Lab_value   5.0  0.94593",[],"{'keyword': {}, 'score': {}}"
856,856,856,0.8830000162124634,24.688661575317383,0.20,MyriadPro-Light,4,-0.25,5723991,23,19,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value  0.20  0.994717",[],"{'keyword': {}, 'score': {}}"
857,857,857,0.8830000162124634,19.0,Adapted from von Minckwitz et al. 2019.,MyriadPro-Light,4,-0.25,3355443,23,20,0,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
858,858,858,0.8830000162124634,19.0,"CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  ",MyriadPro-Light,4,-0.25,3355443,23,20,1,"{'concept_id': {0: 'C1512496'}, 'canonical_name': {0: 'Hormone Receptor Test'}, 'aliases': {0: []}, 'types': {0: ['T059']}, 'definition': {0: 'A hormone receptor test measures the amount of certain hormone receptors proteins in cancer tissue. Hormones (such as estrogen and progesterone that naturally occur in the body) can attach to these proteins. If the test is positive, it indicates that the hormone is probably helping the cancer cells grow.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}","{'concept_id': {0: 'C0034808'}, 'canonical_name': {0: 'Receptors, Gastrointestinal Hormone'}, 'aliases': {0: ['Gastrointestinal Peptides Receptors', 'Receptors, Intestinal Hormone', 'Gastrointestinal Hormone Receptors', 'Receptors, Gastrointestinal Peptides', 'Gastrointestinal Hormone Receptor', 'Gastrointestinal Hormones Receptors', 'Hormone Receptors, Intestinal', 'Peptides Receptors, Gastrointestinal', 'Hormone Receptor, Intestinal', 'Intestinal Hormone Receptors', 'Hormone Receptors, Gastrointestinal', 'Hormones Receptors, Gastrointestinal', 'Intestinal Hormone Receptor', 'Receptor, Intestinal Hormone', 'Hormone Receptor, Gastrointestinal', 'Receptors, Gastrointestinal Hormones', 'Receptor, Gastrointestinal Hormone']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: 'Cell surface proteins that bind gastrointestinal hormones with high affinity and trigger intracellular changes influencing the behavior of cells. Most gastrointestinal hormones also act as neurotransmitters so these receptors are also present in the central and peripheral nervous systems.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}",{},"{'concept_id': {0: 'C1152812'}, 'canonical_name': {0: 'growth hormone receptor activity'}, 'aliases': {0: []}, 'types': {0: ['T044']}, 'definition': {0: 'Combining with a growth hormone and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. [GOC:ai, GOC:signaling]'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}","{'concept_id': {0: 'C4722330'}, 'canonical_name': {0: 'Thyroid hormone receptor defect'}, 'aliases': {0: ['Thyroid hormone resistance', 'End-organ unresponsiveness to thyroid hormone', 'Elevated serum levels of free thyroid hormone with nonsuppressed TSH', 'Resistance to thyroid hormone', 'Impaired sensitivity to thyroid hormone']}, 'types': {0: ['T047']}, 'definition': {0: 'Decreased response to thyroid hormones in peripheral tissues and in the pituitary gland.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'receptor hr hormone', 1: 'confidence interval er', 2: 'oestrogen receptor', 3: 'interval er', 4: 'ci confidence interval'}, 'score': {0: 0.8637, 1: 0.7731, 2: 0.7447, 3: 0.7087, 4: 0.5439}}"
859,859,859,0.8830000162124634,19.0,"IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.",MyriadPro-Light,4,-0.25,3355443,23,20,2,"{'concept_id': {0: 'C4082178'}, 'canonical_name': {0: 'Progesterone Receptor, human'}, 'aliases': {0: ['PRB', 'PGR', 'Nuclear Receptor Subfamily 3 Group C Member 3', 'Progesterone Receptor Isoform B', 'Progesterone Receptor B', 'PgR', 'Progesterone Receptor']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: 'Progesterone receptor (933 aa, ~99 kDa) is encoded by the human PGR gene. This protein is involved in the regulation of transcription.'}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.'}}","{'concept_id': {0: 'C0385053'}, 'canonical_name': {0: 'progesterone receptors B'}, 'aliases': {0: ['progesterone receptor B', 'receptor B, progesterone']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: None}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.'}}",{},"{'concept_id': {0: 'C1157305'}, 'canonical_name': {0: 'progesterone biosynthetic process'}, 'aliases': {0: ['progesterone anabolism', 'progesterone formation', 'progesterone synthesis', 'progesterone biosynthesis']}, 'types': {0: ['T044']}, 'definition': {0: 'The chemical reactions and pathways resulting in the formation of progesterone, a steroid hormone produced in the ovary which prepares and maintains the uterus for pregnancy. Also found in plants. [GOC:jl, http://www.cogsci.princeton.edu/]'}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.'}}",{},"Empty DataFrame
Columns: []
Index: []","[('progesterone receptor', 'DRUG')]","{'keyword': {0: 'free survival ne', 1: 'idfs invasive disease', 2: 'progesterone receptor', 3: 'ne evaluable', 4: 'evaluable pr'}, 'score': {0: 0.8122, 1: 0.7718, 2: 0.6953, 3: 0.562, 4: 0.3307}}"
860,860,860,0.8830000162124634,24.688661575317383,Trastuzumab better,MyriadPro-Light,4,-0.25,5723991,23,21,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab better'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab better'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab better'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999839
1    Lab_value       better  0.999615","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab better'}, 'score': {0: 1.0}}"
861,861,861,0.8830000162124634,24.688661575317383,Kadcyla better,MyriadPro-Light,4,-0.25,5723991,23,21,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla better'}, 'text': {0: 'Kadcyla better'}}",{},{},{},{},"           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.988854
1             Lab_value   better  0.999646",[],"{'keyword': {0: 'kadcyla better'}, 'score': {0: 1.0}}"
862,862,862,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,23,22,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
863,863,863,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,23,22,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
864,864,864,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,23,22,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
865,865,865,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,23,22,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
866,866,866,0.9169999957084656,98.0,The effect of Kadcyla was consistent  ,ConduitITC-Bold,20,-0.2349999994039535,8194925,24,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}","{'concept_id': {0: 'C1158774'}, 'canonical_name': {0: 'carbon catabolite repression of transcription by glucose'}, 'aliases': {0: ['down regulation of transcription by glucose', 'glucose effect', 'glucose repression', 'down-regulation of transcription by glucose', 'downregulation of transcription by glucose']}, 'types': {0: ['T045']}, 'definition': {0: 'A transcription regulation process in which the presence of glucose leads to a decrease in the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other carbon sources. Carbon catabolite repression is a mechanism of genetic regulation which the accumulation of catabolites of one substance in the cell represses the formation of enzymes that contribute to the catabolism of other substances. [ISBN:0198506732, PMID:11018147]'}, 'entity': {0: 'effect'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}",{},"  entity_group       value     score
0  Coreference     Kadcyla  0.981526
1    Lab_value  consistent  0.999529","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla consistent', 1: 'effect kadcyla consistent', 2: 'effect kadcyla'}, 'score': {0: 0.8612, 1: 0.8439, 2: 0.7451}}"
867,867,867,0.9169999957084656,98.0,across most patient subgroups,ConduitITC-Bold,20,-0.2349999994039535,8194925,24,1,1,"{'concept_id': {0: 'C0751987'}, 'canonical_name': {0: 'Betaproteobacteria'}, 'aliases': {0: ['Purple bacteria, beta subdivision', 'Proteobacteria beta subdivision', 'Betaproteobacteria', 'beta subgroup', 'beta Proteobacteria', 'Class Betaproteobacteria', 'beta subdivision', 'beta proteobacteria', 'Class Betaproteobacteria (organism)', 'Proteobacteria beta']}, 'types': {0: ['T007']}, 'definition': {0: 'A class in the phylum PROTEOBACTERIA comprised of chemoheterotrophs and chemoautotrophs which derive nutrients from decomposition of organic material.'}, 'entity': {0: 'subgroups'}, 'text': {0: 'across most patient subgroups'}}","{'concept_id': {0: 'C4277550'}, 'canonical_name': {0: 'Patient Portals'}, 'aliases': {0: ['Patient Internet Portals', 'Web Portals, Patient', 'Web Portal, Patient', 'Patient Internet Portal', 'Portals, Patient Web', 'Portal, Patient Web', 'Portal, Patient Internet', 'Patient Web Portals', 'Internet Portal, Patient', 'Internet Portals, Patient', 'Patient Portal', 'Patient Web Portal', 'Portals, Patient Internet', 'Portal, Patient']}, 'types': {0: ['T170']}, 'definition': {0: 'A secure online website that provides patients convenient 24-hour access to personal health information via an Internet connection.'}, 'entity': {0: 'patient'}, 'text': {0: 'across most patient subgroups'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'patient subgroups'}, 'score': {0: 0.7486}}"
868,868,868,0.9520000219345092,25.0,Subgroup,MyriadPro-Regular,4,-0.25,5723991,24,2,0,"{'concept_id': {0: 'C0751987'}, 'canonical_name': {0: 'Betaproteobacteria'}, 'aliases': {0: ['Purple bacteria, beta subdivision', 'Proteobacteria beta subdivision', 'Betaproteobacteria', 'beta subgroup', 'beta Proteobacteria', 'Class Betaproteobacteria', 'beta subdivision', 'beta proteobacteria', 'Class Betaproteobacteria (organism)', 'Proteobacteria beta']}, 'types': {0: ['T007']}, 'definition': {0: 'A class in the phylum PROTEOBACTERIA comprised of chemoheterotrophs and chemoautotrophs which derive nutrients from decomposition of organic material.'}, 'entity': {0: 'Subgroup'}, 'text': {0: 'Subgroup'}}",{},{},{},{},"           entity_group     value     score
0  Detailed_description  Subgroup  0.984178",[],"{'keyword': {}, 'score': {}}"
869,869,869,0.9520000219345092,25.0,Kadcyla,MyriadPro-Regular,4,-0.25,5723991,24,2,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
870,870,870,0.9520000219345092,25.0,Trastuzumab,MyriadPro-Regular,4,-0.25,5723991,24,2,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
871,871,871,0.9520000219345092,25.0,Hazard ratio for IDFS event (95% CI),MyriadPro-Regular,4,-0.25,5723991,24,2,3,"{'concept_id': {0: 'C1417638'}, 'canonical_name': {0: 'NDUFB6 gene'}, 'aliases': {0: ['NDUFB6', 'COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, B17 SUBUNIT', 'NADH-ubiquinone oxidoreductase beta subunit, 6', 'NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa', 'CI', 'NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 (17kD, B17)', 'NADH:ubiquinone oxidoreductase subunit B6', 'NADH-ubiquinone oxidoreductase B17 subunit', 'B17', 'complex I, mitochondrial respiratory chain, B17 subunit', 'NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 6', 'NDUFB6 gene']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'CI'}, 'text': {0: 'Hazard ratio for IDFS event (95% CI)'}}",{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: 'Hazard ratio for IDFS event (95% CI)'}}",{},"           entity_group         value     score
0  Diagnostic_procedure  Hazard ratio  0.997832",[],"{'keyword': {0: 'hazard ratio', 1: 'event 95 ci', 2: 'idfs event', 3: '95 ci', 4: 'event 95'}, 'score': {0: 0.8621, 1: 0.8066, 2: 0.7644, 3: 0.7367, 4: 0.6039}}"
872,872,872,0.9520000219345092,25.0,3-year IDFS rate (%),MyriadPro-Regular,4,-0.25,5723991,24,2,4,{},{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: '3-year IDFS rate (%)'}}",{},"           entity_group      value     score
0              Duration     3-year  0.817769
1  Diagnostic_procedure  IDFS rate  0.999706",[],"{'keyword': {0: 'idfs rate', 1: 'year idfs rate', 2: 'year idfs'}, 'score': {0: 0.8784, 1: 0.838, 2: 0.7549}}"
873,873,873,0.8830000162124634,25.0,no. of patients with an invasive dis-,MyriadPro-Light,4,-0.25,5723991,24,3,0,"{'concept_id': {0: 'C1334278'}, 'canonical_name': {0: 'Invasive Lesion'}, 'aliases': {0: ['Invasive Lesion']}, 'types': {0: ['T033']}, 'definition': {0: 'A malignant cellular population that has increased in size and infiltrates the surrounding tissues.'}, 'entity': {0: 'invasive'}, 'text': {0: 'no. of patients with an invasive dis-'}}","{'concept_id': {0: 'C2936533'}, 'canonical_name': {0: 'Invasive Species'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Non-native species that threaten ecosystems, habitats, or other species and are likely to cause economic or environmental harm or harm to human health.'}, 'entity': {0: 'invasive'}, 'text': {0: 'no. of patients with an invasive dis-'}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'no. of patients with an invasive dis-'}}",{},"           entity_group     value     score
0  Detailed_description  invasive  0.999970
1  Detailed_description      dis-  0.980101",[],"{'keyword': {0: 'patients invasive dis', 1: 'patients invasive', 2: 'invasive dis'}, 'score': {0: 0.6283, 1: 0.5813, 2: 0.5606}}"
874,874,874,0.8830000162124634,25.0,ease event/total no.,MyriadPro-Light,4,-0.25,5723991,24,3,1,{},{},{},{},{},"           entity_group value     score
0  Detailed_description  ease  0.999821",[],"{'keyword': {0: 'ease event total', 1: 'ease event', 2: 'event total'}, 'score': {0: 0.8999, 1: 0.8672, 2: 0.8524}}"
875,875,875,0.8830000162124634,25.0,Kadcyla,MyriadPro-Light,4,-0.25,5723991,24,3,2,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
876,876,876,0.8830000162124634,25.0,Trastuzumab,MyriadPro-Light,4,-0.25,5723991,24,3,3,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
877,877,877,0.8830000162124634,24.0,Pathological nodal status after preoperative ,MyriadPro-Light,4,-0.25,5723991,24,4,0,"{'concept_id': {0: 'C0178808'}, 'canonical_name': {0: 'Preoperative state'}, 'aliases': {0: ['preoperative state', 'Preoperative state', 'Preoperative state (finding)']}, 'types': {0: ['T033']}, 'definition': {0: 'condition of the patient preceding surgery.'}, 'entity': {0: 'preoperative'}, 'text': {0: 'Pathological nodal status after preoperative '}}","{'concept_id': {0: 'C5392083'}, 'canonical_name': {0: 'Preoperative Exercise'}, 'aliases': {0: ['Pre-operative Conditionings', 'Pre-operative Conditioning', 'Preoperative Conditionings', 'Pre operative Exercise', 'Rehabilitation, Pre-operative', 'Pre-operative Rehabilitations', 'Pre operative Rehabilitation', 'Preoperative Conditioning', 'Preoperative Rehabilitations', 'Conditioning, Preoperative', 'Exercise, Preoperative', 'Pre-operative Exercises', 'Exercise, Pre-operative', 'Pre operative Conditioning', 'Pre-operative Exercise', 'Preoperative Rehabilitation', 'Conditioning, Pre-operative', 'Preoperative Exercises', 'Rehabilitation, Preoperative', 'Pre-operative Rehabilitation']}, 'types': {0: ['T061']}, 'definition': {0: 'Various physical exercises implemented before a surgery designed for better TREATMENT OUTCOME.'}, 'entity': {0: 'preoperative'}, 'text': {0: 'Pathological nodal status after preoperative '}}",{},{},"{'concept_id': {0: 'C0016663'}, 'canonical_name': {0: 'Pathologic fracture'}, 'aliases': {0: ['Spontaneous fractures', 'Pathologic fractures', 'Spontaneous fracture']}, 'types': {0: ['T046']}, 'definition': {0: 'Fractures occurring as a result of disease of a bone or from some undiscoverable cause, and not due to trauma. (Dorland, 27th ed)'}, 'entity': {0: 'Pathological'}, 'text': {0: 'Pathological nodal status after preoperative '}}","           entity_group         value     score
0             Lab_value  Pathological  0.586501
1             Lab_value         nodal  0.547940
2  Diagnostic_procedure        status  0.992502",[],"{'keyword': {0: 'pathological nodal status', 1: 'nodal status preoperative', 2: 'pathological nodal', 3: 'status preoperative', 4: 'nodal status'}, 'score': {0: 0.9169, 1: 0.9008, 2: 0.8391, 3: 0.7896, 4: 0.7896}}"
878,878,878,0.8830000162124634,24.0,therapy,MyriadPro-Light,4,-0.25,5723991,24,4,1,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy'}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy'}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  therapy  0.970922",[],"{'keyword': {}, 'score': {}}"
879,879,879,0.8830000162124634,24.0,Node-positive,MyriadPro-Light,4,-0.25,5723991,24,5,0,"{'concept_id': {0: 'C0746319'}, 'canonical_name': {0: 'Positive Lymph Node'}, 'aliases': {0: ['node-positive', 'lymph node positive', 'nodes positives', 'positive lymph node', 'Positive Lymph Node', 'lymph nodes positive']}, 'types': {0: ['T033']}, 'definition': {0: 'The presence of metastatic cancer cells in a lymph node.'}, 'entity': {0: 'Node-positive'}, 'text': {0: 'Node-positive'}}",{},{},{},{},"  entity_group          value     score
0    Lab_value  Node-positive  0.482408",[],"{'keyword': {0: 'node positive'}, 'score': {0: 0.983}}"
880,880,880,0.8830000162124634,24.0,62/343,MyriadPro-Light,4,-0.25,5723991,24,5,1,{},{},{},{},{},"  entity_group   value    score
0    Lab_value  62/343  0.99955",[],"{'keyword': {0: '62 343'}, 'score': {0: 0.9251}}"
881,881,881,0.8830000162124634,24.0,103/346,MyriadPro-Light,4,-0.25,5723991,24,5,2,{},{},{},{},{},"  entity_group    value     score
0    Lab_value  103/346  0.999634",[],"{'keyword': {0: '103 346'}, 'score': {0: 0.9119}}"
882,882,882,0.8830000162124634,24.0,0.52 (0.38–0.71),MyriadPro-Light,4,-0.25,5723991,24,5,3,{},{},{},{},{},"  entity_group      value    score
0    Lab_value     0.52 (  0.98543
1    Lab_value  0.38–0.71  0.75584",[],"{'keyword': {0: '52 38', 1: '38 71', 2: '52 38 71'}, 'score': {0: 0.7536, 1: 0.693, 2: 0.6896}}"
883,883,883,0.8830000162124634,24.0,83.0,MyriadPro-Light,4,-0.25,5723991,24,5,4,{},{},{},{},{},"  entity_group value    score
0    Lab_value  83.0  0.99965",[],"{'keyword': {}, 'score': {}}"
884,884,884,0.8830000162124634,24.0,67.7,MyriadPro-Light,4,-0.25,5723991,24,5,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  67.7  0.999013",[],"{'keyword': {}, 'score': {}}"
885,885,885,0.8830000162124634,24.0,Node-negative or NE,MyriadPro-Light,4,-0.25,5723991,24,6,0,"{'concept_id': {0: 'C0332125'}, 'canonical_name': {0: 'No evidence of'}, 'aliases': {0: ['No evidence of (contextual qualifier)', 'No evidence for', 'No evidence of (contextual qualifier) (qualifier value)', 'No evidence of', 'NE']}, 'types': {0: ['T080']}, 'definition': {0: None}, 'entity': {0: 'NE'}, 'text': {0: 'Node-negative or NE'}}",{},{},{},{},"           entity_group          value     score
0  Detailed_description  Node-negative  0.988919
1             Lab_value  Node-negative  0.931928
2  Detailed_description             NE  0.965639",[],"{'keyword': {0: 'node negative', 1: 'negative ne', 2: 'node negative ne'}, 'score': {0: 0.9443, 1: 0.8618, 2: 0.8417}}"
886,886,886,0.8830000162124634,24.0,29/400,MyriadPro-Light,4,-0.25,5723991,24,6,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  29/400  0.999725",[],"{'keyword': {0: '29 400'}, 'score': {0: 0.9014}}"
887,887,887,0.8830000162124634,24.0,62/397,MyriadPro-Light,4,-0.25,5723991,24,6,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  62/397  0.999772",[],"{'keyword': {0: '62 397'}, 'score': {0: 0.8725}}"
888,888,888,0.8830000162124634,24.0,0.44 (0.28–0.68),MyriadPro-Light,4,-0.25,5723991,24,6,3,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.44 (  0.940563
1    Lab_value  0.28–0.68  0.788873",[],"{'keyword': {0: '44 28', 1: '44 28 68', 2: '28 68'}, 'score': {0: 0.7008, 1: 0.6622, 2: 0.613}}"
889,889,889,0.8830000162124634,24.0,92.8,MyriadPro-Light,4,-0.25,5723991,24,6,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  92.8  0.997963",[],"{'keyword': {}, 'score': {}}"
890,890,890,0.8830000162124634,24.0,84.6,MyriadPro-Light,4,-0.25,5723991,24,6,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  84.6  0.999452",[],"{'keyword': {}, 'score': {}}"
891,891,891,0.8830000162124634,24.0,Primary tumour stage at definitive surgery,MyriadPro-Light,4,-0.25,5723991,24,7,0,"{'concept_id': {0: 'C0443196'}, 'canonical_name': {0: 'Definitive'}, 'aliases': {0: ['definitive', 'Definitive (qualifier value)', 'Definitive']}, 'types': {0: ['T079']}, 'definition': {0: 'Supplying or being a final or conclusive settlement or result.'}, 'entity': {0: 'definitive surgery'}, 'text': {0: 'Primary tumour stage at definitive surgery'}}",{},{},{},{},"            entity_group       value     score
0   Detailed_description     Primary  0.999939
1           Sign_symptom      tumour  0.999067
2   Detailed_description       stage  0.999344
3   Detailed_description  definitive  0.999961
4  Therapeutic_procedure     surgery  0.985831",[],"{'keyword': {0: 'primary tumour stage', 1: 'stage definitive surgery', 2: 'stage definitive', 3: 'definitive surgery', 4: 'primary tumour'}, 'score': {0: 0.9314, 1: 0.8484, 2: 0.807, 3: 0.6287, 4: 0.5263}}"
892,892,892,0.8830000162124634,24.0,"ypT0, ypT1a, ypT1b, ypT1mic, ypTis",MyriadPro-Light,4,-0.25,5723991,24,8,0,"{'concept_id': {0: 'C1711128'}, 'canonical_name': {0: 'pT1a Stage Finding'}, 'aliases': {0: ['Tumor Stage pT1a', 'pT1a TNM Finding', 'pT1a Stage Finding', 'pT1a Primary Tumor Finding', 'pT1a Primary Tumor Stage Finding', 'pT1a Tumor Stage', 'pT1a Stage', 'pT1a Tumor Finding', 'pT1a Cancer Stage Finding', 'pT1a']}, 'types': {0: ['T033']}, 'definition': {0: 'A pathologic primary tumor TNM stage finding. The definition of pT1a stage finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1a stage finding is defined as follows: cancer with tumor size more than 0.1 cm, but not more than 0.5 cm in greatest dimension; for lung cancer, pT1a stage finding is defined as follows: cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. (from AJCC 7th Ed.)'}, 'entity': {0: 'ypT1a'}, 'text': {0: 'ypT0, ypT1a, ypT1b, ypT1mic, ypTis'}}",{},{},{},{},"           entity_group                           value     score
0  Diagnostic_procedure  ypT0 ypT1a ypT1b ypT1mic ypTis  0.980214
1  Diagnostic_procedure             ypT1a ypT1b ypT1mic  0.573250
2  Detailed_description                         ypT1mic  0.385590
3  Diagnostic_procedure                           ypTis  0.768532",[],"{'keyword': {0: 'ypt0 ypt1a ypt1b', 1: 'ypt0 ypt1a', 2: 'ypt1mic yptis', 3: 'ypt1a ypt1b', 4: 'ypt1b ypt1mic yptis'}, 'score': {0: 0.9303, 1: 0.9103, 2: 0.7826, 3: 0.7521, 4: 0.752}}"
893,893,893,0.8830000162124634,24.0,40/331,MyriadPro-Light,4,-0.25,5723991,24,8,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  40/331  0.971619",[],"{'keyword': {0: '40 331'}, 'score': {0: 0.9135}}"
894,894,894,0.8830000162124634,24.0,52/306,MyriadPro-Light,4,-0.25,5723991,24,8,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  52/306  0.995912",[],"{'keyword': {0: '52 306'}, 'score': {0: 0.9044}}"
895,895,895,0.8830000162124634,24.0,0.66 (0.44–1.00),MyriadPro-Light,4,-0.25,5723991,24,8,3,{},{},{},{},{},"  entity_group           value     score
0    Lab_value            0.66  0.998899
1    Lab_value  0.66 0.44–1.00  0.569234",[],"{'keyword': {0: '66 44', 1: '66 44 00', 2: '44 00'}, 'score': {0: 0.7999, 1: 0.7836, 2: 0.6241}}"
896,896,896,0.8830000162124634,24.0,88.3,MyriadPro-Light,4,-0.25,5723991,24,8,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  88.3  0.999122",[],"{'keyword': {}, 'score': {}}"
897,897,897,0.8830000162124634,24.0,83.6,MyriadPro-Light,4,-0.25,5723991,24,8,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  83.6  0.999273",[],"{'keyword': {}, 'score': {}}"
898,898,898,0.8830000162124634,24.0,"ypT1, ypT1c",MyriadPro-Light,4,-0.25,5723991,24,9,0,"{'concept_id': {0: 'C1419187'}, 'canonical_name': {0: 'RAB1A gene'}, 'aliases': {0: ['Rab GTPase YPT1 homolog (yeast)', 'RAB1', 'RAB1A, member RAS oncogene family', 'RAS-ASSOCIATED PROTEIN RAB1', 'YPT1', 'RAB1A gene', 'RAB1A']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'ypT1'}, 'text': {0: 'ypT1, ypT1c'}}",{},{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  ypT1 ypT1c  0.998739
1  Diagnostic_procedure       ypT1c  0.611908",[],"{'keyword': {0: 'ypt1 ypt1c'}, 'score': {0: 0.9424}}"
899,899,899,0.8830000162124634,24.0,14/175,MyriadPro-Light,4,-0.25,5723991,24,9,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  14/175  0.831443",[],"{'keyword': {0: '14 175'}, 'score': {0: 0.9024}}"
900,900,900,0.8830000162124634,24.0,42/184,MyriadPro-Light,4,-0.25,5723991,24,9,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  42/184  0.917595",[],"{'keyword': {0: '42 184'}, 'score': {0: 0.937}}"
901,901,901,0.8830000162124634,24.0,0.34 (0.19–0.62),MyriadPro-Light,4,-0.25,5723991,24,9,3,{},{},{},{},{},"  entity_group           value     score
0    Lab_value          0.34 (  0.957896
1    Lab_value  0.34 0.19–0.62  0.710747",[],"{'keyword': {0: '34 19', 1: '34 19 62', 2: '19 62'}, 'score': {0: 0.6669, 1: 0.6649, 2: 0.5786}}"
902,902,902,0.8830000162124634,24.0,91.9,MyriadPro-Light,4,-0.25,5723991,24,9,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  91.9  0.995429",[],"{'keyword': {}, 'score': {}}"
903,903,903,0.8830000162124634,24.0,75.9,MyriadPro-Light,4,-0.25,5723991,24,9,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  75.9  0.999323",[],"{'keyword': {}, 'score': {}}"
904,904,904,0.8830000162124634,24.0,ypT2,MyriadPro-Light,4,-0.25,5723991,24,10,0,"{'concept_id': {0: 'C1840299'}, 'canonical_name': {0: 'Hypotrichosis Simplex of Scalp'}, 'aliases': {0: ['HYPOTRICHOSIS 2', 'HTSS1', 'HTSS', 'Hereditary hypotrichosis simplex of scalp (disorder)', 'HYPT2', 'Hereditary hypotrichosis simplex of scalp', 'Hypotrichosis simplex of scalp', 'Hypotrichosis, Spanish Type', 'HYPOTRICHOSIS, SPANISH TYPE', 'HYPOTRICHOSIS SIMPLEX OF THE SCALP 1', 'Hereditary hypotrichosis simplex of the scalp', 'Hypotrichosis simplex of the scalp']}, 'types': {0: ['T047']}, 'definition': {0: 'Hypotrichosis simplex of the scalp (HSS) has manifestation of diffuse progressive hair loss that is confined to the scalp. Prevalence is unknown but HSS has been described in multiple members (males and females) of several large families. Progressive hair loss generally begins during the first decade of life and most patients are completely bald by the third decade of life. Body, axillary and facial hair, as well as the eyebrows and eyelashes are unaffected. There are no anomalies of the skin, nails and teeth. The causative gene CDSN (encoding the keratinocyte adhesion molecule, corneodesmosin) has been mapped to chromosome 6p21.3. Transmitted in an autosomal dominant manner.'}, 'entity': {0: 'ypT2'}, 'text': {0: 'ypT2'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypT2  0.998105",[],"{'keyword': {}, 'score': {}}"
905,905,905,0.8830000162124634,24.0,25/174,MyriadPro-Light,4,-0.25,5723991,24,10,1,{},{},{},{},{},"  entity_group   value    score
0    Lab_value  25/174  0.99799",[],"{'keyword': {0: '25 174'}, 'score': {0: 0.92}}"
906,906,906,0.8830000162124634,24.0,44/185,MyriadPro-Light,4,-0.25,5723991,24,10,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  44/185  0.962722",[],"{'keyword': {0: '44 185'}, 'score': {0: 0.94}}"
907,907,907,0.8830000162124634,24.0,0.50 (0.31–0.82),MyriadPro-Light,4,-0.25,5723991,24,10,3,{},{},{},{},{},"  entity_group           value     score
0    Lab_value          0.50 (  0.913195
1    Lab_value  0.50 0.31–0.82  0.765733
2    Lab_value       0.31–0.82  0.717574",[],"{'keyword': {0: '50 31', 1: '31 82', 2: '50 31 82'}, 'score': {0: 0.7461, 1: 0.6432, 2: 0.6166}}"
908,908,908,0.8830000162124634,24.0,88.3,MyriadPro-Light,4,-0.25,5723991,24,10,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  88.3  0.999122",[],"{'keyword': {}, 'score': {}}"
909,909,909,0.8830000162124634,24.0,74.3,MyriadPro-Light,4,-0.25,5723991,24,10,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  74.3  0.999471",[],"{'keyword': {}, 'score': {}}"
910,910,910,0.8830000162124634,24.0,ypT3,MyriadPro-Light,4,-0.25,5723991,24,11,0,{},{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypT3  0.986273",[],"{'keyword': {}, 'score': {}}"
911,911,911,0.8830000162124634,24.0,9/51,MyriadPro-Light,4,-0.25,5723991,24,11,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value  9/51  0.999672",[],"{'keyword': {}, 'score': {}}"
912,912,912,0.8830000162124634,24.0,21/57,MyriadPro-Light,4,-0.25,5723991,24,11,2,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  21/57  0.99921",[],"{'keyword': {0: '21 57'}, 'score': {0: 0.8219}}"
913,913,913,0.8830000162124634,24.0,0.40 (0.18–0.88),MyriadPro-Light,4,-0.25,5723991,24,11,3,{},{},{},{},{},"  entity_group           value     score
0    Lab_value          0.40 (  0.915262
1    Lab_value  0.40 0.18–0.88  0.848215",[],"{'keyword': {0: '40 18', 1: '40 18 88', 2: '18 88'}, 'score': {0: 0.725, 1: 0.7, 2: 0.6326}}"
914,914,914,0.8830000162124634,24.0,79.8,MyriadPro-Light,4,-0.25,5723991,24,11,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  79.8  0.998995",[],"{'keyword': {}, 'score': {}}"
915,915,915,0.8830000162124634,24.0,61.1,MyriadPro-Light,4,-0.25,5723991,24,11,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  61.1  0.993431",[],"{'keyword': {}, 'score': {}}"
916,916,916,0.8830000162124634,24.0,ypT4,MyriadPro-Light,4,-0.25,5723991,24,12,0,{},{},{},{},{},"           entity_group value    score
0  Diagnostic_procedure  ypT4  0.94851",[],"{'keyword': {}, 'score': {}}"
917,917,917,0.8830000162124634,24.0,3/12,MyriadPro-Light,4,-0.25,5723991,24,12,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value  3/12  0.998447",[],"{'keyword': {}, 'score': {}}"
918,918,918,0.8830000162124634,24.0,6/11,MyriadPro-Light,4,-0.25,5723991,24,12,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value  6/11  0.997095",[],"{'keyword': {}, 'score': {}}"
919,919,919,0.8830000162124634,24.0,0.29 (0.07–1.17),MyriadPro-Light,4,-0.25,5723991,24,12,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value  0.29  0.99896",[],"{'keyword': {0: '29 07 17', 1: '29 07', 2: '07 17'}, 'score': {0: 0.7051, 1: 0.6825, 2: 0.5794}}"
920,920,920,0.8830000162124634,24.0,70.0,MyriadPro-Light,4,-0.25,5723991,24,12,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  70.0  0.999297",[],"{'keyword': {}, 'score': {}}"
921,921,921,0.8830000162124634,24.0,30.0,MyriadPro-Light,4,-0.25,5723991,24,12,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  30.0  0.987688",[],"{'keyword': {}, 'score': {}}"
922,922,922,0.8830000162124634,24.0,Regional lymph-node stage at definitive surgery,MyriadPro-Light,4,-0.25,5723991,24,13,0,"{'concept_id': {0: 'C0443196'}, 'canonical_name': {0: 'Definitive'}, 'aliases': {0: ['definitive', 'Definitive (qualifier value)', 'Definitive']}, 'types': {0: ['T079']}, 'definition': {0: 'Supplying or being a final or conclusive settlement or result.'}, 'entity': {0: 'definitive surgery'}, 'text': {0: 'Regional lymph-node stage at definitive surgery'}}",{},{},{},{},"           entity_group                value     score
0  Detailed_description             Regional  0.999909
1  Biological_structure  Regional lymph-node  0.854901
2  Detailed_description     lymph-node stage  0.924626
3  Detailed_description           definitive  0.999955
4           Coreference              surgery  0.864219",[],"{'keyword': {0: 'lymph node stage', 1: 'stage definitive surgery', 2: 'stage definitive', 3: 'regional lymph', 4: 'definitive surgery'}, 'score': {0: 0.9317, 1: 0.8304, 2: 0.8159, 3: 0.6535, 4: 0.6192}}"
923,923,923,0.8830000162124634,24.0,ypN0,MyriadPro-Light,4,-0.25,5723991,24,14,0,{},{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypN0  0.857369
1             Lab_value  ypN0  0.541079
2          Sign_symptom  ypN0  0.486708",[],"{'keyword': {}, 'score': {}}"
924,924,924,0.8830000162124634,24.0,28/344,MyriadPro-Light,4,-0.25,5723991,24,14,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  28/344  0.961965",[],"{'keyword': {0: '28 344'}, 'score': {0: 0.9256}}"
925,925,925,0.8830000162124634,24.0,56/335,MyriadPro-Light,4,-0.25,5723991,24,14,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  56/335  0.998965",[],"{'keyword': {0: '56 335'}, 'score': {0: 0.8904}}"
926,926,926,0.8830000162124634,24.0,0.46 (0.30–0.73),MyriadPro-Light,4,-0.25,5723991,24,14,3,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.46 (  0.957686
1    Lab_value  0.30–0.73  0.776014",[],"{'keyword': {0: '46 30', 1: '46 30 73', 2: '30 73'}, 'score': {0: 0.7226, 1: 0.674, 2: 0.6348}}"
927,927,927,0.8830000162124634,24.0,91.9,MyriadPro-Light,4,-0.25,5723991,24,14,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  91.9  0.995429",[],"{'keyword': {}, 'score': {}}"
928,928,928,0.8830000162124634,24.0,83.9,MyriadPro-Light,4,-0.25,5723991,24,14,5,{},{},{},{},{},"  entity_group value    score
0    Lab_value  83.9  0.99925",[],"{'keyword': {}, 'score': {}}"
929,929,929,0.8830000162124634,24.0,ypN1,MyriadPro-Light,4,-0.25,5723991,24,15,0,{},{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypN1  0.998739",[],"{'keyword': {}, 'score': {}}"
930,930,930,0.8830000162124634,24.0,29/220,MyriadPro-Light,4,-0.25,5723991,24,15,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  29/220  0.992549",[],"{'keyword': {0: '29 220'}, 'score': {0: 0.8768}}"
931,931,931,0.8830000162124634,24.0,50/213,MyriadPro-Light,4,-0.25,5723991,24,15,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  50/213  0.950679",[],"{'keyword': {0: '50 213'}, 'score': {0: 0.9193}}"
932,932,932,0.8830000162124634,24.0,0.49 (0.31–0.78),MyriadPro-Light,4,-0.25,5723991,24,15,3,{},{},{},{},{},"  entity_group           value     score
0    Lab_value            0.49  0.999323
1    Lab_value  0.49 0.31–0.78  0.781114
2    Lab_value       0.31–0.78  0.761368",[],"{'keyword': {0: '49 31', 1: '49 31 78', 2: '31 78'}, 'score': {0: 0.7161, 1: 0.6947, 2: 0.6829}}"
933,933,933,0.8830000162124634,24.0,88.9,MyriadPro-Light,4,-0.25,5723991,24,15,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  88.9  0.999334",[],"{'keyword': {}, 'score': {}}"
934,934,934,0.8830000162124634,24.0,75.8,MyriadPro-Light,4,-0.25,5723991,24,15,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  75.8  0.999352",[],"{'keyword': {}, 'score': {}}"
935,935,935,0.8830000162124634,24.0,ypN2,MyriadPro-Light,4,-0.25,5723991,24,16,0,{},{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypN2  0.999481",[],"{'keyword': {}, 'score': {}}"
936,936,936,0.8830000162124634,24.0,16/86,MyriadPro-Light,4,-0.25,5723991,24,16,1,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  16/86  0.996927",[],"{'keyword': {0: '16 86'}, 'score': {0: 0.888}}"
937,937,937,0.8830000162124634,24.0,38/103,MyriadPro-Light,4,-0.25,5723991,24,16,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  38/103  0.930381",[],"{'keyword': {0: '38 103'}, 'score': {0: 0.8808}}"
938,938,938,0.8830000162124634,24.0,0.43 (0.24–0.77),MyriadPro-Light,4,-0.25,5723991,24,16,3,{},{},{},{},{},"  entity_group           value     score
0    Lab_value          0.43 (  0.931692
1    Lab_value  0.43 0.24–0.77  0.672407",[],"{'keyword': {0: '43 24', 1: '43 24 77', 2: '24 77'}, 'score': {0: 0.7188, 1: 0.7158, 2: 0.6412}}"
939,939,939,0.8830000162124634,24.0,81.1,MyriadPro-Light,4,-0.25,5723991,24,16,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  81.1  0.997878",[],"{'keyword': {}, 'score': {}}"
940,940,940,0.8830000162124634,24.0,58.2,MyriadPro-Light,4,-0.25,5723991,24,16,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  58.2  0.999203",[],"{'keyword': {}, 'score': {}}"
941,941,941,0.8830000162124634,24.0,ypN3,MyriadPro-Light,4,-0.25,5723991,24,17,0,{},{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypN3  0.998871",[],"{'keyword': {}, 'score': {}}"
942,942,942,0.8830000162124634,24.0,17/37,MyriadPro-Light,4,-0.25,5723991,24,17,1,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  17/37  0.999037",[],"{'keyword': {0: '17 37'}, 'score': {0: 0.8519}}"
943,943,943,0.8830000162124634,24.0,15/30,MyriadPro-Light,4,-0.25,5723991,24,17,2,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  15/30  0.999686",[],"{'keyword': {0: '15 30'}, 'score': {0: 0.8085}}"
944,944,944,0.8830000162124634,24.0,0.71 (0.35–1.42),MyriadPro-Light,4,-0.25,5723991,24,17,3,{},{},{},{},{},"  entity_group           value     score
0    Lab_value          0.71 (  0.891476
1    Lab_value  0.71 0.35–1.42  0.904893
2    Lab_value       0.35–1.42  0.648296",[],"{'keyword': {0: '71 35', 1: '71 35 42', 2: '35 42'}, 'score': {0: 0.7959, 1: 0.7776, 2: 0.562}}"
945,945,945,0.8830000162124634,24.0,52.0,MyriadPro-Light,4,-0.25,5723991,24,17,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  52.0  0.999369",[],"{'keyword': {}, 'score': {}}"
946,946,946,0.8830000162124634,24.0,40.6,MyriadPro-Light,4,-0.25,5723991,24,17,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  40.6  0.996315",[],"{'keyword': {}, 'score': {}}"
947,947,947,0.8830000162124634,24.0,ypNX,MyriadPro-Light,4,-0.25,5723991,24,18,0,{},{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypNX  0.767269",[],"{'keyword': {}, 'score': {}}"
948,948,948,0.8830000162124634,24.0,1/56,MyriadPro-Light,4,-0.25,5723991,24,18,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value  1/56  0.999747",[],"{'keyword': {}, 'score': {}}"
949,949,949,0.8830000162124634,24.0,6/62,MyriadPro-Light,4,-0.25,5723991,24,18,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value  6/62  0.997751",[],"{'keyword': {}, 'score': {}}"
950,950,950,0.8830000162124634,24.0,0.17 (0.02–1.38),MyriadPro-Light,4,-0.25,5723991,24,18,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value  0.17  0.997994",[],"{'keyword': {0: '02 38', 1: '17 02 38', 2: '17 02'}, 'score': {0: 0.564, 1: 0.5598, 2: 0.4824}}"
951,951,951,0.8830000162124634,24.0,98.1,MyriadPro-Light,4,-0.25,5723991,24,18,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  98.1  0.994896",[],"{'keyword': {}, 'score': {}}"
952,952,952,0.8830000162124634,24.0,88.7,MyriadPro-Light,4,-0.25,5723991,24,18,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  88.7  0.998302",[],"{'keyword': {}, 'score': {}}"
953,953,953,0.8830000162124634,24.688661575317383,0.15,MyriadPro-Light,4,-0.25,5723991,24,19,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value  0.15  0.996109",[],"{'keyword': {}, 'score': {}}"
954,954,954,0.8830000162124634,24.688661575317383,0.5,MyriadPro-Light,4,-0.25,5723991,24,19,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   0.5  0.999093","[('0.5', 'STRENGTH')]","{'keyword': {}, 'score': {}}"
955,955,955,0.8830000162124634,24.688661575317383,1.0,MyriadPro-Light,4,-0.25,5723991,24,19,2,{},{},{},{},{},"           entity_group value     score
0  Detailed_description   1.0  0.501226
1             Lab_value   1.0  0.710047",[],"{'keyword': {}, 'score': {}}"
956,956,956,0.8830000162124634,24.688661575317383,2.0,MyriadPro-Light,4,-0.25,5723991,24,19,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   2.0  0.883895",[],"{'keyword': {}, 'score': {}}"
957,957,957,0.8830000162124634,24.688661575317383,5.0,MyriadPro-Light,4,-0.25,5723991,24,19,4,{},{},{},{},{},"  entity_group value    score
0    Lab_value   5.0  0.94593",[],"{'keyword': {}, 'score': {}}"
958,958,958,0.8830000162124634,24.688661575317383,0.20,MyriadPro-Light,4,-0.25,5723991,24,20,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value  0.20  0.994717",[],"{'keyword': {}, 'score': {}}"
959,959,959,0.8830000162124634,19.0,Adapted from von Minckwitz et al. 2019.,MyriadPro-Light,4,-0.25,3355443,24,21,0,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
960,960,960,0.8830000162124634,19.0,"CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  ",MyriadPro-Light,4,-0.25,3355443,24,21,1,"{'concept_id': {0: 'C1512496'}, 'canonical_name': {0: 'Hormone Receptor Test'}, 'aliases': {0: []}, 'types': {0: ['T059']}, 'definition': {0: 'A hormone receptor test measures the amount of certain hormone receptors proteins in cancer tissue. Hormones (such as estrogen and progesterone that naturally occur in the body) can attach to these proteins. If the test is positive, it indicates that the hormone is probably helping the cancer cells grow.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}","{'concept_id': {0: 'C0034808'}, 'canonical_name': {0: 'Receptors, Gastrointestinal Hormone'}, 'aliases': {0: ['Gastrointestinal Peptides Receptors', 'Receptors, Intestinal Hormone', 'Gastrointestinal Hormone Receptors', 'Receptors, Gastrointestinal Peptides', 'Gastrointestinal Hormone Receptor', 'Gastrointestinal Hormones Receptors', 'Hormone Receptors, Intestinal', 'Peptides Receptors, Gastrointestinal', 'Hormone Receptor, Intestinal', 'Intestinal Hormone Receptors', 'Hormone Receptors, Gastrointestinal', 'Hormones Receptors, Gastrointestinal', 'Intestinal Hormone Receptor', 'Receptor, Intestinal Hormone', 'Hormone Receptor, Gastrointestinal', 'Receptors, Gastrointestinal Hormones', 'Receptor, Gastrointestinal Hormone']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: 'Cell surface proteins that bind gastrointestinal hormones with high affinity and trigger intracellular changes influencing the behavior of cells. Most gastrointestinal hormones also act as neurotransmitters so these receptors are also present in the central and peripheral nervous systems.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}",{},"{'concept_id': {0: 'C1152812'}, 'canonical_name': {0: 'growth hormone receptor activity'}, 'aliases': {0: []}, 'types': {0: ['T044']}, 'definition': {0: 'Combining with a growth hormone and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. [GOC:ai, GOC:signaling]'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}","{'concept_id': {0: 'C4722330'}, 'canonical_name': {0: 'Thyroid hormone receptor defect'}, 'aliases': {0: ['Thyroid hormone resistance', 'End-organ unresponsiveness to thyroid hormone', 'Elevated serum levels of free thyroid hormone with nonsuppressed TSH', 'Resistance to thyroid hormone', 'Impaired sensitivity to thyroid hormone']}, 'types': {0: ['T047']}, 'definition': {0: 'Decreased response to thyroid hormones in peripheral tissues and in the pituitary gland.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'receptor hr hormone', 1: 'confidence interval er', 2: 'oestrogen receptor', 3: 'interval er', 4: 'ci confidence interval'}, 'score': {0: 0.8637, 1: 0.7731, 2: 0.7447, 3: 0.7087, 4: 0.5439}}"
961,961,961,0.8830000162124634,19.0,"IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.",MyriadPro-Light,4,-0.25,3355443,24,21,2,"{'concept_id': {0: 'C4082178'}, 'canonical_name': {0: 'Progesterone Receptor, human'}, 'aliases': {0: ['PRB', 'PGR', 'Nuclear Receptor Subfamily 3 Group C Member 3', 'Progesterone Receptor Isoform B', 'Progesterone Receptor B', 'PgR', 'Progesterone Receptor']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: 'Progesterone receptor (933 aa, ~99 kDa) is encoded by the human PGR gene. This protein is involved in the regulation of transcription.'}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.'}}","{'concept_id': {0: 'C0385053'}, 'canonical_name': {0: 'progesterone receptors B'}, 'aliases': {0: ['progesterone receptor B', 'receptor B, progesterone']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: None}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.'}}",{},"{'concept_id': {0: 'C1157305'}, 'canonical_name': {0: 'progesterone biosynthetic process'}, 'aliases': {0: ['progesterone anabolism', 'progesterone formation', 'progesterone synthesis', 'progesterone biosynthesis']}, 'types': {0: ['T044']}, 'definition': {0: 'The chemical reactions and pathways resulting in the formation of progesterone, a steroid hormone produced in the ovary which prepares and maintains the uterus for pregnancy. Also found in plants. [GOC:jl, http://www.cogsci.princeton.edu/]'}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.'}}",{},"Empty DataFrame
Columns: []
Index: []","[('progesterone receptor', 'DRUG')]","{'keyword': {0: 'free survival ne', 1: 'idfs invasive disease', 2: 'progesterone receptor', 3: 'ne evaluable', 4: 'evaluable pr'}, 'score': {0: 0.8122, 1: 0.7718, 2: 0.6953, 3: 0.562, 4: 0.3307}}"
962,962,962,0.8830000162124634,24.688661575317383,Trastuzumab better,MyriadPro-Light,4,-0.25,5723991,24,22,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab better'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab better'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab better'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999839
1    Lab_value       better  0.999615","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab better'}, 'score': {0: 1.0}}"
963,963,963,0.8830000162124634,24.688661575317383,Kadcyla better,MyriadPro-Light,4,-0.25,5723991,24,22,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla better'}, 'text': {0: 'Kadcyla better'}}",{},{},{},{},"           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.988854
1             Lab_value   better  0.999646",[],"{'keyword': {0: 'kadcyla better'}, 'score': {0: 1.0}}"
964,964,964,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,24,23,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
965,965,965,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,24,23,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
966,966,966,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,24,23,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
967,967,967,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,24,23,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
968,968,968,0.75,98.0,The effect of Kadcyla was consistent  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,25,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}","{'concept_id': {0: 'C1158774'}, 'canonical_name': {0: 'carbon catabolite repression of transcription by glucose'}, 'aliases': {0: ['down regulation of transcription by glucose', 'glucose effect', 'glucose repression', 'down-regulation of transcription by glucose', 'downregulation of transcription by glucose']}, 'types': {0: ['T045']}, 'definition': {0: 'A transcription regulation process in which the presence of glucose leads to a decrease in the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other carbon sources. Carbon catabolite repression is a mechanism of genetic regulation which the accumulation of catabolites of one substance in the cell represses the formation of enzymes that contribute to the catabolism of other substances. [ISBN:0198506732, PMID:11018147]'}, 'entity': {0: 'effect'}, 'text': {0: 'The effect of Kadcyla was consistent  '}}",{},"  entity_group       value     score
0  Coreference     Kadcyla  0.981526
1    Lab_value  consistent  0.999529","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla consistent', 1: 'effect kadcyla consistent', 2: 'effect kadcyla'}, 'score': {0: 0.8612, 1: 0.8439, 2: 0.7451}}"
969,969,969,0.75,98.0,across most patient subgroups,ConduitITC-Bold,20,-0.1700000017881393,8194925,25,1,1,"{'concept_id': {0: 'C0751987'}, 'canonical_name': {0: 'Betaproteobacteria'}, 'aliases': {0: ['Purple bacteria, beta subdivision', 'Proteobacteria beta subdivision', 'Betaproteobacteria', 'beta subgroup', 'beta Proteobacteria', 'Class Betaproteobacteria', 'beta subdivision', 'beta proteobacteria', 'Class Betaproteobacteria (organism)', 'Proteobacteria beta']}, 'types': {0: ['T007']}, 'definition': {0: 'A class in the phylum PROTEOBACTERIA comprised of chemoheterotrophs and chemoautotrophs which derive nutrients from decomposition of organic material.'}, 'entity': {0: 'subgroups'}, 'text': {0: 'across most patient subgroups'}}","{'concept_id': {0: 'C4277550'}, 'canonical_name': {0: 'Patient Portals'}, 'aliases': {0: ['Patient Internet Portals', 'Web Portals, Patient', 'Web Portal, Patient', 'Patient Internet Portal', 'Portals, Patient Web', 'Portal, Patient Web', 'Portal, Patient Internet', 'Patient Web Portals', 'Internet Portal, Patient', 'Internet Portals, Patient', 'Patient Portal', 'Patient Web Portal', 'Portals, Patient Internet', 'Portal, Patient']}, 'types': {0: ['T170']}, 'definition': {0: 'A secure online website that provides patients convenient 24-hour access to personal health information via an Internet connection.'}, 'entity': {0: 'patient'}, 'text': {0: 'across most patient subgroups'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'patient subgroups'}, 'score': {0: 0.7486}}"
970,970,970,0.944000005722046,25.0,Subgroup,UniversSB-Medium,4,-0.2349999994039535,5723991,25,2,0,"{'concept_id': {0: 'C0751987'}, 'canonical_name': {0: 'Betaproteobacteria'}, 'aliases': {0: ['Purple bacteria, beta subdivision', 'Proteobacteria beta subdivision', 'Betaproteobacteria', 'beta subgroup', 'beta Proteobacteria', 'Class Betaproteobacteria', 'beta subdivision', 'beta proteobacteria', 'Class Betaproteobacteria (organism)', 'Proteobacteria beta']}, 'types': {0: ['T007']}, 'definition': {0: 'A class in the phylum PROTEOBACTERIA comprised of chemoheterotrophs and chemoautotrophs which derive nutrients from decomposition of organic material.'}, 'entity': {0: 'Subgroup'}, 'text': {0: 'Subgroup'}}",{},{},{},{},"           entity_group     value     score
0  Detailed_description  Subgroup  0.984178",[],"{'keyword': {}, 'score': {}}"
971,971,971,0.944000005722046,25.0,Kadcyla,UniversSB-Medium,4,-0.2349999994039535,5723991,25,2,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
972,972,972,0.944000005722046,25.0,Trastuzumab,UniversSB-Medium,4,-0.2349999994039535,5723991,25,2,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
973,973,973,0.944000005722046,25.0,Hazard ratio for IDFS event (95% CI),UniversSB-Medium,4,-0.2349999994039535,5723991,25,2,3,"{'concept_id': {0: 'C1417638'}, 'canonical_name': {0: 'NDUFB6 gene'}, 'aliases': {0: ['NDUFB6', 'COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, B17 SUBUNIT', 'NADH-ubiquinone oxidoreductase beta subunit, 6', 'NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa', 'CI', 'NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 (17kD, B17)', 'NADH:ubiquinone oxidoreductase subunit B6', 'NADH-ubiquinone oxidoreductase B17 subunit', 'B17', 'complex I, mitochondrial respiratory chain, B17 subunit', 'NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 6', 'NDUFB6 gene']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'CI'}, 'text': {0: 'Hazard ratio for IDFS event (95% CI)'}}",{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: 'Hazard ratio for IDFS event (95% CI)'}}",{},"           entity_group         value     score
0  Diagnostic_procedure  Hazard ratio  0.997832",[],"{'keyword': {0: 'hazard ratio', 1: 'event 95 ci', 2: 'idfs event', 3: '95 ci', 4: 'event 95'}, 'score': {0: 0.8621, 1: 0.8066, 2: 0.7644, 3: 0.7367, 4: 0.6039}}"
974,974,974,0.944000005722046,25.0,3-year IDFS rate (%),UniversSB-Medium,4,-0.2349999994039535,5723991,25,2,4,{},{},{},"{'concept_id': {0: 'C1150650'}, 'canonical_name': {0: 'ATP:isocitrate dehydrogenase (NADP+) phosphotransferase activity'}, 'aliases': {0: ['IDHK/P', 'IDH kinase activity', 'isocitrate dehydrogenase kinase activity', 'IDH-K/P', 'isocitrate dehydrogenase (NADP) kinase activity', '[isocitrate dehydrogenase (NADP+)] kinase activity', 'isocitrate dehydrogenase kinase (phosphorylating) activity', 'isocitrate dehydrogenase (NADP+) kinase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + (isocitrate dehydrogenase (NADP)) = ADP + (isocitrate dehydrogenase (NADP)) phosphate. [EC:2.7.11.5]'}, 'entity': {0: 'IDFS'}, 'text': {0: '3-year IDFS rate (%)'}}",{},"           entity_group      value     score
0              Duration     3-year  0.817769
1  Diagnostic_procedure  IDFS rate  0.999706",[],"{'keyword': {0: 'idfs rate', 1: 'year idfs rate', 2: 'year idfs'}, 'score': {0: 0.8784, 1: 0.838, 2: 0.7549}}"
975,975,975,0.9470000267028807,25.0,no. of patients with an invasive ,UniversSB-Light,4,-0.2329999953508377,5723991,25,3,0,"{'concept_id': {0: 'C1334278'}, 'canonical_name': {0: 'Invasive Lesion'}, 'aliases': {0: ['Invasive Lesion']}, 'types': {0: ['T033']}, 'definition': {0: 'A malignant cellular population that has increased in size and infiltrates the surrounding tissues.'}, 'entity': {0: 'invasive'}, 'text': {0: 'no. of patients with an invasive '}}","{'concept_id': {0: 'C2936533'}, 'canonical_name': {0: 'Invasive Species'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Non-native species that threaten ecosystems, habitats, or other species and are likely to cause economic or environmental harm or harm to human health.'}, 'entity': {0: 'invasive'}, 'text': {0: 'no. of patients with an invasive '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'no. of patients with an invasive '}}",{},"           entity_group     value     score
0  Detailed_description  invasive  0.999888",[],"{'keyword': {0: 'patients invasive'}, 'score': {0: 0.5747}}"
976,976,976,0.9470000267028807,25.0,disease event/total no.,UniversSB-Light,4,-0.2329999953508377,5723991,25,3,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'disease event total', 1: 'event total', 2: 'disease event'}, 'score': {0: 0.9121, 1: 0.8391, 2: 0.6522}}"
977,977,977,0.9470000267028807,25.0,Kadcyla,UniversSB-Light,4,-0.2329999953508377,5723991,25,3,2,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
978,978,978,0.9470000267028807,25.0,Trastuzumab,UniversSB-Light,4,-0.2329999953508377,5723991,25,3,3,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
979,979,979,0.9470000267028807,24.0,All patients,UniversSB-Light,4,-0.2329999953508377,5723991,25,4,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'All patients'}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'All patients'}}",{},{},{},"           entity_group         value     score
0  Detailed_description  All patients  0.686864",[],"{'keyword': {}, 'score': {}}"
980,980,980,0.9470000267028807,24.0,91/743,UniversSB-Light,4,-0.2329999953508377,5723991,25,4,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  91/743  0.999071",[],"{'keyword': {0: '91 743'}, 'score': {0: 0.9052}}"
981,981,981,0.9470000267028807,24.0,165/743,UniversSB-Light,4,-0.2329999953508377,5723991,25,4,2,{},{},{},{},{},"  entity_group    value     score
0    Lab_value  165/743  0.994471",[],"{'keyword': {0: '165 743'}, 'score': {0: 0.9102}}"
982,982,982,0.9470000267028807,24.0,0.50 (0.39–0.64),UniversSB-Light,4,-0.2329999953508377,5723991,25,4,3,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.50 (  0.984410
1    Lab_value  0.39–0.64  0.797765",[],"{'keyword': {0: '50 39', 1: '39 64', 2: '50 39 64'}, 'score': {0: 0.7748, 1: 0.6913, 2: 0.6562}}"
983,983,983,0.9470000267028807,24.0,88.3,UniversSB-Light,4,-0.2329999953508377,5723991,25,4,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  88.3  0.999122",[],"{'keyword': {}, 'score': {}}"
984,984,984,0.9470000267028807,24.0,77.0,UniversSB-Light,4,-0.2329999953508377,5723991,25,4,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  77.0  0.999825",[],"{'keyword': {}, 'score': {}}"
985,985,985,0.9470000267028807,24.0,Age group,UniversSB-Light,4,-0.2329999953508377,5723991,25,5,0,"{'concept_id': {0: 'C1830159'}, 'canonical_name': {0: 'Age group:Type:Point in time:^Patient:Ordinal'}, 'aliases': {0: ['Age group', 'Age group:Type:To identify measures at a point in time:^Patient:Ordinal', 'Age group:Type:Pt:^Patient:Ord']}, 'types': {0: ['T201']}, 'definition': {0: None}, 'entity': {0: 'Age group'}, 'text': {0: 'Age group'}}","{'concept_id': {0: 'C0027362'}, 'canonical_name': {0: 'Age Groups'}, 'aliases': {0: ['Age Group', 'Group, Age']}, 'types': {0: ['T100']}, 'definition': {0: 'Persons classified by age from birth (INFANT, NEWBORN) to octogenarians and older (AGED, 80 AND OVER).'}, 'entity': {0: 'Age group'}, 'text': {0: 'Age group'}}",{},{},{},"           entity_group      value     score
0  Diagnostic_procedure  Age group  0.817007",[],"{'keyword': {0: 'age group'}, 'score': {0: 1.0}}"
986,986,986,0.9470000267028807,24.0,<40 years,UniversSB-Light,4,-0.2329999953508377,5723991,25,6,0,"{'concept_id': {0: 'C3843646'}, 'canonical_name': {0: 'One to Two Years'}, 'aliases': {0: ['1 to 2 Years', '1-2 years']}, 'types': {0: ['T079']}, 'definition': {0: 'An indication that something has lasted, or occurred during, one to two years.'}, 'entity': {0: 'years'}, 'text': {0: '<40 years'}}",{},{},{},{},"  entity_group       value     score
0     Duration  < 40 years  0.982235",[],"{'keyword': {0: '40 years'}, 'score': {0: 0.7648}}"
987,987,987,0.9470000267028807,24.0,20/143,UniversSB-Light,4,-0.2329999953508377,5723991,25,6,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  20/143  0.871735",[],"{'keyword': {0: '20 143'}, 'score': {0: 0.8982}}"
988,988,988,0.9470000267028807,24.0,37/153,UniversSB-Light,4,-0.2329999953508377,5723991,25,6,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  37/153  0.993976",[],"{'keyword': {0: '37 153'}, 'score': {0: 0.9094}}"
989,989,989,0.9470000267028807,24.0,0.50 (0.29–0.36),UniversSB-Light,4,-0.2329999953508377,5723991,25,6,3,{},{},{},{},{},"  entity_group           value     score
0    Lab_value          0.50 (  0.914456
1    Lab_value  0.50 0.29–0.36  0.774167
2    Lab_value       0.29–0.36  0.708873",[],"{'keyword': {0: '50 29', 1: '50 29 36', 2: '29 36'}, 'score': {0: 0.7309, 1: 0.6744, 2: 0.6039}}"
990,990,990,0.9470000267028807,24.0,86.5,UniversSB-Light,4,-0.2329999953508377,5723991,25,6,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  86.5  0.999513",[],"{'keyword': {}, 'score': {}}"
991,991,991,0.9470000267028807,24.0,74.9,UniversSB-Light,4,-0.2329999953508377,5723991,25,6,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  74.9  0.999394",[],"{'keyword': {}, 'score': {}}"
992,992,992,0.9470000267028807,24.0,40–64 years,UniversSB-Light,4,-0.2329999953508377,5723991,25,7,0,"{'concept_id': {0: 'C3843646'}, 'canonical_name': {0: 'One to Two Years'}, 'aliases': {0: ['1 to 2 Years', '1-2 years']}, 'types': {0: ['T079']}, 'definition': {0: 'An indication that something has lasted, or occurred during, one to two years.'}, 'entity': {0: 'years'}, 'text': {0: '40–64 years'}}",{},{},{},{},"  entity_group        value     score
0     Duration  40–64 years  0.990326",[],"{'keyword': {0: '40 64 years', 1: '64 years', 2: '40 64'}, 'score': {0: 0.9496, 1: 0.904, 2: 0.8886}}"
993,993,993,0.9470000267028807,24.0,64/542,UniversSB-Light,4,-0.2329999953508377,5723991,25,7,1,{},{},{},{},{},"  entity_group   value    score
0    Lab_value  64/542  0.99957",[],"{'keyword': {0: '64 542'}, 'score': {0: 0.8752}}"
994,994,994,0.9470000267028807,24.0,113/522,UniversSB-Light,4,-0.2329999953508377,5723991,25,7,2,{},{},{},{},{},"  entity_group    value     score
0    Lab_value  113/522  0.999293",[],"{'keyword': {0: '113 522'}, 'score': {0: 0.8476}}"
995,995,995,0.9470000267028807,24.0,0.49 (0.36–0.67),UniversSB-Light,4,-0.2329999953508377,5723991,25,7,3,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.49 (  0.978429
1    Lab_value  0.36–0.67  0.832066",[],"{'keyword': {0: '36 67', 1: '49 36', 2: '49 36 67'}, 'score': {0: 0.7391, 1: 0.7297, 2: 0.7293}}"
996,996,996,0.9470000267028807,24.0,88.8,UniversSB-Light,4,-0.2329999953508377,5723991,25,7,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  88.8  0.999285",[],"{'keyword': {}, 'score': {}}"
997,997,997,0.9470000267028807,24.0,77.1,UniversSB-Light,4,-0.2329999953508377,5723991,25,7,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  77.1  0.997772",[],"{'keyword': {}, 'score': {}}"
998,998,998,0.9319999814033508,24.0,≥,Ubuntu,4,-0.1889999955892563,5723991,25,8,0,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
999,999,999,0.9470000267028807,24.0,7/58,UniversSB-Light,4,-0.2329999953508377,5723991,25,8,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value  7/58  0.997541",[],"{'keyword': {}, 'score': {}}"
1000,1000,1000,0.9470000267028807,24.0,15/68,UniversSB-Light,4,-0.2329999953508377,5723991,25,8,2,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  15/68  0.999253",[],"{'keyword': {0: '15 68'}, 'score': {0: 0.8441}}"
1001,1001,1001,0.9470000267028807,24.0,0.55 (0.22–1.34),UniversSB-Light,4,-0.2329999953508377,5723991,25,8,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value  0.55  0.999334",[],"{'keyword': {0: '55 22 34', 1: '55 22', 2: '22 34'}, 'score': {0: 0.7397, 1: 0.7238, 2: 0.5203}}"
1002,1002,1002,0.9470000267028807,24.0,87.4,UniversSB-Light,4,-0.2329999953508377,5723991,25,8,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  87.4  0.998877",[],"{'keyword': {}, 'score': {}}"
1003,1003,1003,0.9470000267028807,24.0,81.1,UniversSB-Light,4,-0.2329999953508377,5723991,25,8,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  81.1  0.997878",[],"{'keyword': {}, 'score': {}}"
1004,1004,1004,0.9470000267028807,24.0,Clinical stage at presentation,UniversSB-Light,4,-0.2329999953508377,5723991,25,9,0,"{'concept_id': {0: 'C0233302'}, 'canonical_name': {0: 'Funic presentation'}, 'aliases': {0: ['Funic Presentation', 'Funic presentation', 'Funis Presentation', 'Presentation of cord', 'Presentation of cord (disorder)', 'Funic presentation (finding)', 'Cord presentation', 'Cord Presentation']}, 'types': {0: ['T033']}, 'definition': {0: 'The positioning of the umbilical cord before the main presenting part of the fetus.'}, 'entity': {0: 'presentation'}, 'text': {0: 'Clinical stage at presentation'}}","{'concept_id': {0: 'C1257986'}, 'canonical_name': {0: 'Cross-Presentation'}, 'aliases': {0: ['Cross Presentation']}, 'types': {0: ['T043']}, 'definition': {0: 'Transfer of exogenous ANTIGEN to the ANTIGEN-PRESENTING CELLS for presentation to naive CD8-POSITIVE LYMPHOCYTES.'}, 'entity': {0: 'presentation'}, 'text': {0: 'Clinical stage at presentation'}}",{},"{'concept_id': {0: 'C0206431'}, 'canonical_name': {0: 'antigen processing and presentation'}, 'aliases': {0: ['antigen processing', 'antigen presentation']}, 'types': {0: ['T043']}, 'definition': {0: 'The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)'}, 'entity': {0: 'presentation'}, 'text': {0: 'Clinical stage at presentation'}}",{},"           entity_group           value     score
0  Diagnostic_procedure  Clinical stage  0.704720
1        Clinical_event    presentation  0.998513",[],"{'keyword': {0: 'clinical stage', 1: 'stage presentation', 2: 'clinical stage presentation'}, 'score': {0: 0.9438, 1: 0.908, 2: 0.8979}}"
1005,1005,1005,0.9470000267028807,24.0,Inoperable breast cancer,UniversSB-Light,4,-0.2329999953508377,5723991,25,10,0,"{'concept_id': {0: 'C0376571'}, 'canonical_name': {0: 'BRCA1 gene'}, 'aliases': {0: ['BRCA1, DNA Repair Associated Gene', 'brca1', 'Gene, BRCA1', 'FANCS', 'BRCA1 gene', 'BRCA1 Gene', 'BRCA1 DNA REPAIR-ASSOCIATED PROTEIN', 'brca1 gene', 'Fanconi anemia, complementation group S', 'BRCA1/BRCA2-containing complex, subunit 1', 'Genes, BRCA1', 'BRCA1 DNA repair associated', 'RNF53', 'BRCC1', 'BRCA1', 'Breast Cancer 1, Early Onset Gene', 'BREAST CANCER 1 GENE', 'breast cancer 1', 'PPP1R53', 'brca 1 gene', 'breast cancer 1, early onset', 'BRCA1 Genes', 'protein phosphatase 1, regulatory subunit 53']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.'}, 'entity': {0: 'Inoperable breast cancer'}, 'text': {0: 'Inoperable breast cancer'}}","{'concept_id': {0: 'C0238033'}, 'canonical_name': {0: 'Breast Carcinoma, Male'}, 'aliases': {0: ['Cancer, Male Breast', 'Breast Cancer, Male', 'Carcinoma, Male Breast', 'Male Breast Carcinoma', 'Male Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A rare malignant tumor of the breast, affecting mostly older men. It accounts for less than 1% of all malignancies in men. The most common histologic type is invasive ductal carcinoma. Most patients are treated with mastectomy.'}, 'entity': {0: 'Inoperable breast cancer'}, 'text': {0: 'Inoperable breast cancer'}}",{},{},{},"           entity_group          value     score
0  Detailed_description     Inoperable  0.999938
1      Disease_disorder  breast cancer  0.969098",[],"{'keyword': {0: 'inoperable breast cancer', 1: 'inoperable breast', 2: 'breast cancer'}, 'score': {0: 1.0, 1: 0.9156, 2: 0.6935}}"
1006,1006,1006,0.9470000267028807,24.0,42/185,UniversSB-Light,4,-0.2329999953508377,5723991,25,10,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  42/185  0.948985",[],"{'keyword': {0: '42 185'}, 'score': {0: 0.9429}}"
1007,1007,1007,0.9470000267028807,24.0,70/190,UniversSB-Light,4,-0.2329999953508377,5723991,25,10,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  70/190  0.846365",[],"{'keyword': {0: '70 190'}, 'score': {0: 0.9112}}"
1008,1008,1008,0.9470000267028807,24.0,0.54 (0.37–0.80),UniversSB-Light,4,-0.2329999953508377,5723991,25,10,3,{},{},{},{},{},"  entity_group           value     score
0    Lab_value          0.54 (  0.969042
1    Lab_value  0.54 0.37–0.80  0.813234
2    Lab_value       0.37–0.80  0.770023",[],"{'keyword': {0: '54 37 80', 1: '54 37', 2: '37 80'}, 'score': {0: 0.7429, 1: 0.7296, 2: 0.7012}}"
1009,1009,1009,0.9470000267028807,24.0,76.0,UniversSB-Light,4,-0.2329999953508377,5723991,25,10,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  76.0  0.999726",[],"{'keyword': {}, 'score': {}}"
1010,1010,1010,0.9470000267028807,24.0,60.2,UniversSB-Light,4,-0.2329999953508377,5723991,25,10,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  60.2  0.995108",[],"{'keyword': {}, 'score': {}}"
1011,1011,1011,0.9470000267028807,24.0,Operable breast cancer,UniversSB-Light,4,-0.2329999953508377,5723991,25,11,0,"{'concept_id': {0: 'C0376571'}, 'canonical_name': {0: 'BRCA1 gene'}, 'aliases': {0: ['BRCA1, DNA Repair Associated Gene', 'brca1', 'Gene, BRCA1', 'FANCS', 'BRCA1 gene', 'BRCA1 Gene', 'BRCA1 DNA REPAIR-ASSOCIATED PROTEIN', 'brca1 gene', 'Fanconi anemia, complementation group S', 'BRCA1/BRCA2-containing complex, subunit 1', 'Genes, BRCA1', 'BRCA1 DNA repair associated', 'RNF53', 'BRCC1', 'BRCA1', 'Breast Cancer 1, Early Onset Gene', 'BREAST CANCER 1 GENE', 'breast cancer 1', 'PPP1R53', 'brca 1 gene', 'breast cancer 1, early onset', 'BRCA1 Genes', 'protein phosphatase 1, regulatory subunit 53']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.'}, 'entity': {0: 'Operable breast cancer'}, 'text': {0: 'Operable breast cancer'}}","{'concept_id': {0: 'C0238033'}, 'canonical_name': {0: 'Breast Carcinoma, Male'}, 'aliases': {0: ['Cancer, Male Breast', 'Breast Cancer, Male', 'Carcinoma, Male Breast', 'Male Breast Carcinoma', 'Male Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A rare malignant tumor of the breast, affecting mostly older men. It accounts for less than 1% of all malignancies in men. The most common histologic type is invasive ductal carcinoma. Most patients are treated with mastectomy.'}, 'entity': {0: 'Operable breast cancer'}, 'text': {0: 'Operable breast cancer'}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'Operable breast cancer'}, 'text': {0: 'Operable breast cancer'}}","           entity_group          value     score
0  Detailed_description       Operable  0.983971
1      Disease_disorder  breast cancer  0.999287",[],"{'keyword': {0: 'operable breast cancer', 1: 'operable breast', 2: 'breast cancer'}, 'score': {0: 1.0, 1: 0.9106, 2: 0.7264}}"
1012,1012,1012,0.9470000267028807,24.0,49/558,UniversSB-Light,4,-0.2329999953508377,5723991,25,11,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  49/558  0.999437",[],"{'keyword': {0: '49 558'}, 'score': {0: 0.8766}}"
1013,1013,1013,0.9470000267028807,24.0,95/553,UniversSB-Light,4,-0.2329999953508377,5723991,25,11,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  95/553  0.999606",[],"{'keyword': {0: '95 553'}, 'score': {0: 0.8497}}"
1014,1014,1014,0.9470000267028807,24.0,0.47 (0.33–0.66),UniversSB-Light,4,-0.2329999953508377,5723991,25,11,3,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.47 (  0.967341
1    Lab_value  0.33–0.66  0.940299",[],"{'keyword': {0: '47 33 66', 1: '33 66', 2: '47 33'}, 'score': {0: 0.6814, 1: 0.6812, 2: 0.6675}}"
1015,1015,1015,0.9470000267028807,24.0,92.3,UniversSB-Light,4,-0.2329999953508377,5723991,25,11,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  92.3  0.994991",[],"{'keyword': {}, 'score': {}}"
1016,1016,1016,0.9470000267028807,24.0,82.8,UniversSB-Light,4,-0.2329999953508377,5723991,25,11,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  82.8  0.998815",[],"{'keyword': {}, 'score': {}}"
1017,1017,1017,0.9470000267028807,24.0,HR status,UniversSB-Light,4,-0.2329999953508377,5723991,25,12,0,"{'concept_id': {0: 'C1415713'}, 'canonical_name': {0: 'HR gene'}, 'aliases': {0: ['HR', 'HAIRLESS, MOUSE, HOMOLOG OF', 'AU', 'HR lysine demethylase and nuclear receptor corepressor', 'hairless homolog (mouse)', 'ALUNC', 'HR LYSINE DEMETHYLASE AND NUCLEAR RECEPTOR COREPRESSOR', 'HR gene', 'hair growth associated']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'HR'}, 'text': {0: 'HR status'}}",{},{},"{'concept_id': {0: 'C2247597'}, 'canonical_name': {0: 'positive regulation of plant-type hypersensitive response'}, 'aliases': {0: ['up-regulation of plant-type hypersensitive response', 'up regulation of plant-type hypersensitive response', 'positive regulation of plant hypersensitive response', 'upregulation of plant-type hypersensitive response', 'positive regulation of HR']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that activates or increases the frequency, rate or extent of the hypersensitive response in a plant. [GOC:pamgo_curators]'}, 'entity': {0: 'HR'}, 'text': {0: 'HR status'}}",{},"           entity_group      value     score
0  Diagnostic_procedure  HR status  0.998637",[],"{'keyword': {0: 'hr status'}, 'score': {0: 1.0}}"
1018,1018,1018,0.9470000267028807,24.0,"Negative (ER-negative and PR-negative, ",UniversSB-Light,4,-0.2329999953508377,5723991,25,13,0,"{'concept_id': {0: 'C3539878'}, 'canonical_name': {0: 'Triple Negative Breast Neoplasms'}, 'aliases': {0: ['Triple Negative Breast Cancer', 'Triple-Negative Breast Neoplasms', 'triple-negative breast cancer', 'TNBC - Triple-negative breast cancer', 'Breast Cancers, Triple-Negative', 'ER-Negative PR-Negative HER2-Negative Breast Cancer', 'Triple-negative breast cancer', 'Breast Cancer, Triple-Negative', 'Triple negative malignant neoplasm of breast (disorder)', 'Triple Negative Breast Neoplasm', 'ER Negative PR Negative HER2 Negative Breast Neoplasms', 'Triple-Negative Breast Cancers', 'Breast Neoplasm, Triple-Negative', 'Triple-Negative Breast Cancer', 'Breast Neoplasms, Triple-Negative', 'ER-Negative PR-Negative HER2-Negative Breast Neoplasms', 'Triple negative malignant neoplasm of breast', 'ER Negative PR Negative HER2 Negative Breast Cancer', 'Triple Negative Breast Neoplasms', 'Triple-Negative Breast Neoplasm']}, 'types': {0: ['T191']}, 'definition': {0: 'Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.'}, 'entity': {0: 'PR-negative'}, 'text': {0: 'Negative (ER-negative and PR-negative, '}}","{'concept_id': {0: 'C3539878'}, 'canonical_name': {0: 'Triple Negative Breast Neoplasm'}, 'aliases': {0: ['Triple-Negative Breast Neoplasm', 'ER-Negative PR-Negative HER2-Negative Breast Neoplasms', 'ER-Negative PR-Negative HER2-Negative Breast Cancer', 'Triple-Negative Breast Neoplasms', 'Breast Neoplasms, Triple-Negative', 'ER Negative PR Negative HER2 Negative Breast Neoplasms', 'Triple Negative Breast Neoplasms', 'Triple-Negative Breast Cancers', 'Breast Cancers, Triple-Negative', 'Breast Cancer, Triple-Negative', 'Breast Neoplasm, Triple-Negative', 'ER Negative PR Negative HER2 Negative Breast Cancer', 'Triple-Negative Breast Cancer', 'Triple Negative Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.'}, 'entity': {0: 'PR-negative'}, 'text': {0: 'Negative (ER-negative and PR-negative, '}}",{},"{'concept_id': {0: 'C1327540'}, 'canonical_name': {0: 'negative regulation of negative chemotaxis'}, 'aliases': {0: ['down-regulation of negative chemotaxis', 'down regulation of negative chemotaxis', 'downregulation of negative chemotaxis']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a motile cell or organism towards a lower concentration in a concentration gradient of a specific chemical. [GOC:ai]'}, 'entity': {0: 'Negative'}, 'text': {0: 'Negative (ER-negative and PR-negative, '}}","{'concept_id': {0: 'C4280805'}, 'canonical_name': {0: 'Impaired oxidative burst'}, 'aliases': {0: ['Negative nitroblue tetrazolium reduction test', 'Negative NBT reduction test']}, 'types': {0: ['T034']}, 'definition': {0: 'In the NBT test, neutrophils change the colorless compound NBT into a compound with a deep blue color. If this test is negative (i.e., no blue color is produced), then this indicates a defect in superoxide-generating NADPH oxidase activity with inability to efficiently kill phagocytized bacteria. [HPO:probinson]'}, 'entity': {0: 'Negative'}, 'text': {0: 'Negative (ER-negative and PR-negative, '}}","  entity_group     value     score
0    Lab_value  Negative  0.999937",[],"{'keyword': {0: 'negative pr negative', 1: 'er negative pr', 2: 'er negative', 3: 'negative pr', 4: 'negative er'}, 'score': {0: 0.9181, 1: 0.9146, 2: 0.9081, 3: 0.9075, 4: 0.8939}}"
1019,1019,1019,0.9470000267028807,24.0,or unknown),UniversSB-Light,4,-0.2329999953508377,5723991,25,13,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1020,1020,1020,0.9470000267028807,24.0,38/209,UniversSB-Light,4,-0.2329999953508377,5723991,25,13,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  38/209  0.993997",[],"{'keyword': {0: '38 209'}, 'score': {0: 0.9155}}"
1021,1021,1021,0.9470000267028807,24.0,61/203,UniversSB-Light,4,-0.2329999953508377,5723991,25,13,3,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  61/203  0.989098",[],"{'keyword': {0: '61 203'}, 'score': {0: 0.9105}}"
1022,1022,1022,0.9470000267028807,24.0,0.50 (0.33–0.74),UniversSB-Light,4,-0.2329999953508377,5723991,25,13,4,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.50 (  0.978005
1    Lab_value  0.33–0.74  0.922554",[],"{'keyword': {0: '50 33', 1: '33 74', 2: '50 33 74'}, 'score': {0: 0.7218, 1: 0.68, 2: 0.6494}}"
1023,1023,1023,0.9470000267028807,24.0,82.1,UniversSB-Light,4,-0.2329999953508377,5723991,25,13,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  82.1  0.996401",[],"{'keyword': {}, 'score': {}}"
1024,1024,1024,0.9470000267028807,24.0,66.6,UniversSB-Light,4,-0.2329999953508377,5723991,25,13,6,{},{},{},{},{},"  entity_group value     score
0    Lab_value  66.6  0.999289",[],"{'keyword': {}, 'score': {}}"
1025,1025,1025,0.9470000267028807,24.0,"Positive (ER-positive and PR-positive,  ",UniversSB-Light,4,-0.2329999953508377,5723991,25,14,0,"{'concept_id': {0: 'C2825490'}, 'canonical_name': {0: 'Positive Charge'}, 'aliases': {0: ['Positive Charge', 'Positive']}, 'types': {0: ['T080']}, 'definition': {0: 'Having a deficiency of electrons; having a higher electric potential.'}, 'entity': {0: 'Positive'}, 'text': {0: 'Positive (ER-positive and PR-positive,  '}}",{},{},"{'concept_id': {0: 'C4235600'}, 'canonical_name': {0: 'positive regulation of establishment of protein localization'}, 'aliases': {0: ['upregulation of protein recruitment', 'positive regulation of establishment of protein localisation', 'up regulation of protein positioning', 'up-regulation of protein positioning', 'upregulation of establishment of protein localisation', 'positive regulation of protein positioning', 'positive regulation of protein recruitment', 'up-regulation of establishment of protein localization', 'upregulation of protein positioning', 'up-regulation of protein recruitment', 'upregulation of establishment of protein localization', 'up regulation of establishment of protein localisation', 'up-regulation of establishment of protein localisation', 'up regulation of establishment of protein localization', 'up regulation of protein recruitment']}, 'types': {0: ['T039']}, 'definition': {0: 'Any process that activates or increases the frequency, rate or extent of establishment of protein localization. [GO_REF:0000058, GOC:TermGenie, PMID:22761445]'}, 'entity': {0: 'Positive'}, 'text': {0: 'Positive (ER-positive and PR-positive,  '}}","{'concept_id': {0: 'C4703609'}, 'canonical_name': {0: 'Anti-mitochondrial M2 antibody positivity'}, 'aliases': {0: ['AMA-M2 positive']}, 'types': {0: ['T034']}, 'definition': {0: 'The presence of M2 anti-mitochondrial antibody (immunoglobulins) in the serum. [LMU:mgriese, PMID:30579751]'}, 'entity': {0: 'Positive'}, 'text': {0: 'Positive (ER-positive and PR-positive,  '}}","  entity_group                    value     score
0    Lab_value                 Positive  0.999952
1    Lab_value  ER-positive PR-positive  0.636249",[],"{'keyword': {0: 'er positive', 1: 'positive er positive', 2: 'positive pr', 3: 'positive er', 4: 'er positive pr'}, 'score': {0: 0.9342, 1: 0.9304, 2: 0.9268, 3: 0.9236, 4: 0.8878}}"
1026,1026,1026,0.9470000267028807,24.0,or both),UniversSB-Light,4,-0.2329999953508377,5723991,25,14,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value  both  0.545316",[],"{'keyword': {}, 'score': {}}"
1027,1027,1027,0.9470000267028807,24.0,53/534,UniversSB-Light,4,-0.2329999953508377,5723991,25,14,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  53/534  0.998756",[],"{'keyword': {0: '53 534'}, 'score': {0: 0.9098}}"
1028,1028,1028,0.9470000267028807,24.0,104/540,UniversSB-Light,4,-0.2329999953508377,5723991,25,14,3,{},{},{},{},{},"  entity_group    value     score
0    Lab_value  104/540  0.998175",[],"{'keyword': {0: '104 540'}, 'score': {0: 0.9335}}"
1029,1029,1029,0.9470000267028807,24.0,0.48 (0.35–0.67),UniversSB-Light,4,-0.2329999953508377,5723991,25,14,4,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.48 (  0.976063
1    Lab_value  0.35–0.67  0.801017",[],"{'keyword': {0: '48 35', 1: '48 35 67', 2: '35 67'}, 'score': {0: 0.7295, 1: 0.6517, 2: 0.6361}}"
1030,1030,1030,0.9470000267028807,24.0,90.7,UniversSB-Light,4,-0.2329999953508377,5723991,25,14,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  90.7  0.951443",[],"{'keyword': {}, 'score': {}}"
1031,1031,1031,0.9470000267028807,24.0,80.7,UniversSB-Light,4,-0.2329999953508377,5723991,25,14,6,{},{},{},{},{},"  entity_group value     score
0    Lab_value  80.7  0.999448",[],"{'keyword': {}, 'score': {}}"
1032,1032,1032,0.9470000267028807,24.0,Preoperative HER2-directed therapy,UniversSB-Light,4,-0.2329999953508377,5723991,25,15,0,"{'concept_id': {0: 'C0178808'}, 'canonical_name': {0: 'Preoperative state'}, 'aliases': {0: ['preoperative state', 'Preoperative state', 'Preoperative state (finding)']}, 'types': {0: ['T033']}, 'definition': {0: 'condition of the patient preceding surgery.'}, 'entity': {0: 'Preoperative'}, 'text': {0: 'Preoperative HER2-directed therapy'}}","{'concept_id': {0: 'C5392083'}, 'canonical_name': {0: 'Preoperative Exercise'}, 'aliases': {0: ['Pre-operative Conditionings', 'Pre-operative Conditioning', 'Preoperative Conditionings', 'Pre operative Exercise', 'Rehabilitation, Pre-operative', 'Pre-operative Rehabilitations', 'Pre operative Rehabilitation', 'Preoperative Conditioning', 'Preoperative Rehabilitations', 'Conditioning, Preoperative', 'Exercise, Preoperative', 'Pre-operative Exercises', 'Exercise, Pre-operative', 'Pre operative Conditioning', 'Pre-operative Exercise', 'Preoperative Rehabilitation', 'Conditioning, Pre-operative', 'Preoperative Exercises', 'Rehabilitation, Preoperative', 'Pre-operative Rehabilitation']}, 'types': {0: ['T061']}, 'definition': {0: 'Various physical exercises implemented before a surgery designed for better TREATMENT OUTCOME.'}, 'entity': {0: 'Preoperative'}, 'text': {0: 'Preoperative HER2-directed therapy'}}",{},{},{},"            entity_group                  value     score
0  Therapeutic_procedure          HER2-directed  0.929885
1  Therapeutic_procedure  HER2-directed therapy  0.850966",[],"{'keyword': {0: 'preoperative her2 directed', 1: 'preoperative her2', 2: 'her2 directed therapy', 3: 'directed therapy', 4: 'her2 directed'}, 'score': {0: 0.8902, 1: 0.8061, 2: 0.8019, 3: 0.7403, 4: 0.6978}}"
1033,1033,1033,0.9470000267028807,24.0,Trastuzumab alone,UniversSB-Light,4,-0.2329999953508377,5723991,25,16,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab alone'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab alone'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab alone'}}",{},{},"           entity_group        value     score
0            Medication  Trastuzumab  0.999842
1  Detailed_description        alone  0.629467","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
1034,1034,1034,0.9470000267028807,24.0,78/600,UniversSB-Light,4,-0.2329999953508377,5723991,25,16,1,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  78/600  0.999577",[],"{'keyword': {0: '78 600'}, 'score': {0: 0.8883}}"
1035,1035,1035,0.9470000267028807,24.0,141/596,UniversSB-Light,4,-0.2329999953508377,5723991,25,16,2,{},{},{},{},{},"  entity_group    value     score
0    Lab_value  141/596  0.999635",[],"{'keyword': {0: '141 596'}, 'score': {0: 0.9094}}"
1036,1036,1036,0.9470000267028807,24.0,0.49 (0.37–0.65),UniversSB-Light,4,-0.2329999953508377,5723991,25,16,3,{},{},{},{},{},"  entity_group      value     score
0    Lab_value     0.49 (  0.967708
1    Lab_value  0.37–0.65  0.736413",[],"{'keyword': {0: '49 37', 1: '49 37 65', 2: '37 65'}, 'score': {0: 0.7745, 1: 0.7657, 2: 0.7363}}"
1037,1037,1037,0.9470000267028807,24.0,87.7,UniversSB-Light,4,-0.2329999953508377,5723991,25,16,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value  87.7  0.998607",[],"{'keyword': {}, 'score': {}}"
1038,1038,1038,0.9470000267028807,24.0,75.9,UniversSB-Light,4,-0.2329999953508377,5723991,25,16,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  75.9  0.999323",[],"{'keyword': {}, 'score': {}}"
1039,1039,1039,0.9169999957084656,30.0,Reference:,ConduitITC-Bold,20,-0.2349999994039535,8194925,25,17,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1040,1040,1040,0.8830000162124634,22.0,1. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628. ,MyriadPro-Light,4,-0.25,3355443,25,17,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'et al', 4: 'engl med 2019'}, 'score': {0: 0.8031, 1: 0.7251, 2: 0.7194, 3: 0.6642, 4: 0.6422}}"
1041,1041,1041,0.9470000267028807,24.0,Trastuzumab plus additional  ,UniversSB-Light,4,-0.2329999953508377,5723991,25,18,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab plus additional  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab plus additional  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab plus additional  '}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999878","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab plus additional', 1: 'trastuzumab plus', 2: 'plus additional'}, 'score': {0: 1.0, 1: 0.9551, 2: 0.9061}}"
1042,1042,1042,0.9470000267028807,24.0,HER2-directed agent or agents,UniversSB-Light,4,-0.2329999953508377,5723991,25,18,1,"{'concept_id': {0: 'C1710439'}, 'canonical_name': {0: 'Topical Dosage Form'}, 'aliases': {0: ['Topical', 'Topical agents', 'Topical Dosage Form', 'Topical Dose Form']}, 'types': {0: ['T122']}, 'definition': {0: 'A substance intended for administration to a body surface.'}, 'entity': {0: 'agents'}, 'text': {0: 'HER2-directed agent or agents'}}","{'concept_id': {0: 'C0013973'}, 'canonical_name': {0: 'Emetics'}, 'aliases': {0: ['Drug, Emetic', 'Agents, Emetic', 'Emetic Agents', 'Emetic Agent', 'Emetic Drugs', 'Drugs, Emetic', 'Emetic Drug', 'Emetic', 'Agent, Emetic']}, 'types': {0: ['T121']}, 'definition': {0: 'Agents that cause vomiting. They may act directly on the gastrointestinal tract, bringing about emesis through local irritant effects, or indirectly, through their effects on the chemoreceptor trigger zone in the postremal area near the medulla.'}, 'entity': {0: 'agents'}, 'text': {0: 'HER2-directed agent or agents'}}",{},{},{},"           entity_group                       value     score
0  Detailed_description               HER2-directed  0.885715
1  Detailed_description  HER2-directed agent agents  0.996651
2  Detailed_description                      agents  0.504430",[],"{'keyword': {0: 'agent agents', 1: 'her2 directed agent', 2: 'her2 directed', 3: 'directed agent', 4: 'directed agent agents'}, 'score': {0: 0.8199, 1: 0.812, 2: 0.7663, 3: 0.7543, 4: 0.7278}}"
1043,1043,1043,0.9470000267028807,24.0,13/143,UniversSB-Light,4,-0.2329999953508377,5723991,25,18,2,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  13/143  0.978334",[],"{'keyword': {0: '13 143'}, 'score': {0: 0.8964}}"
1044,1044,1044,0.9470000267028807,24.0,24/147,UniversSB-Light,4,-0.2329999953508377,5723991,25,18,3,{},{},{},{},{},"  entity_group   value     score
0    Lab_value  24/147  0.890299",[],"{'keyword': {0: '24 147'}, 'score': {0: 0.8901}}"
1045,1045,1045,0.9470000267028807,24.0,0.54 (0.27–1.06),UniversSB-Light,4,-0.2329999953508377,5723991,25,18,4,{},{},{},{},{},"  entity_group value    score
0    Lab_value  0.54  0.99934",[],"{'keyword': {0: '54 27', 1: '54 27 06', 2: '27 06'}, 'score': {0: 0.7083, 1: 0.6951, 2: 0.6258}}"
1046,1046,1046,0.9470000267028807,24.0,90.9,UniversSB-Light,4,-0.2329999953508377,5723991,25,18,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value  90.9  0.994503",[],"{'keyword': {}, 'score': {}}"
1047,1047,1047,0.9470000267028807,24.0,81.8,UniversSB-Light,4,-0.2329999953508377,5723991,25,18,6,{},{},{},{},{},"  entity_group value     score
0    Lab_value  81.8  0.999384",[],"{'keyword': {}, 'score': {}}"
1048,1048,1048,0.9470000267028807,24.688661575317383,0.15,UniversSB-Light,4,-0.2329999953508377,5723991,25,19,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value  0.15  0.996109",[],"{'keyword': {}, 'score': {}}"
1049,1049,1049,0.9470000267028807,24.688661575317383,0.5,UniversSB-Light,4,-0.2329999953508377,5723991,25,19,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   0.5  0.999093","[('0.5', 'STRENGTH')]","{'keyword': {}, 'score': {}}"
1050,1050,1050,0.9470000267028807,24.688661575317383,1.0,UniversSB-Light,4,-0.2329999953508377,5723991,25,19,2,{},{},{},{},{},"           entity_group value     score
0  Detailed_description   1.0  0.501226
1             Lab_value   1.0  0.710047",[],"{'keyword': {}, 'score': {}}"
1051,1051,1051,0.9470000267028807,24.688661575317383,2.0,UniversSB-Light,4,-0.2329999953508377,5723991,25,19,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   2.0  0.883895",[],"{'keyword': {}, 'score': {}}"
1052,1052,1052,0.9470000267028807,24.688661575317383,5.0,UniversSB-Light,4,-0.2329999953508377,5723991,25,19,4,{},{},{},{},{},"  entity_group value    score
0    Lab_value   5.0  0.94593",[],"{'keyword': {}, 'score': {}}"
1053,1053,1053,0.9470000267028807,24.688661575317383,0.20,UniversSB-Light,4,-0.2329999953508377,5723991,25,20,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value  0.20  0.994717",[],"{'keyword': {}, 'score': {}}"
1054,1054,1054,0.9470000267028807,19.0,Adapted from von Minckwitz et al. 2019.,UniversSB-Light,4,-0.2329999953508377,3355443,25,21,0,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
1055,1055,1055,0.9470000267028807,19.0,"CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  ",UniversSB-Light,4,-0.2329999953508377,3355443,25,21,1,"{'concept_id': {0: 'C1512496'}, 'canonical_name': {0: 'Hormone Receptor Test'}, 'aliases': {0: []}, 'types': {0: ['T059']}, 'definition': {0: 'A hormone receptor test measures the amount of certain hormone receptors proteins in cancer tissue. Hormones (such as estrogen and progesterone that naturally occur in the body) can attach to these proteins. If the test is positive, it indicates that the hormone is probably helping the cancer cells grow.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}","{'concept_id': {0: 'C0034808'}, 'canonical_name': {0: 'Receptors, Gastrointestinal Hormone'}, 'aliases': {0: ['Gastrointestinal Peptides Receptors', 'Receptors, Intestinal Hormone', 'Gastrointestinal Hormone Receptors', 'Receptors, Gastrointestinal Peptides', 'Gastrointestinal Hormone Receptor', 'Gastrointestinal Hormones Receptors', 'Hormone Receptors, Intestinal', 'Peptides Receptors, Gastrointestinal', 'Hormone Receptor, Intestinal', 'Intestinal Hormone Receptors', 'Hormone Receptors, Gastrointestinal', 'Hormones Receptors, Gastrointestinal', 'Intestinal Hormone Receptor', 'Receptor, Intestinal Hormone', 'Hormone Receptor, Gastrointestinal', 'Receptors, Gastrointestinal Hormones', 'Receptor, Gastrointestinal Hormone']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: 'Cell surface proteins that bind gastrointestinal hormones with high affinity and trigger intracellular changes influencing the behavior of cells. Most gastrointestinal hormones also act as neurotransmitters so these receptors are also present in the central and peripheral nervous systems.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}",{},"{'concept_id': {0: 'C1152812'}, 'canonical_name': {0: 'growth hormone receptor activity'}, 'aliases': {0: []}, 'types': {0: ['T044']}, 'definition': {0: 'Combining with a growth hormone and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. [GOC:ai, GOC:signaling]'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}","{'concept_id': {0: 'C4722330'}, 'canonical_name': {0: 'Thyroid hormone receptor defect'}, 'aliases': {0: ['Thyroid hormone resistance', 'End-organ unresponsiveness to thyroid hormone', 'Elevated serum levels of free thyroid hormone with nonsuppressed TSH', 'Resistance to thyroid hormone', 'Impaired sensitivity to thyroid hormone']}, 'types': {0: ['T047']}, 'definition': {0: 'Decreased response to thyroid hormones in peripheral tissues and in the pituitary gland.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'CI, confidence interval; ER, oestrogen receptor; HR, hormone receptor;  '}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'receptor hr hormone', 1: 'confidence interval er', 2: 'oestrogen receptor', 3: 'interval er', 4: 'ci confidence interval'}, 'score': {0: 0.8637, 1: 0.7731, 2: 0.7447, 3: 0.7087, 4: 0.5439}}"
1056,1056,1056,0.9470000267028807,19.0,"IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.",UniversSB-Light,4,-0.2329999953508377,3355443,25,21,2,"{'concept_id': {0: 'C4082178'}, 'canonical_name': {0: 'Progesterone Receptor, human'}, 'aliases': {0: ['PRB', 'PGR', 'Nuclear Receptor Subfamily 3 Group C Member 3', 'Progesterone Receptor Isoform B', 'Progesterone Receptor B', 'PgR', 'Progesterone Receptor']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: 'Progesterone receptor (933 aa, ~99 kDa) is encoded by the human PGR gene. This protein is involved in the regulation of transcription.'}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.'}}","{'concept_id': {0: 'C0385053'}, 'canonical_name': {0: 'progesterone receptors B'}, 'aliases': {0: ['progesterone receptor B', 'receptor B, progesterone']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: None}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.'}}",{},"{'concept_id': {0: 'C1157305'}, 'canonical_name': {0: 'progesterone biosynthetic process'}, 'aliases': {0: ['progesterone anabolism', 'progesterone formation', 'progesterone synthesis', 'progesterone biosynthesis']}, 'types': {0: ['T044']}, 'definition': {0: 'The chemical reactions and pathways resulting in the formation of progesterone, a steroid hormone produced in the ovary which prepares and maintains the uterus for pregnancy. Also found in plants. [GOC:jl, http://www.cogsci.princeton.edu/]'}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'IDFS, invasive disease-free survival; NE, not evaluable; PR, progesterone receptor.'}}",{},"Empty DataFrame
Columns: []
Index: []","[('progesterone receptor', 'DRUG')]","{'keyword': {0: 'free survival ne', 1: 'idfs invasive disease', 2: 'progesterone receptor', 3: 'ne evaluable', 4: 'evaluable pr'}, 'score': {0: 0.8122, 1: 0.7718, 2: 0.6953, 3: 0.562, 4: 0.3307}}"
1057,1057,1057,0.9470000267028807,24.688661575317383,Trastuzumab better,UniversSB-Light,4,-0.2329999953508377,5723991,25,22,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab better'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab better'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab better'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999839
1    Lab_value       better  0.999615","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab better'}, 'score': {0: 1.0}}"
1058,1058,1058,0.9470000267028807,24.688661575317383,Kadcyla better,UniversSB-Light,4,-0.2329999953508377,5723991,25,22,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla better'}, 'text': {0: 'Kadcyla better'}}",{},{},{},{},"           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.988854
1             Lab_value   better  0.999646",[],"{'keyword': {0: 'kadcyla better'}, 'score': {0: 1.0}}"
1059,1059,1059,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,25,23,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1060,1060,1060,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,25,23,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1061,1061,1061,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,25,23,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1062,1062,1062,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,25,23,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1063,1063,1063,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,25,24,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1064,1064,1064,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,25,24,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1065,1065,1065,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,25,24,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1066,1066,1066,0.75,98.0,The efficacy and safety profile of Kadcyla  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,26,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}",{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","  entity_group    value     score
0  Coreference  Kadcyla  0.860627","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'safety profile kadcyla', 1: 'safety profile', 2: 'efficacy safety', 3: 'profile kadcyla', 4: 'efficacy safety profile'}, 'score': {0: 0.7898, 1: 0.7881, 2: 0.7539, 3: 0.7067, 4: 0.7039}}"
1067,1067,1067,0.75,98.0,were confirmed in a phase 3 study,ConduitITC-Bold,20,-0.1700000017881393,8194925,26,1,1,"{'concept_id': {0: 'C0920321'}, 'canonical_name': {0: 'Phase I Clinical Trials'}, 'aliases': {0: ['Phase 1 Clinical Trials', 'Phase I Study', 'phase i clinical trials', 'phase 1 clinical trials', 'clinical trial phase I', 'Phase 1 Clinical Trial', 'phase i trial', 'Clinical Trials, Phase 1', 'Clinical Trials, Phase I', 'i phase trials', 'phase i clinical trial', 'Phase I Clinical Trial', 'Phase I Protocol', 'clinical trial phase i', 'Phase I Trial', 'Clinical Trials, Phase I as Topic', 'phase i study', 'phase I trial', 'Phase I Clinical Trials', 'Early-Stage Clinical Trials', 'trial phase i', 'Phase 1 Study']}, 'types': {0: ['T062']}, 'definition': {0: 'Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}","{'concept_id': {0: 'C0085973'}, 'canonical_name': {0: 'Case Study'}, 'aliases': {0: ['Case Studies']}, 'types': {0: ['T170']}, 'definition': {0: 'An uncontrolled observational study containing a detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin).'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}",{},{},{},"           entity_group          value     score
0             Lab_value      confirmed  0.596251
1  Diagnostic_procedure  phase 3 study  0.984973",[],"{'keyword': {0: 'confirmed phase', 1: 'confirmed phase study', 2: 'phase study'}, 'score': {0: 0.8854, 1: 0.793, 2: 0.6105}}"
1068,1068,1068,0.944000005722046,27.0,Kadcyla ,UniversSB-Bold,20,-0.2469999939203262,16777215,26,2,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
1069,1069,1069,0.944000005722046,27.0,3.6 mg/kg IV ,UniversSB-Bold,20,-0.2469999939203262,16777215,26,2,1,{},{},{},{},{},"     entity_group      value     score
0       Lab_value    3.6 3.6  0.759886
1          Dosage  3.6 mg/kg  0.781887
2  Administration         IV  0.929909","[('3.6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7689, 1: 0.7403, 2: 0.7102}}"
1070,1070,1070,0.944000005722046,27.0,(n=743),UniversSB-Bold,20,-0.2469999939203262,16777215,26,2,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1071,1071,1071,0.9470000267028807,28.0,"KATHERINE was a phase 3, open-label, ",UniversSB-Light,4,-0.2329999953508377,3355443,26,3,0,"{'concept_id': {0: 'C0205390'}, 'canonical_name': {0: 'Phase'}, 'aliases': {0: ['Phased', 'Phase', 'Phase (attribute)', 'phase', 'Stage']}, 'types': {0: ['T079']}, 'definition': {0: 'A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, '}}","{'concept_id': {0: 'C0080129'}, 'canonical_name': {0: 'S Phase'}, 'aliases': {0: ['S Period', 'Phase, S', 'Period, S', 'Phases, S', 'Periods, S', 'S Periods', 'S Phases']}, 'types': {0: ['T079']}, 'definition': {0: 'Phase of the CELL CYCLE following G1 and preceding G2 when the entire DNA content of the nucleus is replicated. It is achieved by bidirectional replication at multiple sites along each chromosome.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []","[('KATHERINE', 'DRUG')]","{'keyword': {0: 'phase open label', 1: 'open label', 2: 'katherine phase open', 3: 'katherine phase', 4: 'phase open'}, 'score': {0: 0.8484, 1: 0.8158, 2: 0.7484, 3: 0.7024, 4: 0.6219}}"
1072,1072,1072,0.9470000267028807,28.0,"randomised, multicentre study which assessed ",UniversSB-Light,4,-0.2329999953508377,3355443,26,3,1,"{'concept_id': {0: 'C1555289'}, 'canonical_name': {0: 'Assessed patient - therapy appropriate'}, 'aliases': {0: ['Assessed Patient']}, 'types': {0: ['T033']}, 'definition': {0: '<p>Assessed patient, therapy is appropriate</p>'}, 'entity': {0: 'assessed'}, 'text': {0: 'randomised, multicentre study which assessed '}}","{'concept_id': {0: 'C1096776'}, 'canonical_name': {0: 'Multicenter Studies'}, 'aliases': {0: ['Multicenter Study']}, 'types': {0: ['T062']}, 'definition': {0: 'A work that reports on a study executed by several cooperating institutions.'}, 'entity': {0: 'multicentre study'}, 'text': {0: 'randomised, multicentre study which assessed '}}",{},{},{},"           entity_group        value     score
0  Detailed_description   randomised  0.997080
1  Diagnostic_procedure  multicentre  0.964970
2  Detailed_description  multicentre  0.856343
3  Diagnostic_procedure        study  0.939489",[],"{'keyword': {0: 'randomised multicentre study', 1: 'multicentre study assessed', 2: 'randomised multicentre', 3: 'multicentre study', 4: 'study assessed'}, 'score': {0: 0.8846, 1: 0.8604, 2: 0.8469, 3: 0.8077, 4: 0.7694}}"
1073,1073,1073,0.9470000267028807,28.0,the efficacy and safety profile of adjuvant ,UniversSB-Light,4,-0.2329999953508377,3355443,26,3,2,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}",{},{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}","  entity_group     value     score
0   Medication  adjuvant  0.919629",[],"{'keyword': {0: 'safety profile', 1: 'safety profile adjuvant', 2: 'profile adjuvant', 3: 'efficacy safety', 4: 'efficacy safety profile'}, 'score': {0: 0.8586, 1: 0.7746, 2: 0.7312, 3: 0.6494, 4: 0.6119}}"
1074,1074,1074,0.9470000267028807,28.0,Kadcyla vs trastuzumab in patients who  ,UniversSB-Light,4,-0.2329999953508377,3355443,26,3,3,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}",{},{},"  entity_group        value     score
0   Medication      Kadcyla  0.588591
1   Medication  trastuzumab  0.999825","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'kadcyla vs trastuzumab', 1: 'kadcyla vs', 2: 'vs trastuzumab patients', 3: 'vs trastuzumab', 4: 'trastuzumab patients'}, 'score': {0: 0.9384, 1: 0.8664, 2: 0.8337, 3: 0.8093, 4: 0.8014}}"
1075,1075,1075,0.9470000267028807,28.0,had residual invasive disease following ,UniversSB-Light,4,-0.2329999953508377,3355443,26,3,4,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following '}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following '}}",{},{},{},"           entity_group             value     score
0  Detailed_description          residual  0.995710
1      Disease_disorder  invasive disease  0.862065",[],"{'keyword': {0: 'residual invasive disease', 1: 'residual invasive', 2: 'invasive disease following', 3: 'invasive disease', 4: 'disease following'}, 'score': {0: 0.9149, 1: 0.9108, 2: 0.8708, 3: 0.8285, 4: 0.8066}}"
1076,1076,1076,0.9470000267028807,28.0,trastuzumab-based neoadjuvant therapy,UniversSB-Light,4,-0.2329999953508377,3355443,26,3,5,{},"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'trastuzumab-based neoadjuvant therapy'}, 'text': {0: 'trastuzumab-based neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0             Medication    trastuzumab-based  0.999863
1  Therapeutic_procedure          neoadjuvant  0.997995
2  Therapeutic_procedure  neoadjuvant therapy  0.997627","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab based neoadjuvant', 1: 'based neoadjuvant therapy', 2: 'neoadjuvant therapy', 3: 'trastuzumab based', 4: 'based neoadjuvant'}, 'score': {0: 0.946, 1: 0.8826, 2: 0.8712, 3: 0.8579, 4: 0.8374}}"
1077,1077,1077,0.9470000267028807,27.0,Surgery,UniversSB-Light,4,-0.2329999953508377,16777215,26,4,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  Surgery  0.998798",[],"{'keyword': {}, 'score': {}}"
1078,1078,1078,0.9470000267028807,27.0,Residual invasive ,UniversSB-Light,4,-0.2329999953508377,16777215,26,5,0,"{'concept_id': {0: 'C1334278'}, 'canonical_name': {0: 'Invasive Lesion'}, 'aliases': {0: ['Invasive Lesion']}, 'types': {0: ['T033']}, 'definition': {0: 'A malignant cellular population that has increased in size and infiltrates the surrounding tissues.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}","{'concept_id': {0: 'C2936533'}, 'canonical_name': {0: 'Invasive Species'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Non-native species that threaten ecosystems, habitats, or other species and are likely to cause economic or environmental harm or harm to human health.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"           entity_group              value     score
0  Detailed_description  Residual invasive  0.999395",[],"{'keyword': {0: 'residual invasive'}, 'score': {0: 1.0}}"
1079,1079,1079,0.9470000267028807,27.0,disease in breast  ,UniversSB-Light,4,-0.2329999953508377,16777215,26,5,1,"{'concept_id': {0: 'C0038293'}, 'canonical_name': {0: 'Sternum'}, 'aliases': {0: ['Bone structure of sternum (body structure)', 'sternums', 'Sternum', 'Sternum/Sternal', 'Breast bone', 'Chest>Sternum', 'Sternal', 'breast bone', 'sternum', 'Sternum, NOS', 'Bone structure of sternum']}, 'types': {0: ['T023']}, 'definition': {0: 'A long, narrow, and flat bone commonly known as BREASTBONE occurring in the midsection of the anterior thoracic segment or chest region, which stabilizes the rib cage and serves as the point of origin for several muscles that move the arms, head, and neck.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","{'concept_id': {0: 'C0024902'}, 'canonical_name': {0: 'Breast Pain'}, 'aliases': {0: ['Mastodynias', 'Mammalgias', 'Mastodynia', 'Mastalgias', 'Mammalgia', 'Pain, Breast', 'Mastalgia', 'Breast Pains', 'Pains, Breast']}, 'types': {0: ['T184']}, 'definition': {0: 'Painful sensation in the breast region.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","           entity_group   value     score
0  Biological_structure  breast  0.999824",[],"{'keyword': {0: 'disease breast'}, 'score': {0: 0.9481}}"
1080,1080,1080,0.9470000267028807,27.0,or axillary lymph ,UniversSB-Light,4,-0.2329999953508377,16777215,26,5,2,"{'concept_id': {0: 'C0229843'}, 'canonical_name': {0: 'Pectoral lymph node group'}, 'aliases': {0: ['Nodi lymphoidei axillarum anteriores', 'Anterior axillary lymph nodes', 'Structure of pectoral axillary lymph node (body structure)', 'Anterior axillary nodes', 'Pectoral axillary lymph node', 'Nodi pectorales', 'Anterior axillary lymph nodes set', 'Pectoral Lymph Node', 'Pectoral lymph node', 'Pectoral lymph node group', 'Pectoral nodes', 'Pectoral axillary lymph node group', 'Pectoral lymph nodes', 'Structure of pectoral axillary lymph node', 'Pectoral lymph node group (body structure)', 'Anterior axillary lymph node', 'Nodi axillarum anteriores', 'Nodus lymphaticus pectoralis axillae', 'Set of pectoral lymph nodes', 'Set of anterior axillary lymph nodes', 'Pectoral lymph nodes set', 'Pectoral axillary lymph nodes', 'Set of pectoral axillary lymph nodes', 'Nodi lymphoidei pectorales']}, 'types': {0: ['T023']}, 'definition': {0: 'An axillary lymph node located along the lower edge of the pectoralis minor.'}, 'entity': {0: 'axillary lymph'}, 'text': {0: 'or axillary lymph '}}",{},{},{},{},"           entity_group           value     score
0  Biological_structure        axillary  0.999927
1  Biological_structure  axillary lymph  0.940007",[],"{'keyword': {0: 'axillary lymph'}, 'score': {0: 0.9521}}"
1081,1081,1081,0.9470000267028807,27.0,nodes,UniversSB-Light,4,-0.2329999953508377,16777215,26,5,3,"{'concept_id': {0: 'C2697524'}, 'canonical_name': {0: 'Graph Node'}, 'aliases': {0: ['Vertex', 'Node', 'Graph Node']}, 'types': {0: ['T077']}, 'definition': {0: 'One of the points that define a graph.'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}","{'concept_id': {0: 'C0037189'}, 'canonical_name': {0: 'Sino-Atrial Nodes'}, 'aliases': {0: ['Sinu-Atrial Node', 'Sino-Atrial Node', 'Sinu-Atrial Nodes', 'Nodes, Sinu-Atrial', 'Sinus Node', 'Nodes, Sinuatrial', 'Node, Sinuatrial', 'Nodes, Sinoatrial', 'Nodes, Sinus', 'Sinoatrial Node', 'Sinus Nodes', 'Sinuatrial Node', 'Node, Sino-Atrial', 'Node, Sinus', 'Node, Sinoatrial', 'Sinoatrial Nodes', 'Sinu Atrial Node', 'Sinuatrial Nodes', 'Sino Atrial Node', 'Nodes, Sino-Atrial', 'Node, Sinu-Atrial']}, 'types': {0: ['T023']}, 'definition': {0: 'The small mass of modified cardiac muscle fibers located at the junction of the superior vena cava (VENA CAVA, SUPERIOR) and right atrium. Contraction impulses probably start in this node, spread over the atrium (HEART ATRIUM) and are then transmitted by the atrioventricular bundle (BUNDLE OF HIS) to the ventricle (HEART VENTRICLE).'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}",{},{},{},"           entity_group  value     score
0  Biological_structure  nodes  0.488832",[],"{'keyword': {}, 'score': {}}"
1082,1082,1082,0.9470000267028807,27.0,"HER2-positive eBC, ",UniversSB-Light,4,-0.2329999953508377,16777215,26,6,0,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  HER2-positive  0.816637",[],"{'keyword': {0: 'her2 positive ebc', 1: 'positive ebc', 2: 'her2 positive'}, 'score': {0: 0.9628, 1: 0.8142, 2: 0.7646}}"
1083,1083,1083,0.9470000267028807,27.0,neoadjuvant ,UniversSB-Light,4,-0.2329999953508377,16777215,26,6,1,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}",{},{},{},"           entity_group        value     score
0  Detailed_description  neoadjuvant  0.956138
1          Sign_symptom  neoadjuvant  0.386592
2               History  neoadjuvant  0.344678",[],"{'keyword': {}, 'score': {}}"
1084,1084,1084,0.9470000267028807,27.0,trastuzumab* plus ,UniversSB-Light,4,-0.2329999953508377,16777215,26,6,2,"{'concept_id': {0: 'C4527338'}, 'canonical_name': {0: 'AC Followed by Docetaxel/Trastuzumab Regimen'}, 'aliases': {0: ['AC-Docetaxel + Trastuzumab', 'AC-T Plus Trastuzumab', 'AC-Taxotere/Herceptin', 'AC Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel/Trastuzumab']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},{},"           entity_group        value     score
0            Medication  trastuzumab  0.999873
1  Detailed_description         plus  0.314542","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab plus'}, 'score': {0: 0.9478}}"
1085,1085,1085,0.9470000267028807,27.0,chemotherapy ,UniversSB-Light,4,-0.2329999953508377,16777215,26,6,3,"{'concept_id': {0: 'C0392920'}, 'canonical_name': {0: 'Chemotherapy Regimen'}, 'aliases': {0: ['chemotherapy regimen', 'Antineoplastic chemotherapy regimen', 'chemotherapies', 'Antineoplastic chemotherapy regimen (regime/therapy)', 'chemotherapy regimens', 'neoplasm chemotherapy', 'neoplasm pharmacotherapy', 'chemotherapy', 'chemo', 'Cancer chemotherapy', 'neoplasm/cancer chemotherapy', 'cancer chemotherapy', 'cancer pharmacotherapy', 'neoplasm/cancer pharmacotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'application of the beneficial effects of drugs to control or cure neoplastic growth.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}","{'concept_id': {0: 'C1868801'}, 'canonical_name': {0: 'Hyperthermic Intraperitoneal Chemotherapy'}, 'aliases': {0: ['Hot Chemotherapy', 'Chemotherapy, Intraperitoneal Hyperthermic', 'Chemotherapy, Hyperthermic Intraperitoneal', 'Chemotherapy, Hot', 'Intraperitoneal Hyperthermic Chemotherapies', 'Intraperitoneal Chemotherapy, Hyperthermic', 'Hyperthermic Chemotherapy, Intraperitoneal', 'HIPEC', 'Intraperitoneal Hyperthermic Chemotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}",{},{},{},"  entity_group         value     score
0   Medication  chemotherapy  0.999848","[('chemotherapy', 'DRUG')]","{'keyword': {}, 'score': {}}"
1086,1086,1086,0.9470000267028807,27.0,(n=1486),UniversSB-Light,4,-0.2329999953508377,16777215,26,6,4,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1087,1087,1087,0.944000005722046,28.0,Primary endpoint,UniversSB-Bold,20,-0.2469999939203262,3355443,26,7,0,"{'concept_id': {0: 'C2349179'}, 'canonical_name': {0: 'End Point'}, 'aliases': {0: ['Endpoint', 'End Point', 'ENDPOINT', 'endpoints', 'endpoint', 'End-Point']}, 'types': {0: ['T080']}, 'definition': {0: 'A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.'}, 'entity': {0: 'Primary endpoint'}, 'text': {0: 'Primary endpoint'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  Primary endpoint  0.940143",[],"{'keyword': {0: 'primary endpoint'}, 'score': {0: 1.0}}"
1088,1088,1088,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,26,7,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1089,1089,1089,0.944000005722046,28.0,Secondary endpoints,UniversSB-Bold,20,-0.2469999939203262,3355443,26,8,0,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}",{},"{'concept_id': {0: 'C1623508'}, 'canonical_name': {0: 'regulation of secondary metabolic process'}, 'aliases': {0: ['regulation of secondary metabolism']}, 'types': {0: ['T040']}, 'definition': {0: 'Any process that modulates the frequency, rate or extent of secondary metabolism, the chemical reactions and pathways involving compounds that are not necessarily required for growth and maintenance of cells, and are often unique to a taxon. [GOC:jl]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C2981150'}, 'canonical_name': {0: 'Uranostaphyloschisis'}, 'aliases': {0: ['Cleft of hard and soft palate', 'Cleft of palate', 'Cleft hard and soft palate', 'Cleft palate', 'Cleft secondary palate', 'Palatoschisis', 'Cleft roof of mouth']}, 'types': {0: ['T019']}, 'definition': {0: 'Cleft palate is a developmental defect of the palate resulting from a failure of fusion of the palatine processes and manifesting as a separation of the roof of the mouth (soft and hard palate). [HPO:probinson]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","           entity_group                value     score
0  Detailed_description  Secondary endpoints  0.811147",[],"{'keyword': {0: 'secondary endpoints'}, 'score': {0: 1.0}}"
1090,1090,1090,0.9470000267028807,27.0,Planned 10 years’ follow-up,UniversSB-Light,4,-0.2329999953508377,16777215,26,9,0,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}",{},{},{},"     entity_group      value     score
0        Duration   10 years  0.999410
1  Clinical_event  follow-up  0.993776",[],"{'keyword': {0: 'planned 10 years', 1: '10 years follow', 2: 'planned 10', 3: '10 years', 4: 'years follow'}, 'score': {0: 0.9349, 1: 0.8297, 2: 0.8114, 3: 0.7473, 4: 0.7286}}"
1091,1091,1091,0.944000005722046,27.0,Trastuzumab  ,UniversSB-Bold,20,-0.2469999939203262,16777215,26,10,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
1092,1092,1092,0.944000005722046,27.0,6 mg/kg IV ,UniversSB-Bold,20,-0.2469999939203262,16777215,26,10,1,"{'concept_id': {0: 'C0439272'}, 'canonical_name': {0: 'ug/g'}, 'aliases': {0: ['Picogram per Microgram', 'Zeptogram per Femtogram', 'Yoctogram per Attogram', 'mg/kg', 'Milligram/kilogram', 'Microgram/gram', 'microgram/g', 'Femtogram per Nanogram', 'Nanogram per Milligram', 'Milligram/kilogram (qualifier value)', 'Microgram/gram (qualifier value)', 'mg kg', 'Microgram per Gram', 'Milligram/Kilogram', 'Milligram per Kilogram', 'Attogram per Picogram', 'microg/g']}, 'types': {0: ['T081']}, 'definition': {0: 'A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.'}, 'entity': {0: 'mg/kg IV'}, 'text': {0: '6 mg/kg IV '}}",{},{},{},{},"     entity_group    value     score
0          Dosage  6 mg/kg  0.909511
1  Administration       IV  0.990577","[('6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7475, 1: 0.7458, 2: 0.6812}}"
1093,1093,1093,0.944000005722046,27.0,(n=743),UniversSB-Bold,20,-0.2469999939203262,16777215,26,10,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1094,1094,1094,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,26,11,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1095,1095,1095,0.9470000267028807,28.0,non-breast cancer as per the  ,UniversSB-Light,4,-0.2329999953508377,3355443,26,11,1,{},"{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'non-breast cancer'}, 'text': {0: 'non-breast cancer as per the  '}}",{},{},{},"       entity_group              value     score
0           History         non-breast  0.647748
1  Disease_disorder  non-breast cancer  0.972177",[],"{'keyword': {0: 'non breast cancer', 1: 'non breast', 2: 'breast cancer'}, 'score': {0: 0.9178, 1: 0.7301, 2: 0.6862}}"
1096,1096,1096,0.9470000267028807,28.0,STEEP definition,UniversSB-Light,4,-0.2329999953508377,3355443,26,11,2,"{'concept_id': {0: 'C3539107'}, 'canonical_name': {0: 'Definition (core metadata concept)'}, 'aliases': {0: ['Definition', 'Definition (core metadata concept)']}, 'types': {0: ['T170']}, 'definition': {0: None}, 'entity': {0: 'definition'}, 'text': {0: 'STEEP definition'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  STEEP definition  0.998824",[],"{'keyword': {0: 'steep definition'}, 'score': {0: 1.0}}"
1097,1097,1097,0.9470000267028807,23.0,Anti-HER2 therapy for a total of 14 cycles. ,UniversSB-Light,4,-0.2329999953508377,3355443,26,12,0,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}",{},{},{},"  entity_group      value     score
0   Medication  Anti-HER2  0.606185
1  Coreference  Anti-HER2  0.565908
2   Medication    therapy  0.542007
3    Lab_value         14  0.923810",[],"{'keyword': {0: 'total 14 cycles', 1: 'therapy total 14', 2: 'anti her2 therapy', 3: 'her2 therapy total', 4: 'anti her2'}, 'score': {0: 0.8392, 1: 0.822, 2: 0.7728, 3: 0.7289, 4: 0.6897}}"
1098,1098,1098,0.9470000267028807,23.0,Radiation and endocrine therapy ,UniversSB-Light,4,-0.2329999953508377,3355443,26,12,1,"{'concept_id': {0: 'C1514396'}, 'canonical_name': {0: 'Preoperative Endocrine Therapy'}, 'aliases': {0: []}, 'types': {0: ['T061']}, 'definition': {0: 'Short term endocrine therapy, prior to surgery, to ""down-stage"" primary breast cancer in order to increase the rate of breast-conserving surgery. (from JMCC 7:557-562, 2000 via Medscape)'}, 'entity': {0: 'endocrine therapy'}, 'text': {0: 'Radiation and endocrine therapy '}}","{'concept_id': {0: 'C2607955'}, 'canonical_name': {0: 'Beta Radiation'}, 'aliases': {0: ['Rays, Beta', 'Ray, Beta', 'Beta Radiations', 'Beta Rays', 'Radiation, Beta', 'Beta Ray', 'Radiations, Beta']}, 'types': {0: ['T070']}, 'definition': {0: 'A stream of high energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus.'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy '}}",{},"{'concept_id': {0: 'C1154958'}, 'canonical_name': {0: 'response to electromagnetic radiation stimulus'}, 'aliases': {0: ['response to radiation stimulus', 'response to radiation']}, 'types': {0: ['T038']}, 'definition': {0: 'Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electromagnetic radiation stimulus. Electromagnetic radiation is a propagating wave in space with electric and magnetic components. These components oscillate at right angles to each other and to the direction of propagation. [GOC:jl, Wikipedia:Electromagnetic_radiation]'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy '}}",{},"            entity_group              value     score
0  Therapeutic_procedure          Radiation  0.994988
1  Therapeutic_procedure  endocrine therapy  0.948940",[],"{'keyword': {0: 'radiation endocrine therapy', 1: 'endocrine therapy', 2: 'radiation endocrine'}, 'score': {0: 0.843, 1: 0.824, 2: 0.8103}}"
1099,1099,1099,0.9470000267028807,23.0,administered according to institutional ,UniversSB-Light,4,-0.2329999953508377,3355443,26,12,2,"{'concept_id': {0: 'C1546848'}, 'canonical_name': {0: 'Living Arrangement - Institution'}, 'aliases': {0: ['Institution']}, 'types': {0: ['T033']}, 'definition': {0: '<p>Institution</p>'}, 'entity': {0: 'institutional'}, 'text': {0: 'administered according to institutional '}}","{'concept_id': {0: 'C5544477'}, 'canonical_name': {0: 'Systemic Racism'}, 'aliases': {0: ['Institutionalized Racisms', 'Racism, Systemic', 'Institutionalized Racism', 'Racism, Institutionalized', 'Structural Racisms', 'Racism, Structural', 'Racism, Institutional', 'Racisms, Systematic', 'Systematic Racisms', 'Racism, Systematic', 'Institutional Racism', 'Systematic Racism', 'Structural Racism']}, 'types': {0: ['T054']}, 'definition': {0: 'Processes of racism that are embedded in laws (local, state, and federal), policies, and practices of society and its institutions that provide advantages to racial groups deemed as superior, while differentially oppressing, disadvantaging, or otherwise neglecting racial groups viewed as inferior. Differential access to the goods, services, and opportunities of society by race. Institutionalized racism is normative, sometimes legalized, and often manifests as inherited disadvantage. It is structural, having been codified in our institutions of custom, practice, and law, so there need not be an identifiable perpetrator. (ttps://www.cdc.gov/chronicdisease/programs-impact/sdoh.htm)'}, 'entity': {0: 'institutional'}, 'text': {0: 'administered according to institutional '}}",{},{},{},"           entity_group                       value     score
0  Detailed_description  according to institutional  0.817311",[],"{'keyword': {0: 'administered according institutional', 1: 'according institutional', 2: 'administered according'}, 'score': {0: 0.9745, 1: 0.8839, 2: 0.8672}}"
1100,1100,1100,0.9470000267028807,23.0,standards and study protocol,UniversSB-Light,4,-0.2329999953508377,3355443,26,12,3,"{'concept_id': {0: 'C2985700'}, 'canonical_name': {0: 'Study Protocol Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic.'}, 'entity': {0: 'study protocol'}, 'text': {0: 'standards and study protocol'}}","{'concept_id': {0: 'C2936643'}, 'canonical_name': {0: 'Standard of Care'}, 'aliases': {0: ['Standards of Care', 'Care Standards', 'Care Standard']}, 'types': {0: ['T058']}, 'definition': {0: 'The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.'}, 'entity': {0: 'standards'}, 'text': {0: 'standards and study protocol'}}",{},{},{},"           entity_group           value     score
0  Diagnostic_procedure       standards  0.946151
1  Diagnostic_procedure  study protocol  0.709869",[],"{'keyword': {0: 'study protocol', 1: 'standards study protocol', 2: 'standards study'}, 'score': {0: 0.906, 1: 0.879, 2: 0.7344}}"
1101,1101,1101,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,26,13,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1102,1102,1102,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,26,13,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1103,1103,1103,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,26,13,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1104,1104,1104,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,26,13,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1105,1105,1105,0.9052734375,23.0,≥,ArialMT,0,-0.2119140625,3355443,26,14,0,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1106,1106,1106,0.9470000267028807,23.0,of treatment including ,UniversSB-Light,4,-0.2329999953508377,3355443,26,14,1,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'treatment including'}, 'score': {0: 0.9499}}"
1107,1107,1107,0.9052734375,22.65237236022949,≥,ArialMT,0,-0.2119140625,3355443,26,14,2,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1108,1108,1108,0.9470000267028807,23.0,therapy and ,UniversSB-Light,4,-0.2329999953508377,3355443,26,14,3,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  therapy  0.826489",[],"{'keyword': {}, 'score': {}}"
1109,1109,1109,0.9470000267028807,23.0,of trastuzumab therapy,UniversSB-Light,4,-0.2329999953508377,3355443,26,14,4,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},{},"  entity_group                value     score
0   Medication          trastuzumab  0.999849
1   Medication  trastuzumab therapy  0.978093","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab therapy'}, 'score': {0: 0.9362}}"
1110,1110,1110,0.944000005722046,28.0,Stratification factors,UniversSB-Bold,20,-0.2469999939203262,3355443,26,15,0,"{'concept_id': {0: 'C1514983'}, 'canonical_name': {0: 'Stratification'}, 'aliases': {0: ['stratification']}, 'types': {0: ['T062']}, 'definition': {0: 'The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.'}, 'entity': {0: 'Stratification factors'}, 'text': {0: 'Stratification factors'}}",{},{},{},{},"           entity_group                   value     score
0  Diagnostic_procedure  Stratification factors  0.970758",[],"{'keyword': {0: 'stratification factors'}, 'score': {0: 1.0}}"
1111,1111,1111,0.9169999957084656,30.0,Reference:,ConduitITC-Bold,20,-0.2349999994039535,8194925,26,16,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1112,1112,1112,0.8830000162124634,22.0,1. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628. ,MyriadPro-Light,4,-0.25,3355443,26,16,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'et al', 4: 'engl med 2019'}, 'score': {0: 0.8031, 1: 0.7251, 2: 0.7194, 3: 0.6642, 4: 0.6422}}"
1113,1113,1113,0.944000005722046,21.0,Inclusion and  ,UniversSB-Bold,20,-0.2469999939203262,16777215,26,17,0,"{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Cellular Inclusion', 'Inclusion Body', 'inclusion bodies', 'Inclusion Bodies', 'inclusion body', 'body inclusion', 'Inclusions, Cellular', 'cellular inclusions', 'Bodies, Inclusion', 'Cellular Inclusions', 'Inclusions', 'cellular inclusion', 'Inclusion, Cellular', 'Body, Inclusion']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}","{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Inclusions, Cellular', 'Inclusion, Cellular', 'Inclusion Body', 'Body, Inclusion', 'Cellular Inclusion', 'Bodies, Inclusion', 'Cellular Inclusions']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"{'concept_id': {0: 'C0205708'}, 'canonical_name': {0: 'cytoplasmic inclusion'}, 'aliases': {0: []}, 'types': {0: ['T026']}, 'definition': {0: 'A stainable aggregation of protein, lipid or small molecules in the cytoplasm.'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"  entity_group      value     score
0  Coreference  Inclusion  0.340508",[],"{'keyword': {}, 'score': {}}"
1114,1114,1114,0.944000005722046,21.0,exclusion criteria,UniversSB-Bold,20,-0.2469999939203262,16777215,26,17,1,"{'concept_id': {0: 'C2827032'}, 'canonical_name': {0: 'Trial Inclusion Exclusion Criteria Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A specific variant of the original trial inclusion exclusion criterion.'}, 'entity': {0: 'exclusion criteria'}, 'text': {0: 'exclusion criteria'}}",{},{},{},{},"           entity_group               value     score
0  Diagnostic_procedure  exclusion criteria  0.534692",[],"{'keyword': {0: 'exclusion criteria'}, 'score': {0: 1.0}}"
1115,1115,1115,0.944000005722046,21.0,Baseline characteristics  ,UniversSB-Bold,20,-0.2469999939203262,16777215,26,18,0,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","           entity_group                     value     score
0  Diagnostic_procedure  Baseline characteristics  0.999933",[],"{'keyword': {0: 'baseline characteristics'}, 'score': {0: 1.0}}"
1116,1116,1116,0.944000005722046,21.0,were well-balanced,UniversSB-Bold,20,-0.2469999939203262,16777215,26,18,1,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  well-balanced  0.999827",[],"{'keyword': {}, 'score': {}}"
1117,1117,1117,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,26,23,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1118,1118,1118,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,26,23,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1119,1119,1119,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,26,23,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1120,1120,1120,0.9470000267028807,28.0,•  ,UniversSB-Light,4,-0.2329999953508377,16162586,26,23,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1121,1121,1121,0.9470000267028807,28.0,neoadjuvant therapy,UniversSB-Light,4,-0.2329999953508377,3355443,26,23,4,"{'concept_id': {0: 'C4744826'}, 'canonical_name': {0: 'Post Neoadjuvant Therapy Sample'}, 'aliases': {0: ['Post Neo-adjuvant Therapy Sample']}, 'types': {0: ['T031']}, 'definition': {0: 'A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}","{'concept_id': {0: 'C0242939'}, 'canonical_name': {0: 'Radiotherapy, Adjuvant'}, 'aliases': {0: ['Radiotherapies, Adjuvant', 'Adjuvant Radiotherapy', 'Adjuvant Radiotherapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0  Therapeutic_procedure          neoadjuvant  0.652529
1  Therapeutic_procedure  neoadjuvant therapy  0.963288",[],"{'keyword': {0: 'neoadjuvant therapy'}, 'score': {0: 1.0}}"
1122,1122,1122,0.9470000267028807,19.0,*Dual neoadjuvant anti-HER2 therapy was also permitted.,UniversSB-Light,4,-0.2329999953508377,3355443,26,24,0,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}",{},{},{},"           entity_group              value     score
0  Detailed_description               Dual  0.999838
1  Detailed_description        neoadjuvant  0.999769
2            Medication        neoadjuvant  0.504794
3            Medication  anti-HER2 therapy  0.946504",[],"{'keyword': {0: 'her2 therapy permitted', 1: 'dual neoadjuvant', 2: 'her2 therapy', 3: 'anti her2', 4: 'neoadjuvant anti'}, 'score': {0: 0.8452, 1: 0.8024, 2: 0.7657, 3: 0.7064, 4: 0.6957}}"
1123,1123,1123,0.9470000267028807,19.0,"DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised ",UniversSB-Light,4,-0.2329999953508377,3355443,26,24,1,"{'concept_id': {0: 'C2828392'}, 'canonical_name': {0: 'Standard (document)'}, 'aliases': {0: ['Standard']}, 'types': {0: ['T170']}, 'definition': {0: 'A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.'}, 'entity': {0: 'standardised'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","{'concept_id': {0: 'C0007620'}, 'canonical_name': {0: 'Cell Survival'}, 'aliases': {0: ['Cell Viability', 'Survival, Cell', 'Viabilities, Cell', 'Cell Viabilities', 'Viability, Cell']}, 'types': {0: ['T043']}, 'definition': {0: 'The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.'}, 'entity': {0: 'overall survival'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","     entity_group        value     score
0  Administration  intravenous  0.999464","[('IV', 'ROUTE'), ('intravenous', 'ROUTE')]","{'keyword': {0: 'survival steep standardised', 1: 'cancer idfs invasive', 2: 'iv intravenous', 3: 'os overall', 4: 'breast cancer'}, 'score': {0: 0.3418, 1: 0.2671, 2: 0.1935, 3: 0.1796, 4: 0.1483}}"
1124,1124,1124,0.9470000267028807,19.0,definitions for efficacy endpoints.,UniversSB-Light,4,-0.2329999953508377,3355443,26,24,2,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'definitions for efficacy endpoints.'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'definitions for efficacy endpoints.'}}",{},{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'definitions for efficacy endpoints.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'definitions efficacy endpoints', 1: 'definitions efficacy', 2: 'efficacy endpoints'}, 'score': {0: 0.8264, 1: 0.816, 2: 0.8015}}"
1125,1125,1125,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,26,25,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1126,1126,1126,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,26,25,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1127,1127,1127,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,26,25,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1128,1128,1128,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,26,25,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1129,1129,1129,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,26,26,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1130,1130,1130,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,26,26,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1131,1131,1131,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,26,26,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1132,1132,1132,0.9169999957084656,98.0,The efficacy and safety profile of Kadcyla  ,ConduitITC-Bold,20,-0.2349999994039535,8194925,27,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}",{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","  entity_group    value     score
0  Coreference  Kadcyla  0.860627","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'safety profile kadcyla', 1: 'safety profile', 2: 'efficacy safety', 3: 'profile kadcyla', 4: 'efficacy safety profile'}, 'score': {0: 0.7898, 1: 0.7881, 2: 0.7539, 3: 0.7067, 4: 0.7039}}"
1133,1133,1133,0.9169999957084656,98.0,were confirmed in a phase 3 study,ConduitITC-Bold,20,-0.2349999994039535,8194925,27,1,1,"{'concept_id': {0: 'C0920321'}, 'canonical_name': {0: 'Phase I Clinical Trials'}, 'aliases': {0: ['Phase 1 Clinical Trials', 'Phase I Study', 'phase i clinical trials', 'phase 1 clinical trials', 'clinical trial phase I', 'Phase 1 Clinical Trial', 'phase i trial', 'Clinical Trials, Phase 1', 'Clinical Trials, Phase I', 'i phase trials', 'phase i clinical trial', 'Phase I Clinical Trial', 'Phase I Protocol', 'clinical trial phase i', 'Phase I Trial', 'Clinical Trials, Phase I as Topic', 'phase i study', 'phase I trial', 'Phase I Clinical Trials', 'Early-Stage Clinical Trials', 'trial phase i', 'Phase 1 Study']}, 'types': {0: ['T062']}, 'definition': {0: 'Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}","{'concept_id': {0: 'C0085973'}, 'canonical_name': {0: 'Case Study'}, 'aliases': {0: ['Case Studies']}, 'types': {0: ['T170']}, 'definition': {0: 'An uncontrolled observational study containing a detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin).'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}",{},{},{},"           entity_group          value     score
0             Lab_value      confirmed  0.596251
1  Diagnostic_procedure  phase 3 study  0.984973",[],"{'keyword': {0: 'confirmed phase', 1: 'confirmed phase study', 2: 'phase study'}, 'score': {0: 0.8854, 1: 0.793, 2: 0.6105}}"
1134,1134,1134,0.9890000224113464,27.0,Kadcyla ,MyriadPro-Bold,20,-0.25,16777215,27,2,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
1135,1135,1135,0.9890000224113464,27.0,3.6 mg/kg IV ,MyriadPro-Bold,20,-0.25,16777215,27,2,1,{},{},{},{},{},"     entity_group      value     score
0       Lab_value    3.6 3.6  0.759886
1          Dosage  3.6 mg/kg  0.781887
2  Administration         IV  0.929909","[('3.6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7689, 1: 0.7403, 2: 0.7102}}"
1136,1136,1136,0.9890000224113464,27.0,(n=743),MyriadPro-Bold,20,-0.25,16777215,27,2,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1137,1137,1137,0.8830000162124634,28.0,"KATHERINE was a phase 3, open-label, randomised, ",MyriadPro-Light,4,-0.25,3355443,27,3,0,"{'concept_id': {0: 'C0205390'}, 'canonical_name': {0: 'Phase'}, 'aliases': {0: ['Phased', 'Phase', 'Phase (attribute)', 'phase', 'Stage']}, 'types': {0: ['T079']}, 'definition': {0: 'A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, randomised, '}}","{'concept_id': {0: 'C0080129'}, 'canonical_name': {0: 'S Phase'}, 'aliases': {0: ['S Period', 'Phase, S', 'Period, S', 'Phases, S', 'Periods, S', 'S Periods', 'S Phases']}, 'types': {0: ['T079']}, 'definition': {0: 'Phase of the CELL CYCLE following G1 and preceding G2 when the entire DNA content of the nucleus is replicated. It is achieved by bidirectional replication at multiple sites along each chromosome.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, randomised, '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []","[('KATHERINE', 'DRUG')]","{'keyword': {0: 'phase open label', 1: 'open label randomised', 2: 'label randomised', 3: 'katherine phase', 4: 'phase open'}, 'score': {0: 0.822, 1: 0.8121, 2: 0.6951, 3: 0.6666, 4: 0.5976}}"
1138,1138,1138,0.8830000162124634,28.0,multicentre study which assessed the efficacy and ,MyriadPro-Light,4,-0.25,3355443,27,3,1,"{'concept_id': {0: 'C5690761'}, 'canonical_name': {0: 'Collective Efficacy'}, 'aliases': {0: ['Collective Efficacies', 'Efficacy, Team', 'Team Efficacy', 'Team Efficacies', 'Efficacy, Collective']}, 'types': {0: ['T054']}, 'definition': {0: 'A group belief and perception in its ability to complete a task successfully. It includes shared belief it can control deviant behavior of a member.'}, 'entity': {0: 'efficacy'}, 'text': {0: 'multicentre study which assessed the efficacy and '}}","{'concept_id': {0: 'C5544503'}, 'canonical_name': {0: 'Vaccine Efficacy'}, 'aliases': {0: ['Efficacy, Vaccine']}, 'types': {0: ['T081']}, 'definition': {0: 'A measurement of disease risk reduction among vaccinated compared to unvaccinated persons under ideal conditions such as in a clinical trial. Such disease reduction measured under typical field conditions is vaccine effectiveness. In contrast vaccine potency is measured in an assay to ensure proper dosing and storage of vaccines whereas vaccine immunogenicity measures its ability to induce an immune response in a vaccinated individual in observational studies.'}, 'entity': {0: 'efficacy'}, 'text': {0: 'multicentre study which assessed the efficacy and '}}",{},{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'multicentre study which assessed the efficacy and '}}","           entity_group              value     score
0  Diagnostic_procedure  multicentre study  0.969557",[],"{'keyword': {0: 'study assessed efficacy', 1: 'study assessed', 2: 'multicentre study assessed', 3: 'multicentre study', 4: 'assessed efficacy'}, 'score': {0: 0.8711, 1: 0.8489, 2: 0.8343, 3: 0.8319, 4: 0.8178}}"
1139,1139,1139,0.8830000162124634,28.0,safety profile of adjuvant Kadcyla vs trastuzumab in ,MyriadPro-Light,4,-0.25,3355443,27,3,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'safety profile of adjuvant Kadcyla vs trastuzumab in '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'safety profile of adjuvant Kadcyla vs trastuzumab in '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'safety profile of adjuvant Kadcyla vs trastuzumab in '}}",{},{},"           entity_group             value     score
0            Medication  adjuvant Kadcyla  0.607131
1  Diagnostic_procedure          adjuvant  0.658503
2  Diagnostic_procedure           Kadcyla  0.576011
3           Coreference           Kadcyla  0.638600
4            Medication       trastuzumab  0.999818","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'safety profile adjuvant', 1: 'safety profile', 2: 'kadcyla vs trastuzumab', 3: 'adjuvant kadcyla', 4: 'kadcyla vs'}, 'score': {0: 0.8627, 1: 0.8578, 2: 0.7999, 3: 0.7579, 4: 0.7464}}"
1140,1140,1140,0.8830000162124634,28.0,patients who  ,MyriadPro-Light,4,-0.25,3355443,27,3,3,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'patients who  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'patients who  '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1141,1141,1141,0.8830000162124634,28.0,had residual invasive disease following trastuzumab-,MyriadPro-Light,4,-0.25,3355443,27,3,4,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following trastuzumab-'}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following trastuzumab-'}}",{},{},{},"           entity_group         value     score
0  Detailed_description      residual  0.983790
1  Detailed_description      invasive  0.997547
2           Coreference       disease  0.421152
3            Medication  trastuzumab-  0.999813","[('trastuzumab-', 'DRUG')]","{'keyword': {0: 'residual invasive disease', 1: 'disease following trastuzumab', 2: 'disease following', 3: 'following trastuzumab', 4: 'invasive disease'}, 'score': {0: 0.8674, 1: 0.8371, 2: 0.8081, 3: 0.7508, 4: 0.7228}}"
1142,1142,1142,0.8830000162124634,28.0,based neoadjuvant therapy,MyriadPro-Light,4,-0.25,3355443,27,3,5,"{'concept_id': {0: 'C4744826'}, 'canonical_name': {0: 'Post Neoadjuvant Therapy Sample'}, 'aliases': {0: ['Post Neo-adjuvant Therapy Sample']}, 'types': {0: ['T031']}, 'definition': {0: 'A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'based neoadjuvant therapy'}}","{'concept_id': {0: 'C0242939'}, 'canonical_name': {0: 'Radiotherapy, Adjuvant'}, 'aliases': {0: ['Radiotherapies, Adjuvant', 'Adjuvant Radiotherapy', 'Adjuvant Radiotherapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'based neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0  Therapeutic_procedure          neoadjuvant  0.999251
1  Therapeutic_procedure  neoadjuvant therapy  0.994513",[],"{'keyword': {0: 'based neoadjuvant therapy', 1: 'based neoadjuvant', 2: 'neoadjuvant therapy'}, 'score': {0: 1.0, 1: 0.9655, 2: 0.938}}"
1143,1143,1143,0.8830000162124634,27.0,Surgery,MyriadPro-Light,4,-0.25,16777215,27,4,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  Surgery  0.998798",[],"{'keyword': {}, 'score': {}}"
1144,1144,1144,0.8830000162124634,27.0,Residual invasive ,MyriadPro-Light,4,-0.25,16777215,27,5,0,"{'concept_id': {0: 'C1334278'}, 'canonical_name': {0: 'Invasive Lesion'}, 'aliases': {0: ['Invasive Lesion']}, 'types': {0: ['T033']}, 'definition': {0: 'A malignant cellular population that has increased in size and infiltrates the surrounding tissues.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}","{'concept_id': {0: 'C2936533'}, 'canonical_name': {0: 'Invasive Species'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Non-native species that threaten ecosystems, habitats, or other species and are likely to cause economic or environmental harm or harm to human health.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"           entity_group              value     score
0  Detailed_description  Residual invasive  0.999395",[],"{'keyword': {0: 'residual invasive'}, 'score': {0: 1.0}}"
1145,1145,1145,0.8830000162124634,27.0,disease in breast  ,MyriadPro-Light,4,-0.25,16777215,27,5,1,"{'concept_id': {0: 'C0038293'}, 'canonical_name': {0: 'Sternum'}, 'aliases': {0: ['Bone structure of sternum (body structure)', 'sternums', 'Sternum', 'Sternum/Sternal', 'Breast bone', 'Chest>Sternum', 'Sternal', 'breast bone', 'sternum', 'Sternum, NOS', 'Bone structure of sternum']}, 'types': {0: ['T023']}, 'definition': {0: 'A long, narrow, and flat bone commonly known as BREASTBONE occurring in the midsection of the anterior thoracic segment or chest region, which stabilizes the rib cage and serves as the point of origin for several muscles that move the arms, head, and neck.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","{'concept_id': {0: 'C0024902'}, 'canonical_name': {0: 'Breast Pain'}, 'aliases': {0: ['Mastodynias', 'Mammalgias', 'Mastodynia', 'Mastalgias', 'Mammalgia', 'Pain, Breast', 'Mastalgia', 'Breast Pains', 'Pains, Breast']}, 'types': {0: ['T184']}, 'definition': {0: 'Painful sensation in the breast region.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","           entity_group   value     score
0  Biological_structure  breast  0.999824",[],"{'keyword': {0: 'disease breast'}, 'score': {0: 0.9481}}"
1146,1146,1146,0.8830000162124634,27.0,or axillary lymph ,MyriadPro-Light,4,-0.25,16777215,27,5,2,"{'concept_id': {0: 'C0229843'}, 'canonical_name': {0: 'Pectoral lymph node group'}, 'aliases': {0: ['Nodi lymphoidei axillarum anteriores', 'Anterior axillary lymph nodes', 'Structure of pectoral axillary lymph node (body structure)', 'Anterior axillary nodes', 'Pectoral axillary lymph node', 'Nodi pectorales', 'Anterior axillary lymph nodes set', 'Pectoral Lymph Node', 'Pectoral lymph node', 'Pectoral lymph node group', 'Pectoral nodes', 'Pectoral axillary lymph node group', 'Pectoral lymph nodes', 'Structure of pectoral axillary lymph node', 'Pectoral lymph node group (body structure)', 'Anterior axillary lymph node', 'Nodi axillarum anteriores', 'Nodus lymphaticus pectoralis axillae', 'Set of pectoral lymph nodes', 'Set of anterior axillary lymph nodes', 'Pectoral lymph nodes set', 'Pectoral axillary lymph nodes', 'Set of pectoral axillary lymph nodes', 'Nodi lymphoidei pectorales']}, 'types': {0: ['T023']}, 'definition': {0: 'An axillary lymph node located along the lower edge of the pectoralis minor.'}, 'entity': {0: 'axillary lymph'}, 'text': {0: 'or axillary lymph '}}",{},{},{},{},"           entity_group           value     score
0  Biological_structure        axillary  0.999927
1  Biological_structure  axillary lymph  0.940007",[],"{'keyword': {0: 'axillary lymph'}, 'score': {0: 0.9521}}"
1147,1147,1147,0.8830000162124634,27.0,nodes,MyriadPro-Light,4,-0.25,16777215,27,5,3,"{'concept_id': {0: 'C2697524'}, 'canonical_name': {0: 'Graph Node'}, 'aliases': {0: ['Vertex', 'Node', 'Graph Node']}, 'types': {0: ['T077']}, 'definition': {0: 'One of the points that define a graph.'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}","{'concept_id': {0: 'C0037189'}, 'canonical_name': {0: 'Sino-Atrial Nodes'}, 'aliases': {0: ['Sinu-Atrial Node', 'Sino-Atrial Node', 'Sinu-Atrial Nodes', 'Nodes, Sinu-Atrial', 'Sinus Node', 'Nodes, Sinuatrial', 'Node, Sinuatrial', 'Nodes, Sinoatrial', 'Nodes, Sinus', 'Sinoatrial Node', 'Sinus Nodes', 'Sinuatrial Node', 'Node, Sino-Atrial', 'Node, Sinus', 'Node, Sinoatrial', 'Sinoatrial Nodes', 'Sinu Atrial Node', 'Sinuatrial Nodes', 'Sino Atrial Node', 'Nodes, Sino-Atrial', 'Node, Sinu-Atrial']}, 'types': {0: ['T023']}, 'definition': {0: 'The small mass of modified cardiac muscle fibers located at the junction of the superior vena cava (VENA CAVA, SUPERIOR) and right atrium. Contraction impulses probably start in this node, spread over the atrium (HEART ATRIUM) and are then transmitted by the atrioventricular bundle (BUNDLE OF HIS) to the ventricle (HEART VENTRICLE).'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}",{},{},{},"           entity_group  value     score
0  Biological_structure  nodes  0.488832",[],"{'keyword': {}, 'score': {}}"
1148,1148,1148,0.8830000162124634,27.0,"HER2-positive eBC, ",MyriadPro-Light,4,-0.25,16777215,27,6,0,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  HER2-positive  0.816637",[],"{'keyword': {0: 'her2 positive ebc', 1: 'positive ebc', 2: 'her2 positive'}, 'score': {0: 0.9628, 1: 0.8142, 2: 0.7646}}"
1149,1149,1149,0.8830000162124634,27.0,neoadjuvant ,MyriadPro-Light,4,-0.25,16777215,27,6,1,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}",{},{},{},"           entity_group        value     score
0  Detailed_description  neoadjuvant  0.956138
1          Sign_symptom  neoadjuvant  0.386592
2               History  neoadjuvant  0.344678",[],"{'keyword': {}, 'score': {}}"
1150,1150,1150,0.8830000162124634,27.0,trastuzumab* plus ,MyriadPro-Light,4,-0.25,16777215,27,6,2,"{'concept_id': {0: 'C4527338'}, 'canonical_name': {0: 'AC Followed by Docetaxel/Trastuzumab Regimen'}, 'aliases': {0: ['AC-Docetaxel + Trastuzumab', 'AC-T Plus Trastuzumab', 'AC-Taxotere/Herceptin', 'AC Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel/Trastuzumab']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},{},"           entity_group        value     score
0            Medication  trastuzumab  0.999873
1  Detailed_description         plus  0.314542","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab plus'}, 'score': {0: 0.9478}}"
1151,1151,1151,0.8830000162124634,27.0,chemotherapy ,MyriadPro-Light,4,-0.25,16777215,27,6,3,"{'concept_id': {0: 'C0392920'}, 'canonical_name': {0: 'Chemotherapy Regimen'}, 'aliases': {0: ['chemotherapy regimen', 'Antineoplastic chemotherapy regimen', 'chemotherapies', 'Antineoplastic chemotherapy regimen (regime/therapy)', 'chemotherapy regimens', 'neoplasm chemotherapy', 'neoplasm pharmacotherapy', 'chemotherapy', 'chemo', 'Cancer chemotherapy', 'neoplasm/cancer chemotherapy', 'cancer chemotherapy', 'cancer pharmacotherapy', 'neoplasm/cancer pharmacotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'application of the beneficial effects of drugs to control or cure neoplastic growth.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}","{'concept_id': {0: 'C1868801'}, 'canonical_name': {0: 'Hyperthermic Intraperitoneal Chemotherapy'}, 'aliases': {0: ['Hot Chemotherapy', 'Chemotherapy, Intraperitoneal Hyperthermic', 'Chemotherapy, Hyperthermic Intraperitoneal', 'Chemotherapy, Hot', 'Intraperitoneal Hyperthermic Chemotherapies', 'Intraperitoneal Chemotherapy, Hyperthermic', 'Hyperthermic Chemotherapy, Intraperitoneal', 'HIPEC', 'Intraperitoneal Hyperthermic Chemotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}",{},{},{},"  entity_group         value     score
0   Medication  chemotherapy  0.999848","[('chemotherapy', 'DRUG')]","{'keyword': {}, 'score': {}}"
1152,1152,1152,0.8830000162124634,27.0,(n=1486),MyriadPro-Light,4,-0.25,16777215,27,6,4,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1153,1153,1153,0.9890000224113464,28.0,Primary endpoint,MyriadPro-Bold,20,-0.25,3355443,27,7,0,"{'concept_id': {0: 'C2349179'}, 'canonical_name': {0: 'End Point'}, 'aliases': {0: ['Endpoint', 'End Point', 'ENDPOINT', 'endpoints', 'endpoint', 'End-Point']}, 'types': {0: ['T080']}, 'definition': {0: 'A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.'}, 'entity': {0: 'Primary endpoint'}, 'text': {0: 'Primary endpoint'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  Primary endpoint  0.940143",[],"{'keyword': {0: 'primary endpoint'}, 'score': {0: 1.0}}"
1154,1154,1154,0.8830000162124634,28.0,•,MyriadPro-Light,4,-0.25,16162586,27,7,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1155,1155,1155,0.9890000224113464,28.0,Secondary endpoints,MyriadPro-Bold,20,-0.25,3355443,27,8,0,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}",{},"{'concept_id': {0: 'C1623508'}, 'canonical_name': {0: 'regulation of secondary metabolic process'}, 'aliases': {0: ['regulation of secondary metabolism']}, 'types': {0: ['T040']}, 'definition': {0: 'Any process that modulates the frequency, rate or extent of secondary metabolism, the chemical reactions and pathways involving compounds that are not necessarily required for growth and maintenance of cells, and are often unique to a taxon. [GOC:jl]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C2981150'}, 'canonical_name': {0: 'Uranostaphyloschisis'}, 'aliases': {0: ['Cleft of hard and soft palate', 'Cleft of palate', 'Cleft hard and soft palate', 'Cleft palate', 'Cleft secondary palate', 'Palatoschisis', 'Cleft roof of mouth']}, 'types': {0: ['T019']}, 'definition': {0: 'Cleft palate is a developmental defect of the palate resulting from a failure of fusion of the palatine processes and manifesting as a separation of the roof of the mouth (soft and hard palate). [HPO:probinson]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","           entity_group                value     score
0  Detailed_description  Secondary endpoints  0.811147",[],"{'keyword': {0: 'secondary endpoints'}, 'score': {0: 1.0}}"
1156,1156,1156,0.8830000162124634,27.0,Planned 10 years’ follow-up,MyriadPro-Light,4,-0.25,16777215,27,9,0,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}",{},{},{},"     entity_group      value     score
0        Duration   10 years  0.999410
1  Clinical_event  follow-up  0.993776",[],"{'keyword': {0: 'planned 10 years', 1: '10 years follow', 2: 'planned 10', 3: '10 years', 4: 'years follow'}, 'score': {0: 0.9349, 1: 0.8297, 2: 0.8114, 3: 0.7473, 4: 0.7286}}"
1157,1157,1157,0.9890000224113464,27.0,Trastuzumab  ,MyriadPro-Bold,20,-0.25,16777215,27,10,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
1158,1158,1158,0.9890000224113464,27.0,6 mg/kg IV ,MyriadPro-Bold,20,-0.25,16777215,27,10,1,"{'concept_id': {0: 'C0439272'}, 'canonical_name': {0: 'ug/g'}, 'aliases': {0: ['Picogram per Microgram', 'Zeptogram per Femtogram', 'Yoctogram per Attogram', 'mg/kg', 'Milligram/kilogram', 'Microgram/gram', 'microgram/g', 'Femtogram per Nanogram', 'Nanogram per Milligram', 'Milligram/kilogram (qualifier value)', 'Microgram/gram (qualifier value)', 'mg kg', 'Microgram per Gram', 'Milligram/Kilogram', 'Milligram per Kilogram', 'Attogram per Picogram', 'microg/g']}, 'types': {0: ['T081']}, 'definition': {0: 'A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.'}, 'entity': {0: 'mg/kg IV'}, 'text': {0: '6 mg/kg IV '}}",{},{},{},{},"     entity_group    value     score
0          Dosage  6 mg/kg  0.909511
1  Administration       IV  0.990577","[('6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7475, 1: 0.7458, 2: 0.6812}}"
1159,1159,1159,0.9890000224113464,27.0,(n=743),MyriadPro-Bold,20,-0.25,16777215,27,10,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1160,1160,1160,0.8830000162124634,28.0,•,MyriadPro-Light,4,-0.25,16162586,27,11,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1161,1161,1161,0.8830000162124634,28.0,non-breast cancer as per the  ,MyriadPro-Light,4,-0.25,3355443,27,11,1,{},"{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'non-breast cancer'}, 'text': {0: 'non-breast cancer as per the  '}}",{},{},{},"       entity_group              value     score
0           History         non-breast  0.647748
1  Disease_disorder  non-breast cancer  0.972177",[],"{'keyword': {0: 'non breast cancer', 1: 'non breast', 2: 'breast cancer'}, 'score': {0: 0.9178, 1: 0.7301, 2: 0.6862}}"
1162,1162,1162,0.8830000162124634,28.0,STEEP definition,MyriadPro-Light,4,-0.25,3355443,27,11,2,"{'concept_id': {0: 'C3539107'}, 'canonical_name': {0: 'Definition (core metadata concept)'}, 'aliases': {0: ['Definition', 'Definition (core metadata concept)']}, 'types': {0: ['T170']}, 'definition': {0: None}, 'entity': {0: 'definition'}, 'text': {0: 'STEEP definition'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  STEEP definition  0.998824",[],"{'keyword': {0: 'steep definition'}, 'score': {0: 1.0}}"
1163,1163,1163,0.8830000162124634,23.0,Anti-HER2 therapy for a total of 14 cycles. ,MyriadPro-Light,4,-0.25,3355443,27,12,0,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}",{},{},{},"  entity_group      value     score
0   Medication  Anti-HER2  0.606185
1  Coreference  Anti-HER2  0.565908
2   Medication    therapy  0.542007
3    Lab_value         14  0.923810",[],"{'keyword': {0: 'total 14 cycles', 1: 'therapy total 14', 2: 'anti her2 therapy', 3: 'her2 therapy total', 4: 'anti her2'}, 'score': {0: 0.8392, 1: 0.822, 2: 0.7728, 3: 0.7289, 4: 0.6897}}"
1164,1164,1164,0.8830000162124634,23.0,Radiation and endocrine therapy administered ,MyriadPro-Light,4,-0.25,3355443,27,12,1,"{'concept_id': {0: 'C1621583'}, 'canonical_name': {0: 'Administer - dosing instruction imperative'}, 'aliases': {0: ['Administer - dosing instruction imperative', 'Administer', 'Administer - dosing instruction imperative (qualifier value)']}, 'types': {0: ['T169']}, 'definition': {0: 'To dispense, apply, or tender something to another, such as administering a medicine.'}, 'entity': {0: 'administered'}, 'text': {0: 'Radiation and endocrine therapy administered '}}","{'concept_id': {0: 'C2607955'}, 'canonical_name': {0: 'Beta Radiation'}, 'aliases': {0: ['Rays, Beta', 'Ray, Beta', 'Beta Radiations', 'Beta Rays', 'Radiation, Beta', 'Beta Ray', 'Radiations, Beta']}, 'types': {0: ['T070']}, 'definition': {0: 'A stream of high energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus.'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy administered '}}",{},"{'concept_id': {0: 'C1154958'}, 'canonical_name': {0: 'response to electromagnetic radiation stimulus'}, 'aliases': {0: ['response to radiation stimulus', 'response to radiation']}, 'types': {0: ['T038']}, 'definition': {0: 'Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electromagnetic radiation stimulus. Electromagnetic radiation is a propagating wave in space with electric and magnetic components. These components oscillate at right angles to each other and to the direction of propagation. [GOC:jl, Wikipedia:Electromagnetic_radiation]'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy administered '}}",{},"            entity_group              value     score
0  Therapeutic_procedure          Radiation  0.999904
1  Therapeutic_procedure  endocrine therapy  0.996250
2         Clinical_event       administered  0.979253",[],"{'keyword': {0: 'therapy administered', 1: 'endocrine therapy', 2: 'endocrine therapy administered', 3: 'radiation endocrine therapy', 4: 'radiation endocrine'}, 'score': {0: 0.837, 1: 0.8363, 2: 0.8236, 3: 0.7269, 4: 0.7235}}"
1165,1165,1165,0.8830000162124634,23.0,according to institutional standards and study ,MyriadPro-Light,4,-0.25,3355443,27,12,2,"{'concept_id': {0: 'C0947630'}, 'canonical_name': {0: 'Scientific Study'}, 'aliases': {0: ['Study', 'Stdy', 'studies', 'scientific studies', 'study', 'scientific study']}, 'types': {0: ['T062']}, 'definition': {0: None}, 'entity': {0: 'study'}, 'text': {0: 'according to institutional standards and study '}}","{'concept_id': {0: 'C0008972'}, 'canonical_name': {0: 'Clinical Study'}, 'aliases': {0: []}, 'types': {0: ['T062']}, 'definition': {0: 'A work that reports on the results of a research study to evaluate interventions or exposures on biomedical or health-related outcomes. The two main types of clinical studies are interventional studies (clinical trials) and observational studies. While most clinical studies concern humans, this publication type may be used for clinical veterinary articles meeting the requisites for humans.'}, 'entity': {0: 'study'}, 'text': {0: 'according to institutional standards and study '}}",{},{},{},"           entity_group                                        value   score
0  Diagnostic_procedure  institutional standards standards and study  0.9774",[],"{'keyword': {0: 'according institutional standards', 1: 'according institutional', 2: 'institutional standards study', 3: 'institutional standards', 4: 'standards study'}, 'score': {0: 0.8588, 1: 0.8302, 2: 0.8209, 3: 0.8115, 4: 0.7987}}"
1166,1166,1166,0.8830000162124634,23.0,protocol,MyriadPro-Light,4,-0.25,3355443,27,12,3,"{'concept_id': {0: 'C1522729'}, 'canonical_name': {0: 'Library Protocol'}, 'aliases': {0: ['Library Protocol', 'Protocol']}, 'types': {0: ['T170']}, 'definition': {0: 'Laboratory protocol used to prepare a Library.'}, 'entity': {0: 'protocol'}, 'text': {0: 'protocol'}}","{'concept_id': {0: 'C0912478'}, 'canonical_name': {0: 'TIC protocol'}, 'aliases': {0: ['TIC regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A regimen consisting of paclitaxel, ifosfamide, mesna and carboplatin used as salvage therapy for the treatment of advanced-stage testicular cancer; also used for the treatment of unresectable and recurrent squamous cell head and neck cancer.'}, 'entity': {0: 'protocol'}, 'text': {0: 'protocol'}}",{},{},{},"           entity_group     value     score
0  Detailed_description  protocol  0.964893",[],"{'keyword': {}, 'score': {}}"
1167,1167,1167,0.8830000162124634,28.0,• ,MyriadPro-Light,4,-0.25,16162586,27,13,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1168,1168,1168,0.8830000162124634,28.0,• ,MyriadPro-Light,4,-0.25,16162586,27,13,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1169,1169,1169,0.8830000162124634,28.0,• ,MyriadPro-Light,4,-0.25,16162586,27,13,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1170,1170,1170,0.8830000162124634,28.0,• ,MyriadPro-Light,4,-0.25,16162586,27,13,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1171,1171,1171,0.9052734375,23.0,≥,ArialMT,0,-0.2119140625,3355443,27,14,0,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1172,1172,1172,0.8830000162124634,23.0,of treatment including ,MyriadPro-Light,4,-0.25,3355443,27,14,1,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'treatment including'}, 'score': {0: 0.9499}}"
1173,1173,1173,0.9052734375,22.65237236022949,≥,ArialMT,0,-0.2119140625,3355443,27,14,2,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1174,1174,1174,0.8830000162124634,23.0,therapy and ,MyriadPro-Light,4,-0.25,3355443,27,14,3,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  therapy  0.826489",[],"{'keyword': {}, 'score': {}}"
1175,1175,1175,0.8830000162124634,23.0,of trastuzumab therapy,MyriadPro-Light,4,-0.25,3355443,27,14,4,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},{},"  entity_group                value     score
0   Medication          trastuzumab  0.999849
1   Medication  trastuzumab therapy  0.978093","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab therapy'}, 'score': {0: 0.9362}}"
1176,1176,1176,0.9890000224113464,28.0,Stratification factors,MyriadPro-Bold,20,-0.25,3355443,27,15,0,"{'concept_id': {0: 'C1514983'}, 'canonical_name': {0: 'Stratification'}, 'aliases': {0: ['stratification']}, 'types': {0: ['T062']}, 'definition': {0: 'The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.'}, 'entity': {0: 'Stratification factors'}, 'text': {0: 'Stratification factors'}}",{},{},{},{},"           entity_group                   value     score
0  Diagnostic_procedure  Stratification factors  0.970758",[],"{'keyword': {0: 'stratification factors'}, 'score': {0: 1.0}}"
1177,1177,1177,0.9890000224113464,21.0,Inclusion and  ,MyriadPro-Bold,20,-0.25,16777215,27,16,0,"{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Cellular Inclusion', 'Inclusion Body', 'inclusion bodies', 'Inclusion Bodies', 'inclusion body', 'body inclusion', 'Inclusions, Cellular', 'cellular inclusions', 'Bodies, Inclusion', 'Cellular Inclusions', 'Inclusions', 'cellular inclusion', 'Inclusion, Cellular', 'Body, Inclusion']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}","{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Inclusions, Cellular', 'Inclusion, Cellular', 'Inclusion Body', 'Body, Inclusion', 'Cellular Inclusion', 'Bodies, Inclusion', 'Cellular Inclusions']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"{'concept_id': {0: 'C0205708'}, 'canonical_name': {0: 'cytoplasmic inclusion'}, 'aliases': {0: []}, 'types': {0: ['T026']}, 'definition': {0: 'A stainable aggregation of protein, lipid or small molecules in the cytoplasm.'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"  entity_group      value     score
0  Coreference  Inclusion  0.340508",[],"{'keyword': {}, 'score': {}}"
1178,1178,1178,0.9890000224113464,21.0,exclusion criteria,MyriadPro-Bold,20,-0.25,16777215,27,16,1,"{'concept_id': {0: 'C2827032'}, 'canonical_name': {0: 'Trial Inclusion Exclusion Criteria Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A specific variant of the original trial inclusion exclusion criterion.'}, 'entity': {0: 'exclusion criteria'}, 'text': {0: 'exclusion criteria'}}",{},{},{},{},"           entity_group               value     score
0  Diagnostic_procedure  exclusion criteria  0.534692",[],"{'keyword': {0: 'exclusion criteria'}, 'score': {0: 1.0}}"
1179,1179,1179,0.9890000224113464,21.0,Baseline characteristics  ,MyriadPro-Bold,20,-0.25,16777215,27,17,0,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","           entity_group                     value     score
0  Diagnostic_procedure  Baseline characteristics  0.999933",[],"{'keyword': {0: 'baseline characteristics'}, 'score': {0: 1.0}}"
1180,1180,1180,0.9890000224113464,21.0,were well-balanced,MyriadPro-Bold,20,-0.25,16777215,27,17,1,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  well-balanced  0.999827",[],"{'keyword': {}, 'score': {}}"
1181,1181,1181,0.8830000162124634,28.0,• ,MyriadPro-Light,4,-0.25,16162586,27,22,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1182,1182,1182,0.8830000162124634,28.0,• ,MyriadPro-Light,4,-0.25,16162586,27,22,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1183,1183,1183,0.8830000162124634,28.0,• ,MyriadPro-Light,4,-0.25,16162586,27,22,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1184,1184,1184,0.8830000162124634,28.0,•  ,MyriadPro-Light,4,-0.25,16162586,27,22,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1185,1185,1185,0.8830000162124634,28.0,neoadjuvant therapy,MyriadPro-Light,4,-0.25,3355443,27,22,4,"{'concept_id': {0: 'C4744826'}, 'canonical_name': {0: 'Post Neoadjuvant Therapy Sample'}, 'aliases': {0: ['Post Neo-adjuvant Therapy Sample']}, 'types': {0: ['T031']}, 'definition': {0: 'A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}","{'concept_id': {0: 'C0242939'}, 'canonical_name': {0: 'Radiotherapy, Adjuvant'}, 'aliases': {0: ['Radiotherapies, Adjuvant', 'Adjuvant Radiotherapy', 'Adjuvant Radiotherapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0  Therapeutic_procedure          neoadjuvant  0.652529
1  Therapeutic_procedure  neoadjuvant therapy  0.963288",[],"{'keyword': {0: 'neoadjuvant therapy'}, 'score': {0: 1.0}}"
1186,1186,1186,0.8830000162124634,19.0,*Dual neoadjuvant anti-HER2 therapy was also permitted.,MyriadPro-Light,4,-0.25,3355443,27,23,0,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}",{},{},{},"           entity_group              value     score
0  Detailed_description               Dual  0.999838
1  Detailed_description        neoadjuvant  0.999769
2            Medication        neoadjuvant  0.504794
3            Medication  anti-HER2 therapy  0.946504",[],"{'keyword': {0: 'her2 therapy permitted', 1: 'dual neoadjuvant', 2: 'her2 therapy', 3: 'anti her2', 4: 'neoadjuvant anti'}, 'score': {0: 0.8452, 1: 0.8024, 2: 0.7657, 3: 0.7064, 4: 0.6957}}"
1187,1187,1187,0.8830000162124634,19.0,"DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised definitions for efficacy ",MyriadPro-Light,4,-0.25,3355443,27,23,1,"{'concept_id': {0: 'C5690761'}, 'canonical_name': {0: 'Collective Efficacy'}, 'aliases': {0: ['Collective Efficacies', 'Efficacy, Team', 'Team Efficacy', 'Team Efficacies', 'Efficacy, Collective']}, 'types': {0: ['T054']}, 'definition': {0: 'A group belief and perception in its ability to complete a task successfully. It includes shared belief it can control deviant behavior of a member.'}, 'entity': {0: 'efficacy'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised definitions for efficacy '}}","{'concept_id': {0: 'C5544503'}, 'canonical_name': {0: 'Vaccine Efficacy'}, 'aliases': {0: ['Efficacy, Vaccine']}, 'types': {0: ['T081']}, 'definition': {0: 'A measurement of disease risk reduction among vaccinated compared to unvaccinated persons under ideal conditions such as in a clinical trial. Such disease reduction measured under typical field conditions is vaccine effectiveness. In contrast vaccine potency is measured in an assay to ensure proper dosing and storage of vaccines whereas vaccine immunogenicity measures its ability to induce an immune response in a vaccinated individual in observational studies.'}, 'entity': {0: 'efficacy'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised definitions for efficacy '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised definitions for efficacy '}}","{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised definitions for efficacy '}}","     entity_group        value     score
0  Administration  intravenous  0.999449","[('IV', 'ROUTE'), ('intravenous', 'ROUTE')]","{'keyword': {0: 'os overall survival', 1: 'survival steep standardised', 2: 'early breast', 3: 'standardised definitions', 4: 'iv intravenous'}, 'score': {0: 0.7454, 1: 0.7382, 2: 0.6689, 3: 0.6011, 4: 0.352}}"
1188,1188,1188,0.8830000162124634,19.0,endpoints.,MyriadPro-Light,4,-0.25,3355443,27,23,2,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'endpoints.'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'endpoints.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1189,1189,1189,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,27,24,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1190,1190,1190,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,27,24,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1191,1191,1191,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,27,24,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1192,1192,1192,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,27,24,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1193,1193,1193,0.9319999814033508,52.0,Inclusion and exclusion criteria,Ubuntu-Bold,20,-0.1889999955892563,8194925,28,1,0,"{'concept_id': {0: 'C2827032'}, 'canonical_name': {0: 'Trial Inclusion Exclusion Criteria Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A specific variant of the original trial inclusion exclusion criterion.'}, 'entity': {0: 'exclusion criteria'}, 'text': {0: 'Inclusion and exclusion criteria'}}","{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Inclusions, Cellular', 'Inclusion, Cellular', 'Inclusion Body', 'Body, Inclusion', 'Cellular Inclusion', 'Bodies, Inclusion', 'Cellular Inclusions']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and exclusion criteria'}}",{},"{'concept_id': {0: 'C0205708'}, 'canonical_name': {0: 'cytoplasmic inclusion'}, 'aliases': {0: []}, 'types': {0: ['T026']}, 'definition': {0: 'A stainable aggregation of protein, lipid or small molecules in the cytoplasm.'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and exclusion criteria'}}",{},"           entity_group      value     score
0  Diagnostic_procedure  Inclusion  0.780870
1  Diagnostic_procedure   criteria  0.866674",[],"{'keyword': {0: 'exclusion criteria', 1: 'inclusion exclusion criteria', 2: 'inclusion exclusion'}, 'score': {0: 0.8399, 1: 0.8237, 2: 0.7108}}"
1194,1194,1194,0.9520000219345092,32.0,Exclusion criteria,MyriadPro-Regular,4,-0.25,5723991,28,2,0,"{'concept_id': {0: 'C2827032'}, 'canonical_name': {0: 'Trial Inclusion Exclusion Criteria Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A specific variant of the original trial inclusion exclusion criterion.'}, 'entity': {0: 'Exclusion criteria'}, 'text': {0: 'Exclusion criteria'}}",{},{},{},{},"           entity_group               value     score
0  Diagnostic_procedure  Exclusion criteria  0.534692",[],"{'keyword': {0: 'exclusion criteria'}, 'score': {0: 1.0}}"
1195,1195,1195,0.9520000219345092,32.0,Inclusion criteria,MyriadPro-Regular,4,-0.25,5723991,28,3,0,"{'concept_id': {0: 'C2827031'}, 'canonical_name': {0: 'Trial Inclusion Exclusion Criteria Rule'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'An axiom that indicates the inclusion and exclusion criteria for possible study subjects.'}, 'entity': {0: 'Inclusion criteria'}, 'text': {0: 'Inclusion criteria'}}",{},{},{},{},"           entity_group               value     score
0  Diagnostic_procedure  Inclusion criteria  0.993227",[],"{'keyword': {0: 'inclusion criteria'}, 'score': {0: 1.0}}"
1196,1196,1196,0.75,98.0,The efficacy and safety profile of Kadcyla  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,28,4,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}",{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","  entity_group    value     score
0  Coreference  Kadcyla  0.860627","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'safety profile kadcyla', 1: 'safety profile', 2: 'efficacy safety', 3: 'profile kadcyla', 4: 'efficacy safety profile'}, 'score': {0: 0.7898, 1: 0.7881, 2: 0.7539, 3: 0.7067, 4: 0.7039}}"
1197,1197,1197,0.75,98.0,were confirmed in a phase 3 study,ConduitITC-Bold,20,-0.1700000017881393,8194925,28,4,1,"{'concept_id': {0: 'C0920321'}, 'canonical_name': {0: 'Phase I Clinical Trials'}, 'aliases': {0: ['Phase 1 Clinical Trials', 'Phase I Study', 'phase i clinical trials', 'phase 1 clinical trials', 'clinical trial phase I', 'Phase 1 Clinical Trial', 'phase i trial', 'Clinical Trials, Phase 1', 'Clinical Trials, Phase I', 'i phase trials', 'phase i clinical trial', 'Phase I Clinical Trial', 'Phase I Protocol', 'clinical trial phase i', 'Phase I Trial', 'Clinical Trials, Phase I as Topic', 'phase i study', 'phase I trial', 'Phase I Clinical Trials', 'Early-Stage Clinical Trials', 'trial phase i', 'Phase 1 Study']}, 'types': {0: ['T062']}, 'definition': {0: 'Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}","{'concept_id': {0: 'C0085973'}, 'canonical_name': {0: 'Case Study'}, 'aliases': {0: ['Case Studies']}, 'types': {0: ['T170']}, 'definition': {0: 'An uncontrolled observational study containing a detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin).'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}",{},{},{},"           entity_group          value     score
0             Lab_value      confirmed  0.596251
1  Diagnostic_procedure  phase 3 study  0.984973",[],"{'keyword': {0: 'confirmed phase', 1: 'confirmed phase study', 2: 'phase study'}, 'score': {0: 0.8854, 1: 0.793, 2: 0.6105}}"
1198,1198,1198,0.8830000162124634,32.0,•,MyriadPro-Light,4,-0.25,16162586,28,5,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1199,1199,1199,0.8830000162124634,32.0,margins after BCS ,MyriadPro-Light,4,-0.25,5723991,28,5,1,"{'concept_id': {0: 'C1412777'}, 'canonical_name': {0: 'BCS1L gene'}, 'aliases': {0: ['BC1 (ubiquinol-cytochrome c reductase) synthesis-like', 'BCS1-like (yeast)', 'BCS', 'BCS1, S. CEREVISIAE, HOMOLOG-LIKE', 'BCS1L', 'BCS1L gene', 'Bjornstad syndrome', 'BCS1 (yeast homolog)-like', 'h-BCS', 'BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone', 'BJS', 'Hs.6719', 'BCS1-like (S. cerevisiae)', 'BCS1 HOMOLOG, UBIQUINOL-CYTOCHROME C REDUCTASE COMPLEX CHAPERONE', 'GRACILE syndrome']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'BCS'}, 'text': {0: 'margins after BCS '}}","{'concept_id': {0: 'C0229985'}, 'canonical_name': {0: 'Surgical Margins'}, 'aliases': {0: ['Margin, Surgical', 'Resection Margins', 'Margins of Excision', 'Excision Margins', 'Margins, Resection', 'Excision Margin', 'Resection Margin', 'Margin, Resection', 'Margins, Surgical', 'Surgical Margin']}, 'types': {0: ['T023']}, 'definition': {0: 'The edges of tissue removed in a surgery for assessment of the effectiveness of a surgical procedure in achieving the local control of a neoplasm and the adequacy of tumor removal. When the margin is negative or not involved by tumor (e.g., CANCER) it suggests all of the tumor has been removed by the surgery.'}, 'entity': {0: 'margins'}, 'text': {0: 'margins after BCS '}}",{},"{'concept_id': {0: 'C2266615'}, 'canonical_name': {0: 'acetyl-CoA synthase activity'}, 'aliases': {0: ['CO-methylating acetyl-CoA synthase activity', 'acetyl-CoA:corrinoid protein O-acetyltransferase activity', 'ACS', 'CO-methylating acetyl-coenzyme A synthase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: acetyl-CoA + corrinoid protein = CO + methylcorrinoid protein + CoA. [EC:2.3.1.169, PMID:1748656]'}, 'entity': {0: 'BCS'}, 'text': {0: 'margins after BCS '}}","{'concept_id': {0: 'C0033036'}, 'canonical_name': {0: 'Premature atrial contractions'}, 'aliases': {0: ['Atrial ectopic beats', 'Atrial premature complex', 'Ectopic supraventricular rhythms', 'PACs', 'Premature supraventricular beats']}, 'types': {0: ['T047']}, 'definition': {0: 'A type of cardiac arrhythmia with premature atrial contractions or beats caused by signals originating from ectopic atrial sites. The ectopic signals may or may not conduct to the HEART VENTRICLES. Atrial premature complexes are characterized by premature P waves on ECG which are different in configuration from the P waves generated by the normal pacemaker complex in the SINOATRIAL NODE.'}, 'entity': {0: 'BCS'}, 'text': {0: 'margins after BCS '}}","           entity_group    value     score
0  Diagnostic_procedure  margins  0.921135
1      Disease_disorder      BCS  0.914108","[('BCS', 'DRUG')]","{'keyword': {0: 'margins bcs'}, 'score': {0: 0.6919}}"
1200,1200,1200,0.8830000162124634,32.0,•,MyriadPro-Light,4,-0.25,16162586,28,6,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1201,1201,1201,0.8830000162124634,32.0,•,MyriadPro-Light,4,-0.25,16162586,28,7,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1202,1202,1202,0.8830000162124634,32.0,"invasive primary breast cancer (clinical tumour stage T1–T4, ",MyriadPro-Light,4,-0.25,5723991,28,7,1,"{'concept_id': {0: 'C1300072'}, 'canonical_name': {0: 'Tumor stage'}, 'aliases': {0: ['staging tumours', 'tumor stage', 'Tumour stage', 'stage tumor', 'staging tumors', 'Neoplasm Stage', 'stages tumors', 'Tumor stage', 'Tumor stage (observable entity)', 'Stage', 'Tumor Stage']}, 'types': {0: ['T201']}, 'definition': {0: 'The extent of a cancer in the body.'}, 'entity': {0: 'clinical tumour stage T1–T4'}, 'text': {0: 'invasive primary breast cancer (clinical tumour stage T1–T4, '}}","{'concept_id': {0: 'C0294028'}, 'canonical_name': {0: 'Breast Cancer 2 Protein'}, 'aliases': {0: ['Fanconi Anemia Complementation Group D1 Protein', 'Fanconi Anemia Group D1 Protein', 'FANCD1 Protein', 'BRCA2 Protein', 'Fanconi Anemia Group D1 Complementing Protein', 'BRCA2 Gene Product', 'Breast Cancer 2 Gene Product']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)'}, 'entity': {0: 'primary breast cancer'}, 'text': {0: 'invasive primary breast cancer (clinical tumour stage T1–T4, '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'invasive primary breast cancer (clinical tumour stage T1–T4, '}}","{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'primary breast cancer'}, 'text': {0: 'invasive primary breast cancer (clinical tumour stage T1–T4, '}}","           entity_group     value     score
0  Detailed_description  invasive  0.999950
1  Detailed_description   primary  0.999788
2      Disease_disorder    breast  0.554931
3  Detailed_description  clinical  0.873143
4          Sign_symptom    tumour  0.966886",[],"{'keyword': {0: 'primary breast cancer', 1: 't1 t4', 2: 'stage t1 t4', 3: 'cancer clinical', 4: 'tumour stage'}, 'score': {0: 0.8438, 1: 0.6728, 2: 0.6706, 3: 0.6361, 4: 0.626}}"
1203,1203,1203,0.8830000162124634,32.0,"nodal stage N0–N3, and metastasis stage M0 excluding ",MyriadPro-Light,4,-0.25,5723991,28,7,2,"{'concept_id': {0: 'C0456533'}, 'canonical_name': {0: 'M - Metastasis stages'}, 'aliases': {0: ['M - Metastasis stages', 'M category', 'M Category', 'Metastasis stages', 'metastasis staging', 'M Classification', 'stage m', 'M category (observable entity)', 'm category', 'M stage']}, 'types': {0: ['T185']}, 'definition': {0: 'One criteria of the TNM staging system. M refers to the presence of metastasis.'}, 'entity': {0: 'metastasis stage M0'}, 'text': {0: 'nodal stage N0–N3, and metastasis stage M0 excluding '}}","{'concept_id': {0: 'C0027627'}, 'canonical_name': {0: 'Neoplasm Metastases'}, 'aliases': {0: ['Neoplasm Metastasis', 'Metastases, Neoplasm', 'Metastase', 'Metastases', 'Metastasis, Neoplasm', 'Metastasis']}, 'types': {0: ['T191']}, 'definition': {0: 'The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.'}, 'entity': {0: 'metastasis stage M0'}, 'text': {0: 'nodal stage N0–N3, and metastasis stage M0 excluding '}}",{},{},{},"           entity_group               value     score
0  Diagnostic_procedure   nodal stage stage  0.995601
1      Disease_disorder          metastasis  0.920580
2             Lab_value                  M0  0.449411
3  Detailed_description  N0–N3 M0 excluding  0.982974",[],"{'keyword': {0: 'stage n0 n3', 1: 'stage m0', 2: 'stage m0 excluding', 3: 'n3 metastasis', 4: 'm0 excluding'}, 'score': {0: 0.8831, 1: 0.8208, 2: 0.7967, 3: 0.5539, 4: 0.4132}}"
1204,1204,1204,0.8830000162124634,32.0,clinical stage T1aN0 or T1bN0) at presentation,MyriadPro-Light,4,-0.25,5723991,28,7,3,"{'concept_id': {0: 'C0233302'}, 'canonical_name': {0: 'Funic presentation'}, 'aliases': {0: ['Funic Presentation', 'Funic presentation', 'Funis Presentation', 'Presentation of cord', 'Presentation of cord (disorder)', 'Funic presentation (finding)', 'Cord presentation', 'Cord Presentation']}, 'types': {0: ['T033']}, 'definition': {0: 'The positioning of the umbilical cord before the main presenting part of the fetus.'}, 'entity': {0: 'presentation'}, 'text': {0: 'clinical stage T1aN0 or T1bN0) at presentation'}}","{'concept_id': {0: 'C1257986'}, 'canonical_name': {0: 'Cross-Presentation'}, 'aliases': {0: ['Cross Presentation']}, 'types': {0: ['T043']}, 'definition': {0: 'Transfer of exogenous ANTIGEN to the ANTIGEN-PRESENTING CELLS for presentation to naive CD8-POSITIVE LYMPHOCYTES.'}, 'entity': {0: 'presentation'}, 'text': {0: 'clinical stage T1aN0 or T1bN0) at presentation'}}",{},"{'concept_id': {0: 'C0206431'}, 'canonical_name': {0: 'antigen processing and presentation'}, 'aliases': {0: ['antigen processing', 'antigen presentation']}, 'types': {0: ['T043']}, 'definition': {0: 'The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)'}, 'entity': {0: 'presentation'}, 'text': {0: 'clinical stage T1aN0 or T1bN0) at presentation'}}",{},"     entity_group         value     score
0  Clinical_event  presentation  0.999385",[],"{'keyword': {0: 'stage t1an0 t1bn0', 1: 'stage t1an0', 2: 't1bn0 presentation', 3: 'clinical stage', 4: 't1an0 t1bn0 presentation'}, 'score': {0: 0.861, 1: 0.8115, 2: 0.8016, 3: 0.8003, 4: 0.7878}}"
1205,1205,1205,0.8830000162124634,32.0,•,MyriadPro-Light,4,-0.25,16162586,28,8,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1206,1206,1206,0.944000005722046,27.0,Kadcyla ,UniversSB-Bold,20,-0.2469999939203262,16777215,28,9,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
1207,1207,1207,0.944000005722046,27.0,3.6 mg/kg IV ,UniversSB-Bold,20,-0.2469999939203262,16777215,28,9,1,{},{},{},{},{},"     entity_group      value     score
0       Lab_value    3.6 3.6  0.759886
1          Dosage  3.6 mg/kg  0.781887
2  Administration         IV  0.929909","[('3.6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7689, 1: 0.7403, 2: 0.7102}}"
1208,1208,1208,0.944000005722046,27.0,(n=743),UniversSB-Bold,20,-0.2469999939203262,16777215,28,9,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1209,1209,1209,0.8830000162124634,32.0,•,MyriadPro-Light,4,-0.25,16162586,28,10,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1210,1210,1210,0.8830000162124634,32.0,surgical specimen of the breast or axillary lymph nodes ,MyriadPro-Light,4,-0.25,5723991,28,10,1,"{'concept_id': {0: 'C0229843'}, 'canonical_name': {0: 'Pectoral lymph node group'}, 'aliases': {0: ['Nodi lymphoidei axillarum anteriores', 'Anterior axillary lymph nodes', 'Structure of pectoral axillary lymph node (body structure)', 'Anterior axillary nodes', 'Pectoral axillary lymph node', 'Nodi pectorales', 'Anterior axillary lymph nodes set', 'Pectoral Lymph Node', 'Pectoral lymph node', 'Pectoral lymph node group', 'Pectoral nodes', 'Pectoral axillary lymph node group', 'Pectoral lymph nodes', 'Structure of pectoral axillary lymph node', 'Pectoral lymph node group (body structure)', 'Anterior axillary lymph node', 'Nodi axillarum anteriores', 'Nodus lymphaticus pectoralis axillae', 'Set of pectoral lymph nodes', 'Set of anterior axillary lymph nodes', 'Pectoral lymph nodes set', 'Pectoral axillary lymph nodes', 'Set of pectoral axillary lymph nodes', 'Nodi lymphoidei pectorales']}, 'types': {0: ['T023']}, 'definition': {0: 'An axillary lymph node located along the lower edge of the pectoralis minor.'}, 'entity': {0: 'axillary lymph nodes'}, 'text': {0: 'surgical specimen of the breast or axillary lymph nodes '}}","{'concept_id': {0: 'C0024204'}, 'canonical_name': {0: 'Nodes, Lymph'}, 'aliases': {0: ['Lymph Node', 'Node, Lymph', 'Lymph Nodes']}, 'types': {0: ['T023']}, 'definition': {0: 'They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.'}, 'entity': {0: 'axillary lymph nodes'}, 'text': {0: 'surgical specimen of the breast or axillary lymph nodes '}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast'}, 'text': {0: 'surgical specimen of the breast or axillary lymph nodes '}}","           entity_group                 value     score
0  Diagnostic_procedure              surgical  0.857119
1  Biological_structure                breast  0.999942
2  Biological_structure              axillary  0.999950
3  Biological_structure  axillary lymph nodes  0.999900",[],"{'keyword': {0: 'surgical specimen breast', 1: 'surgical specimen', 2: 'axillary lymph', 3: 'lymph nodes', 4: 'breast axillary lymph'}, 'score': {0: 0.9199, 1: 0.9149, 2: 0.843, 3: 0.8362, 4: 0.816}}"
1211,1211,1211,0.8830000162124634,32.0,  –  NYHA class II–IV heart failure ,MyriadPro-Light,4,-0.25,5723991,28,11,0,{},{},{},{},{},"           entity_group          value     score
0  Diagnostic_procedure           NYHA  0.782757
1             Lab_value    class II–IV  0.957132
2  Detailed_description          II–IV  0.490845
3      Disease_disorder  heart failure  0.999629",[],"{'keyword': {0: 'nyha class', 1: 'iv heart failure', 2: 'ii iv heart', 3: 'class ii', 4: 'class ii iv'}, 'score': {0: 0.887, 1: 0.8469, 2: 0.7779, 3: 0.7547, 4: 0.5642}}"
1212,1212,1212,0.8830000162124634,32.0, or,MyriadPro-Light,4,-0.25,5723991,28,11,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1213,1213,1213,0.9470000267028807,28.0,"KATHERINE was a phase 3, open-label, ",UniversSB-Light,4,-0.2329999953508377,3355443,28,12,0,"{'concept_id': {0: 'C0205390'}, 'canonical_name': {0: 'Phase'}, 'aliases': {0: ['Phased', 'Phase', 'Phase (attribute)', 'phase', 'Stage']}, 'types': {0: ['T079']}, 'definition': {0: 'A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, '}}","{'concept_id': {0: 'C0080129'}, 'canonical_name': {0: 'S Phase'}, 'aliases': {0: ['S Period', 'Phase, S', 'Period, S', 'Phases, S', 'Periods, S', 'S Periods', 'S Phases']}, 'types': {0: ['T079']}, 'definition': {0: 'Phase of the CELL CYCLE following G1 and preceding G2 when the entire DNA content of the nucleus is replicated. It is achieved by bidirectional replication at multiple sites along each chromosome.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []","[('KATHERINE', 'DRUG')]","{'keyword': {0: 'phase open label', 1: 'open label', 2: 'katherine phase open', 3: 'katherine phase', 4: 'phase open'}, 'score': {0: 0.8484, 1: 0.8158, 2: 0.7484, 3: 0.7024, 4: 0.6219}}"
1214,1214,1214,0.9470000267028807,28.0,"randomised, multicentre study which assessed ",UniversSB-Light,4,-0.2329999953508377,3355443,28,12,1,"{'concept_id': {0: 'C1555289'}, 'canonical_name': {0: 'Assessed patient - therapy appropriate'}, 'aliases': {0: ['Assessed Patient']}, 'types': {0: ['T033']}, 'definition': {0: '<p>Assessed patient, therapy is appropriate</p>'}, 'entity': {0: 'assessed'}, 'text': {0: 'randomised, multicentre study which assessed '}}","{'concept_id': {0: 'C1096776'}, 'canonical_name': {0: 'Multicenter Studies'}, 'aliases': {0: ['Multicenter Study']}, 'types': {0: ['T062']}, 'definition': {0: 'A work that reports on a study executed by several cooperating institutions.'}, 'entity': {0: 'multicentre study'}, 'text': {0: 'randomised, multicentre study which assessed '}}",{},{},{},"           entity_group        value     score
0  Detailed_description   randomised  0.997080
1  Diagnostic_procedure  multicentre  0.964970
2  Detailed_description  multicentre  0.856343
3  Diagnostic_procedure        study  0.939489",[],"{'keyword': {0: 'randomised multicentre study', 1: 'multicentre study assessed', 2: 'randomised multicentre', 3: 'multicentre study', 4: 'study assessed'}, 'score': {0: 0.8846, 1: 0.8604, 2: 0.8469, 3: 0.8077, 4: 0.7694}}"
1215,1215,1215,0.9470000267028807,28.0,the efficacy and safety profile of adjuvant ,UniversSB-Light,4,-0.2329999953508377,3355443,28,12,2,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}",{},{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}","  entity_group     value     score
0   Medication  adjuvant  0.919629",[],"{'keyword': {0: 'safety profile', 1: 'safety profile adjuvant', 2: 'profile adjuvant', 3: 'efficacy safety', 4: 'efficacy safety profile'}, 'score': {0: 0.8586, 1: 0.7746, 2: 0.7312, 3: 0.6494, 4: 0.6119}}"
1216,1216,1216,0.9470000267028807,28.0,Kadcyla vs trastuzumab in patients who  ,UniversSB-Light,4,-0.2329999953508377,3355443,28,12,3,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}",{},{},"  entity_group        value     score
0   Medication      Kadcyla  0.588591
1   Medication  trastuzumab  0.999825","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'kadcyla vs trastuzumab', 1: 'kadcyla vs', 2: 'vs trastuzumab patients', 3: 'vs trastuzumab', 4: 'trastuzumab patients'}, 'score': {0: 0.9384, 1: 0.8664, 2: 0.8337, 3: 0.8093, 4: 0.8014}}"
1217,1217,1217,0.9470000267028807,28.0,had residual invasive disease following ,UniversSB-Light,4,-0.2329999953508377,3355443,28,12,4,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following '}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following '}}",{},{},{},"           entity_group             value     score
0  Detailed_description          residual  0.995710
1      Disease_disorder  invasive disease  0.862065",[],"{'keyword': {0: 'residual invasive disease', 1: 'residual invasive', 2: 'invasive disease following', 3: 'invasive disease', 4: 'disease following'}, 'score': {0: 0.9149, 1: 0.9108, 2: 0.8708, 3: 0.8285, 4: 0.8066}}"
1218,1218,1218,0.9470000267028807,28.0,trastuzumab-based neoadjuvant therapy,UniversSB-Light,4,-0.2329999953508377,3355443,28,12,5,{},"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'trastuzumab-based neoadjuvant therapy'}, 'text': {0: 'trastuzumab-based neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0             Medication    trastuzumab-based  0.999863
1  Therapeutic_procedure          neoadjuvant  0.997995
2  Therapeutic_procedure  neoadjuvant therapy  0.997627","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab based neoadjuvant', 1: 'based neoadjuvant therapy', 2: 'neoadjuvant therapy', 3: 'trastuzumab based', 4: 'based neoadjuvant'}, 'score': {0: 0.946, 1: 0.8826, 2: 0.8712, 3: 0.8579, 4: 0.8374}}"
1219,1219,1219,0.8830000162124634,32.0,•,MyriadPro-Light,4,-0.25,16162586,28,13,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1220,1220,1220,0.8830000162124634,32.0,administered with trastuzumab ,MyriadPro-Light,4,-0.25,5723991,28,13,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'administered with trastuzumab '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'administered with trastuzumab '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'administered with trastuzumab '}}",{},{},"  entity_group        value     score
0   Medication  trastuzumab  0.999811","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'administered trastuzumab'}, 'score': {0: 0.9188}}"
1221,1221,1221,0.9470000267028807,27.0,Surgery,UniversSB-Light,4,-0.2329999953508377,16777215,28,14,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  Surgery  0.998798",[],"{'keyword': {}, 'score': {}}"
1222,1222,1222,0.9470000267028807,27.0,Residual invasive ,UniversSB-Light,4,-0.2329999953508377,16777215,28,15,0,"{'concept_id': {0: 'C1334278'}, 'canonical_name': {0: 'Invasive Lesion'}, 'aliases': {0: ['Invasive Lesion']}, 'types': {0: ['T033']}, 'definition': {0: 'A malignant cellular population that has increased in size and infiltrates the surrounding tissues.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}","{'concept_id': {0: 'C2936533'}, 'canonical_name': {0: 'Invasive Species'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Non-native species that threaten ecosystems, habitats, or other species and are likely to cause economic or environmental harm or harm to human health.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"           entity_group              value     score
0  Detailed_description  Residual invasive  0.999395",[],"{'keyword': {0: 'residual invasive'}, 'score': {0: 1.0}}"
1223,1223,1223,0.9470000267028807,27.0,disease in breast  ,UniversSB-Light,4,-0.2329999953508377,16777215,28,15,1,"{'concept_id': {0: 'C0038293'}, 'canonical_name': {0: 'Sternum'}, 'aliases': {0: ['Bone structure of sternum (body structure)', 'sternums', 'Sternum', 'Sternum/Sternal', 'Breast bone', 'Chest>Sternum', 'Sternal', 'breast bone', 'sternum', 'Sternum, NOS', 'Bone structure of sternum']}, 'types': {0: ['T023']}, 'definition': {0: 'A long, narrow, and flat bone commonly known as BREASTBONE occurring in the midsection of the anterior thoracic segment or chest region, which stabilizes the rib cage and serves as the point of origin for several muscles that move the arms, head, and neck.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","{'concept_id': {0: 'C0024902'}, 'canonical_name': {0: 'Breast Pain'}, 'aliases': {0: ['Mastodynias', 'Mammalgias', 'Mastodynia', 'Mastalgias', 'Mammalgia', 'Pain, Breast', 'Mastalgia', 'Breast Pains', 'Pains, Breast']}, 'types': {0: ['T184']}, 'definition': {0: 'Painful sensation in the breast region.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","           entity_group   value     score
0  Biological_structure  breast  0.999824",[],"{'keyword': {0: 'disease breast'}, 'score': {0: 0.9481}}"
1224,1224,1224,0.9470000267028807,27.0,or axillary lymph ,UniversSB-Light,4,-0.2329999953508377,16777215,28,15,2,"{'concept_id': {0: 'C0229843'}, 'canonical_name': {0: 'Pectoral lymph node group'}, 'aliases': {0: ['Nodi lymphoidei axillarum anteriores', 'Anterior axillary lymph nodes', 'Structure of pectoral axillary lymph node (body structure)', 'Anterior axillary nodes', 'Pectoral axillary lymph node', 'Nodi pectorales', 'Anterior axillary lymph nodes set', 'Pectoral Lymph Node', 'Pectoral lymph node', 'Pectoral lymph node group', 'Pectoral nodes', 'Pectoral axillary lymph node group', 'Pectoral lymph nodes', 'Structure of pectoral axillary lymph node', 'Pectoral lymph node group (body structure)', 'Anterior axillary lymph node', 'Nodi axillarum anteriores', 'Nodus lymphaticus pectoralis axillae', 'Set of pectoral lymph nodes', 'Set of anterior axillary lymph nodes', 'Pectoral lymph nodes set', 'Pectoral axillary lymph nodes', 'Set of pectoral axillary lymph nodes', 'Nodi lymphoidei pectorales']}, 'types': {0: ['T023']}, 'definition': {0: 'An axillary lymph node located along the lower edge of the pectoralis minor.'}, 'entity': {0: 'axillary lymph'}, 'text': {0: 'or axillary lymph '}}",{},{},{},{},"           entity_group           value     score
0  Biological_structure        axillary  0.999927
1  Biological_structure  axillary lymph  0.940007",[],"{'keyword': {0: 'axillary lymph'}, 'score': {0: 0.9521}}"
1225,1225,1225,0.9470000267028807,27.0,nodes,UniversSB-Light,4,-0.2329999953508377,16777215,28,15,3,"{'concept_id': {0: 'C2697524'}, 'canonical_name': {0: 'Graph Node'}, 'aliases': {0: ['Vertex', 'Node', 'Graph Node']}, 'types': {0: ['T077']}, 'definition': {0: 'One of the points that define a graph.'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}","{'concept_id': {0: 'C0037189'}, 'canonical_name': {0: 'Sino-Atrial Nodes'}, 'aliases': {0: ['Sinu-Atrial Node', 'Sino-Atrial Node', 'Sinu-Atrial Nodes', 'Nodes, Sinu-Atrial', 'Sinus Node', 'Nodes, Sinuatrial', 'Node, Sinuatrial', 'Nodes, Sinoatrial', 'Nodes, Sinus', 'Sinoatrial Node', 'Sinus Nodes', 'Sinuatrial Node', 'Node, Sino-Atrial', 'Node, Sinus', 'Node, Sinoatrial', 'Sinoatrial Nodes', 'Sinu Atrial Node', 'Sinuatrial Nodes', 'Sino Atrial Node', 'Nodes, Sino-Atrial', 'Node, Sinu-Atrial']}, 'types': {0: ['T023']}, 'definition': {0: 'The small mass of modified cardiac muscle fibers located at the junction of the superior vena cava (VENA CAVA, SUPERIOR) and right atrium. Contraction impulses probably start in this node, spread over the atrium (HEART ATRIUM) and are then transmitted by the atrioventricular bundle (BUNDLE OF HIS) to the ventricle (HEART VENTRICLE).'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}",{},{},{},"           entity_group  value     score
0  Biological_structure  nodes  0.488832",[],"{'keyword': {}, 'score': {}}"
1226,1226,1226,0.8830000162124634,32.0,  –  A history of a reduction in LVEF to <40% with previous ,MyriadPro-Light,4,-0.25,5723991,28,16,0,"{'concept_id': {0: 'C1293152'}, 'canonical_name': {0: 'Reduction procedure'}, 'aliases': {0: ['Reduction', 'Reduction procedure', 'Reduction procedure (procedure)']}, 'types': {0: ['T061']}, 'definition': {0: None}, 'entity': {0: 'reduction'}, 'text': {0: '  –  A history of a reduction in LVEF to <40% with previous '}}","{'concept_id': {0: 'C0679771'}, 'canonical_name': {0: 'Harm Reduction'}, 'aliases': {0: ['Minimization, Harm', 'Reduction, Harm', 'Harm Minimization']}, 'types': {0: ['T061']}, 'definition': {0: 'The application of methods designed to reduce the risk of harm associated with certain behaviors without reduction in frequency of those behaviors. The risk-associated behaviors include ongoing and active addictive behaviors.'}, 'entity': {0: 'reduction'}, 'text': {0: '  –  A history of a reduction in LVEF to <40% with previous '}}",{},"{'concept_id': {0: 'C1522821'}, 'canonical_name': {0: 'acidification'}, 'aliases': {0: ['pH reduction']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that reduces the internal pH of an organism, part of an organism or a cell, measured by the concentration of the hydrogen ion. [GOC:go_curators]'}, 'entity': {0: 'reduction'}, 'text': {0: '  –  A history of a reduction in LVEF to <40% with previous '}}",{},"           entity_group      value     score
0             Lab_value  reduction  0.998664
1  Diagnostic_procedure       LVEF  0.999712
2             Lab_value     < 40 %  0.999899",[],"{'keyword': {0: 'reduction lvef 40', 1: 'history reduction lvef', 2: 'history reduction', 3: 'lvef 40', 4: 'lvef 40 previous'}, 'score': {0: 0.905, 1: 0.9019, 2: 0.7271, 3: 0.6121, 4: 0.6039}}"
1227,1227,1227,0.8830000162124634,32.0,therapy,MyriadPro-Light,4,-0.25,5723991,28,16,1,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy'}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy'}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  therapy  0.970922",[],"{'keyword': {}, 'score': {}}"
1228,1228,1228,0.9470000267028807,27.0,"HER2-positive eBC, ",UniversSB-Light,4,-0.2329999953508377,16777215,28,17,0,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  HER2-positive  0.816637",[],"{'keyword': {0: 'her2 positive ebc', 1: 'positive ebc', 2: 'her2 positive'}, 'score': {0: 0.9628, 1: 0.8142, 2: 0.7646}}"
1229,1229,1229,0.9470000267028807,27.0,neoadjuvant ,UniversSB-Light,4,-0.2329999953508377,16777215,28,17,1,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}",{},{},{},"           entity_group        value     score
0  Detailed_description  neoadjuvant  0.956138
1          Sign_symptom  neoadjuvant  0.386592
2               History  neoadjuvant  0.344678",[],"{'keyword': {}, 'score': {}}"
1230,1230,1230,0.9470000267028807,27.0,trastuzumab* plus ,UniversSB-Light,4,-0.2329999953508377,16777215,28,17,2,"{'concept_id': {0: 'C4527338'}, 'canonical_name': {0: 'AC Followed by Docetaxel/Trastuzumab Regimen'}, 'aliases': {0: ['AC-Docetaxel + Trastuzumab', 'AC-T Plus Trastuzumab', 'AC-Taxotere/Herceptin', 'AC Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel/Trastuzumab']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},{},"           entity_group        value     score
0            Medication  trastuzumab  0.999873
1  Detailed_description         plus  0.314542","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab plus'}, 'score': {0: 0.9478}}"
1231,1231,1231,0.9470000267028807,27.0,chemotherapy ,UniversSB-Light,4,-0.2329999953508377,16777215,28,17,3,"{'concept_id': {0: 'C0392920'}, 'canonical_name': {0: 'Chemotherapy Regimen'}, 'aliases': {0: ['chemotherapy regimen', 'Antineoplastic chemotherapy regimen', 'chemotherapies', 'Antineoplastic chemotherapy regimen (regime/therapy)', 'chemotherapy regimens', 'neoplasm chemotherapy', 'neoplasm pharmacotherapy', 'chemotherapy', 'chemo', 'Cancer chemotherapy', 'neoplasm/cancer chemotherapy', 'cancer chemotherapy', 'cancer pharmacotherapy', 'neoplasm/cancer pharmacotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'application of the beneficial effects of drugs to control or cure neoplastic growth.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}","{'concept_id': {0: 'C1868801'}, 'canonical_name': {0: 'Hyperthermic Intraperitoneal Chemotherapy'}, 'aliases': {0: ['Hot Chemotherapy', 'Chemotherapy, Intraperitoneal Hyperthermic', 'Chemotherapy, Hyperthermic Intraperitoneal', 'Chemotherapy, Hot', 'Intraperitoneal Hyperthermic Chemotherapies', 'Intraperitoneal Chemotherapy, Hyperthermic', 'Hyperthermic Chemotherapy, Intraperitoneal', 'HIPEC', 'Intraperitoneal Hyperthermic Chemotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}",{},{},{},"  entity_group         value     score
0   Medication  chemotherapy  0.999848","[('chemotherapy', 'DRUG')]","{'keyword': {}, 'score': {}}"
1232,1232,1232,0.9470000267028807,27.0,(n=1486),UniversSB-Light,4,-0.2329999953508377,16777215,28,17,4,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1233,1233,1233,0.944000005722046,28.0,Primary endpoint,UniversSB-Bold,20,-0.2469999939203262,3355443,28,18,0,"{'concept_id': {0: 'C2349179'}, 'canonical_name': {0: 'End Point'}, 'aliases': {0: ['Endpoint', 'End Point', 'ENDPOINT', 'endpoints', 'endpoint', 'End-Point']}, 'types': {0: ['T080']}, 'definition': {0: 'A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.'}, 'entity': {0: 'Primary endpoint'}, 'text': {0: 'Primary endpoint'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  Primary endpoint  0.940143",[],"{'keyword': {0: 'primary endpoint'}, 'score': {0: 1.0}}"
1234,1234,1234,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,28,18,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1235,1235,1235,0.944000005722046,28.0,Secondary endpoints,UniversSB-Bold,20,-0.2469999939203262,3355443,28,19,0,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}",{},"{'concept_id': {0: 'C1623508'}, 'canonical_name': {0: 'regulation of secondary metabolic process'}, 'aliases': {0: ['regulation of secondary metabolism']}, 'types': {0: ['T040']}, 'definition': {0: 'Any process that modulates the frequency, rate or extent of secondary metabolism, the chemical reactions and pathways involving compounds that are not necessarily required for growth and maintenance of cells, and are often unique to a taxon. [GOC:jl]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C2981150'}, 'canonical_name': {0: 'Uranostaphyloschisis'}, 'aliases': {0: ['Cleft of hard and soft palate', 'Cleft of palate', 'Cleft hard and soft palate', 'Cleft palate', 'Cleft secondary palate', 'Palatoschisis', 'Cleft roof of mouth']}, 'types': {0: ['T019']}, 'definition': {0: 'Cleft palate is a developmental defect of the palate resulting from a failure of fusion of the palatine processes and manifesting as a separation of the roof of the mouth (soft and hard palate). [HPO:probinson]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","           entity_group                value     score
0  Detailed_description  Secondary endpoints  0.811147",[],"{'keyword': {0: 'secondary endpoints'}, 'score': {0: 1.0}}"
1236,1236,1236,0.8830000162124634,32.0,  –  Patients must have completed ,MyriadPro-Light,4,-0.25,5723991,28,20,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'Patients'}, 'text': {0: '  –  Patients must have completed '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'Patients'}, 'text': {0: '  –  Patients must have completed '}}",{},{},{},"   entity_group      value     score
0  Sign_symptom  completed  0.280856",[],"{'keyword': {0: 'patients completed'}, 'score': {0: 0.6623}}"
1237,1237,1237,0.8830000162124634,32.0,neoadjuvant therapy containing ,MyriadPro-Light,4,-0.25,5723991,28,20,1,"{'concept_id': {0: 'C4744826'}, 'canonical_name': {0: 'Post Neoadjuvant Therapy Sample'}, 'aliases': {0: ['Post Neo-adjuvant Therapy Sample']}, 'types': {0: ['T031']}, 'definition': {0: 'A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy containing '}}","{'concept_id': {0: 'C0242939'}, 'canonical_name': {0: 'Radiotherapy, Adjuvant'}, 'aliases': {0: ['Radiotherapies, Adjuvant', 'Adjuvant Radiotherapy', 'Adjuvant Radiotherapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy containing '}}",{},{},{},"            entity_group                value     score
0  Therapeutic_procedure          neoadjuvant  0.620815
1  Therapeutic_procedure  neoadjuvant therapy  0.815962",[],"{'keyword': {0: 'neoadjuvant therapy containing', 1: 'neoadjuvant therapy', 2: 'therapy containing'}, 'score': {0: 1.0, 1: 0.954, 2: 0.8231}}"
1238,1238,1238,0.8830000162124634,32.0,therapy and ,MyriadPro-Light,4,-0.25,5723991,28,20,2,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  therapy  0.826489",[],"{'keyword': {}, 'score': {}}"
1239,1239,1239,0.9470000267028807,27.0,Planned 10 years’ follow-up,UniversSB-Light,4,-0.2329999953508377,16777215,28,21,0,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}",{},{},{},"     entity_group      value     score
0        Duration   10 years  0.999410
1  Clinical_event  follow-up  0.993776",[],"{'keyword': {0: 'planned 10 years', 1: '10 years follow', 2: 'planned 10', 3: '10 years', 4: 'years follow'}, 'score': {0: 0.9349, 1: 0.8297, 2: 0.8114, 3: 0.7473, 4: 0.7286}}"
1240,1240,1240,0.944000005722046,27.0,Trastuzumab  ,UniversSB-Bold,20,-0.2469999939203262,16777215,28,22,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
1241,1241,1241,0.944000005722046,27.0,6 mg/kg IV ,UniversSB-Bold,20,-0.2469999939203262,16777215,28,22,1,"{'concept_id': {0: 'C0439272'}, 'canonical_name': {0: 'ug/g'}, 'aliases': {0: ['Picogram per Microgram', 'Zeptogram per Femtogram', 'Yoctogram per Attogram', 'mg/kg', 'Milligram/kilogram', 'Microgram/gram', 'microgram/g', 'Femtogram per Nanogram', 'Nanogram per Milligram', 'Milligram/kilogram (qualifier value)', 'Microgram/gram (qualifier value)', 'mg kg', 'Microgram per Gram', 'Milligram/Kilogram', 'Milligram per Kilogram', 'Attogram per Picogram', 'microg/g']}, 'types': {0: ['T081']}, 'definition': {0: 'A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.'}, 'entity': {0: 'mg/kg IV'}, 'text': {0: '6 mg/kg IV '}}",{},{},{},{},"     entity_group    value     score
0          Dosage  6 mg/kg  0.909511
1  Administration       IV  0.990577","[('6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7475, 1: 0.7458, 2: 0.6812}}"
1242,1242,1242,0.944000005722046,27.0,(n=743),UniversSB-Bold,20,-0.2469999939203262,16777215,28,22,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1243,1243,1243,0.8830000162124634,32.0,     ,MyriadPro-Light,4,-0.25,5723991,28,23,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1244,1244,1244,0.8830000162124634,32.0,  ,MyriadPro-Light,4,-0.25,5723991,28,24,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1245,1245,1245,0.8830000162124634,32.0, –  Slightly shorter treatment durations were permitted for ,MyriadPro-Light,4,-0.25,5723991,28,24,1,"{'concept_id': {0: 'C2709058'}, 'canonical_name': {0: 'During Treatment'}, 'aliases': {0: ['During Therapy', 'during treatment']}, 'types': {0: ['T079']}, 'definition': {0: 'Occurring during the time that a subject received treatment.'}, 'entity': {0: 'treatment durations'}, 'text': {0: ' –  Slightly shorter treatment durations were permitted for '}}","{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Treatments'}, 'aliases': {0: ['Therapy', 'Treatment', 'Therapeutics', 'Therapeutic', 'Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'treatment durations'}, 'text': {0: ' –  Slightly shorter treatment durations were permitted for '}}",{},{},{},"            entity_group      value     score
0              Lab_value    shorter  0.859777
1  Therapeutic_procedure  treatment  0.996865",[],"{'keyword': {0: 'slightly shorter treatment', 1: 'slightly shorter', 2: 'shorter treatment', 3: 'durations permitted', 4: 'treatment durations'}, 'score': {0: 0.8811, 1: 0.8742, 2: 0.7231, 3: 0.7225, 4: 0.6896}}"
1246,1246,1246,0.8830000162124634,32.0,dose-dense regimens,MyriadPro-Light,4,-0.25,5723991,28,24,2,"{'concept_id': {0: 'C5556908'}, 'canonical_name': {0: 'Dose-dense Rituximab Regimen'}, 'aliases': {0: ['Dose-dense Rituximab', 'Dose-dense Rituxan']}, 'types': {0: ['T061']}, 'definition': {0: 'A regimen consisting of dose-dense rituximab that can be used for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).'}, 'entity': {0: 'dose-dense regimens'}, 'text': {0: 'dose-dense regimens'}}",{},{},{},{},"           entity_group                value     score
0  Detailed_description  dose-dense regimens  0.814426",[],"{'keyword': {0: 'dose dense regimens', 1: 'dense regimens', 2: 'dose dense'}, 'score': {0: 0.9723, 1: 0.8875, 2: 0.8616}}"
1247,1247,1247,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,28,25,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1248,1248,1248,0.9470000267028807,28.0,non-breast cancer as per the  ,UniversSB-Light,4,-0.2329999953508377,3355443,28,25,1,{},"{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'non-breast cancer'}, 'text': {0: 'non-breast cancer as per the  '}}",{},{},{},"       entity_group              value     score
0           History         non-breast  0.647748
1  Disease_disorder  non-breast cancer  0.972177",[],"{'keyword': {0: 'non breast cancer', 1: 'non breast', 2: 'breast cancer'}, 'score': {0: 0.9178, 1: 0.7301, 2: 0.6862}}"
1249,1249,1249,0.9470000267028807,28.0,STEEP definition,UniversSB-Light,4,-0.2329999953508377,3355443,28,25,2,"{'concept_id': {0: 'C3539107'}, 'canonical_name': {0: 'Definition (core metadata concept)'}, 'aliases': {0: ['Definition', 'Definition (core metadata concept)']}, 'types': {0: ['T170']}, 'definition': {0: None}, 'entity': {0: 'definition'}, 'text': {0: 'STEEP definition'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  STEEP definition  0.998824",[],"{'keyword': {0: 'steep definition'}, 'score': {0: 1.0}}"
1250,1250,1250,0.9470000267028807,23.0,Anti-HER2 therapy for a total of 14 cycles. ,UniversSB-Light,4,-0.2329999953508377,3355443,28,26,0,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}",{},{},{},"  entity_group      value     score
0   Medication  Anti-HER2  0.606185
1  Coreference  Anti-HER2  0.565908
2   Medication    therapy  0.542007
3    Lab_value         14  0.923810",[],"{'keyword': {0: 'total 14 cycles', 1: 'therapy total 14', 2: 'anti her2 therapy', 3: 'her2 therapy total', 4: 'anti her2'}, 'score': {0: 0.8392, 1: 0.822, 2: 0.7728, 3: 0.7289, 4: 0.6897}}"
1251,1251,1251,0.9470000267028807,23.0,Radiation and endocrine therapy ,UniversSB-Light,4,-0.2329999953508377,3355443,28,26,1,"{'concept_id': {0: 'C1514396'}, 'canonical_name': {0: 'Preoperative Endocrine Therapy'}, 'aliases': {0: []}, 'types': {0: ['T061']}, 'definition': {0: 'Short term endocrine therapy, prior to surgery, to ""down-stage"" primary breast cancer in order to increase the rate of breast-conserving surgery. (from JMCC 7:557-562, 2000 via Medscape)'}, 'entity': {0: 'endocrine therapy'}, 'text': {0: 'Radiation and endocrine therapy '}}","{'concept_id': {0: 'C2607955'}, 'canonical_name': {0: 'Beta Radiation'}, 'aliases': {0: ['Rays, Beta', 'Ray, Beta', 'Beta Radiations', 'Beta Rays', 'Radiation, Beta', 'Beta Ray', 'Radiations, Beta']}, 'types': {0: ['T070']}, 'definition': {0: 'A stream of high energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus.'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy '}}",{},"{'concept_id': {0: 'C1154958'}, 'canonical_name': {0: 'response to electromagnetic radiation stimulus'}, 'aliases': {0: ['response to radiation stimulus', 'response to radiation']}, 'types': {0: ['T038']}, 'definition': {0: 'Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electromagnetic radiation stimulus. Electromagnetic radiation is a propagating wave in space with electric and magnetic components. These components oscillate at right angles to each other and to the direction of propagation. [GOC:jl, Wikipedia:Electromagnetic_radiation]'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy '}}",{},"            entity_group              value     score
0  Therapeutic_procedure          Radiation  0.994988
1  Therapeutic_procedure  endocrine therapy  0.948940",[],"{'keyword': {0: 'radiation endocrine therapy', 1: 'endocrine therapy', 2: 'radiation endocrine'}, 'score': {0: 0.843, 1: 0.824, 2: 0.8103}}"
1252,1252,1252,0.9470000267028807,23.0,administered according to institutional ,UniversSB-Light,4,-0.2329999953508377,3355443,28,26,2,"{'concept_id': {0: 'C1546848'}, 'canonical_name': {0: 'Living Arrangement - Institution'}, 'aliases': {0: ['Institution']}, 'types': {0: ['T033']}, 'definition': {0: '<p>Institution</p>'}, 'entity': {0: 'institutional'}, 'text': {0: 'administered according to institutional '}}","{'concept_id': {0: 'C5544477'}, 'canonical_name': {0: 'Systemic Racism'}, 'aliases': {0: ['Institutionalized Racisms', 'Racism, Systemic', 'Institutionalized Racism', 'Racism, Institutionalized', 'Structural Racisms', 'Racism, Structural', 'Racism, Institutional', 'Racisms, Systematic', 'Systematic Racisms', 'Racism, Systematic', 'Institutional Racism', 'Systematic Racism', 'Structural Racism']}, 'types': {0: ['T054']}, 'definition': {0: 'Processes of racism that are embedded in laws (local, state, and federal), policies, and practices of society and its institutions that provide advantages to racial groups deemed as superior, while differentially oppressing, disadvantaging, or otherwise neglecting racial groups viewed as inferior. Differential access to the goods, services, and opportunities of society by race. Institutionalized racism is normative, sometimes legalized, and often manifests as inherited disadvantage. It is structural, having been codified in our institutions of custom, practice, and law, so there need not be an identifiable perpetrator. (ttps://www.cdc.gov/chronicdisease/programs-impact/sdoh.htm)'}, 'entity': {0: 'institutional'}, 'text': {0: 'administered according to institutional '}}",{},{},{},"           entity_group                       value     score
0  Detailed_description  according to institutional  0.817311",[],"{'keyword': {0: 'administered according institutional', 1: 'according institutional', 2: 'administered according'}, 'score': {0: 0.9745, 1: 0.8839, 2: 0.8672}}"
1253,1253,1253,0.9470000267028807,23.0,standards and study protocol,UniversSB-Light,4,-0.2329999953508377,3355443,28,26,3,"{'concept_id': {0: 'C2985700'}, 'canonical_name': {0: 'Study Protocol Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic.'}, 'entity': {0: 'study protocol'}, 'text': {0: 'standards and study protocol'}}","{'concept_id': {0: 'C2936643'}, 'canonical_name': {0: 'Standard of Care'}, 'aliases': {0: ['Standards of Care', 'Care Standards', 'Care Standard']}, 'types': {0: ['T058']}, 'definition': {0: 'The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.'}, 'entity': {0: 'standards'}, 'text': {0: 'standards and study protocol'}}",{},{},{},"           entity_group           value     score
0  Diagnostic_procedure       standards  0.946151
1  Diagnostic_procedure  study protocol  0.709869",[],"{'keyword': {0: 'study protocol', 1: 'standards study protocol', 2: 'standards study'}, 'score': {0: 0.906, 1: 0.879, 2: 0.7344}}"
1254,1254,1254,0.8830000162124634,32.0,  ,MyriadPro-Light,4,-0.25,5723991,28,27,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1255,1255,1255,0.8830000162124634,32.0, –  Anthracyclines and alkylating agents were permitted ,MyriadPro-Light,4,-0.25,5723991,28,27,1,"{'concept_id': {0: 'C0002074'}, 'canonical_name': {0: 'Alkylation'}, 'aliases': {0: ['Alkylation Process', 'alkylation', 'Alkylations', 'alkyl transfer', 'Alkylation']}, 'types': {0: ['T070']}, 'definition': {0: 'The covalent bonding of an alkyl group to an organic compound. It can occur by a simple addition reaction or by substitution of another functional group.'}, 'entity': {0: 'alkylating agents'}, 'text': {0: ' –  Anthracyclines and alkylating agents were permitted '}}","{'concept_id': {0: 'C0149214'}, 'canonical_name': {0: 'yoshi 864'}, 'aliases': {0: ['alkylating agent 864']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'An alkylsulfonate. Yoshi-864 alkylates and crosslinks DNA, thereby inhibiting DNA replication. Check for ""https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1416"" active clinical trials using this agent. (""http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1416"" NCI Thesaurus)'}, 'entity': {0: 'alkylating agents'}, 'text': {0: ' –  Anthracyclines and alkylating agents were permitted '}}",{},{},{},"           entity_group              value     score
0  Diagnostic_procedure     Anthracyclines  0.500109
1            Medication     Anthracyclines  0.893999
2            Medication  alkylating agents  0.913110","[('Anthracyclines', 'DRUG'), ('alkylating agents', 'DRUG')]","{'keyword': {0: 'agents permitted', 1: 'alkylating agents permitted', 2: 'anthracyclines alkylating', 3: 'anthracyclines alkylating agents', 4: 'alkylating agents'}, 'score': {0: 0.8376, 1: 0.8345, 2: 0.6808, 3: 0.657, 4: 0.6227}}"
1256,1256,1256,0.8830000162124634,32.0,"according to local standards, as  ",MyriadPro-Light,4,-0.25,5723991,28,27,2,"{'concept_id': {0: 'C2936643'}, 'canonical_name': {0: 'Standard of Care'}, 'aliases': {0: ['standards therapy', 'Standards of Care', 'therapy standard', 'Care Standards', 'Care Standard', 'standard therapy']}, 'types': {0: ['T058']}, 'definition': {0: 'The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.'}, 'entity': {0: 'local standards'}, 'text': {0: 'according to local standards, as  '}}","{'concept_id': {0: 'C2936643'}, 'canonical_name': {0: 'Standard of Care'}, 'aliases': {0: ['Standards of Care', 'Care Standards', 'Care Standard']}, 'types': {0: ['T058']}, 'definition': {0: 'The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.'}, 'entity': {0: 'local standards'}, 'text': {0: 'according to local standards, as  '}}",{},{},{},"           entity_group value     score
0  Detailed_description    as  0.673631",[],"{'keyword': {0: 'according local standards', 1: 'according local', 2: 'local standards'}, 'score': {0: 0.8491, 1: 0.8488, 2: 0.7936}}"
1257,1257,1257,0.8830000162124634,32.0,were additional HER2-targeted agents,MyriadPro-Light,4,-0.25,5723991,28,27,3,"{'concept_id': {0: 'C5235659'}, 'canonical_name': {0: 'HER2-targeting Agent'}, 'aliases': {0: ['ERBB2-Targeting Agent']}, 'types': {0: ['T121']}, 'definition': {0: 'Any agent that targets the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2/neu; HER-2; erbB-2).'}, 'entity': {0: 'HER2-targeted agents'}, 'text': {0: 'were additional HER2-targeted agents'}}",{},{},{},{},"  entity_group                 value     score
0   Medication         HER2-targeted  0.997773
1   Medication  HER2-targeted agents  0.993993",[],"{'keyword': {0: 'targeted agents', 1: 'her2 targeted agents', 2: 'additional her2 targeted', 3: 'additional her2', 4: 'her2 targeted'}, 'score': {0: 0.8156, 1: 0.8141, 2: 0.8031, 3: 0.7886, 4: 0.6899}}"
1258,1258,1258,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,28,28,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1259,1259,1259,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,28,28,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1260,1260,1260,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,28,28,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1261,1261,1261,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,28,28,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1262,1262,1262,0.9052734375,23.0,≥,ArialMT,0,-0.2119140625,3355443,28,29,0,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1263,1263,1263,0.9470000267028807,23.0,of treatment including ,UniversSB-Light,4,-0.2329999953508377,3355443,28,29,1,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'treatment including'}, 'score': {0: 0.9499}}"
1264,1264,1264,0.9052734375,22.65237236022949,≥,ArialMT,0,-0.2119140625,3355443,28,29,2,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1265,1265,1265,0.9470000267028807,23.0,therapy and ,UniversSB-Light,4,-0.2329999953508377,3355443,28,29,3,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  therapy  0.826489",[],"{'keyword': {}, 'score': {}}"
1266,1266,1266,0.9470000267028807,23.0,of trastuzumab therapy,UniversSB-Light,4,-0.2329999953508377,3355443,28,29,4,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},{},"  entity_group                value     score
0   Medication          trastuzumab  0.999849
1   Medication  trastuzumab therapy  0.978093","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab therapy'}, 'score': {0: 0.9362}}"
1267,1267,1267,0.944000005722046,28.0,Stratification factors,UniversSB-Bold,20,-0.2469999939203262,3355443,28,30,0,"{'concept_id': {0: 'C1514983'}, 'canonical_name': {0: 'Stratification'}, 'aliases': {0: ['stratification']}, 'types': {0: ['T062']}, 'definition': {0: 'The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.'}, 'entity': {0: 'Stratification factors'}, 'text': {0: 'Stratification factors'}}",{},{},{},{},"           entity_group                   value     score
0  Diagnostic_procedure  Stratification factors  0.970758",[],"{'keyword': {0: 'stratification factors'}, 'score': {0: 1.0}}"
1268,1268,1268,0.944000005722046,21.0,Inclusion and  ,UniversSB-Bold,20,-0.2469999939203262,16777215,28,31,0,"{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Cellular Inclusion', 'Inclusion Body', 'inclusion bodies', 'Inclusion Bodies', 'inclusion body', 'body inclusion', 'Inclusions, Cellular', 'cellular inclusions', 'Bodies, Inclusion', 'Cellular Inclusions', 'Inclusions', 'cellular inclusion', 'Inclusion, Cellular', 'Body, Inclusion']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}","{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Inclusions, Cellular', 'Inclusion, Cellular', 'Inclusion Body', 'Body, Inclusion', 'Cellular Inclusion', 'Bodies, Inclusion', 'Cellular Inclusions']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"{'concept_id': {0: 'C0205708'}, 'canonical_name': {0: 'cytoplasmic inclusion'}, 'aliases': {0: []}, 'types': {0: ['T026']}, 'definition': {0: 'A stainable aggregation of protein, lipid or small molecules in the cytoplasm.'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"  entity_group      value     score
0  Coreference  Inclusion  0.340508",[],"{'keyword': {}, 'score': {}}"
1269,1269,1269,0.944000005722046,21.0,exclusion criteria,UniversSB-Bold,20,-0.2469999939203262,16777215,28,31,1,"{'concept_id': {0: 'C2827032'}, 'canonical_name': {0: 'Trial Inclusion Exclusion Criteria Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A specific variant of the original trial inclusion exclusion criterion.'}, 'entity': {0: 'exclusion criteria'}, 'text': {0: 'exclusion criteria'}}",{},{},{},{},"           entity_group               value     score
0  Diagnostic_procedure  exclusion criteria  0.534692",[],"{'keyword': {0: 'exclusion criteria'}, 'score': {0: 1.0}}"
1270,1270,1270,0.944000005722046,21.0,Baseline characteristics  ,UniversSB-Bold,20,-0.2469999939203262,16777215,28,32,0,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","           entity_group                     value     score
0  Diagnostic_procedure  Baseline characteristics  0.999933",[],"{'keyword': {0: 'baseline characteristics'}, 'score': {0: 1.0}}"
1271,1271,1271,0.944000005722046,21.0,were well-balanced,UniversSB-Bold,20,-0.2469999939203262,16777215,28,32,1,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  well-balanced  0.999827",[],"{'keyword': {}, 'score': {}}"
1272,1272,1272,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,28,37,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1273,1273,1273,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,28,37,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1274,1274,1274,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,28,37,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1275,1275,1275,0.9470000267028807,28.0,•  ,UniversSB-Light,4,-0.2329999953508377,16162586,28,37,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1276,1276,1276,0.9470000267028807,28.0,neoadjuvant therapy,UniversSB-Light,4,-0.2329999953508377,3355443,28,37,4,"{'concept_id': {0: 'C4744826'}, 'canonical_name': {0: 'Post Neoadjuvant Therapy Sample'}, 'aliases': {0: ['Post Neo-adjuvant Therapy Sample']}, 'types': {0: ['T031']}, 'definition': {0: 'A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}","{'concept_id': {0: 'C0242939'}, 'canonical_name': {0: 'Radiotherapy, Adjuvant'}, 'aliases': {0: ['Radiotherapies, Adjuvant', 'Adjuvant Radiotherapy', 'Adjuvant Radiotherapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0  Therapeutic_procedure          neoadjuvant  0.652529
1  Therapeutic_procedure  neoadjuvant therapy  0.963288",[],"{'keyword': {0: 'neoadjuvant therapy'}, 'score': {0: 1.0}}"
1277,1277,1277,0.9470000267028807,19.0,*Dual neoadjuvant anti-HER2 therapy was also permitted.,UniversSB-Light,4,-0.2329999953508377,3355443,28,38,0,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}",{},{},{},"           entity_group              value     score
0  Detailed_description               Dual  0.999838
1  Detailed_description        neoadjuvant  0.999769
2            Medication        neoadjuvant  0.504794
3            Medication  anti-HER2 therapy  0.946504",[],"{'keyword': {0: 'her2 therapy permitted', 1: 'dual neoadjuvant', 2: 'her2 therapy', 3: 'anti her2', 4: 'neoadjuvant anti'}, 'score': {0: 0.8452, 1: 0.8024, 2: 0.7657, 3: 0.7064, 4: 0.6957}}"
1278,1278,1278,0.9470000267028807,19.0,"DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised ",UniversSB-Light,4,-0.2329999953508377,3355443,28,38,1,"{'concept_id': {0: 'C2828392'}, 'canonical_name': {0: 'Standard (document)'}, 'aliases': {0: ['Standard']}, 'types': {0: ['T170']}, 'definition': {0: 'A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.'}, 'entity': {0: 'standardised'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","{'concept_id': {0: 'C0007620'}, 'canonical_name': {0: 'Cell Survival'}, 'aliases': {0: ['Cell Viability', 'Survival, Cell', 'Viabilities, Cell', 'Cell Viabilities', 'Viability, Cell']}, 'types': {0: ['T043']}, 'definition': {0: 'The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.'}, 'entity': {0: 'overall survival'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","     entity_group        value     score
0  Administration  intravenous  0.999464","[('IV', 'ROUTE'), ('intravenous', 'ROUTE')]","{'keyword': {0: 'survival steep standardised', 1: 'cancer idfs invasive', 2: 'iv intravenous', 3: 'os overall', 4: 'breast cancer'}, 'score': {0: 0.3418, 1: 0.2671, 2: 0.1935, 3: 0.1796, 4: 0.1483}}"
1279,1279,1279,0.9470000267028807,19.0,definitions for efficacy endpoints.,UniversSB-Light,4,-0.2329999953508377,3355443,28,38,2,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'definitions for efficacy endpoints.'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'definitions for efficacy endpoints.'}}",{},{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'definitions for efficacy endpoints.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'definitions efficacy endpoints', 1: 'definitions efficacy', 2: 'efficacy endpoints'}, 'score': {0: 0.8264, 1: 0.816, 2: 0.8015}}"
1280,1280,1280,0.8830000162124634,19.0,"BCS, breast-conserving surgery; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.",MyriadPro-Light,4,-0.25,3355443,28,39,0,"{'concept_id': {0: 'C1882085'}, 'canonical_name': {0: 'New York Heart Association Class II'}, 'aliases': {0: ['NYHA Class II']}, 'types': {0: ['T033']}, 'definition': {0: 'A finding associated with a patient with defined or presumed cardiac disease with slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, or dyspnea. (from The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253-256.)'}, 'entity': {0: 'New York Heart Association'}, 'text': {0: 'BCS, breast-conserving surgery; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.'}}","{'concept_id': {0: 'C0027976'}, 'canonical_name': {0: 'New York'}, 'aliases': {0: []}, 'types': {0: ['T083']}, 'definition': {0: 'State bounded on the north by Lake Ontario and Canada, on the east by Vermont, Massachusetts, and Connecticut, on the south by the Atlantic Ocean, New Jersey, and Pennsylvania, and on the west by Pennsylvania, Lake Erie, and Canada.'}, 'entity': {0: 'New York Heart Association'}, 'text': {0: 'BCS, breast-conserving surgery; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.'}}",{},"{'concept_id': {0: 'C2266615'}, 'canonical_name': {0: 'acetyl-CoA synthase activity'}, 'aliases': {0: ['CO-methylating acetyl-CoA synthase activity', 'acetyl-CoA:corrinoid protein O-acetyltransferase activity', 'ACS', 'CO-methylating acetyl-coenzyme A synthase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: acetyl-CoA + corrinoid protein = CO + methylcorrinoid protein + CoA. [EC:2.3.1.169, PMID:1748656]'}, 'entity': {0: 'BCS'}, 'text': {0: 'BCS, breast-conserving surgery; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.'}}","{'concept_id': {0: 'C0033036'}, 'canonical_name': {0: 'Premature atrial contractions'}, 'aliases': {0: ['Atrial ectopic beats', 'Atrial premature complex', 'Ectopic supraventricular rhythms', 'PACs', 'Premature supraventricular beats']}, 'types': {0: ['T047']}, 'definition': {0: 'A type of cardiac arrhythmia with premature atrial contractions or beats caused by signals originating from ectopic atrial sites. The ectopic signals may or may not conduct to the HEART VENTRICLES. Atrial premature complexes are characterized by premature P waves on ECG which are different in configuration from the P waves generated by the normal pacemaker complex in the SINOATRIAL NODE.'}, 'entity': {0: 'BCS'}, 'text': {0: 'BCS, breast-conserving surgery; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'bcs breast conserving', 1: 'surgery lvef left', 2: 'new york', 3: 'york heart association', 4: 'ejection fraction'}, 'score': {0: 0.8566, 1: 0.7105, 2: 0.6755, 3: 0.6048, 4: 0.4305}}"
1281,1281,1281,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,28,41,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1282,1282,1282,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,28,41,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1283,1283,1283,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,28,41,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1284,1284,1284,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,28,41,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1285,1285,1285,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,28,42,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1286,1286,1286,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,28,42,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1287,1287,1287,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,28,42,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1288,1288,1288,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,28,42,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1289,1289,1289,0.75,98.0,The efficacy and safety profile of Kadcyla  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,29,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}",{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","  entity_group    value     score
0  Coreference  Kadcyla  0.860627","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'safety profile kadcyla', 1: 'safety profile', 2: 'efficacy safety', 3: 'profile kadcyla', 4: 'efficacy safety profile'}, 'score': {0: 0.7898, 1: 0.7881, 2: 0.7539, 3: 0.7067, 4: 0.7039}}"
1290,1290,1290,0.75,98.0,were confirmed in a phase 3 study,ConduitITC-Bold,20,-0.1700000017881393,8194925,29,1,1,"{'concept_id': {0: 'C0920321'}, 'canonical_name': {0: 'Phase I Clinical Trials'}, 'aliases': {0: ['Phase 1 Clinical Trials', 'Phase I Study', 'phase i clinical trials', 'phase 1 clinical trials', 'clinical trial phase I', 'Phase 1 Clinical Trial', 'phase i trial', 'Clinical Trials, Phase 1', 'Clinical Trials, Phase I', 'i phase trials', 'phase i clinical trial', 'Phase I Clinical Trial', 'Phase I Protocol', 'clinical trial phase i', 'Phase I Trial', 'Clinical Trials, Phase I as Topic', 'phase i study', 'phase I trial', 'Phase I Clinical Trials', 'Early-Stage Clinical Trials', 'trial phase i', 'Phase 1 Study']}, 'types': {0: ['T062']}, 'definition': {0: 'Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}","{'concept_id': {0: 'C0085973'}, 'canonical_name': {0: 'Case Study'}, 'aliases': {0: ['Case Studies']}, 'types': {0: ['T170']}, 'definition': {0: 'An uncontrolled observational study containing a detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin).'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}",{},{},{},"           entity_group          value     score
0             Lab_value      confirmed  0.596251
1  Diagnostic_procedure  phase 3 study  0.984973",[],"{'keyword': {0: 'confirmed phase', 1: 'confirmed phase study', 2: 'phase study'}, 'score': {0: 0.8854, 1: 0.793, 2: 0.6105}}"
1291,1291,1291,0.944000005722046,27.0,Kadcyla ,UniversSB-Bold,20,-0.2469999939203262,16777215,29,2,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
1292,1292,1292,0.944000005722046,27.0,3.6 mg/kg IV ,UniversSB-Bold,20,-0.2469999939203262,16777215,29,2,1,{},{},{},{},{},"     entity_group      value     score
0       Lab_value    3.6 3.6  0.759886
1          Dosage  3.6 mg/kg  0.781887
2  Administration         IV  0.929909","[('3.6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7689, 1: 0.7403, 2: 0.7102}}"
1293,1293,1293,0.944000005722046,27.0,(n=743),UniversSB-Bold,20,-0.2469999939203262,16777215,29,2,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1294,1294,1294,0.9470000267028807,28.0,"KATHERINE was a phase 3, open-label, ",UniversSB-Light,4,-0.2329999953508377,3355443,29,3,0,"{'concept_id': {0: 'C0205390'}, 'canonical_name': {0: 'Phase'}, 'aliases': {0: ['Phased', 'Phase', 'Phase (attribute)', 'phase', 'Stage']}, 'types': {0: ['T079']}, 'definition': {0: 'A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, '}}","{'concept_id': {0: 'C0080129'}, 'canonical_name': {0: 'S Phase'}, 'aliases': {0: ['S Period', 'Phase, S', 'Period, S', 'Phases, S', 'Periods, S', 'S Periods', 'S Phases']}, 'types': {0: ['T079']}, 'definition': {0: 'Phase of the CELL CYCLE following G1 and preceding G2 when the entire DNA content of the nucleus is replicated. It is achieved by bidirectional replication at multiple sites along each chromosome.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []","[('KATHERINE', 'DRUG')]","{'keyword': {0: 'phase open label', 1: 'open label', 2: 'katherine phase open', 3: 'katherine phase', 4: 'phase open'}, 'score': {0: 0.8484, 1: 0.8158, 2: 0.7484, 3: 0.7024, 4: 0.6219}}"
1295,1295,1295,0.9470000267028807,28.0,"randomised, multicentre study which assessed ",UniversSB-Light,4,-0.2329999953508377,3355443,29,3,1,"{'concept_id': {0: 'C1555289'}, 'canonical_name': {0: 'Assessed patient - therapy appropriate'}, 'aliases': {0: ['Assessed Patient']}, 'types': {0: ['T033']}, 'definition': {0: '<p>Assessed patient, therapy is appropriate</p>'}, 'entity': {0: 'assessed'}, 'text': {0: 'randomised, multicentre study which assessed '}}","{'concept_id': {0: 'C1096776'}, 'canonical_name': {0: 'Multicenter Studies'}, 'aliases': {0: ['Multicenter Study']}, 'types': {0: ['T062']}, 'definition': {0: 'A work that reports on a study executed by several cooperating institutions.'}, 'entity': {0: 'multicentre study'}, 'text': {0: 'randomised, multicentre study which assessed '}}",{},{},{},"           entity_group        value     score
0  Detailed_description   randomised  0.997080
1  Diagnostic_procedure  multicentre  0.964970
2  Detailed_description  multicentre  0.856343
3  Diagnostic_procedure        study  0.939489",[],"{'keyword': {0: 'randomised multicentre study', 1: 'multicentre study assessed', 2: 'randomised multicentre', 3: 'multicentre study', 4: 'study assessed'}, 'score': {0: 0.8846, 1: 0.8604, 2: 0.8469, 3: 0.8077, 4: 0.7694}}"
1296,1296,1296,0.9470000267028807,28.0,the efficacy and safety profile of adjuvant ,UniversSB-Light,4,-0.2329999953508377,3355443,29,3,2,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}",{},{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}","  entity_group     value     score
0   Medication  adjuvant  0.919629",[],"{'keyword': {0: 'safety profile', 1: 'safety profile adjuvant', 2: 'profile adjuvant', 3: 'efficacy safety', 4: 'efficacy safety profile'}, 'score': {0: 0.8586, 1: 0.7746, 2: 0.7312, 3: 0.6494, 4: 0.6119}}"
1297,1297,1297,0.9470000267028807,28.0,Kadcyla vs trastuzumab in patients who  ,UniversSB-Light,4,-0.2329999953508377,3355443,29,3,3,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}",{},{},"  entity_group        value     score
0   Medication      Kadcyla  0.588591
1   Medication  trastuzumab  0.999825","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'kadcyla vs trastuzumab', 1: 'kadcyla vs', 2: 'vs trastuzumab patients', 3: 'vs trastuzumab', 4: 'trastuzumab patients'}, 'score': {0: 0.9384, 1: 0.8664, 2: 0.8337, 3: 0.8093, 4: 0.8014}}"
1298,1298,1298,0.9470000267028807,28.0,had residual invasive disease following ,UniversSB-Light,4,-0.2329999953508377,3355443,29,3,4,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following '}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following '}}",{},{},{},"           entity_group             value     score
0  Detailed_description          residual  0.995710
1      Disease_disorder  invasive disease  0.862065",[],"{'keyword': {0: 'residual invasive disease', 1: 'residual invasive', 2: 'invasive disease following', 3: 'invasive disease', 4: 'disease following'}, 'score': {0: 0.9149, 1: 0.9108, 2: 0.8708, 3: 0.8285, 4: 0.8066}}"
1299,1299,1299,0.9470000267028807,28.0,trastuzumab-based neoadjuvant therapy,UniversSB-Light,4,-0.2329999953508377,3355443,29,3,5,{},"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'trastuzumab-based neoadjuvant therapy'}, 'text': {0: 'trastuzumab-based neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0             Medication    trastuzumab-based  0.999863
1  Therapeutic_procedure          neoadjuvant  0.997995
2  Therapeutic_procedure  neoadjuvant therapy  0.997627","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab based neoadjuvant', 1: 'based neoadjuvant therapy', 2: 'neoadjuvant therapy', 3: 'trastuzumab based', 4: 'based neoadjuvant'}, 'score': {0: 0.946, 1: 0.8826, 2: 0.8712, 3: 0.8579, 4: 0.8374}}"
1300,1300,1300,0.9470000267028807,27.0,Surgery,UniversSB-Light,4,-0.2329999953508377,16777215,29,4,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  Surgery  0.998798",[],"{'keyword': {}, 'score': {}}"
1301,1301,1301,0.9470000267028807,27.0,Residual invasive ,UniversSB-Light,4,-0.2329999953508377,16777215,29,5,0,"{'concept_id': {0: 'C1334278'}, 'canonical_name': {0: 'Invasive Lesion'}, 'aliases': {0: ['Invasive Lesion']}, 'types': {0: ['T033']}, 'definition': {0: 'A malignant cellular population that has increased in size and infiltrates the surrounding tissues.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}","{'concept_id': {0: 'C2936533'}, 'canonical_name': {0: 'Invasive Species'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Non-native species that threaten ecosystems, habitats, or other species and are likely to cause economic or environmental harm or harm to human health.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"           entity_group              value     score
0  Detailed_description  Residual invasive  0.999395",[],"{'keyword': {0: 'residual invasive'}, 'score': {0: 1.0}}"
1302,1302,1302,0.9470000267028807,27.0,disease in breast  ,UniversSB-Light,4,-0.2329999953508377,16777215,29,5,1,"{'concept_id': {0: 'C0038293'}, 'canonical_name': {0: 'Sternum'}, 'aliases': {0: ['Bone structure of sternum (body structure)', 'sternums', 'Sternum', 'Sternum/Sternal', 'Breast bone', 'Chest>Sternum', 'Sternal', 'breast bone', 'sternum', 'Sternum, NOS', 'Bone structure of sternum']}, 'types': {0: ['T023']}, 'definition': {0: 'A long, narrow, and flat bone commonly known as BREASTBONE occurring in the midsection of the anterior thoracic segment or chest region, which stabilizes the rib cage and serves as the point of origin for several muscles that move the arms, head, and neck.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","{'concept_id': {0: 'C0024902'}, 'canonical_name': {0: 'Breast Pain'}, 'aliases': {0: ['Mastodynias', 'Mammalgias', 'Mastodynia', 'Mastalgias', 'Mammalgia', 'Pain, Breast', 'Mastalgia', 'Breast Pains', 'Pains, Breast']}, 'types': {0: ['T184']}, 'definition': {0: 'Painful sensation in the breast region.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","           entity_group   value     score
0  Biological_structure  breast  0.999824",[],"{'keyword': {0: 'disease breast'}, 'score': {0: 0.9481}}"
1303,1303,1303,0.9470000267028807,27.0,or axillary lymph ,UniversSB-Light,4,-0.2329999953508377,16777215,29,5,2,"{'concept_id': {0: 'C0229843'}, 'canonical_name': {0: 'Pectoral lymph node group'}, 'aliases': {0: ['Nodi lymphoidei axillarum anteriores', 'Anterior axillary lymph nodes', 'Structure of pectoral axillary lymph node (body structure)', 'Anterior axillary nodes', 'Pectoral axillary lymph node', 'Nodi pectorales', 'Anterior axillary lymph nodes set', 'Pectoral Lymph Node', 'Pectoral lymph node', 'Pectoral lymph node group', 'Pectoral nodes', 'Pectoral axillary lymph node group', 'Pectoral lymph nodes', 'Structure of pectoral axillary lymph node', 'Pectoral lymph node group (body structure)', 'Anterior axillary lymph node', 'Nodi axillarum anteriores', 'Nodus lymphaticus pectoralis axillae', 'Set of pectoral lymph nodes', 'Set of anterior axillary lymph nodes', 'Pectoral lymph nodes set', 'Pectoral axillary lymph nodes', 'Set of pectoral axillary lymph nodes', 'Nodi lymphoidei pectorales']}, 'types': {0: ['T023']}, 'definition': {0: 'An axillary lymph node located along the lower edge of the pectoralis minor.'}, 'entity': {0: 'axillary lymph'}, 'text': {0: 'or axillary lymph '}}",{},{},{},{},"           entity_group           value     score
0  Biological_structure        axillary  0.999927
1  Biological_structure  axillary lymph  0.940007",[],"{'keyword': {0: 'axillary lymph'}, 'score': {0: 0.9521}}"
1304,1304,1304,0.9470000267028807,27.0,nodes,UniversSB-Light,4,-0.2329999953508377,16777215,29,5,3,"{'concept_id': {0: 'C2697524'}, 'canonical_name': {0: 'Graph Node'}, 'aliases': {0: ['Vertex', 'Node', 'Graph Node']}, 'types': {0: ['T077']}, 'definition': {0: 'One of the points that define a graph.'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}","{'concept_id': {0: 'C0037189'}, 'canonical_name': {0: 'Sino-Atrial Nodes'}, 'aliases': {0: ['Sinu-Atrial Node', 'Sino-Atrial Node', 'Sinu-Atrial Nodes', 'Nodes, Sinu-Atrial', 'Sinus Node', 'Nodes, Sinuatrial', 'Node, Sinuatrial', 'Nodes, Sinoatrial', 'Nodes, Sinus', 'Sinoatrial Node', 'Sinus Nodes', 'Sinuatrial Node', 'Node, Sino-Atrial', 'Node, Sinus', 'Node, Sinoatrial', 'Sinoatrial Nodes', 'Sinu Atrial Node', 'Sinuatrial Nodes', 'Sino Atrial Node', 'Nodes, Sino-Atrial', 'Node, Sinu-Atrial']}, 'types': {0: ['T023']}, 'definition': {0: 'The small mass of modified cardiac muscle fibers located at the junction of the superior vena cava (VENA CAVA, SUPERIOR) and right atrium. Contraction impulses probably start in this node, spread over the atrium (HEART ATRIUM) and are then transmitted by the atrioventricular bundle (BUNDLE OF HIS) to the ventricle (HEART VENTRICLE).'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}",{},{},{},"           entity_group  value     score
0  Biological_structure  nodes  0.488832",[],"{'keyword': {}, 'score': {}}"
1305,1305,1305,0.9470000267028807,27.0,"HER2-positive eBC, ",UniversSB-Light,4,-0.2329999953508377,16777215,29,6,0,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  HER2-positive  0.816637",[],"{'keyword': {0: 'her2 positive ebc', 1: 'positive ebc', 2: 'her2 positive'}, 'score': {0: 0.9628, 1: 0.8142, 2: 0.7646}}"
1306,1306,1306,0.9470000267028807,27.0,neoadjuvant ,UniversSB-Light,4,-0.2329999953508377,16777215,29,6,1,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}",{},{},{},"           entity_group        value     score
0  Detailed_description  neoadjuvant  0.956138
1          Sign_symptom  neoadjuvant  0.386592
2               History  neoadjuvant  0.344678",[],"{'keyword': {}, 'score': {}}"
1307,1307,1307,0.9470000267028807,27.0,trastuzumab* plus ,UniversSB-Light,4,-0.2329999953508377,16777215,29,6,2,"{'concept_id': {0: 'C4527338'}, 'canonical_name': {0: 'AC Followed by Docetaxel/Trastuzumab Regimen'}, 'aliases': {0: ['AC-Docetaxel + Trastuzumab', 'AC-T Plus Trastuzumab', 'AC-Taxotere/Herceptin', 'AC Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel/Trastuzumab']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},{},"           entity_group        value     score
0            Medication  trastuzumab  0.999873
1  Detailed_description         plus  0.314542","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab plus'}, 'score': {0: 0.9478}}"
1308,1308,1308,0.9470000267028807,27.0,chemotherapy ,UniversSB-Light,4,-0.2329999953508377,16777215,29,6,3,"{'concept_id': {0: 'C0392920'}, 'canonical_name': {0: 'Chemotherapy Regimen'}, 'aliases': {0: ['chemotherapy regimen', 'Antineoplastic chemotherapy regimen', 'chemotherapies', 'Antineoplastic chemotherapy regimen (regime/therapy)', 'chemotherapy regimens', 'neoplasm chemotherapy', 'neoplasm pharmacotherapy', 'chemotherapy', 'chemo', 'Cancer chemotherapy', 'neoplasm/cancer chemotherapy', 'cancer chemotherapy', 'cancer pharmacotherapy', 'neoplasm/cancer pharmacotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'application of the beneficial effects of drugs to control or cure neoplastic growth.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}","{'concept_id': {0: 'C1868801'}, 'canonical_name': {0: 'Hyperthermic Intraperitoneal Chemotherapy'}, 'aliases': {0: ['Hot Chemotherapy', 'Chemotherapy, Intraperitoneal Hyperthermic', 'Chemotherapy, Hyperthermic Intraperitoneal', 'Chemotherapy, Hot', 'Intraperitoneal Hyperthermic Chemotherapies', 'Intraperitoneal Chemotherapy, Hyperthermic', 'Hyperthermic Chemotherapy, Intraperitoneal', 'HIPEC', 'Intraperitoneal Hyperthermic Chemotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}",{},{},{},"  entity_group         value     score
0   Medication  chemotherapy  0.999848","[('chemotherapy', 'DRUG')]","{'keyword': {}, 'score': {}}"
1309,1309,1309,0.9470000267028807,27.0,(n=1486),UniversSB-Light,4,-0.2329999953508377,16777215,29,6,4,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1310,1310,1310,0.944000005722046,28.0,Primary endpoint,UniversSB-Bold,20,-0.2469999939203262,3355443,29,7,0,"{'concept_id': {0: 'C2349179'}, 'canonical_name': {0: 'End Point'}, 'aliases': {0: ['Endpoint', 'End Point', 'ENDPOINT', 'endpoints', 'endpoint', 'End-Point']}, 'types': {0: ['T080']}, 'definition': {0: 'A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.'}, 'entity': {0: 'Primary endpoint'}, 'text': {0: 'Primary endpoint'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  Primary endpoint  0.940143",[],"{'keyword': {0: 'primary endpoint'}, 'score': {0: 1.0}}"
1311,1311,1311,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,29,7,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1312,1312,1312,0.944000005722046,28.0,Secondary endpoints,UniversSB-Bold,20,-0.2469999939203262,3355443,29,8,0,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}",{},"{'concept_id': {0: 'C1623508'}, 'canonical_name': {0: 'regulation of secondary metabolic process'}, 'aliases': {0: ['regulation of secondary metabolism']}, 'types': {0: ['T040']}, 'definition': {0: 'Any process that modulates the frequency, rate or extent of secondary metabolism, the chemical reactions and pathways involving compounds that are not necessarily required for growth and maintenance of cells, and are often unique to a taxon. [GOC:jl]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C2981150'}, 'canonical_name': {0: 'Uranostaphyloschisis'}, 'aliases': {0: ['Cleft of hard and soft palate', 'Cleft of palate', 'Cleft hard and soft palate', 'Cleft palate', 'Cleft secondary palate', 'Palatoschisis', 'Cleft roof of mouth']}, 'types': {0: ['T019']}, 'definition': {0: 'Cleft palate is a developmental defect of the palate resulting from a failure of fusion of the palatine processes and manifesting as a separation of the roof of the mouth (soft and hard palate). [HPO:probinson]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","           entity_group                value     score
0  Detailed_description  Secondary endpoints  0.811147",[],"{'keyword': {0: 'secondary endpoints'}, 'score': {0: 1.0}}"
1313,1313,1313,0.9470000267028807,27.0,Planned 10 years’ follow-up,UniversSB-Light,4,-0.2329999953508377,16777215,29,9,0,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}",{},{},{},"     entity_group      value     score
0        Duration   10 years  0.999410
1  Clinical_event  follow-up  0.993776",[],"{'keyword': {0: 'planned 10 years', 1: '10 years follow', 2: 'planned 10', 3: '10 years', 4: 'years follow'}, 'score': {0: 0.9349, 1: 0.8297, 2: 0.8114, 3: 0.7473, 4: 0.7286}}"
1314,1314,1314,0.944000005722046,27.0,Trastuzumab  ,UniversSB-Bold,20,-0.2469999939203262,16777215,29,10,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
1315,1315,1315,0.944000005722046,27.0,6 mg/kg IV ,UniversSB-Bold,20,-0.2469999939203262,16777215,29,10,1,"{'concept_id': {0: 'C0439272'}, 'canonical_name': {0: 'ug/g'}, 'aliases': {0: ['Picogram per Microgram', 'Zeptogram per Femtogram', 'Yoctogram per Attogram', 'mg/kg', 'Milligram/kilogram', 'Microgram/gram', 'microgram/g', 'Femtogram per Nanogram', 'Nanogram per Milligram', 'Milligram/kilogram (qualifier value)', 'Microgram/gram (qualifier value)', 'mg kg', 'Microgram per Gram', 'Milligram/Kilogram', 'Milligram per Kilogram', 'Attogram per Picogram', 'microg/g']}, 'types': {0: ['T081']}, 'definition': {0: 'A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.'}, 'entity': {0: 'mg/kg IV'}, 'text': {0: '6 mg/kg IV '}}",{},{},{},{},"     entity_group    value     score
0          Dosage  6 mg/kg  0.909511
1  Administration       IV  0.990577","[('6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7475, 1: 0.7458, 2: 0.6812}}"
1316,1316,1316,0.944000005722046,27.0,(n=743),UniversSB-Bold,20,-0.2469999939203262,16777215,29,10,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1317,1317,1317,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,29,11,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1318,1318,1318,0.9470000267028807,28.0,non-breast cancer as per the  ,UniversSB-Light,4,-0.2329999953508377,3355443,29,11,1,{},"{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'non-breast cancer'}, 'text': {0: 'non-breast cancer as per the  '}}",{},{},{},"       entity_group              value     score
0           History         non-breast  0.647748
1  Disease_disorder  non-breast cancer  0.972177",[],"{'keyword': {0: 'non breast cancer', 1: 'non breast', 2: 'breast cancer'}, 'score': {0: 0.9178, 1: 0.7301, 2: 0.6862}}"
1319,1319,1319,0.9470000267028807,28.0,STEEP definition,UniversSB-Light,4,-0.2329999953508377,3355443,29,11,2,"{'concept_id': {0: 'C3539107'}, 'canonical_name': {0: 'Definition (core metadata concept)'}, 'aliases': {0: ['Definition', 'Definition (core metadata concept)']}, 'types': {0: ['T170']}, 'definition': {0: None}, 'entity': {0: 'definition'}, 'text': {0: 'STEEP definition'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  STEEP definition  0.998824",[],"{'keyword': {0: 'steep definition'}, 'score': {0: 1.0}}"
1320,1320,1320,0.9470000267028807,23.0,Anti-HER2 therapy for a total of 14 cycles. ,UniversSB-Light,4,-0.2329999953508377,3355443,29,12,0,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}",{},{},{},"  entity_group      value     score
0   Medication  Anti-HER2  0.606185
1  Coreference  Anti-HER2  0.565908
2   Medication    therapy  0.542007
3    Lab_value         14  0.923810",[],"{'keyword': {0: 'total 14 cycles', 1: 'therapy total 14', 2: 'anti her2 therapy', 3: 'her2 therapy total', 4: 'anti her2'}, 'score': {0: 0.8392, 1: 0.822, 2: 0.7728, 3: 0.7289, 4: 0.6897}}"
1321,1321,1321,0.9470000267028807,23.0,Radiation and endocrine therapy ,UniversSB-Light,4,-0.2329999953508377,3355443,29,12,1,"{'concept_id': {0: 'C1514396'}, 'canonical_name': {0: 'Preoperative Endocrine Therapy'}, 'aliases': {0: []}, 'types': {0: ['T061']}, 'definition': {0: 'Short term endocrine therapy, prior to surgery, to ""down-stage"" primary breast cancer in order to increase the rate of breast-conserving surgery. (from JMCC 7:557-562, 2000 via Medscape)'}, 'entity': {0: 'endocrine therapy'}, 'text': {0: 'Radiation and endocrine therapy '}}","{'concept_id': {0: 'C2607955'}, 'canonical_name': {0: 'Beta Radiation'}, 'aliases': {0: ['Rays, Beta', 'Ray, Beta', 'Beta Radiations', 'Beta Rays', 'Radiation, Beta', 'Beta Ray', 'Radiations, Beta']}, 'types': {0: ['T070']}, 'definition': {0: 'A stream of high energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus.'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy '}}",{},"{'concept_id': {0: 'C1154958'}, 'canonical_name': {0: 'response to electromagnetic radiation stimulus'}, 'aliases': {0: ['response to radiation stimulus', 'response to radiation']}, 'types': {0: ['T038']}, 'definition': {0: 'Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electromagnetic radiation stimulus. Electromagnetic radiation is a propagating wave in space with electric and magnetic components. These components oscillate at right angles to each other and to the direction of propagation. [GOC:jl, Wikipedia:Electromagnetic_radiation]'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy '}}",{},"            entity_group              value     score
0  Therapeutic_procedure          Radiation  0.994988
1  Therapeutic_procedure  endocrine therapy  0.948940",[],"{'keyword': {0: 'radiation endocrine therapy', 1: 'endocrine therapy', 2: 'radiation endocrine'}, 'score': {0: 0.843, 1: 0.824, 2: 0.8103}}"
1322,1322,1322,0.9470000267028807,23.0,administered according to institutional ,UniversSB-Light,4,-0.2329999953508377,3355443,29,12,2,"{'concept_id': {0: 'C1546848'}, 'canonical_name': {0: 'Living Arrangement - Institution'}, 'aliases': {0: ['Institution']}, 'types': {0: ['T033']}, 'definition': {0: '<p>Institution</p>'}, 'entity': {0: 'institutional'}, 'text': {0: 'administered according to institutional '}}","{'concept_id': {0: 'C5544477'}, 'canonical_name': {0: 'Systemic Racism'}, 'aliases': {0: ['Institutionalized Racisms', 'Racism, Systemic', 'Institutionalized Racism', 'Racism, Institutionalized', 'Structural Racisms', 'Racism, Structural', 'Racism, Institutional', 'Racisms, Systematic', 'Systematic Racisms', 'Racism, Systematic', 'Institutional Racism', 'Systematic Racism', 'Structural Racism']}, 'types': {0: ['T054']}, 'definition': {0: 'Processes of racism that are embedded in laws (local, state, and federal), policies, and practices of society and its institutions that provide advantages to racial groups deemed as superior, while differentially oppressing, disadvantaging, or otherwise neglecting racial groups viewed as inferior. Differential access to the goods, services, and opportunities of society by race. Institutionalized racism is normative, sometimes legalized, and often manifests as inherited disadvantage. It is structural, having been codified in our institutions of custom, practice, and law, so there need not be an identifiable perpetrator. (ttps://www.cdc.gov/chronicdisease/programs-impact/sdoh.htm)'}, 'entity': {0: 'institutional'}, 'text': {0: 'administered according to institutional '}}",{},{},{},"           entity_group                       value     score
0  Detailed_description  according to institutional  0.817311",[],"{'keyword': {0: 'administered according institutional', 1: 'according institutional', 2: 'administered according'}, 'score': {0: 0.9745, 1: 0.8839, 2: 0.8672}}"
1323,1323,1323,0.9470000267028807,23.0,standards and study protocol,UniversSB-Light,4,-0.2329999953508377,3355443,29,12,3,"{'concept_id': {0: 'C2985700'}, 'canonical_name': {0: 'Study Protocol Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic.'}, 'entity': {0: 'study protocol'}, 'text': {0: 'standards and study protocol'}}","{'concept_id': {0: 'C2936643'}, 'canonical_name': {0: 'Standard of Care'}, 'aliases': {0: ['Standards of Care', 'Care Standards', 'Care Standard']}, 'types': {0: ['T058']}, 'definition': {0: 'The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.'}, 'entity': {0: 'standards'}, 'text': {0: 'standards and study protocol'}}",{},{},{},"           entity_group           value     score
0  Diagnostic_procedure       standards  0.946151
1  Diagnostic_procedure  study protocol  0.709869",[],"{'keyword': {0: 'study protocol', 1: 'standards study protocol', 2: 'standards study'}, 'score': {0: 0.906, 1: 0.879, 2: 0.7344}}"
1324,1324,1324,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,29,13,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1325,1325,1325,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,29,13,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1326,1326,1326,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,29,13,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1327,1327,1327,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,29,13,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1328,1328,1328,0.9052734375,23.0,≥,ArialMT,0,-0.2119140625,3355443,29,14,0,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1329,1329,1329,0.9470000267028807,23.0,of treatment including ,UniversSB-Light,4,-0.2329999953508377,3355443,29,14,1,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'treatment including'}, 'score': {0: 0.9499}}"
1330,1330,1330,0.9052734375,22.65237236022949,≥,ArialMT,0,-0.2119140625,3355443,29,14,2,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1331,1331,1331,0.9470000267028807,23.0,therapy and ,UniversSB-Light,4,-0.2329999953508377,3355443,29,14,3,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  therapy  0.826489",[],"{'keyword': {}, 'score': {}}"
1332,1332,1332,0.9470000267028807,23.0,of trastuzumab therapy,UniversSB-Light,4,-0.2329999953508377,3355443,29,14,4,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},{},"  entity_group                value     score
0   Medication          trastuzumab  0.999849
1   Medication  trastuzumab therapy  0.978093","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab therapy'}, 'score': {0: 0.9362}}"
1333,1333,1333,0.944000005722046,28.0,Stratification factors,UniversSB-Bold,20,-0.2469999939203262,3355443,29,15,0,"{'concept_id': {0: 'C1514983'}, 'canonical_name': {0: 'Stratification'}, 'aliases': {0: ['stratification']}, 'types': {0: ['T062']}, 'definition': {0: 'The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.'}, 'entity': {0: 'Stratification factors'}, 'text': {0: 'Stratification factors'}}",{},{},{},{},"           entity_group                   value     score
0  Diagnostic_procedure  Stratification factors  0.970758",[],"{'keyword': {0: 'stratification factors'}, 'score': {0: 1.0}}"
1334,1334,1334,0.9169999957084656,30.0,Reference:,ConduitITC-Bold,20,-0.2349999994039535,8194925,29,16,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1335,1335,1335,0.8830000162124634,22.0,1. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628. ,MyriadPro-Light,4,-0.25,3355443,29,16,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'et al', 4: 'engl med 2019'}, 'score': {0: 0.8031, 1: 0.7251, 2: 0.7194, 3: 0.6642, 4: 0.6422}}"
1336,1336,1336,0.944000005722046,21.0,Inclusion and  ,UniversSB-Bold,20,-0.2469999939203262,16777215,29,17,0,"{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Cellular Inclusion', 'Inclusion Body', 'inclusion bodies', 'Inclusion Bodies', 'inclusion body', 'body inclusion', 'Inclusions, Cellular', 'cellular inclusions', 'Bodies, Inclusion', 'Cellular Inclusions', 'Inclusions', 'cellular inclusion', 'Inclusion, Cellular', 'Body, Inclusion']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}","{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Inclusions, Cellular', 'Inclusion, Cellular', 'Inclusion Body', 'Body, Inclusion', 'Cellular Inclusion', 'Bodies, Inclusion', 'Cellular Inclusions']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"{'concept_id': {0: 'C0205708'}, 'canonical_name': {0: 'cytoplasmic inclusion'}, 'aliases': {0: []}, 'types': {0: ['T026']}, 'definition': {0: 'A stainable aggregation of protein, lipid or small molecules in the cytoplasm.'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"  entity_group      value     score
0  Coreference  Inclusion  0.340508",[],"{'keyword': {}, 'score': {}}"
1337,1337,1337,0.944000005722046,21.0,exclusion criteria,UniversSB-Bold,20,-0.2469999939203262,16777215,29,17,1,"{'concept_id': {0: 'C2827032'}, 'canonical_name': {0: 'Trial Inclusion Exclusion Criteria Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A specific variant of the original trial inclusion exclusion criterion.'}, 'entity': {0: 'exclusion criteria'}, 'text': {0: 'exclusion criteria'}}",{},{},{},{},"           entity_group               value     score
0  Diagnostic_procedure  exclusion criteria  0.534692",[],"{'keyword': {0: 'exclusion criteria'}, 'score': {0: 1.0}}"
1338,1338,1338,0.944000005722046,21.0,Baseline characteristics  ,UniversSB-Bold,20,-0.2469999939203262,16777215,29,18,0,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","           entity_group                     value     score
0  Diagnostic_procedure  Baseline characteristics  0.999933",[],"{'keyword': {0: 'baseline characteristics'}, 'score': {0: 1.0}}"
1339,1339,1339,0.944000005722046,21.0,were well-balanced,UniversSB-Bold,20,-0.2469999939203262,16777215,29,18,1,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  well-balanced  0.999827",[],"{'keyword': {}, 'score': {}}"
1340,1340,1340,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,29,23,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1341,1341,1341,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,29,23,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1342,1342,1342,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,29,23,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1343,1343,1343,0.9470000267028807,28.0,•  ,UniversSB-Light,4,-0.2329999953508377,16162586,29,23,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1344,1344,1344,0.9470000267028807,28.0,neoadjuvant therapy,UniversSB-Light,4,-0.2329999953508377,3355443,29,23,4,"{'concept_id': {0: 'C4744826'}, 'canonical_name': {0: 'Post Neoadjuvant Therapy Sample'}, 'aliases': {0: ['Post Neo-adjuvant Therapy Sample']}, 'types': {0: ['T031']}, 'definition': {0: 'A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}","{'concept_id': {0: 'C0242939'}, 'canonical_name': {0: 'Radiotherapy, Adjuvant'}, 'aliases': {0: ['Radiotherapies, Adjuvant', 'Adjuvant Radiotherapy', 'Adjuvant Radiotherapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0  Therapeutic_procedure          neoadjuvant  0.652529
1  Therapeutic_procedure  neoadjuvant therapy  0.963288",[],"{'keyword': {0: 'neoadjuvant therapy'}, 'score': {0: 1.0}}"
1345,1345,1345,0.9470000267028807,19.0,*Dual neoadjuvant anti-HER2 therapy was also permitted.,UniversSB-Light,4,-0.2329999953508377,3355443,29,24,0,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}",{},{},{},"           entity_group              value     score
0  Detailed_description               Dual  0.999838
1  Detailed_description        neoadjuvant  0.999769
2            Medication        neoadjuvant  0.504794
3            Medication  anti-HER2 therapy  0.946504",[],"{'keyword': {0: 'her2 therapy permitted', 1: 'dual neoadjuvant', 2: 'her2 therapy', 3: 'anti her2', 4: 'neoadjuvant anti'}, 'score': {0: 0.8452, 1: 0.8024, 2: 0.7657, 3: 0.7064, 4: 0.6957}}"
1346,1346,1346,0.9470000267028807,19.0,"DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised ",UniversSB-Light,4,-0.2329999953508377,3355443,29,24,1,"{'concept_id': {0: 'C2828392'}, 'canonical_name': {0: 'Standard (document)'}, 'aliases': {0: ['Standard']}, 'types': {0: ['T170']}, 'definition': {0: 'A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.'}, 'entity': {0: 'standardised'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","{'concept_id': {0: 'C0007620'}, 'canonical_name': {0: 'Cell Survival'}, 'aliases': {0: ['Cell Viability', 'Survival, Cell', 'Viabilities, Cell', 'Cell Viabilities', 'Viability, Cell']}, 'types': {0: ['T043']}, 'definition': {0: 'The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.'}, 'entity': {0: 'overall survival'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","     entity_group        value     score
0  Administration  intravenous  0.999464","[('IV', 'ROUTE'), ('intravenous', 'ROUTE')]","{'keyword': {0: 'survival steep standardised', 1: 'cancer idfs invasive', 2: 'iv intravenous', 3: 'os overall', 4: 'breast cancer'}, 'score': {0: 0.3418, 1: 0.2671, 2: 0.1935, 3: 0.1796, 4: 0.1483}}"
1347,1347,1347,0.9470000267028807,19.0,definitions for efficacy endpoints.,UniversSB-Light,4,-0.2329999953508377,3355443,29,24,2,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'definitions for efficacy endpoints.'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'definitions for efficacy endpoints.'}}",{},{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'definitions for efficacy endpoints.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'definitions efficacy endpoints', 1: 'definitions efficacy', 2: 'efficacy endpoints'}, 'score': {0: 0.8264, 1: 0.816, 2: 0.8015}}"
1348,1348,1348,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,29,25,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1349,1349,1349,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,29,25,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1350,1350,1350,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,29,25,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1351,1351,1351,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,29,25,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1352,1352,1352,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,29,26,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1353,1353,1353,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,29,26,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1354,1354,1354,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,29,26,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1355,1355,1355,0.9319999814033508,52.0,Baseline characteristics were well-balanced between treatment arms,Ubuntu-Bold,20,-0.1889999955892563,8194925,30,1,0,"{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Therapeutic procedure'}, 'aliases': {0: ['TX', 'therapies', 'treatments', 'Therapeutic', 'Therapeutic procedure', 'Therapeutic procedure, NOS', 'methods treatment', 'Therapies', 'therapeutic method', 'Therapy', 'Therapeutics', 'treatment', 'Treatment', 'Therapeutic Interventions', 'Therapy (regime/therapy)', 'Treatments', 'Therapeutic Technique', 'Therapeutic Procedure', 'Therapeutic procedure (procedure)', 'therapy', 'therapeutic procedure', 'Therapy, NOS', 'method treatment', 'treatment method', 'Therapeutic Method', 'therapeutics']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'treatment arms'}, 'text': {0: 'Baseline characteristics were well-balanced between treatment arms'}}","{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Treatments'}, 'aliases': {0: ['Therapy', 'Treatment', 'Therapeutics', 'Therapeutic', 'Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'treatment arms'}, 'text': {0: 'Baseline characteristics were well-balanced between treatment arms'}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics were well-balanced between treatment arms'}}","            entity_group                     value     score
0   Diagnostic_procedure  Baseline characteristics  0.999944
1              Lab_value             well-balanced  0.999882
2  Therapeutic_procedure                 treatment  0.784442
3   Detailed_description                      arms  0.984581",[],"{'keyword': {0: 'baseline characteristics balanced', 1: 'baseline characteristics', 2: 'balanced treatment arms', 3: 'characteristics balanced treatment', 4: 'treatment arms'}, 'score': {0: 0.5873, 1: 0.4389, 2: 0.3998, 3: 0.3246, 4: 0.2371}}"
1356,1356,1356,0.9890000224113464,24.0,Trastuzumab (n=743),MyriadPro-Bold,20,-0.25,16777215,30,2,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999833","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab 743'}, 'score': {0: 0.8631}}"
1357,1357,1357,0.9890000224113464,24.0,Kadcyla (n=743),MyriadPro-Bold,20,-0.25,16777215,30,2,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}",{},{},"           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.969694",[],"{'keyword': {0: 'kadcyla 743'}, 'score': {0: 0.8404}}"
1358,1358,1358,0.9890000224113464,24.0,Characteristic,MyriadPro-Bold,20,-0.25,16777215,30,3,0,"{'concept_id': {0: 'C0596150'}, 'canonical_name': {0: 'bacteria characteristic'}, 'aliases': {0: []}, 'types': {0: ['T080']}, 'definition': {0: 'characteristics or classification systems of bacteria; includes staining patterns, oxygen requirements, and nutrient requirements.'}, 'entity': {0: 'Characteristic'}, 'text': {0: 'Characteristic'}}","{'concept_id': {0: 'C0015579'}, 'canonical_name': {0: 'Family Characteristics'}, 'aliases': {0: ['Characteristics, Family', 'Characteristic, Family', 'Family Characteristic']}, 'types': {0: ['T102']}, 'definition': {0: 'Size and composition of the family.'}, 'entity': {0: 'Characteristic'}, 'text': {0: 'Characteristic'}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'Characteristic'}, 'text': {0: 'Characteristic'}}","           entity_group           value    score
0  Detailed_description  Characteristic  0.99133",[],"{'keyword': {}, 'score': {}}"
1359,1359,1359,0.8830000162124634,24.0,"Median age, years",MyriadPro-Light,4,-0.25,3355443,30,4,0,"{'concept_id': {0: 'C3843646'}, 'canonical_name': {0: 'One to Two Years'}, 'aliases': {0: ['1 to 2 Years', '1-2 years']}, 'types': {0: ['T079']}, 'definition': {0: 'An indication that something has lasted, or occurred during, one to two years.'}, 'entity': {0: 'years'}, 'text': {0: 'Median age, years'}}",{},{},{},{},"  entity_group  value     score
0     Duration      ,  0.535920
1    Lab_value  years  0.311816",[],"{'keyword': {0: 'median age years', 1: 'median age', 2: 'age years'}, 'score': {0: 0.9512, 1: 0.8872, 2: 0.8222}}"
1360,1360,1360,0.8830000162124634,24.0,49 (24–79),MyriadPro-Light,4,-0.25,3355443,30,4,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value    49  0.999188",[],"{'keyword': {0: '49 24 79', 1: '49 24', 2: '24 79'}, 'score': {0: 0.8689, 1: 0.8586, 2: 0.8344}}"
1361,1361,1361,0.8830000162124634,24.0,49 (23–80),MyriadPro-Light,4,-0.25,3355443,30,4,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    49  0.998933",[],"{'keyword': {0: '49 23', 1: '49 23 80', 2: '23 80'}, 'score': {0: 0.8497, 1: 0.8187, 2: 0.7463}}"
1362,1362,1362,0.75,98.0,The efficacy and safety profile of Kadcyla  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,30,5,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}",{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","  entity_group    value     score
0  Coreference  Kadcyla  0.860627","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'safety profile kadcyla', 1: 'safety profile', 2: 'efficacy safety', 3: 'profile kadcyla', 4: 'efficacy safety profile'}, 'score': {0: 0.7898, 1: 0.7881, 2: 0.7539, 3: 0.7067, 4: 0.7039}}"
1363,1363,1363,0.75,98.0,were confirmed in a phase 3 study,ConduitITC-Bold,20,-0.1700000017881393,8194925,30,5,1,"{'concept_id': {0: 'C0920321'}, 'canonical_name': {0: 'Phase I Clinical Trials'}, 'aliases': {0: ['Phase 1 Clinical Trials', 'Phase I Study', 'phase i clinical trials', 'phase 1 clinical trials', 'clinical trial phase I', 'Phase 1 Clinical Trial', 'phase i trial', 'Clinical Trials, Phase 1', 'Clinical Trials, Phase I', 'i phase trials', 'phase i clinical trial', 'Phase I Clinical Trial', 'Phase I Protocol', 'clinical trial phase i', 'Phase I Trial', 'Clinical Trials, Phase I as Topic', 'phase i study', 'phase I trial', 'Phase I Clinical Trials', 'Early-Stage Clinical Trials', 'trial phase i', 'Phase 1 Study']}, 'types': {0: ['T062']}, 'definition': {0: 'Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}","{'concept_id': {0: 'C0085973'}, 'canonical_name': {0: 'Case Study'}, 'aliases': {0: ['Case Studies']}, 'types': {0: ['T170']}, 'definition': {0: 'An uncontrolled observational study containing a detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin).'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}",{},{},{},"           entity_group          value     score
0             Lab_value      confirmed  0.596251
1  Diagnostic_procedure  phase 3 study  0.984973",[],"{'keyword': {0: 'confirmed phase', 1: 'confirmed phase study', 2: 'phase study'}, 'score': {0: 0.8854, 1: 0.793, 2: 0.6105}}"
1364,1364,1364,0.9890000224113464,24.0,"Race or ethnic group, n (%)*",MyriadPro-Bold,20,-0.25,3355443,30,6,0,"{'concept_id': {0: 'C0018422'}, 'canonical_name': {0: 'Roma ethnic group'}, 'aliases': {0: ['Roma (ethnic group)', 'Gypsies', 'Gipsy', 'Gypsies (ethnic group)', 'Gipsies', 'Romanies', 'Gypsy', 'Romani', 'gypsy', 'Romany', 'gypsies', 'Roma']}, 'types': {0: ['T098']}, 'definition': {0: 'Ethnic group originating in India and entering Europe in the 14th or 15th century.'}, 'entity': {0: 'ethnic group'}, 'text': {0: 'Race or ethnic group, n (%)*'}}","{'concept_id': {0: 'C5441552'}, 'canonical_name': {0: 'Ethnic Group'}, 'aliases': {0: ['Ethnic Groups']}, 'types': {0: ['T098']}, 'definition': {0: 'a group of people with a common cultural heritage that sets them apart from others in a variety of social relationships.'}, 'entity': {0: 'ethnic group'}, 'text': {0: 'Race or ethnic group, n (%)*'}}",{},{},{},"     entity_group value     score
0  Family_history  Race  0.809349",[],"{'keyword': {0: 'race ethnic group', 1: 'ethnic group', 2: 'race ethnic'}, 'score': {0: 0.8677, 1: 0.8241, 2: 0.815}}"
1365,1365,1365,0.8830000162124634,24.0,White,MyriadPro-Light,4,-0.25,3355443,30,6,1,"{'concept_id': {0: 'C0220938'}, 'canonical_name': {0: 'White color'}, 'aliases': {0: ['White color', 'White - colour', 'coloring white', 'coloured white', 'White color (finding)', 'White color (qualifier value)', 'color white', 'White', 'the finding of white color', 'White colour', 'white colour', 'white color', 'white (color)', 'white', 'White Color', 'colored white', 'White - color']}, 'types': {0: ['T080']}, 'definition': {0: 'The achromatic color of maximum lightness; the color of objects that reflect nearly all light of all visible wavelengths; the complement or antagonist of black, the other extreme of the neutral gray series.'}, 'entity': {0: 'White'}, 'text': {0: 'White'}}","{'concept_id': {0: 'C1140552'}, 'canonical_name': {0: 'Delphinapterus leucas'}, 'aliases': {0: ['Whale, White', 'Beluga Whale', 'White Whale', 'White Whales', 'Whales, White', 'Beluga Whales']}, 'types': {0: ['T015']}, 'definition': {0: 'The species Delphinapterus leucas, in the family Monodontidae, found primarily in the Arctic Ocean and adjoining seas. They are small WHALES lacking a dorsal fin.'}, 'entity': {0: 'White'}, 'text': {0: 'White'}}","{'concept_id': {0: 'C3474474'}, 'canonical_name': {0: 'white pine oil'}, 'aliases': {0: []}, 'types': {0: ['T109']}, 'definition': {0: 'The essential oil of Pinus strobus. White pine oil may be used for skincare preparations and aromatherapy. It is also used commonly in household cleaning products.'}, 'entity': {0: 'White'}, 'text': {0: 'White'}}","{'concept_id': {0: 'C2611052'}, 'canonical_name': {0: 'white fat cell proliferation'}, 'aliases': {0: ['white adipose cell proliferation', 'white adipocyte proliferation']}, 'types': {0: ['T043']}, 'definition': {0: 'The multiplication or reproduction of white fat cells by cell division, resulting in the expansion of their population. [CL:0000448, GOC:mah, GOC:sl]'}, 'entity': {0: 'White'}, 'text': {0: 'White'}}","{'concept_id': {0: 'C0302302'}, 'canonical_name': {0: 'Closed comedo'}, 'aliases': {0: ['Whitehead']}, 'types': {0: ['T046']}, 'definition': {0: 'A comedo in which the top of the pore is not stretched open and thus does not expose the clogged portion (which would appear black), hence the name whitehead. []'}, 'entity': {0: 'White'}, 'text': {0: 'White'}}","  entity_group  value     score
0        Color  White  0.908465",[],"{'keyword': {}, 'score': {}}"
1366,1366,1366,0.8830000162124634,24.0,Asian,MyriadPro-Light,4,-0.25,3355443,30,6,2,"{'concept_id': {0: 'C1524069'}, 'canonical_name': {0: 'Asian Indian'}, 'aliases': {0: ['Indian (East Indian)', 'Indian race', 'Indian', 'INDIAN', 'Indians', 'Indian (East Indian) (ethnic group)', 'Asian Indian', 'Indian (racial group)', 'indian', 'Asian Indians']}, 'types': {0: ['T098']}, 'definition': {0: 'A person having origins in the original peoples of the Indian sub-continent.'}, 'entity': {0: 'Asian'}, 'text': {0: 'Asian'}}","{'concept_id': {0: 'C0003980'}, 'canonical_name': {0: 'Asia'}, 'aliases': {0: []}, 'types': {0: ['T083']}, 'definition': {0: ""The largest of the continents. It was known to the Romans more specifically as what we know today as Asia Minor. The name comes from at least two possible sources: from the Assyrian asu (to rise) or from the Sanskrit usa (dawn), both with reference to its being the land of the rising sun, i.e., eastern as opposed to Europe, to the west. (From Webster's New Geographical Dictionary, 1988, p82 & Room, Brewer's Dictionary of Names, 1992, p34)""}, 'entity': {0: 'Asian'}, 'text': {0: 'Asian'}}",{},{},{},"           entity_group  value     score
0  Detailed_description  Asian  0.380416",[],"{'keyword': {}, 'score': {}}"
1367,1367,1367,0.8830000162124634,24.0,Black ,MyriadPro-Light,4,-0.25,3355443,30,6,3,"{'concept_id': {0: 'C0439541'}, 'canonical_name': {0: 'Black color'}, 'aliases': {0: ['black coloring', 'black', 'Black color (qualifier value)', 'Black', 'black (color)', 'Black color', 'Black colour', 'black colored', 'black [color]', 'black color']}, 'types': {0: ['T080']}, 'definition': {0: 'This answer string has been used in various answer lists in both color context (of specimen, for example) and racial context.'}, 'entity': {0: 'Black'}, 'text': {0: 'Black '}}","{'concept_id': {0: 'C1140702'}, 'canonical_name': {0: 'Nigella sativa'}, 'aliases': {0: ['sativa, Nigella', 'Kalonji', 'Cumins, Black', 'Black Cumin', 'Nigella sativas', 'Black Cumins', 'Kalonjus', 'Cumin, Black']}, 'types': {0: ['T002']}, 'definition': {0: 'A plant genus of the family RANUNCULACEAE that contains alpha-hederin, a triterpene saponin in the seeds, and is the source of black seed oil.'}, 'entity': {0: 'Black'}, 'text': {0: 'Black '}}",{},{},{},"  entity_group  value     score
0        Color  Black  0.969389",[],"{'keyword': {}, 'score': {}}"
1368,1368,1368,0.8830000162124634,24.0,American Indian or Alaskan Native,MyriadPro-Light,4,-0.25,3355443,30,6,4,"{'concept_id': {0: 'C0597091'}, 'canonical_name': {0: 'Alaskan Native American'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Native Americans whose ethnic origins are above the 48th parallel.'}, 'entity': {0: 'Alaskan Native'}, 'text': {0: 'American Indian or Alaskan Native'}}","{'concept_id': {0: 'C0682125'}, 'canonical_name': {0: 'Alaskan Natives'}, 'aliases': {0: ['Alaska Natives', ""Alaska's Indigenous People"", ""People, Alaska's Indigenous"", 'Alaskas Indigenous People', 'Alaska Indigenous People', 'Native, Alaskan', 'Alaskan, Indigenous', 'Alaskans, Indigenous', 'Native Alaskan', 'Alaskans, Native', ""Indigenous People, Alaska's"", ""Alaska's Indigenous Peoples"", 'Natives, Alaskan', 'Alaskan Native', 'Indigenous People of Alaska', 'Indigenous Alaskans', 'Alaska Indigenous Peoples', ""Indigenous Peoples, Alaska's"", ""Peoples, Alaska's Indigenous"", 'Alaska Native', 'Natives, Alaska', 'Indigenous Alaskan', 'Native Alaskans', 'Alaskan, Native']}, 'types': {0: ['T098']}, 'definition': {0: 'Persons having origins in any indigenous people of ALASKA and their descendants.'}, 'entity': {0: 'Alaskan Native'}, 'text': {0: 'American Indian or Alaskan Native'}}",{},{},{},"          entity_group            value     score
0  Personal_background  American Indian  0.588719
1  Personal_background   Alaskan Native  0.604257",[],"{'keyword': {0: 'indian alaskan native', 1: 'alaskan native', 2: 'american indian alaskan', 3: 'indian alaskan', 4: 'american indian'}, 'score': {0: 0.9173, 1: 0.9149, 2: 0.9035, 3: 0.8891, 4: 0.8793}}"
1369,1369,1369,0.944000005722046,27.0,Kadcyla ,UniversSB-Bold,20,-0.2469999939203262,16777215,30,7,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
1370,1370,1370,0.944000005722046,27.0,3.6 mg/kg IV ,UniversSB-Bold,20,-0.2469999939203262,16777215,30,7,1,{},{},{},{},{},"     entity_group      value     score
0       Lab_value    3.6 3.6  0.759886
1          Dosage  3.6 mg/kg  0.781887
2  Administration         IV  0.929909","[('3.6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7689, 1: 0.7403, 2: 0.7102}}"
1371,1371,1371,0.944000005722046,27.0,(n=743),UniversSB-Bold,20,-0.2469999939203262,16777215,30,7,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1372,1372,1372,0.8830000162124634,24.0,551 (74.2),MyriadPro-Light,4,-0.25,3355443,30,8,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   551  0.978021",[],"{'keyword': {0: '551 74'}, 'score': {0: 0.8558}}"
1373,1373,1373,0.8830000162124634,24.0,65 (8.7),MyriadPro-Light,4,-0.25,3355443,30,8,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value    65  0.999698",[],"{'keyword': {}, 'score': {}}"
1374,1374,1374,0.8830000162124634,24.0,21 (2.8),MyriadPro-Light,4,-0.25,3355443,30,8,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value    21  0.99976",[],"{'keyword': {}, 'score': {}}"
1375,1375,1375,0.8830000162124634,24.0,36 (4.8),MyriadPro-Light,4,-0.25,3355443,30,8,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    36  0.999688",[],"{'keyword': {}, 'score': {}}"
1376,1376,1376,0.8830000162124634,24.0,70 (9.4),MyriadPro-Light,4,-0.25,3355443,30,8,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    70  0.999306",[],"{'keyword': {}, 'score': {}}"
1377,1377,1377,0.8830000162124634,24.0,531 (71.5),MyriadPro-Light,4,-0.25,3355443,30,9,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   531  0.987707",[],"{'keyword': {0: '531 71'}, 'score': {0: 0.7915}}"
1378,1378,1378,0.8830000162124634,24.0,64 (8.6),MyriadPro-Light,4,-0.25,3355443,30,9,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value    64  0.999368",[],"{'keyword': {}, 'score': {}}"
1379,1379,1379,0.8830000162124634,24.0,19 (2.6),MyriadPro-Light,4,-0.25,3355443,30,9,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    19  0.999538",[],"{'keyword': {}, 'score': {}}"
1380,1380,1380,0.8830000162124634,24.0,50 (6.7),MyriadPro-Light,4,-0.25,3355443,30,9,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    50  0.999561",[],"{'keyword': {}, 'score': {}}"
1381,1381,1381,0.8830000162124634,24.0,79 (10.6),MyriadPro-Light,4,-0.25,3355443,30,9,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    79  0.999844",[],"{'keyword': {0: '79 10'}, 'score': {0: 0.7839}}"
1382,1382,1382,0.8830000162124634,24.0,Multiple or unknown,MyriadPro-Light,4,-0.25,3355443,30,10,0,"{'concept_id': {0: 'C0032989'}, 'canonical_name': {0: 'Multiple Pregnancy'}, 'aliases': {0: ['Pregnancy, Multiple', 'gestations multiple', 'Multiple pregnancy (disorder)', 'pregnancy multiple', 'Multiple Gestation', 'Multiple pregnancy', 'Multiple Pregnancy', 'PREGNANCY MULTIPLE', 'Pregnancy, multiple', 'Multiple Pregnancies', 'Unspecified multiple gestation, unspecified as to episode of care', 'Unspecified multiple gestation', 'Multiple gestation pregnancy', 'Multiple gestation, NOS', 'multiple gestation', 'MULTIPLE PREGNANCY', 'multiple pregnancies', 'Multiple gestation', 'multiple pregnancy', 'multiples pregnancy', 'Unspecified multiple gestation, unspecified as to episode of care or not applicable', 'Pregnancies, Multiple', 'Multiple pregnancy, NOS', 'gestation multiple']}, 'types': {0: ['T033']}, 'definition': {0: 'The condition of carrying two or more FETUSES simultaneously.'}, 'entity': {0: 'Multiple'}, 'text': {0: 'Multiple or unknown'}}","{'concept_id': {0: 'C0026769'}, 'canonical_name': {0: 'MS (Multiple Sclerosis)'}, 'aliases': {0: ['Multiple Sclerosis', 'Disseminated Sclerosis', 'Sclerosis, Multiple', 'Sclerosis, Disseminated']}, 'types': {0: ['T047']}, 'definition': {0: 'An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)'}, 'entity': {0: 'Multiple'}, 'text': {0: 'Multiple or unknown'}}",{},"{'concept_id': {0: 'C5137646'}, 'canonical_name': {0: 'multiple synapse bouton, contacting multiple dendrites'}, 'aliases': {0: ['type 2 multisynaptic bouton', 'MSB2', 'type 2 multi-synapse bouton', 'type 2 multi-synaptic bouton', 'type 2 multisynapse bouton', 'type 2 multiple-synapse bouton', 'type 2 multiple spine synapse bouton']}, 'types': {0: ['T026']}, 'definition': {0: 'A single axon terminal bouton making contact onto two or more dendritic spines protruding from multiple dendrites. [GOC:aruk, GOC:bc, PMID:10586883, PMID:11248111, PMID:22028887, PMID:24487234, PMID:7482800, PMID:8366344]'}, 'entity': {0: 'Multiple'}, 'text': {0: 'Multiple or unknown'}}","{'concept_id': {0: 'C0026764'}, 'canonical_name': {0: 'Multiple myeloma'}, 'aliases': {0: [""Kahler's disease""]}, 'types': {0: ['T191']}, 'definition': {0: 'A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.'}, 'entity': {0: 'Multiple'}, 'text': {0: 'Multiple or unknown'}}","           entity_group     value     score
0  Detailed_description  Multiple  0.756387
1             Lab_value   unknown  0.436689",[],"{'keyword': {0: 'multiple unknown'}, 'score': {0: 0.9384}}"
1383,1383,1383,0.9470000267028807,28.0,"KATHERINE was a phase 3, open-label, ",UniversSB-Light,4,-0.2329999953508377,3355443,30,11,0,"{'concept_id': {0: 'C0205390'}, 'canonical_name': {0: 'Phase'}, 'aliases': {0: ['Phased', 'Phase', 'Phase (attribute)', 'phase', 'Stage']}, 'types': {0: ['T079']}, 'definition': {0: 'A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, '}}","{'concept_id': {0: 'C0080129'}, 'canonical_name': {0: 'S Phase'}, 'aliases': {0: ['S Period', 'Phase, S', 'Period, S', 'Phases, S', 'Periods, S', 'S Periods', 'S Phases']}, 'types': {0: ['T079']}, 'definition': {0: 'Phase of the CELL CYCLE following G1 and preceding G2 when the entire DNA content of the nucleus is replicated. It is achieved by bidirectional replication at multiple sites along each chromosome.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []","[('KATHERINE', 'DRUG')]","{'keyword': {0: 'phase open label', 1: 'open label', 2: 'katherine phase open', 3: 'katherine phase', 4: 'phase open'}, 'score': {0: 0.8484, 1: 0.8158, 2: 0.7484, 3: 0.7024, 4: 0.6219}}"
1384,1384,1384,0.9470000267028807,28.0,"randomised, multicentre study which assessed ",UniversSB-Light,4,-0.2329999953508377,3355443,30,11,1,"{'concept_id': {0: 'C1555289'}, 'canonical_name': {0: 'Assessed patient - therapy appropriate'}, 'aliases': {0: ['Assessed Patient']}, 'types': {0: ['T033']}, 'definition': {0: '<p>Assessed patient, therapy is appropriate</p>'}, 'entity': {0: 'assessed'}, 'text': {0: 'randomised, multicentre study which assessed '}}","{'concept_id': {0: 'C1096776'}, 'canonical_name': {0: 'Multicenter Studies'}, 'aliases': {0: ['Multicenter Study']}, 'types': {0: ['T062']}, 'definition': {0: 'A work that reports on a study executed by several cooperating institutions.'}, 'entity': {0: 'multicentre study'}, 'text': {0: 'randomised, multicentre study which assessed '}}",{},{},{},"           entity_group        value     score
0  Detailed_description   randomised  0.997080
1  Diagnostic_procedure  multicentre  0.964970
2  Detailed_description  multicentre  0.856343
3  Diagnostic_procedure        study  0.939489",[],"{'keyword': {0: 'randomised multicentre study', 1: 'multicentre study assessed', 2: 'randomised multicentre', 3: 'multicentre study', 4: 'study assessed'}, 'score': {0: 0.8846, 1: 0.8604, 2: 0.8469, 3: 0.8077, 4: 0.7694}}"
1385,1385,1385,0.9470000267028807,28.0,the efficacy and safety profile of adjuvant ,UniversSB-Light,4,-0.2329999953508377,3355443,30,11,2,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}",{},{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}","  entity_group     value     score
0   Medication  adjuvant  0.919629",[],"{'keyword': {0: 'safety profile', 1: 'safety profile adjuvant', 2: 'profile adjuvant', 3: 'efficacy safety', 4: 'efficacy safety profile'}, 'score': {0: 0.8586, 1: 0.7746, 2: 0.7312, 3: 0.6494, 4: 0.6119}}"
1386,1386,1386,0.9470000267028807,28.0,Kadcyla vs trastuzumab in patients who  ,UniversSB-Light,4,-0.2329999953508377,3355443,30,11,3,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}",{},{},"  entity_group        value     score
0   Medication      Kadcyla  0.588591
1   Medication  trastuzumab  0.999825","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'kadcyla vs trastuzumab', 1: 'kadcyla vs', 2: 'vs trastuzumab patients', 3: 'vs trastuzumab', 4: 'trastuzumab patients'}, 'score': {0: 0.9384, 1: 0.8664, 2: 0.8337, 3: 0.8093, 4: 0.8014}}"
1387,1387,1387,0.9470000267028807,28.0,had residual invasive disease following ,UniversSB-Light,4,-0.2329999953508377,3355443,30,11,4,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following '}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following '}}",{},{},{},"           entity_group             value     score
0  Detailed_description          residual  0.995710
1      Disease_disorder  invasive disease  0.862065",[],"{'keyword': {0: 'residual invasive disease', 1: 'residual invasive', 2: 'invasive disease following', 3: 'invasive disease', 4: 'disease following'}, 'score': {0: 0.9149, 1: 0.9108, 2: 0.8708, 3: 0.8285, 4: 0.8066}}"
1388,1388,1388,0.9470000267028807,28.0,trastuzumab-based neoadjuvant therapy,UniversSB-Light,4,-0.2329999953508377,3355443,30,11,5,{},"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'trastuzumab-based neoadjuvant therapy'}, 'text': {0: 'trastuzumab-based neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0             Medication    trastuzumab-based  0.999863
1  Therapeutic_procedure          neoadjuvant  0.997995
2  Therapeutic_procedure  neoadjuvant therapy  0.997627","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab based neoadjuvant', 1: 'based neoadjuvant therapy', 2: 'neoadjuvant therapy', 3: 'trastuzumab based', 4: 'based neoadjuvant'}, 'score': {0: 0.946, 1: 0.8826, 2: 0.8712, 3: 0.8579, 4: 0.8374}}"
1389,1389,1389,0.9890000224113464,24.0,"Clinical stage at presentation, n (%)",MyriadPro-Bold,20,-0.25,3355443,30,12,0,"{'concept_id': {0: 'C0233302'}, 'canonical_name': {0: 'Funic presentation'}, 'aliases': {0: ['Funic Presentation', 'Funic presentation', 'Funis Presentation', 'Presentation of cord', 'Presentation of cord (disorder)', 'Funic presentation (finding)', 'Cord presentation', 'Cord Presentation']}, 'types': {0: ['T033']}, 'definition': {0: 'The positioning of the umbilical cord before the main presenting part of the fetus.'}, 'entity': {0: 'presentation'}, 'text': {0: 'Clinical stage at presentation, n (%)'}}","{'concept_id': {0: 'C1257986'}, 'canonical_name': {0: 'Cross-Presentation'}, 'aliases': {0: ['Cross Presentation']}, 'types': {0: ['T043']}, 'definition': {0: 'Transfer of exogenous ANTIGEN to the ANTIGEN-PRESENTING CELLS for presentation to naive CD8-POSITIVE LYMPHOCYTES.'}, 'entity': {0: 'presentation'}, 'text': {0: 'Clinical stage at presentation, n (%)'}}",{},"{'concept_id': {0: 'C0206431'}, 'canonical_name': {0: 'antigen processing and presentation'}, 'aliases': {0: ['antigen processing', 'antigen presentation']}, 'types': {0: ['T043']}, 'definition': {0: 'The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)'}, 'entity': {0: 'presentation'}, 'text': {0: 'Clinical stage at presentation, n (%)'}}",{},"           entity_group           value     score
0  Diagnostic_procedure  Clinical stage  0.992793",[],"{'keyword': {0: 'clinical stage', 1: 'stage presentation', 2: 'clinical stage presentation'}, 'score': {0: 0.8154, 1: 0.7987, 2: 0.778}}"
1390,1390,1390,0.8830000162124634,24.0,Inoperable breast cancer,MyriadPro-Light,4,-0.25,3355443,30,12,1,"{'concept_id': {0: 'C0376571'}, 'canonical_name': {0: 'BRCA1 gene'}, 'aliases': {0: ['BRCA1, DNA Repair Associated Gene', 'brca1', 'Gene, BRCA1', 'FANCS', 'BRCA1 gene', 'BRCA1 Gene', 'BRCA1 DNA REPAIR-ASSOCIATED PROTEIN', 'brca1 gene', 'Fanconi anemia, complementation group S', 'BRCA1/BRCA2-containing complex, subunit 1', 'Genes, BRCA1', 'BRCA1 DNA repair associated', 'RNF53', 'BRCC1', 'BRCA1', 'Breast Cancer 1, Early Onset Gene', 'BREAST CANCER 1 GENE', 'breast cancer 1', 'PPP1R53', 'brca 1 gene', 'breast cancer 1, early onset', 'BRCA1 Genes', 'protein phosphatase 1, regulatory subunit 53']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.'}, 'entity': {0: 'Inoperable breast cancer'}, 'text': {0: 'Inoperable breast cancer'}}","{'concept_id': {0: 'C0238033'}, 'canonical_name': {0: 'Breast Carcinoma, Male'}, 'aliases': {0: ['Cancer, Male Breast', 'Breast Cancer, Male', 'Carcinoma, Male Breast', 'Male Breast Carcinoma', 'Male Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A rare malignant tumor of the breast, affecting mostly older men. It accounts for less than 1% of all malignancies in men. The most common histologic type is invasive ductal carcinoma. Most patients are treated with mastectomy.'}, 'entity': {0: 'Inoperable breast cancer'}, 'text': {0: 'Inoperable breast cancer'}}",{},{},{},"           entity_group          value     score
0  Detailed_description     Inoperable  0.999938
1      Disease_disorder  breast cancer  0.969098",[],"{'keyword': {0: 'inoperable breast cancer', 1: 'inoperable breast', 2: 'breast cancer'}, 'score': {0: 1.0, 1: 0.9156, 2: 0.6935}}"
1391,1391,1391,0.8830000162124634,24.0,Operable breast cancer,MyriadPro-Light,4,-0.25,3355443,30,13,0,"{'concept_id': {0: 'C0376571'}, 'canonical_name': {0: 'BRCA1 gene'}, 'aliases': {0: ['BRCA1, DNA Repair Associated Gene', 'brca1', 'Gene, BRCA1', 'FANCS', 'BRCA1 gene', 'BRCA1 Gene', 'BRCA1 DNA REPAIR-ASSOCIATED PROTEIN', 'brca1 gene', 'Fanconi anemia, complementation group S', 'BRCA1/BRCA2-containing complex, subunit 1', 'Genes, BRCA1', 'BRCA1 DNA repair associated', 'RNF53', 'BRCC1', 'BRCA1', 'Breast Cancer 1, Early Onset Gene', 'BREAST CANCER 1 GENE', 'breast cancer 1', 'PPP1R53', 'brca 1 gene', 'breast cancer 1, early onset', 'BRCA1 Genes', 'protein phosphatase 1, regulatory subunit 53']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.'}, 'entity': {0: 'Operable breast cancer'}, 'text': {0: 'Operable breast cancer'}}","{'concept_id': {0: 'C0238033'}, 'canonical_name': {0: 'Breast Carcinoma, Male'}, 'aliases': {0: ['Cancer, Male Breast', 'Breast Cancer, Male', 'Carcinoma, Male Breast', 'Male Breast Carcinoma', 'Male Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A rare malignant tumor of the breast, affecting mostly older men. It accounts for less than 1% of all malignancies in men. The most common histologic type is invasive ductal carcinoma. Most patients are treated with mastectomy.'}, 'entity': {0: 'Operable breast cancer'}, 'text': {0: 'Operable breast cancer'}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'Operable breast cancer'}, 'text': {0: 'Operable breast cancer'}}","           entity_group          value     score
0  Detailed_description       Operable  0.983971
1      Disease_disorder  breast cancer  0.999287",[],"{'keyword': {0: 'operable breast cancer', 1: 'operable breast', 2: 'breast cancer'}, 'score': {0: 1.0, 1: 0.9106, 2: 0.7264}}"
1392,1392,1392,0.8830000162124634,24.0,185 (24.9),MyriadPro-Light,4,-0.25,3355443,30,13,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   185  0.999768",[],"{'keyword': {0: '185 24'}, 'score': {0: 0.7828}}"
1393,1393,1393,0.8830000162124634,24.0,558 (75.1),MyriadPro-Light,4,-0.25,3355443,30,13,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value   558  0.915754",[],"{'keyword': {0: '558 75'}, 'score': {0: 0.7885}}"
1394,1394,1394,0.8830000162124634,24.0,190 (25.6),MyriadPro-Light,4,-0.25,3355443,30,13,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   190  0.999488",[],"{'keyword': {0: '190 25'}, 'score': {0: 0.831}}"
1395,1395,1395,0.8830000162124634,24.0,553 (74.4),MyriadPro-Light,4,-0.25,3355443,30,13,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value   553  0.966153",[],"{'keyword': {0: '553 74'}, 'score': {0: 0.8345}}"
1396,1396,1396,0.9470000267028807,27.0,Surgery,UniversSB-Light,4,-0.2329999953508377,16777215,30,14,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  Surgery  0.998798",[],"{'keyword': {}, 'score': {}}"
1397,1397,1397,0.9470000267028807,27.0,Residual invasive ,UniversSB-Light,4,-0.2329999953508377,16777215,30,15,0,"{'concept_id': {0: 'C1334278'}, 'canonical_name': {0: 'Invasive Lesion'}, 'aliases': {0: ['Invasive Lesion']}, 'types': {0: ['T033']}, 'definition': {0: 'A malignant cellular population that has increased in size and infiltrates the surrounding tissues.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}","{'concept_id': {0: 'C2936533'}, 'canonical_name': {0: 'Invasive Species'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Non-native species that threaten ecosystems, habitats, or other species and are likely to cause economic or environmental harm or harm to human health.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"           entity_group              value     score
0  Detailed_description  Residual invasive  0.999395",[],"{'keyword': {0: 'residual invasive'}, 'score': {0: 1.0}}"
1398,1398,1398,0.9470000267028807,27.0,disease in breast  ,UniversSB-Light,4,-0.2329999953508377,16777215,30,15,1,"{'concept_id': {0: 'C0038293'}, 'canonical_name': {0: 'Sternum'}, 'aliases': {0: ['Bone structure of sternum (body structure)', 'sternums', 'Sternum', 'Sternum/Sternal', 'Breast bone', 'Chest>Sternum', 'Sternal', 'breast bone', 'sternum', 'Sternum, NOS', 'Bone structure of sternum']}, 'types': {0: ['T023']}, 'definition': {0: 'A long, narrow, and flat bone commonly known as BREASTBONE occurring in the midsection of the anterior thoracic segment or chest region, which stabilizes the rib cage and serves as the point of origin for several muscles that move the arms, head, and neck.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","{'concept_id': {0: 'C0024902'}, 'canonical_name': {0: 'Breast Pain'}, 'aliases': {0: ['Mastodynias', 'Mammalgias', 'Mastodynia', 'Mastalgias', 'Mammalgia', 'Pain, Breast', 'Mastalgia', 'Breast Pains', 'Pains, Breast']}, 'types': {0: ['T184']}, 'definition': {0: 'Painful sensation in the breast region.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","           entity_group   value     score
0  Biological_structure  breast  0.999824",[],"{'keyword': {0: 'disease breast'}, 'score': {0: 0.9481}}"
1399,1399,1399,0.9470000267028807,27.0,or axillary lymph ,UniversSB-Light,4,-0.2329999953508377,16777215,30,15,2,"{'concept_id': {0: 'C0229843'}, 'canonical_name': {0: 'Pectoral lymph node group'}, 'aliases': {0: ['Nodi lymphoidei axillarum anteriores', 'Anterior axillary lymph nodes', 'Structure of pectoral axillary lymph node (body structure)', 'Anterior axillary nodes', 'Pectoral axillary lymph node', 'Nodi pectorales', 'Anterior axillary lymph nodes set', 'Pectoral Lymph Node', 'Pectoral lymph node', 'Pectoral lymph node group', 'Pectoral nodes', 'Pectoral axillary lymph node group', 'Pectoral lymph nodes', 'Structure of pectoral axillary lymph node', 'Pectoral lymph node group (body structure)', 'Anterior axillary lymph node', 'Nodi axillarum anteriores', 'Nodus lymphaticus pectoralis axillae', 'Set of pectoral lymph nodes', 'Set of anterior axillary lymph nodes', 'Pectoral lymph nodes set', 'Pectoral axillary lymph nodes', 'Set of pectoral axillary lymph nodes', 'Nodi lymphoidei pectorales']}, 'types': {0: ['T023']}, 'definition': {0: 'An axillary lymph node located along the lower edge of the pectoralis minor.'}, 'entity': {0: 'axillary lymph'}, 'text': {0: 'or axillary lymph '}}",{},{},{},{},"           entity_group           value     score
0  Biological_structure        axillary  0.999927
1  Biological_structure  axillary lymph  0.940007",[],"{'keyword': {0: 'axillary lymph'}, 'score': {0: 0.9521}}"
1400,1400,1400,0.9470000267028807,27.0,nodes,UniversSB-Light,4,-0.2329999953508377,16777215,30,15,3,"{'concept_id': {0: 'C2697524'}, 'canonical_name': {0: 'Graph Node'}, 'aliases': {0: ['Vertex', 'Node', 'Graph Node']}, 'types': {0: ['T077']}, 'definition': {0: 'One of the points that define a graph.'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}","{'concept_id': {0: 'C0037189'}, 'canonical_name': {0: 'Sino-Atrial Nodes'}, 'aliases': {0: ['Sinu-Atrial Node', 'Sino-Atrial Node', 'Sinu-Atrial Nodes', 'Nodes, Sinu-Atrial', 'Sinus Node', 'Nodes, Sinuatrial', 'Node, Sinuatrial', 'Nodes, Sinoatrial', 'Nodes, Sinus', 'Sinoatrial Node', 'Sinus Nodes', 'Sinuatrial Node', 'Node, Sino-Atrial', 'Node, Sinus', 'Node, Sinoatrial', 'Sinoatrial Nodes', 'Sinu Atrial Node', 'Sinuatrial Nodes', 'Sino Atrial Node', 'Nodes, Sino-Atrial', 'Node, Sinu-Atrial']}, 'types': {0: ['T023']}, 'definition': {0: 'The small mass of modified cardiac muscle fibers located at the junction of the superior vena cava (VENA CAVA, SUPERIOR) and right atrium. Contraction impulses probably start in this node, spread over the atrium (HEART ATRIUM) and are then transmitted by the atrioventricular bundle (BUNDLE OF HIS) to the ventricle (HEART VENTRICLE).'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}",{},{},{},"           entity_group  value     score
0  Biological_structure  nodes  0.488832",[],"{'keyword': {}, 'score': {}}"
1401,1401,1401,0.9470000267028807,27.0,"HER2-positive eBC, ",UniversSB-Light,4,-0.2329999953508377,16777215,30,16,0,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  HER2-positive  0.816637",[],"{'keyword': {0: 'her2 positive ebc', 1: 'positive ebc', 2: 'her2 positive'}, 'score': {0: 0.9628, 1: 0.8142, 2: 0.7646}}"
1402,1402,1402,0.9470000267028807,27.0,neoadjuvant ,UniversSB-Light,4,-0.2329999953508377,16777215,30,16,1,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}",{},{},{},"           entity_group        value     score
0  Detailed_description  neoadjuvant  0.956138
1          Sign_symptom  neoadjuvant  0.386592
2               History  neoadjuvant  0.344678",[],"{'keyword': {}, 'score': {}}"
1403,1403,1403,0.9470000267028807,27.0,trastuzumab* plus ,UniversSB-Light,4,-0.2329999953508377,16777215,30,16,2,"{'concept_id': {0: 'C4527338'}, 'canonical_name': {0: 'AC Followed by Docetaxel/Trastuzumab Regimen'}, 'aliases': {0: ['AC-Docetaxel + Trastuzumab', 'AC-T Plus Trastuzumab', 'AC-Taxotere/Herceptin', 'AC Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel/Trastuzumab']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},{},"           entity_group        value     score
0            Medication  trastuzumab  0.999873
1  Detailed_description         plus  0.314542","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab plus'}, 'score': {0: 0.9478}}"
1404,1404,1404,0.9470000267028807,27.0,chemotherapy ,UniversSB-Light,4,-0.2329999953508377,16777215,30,16,3,"{'concept_id': {0: 'C0392920'}, 'canonical_name': {0: 'Chemotherapy Regimen'}, 'aliases': {0: ['chemotherapy regimen', 'Antineoplastic chemotherapy regimen', 'chemotherapies', 'Antineoplastic chemotherapy regimen (regime/therapy)', 'chemotherapy regimens', 'neoplasm chemotherapy', 'neoplasm pharmacotherapy', 'chemotherapy', 'chemo', 'Cancer chemotherapy', 'neoplasm/cancer chemotherapy', 'cancer chemotherapy', 'cancer pharmacotherapy', 'neoplasm/cancer pharmacotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'application of the beneficial effects of drugs to control or cure neoplastic growth.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}","{'concept_id': {0: 'C1868801'}, 'canonical_name': {0: 'Hyperthermic Intraperitoneal Chemotherapy'}, 'aliases': {0: ['Hot Chemotherapy', 'Chemotherapy, Intraperitoneal Hyperthermic', 'Chemotherapy, Hyperthermic Intraperitoneal', 'Chemotherapy, Hot', 'Intraperitoneal Hyperthermic Chemotherapies', 'Intraperitoneal Chemotherapy, Hyperthermic', 'Hyperthermic Chemotherapy, Intraperitoneal', 'HIPEC', 'Intraperitoneal Hyperthermic Chemotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}",{},{},{},"  entity_group         value     score
0   Medication  chemotherapy  0.999848","[('chemotherapy', 'DRUG')]","{'keyword': {}, 'score': {}}"
1405,1405,1405,0.9470000267028807,27.0,(n=1486),UniversSB-Light,4,-0.2329999953508377,16777215,30,16,4,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1406,1406,1406,0.944000005722046,28.0,Primary endpoint,UniversSB-Bold,20,-0.2469999939203262,3355443,30,17,0,"{'concept_id': {0: 'C2349179'}, 'canonical_name': {0: 'End Point'}, 'aliases': {0: ['Endpoint', 'End Point', 'ENDPOINT', 'endpoints', 'endpoint', 'End-Point']}, 'types': {0: ['T080']}, 'definition': {0: 'A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.'}, 'entity': {0: 'Primary endpoint'}, 'text': {0: 'Primary endpoint'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  Primary endpoint  0.940143",[],"{'keyword': {0: 'primary endpoint'}, 'score': {0: 1.0}}"
1407,1407,1407,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,30,17,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1408,1408,1408,0.944000005722046,28.0,Secondary endpoints,UniversSB-Bold,20,-0.2469999939203262,3355443,30,18,0,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}",{},"{'concept_id': {0: 'C1623508'}, 'canonical_name': {0: 'regulation of secondary metabolic process'}, 'aliases': {0: ['regulation of secondary metabolism']}, 'types': {0: ['T040']}, 'definition': {0: 'Any process that modulates the frequency, rate or extent of secondary metabolism, the chemical reactions and pathways involving compounds that are not necessarily required for growth and maintenance of cells, and are often unique to a taxon. [GOC:jl]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C2981150'}, 'canonical_name': {0: 'Uranostaphyloschisis'}, 'aliases': {0: ['Cleft of hard and soft palate', 'Cleft of palate', 'Cleft hard and soft palate', 'Cleft palate', 'Cleft secondary palate', 'Palatoschisis', 'Cleft roof of mouth']}, 'types': {0: ['T019']}, 'definition': {0: 'Cleft palate is a developmental defect of the palate resulting from a failure of fusion of the palatine processes and manifesting as a separation of the roof of the mouth (soft and hard palate). [HPO:probinson]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","           entity_group                value     score
0  Detailed_description  Secondary endpoints  0.811147",[],"{'keyword': {0: 'secondary endpoints'}, 'score': {0: 1.0}}"
1409,1409,1409,0.9890000224113464,24.0,"HR status, n (%)",MyriadPro-Bold,20,-0.25,3355443,30,19,0,"{'concept_id': {0: 'C4764257'}, 'canonical_name': {0: 'Androgen Receptor Status'}, 'aliases': {0: ['AR Status']}, 'types': {0: ['T033']}, 'definition': {0: 'Refers to the presence or absence of androgen receptor molecules on the surface of a cells in a specimen.'}, 'entity': {0: 'status'}, 'text': {0: 'HR status, n (%)'}}","{'concept_id': {0: 'C0699806'}, 'canonical_name': {0: 'Social Status'}, 'aliases': {0: []}, 'types': {0: ['T080']}, 'definition': {0: 'The relative prestige, authority, and privilege of an individual or group.'}, 'entity': {0: 'status'}, 'text': {0: 'HR status, n (%)'}}",{},"{'concept_id': {0: 'C2247597'}, 'canonical_name': {0: 'positive regulation of plant-type hypersensitive response'}, 'aliases': {0: ['up-regulation of plant-type hypersensitive response', 'up regulation of plant-type hypersensitive response', 'positive regulation of plant hypersensitive response', 'upregulation of plant-type hypersensitive response', 'positive regulation of HR']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that activates or increases the frequency, rate or extent of the hypersensitive response in a plant. [GOC:pamgo_curators]'}, 'entity': {0: 'HR'}, 'text': {0: 'HR status, n (%)'}}",{},"           entity_group value     score
0  Diagnostic_procedure    HR  0.999529",[],"{'keyword': {0: 'hr status'}, 'score': {0: 0.7691}}"
1410,1410,1410,0.8830000162124634,24.0,ER-negative and PR-negative or status unknown ,MyriadPro-Light,4,-0.25,3355443,30,19,1,"{'concept_id': {0: 'C4764257'}, 'canonical_name': {0: 'Androgen Receptor Status'}, 'aliases': {0: ['AR Status']}, 'types': {0: ['T033']}, 'definition': {0: 'Refers to the presence or absence of androgen receptor molecules on the surface of a cells in a specimen.'}, 'entity': {0: 'status'}, 'text': {0: 'ER-negative and PR-negative or status unknown '}}","{'concept_id': {0: 'C0699806'}, 'canonical_name': {0: 'Social Status'}, 'aliases': {0: []}, 'types': {0: ['T080']}, 'definition': {0: 'The relative prestige, authority, and privilege of an individual or group.'}, 'entity': {0: 'status'}, 'text': {0: 'ER-negative and PR-negative or status unknown '}}",{},{},{},"           entity_group                    value     score
0  Diagnostic_procedure              ER-negative  0.993134
1             Lab_value  ER-negative PR-negative  0.998064
2             Lab_value              PR-negative  0.998233
3  Diagnostic_procedure           status unknown  0.923751",[],"{'keyword': {0: 'er negative pr', 1: 'negative pr', 2: 'pr negative', 3: 'negative status', 4: 'negative status unknown'}, 'score': {0: 0.9167, 1: 0.8793, 2: 0.8667, 3: 0.8489, 4: 0.7805}}"
1411,1411,1411,0.8830000162124634,24.0,"ER-positive, PR-positive, or both",MyriadPro-Light,4,-0.25,3355443,30,19,2,{},{},{},{},{},"           entity_group        value     score
0  Detailed_description  ER-positive  0.555667
1             Lab_value         both  0.969004",[],"{'keyword': {0: 'er positive pr', 1: 'er positive', 2: 'positive pr positive', 3: 'positive pr', 4: 'pr positive'}, 'score': {0: 0.8652, 1: 0.8573, 2: 0.855, 3: 0.8525, 4: 0.8389}}"
1412,1412,1412,0.8830000162124634,24.0,209 (28.1),MyriadPro-Light,4,-0.25,3355443,30,19,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   209  0.999589",[],"{'keyword': {0: '209 28'}, 'score': {0: 0.8788}}"
1413,1413,1413,0.8830000162124634,24.0,534 (71.9),MyriadPro-Light,4,-0.25,3355443,30,19,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value   534  0.974788",[],"{'keyword': {0: '534 71'}, 'score': {0: 0.7976}}"
1414,1414,1414,0.8830000162124634,24.0,203 (27.3),MyriadPro-Light,4,-0.25,3355443,30,19,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value   203  0.999749",[],"{'keyword': {0: '203 27'}, 'score': {0: 0.874}}"
1415,1415,1415,0.8830000162124634,24.0,540 (72.7),MyriadPro-Light,4,-0.25,3355443,30,19,6,{},{},{},{},{},"  entity_group value     score
0    Lab_value   540  0.999049",[],"{'keyword': {0: '540 72'}, 'score': {0: 0.6415}}"
1416,1416,1416,0.9470000267028807,27.0,Planned 10 years’ follow-up,UniversSB-Light,4,-0.2329999953508377,16777215,30,20,0,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}",{},{},{},"     entity_group      value     score
0        Duration   10 years  0.999410
1  Clinical_event  follow-up  0.993776",[],"{'keyword': {0: 'planned 10 years', 1: '10 years follow', 2: 'planned 10', 3: '10 years', 4: 'years follow'}, 'score': {0: 0.9349, 1: 0.8297, 2: 0.8114, 3: 0.7473, 4: 0.7286}}"
1417,1417,1417,0.944000005722046,27.0,Trastuzumab  ,UniversSB-Bold,20,-0.2469999939203262,16777215,30,21,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
1418,1418,1418,0.944000005722046,27.0,6 mg/kg IV ,UniversSB-Bold,20,-0.2469999939203262,16777215,30,21,1,"{'concept_id': {0: 'C0439272'}, 'canonical_name': {0: 'ug/g'}, 'aliases': {0: ['Picogram per Microgram', 'Zeptogram per Femtogram', 'Yoctogram per Attogram', 'mg/kg', 'Milligram/kilogram', 'Microgram/gram', 'microgram/g', 'Femtogram per Nanogram', 'Nanogram per Milligram', 'Milligram/kilogram (qualifier value)', 'Microgram/gram (qualifier value)', 'mg kg', 'Microgram per Gram', 'Milligram/Kilogram', 'Milligram per Kilogram', 'Attogram per Picogram', 'microg/g']}, 'types': {0: ['T081']}, 'definition': {0: 'A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.'}, 'entity': {0: 'mg/kg IV'}, 'text': {0: '6 mg/kg IV '}}",{},{},{},{},"     entity_group    value     score
0          Dosage  6 mg/kg  0.909511
1  Administration       IV  0.990577","[('6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7475, 1: 0.7458, 2: 0.6812}}"
1419,1419,1419,0.944000005722046,27.0,(n=743),UniversSB-Bold,20,-0.2469999939203262,16777215,30,21,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1420,1420,1420,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,30,22,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1421,1421,1421,0.9470000267028807,28.0,non-breast cancer as per the  ,UniversSB-Light,4,-0.2329999953508377,3355443,30,22,1,{},"{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'non-breast cancer'}, 'text': {0: 'non-breast cancer as per the  '}}",{},{},{},"       entity_group              value     score
0           History         non-breast  0.647748
1  Disease_disorder  non-breast cancer  0.972177",[],"{'keyword': {0: 'non breast cancer', 1: 'non breast', 2: 'breast cancer'}, 'score': {0: 0.9178, 1: 0.7301, 2: 0.6862}}"
1422,1422,1422,0.9470000267028807,28.0,STEEP definition,UniversSB-Light,4,-0.2329999953508377,3355443,30,22,2,"{'concept_id': {0: 'C3539107'}, 'canonical_name': {0: 'Definition (core metadata concept)'}, 'aliases': {0: ['Definition', 'Definition (core metadata concept)']}, 'types': {0: ['T170']}, 'definition': {0: None}, 'entity': {0: 'definition'}, 'text': {0: 'STEEP definition'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  STEEP definition  0.998824",[],"{'keyword': {0: 'steep definition'}, 'score': {0: 1.0}}"
1423,1423,1423,0.9470000267028807,23.0,Anti-HER2 therapy for a total of 14 cycles. ,UniversSB-Light,4,-0.2329999953508377,3355443,30,23,0,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}",{},{},{},"  entity_group      value     score
0   Medication  Anti-HER2  0.606185
1  Coreference  Anti-HER2  0.565908
2   Medication    therapy  0.542007
3    Lab_value         14  0.923810",[],"{'keyword': {0: 'total 14 cycles', 1: 'therapy total 14', 2: 'anti her2 therapy', 3: 'her2 therapy total', 4: 'anti her2'}, 'score': {0: 0.8392, 1: 0.822, 2: 0.7728, 3: 0.7289, 4: 0.6897}}"
1424,1424,1424,0.9470000267028807,23.0,Radiation and endocrine therapy ,UniversSB-Light,4,-0.2329999953508377,3355443,30,23,1,"{'concept_id': {0: 'C1514396'}, 'canonical_name': {0: 'Preoperative Endocrine Therapy'}, 'aliases': {0: []}, 'types': {0: ['T061']}, 'definition': {0: 'Short term endocrine therapy, prior to surgery, to ""down-stage"" primary breast cancer in order to increase the rate of breast-conserving surgery. (from JMCC 7:557-562, 2000 via Medscape)'}, 'entity': {0: 'endocrine therapy'}, 'text': {0: 'Radiation and endocrine therapy '}}","{'concept_id': {0: 'C2607955'}, 'canonical_name': {0: 'Beta Radiation'}, 'aliases': {0: ['Rays, Beta', 'Ray, Beta', 'Beta Radiations', 'Beta Rays', 'Radiation, Beta', 'Beta Ray', 'Radiations, Beta']}, 'types': {0: ['T070']}, 'definition': {0: 'A stream of high energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus.'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy '}}",{},"{'concept_id': {0: 'C1154958'}, 'canonical_name': {0: 'response to electromagnetic radiation stimulus'}, 'aliases': {0: ['response to radiation stimulus', 'response to radiation']}, 'types': {0: ['T038']}, 'definition': {0: 'Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electromagnetic radiation stimulus. Electromagnetic radiation is a propagating wave in space with electric and magnetic components. These components oscillate at right angles to each other and to the direction of propagation. [GOC:jl, Wikipedia:Electromagnetic_radiation]'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy '}}",{},"            entity_group              value     score
0  Therapeutic_procedure          Radiation  0.994988
1  Therapeutic_procedure  endocrine therapy  0.948940",[],"{'keyword': {0: 'radiation endocrine therapy', 1: 'endocrine therapy', 2: 'radiation endocrine'}, 'score': {0: 0.843, 1: 0.824, 2: 0.8103}}"
1425,1425,1425,0.9470000267028807,23.0,administered according to institutional ,UniversSB-Light,4,-0.2329999953508377,3355443,30,23,2,"{'concept_id': {0: 'C1546848'}, 'canonical_name': {0: 'Living Arrangement - Institution'}, 'aliases': {0: ['Institution']}, 'types': {0: ['T033']}, 'definition': {0: '<p>Institution</p>'}, 'entity': {0: 'institutional'}, 'text': {0: 'administered according to institutional '}}","{'concept_id': {0: 'C5544477'}, 'canonical_name': {0: 'Systemic Racism'}, 'aliases': {0: ['Institutionalized Racisms', 'Racism, Systemic', 'Institutionalized Racism', 'Racism, Institutionalized', 'Structural Racisms', 'Racism, Structural', 'Racism, Institutional', 'Racisms, Systematic', 'Systematic Racisms', 'Racism, Systematic', 'Institutional Racism', 'Systematic Racism', 'Structural Racism']}, 'types': {0: ['T054']}, 'definition': {0: 'Processes of racism that are embedded in laws (local, state, and federal), policies, and practices of society and its institutions that provide advantages to racial groups deemed as superior, while differentially oppressing, disadvantaging, or otherwise neglecting racial groups viewed as inferior. Differential access to the goods, services, and opportunities of society by race. Institutionalized racism is normative, sometimes legalized, and often manifests as inherited disadvantage. It is structural, having been codified in our institutions of custom, practice, and law, so there need not be an identifiable perpetrator. (ttps://www.cdc.gov/chronicdisease/programs-impact/sdoh.htm)'}, 'entity': {0: 'institutional'}, 'text': {0: 'administered according to institutional '}}",{},{},{},"           entity_group                       value     score
0  Detailed_description  according to institutional  0.817311",[],"{'keyword': {0: 'administered according institutional', 1: 'according institutional', 2: 'administered according'}, 'score': {0: 0.9745, 1: 0.8839, 2: 0.8672}}"
1426,1426,1426,0.9470000267028807,23.0,standards and study protocol,UniversSB-Light,4,-0.2329999953508377,3355443,30,23,3,"{'concept_id': {0: 'C2985700'}, 'canonical_name': {0: 'Study Protocol Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic.'}, 'entity': {0: 'study protocol'}, 'text': {0: 'standards and study protocol'}}","{'concept_id': {0: 'C2936643'}, 'canonical_name': {0: 'Standard of Care'}, 'aliases': {0: ['Standards of Care', 'Care Standards', 'Care Standard']}, 'types': {0: ['T058']}, 'definition': {0: 'The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.'}, 'entity': {0: 'standards'}, 'text': {0: 'standards and study protocol'}}",{},{},{},"           entity_group           value     score
0  Diagnostic_procedure       standards  0.946151
1  Diagnostic_procedure  study protocol  0.709869",[],"{'keyword': {0: 'study protocol', 1: 'standards study protocol', 2: 'standards study'}, 'score': {0: 0.906, 1: 0.879, 2: 0.7344}}"
1427,1427,1427,0.8830000162124634,24.0,335 (45.1),MyriadPro-Light,4,-0.25,3355443,30,24,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   335  0.999583",[],"{'keyword': {0: '335 45'}, 'score': {0: 0.8303}}"
1428,1428,1428,0.8830000162124634,24.0,213 (28.7),MyriadPro-Light,4,-0.25,3355443,30,24,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   213  0.999495",[],"{'keyword': {0: '213 28'}, 'score': {0: 0.7921}}"
1429,1429,1429,0.8830000162124634,24.0,103 (13.9),MyriadPro-Light,4,-0.25,3355443,30,24,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value   103  0.999743",[],"{'keyword': {0: '103 13'}, 'score': {0: 0.8354}}"
1430,1430,1430,0.8830000162124634,24.0,30 (4.0),MyriadPro-Light,4,-0.25,3355443,30,24,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    30  0.999718",[],"{'keyword': {}, 'score': {}}"
1431,1431,1431,0.8830000162124634,24.0,62 (8.3),MyriadPro-Light,4,-0.25,3355443,30,24,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    62  0.999697",[],"{'keyword': {}, 'score': {}}"
1432,1432,1432,0.8830000162124634,24.0,344 (46.3),MyriadPro-Light,4,-0.25,3355443,30,25,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value   344  0.99978",[],"{'keyword': {0: '344 46'}, 'score': {0: 0.8612}}"
1433,1433,1433,0.8830000162124634,24.0,220 (29.6),MyriadPro-Light,4,-0.25,3355443,30,25,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   220  0.999593",[],"{'keyword': {0: '220 29'}, 'score': {0: 0.8452}}"
1434,1434,1434,0.8830000162124634,24.0,86 (11.6),MyriadPro-Light,4,-0.25,3355443,30,25,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    86  0.999786",[],"{'keyword': {0: '86 11'}, 'score': {0: 0.7571}}"
1435,1435,1435,0.8830000162124634,24.0,37 (5.0),MyriadPro-Light,4,-0.25,3355443,30,25,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value    37  0.99966",[],"{'keyword': {}, 'score': {}}"
1436,1436,1436,0.8830000162124634,24.0,56 (7.5),MyriadPro-Light,4,-0.25,3355443,30,25,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    56  0.999353",[],"{'keyword': {}, 'score': {}}"
1437,1437,1437,0.9890000224113464,24.0,"Regional lymph node stage (at definitive surgery), n (%)",MyriadPro-Bold,20,-0.25,3355443,30,26,0,"{'concept_id': {0: 'C0443196'}, 'canonical_name': {0: 'Definitive'}, 'aliases': {0: ['definitive', 'Definitive (qualifier value)', 'Definitive']}, 'types': {0: ['T079']}, 'definition': {0: 'Supplying or being a final or conclusive settlement or result.'}, 'entity': {0: 'definitive surgery'}, 'text': {0: 'Regional lymph node stage (at definitive surgery), n (%)'}}",{},{},{},{},"           entity_group                       value     score
0  Detailed_description                    Regional  0.999849
1  Diagnostic_procedure              Regional lymph  0.782678
2  Detailed_description                       lymph  0.878663
3  Diagnostic_procedure            lymph node stage  0.780716
4             Lab_value  Regional node definitive n  0.995701",[],"{'keyword': {0: 'regional lymph node', 1: 'lymph node stage', 2: 'definitive surgery', 3: 'stage definitive', 4: 'stage definitive surgery'}, 'score': {0: 0.7815, 1: 0.7718, 2: 0.6751, 3: 0.667, 4: 0.6282}}"
1438,1438,1438,0.8830000162124634,24.0,ypN0,MyriadPro-Light,4,-0.25,3355443,30,26,1,{},{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypN0  0.857369
1             Lab_value  ypN0  0.541079
2          Sign_symptom  ypN0  0.486708",[],"{'keyword': {}, 'score': {}}"
1439,1439,1439,0.8830000162124634,24.0,ypN1,MyriadPro-Light,4,-0.25,3355443,30,26,2,{},{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypN1  0.998739",[],"{'keyword': {}, 'score': {}}"
1440,1440,1440,0.8830000162124634,24.0,ypN2,MyriadPro-Light,4,-0.25,3355443,30,26,3,{},{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypN2  0.999481",[],"{'keyword': {}, 'score': {}}"
1441,1441,1441,0.8830000162124634,24.0,ypN3,MyriadPro-Light,4,-0.25,3355443,30,26,4,{},{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypN3  0.998871",[],"{'keyword': {}, 'score': {}}"
1442,1442,1442,0.8830000162124634,24.0,ypNX,MyriadPro-Light,4,-0.25,3355443,30,26,5,{},{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure  ypNX  0.767269",[],"{'keyword': {}, 'score': {}}"
1443,1443,1443,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,30,27,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1444,1444,1444,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,30,27,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1445,1445,1445,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,30,27,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1446,1446,1446,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,30,27,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1447,1447,1447,0.9052734375,23.0,≥,ArialMT,0,-0.2119140625,3355443,30,28,0,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1448,1448,1448,0.9470000267028807,23.0,of treatment including ,UniversSB-Light,4,-0.2329999953508377,3355443,30,28,1,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'treatment including'}, 'score': {0: 0.9499}}"
1449,1449,1449,0.9052734375,22.65237236022949,≥,ArialMT,0,-0.2119140625,3355443,30,28,2,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1450,1450,1450,0.9470000267028807,23.0,therapy and ,UniversSB-Light,4,-0.2329999953508377,3355443,30,28,3,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  therapy  0.826489",[],"{'keyword': {}, 'score': {}}"
1451,1451,1451,0.9470000267028807,23.0,of trastuzumab therapy,UniversSB-Light,4,-0.2329999953508377,3355443,30,28,4,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},{},"  entity_group                value     score
0   Medication          trastuzumab  0.999849
1   Medication  trastuzumab therapy  0.978093","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab therapy'}, 'score': {0: 0.9362}}"
1452,1452,1452,0.8830000162124634,24.0,"Previous use of anthracycline, n (%)",MyriadPro-Light,4,-0.25,3355443,30,29,0,"{'concept_id': {0: 'C0282564'}, 'canonical_name': {0: 'Anthracyclines'}, 'aliases': {0: ['anthracyclines', 'anthracycline', 'Anthracyclines', 'Anthracycline']}, 'types': {0: ['T109']}, 'definition': {0: 'Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.'}, 'entity': {0: 'anthracycline'}, 'text': {0: 'Previous use of anthracycline, n (%)'}}","{'concept_id': {0: 'C0282564'}, 'canonical_name': {0: 'Anthracyclines'}, 'aliases': {0: ['Anthracycline']}, 'types': {0: ['T109']}, 'definition': {0: 'Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.'}, 'entity': {0: 'anthracycline'}, 'text': {0: 'Previous use of anthracycline, n (%)'}}",{},{},{},"           entity_group          value     score
0  Detailed_description  anthracycline  0.946722","[('anthracycline', 'DRUG')]","{'keyword': {0: 'previous use anthracycline', 1: 'use anthracycline', 2: 'previous use'}, 'score': {0: 0.8823, 1: 0.8744, 2: 0.8447}}"
1453,1453,1453,0.8830000162124634,24.0,579 (77.9),MyriadPro-Light,4,-0.25,3355443,30,29,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   579  0.985521",[],"{'keyword': {0: '579 77'}, 'score': {0: 0.7859}}"
1454,1454,1454,0.8830000162124634,24.0,564 (75.9),MyriadPro-Light,4,-0.25,3355443,30,29,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value   564  0.938448",[],"{'keyword': {0: '564 75'}, 'score': {0: 0.7971}}"
1455,1455,1455,0.944000005722046,28.0,Stratification factors,UniversSB-Bold,20,-0.2469999939203262,3355443,30,30,0,"{'concept_id': {0: 'C1514983'}, 'canonical_name': {0: 'Stratification'}, 'aliases': {0: ['stratification']}, 'types': {0: ['T062']}, 'definition': {0: 'The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.'}, 'entity': {0: 'Stratification factors'}, 'text': {0: 'Stratification factors'}}",{},{},{},{},"           entity_group                   value     score
0  Diagnostic_procedure  Stratification factors  0.970758",[],"{'keyword': {0: 'stratification factors'}, 'score': {0: 1.0}}"
1456,1456,1456,0.944000005722046,21.0,Inclusion and  ,UniversSB-Bold,20,-0.2469999939203262,16777215,30,31,0,"{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Cellular Inclusion', 'Inclusion Body', 'inclusion bodies', 'Inclusion Bodies', 'inclusion body', 'body inclusion', 'Inclusions, Cellular', 'cellular inclusions', 'Bodies, Inclusion', 'Cellular Inclusions', 'Inclusions', 'cellular inclusion', 'Inclusion, Cellular', 'Body, Inclusion']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}","{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Inclusions, Cellular', 'Inclusion, Cellular', 'Inclusion Body', 'Body, Inclusion', 'Cellular Inclusion', 'Bodies, Inclusion', 'Cellular Inclusions']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"{'concept_id': {0: 'C0205708'}, 'canonical_name': {0: 'cytoplasmic inclusion'}, 'aliases': {0: []}, 'types': {0: ['T026']}, 'definition': {0: 'A stainable aggregation of protein, lipid or small molecules in the cytoplasm.'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"  entity_group      value     score
0  Coreference  Inclusion  0.340508",[],"{'keyword': {}, 'score': {}}"
1457,1457,1457,0.944000005722046,21.0,exclusion criteria,UniversSB-Bold,20,-0.2469999939203262,16777215,30,31,1,"{'concept_id': {0: 'C2827032'}, 'canonical_name': {0: 'Trial Inclusion Exclusion Criteria Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A specific variant of the original trial inclusion exclusion criterion.'}, 'entity': {0: 'exclusion criteria'}, 'text': {0: 'exclusion criteria'}}",{},{},{},{},"           entity_group               value     score
0  Diagnostic_procedure  exclusion criteria  0.534692",[],"{'keyword': {0: 'exclusion criteria'}, 'score': {0: 1.0}}"
1458,1458,1458,0.944000005722046,21.0,Baseline characteristics  ,UniversSB-Bold,20,-0.2469999939203262,16777215,30,32,0,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","           entity_group                     value     score
0  Diagnostic_procedure  Baseline characteristics  0.999933",[],"{'keyword': {0: 'baseline characteristics'}, 'score': {0: 1.0}}"
1459,1459,1459,0.944000005722046,21.0,were well-balanced,UniversSB-Bold,20,-0.2469999939203262,16777215,30,32,1,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  well-balanced  0.999827",[],"{'keyword': {}, 'score': {}}"
1460,1460,1460,0.8830000162124634,24.0,596 (80.2),MyriadPro-Light,4,-0.25,3355443,30,33,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   596  0.996325",[],"{'keyword': {0: '596 80'}, 'score': {0: 0.76}}"
1461,1461,1461,0.8830000162124634,24.0,139 (18.7),MyriadPro-Light,4,-0.25,3355443,30,33,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   139  0.999716",[],"{'keyword': {0: '139 18'}, 'score': {0: 0.7814}}"
1462,1462,1462,0.8830000162124634,24.0,8 (1.1),MyriadPro-Light,4,-0.25,3355443,30,33,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     8  0.999834",[],"{'keyword': {}, 'score': {}}"
1463,1463,1463,0.8830000162124634,24.0,600 (80.8),MyriadPro-Light,4,-0.25,3355443,30,34,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value   600  0.999452",[],"{'keyword': {0: '600 80'}, 'score': {0: 0.7813}}"
1464,1464,1464,0.8830000162124634,24.0,133 (17.9),MyriadPro-Light,4,-0.25,3355443,30,34,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   133  0.999757",[],"{'keyword': {0: '133 17'}, 'score': {0: 0.7952}}"
1465,1465,1465,0.8830000162124634,24.0,10 (1.3),MyriadPro-Light,4,-0.25,3355443,30,34,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value    10  0.99962",[],"{'keyword': {}, 'score': {}}"
1466,1466,1466,0.9890000224113464,24.0,"Neoadjuvant HER2-targeted therapy, n (%)",MyriadPro-Bold,20,-0.25,3355443,30,35,0,"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Neoadjuvant Therapy'}, 'aliases': {0: ['Preoperative Therapy', 'Therapy, Neoadjuvant', 'neoadjuvant treatment', 'Neoadjuvant Treatment', 'Neoadjuvant Treatments', 'Neoadjuvant Therapies', 'Neoadjuvant', 'Induction Therapy', 'Neoadjuvant Therapy', 'induction therapy', 'Treatment, Neoadjuvant', 'neoadjuvant therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'Neoadjuvant HER2-targeted therapy'}, 'text': {0: 'Neoadjuvant HER2-targeted therapy, n (%)'}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'Neoadjuvant HER2-targeted therapy'}, 'text': {0: 'Neoadjuvant HER2-targeted therapy, n (%)'}}",{},{},{},"           entity_group        value     score
0  Detailed_description  Neoadjuvant  0.999514",[],"{'keyword': {0: 'neoadjuvant her2 targeted', 1: 'targeted therapy', 2: 'her2 targeted therapy', 3: 'her2 targeted', 4: 'neoadjuvant her2'}, 'score': {0: 0.8749, 1: 0.7781, 2: 0.7632, 3: 0.7236, 4: 0.7201}}"
1467,1467,1467,0.8830000162124634,24.0,Trastuzumab alone,MyriadPro-Light,4,-0.25,3355443,30,35,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab alone'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab alone'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab alone'}}",{},{},"           entity_group        value     score
0            Medication  Trastuzumab  0.999842
1  Detailed_description        alone  0.629467","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
1468,1468,1468,0.8830000162124634,24.0,PERJETA-trastuzumab,MyriadPro-Light,4,-0.25,3355443,30,35,2,{},{},{},{},{},"  entity_group                value     score
0   Medication  PERJETA-trastuzumab  0.999753","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'perjeta trastuzumab'}, 'score': {0: 0.9207}}"
1469,1469,1469,0.8830000162124634,24.0,Trastuzumab plus other HER2-targeted therapy,MyriadPro-Light,4,-0.25,3355443,30,35,3,"{'concept_id': {0: 'C2985566'}, 'canonical_name': {0: 'Targeted Therapy'}, 'aliases': {0: ['targeted therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.'}, 'entity': {0: 'HER2-targeted therapy'}, 'text': {0: 'Trastuzumab plus other HER2-targeted therapy'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab plus other HER2-targeted therapy'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab plus other HER2-targeted therapy'}}",{},{},"            entity_group          value     score
0             Medication    Trastuzumab  0.999873
1   Detailed_description  HER2-targeted  0.893456
2  Therapeutic_procedure        therapy  0.989577","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab plus her2', 1: 'trastuzumab plus', 2: 'plus her2 targeted', 3: 'plus her2', 4: 'targeted therapy'}, 'score': {0: 0.9051, 1: 0.9037, 2: 0.8756, 3: 0.8379, 4: 0.7659}}"
1470,1470,1470,0.8830000162124634,19.952899932861328,*Race or ethnic group was reported by the ,MyriadPro-Light,4,-0.25,5723991,30,40,0,"{'concept_id': {0: 'C0018422'}, 'canonical_name': {0: 'Roma ethnic group'}, 'aliases': {0: ['Roma (ethnic group)', 'Gypsies', 'Gipsy', 'Gypsies (ethnic group)', 'Gipsies', 'Romanies', 'Gypsy', 'Romani', 'gypsy', 'Romany', 'gypsies', 'Roma']}, 'types': {0: ['T098']}, 'definition': {0: 'Ethnic group originating in India and entering Europe in the 14th or 15th century.'}, 'entity': {0: 'ethnic group'}, 'text': {0: '*Race or ethnic group was reported by the '}}","{'concept_id': {0: 'C5441552'}, 'canonical_name': {0: 'Ethnic Group'}, 'aliases': {0: ['Ethnic Groups']}, 'types': {0: ['T098']}, 'definition': {0: 'a group of people with a common cultural heritage that sets them apart from others in a variety of social relationships.'}, 'entity': {0: 'ethnic group'}, 'text': {0: '*Race or ethnic group was reported by the '}}",{},{},{},"     entity_group             value     score
0         History  Race or reported  0.562348
1  Family_history      ethnic group  0.683429",[],"{'keyword': {0: 'race ethnic group', 1: 'ethnic group reported', 2: 'group reported', 3: 'ethnic group', 4: 'race ethnic'}, 'score': {0: 0.82, 1: 0.819, 2: 0.8095, 3: 0.7849, 4: 0.7723}}"
1471,1471,1471,0.8830000162124634,19.952899932861328,investigators.,MyriadPro-Light,4,-0.25,5723991,30,40,1,"{'concept_id': {0: 'C1261322'}, 'canonical_name': {0: 'Evaluation procedure'}, 'aliases': {0: ['assessment', 'Evaluation - action', 'Evaluation procedure', 'Assessment', 'clinical investigation', 'evaluation', 'assessment procedure', 'Evaluation procedure (procedure)', 'Evaluation - action (qualifier value)', 'Investigations', 'Investigation', 'Evaluation', 'Patient evaluation - action', 'Assessment Procedures', 'assessments', 'Clinical evaluation']}, 'types': {0: ['T058']}, 'definition': {0: 'The act or process of a systematic and thorough examination; research, study; the process of inquiring into or following up, intended to develop facts.'}, 'entity': {0: 'investigators'}, 'text': {0: 'investigators.'}}","{'concept_id': {0: 'C0035173'}, 'canonical_name': {0: 'Researcher'}, 'aliases': {0: ['Investigator', 'Investigators', 'Researchers', 'Personnel, Research', 'Research Personnel']}, 'types': {0: ['T097']}, 'definition': {0: 'Those individuals engaged in research.'}, 'entity': {0: 'investigators'}, 'text': {0: 'investigators.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1472,1472,1472,0.8830000162124634,19.952899932861328,"†The American Indian category includes North, ",MyriadPro-Light,4,-0.25,5723991,30,40,2,"{'concept_id': {0: 'C3658205'}, 'canonical_name': {0: 'Asia, Northern'}, 'aliases': {0: ['North Asia', 'Northern Asia']}, 'types': {0: ['T083']}, 'definition': {0: 'A subregion of Asia, consisting of Asian portion of Russia.'}, 'entity': {0: 'North'}, 'text': {0: '†The American Indian category includes North, '}}","{'concept_id': {0: 'C5690840'}, 'canonical_name': {0: 'North Asian People'}, 'aliases': {0: ['North Asians', 'Person, Northern Asian', 'Asian, North', 'Asian People, North', 'Northern Asian Peoples', 'Northern Asian Person', 'Northern Asian Persons', 'Asian, Northern', 'Asian Person, North', 'North Asian Person', 'Peoples, North Asian', 'People, Northern Asian', 'People, North Asian', 'Asian Person, Northern', 'Northern Asian People', 'Person, North Asian', 'North Asian Peoples', 'Northern Asians', 'Persons, Northern Asian', 'North Asian Persons']}, 'types': {0: ['T098']}, 'definition': {0: 'People native to or inhabitants of the NORTHERN ASIA including SIBERIA .'}, 'entity': {0: 'North'}, 'text': {0: '†The American Indian category includes North, '}}",{},{},{},"           entity_group     value     score
0  Detailed_description  American  0.691735
1   Personal_background    Indian  0.351237",[],"{'keyword': {0: 'category includes north', 1: 'american indian category', 2: 'american indian', 3: 'indian category includes', 4: 'category includes'}, 'score': {0: 0.7951, 1: 0.794, 2: 0.7694, 3: 0.7526, 4: 0.602}}"
1473,1473,1473,0.8830000162124634,19.952899932861328,"Central, and South American Indians.",MyriadPro-Light,4,-0.25,5723991,30,40,3,"{'concept_id': {0: 'C2699496'}, 'canonical_name': {0: 'South or Central American Indian'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Denotes a person having origins in one of the indigenous people of South or Central America such as Mayans or Incas.'}, 'entity': {0: 'South American Indians'}, 'text': {0: 'Central, and South American Indians.'}}","{'concept_id': {0: 'C0002460'}, 'canonical_name': {0: 'Indians, American'}, 'aliases': {0: ['American Indian', 'American Indians']}, 'types': {0: ['T098']}, 'definition': {0: 'Denotes a person having origins in one of the indigenous peoples of North America, who lived on the continent prior to the European colonization. The term includes individuals belonging to a large number of tribes, states, and ethnic groups, many of them still enduring as communities.'}, 'entity': {0: 'South American Indians'}, 'text': {0: 'Central, and South American Indians.'}}",{},{},"{'concept_id': {0: 'C0205099'}, 'canonical_name': {0: 'Central'}, 'aliases': {0: []}, 'types': {0: ['T082']}, 'definition': {0: 'A point or area that is approximately central within some larger region or structure.'}, 'entity': {0: 'Central'}, 'text': {0: 'Central, and South American Indians.'}}","           entity_group  value     score
0  Detailed_description  South  0.521091",[],"{'keyword': {0: 'south american indians', 1: 'central south american', 2: 'american indians', 3: 'south american', 4: 'central south'}, 'score': {0: 0.8914, 1: 0.8603, 2: 0.8564, 3: 0.8121, 4: 0.7297}}"
1474,1474,1474,0.8830000162124634,19.952899932861328,‡Inoperable breast cancer was defined as ,MyriadPro-Light,4,-0.25,5723991,30,40,4,"{'concept_id': {0: 'C0376571'}, 'canonical_name': {0: 'BRCA1 gene'}, 'aliases': {0: ['BRCA1, DNA Repair Associated Gene', 'brca1', 'Gene, BRCA1', 'FANCS', 'BRCA1 gene', 'BRCA1 Gene', 'BRCA1 DNA REPAIR-ASSOCIATED PROTEIN', 'brca1 gene', 'Fanconi anemia, complementation group S', 'BRCA1/BRCA2-containing complex, subunit 1', 'Genes, BRCA1', 'BRCA1 DNA repair associated', 'RNF53', 'BRCC1', 'BRCA1', 'Breast Cancer 1, Early Onset Gene', 'BREAST CANCER 1 GENE', 'breast cancer 1', 'PPP1R53', 'brca 1 gene', 'breast cancer 1, early onset', 'BRCA1 Genes', 'protein phosphatase 1, regulatory subunit 53']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.'}, 'entity': {0: 'breast cancer'}, 'text': {0: '‡Inoperable breast cancer was defined as '}}","{'concept_id': {0: 'C0294028'}, 'canonical_name': {0: 'Breast Cancer 2 Protein'}, 'aliases': {0: ['Fanconi Anemia Complementation Group D1 Protein', 'Fanconi Anemia Group D1 Protein', 'FANCD1 Protein', 'BRCA2 Protein', 'Fanconi Anemia Group D1 Complementing Protein', 'BRCA2 Gene Product', 'Breast Cancer 2 Gene Product']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)'}, 'entity': {0: 'breast cancer'}, 'text': {0: '‡Inoperable breast cancer was defined as '}}",{},{},"{'concept_id': {0: 'C0006826'}, 'canonical_name': {0: 'Cancer'}, 'aliases': {0: []}, 'types': {0: ['T191']}, 'definition': {0: 'A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.'}, 'entity': {0: 'breast cancer'}, 'text': {0: '‡Inoperable breast cancer was defined as '}}","           entity_group          value     score
0  Detailed_description    ‡Inoperable  0.999717
1      Disease_disorder  breast cancer  0.990994",[],"{'keyword': {0: 'inoperable breast cancer', 1: 'inoperable breast', 2: 'breast cancer defined', 3: 'breast cancer', 4: 'cancer defined'}, 'score': {0: 0.8665, 1: 0.7948, 2: 0.762, 3: 0.6778, 4: 0.6168}}"
1475,1475,1475,0.8830000162124634,19.952899932861328,"tumour stage T4, ",MyriadPro-Light,4,-0.25,5723991,30,40,5,"{'concept_id': {0: 'C0475395'}, 'canonical_name': {0: 'Tumor stage T4a'}, 'aliases': {0: ['T4a', 'T4a Tumor Stage', 'T4a Primary Tumor Finding', 'T4a Primary Tumor Stage Finding', 'Tumour stage T4a', 'T4a TNM Finding', 'T4a Stage', 'T4a Stage Finding', 'Tumor Stage T4a', 'T4a Cancer Stage Finding', 'T4a Tumor Finding', 'Tumor stage T4a (finding)']}, 'types': {0: ['T033']}, 'definition': {0: 'A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4a TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the prostatic stroma, uterus, and vagina; for gastric cancer it refers to a primary tumor that invades the serosa (visceral peritoneum); for colorectal cancer it refers to a primary tumor that penetrates to the surface of the visceral peritoneum.'}, 'entity': {0: 'tumour stage T4'}, 'text': {0: 'tumour stage T4, '}}",{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'tumour stage t4', 1: 'stage t4', 2: 'tumour stage'}, 'score': {0: 0.9729, 1: 0.9023, 2: 0.8528}}"
1476,1476,1476,0.8830000162124634,19.952899932861328,"stage M0 or tumour stage Tx, nodal stage N2 or ",MyriadPro-Light,4,-0.25,5723991,30,40,6,"{'concept_id': {0: 'C0441960'}, 'canonical_name': {0: 'N2 category (finding)'}, 'aliases': {0: ['N2 Lymph Node Finding', 'N2 Regional Lymph Node Stage Finding', 'N2 Stage', 'Node Stage N2', 'N2', 'N2 Node Finding', 'N2 Cancer Stage Finding', 'N2 TNM Finding', 'Lymph Node Stage N2', 'Node stage N2', 'N2 Regional Lymph Nodes Finding', 'N2 Stage Finding', 'N2 Lymph Node Stage', 'N2 category', 'N2 category (finding)', 'N2 Node Stage', 'N2 stage']}, 'types': {0: ['T033']}, 'definition': {0: 'A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes. The definition of N2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4-9 axillary lymph nodes; for cutaneous melanoma it refers to metastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4 or more regional lymph nodes; and for bladder cancer it refers to metastases in multiple regional lymph nodes in the true pelvis.'}, 'entity': {0: 'nodal stage N2'}, 'text': {0: 'stage M0 or tumour stage Tx, nodal stage N2 or '}}",{},{},{},"{'concept_id': {0: 'C0027651'}, 'canonical_name': {0: 'Oncology'}, 'aliases': {0: ['Oncological abnormality', 'Neoplasia', 'Tumour', 'Neoplasm', 'Tumor']}, 'types': {0: ['T191']}, 'definition': {0: 'New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.'}, 'entity': {0: 'tumour stage'}, 'text': {0: 'stage M0 or tumour stage Tx, nodal stage N2 or '}}","           entity_group                       value     score
0  Detailed_description        stage stage stage M0  0.964901
1  Detailed_description                      tumour  0.943368
2          Sign_symptom                      tumour  0.990943
3  Detailed_description  nodal stage stage stage N2  0.998569",[],"{'keyword': {0: 'stage m0', 1: 'stage m0 tumour', 2: 'm0 tumour stage', 3: 'm0 tumour', 4: 'stage tx nodal'}, 'score': {0: 0.952, 1: 0.8968, 2: 0.8781, 3: 0.7514, 4: 0.3239}}"
1477,1477,1477,0.8830000162124634,19.952899932861328,"N3, and metastasis  ",MyriadPro-Light,4,-0.25,5723991,30,40,7,"{'concept_id': {0: 'C2939419'}, 'canonical_name': {0: 'Secondary Neoplasm'}, 'aliases': {0: ['Secondary malignant neoplastic disease (disorder)', 'Secondary malignancies', 'Metastasis', 'Metastases', 'Tumor metastasis', 'Metastatic neoplasm (disease)', 'Metastatic Malignant Neoplasm', 'Secondary Tumor', 'secondary neoplasm', 'Secondary tumour', 'Secondary tumor', 'Secondary neoplasm', 'Secondary malignant neoplastic disease', 'Metastatic neoplasm', 'Tumour metastasis', 'CA - Secondary cancer', 'Secondary malignant deposit', 'Secondaries', 'Secondary cancer', 'Metastatic malignant disease', 'Metastatic Cancer', 'Metastatic cancer', 'Secondary Neoplasm', 'Metastatic disease']}, 'types': {0: ['T191']}, 'definition': {0: 'A malignant tumor that has spread from its original (primary) site of growth to another site close to or distant from the primary site.'}, 'entity': {0: 'metastasis'}, 'text': {0: 'N3, and metastasis  '}}","{'concept_id': {0: 'C1513276'}, 'canonical_name': {0: 'Neoplasm Micrometastasis'}, 'aliases': {0: ['Micrometastases, Neoplasm', 'Micrometastasis, Neoplasm', 'Neoplasm Micrometastase', 'Micrometastases', 'Micrometastasis', 'Neoplasm Micrometastases', 'Micrometastase, Neoplasm']}, 'types': {0: ['T033']}, 'definition': {0: 'Newly arising secondary tumors so small they are difficult to detect by physical examination or routine imaging techniques.'}, 'entity': {0: 'metastasis'}, 'text': {0: 'N3, and metastasis  '}}",{},{},{},"   entity_group       value     score
0  Sign_symptom  metastasis  0.997276",[],"{'keyword': {0: 'n3 metastasis'}, 'score': {0: 0.8743}}"
1478,1478,1478,0.8830000162124634,19.952899932861328,stage M0.,MyriadPro-Light,4,-0.25,5723991,30,40,8,"{'concept_id': {0: 'C5670635'}, 'canonical_name': {0: 'Stage M0 Pineoblastoma'}, 'aliases': {0: []}, 'types': {0: ['T185']}, 'definition': {0: 'No evidence of subarachnoid or hematogenous metastasis.'}, 'entity': {0: 'stage M0'}, 'text': {0: 'stage M0.'}}",{},{},{},"{'concept_id': {0: 'C4703697'}, 'canonical_name': {0: 'Retinopathy of prematurity stage 5b'}, 'aliases': {0: ['ROP stage 5b']}, 'types': {0: ['T047']}, 'definition': {0: 'A closed funnel detachment of the retina with generally traction in all four quadrants. [ISBN:978-3-319-52190-9]'}, 'entity': {0: 'stage M0'}, 'text': {0: 'stage M0.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'stage m0'}, 'score': {0: 0.9723}}"
1479,1479,1479,0.8830000162124634,19.952899932861328,§Operable breast cancer was defined as tumour ,MyriadPro-Light,4,-0.25,5723991,30,40,9,"{'concept_id': {0: 'C0013449'}, 'canonical_name': {0: 'Ear Neoplasms'}, 'aliases': {0: ['Neoplasm of ear (disorder)', 'Ear Tumor', 'Neoplasm of the ear', 'Tumor of the Ear', 'Ear Neoplasms', 'Tumor of Ear', 'Neoplasms, Ear', 'Aural neoplasm', 'Ear tumor', 'Ear--Tumors', 'Neoplasm of ear', 'Neoplasm, Ear', 'Ear Neoplasm', 'Ear tumour', 'ear neoplasm', 'Neoplasm of the Ear', 'Neoplasm of Ear']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR).'}, 'entity': {0: 'tumour'}, 'text': {0: '§Operable breast cancer was defined as tumour '}}","{'concept_id': {0: 'C0294028'}, 'canonical_name': {0: 'Breast Cancer 2 Protein'}, 'aliases': {0: ['Fanconi Anemia Complementation Group D1 Protein', 'Fanconi Anemia Group D1 Protein', 'FANCD1 Protein', 'BRCA2 Protein', 'Fanconi Anemia Group D1 Complementing Protein', 'BRCA2 Gene Product', 'Breast Cancer 2 Gene Product']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)'}, 'entity': {0: 'breast cancer'}, 'text': {0: '§Operable breast cancer was defined as tumour '}}",{},"{'concept_id': {0: 'C1819848'}, 'canonical_name': {0: 'positive regulation of response to tumor cell'}, 'aliases': {0: ['up regulation of response to tumor cell', 'positive regulation of response to tumour cell', 'upregulation of response to tumor cell', 'up-regulation of response to tumor cell']}, 'types': {0: ['T039']}, 'definition': {0: 'Any process that activates or increases the frequency, rate, or extent of a response to tumor cell. [GOC:add]'}, 'entity': {0: 'tumour'}, 'text': {0: '§Operable breast cancer was defined as tumour '}}","{'concept_id': {0: 'C0023761'}, 'canonical_name': {0: 'Lip tumor'}, 'aliases': {0: ['Tumor of the lip', 'Neoplasm of the lip', 'Tumour of the lip', 'Lip tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the LIP.'}, 'entity': {0: 'tumour'}, 'text': {0: '§Operable breast cancer was defined as tumour '}}","           entity_group          value     score
0  Detailed_description      §Operable  0.949398
1      Disease_disorder  breast cancer  0.993496
2          Sign_symptom         tumour  0.999757",[],"{'keyword': {0: 'operable breast', 1: 'breast cancer defined', 2: 'cancer defined tumour', 3: 'breast cancer', 4: 'cancer defined'}, 'score': {0: 0.8451, 1: 0.8236, 2: 0.8186, 3: 0.7037, 4: 0.6671}}"
1480,1480,1480,0.8830000162124634,19.952899932861328,"stage T1 to T3, nodal stage N0 or N1, and ",MyriadPro-Light,4,-0.25,5723991,30,40,10,"{'concept_id': {0: 'C5441538'}, 'canonical_name': {0: 'N1 (Mild nonalcoholic steatohepatitis)'}, 'aliases': {0: ['N1']}, 'types': {0: ['T033']}, 'definition': {0: 'Mild nonalcoholic steatohepatitis'}, 'entity': {0: 'N1'}, 'text': {0: 'stage T1 to T3, nodal stage N0 or N1, and '}}","{'concept_id': {0: 'C0108779'}, 'canonical_name': {0: 'T3 Antigen'}, 'aliases': {0: ['Antigens, CD3', 'CD3 Antigen', 'T3 Complex', 'Antigens, T3', 'T3 Antigens', 'CD3 Complex', 'CD3 Antigens', 'Antigen, T3', 'Antigen, CD3']}, 'types': {0: ['T116', 'T129']}, 'definition': {0: 'Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).'}, 'entity': {0: 'T3'}, 'text': {0: 'stage T1 to T3, nodal stage N0 or N1, and '}}",{},{},"{'concept_id': {0: 'C4703697'}, 'canonical_name': {0: 'Retinopathy of prematurity stage 5b'}, 'aliases': {0: ['ROP stage 5b']}, 'types': {0: ['T047']}, 'definition': {0: 'A closed funnel detachment of the retina with generally traction in all four quadrants. [ISBN:978-3-319-52190-9]'}, 'entity': {0: 'stage T1'}, 'text': {0: 'stage T1 to T3, nodal stage N0 or N1, and '}}","           entity_group        value     score
0  Detailed_description  stage stage  0.718629
1  Detailed_description        nodal  0.979935",[],"{'keyword': {0: 'stage n0 n1', 1: 'stage t1 t3', 2: 't1 t3 nodal', 3: 't1 t3', 4: 't3 nodal'}, 'score': {0: 0.9335, 1: 0.8951, 2: 0.7658, 3: 0.7223, 4: 0.5767}}"
1481,1481,1481,0.8830000162124634,19.952899932861328,metastasis stage M0.,MyriadPro-Light,4,-0.25,5723991,30,40,11,"{'concept_id': {0: 'C0456533'}, 'canonical_name': {0: 'M - Metastasis stages'}, 'aliases': {0: ['M - Metastasis stages', 'M category', 'M Category', 'Metastasis stages', 'metastasis staging', 'M Classification', 'stage m', 'M category (observable entity)', 'm category', 'M stage']}, 'types': {0: ['T185']}, 'definition': {0: 'One criteria of the TNM staging system. M refers to the presence of metastasis.'}, 'entity': {0: 'metastasis stage M0'}, 'text': {0: 'metastasis stage M0.'}}","{'concept_id': {0: 'C0027627'}, 'canonical_name': {0: 'Neoplasm Metastases'}, 'aliases': {0: ['Neoplasm Metastasis', 'Metastases, Neoplasm', 'Metastase', 'Metastases', 'Metastasis, Neoplasm', 'Metastasis']}, 'types': {0: ['T191']}, 'definition': {0: 'The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.'}, 'entity': {0: 'metastasis stage M0'}, 'text': {0: 'metastasis stage M0.'}}",{},{},{},"       entity_group             value     score
0      Sign_symptom        metastasis  0.967942
1  Disease_disorder  metastasis stage  0.342263",[],"{'keyword': {0: 'metastasis stage m0', 1: 'stage m0', 2: 'metastasis stage'}, 'score': {0: 0.9732, 1: 0.8807, 2: 0.63}}"
1482,1482,1482,0.8830000162124634,19.952899932861328,¶If extensive axillary evaluation was done prior ,MyriadPro-Light,4,-0.25,5723991,30,40,12,{},{},{},{},{},"           entity_group                value     score
0  Detailed_description            extensive  0.966233
1  Diagnostic_procedure             axillary  0.999902
2  Diagnostic_procedure  axillary evaluation  0.999377
3                  Date                prior  0.974748",[],"{'keyword': {0: 'axillary evaluation prior', 1: 'evaluation prior', 2: 'axillary evaluation', 3: 'extensive axillary', 4: 'extensive axillary evaluation'}, 'score': {0: 0.7442, 1: 0.715, 2: 0.6823, 3: 0.6773, 4: 0.5802}}"
1483,1483,1483,0.8830000162124634,19.952899932861328,to neoadjuvant therapy or if sentinel lymph ,MyriadPro-Light,4,-0.25,5723991,30,40,13,"{'concept_id': {0: 'C0796693'}, 'canonical_name': {0: 'Sentinel Lymph Node Biopsy'}, 'aliases': {0: ['Sentinel node biopsy', 'Sentinel Lymph Node Biopsy', 'Biopsy, Sentinel Lymph Node', 'sentinel lymph node biopsy', 'Sentinel lymph node biopsy (procedure)', 'biopsies node sentinel', 'biopsy node sentinels', 'biopsy sentinel node', 'Sentinel lymph node biopsy', 'Lymph Node Biopsy, Sentinel', 'Sentinel Node Biopsy', 'biopsy node sentinel', 'sentinel node biopsy']}, 'types': {0: ['T060']}, 'definition': {0: 'A diagnostic procedure used to determine whether LYMPHATIC METASTASIS has occurred. The SENTINEL LYMPH NODE is the first lymph node to receive drainage from a neoplasm.'}, 'entity': {0: 'sentinel lymph'}, 'text': {0: 'to neoadjuvant therapy or if sentinel lymph '}}","{'concept_id': {0: 'C0024202'}, 'canonical_name': {0: 'Lymph'}, 'aliases': {0: ['Lymphs']}, 'types': {0: ['T031']}, 'definition': {0: 'The interstitial fluid that is in the LYMPHATIC SYSTEM.'}, 'entity': {0: 'sentinel lymph'}, 'text': {0: 'to neoadjuvant therapy or if sentinel lymph '}}",{},{},{},"            entity_group           value     score
0             Medication     neoadjuvant  0.592046
1  Therapeutic_procedure     neoadjuvant  0.623801
2  Therapeutic_procedure         therapy  0.715589
3   Biological_structure  sentinel lymph  0.999735",[],"{'keyword': {0: 'sentinel lymph', 1: 'neoadjuvant therapy sentinel', 2: 'neoadjuvant therapy', 3: 'therapy sentinel', 4: 'therapy sentinel lymph'}, 'score': {0: 0.8743, 1: 0.8716, 2: 0.8535, 3: 0.821, 4: 0.7739}}"
1484,1484,1484,0.8830000162124634,19.952899932861328,nodes were evaluated before neoadjuvant ,MyriadPro-Light,4,-0.25,5723991,30,40,14,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'nodes were evaluated before neoadjuvant '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'nodes were evaluated before neoadjuvant '}}",{},{},{},"           entity_group        value     score
0  Diagnostic_procedure        nodes  0.998298
1  Diagnostic_procedure    evaluated  0.968546
2  Detailed_description  neoadjuvant  0.800057",[],"{'keyword': {0: 'nodes evaluated neoadjuvant', 1: 'nodes evaluated', 2: 'evaluated neoadjuvant'}, 'score': {0: 0.8614, 1: 0.7062, 2: 0.6582}}"
1485,1485,1485,0.8830000162124634,19.952899932861328,therapy and were found not to involve tumour ,MyriadPro-Light,4,-0.25,5723991,30,40,15,"{'concept_id': {0: 'C0013449'}, 'canonical_name': {0: 'Ear Neoplasms'}, 'aliases': {0: ['Neoplasm of ear (disorder)', 'Ear Tumor', 'Neoplasm of the ear', 'Tumor of the Ear', 'Ear Neoplasms', 'Tumor of Ear', 'Neoplasms, Ear', 'Aural neoplasm', 'Ear tumor', 'Ear--Tumors', 'Neoplasm of ear', 'Neoplasm, Ear', 'Ear Neoplasm', 'Ear tumour', 'ear neoplasm', 'Neoplasm of the Ear', 'Neoplasm of Ear']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR).'}, 'entity': {0: 'tumour'}, 'text': {0: 'therapy and were found not to involve tumour '}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and were found not to involve tumour '}}",{},"{'concept_id': {0: 'C1819848'}, 'canonical_name': {0: 'positive regulation of response to tumor cell'}, 'aliases': {0: ['up regulation of response to tumor cell', 'positive regulation of response to tumour cell', 'upregulation of response to tumor cell', 'up-regulation of response to tumor cell']}, 'types': {0: ['T039']}, 'definition': {0: 'Any process that activates or increases the frequency, rate, or extent of a response to tumor cell. [GOC:add]'}, 'entity': {0: 'tumour'}, 'text': {0: 'therapy and were found not to involve tumour '}}","{'concept_id': {0: 'C0023761'}, 'canonical_name': {0: 'Lip tumor'}, 'aliases': {0: ['Tumor of the lip', 'Neoplasm of the lip', 'Tumour of the lip', 'Lip tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the LIP.'}, 'entity': {0: 'tumour'}, 'text': {0: 'therapy and were found not to involve tumour '}}","   entity_group   value     score
0  Sign_symptom  tumour  0.903021",[],"{'keyword': {0: 'involve tumour', 1: 'therapy involve', 2: 'therapy involve tumour'}, 'score': {0: 0.4089, 1: 0.3913, 2: 0.3864}}"
1486,1486,1486,0.8830000162124634,19.952899932861328,"or had only micrometastases, further axillary ",MyriadPro-Light,4,-0.25,5723991,30,40,16,"{'concept_id': {0: 'C0238729'}, 'canonical_name': {0: 'Mass of axilla'}, 'aliases': {0: ['Lump of axilla', 'Axillary Mass', 'Mass of axilla (finding)', 'axillary lumps', 'axillary lump', 'axilla mass', 'AXILLARY MASS', 'axilla lump', 'mass axilla', 'axillary mass']}, 'types': {0: ['T033']}, 'definition': {0: 'An abnormal growth in the axilla.'}, 'entity': {0: 'axillary'}, 'text': {0: 'or had only micrometastases, further axillary '}}","{'concept_id': {0: 'C0004454'}, 'canonical_name': {0: 'Underarm'}, 'aliases': {0: ['Axilla', 'Armpit']}, 'types': {0: ['T029']}, 'definition': {0: 'Area of the human body underneath the SHOULDER JOINT, also known as the armpit or underarm.'}, 'entity': {0: 'axillary'}, 'text': {0: 'or had only micrometastases, further axillary '}}",{},{},"{'concept_id': {0: 'C1859392'}, 'canonical_name': {0: 'Absent axillary hair'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Absence of axillary hair. [HPO:probinson]'}, 'entity': {0: 'axillary'}, 'text': {0: 'or had only micrometastases, further axillary '}}","           entity_group            value     score
0  Detailed_description  micrometastases  0.989099
1  Biological_structure         axillary  0.950540",[],"{'keyword': {0: 'micrometastases axillary'}, 'score': {0: 0.8548}}"
1487,1487,1487,0.8830000162124634,19.952899932861328,evaluation was not required and the patient was ,MyriadPro-Light,4,-0.25,5723991,30,40,17,"{'concept_id': {0: 'C1578481'}, 'canonical_name': {0: 'Mail Claim Party - Patient'}, 'aliases': {0: ['Patient']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'patient'}, 'text': {0: 'evaluation was not required and the patient was '}}","{'concept_id': {0: 'C4277550'}, 'canonical_name': {0: 'Patient Portals'}, 'aliases': {0: ['Patient Internet Portals', 'Web Portals, Patient', 'Web Portal, Patient', 'Patient Internet Portal', 'Portals, Patient Web', 'Portal, Patient Web', 'Portal, Patient Internet', 'Patient Web Portals', 'Internet Portal, Patient', 'Internet Portals, Patient', 'Patient Portal', 'Patient Web Portal', 'Portals, Patient Internet', 'Portal, Patient']}, 'types': {0: ['T170']}, 'definition': {0: 'A secure online website that provides patients convenient 24-hour access to personal health information via an Internet connection.'}, 'entity': {0: 'patient'}, 'text': {0: 'evaluation was not required and the patient was '}}",{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  evaluation  0.999628",[],"{'keyword': {0: 'required patient', 1: 'evaluation required patient', 2: 'evaluation required'}, 'score': {0: 0.4232, 1: 0.3896, 2: 0.3458}}"
1488,1488,1488,0.8830000162124634,19.952899932861328,classified as “not done” with respect to this ,MyriadPro-Light,4,-0.25,5723991,30,40,18,{},{},{},{},{},"  entity_group value     score
0  Coreference  this  0.904218",[],"{'keyword': {0: 'classified respect'}, 'score': {0: 0.6664}}"
1489,1489,1489,0.8830000162124634,19.952899932861328,variable.,MyriadPro-Light,4,-0.25,5723991,30,40,19,"{'concept_id': {0: 'C1706317'}, 'canonical_name': {0: 'Long Variable'}, 'aliases': {0: ['Long Value', 'Long Variable', 'Long Data Type', 'Long']}, 'types': {0: ['T080']}, 'definition': {0: 'A variable that is stored as a signed 64-bit (8-byte) integer.'}, 'entity': {0: 'variable'}, 'text': {0: 'variable.'}}","{'concept_id': {0: 'C0877857'}, 'canonical_name': {0: 'Immunoglobulin Variable Region'}, 'aliases': {0: ['Variable Regions, Immunoglobulin', 'Regions, Immunoglobulin Variable', 'Immunoglobulin Variable Regions', 'Variable Regions, Ig', 'Immunoglobulin V', 'Ig Variable Regions', 'Variable Region, Ig', 'Variable Region, Immunoglobulin', 'Ig Variable Region']}, 'types': {0: ['T116', 'T129']}, 'definition': {0: 'That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.'}, 'entity': {0: 'variable'}, 'text': {0: 'variable.'}}",{},{},"{'concept_id': {0: 'C1861403'}, 'canonical_name': {0: 'Variable expressivity'}, 'aliases': {0: ['Variable severity']}, 'types': {0: ['T033']}, 'definition': {0: 'A variable severity of phenotypic features. [HPO:probinson]'}, 'entity': {0: 'variable'}, 'text': {0: 'variable.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1490,1490,1490,0.8830000162124634,19.952899932861328,"#Other HER2-targeted agents were neratinib, ",MyriadPro-Light,4,-0.25,5723991,30,40,20,"{'concept_id': {0: 'C5204928'}, 'canonical_name': {0: 'Neratinib Regimen'}, 'aliases': {0: ['Nerlynx Regimen', 'Neratinib Maleate Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemotherapy regimen consisting of neratinib that may be used in the treatment of HER2-positive breast cancer.'}, 'entity': {0: 'neratinib'}, 'text': {0: '#Other HER2-targeted agents were neratinib, '}}","{'concept_id': {0: 'C4080091'}, 'canonical_name': {0: 'lorlatinib'}, 'aliases': {0: ['(10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile', 'loratinib']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.'}, 'entity': {0: 'neratinib'}, 'text': {0: '#Other HER2-targeted agents were neratinib, '}}","{'concept_id': {0: 'C4519542'}, 'canonical_name': {0: 'neratinib maleate'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'The maleate salt form of neratinib, an orally available, quinazoline-based, irreversible inhibitor of both the receptor tyrosine kinases (RTKs) human epidermal growth factor receptor 2 (HER2; ERBB2) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, neratinib targets and covalently binds to the cysteine residue in the ATP-binding pockets of both HER2 and EGFR. This inhibits their activity and results in the inhibition of downstream signal transduction events, induces cell cycle arrest, apoptosis and ultimately decreases cellular proliferation in HER2- and EGFR-expressing tumor cells. EGFR and HER2, RTKs that are mutated or overactivated in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization.'}, 'entity': {0: 'neratinib'}, 'text': {0: '#Other HER2-targeted agents were neratinib, '}}",{},{},"  entity_group          value     score
0   Medication  HER2-targeted  0.681600
1   Medication      neratinib  0.998868","[('neratinib', 'DRUG')]","{'keyword': {0: 'targeted agents neratinib', 1: 'her2 targeted agents', 2: 'targeted agents', 3: 'her2 targeted', 4: 'agents neratinib'}, 'score': {0: 0.8628, 1: 0.8311, 2: 0.8097, 3: 0.7928, 4: 0.7459}}"
1491,1491,1491,0.8830000162124634,19.952899932861328,"dacomitinib, afatinib, and lapatinib.",MyriadPro-Light,4,-0.25,5723991,30,40,21,"{'concept_id': {0: 'C5204913'}, 'canonical_name': {0: 'Lapatinib Regimen'}, 'aliases': {0: ['Tykerb Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemotherapy regimen consisting of lapatinib that may be used in the treatment of bone cancer.'}, 'entity': {0: 'lapatinib'}, 'text': {0: 'dacomitinib, afatinib, and lapatinib.'}}","{'concept_id': {0: 'C1504917'}, 'canonical_name': {0: 'Lapatinib Ditosylate'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.'}, 'entity': {0: 'lapatinib'}, 'text': {0: 'dacomitinib, afatinib, and lapatinib.'}}","{'concept_id': {0: 'C1506770'}, 'canonical_name': {0: 'lapatinib'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: 'A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.'}, 'entity': {0: 'lapatinib'}, 'text': {0: 'dacomitinib, afatinib, and lapatinib.'}}",{},{},"  entity_group               value     score
0   Medication         dacomitinib  0.998676
1   Medication            afatinib  0.999756
2   Medication  afatinib lapatinib  0.898509
3   Medication           lapatinib  0.999779","[('dacomitinib', 'DRUG'), ('afatinib', 'DRUG'), ('lapatinib', 'DRUG')]","{'keyword': {0: 'dacomitinib afatinib', 1: 'dacomitinib afatinib lapatinib', 2: 'afatinib lapatinib'}, 'score': {0: 0.7964, 1: 0.7807, 2: 0.7052}}"
1492,1492,1492,0.8830000162124634,19.952899932861328,"ER, oestrogen receptor; HR, hormone receptor; ",MyriadPro-Light,4,-0.25,5723991,30,40,22,"{'concept_id': {0: 'C1512496'}, 'canonical_name': {0: 'Hormone Receptor Test'}, 'aliases': {0: []}, 'types': {0: ['T059']}, 'definition': {0: 'A hormone receptor test measures the amount of certain hormone receptors proteins in cancer tissue. Hormones (such as estrogen and progesterone that naturally occur in the body) can attach to these proteins. If the test is positive, it indicates that the hormone is probably helping the cancer cells grow.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'ER, oestrogen receptor; HR, hormone receptor; '}}","{'concept_id': {0: 'C0034808'}, 'canonical_name': {0: 'Receptors, Gastrointestinal Hormone'}, 'aliases': {0: ['Gastrointestinal Peptides Receptors', 'Receptors, Intestinal Hormone', 'Gastrointestinal Hormone Receptors', 'Receptors, Gastrointestinal Peptides', 'Gastrointestinal Hormone Receptor', 'Gastrointestinal Hormones Receptors', 'Hormone Receptors, Intestinal', 'Peptides Receptors, Gastrointestinal', 'Hormone Receptor, Intestinal', 'Intestinal Hormone Receptors', 'Hormone Receptors, Gastrointestinal', 'Hormones Receptors, Gastrointestinal', 'Intestinal Hormone Receptor', 'Receptor, Intestinal Hormone', 'Hormone Receptor, Gastrointestinal', 'Receptors, Gastrointestinal Hormones', 'Receptor, Gastrointestinal Hormone']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: 'Cell surface proteins that bind gastrointestinal hormones with high affinity and trigger intracellular changes influencing the behavior of cells. Most gastrointestinal hormones also act as neurotransmitters so these receptors are also present in the central and peripheral nervous systems.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'ER, oestrogen receptor; HR, hormone receptor; '}}",{},"{'concept_id': {0: 'C1152812'}, 'canonical_name': {0: 'growth hormone receptor activity'}, 'aliases': {0: []}, 'types': {0: ['T044']}, 'definition': {0: 'Combining with a growth hormone and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. [GOC:ai, GOC:signaling]'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'ER, oestrogen receptor; HR, hormone receptor; '}}","{'concept_id': {0: 'C4722330'}, 'canonical_name': {0: 'Thyroid hormone receptor defect'}, 'aliases': {0: ['Thyroid hormone resistance', 'End-organ unresponsiveness to thyroid hormone', 'Elevated serum levels of free thyroid hormone with nonsuppressed TSH', 'Resistance to thyroid hormone', 'Impaired sensitivity to thyroid hormone']}, 'types': {0: ['T047']}, 'definition': {0: 'Decreased response to thyroid hormones in peripheral tissues and in the pituitary gland.'}, 'entity': {0: 'hormone receptor'}, 'text': {0: 'ER, oestrogen receptor; HR, hormone receptor; '}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'receptor hr hormone', 1: 'hormone receptor', 2: 'er oestrogen receptor', 3: 'hr hormone', 4: 'oestrogen receptor'}, 'score': {0: 0.9024, 1: 0.8545, 2: 0.8464, 3: 0.8031, 4: 0.7915}}"
1493,1493,1493,0.8830000162124634,19.952899932861328,"PR, progesterone receptor.",MyriadPro-Light,4,-0.25,5723991,30,40,23,"{'concept_id': {0: 'C4082178'}, 'canonical_name': {0: 'Progesterone Receptor, human'}, 'aliases': {0: ['PRB', 'PGR', 'Nuclear Receptor Subfamily 3 Group C Member 3', 'Progesterone Receptor Isoform B', 'Progesterone Receptor B', 'PgR', 'Progesterone Receptor']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: 'Progesterone receptor (933 aa, ~99 kDa) is encoded by the human PGR gene. This protein is involved in the regulation of transcription.'}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'PR, progesterone receptor.'}}","{'concept_id': {0: 'C0385053'}, 'canonical_name': {0: 'progesterone receptors B'}, 'aliases': {0: ['progesterone receptor B', 'receptor B, progesterone']}, 'types': {0: ['T116', 'T192']}, 'definition': {0: None}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'PR, progesterone receptor.'}}",{},"{'concept_id': {0: 'C1157305'}, 'canonical_name': {0: 'progesterone biosynthetic process'}, 'aliases': {0: ['progesterone anabolism', 'progesterone formation', 'progesterone synthesis', 'progesterone biosynthesis']}, 'types': {0: ['T044']}, 'definition': {0: 'The chemical reactions and pathways resulting in the formation of progesterone, a steroid hormone produced in the ovary which prepares and maintains the uterus for pregnancy. Also found in plants. [GOC:jl, http://www.cogsci.princeton.edu/]'}, 'entity': {0: 'progesterone receptor'}, 'text': {0: 'PR, progesterone receptor.'}}",{},"Empty DataFrame
Columns: []
Index: []","[('progesterone receptor', 'DRUG')]","{'keyword': {0: 'pr progesterone receptor', 1: 'pr progesterone', 2: 'progesterone receptor'}, 'score': {0: 0.9137, 1: 0.9054, 2: 0.8537}}"
1494,1494,1494,0.8830000162124634,19.952899932861328,Adapted from von Minckwitz et al. 2019.,MyriadPro-Light,4,-0.25,5723991,30,40,24,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
1495,1495,1495,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,30,41,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1496,1496,1496,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,30,41,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1497,1497,1497,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,30,41,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1498,1498,1498,0.9470000267028807,28.0,•  ,UniversSB-Light,4,-0.2329999953508377,16162586,30,41,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1499,1499,1499,0.9470000267028807,28.0,neoadjuvant therapy,UniversSB-Light,4,-0.2329999953508377,3355443,30,41,4,"{'concept_id': {0: 'C4744826'}, 'canonical_name': {0: 'Post Neoadjuvant Therapy Sample'}, 'aliases': {0: ['Post Neo-adjuvant Therapy Sample']}, 'types': {0: ['T031']}, 'definition': {0: 'A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}","{'concept_id': {0: 'C0242939'}, 'canonical_name': {0: 'Radiotherapy, Adjuvant'}, 'aliases': {0: ['Radiotherapies, Adjuvant', 'Adjuvant Radiotherapy', 'Adjuvant Radiotherapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0  Therapeutic_procedure          neoadjuvant  0.652529
1  Therapeutic_procedure  neoadjuvant therapy  0.963288",[],"{'keyword': {0: 'neoadjuvant therapy'}, 'score': {0: 1.0}}"
1500,1500,1500,0.9470000267028807,19.0,*Dual neoadjuvant anti-HER2 therapy was also permitted.,UniversSB-Light,4,-0.2329999953508377,3355443,30,42,0,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}",{},{},{},"           entity_group              value     score
0  Detailed_description               Dual  0.999838
1  Detailed_description        neoadjuvant  0.999769
2            Medication        neoadjuvant  0.504794
3            Medication  anti-HER2 therapy  0.946504",[],"{'keyword': {0: 'her2 therapy permitted', 1: 'dual neoadjuvant', 2: 'her2 therapy', 3: 'anti her2', 4: 'neoadjuvant anti'}, 'score': {0: 0.8452, 1: 0.8024, 2: 0.7657, 3: 0.7064, 4: 0.6957}}"
1501,1501,1501,0.9470000267028807,19.0,"DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised ",UniversSB-Light,4,-0.2329999953508377,3355443,30,42,1,"{'concept_id': {0: 'C2828392'}, 'canonical_name': {0: 'Standard (document)'}, 'aliases': {0: ['Standard']}, 'types': {0: ['T170']}, 'definition': {0: 'A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.'}, 'entity': {0: 'standardised'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","{'concept_id': {0: 'C0007620'}, 'canonical_name': {0: 'Cell Survival'}, 'aliases': {0: ['Cell Viability', 'Survival, Cell', 'Viabilities, Cell', 'Cell Viabilities', 'Viability, Cell']}, 'types': {0: ['T043']}, 'definition': {0: 'The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.'}, 'entity': {0: 'overall survival'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","     entity_group        value     score
0  Administration  intravenous  0.999464","[('IV', 'ROUTE'), ('intravenous', 'ROUTE')]","{'keyword': {0: 'survival steep standardised', 1: 'cancer idfs invasive', 2: 'iv intravenous', 3: 'os overall', 4: 'breast cancer'}, 'score': {0: 0.3418, 1: 0.2671, 2: 0.1935, 3: 0.1796, 4: 0.1483}}"
1502,1502,1502,0.9470000267028807,19.0,definitions for efficacy endpoints.,UniversSB-Light,4,-0.2329999953508377,3355443,30,42,2,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'definitions for efficacy endpoints.'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'definitions for efficacy endpoints.'}}",{},{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'definitions for efficacy endpoints.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'definitions efficacy endpoints', 1: 'definitions efficacy', 2: 'efficacy endpoints'}, 'score': {0: 0.8264, 1: 0.816, 2: 0.8015}}"
1503,1503,1503,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,30,44,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1504,1504,1504,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,30,44,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1505,1505,1505,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,30,44,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1506,1506,1506,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,30,44,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1507,1507,1507,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,30,45,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1508,1508,1508,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,30,45,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1509,1509,1509,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,30,45,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1510,1510,1510,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,30,45,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1511,1511,1511,0.75,98.0,The efficacy and safety profile of Kadcyla  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,31,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla  '}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}",{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'The efficacy and safety profile of Kadcyla  '}}","  entity_group    value     score
0  Coreference  Kadcyla  0.860627","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'safety profile kadcyla', 1: 'safety profile', 2: 'efficacy safety', 3: 'profile kadcyla', 4: 'efficacy safety profile'}, 'score': {0: 0.7898, 1: 0.7881, 2: 0.7539, 3: 0.7067, 4: 0.7039}}"
1512,1512,1512,0.75,98.0,were confirmed in a phase 3 study,ConduitITC-Bold,20,-0.1700000017881393,8194925,31,1,1,"{'concept_id': {0: 'C0920321'}, 'canonical_name': {0: 'Phase I Clinical Trials'}, 'aliases': {0: ['Phase 1 Clinical Trials', 'Phase I Study', 'phase i clinical trials', 'phase 1 clinical trials', 'clinical trial phase I', 'Phase 1 Clinical Trial', 'phase i trial', 'Clinical Trials, Phase 1', 'Clinical Trials, Phase I', 'i phase trials', 'phase i clinical trial', 'Phase I Clinical Trial', 'Phase I Protocol', 'clinical trial phase i', 'Phase I Trial', 'Clinical Trials, Phase I as Topic', 'phase i study', 'phase I trial', 'Phase I Clinical Trials', 'Early-Stage Clinical Trials', 'trial phase i', 'Phase 1 Study']}, 'types': {0: ['T062']}, 'definition': {0: 'Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}","{'concept_id': {0: 'C0085973'}, 'canonical_name': {0: 'Case Study'}, 'aliases': {0: ['Case Studies']}, 'types': {0: ['T170']}, 'definition': {0: 'An uncontrolled observational study containing a detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin).'}, 'entity': {0: 'phase 3 study'}, 'text': {0: 'were confirmed in a phase 3 study'}}",{},{},{},"           entity_group          value     score
0             Lab_value      confirmed  0.596251
1  Diagnostic_procedure  phase 3 study  0.984973",[],"{'keyword': {0: 'confirmed phase', 1: 'confirmed phase study', 2: 'phase study'}, 'score': {0: 0.8854, 1: 0.793, 2: 0.6105}}"
1513,1513,1513,0.944000005722046,27.0,Kadcyla ,UniversSB-Bold,20,-0.2469999939203262,16777215,31,2,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
1514,1514,1514,0.944000005722046,27.0,3.6 mg/kg IV ,UniversSB-Bold,20,-0.2469999939203262,16777215,31,2,1,{},{},{},{},{},"     entity_group      value     score
0       Lab_value    3.6 3.6  0.759886
1          Dosage  3.6 mg/kg  0.781887
2  Administration         IV  0.929909","[('3.6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7689, 1: 0.7403, 2: 0.7102}}"
1515,1515,1515,0.944000005722046,27.0,(n=743),UniversSB-Bold,20,-0.2469999939203262,16777215,31,2,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1516,1516,1516,0.9470000267028807,28.0,"KATHERINE was a phase 3, open-label, ",UniversSB-Light,4,-0.2329999953508377,3355443,31,3,0,"{'concept_id': {0: 'C0205390'}, 'canonical_name': {0: 'Phase'}, 'aliases': {0: ['Phased', 'Phase', 'Phase (attribute)', 'phase', 'Stage']}, 'types': {0: ['T079']}, 'definition': {0: 'A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, '}}","{'concept_id': {0: 'C0080129'}, 'canonical_name': {0: 'S Phase'}, 'aliases': {0: ['S Period', 'Phase, S', 'Period, S', 'Phases, S', 'Periods, S', 'S Periods', 'S Phases']}, 'types': {0: ['T079']}, 'definition': {0: 'Phase of the CELL CYCLE following G1 and preceding G2 when the entire DNA content of the nucleus is replicated. It is achieved by bidirectional replication at multiple sites along each chromosome.'}, 'entity': {0: 'phase 3'}, 'text': {0: 'KATHERINE was a phase 3, open-label, '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []","[('KATHERINE', 'DRUG')]","{'keyword': {0: 'phase open label', 1: 'open label', 2: 'katherine phase open', 3: 'katherine phase', 4: 'phase open'}, 'score': {0: 0.8484, 1: 0.8158, 2: 0.7484, 3: 0.7024, 4: 0.6219}}"
1517,1517,1517,0.9470000267028807,28.0,"randomised, multicentre study which assessed ",UniversSB-Light,4,-0.2329999953508377,3355443,31,3,1,"{'concept_id': {0: 'C1555289'}, 'canonical_name': {0: 'Assessed patient - therapy appropriate'}, 'aliases': {0: ['Assessed Patient']}, 'types': {0: ['T033']}, 'definition': {0: '<p>Assessed patient, therapy is appropriate</p>'}, 'entity': {0: 'assessed'}, 'text': {0: 'randomised, multicentre study which assessed '}}","{'concept_id': {0: 'C1096776'}, 'canonical_name': {0: 'Multicenter Studies'}, 'aliases': {0: ['Multicenter Study']}, 'types': {0: ['T062']}, 'definition': {0: 'A work that reports on a study executed by several cooperating institutions.'}, 'entity': {0: 'multicentre study'}, 'text': {0: 'randomised, multicentre study which assessed '}}",{},{},{},"           entity_group        value     score
0  Detailed_description   randomised  0.997080
1  Diagnostic_procedure  multicentre  0.964970
2  Detailed_description  multicentre  0.856343
3  Diagnostic_procedure        study  0.939489",[],"{'keyword': {0: 'randomised multicentre study', 1: 'multicentre study assessed', 2: 'randomised multicentre', 3: 'multicentre study', 4: 'study assessed'}, 'score': {0: 0.8846, 1: 0.8604, 2: 0.8469, 3: 0.8077, 4: 0.7694}}"
1518,1518,1518,0.9470000267028807,28.0,the efficacy and safety profile of adjuvant ,UniversSB-Light,4,-0.2329999953508377,3355443,31,3,2,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'adjuvant'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}",{},{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'the efficacy and safety profile of adjuvant '}}","  entity_group     value     score
0   Medication  adjuvant  0.919629",[],"{'keyword': {0: 'safety profile', 1: 'safety profile adjuvant', 2: 'profile adjuvant', 3: 'efficacy safety', 4: 'efficacy safety profile'}, 'score': {0: 0.8586, 1: 0.7746, 2: 0.7312, 3: 0.6494, 4: 0.6119}}"
1519,1519,1519,0.9470000267028807,28.0,Kadcyla vs trastuzumab in patients who  ,UniversSB-Light,4,-0.2329999953508377,3355443,31,3,3,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'Kadcyla vs trastuzumab in patients who  '}}",{},{},"  entity_group        value     score
0   Medication      Kadcyla  0.588591
1   Medication  trastuzumab  0.999825","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'kadcyla vs trastuzumab', 1: 'kadcyla vs', 2: 'vs trastuzumab patients', 3: 'vs trastuzumab', 4: 'trastuzumab patients'}, 'score': {0: 0.9384, 1: 0.8664, 2: 0.8337, 3: 0.8093, 4: 0.8014}}"
1520,1520,1520,0.9470000267028807,28.0,had residual invasive disease following ,UniversSB-Light,4,-0.2329999953508377,3355443,31,3,4,"{'concept_id': {0: 'C0205281'}, 'canonical_name': {0: 'Invasive'}, 'aliases': {0: ['Invasive (qualifier value)', 'Invasive', 'invasive']}, 'types': {0: ['T080']}, 'definition': {0: 'Marked by a tendency to spread, especially into healthy surrounding tissue.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following '}}","{'concept_id': {0: 'C0008493'}, 'canonical_name': {0: 'Hydatidiform Mole, Invasive'}, 'aliases': {0: ['Moles, Invasive Hydatidiform', 'Chorioadenoma', 'Invasive Hydatidiform Moles', 'Mole, Invasive', 'Hydatidiform Moles, Invasive', 'Invasive Hydatidiform Mole', 'Moles, Invasive', 'Mole, Invasive Hydatidiform', 'Invasive Mole', 'Invasive Moles', 'Chorioadenomas']}, 'types': {0: ['T191']}, 'definition': {0: 'A uterine tumor derived from persistent gestational TROPHOBLASTS, most likely after a molar pregnancy (HYDATIDIFORM MOLE). Invasive hyadatiform mole develops in about 15% of patients after evacuation of a complete mole and less frequently after other types of gestation. It may perforate the MYOMETRIUM and erode uterine vessels causing hemorrhage.'}, 'entity': {0: 'invasive disease'}, 'text': {0: 'had residual invasive disease following '}}",{},{},{},"           entity_group             value     score
0  Detailed_description          residual  0.995710
1      Disease_disorder  invasive disease  0.862065",[],"{'keyword': {0: 'residual invasive disease', 1: 'residual invasive', 2: 'invasive disease following', 3: 'invasive disease', 4: 'disease following'}, 'score': {0: 0.9149, 1: 0.9108, 2: 0.8708, 3: 0.8285, 4: 0.8066}}"
1521,1521,1521,0.9470000267028807,28.0,trastuzumab-based neoadjuvant therapy,UniversSB-Light,4,-0.2329999953508377,3355443,31,3,5,{},"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'trastuzumab-based neoadjuvant therapy'}, 'text': {0: 'trastuzumab-based neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0             Medication    trastuzumab-based  0.999863
1  Therapeutic_procedure          neoadjuvant  0.997995
2  Therapeutic_procedure  neoadjuvant therapy  0.997627","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab based neoadjuvant', 1: 'based neoadjuvant therapy', 2: 'neoadjuvant therapy', 3: 'trastuzumab based', 4: 'based neoadjuvant'}, 'score': {0: 0.946, 1: 0.8826, 2: 0.8712, 3: 0.8579, 4: 0.8374}}"
1522,1522,1522,0.9470000267028807,27.0,Surgery,UniversSB-Light,4,-0.2329999953508377,16777215,31,4,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  Surgery  0.998798",[],"{'keyword': {}, 'score': {}}"
1523,1523,1523,0.9470000267028807,27.0,Residual invasive ,UniversSB-Light,4,-0.2329999953508377,16777215,31,5,0,"{'concept_id': {0: 'C1334278'}, 'canonical_name': {0: 'Invasive Lesion'}, 'aliases': {0: ['Invasive Lesion']}, 'types': {0: ['T033']}, 'definition': {0: 'A malignant cellular population that has increased in size and infiltrates the surrounding tissues.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}","{'concept_id': {0: 'C2936533'}, 'canonical_name': {0: 'Invasive Species'}, 'aliases': {0: []}, 'types': {0: ['T098']}, 'definition': {0: 'Non-native species that threaten ecosystems, habitats, or other species and are likely to cause economic or environmental harm or harm to human health.'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'Residual invasive '}}",{},"           entity_group              value     score
0  Detailed_description  Residual invasive  0.999395",[],"{'keyword': {0: 'residual invasive'}, 'score': {0: 1.0}}"
1524,1524,1524,0.9470000267028807,27.0,disease in breast  ,UniversSB-Light,4,-0.2329999953508377,16777215,31,5,1,"{'concept_id': {0: 'C0038293'}, 'canonical_name': {0: 'Sternum'}, 'aliases': {0: ['Bone structure of sternum (body structure)', 'sternums', 'Sternum', 'Sternum/Sternal', 'Breast bone', 'Chest>Sternum', 'Sternal', 'breast bone', 'sternum', 'Sternum, NOS', 'Bone structure of sternum']}, 'types': {0: ['T023']}, 'definition': {0: 'A long, narrow, and flat bone commonly known as BREASTBONE occurring in the midsection of the anterior thoracic segment or chest region, which stabilizes the rib cage and serves as the point of origin for several muscles that move the arms, head, and neck.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","{'concept_id': {0: 'C0024902'}, 'canonical_name': {0: 'Breast Pain'}, 'aliases': {0: ['Mastodynias', 'Mammalgias', 'Mastodynia', 'Mastalgias', 'Mammalgia', 'Pain, Breast', 'Mastalgia', 'Breast Pains', 'Pains, Breast']}, 'types': {0: ['T184']}, 'definition': {0: 'Painful sensation in the breast region.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast  '}, 'text': {0: 'disease in breast  '}}","           entity_group   value     score
0  Biological_structure  breast  0.999824",[],"{'keyword': {0: 'disease breast'}, 'score': {0: 0.9481}}"
1525,1525,1525,0.9470000267028807,27.0,or axillary lymph ,UniversSB-Light,4,-0.2329999953508377,16777215,31,5,2,"{'concept_id': {0: 'C0229843'}, 'canonical_name': {0: 'Pectoral lymph node group'}, 'aliases': {0: ['Nodi lymphoidei axillarum anteriores', 'Anterior axillary lymph nodes', 'Structure of pectoral axillary lymph node (body structure)', 'Anterior axillary nodes', 'Pectoral axillary lymph node', 'Nodi pectorales', 'Anterior axillary lymph nodes set', 'Pectoral Lymph Node', 'Pectoral lymph node', 'Pectoral lymph node group', 'Pectoral nodes', 'Pectoral axillary lymph node group', 'Pectoral lymph nodes', 'Structure of pectoral axillary lymph node', 'Pectoral lymph node group (body structure)', 'Anterior axillary lymph node', 'Nodi axillarum anteriores', 'Nodus lymphaticus pectoralis axillae', 'Set of pectoral lymph nodes', 'Set of anterior axillary lymph nodes', 'Pectoral lymph nodes set', 'Pectoral axillary lymph nodes', 'Set of pectoral axillary lymph nodes', 'Nodi lymphoidei pectorales']}, 'types': {0: ['T023']}, 'definition': {0: 'An axillary lymph node located along the lower edge of the pectoralis minor.'}, 'entity': {0: 'axillary lymph'}, 'text': {0: 'or axillary lymph '}}",{},{},{},{},"           entity_group           value     score
0  Biological_structure        axillary  0.999927
1  Biological_structure  axillary lymph  0.940007",[],"{'keyword': {0: 'axillary lymph'}, 'score': {0: 0.9521}}"
1526,1526,1526,0.9470000267028807,27.0,nodes,UniversSB-Light,4,-0.2329999953508377,16777215,31,5,3,"{'concept_id': {0: 'C2697524'}, 'canonical_name': {0: 'Graph Node'}, 'aliases': {0: ['Vertex', 'Node', 'Graph Node']}, 'types': {0: ['T077']}, 'definition': {0: 'One of the points that define a graph.'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}","{'concept_id': {0: 'C0037189'}, 'canonical_name': {0: 'Sino-Atrial Nodes'}, 'aliases': {0: ['Sinu-Atrial Node', 'Sino-Atrial Node', 'Sinu-Atrial Nodes', 'Nodes, Sinu-Atrial', 'Sinus Node', 'Nodes, Sinuatrial', 'Node, Sinuatrial', 'Nodes, Sinoatrial', 'Nodes, Sinus', 'Sinoatrial Node', 'Sinus Nodes', 'Sinuatrial Node', 'Node, Sino-Atrial', 'Node, Sinus', 'Node, Sinoatrial', 'Sinoatrial Nodes', 'Sinu Atrial Node', 'Sinuatrial Nodes', 'Sino Atrial Node', 'Nodes, Sino-Atrial', 'Node, Sinu-Atrial']}, 'types': {0: ['T023']}, 'definition': {0: 'The small mass of modified cardiac muscle fibers located at the junction of the superior vena cava (VENA CAVA, SUPERIOR) and right atrium. Contraction impulses probably start in this node, spread over the atrium (HEART ATRIUM) and are then transmitted by the atrioventricular bundle (BUNDLE OF HIS) to the ventricle (HEART VENTRICLE).'}, 'entity': {0: 'nodes'}, 'text': {0: 'nodes'}}",{},{},{},"           entity_group  value     score
0  Biological_structure  nodes  0.488832",[],"{'keyword': {}, 'score': {}}"
1527,1527,1527,0.9470000267028807,27.0,"HER2-positive eBC, ",UniversSB-Light,4,-0.2329999953508377,16777215,31,6,0,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  HER2-positive  0.816637",[],"{'keyword': {0: 'her2 positive ebc', 1: 'positive ebc', 2: 'her2 positive'}, 'score': {0: 0.9628, 1: 0.8142, 2: 0.7646}}"
1528,1528,1528,0.9470000267028807,27.0,neoadjuvant ,UniversSB-Light,4,-0.2329999953508377,16777215,31,6,1,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant'}, 'text': {0: 'neoadjuvant '}}",{},{},{},"           entity_group        value     score
0  Detailed_description  neoadjuvant  0.956138
1          Sign_symptom  neoadjuvant  0.386592
2               History  neoadjuvant  0.344678",[],"{'keyword': {}, 'score': {}}"
1529,1529,1529,0.9470000267028807,27.0,trastuzumab* plus ,UniversSB-Light,4,-0.2329999953508377,16777215,31,6,2,"{'concept_id': {0: 'C4527338'}, 'canonical_name': {0: 'AC Followed by Docetaxel/Trastuzumab Regimen'}, 'aliases': {0: ['AC-Docetaxel + Trastuzumab', 'AC-T Plus Trastuzumab', 'AC-Taxotere/Herceptin', 'AC Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel + Trastuzumab', 'Doxorubicin/Cyclophosphamide Followed by Docetaxel/Trastuzumab']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab* plus'}, 'text': {0: 'trastuzumab* plus '}}",{},{},"           entity_group        value     score
0            Medication  trastuzumab  0.999873
1  Detailed_description         plus  0.314542","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab plus'}, 'score': {0: 0.9478}}"
1530,1530,1530,0.9470000267028807,27.0,chemotherapy ,UniversSB-Light,4,-0.2329999953508377,16777215,31,6,3,"{'concept_id': {0: 'C0392920'}, 'canonical_name': {0: 'Chemotherapy Regimen'}, 'aliases': {0: ['chemotherapy regimen', 'Antineoplastic chemotherapy regimen', 'chemotherapies', 'Antineoplastic chemotherapy regimen (regime/therapy)', 'chemotherapy regimens', 'neoplasm chemotherapy', 'neoplasm pharmacotherapy', 'chemotherapy', 'chemo', 'Cancer chemotherapy', 'neoplasm/cancer chemotherapy', 'cancer chemotherapy', 'cancer pharmacotherapy', 'neoplasm/cancer pharmacotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'application of the beneficial effects of drugs to control or cure neoplastic growth.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}","{'concept_id': {0: 'C1868801'}, 'canonical_name': {0: 'Hyperthermic Intraperitoneal Chemotherapy'}, 'aliases': {0: ['Hot Chemotherapy', 'Chemotherapy, Intraperitoneal Hyperthermic', 'Chemotherapy, Hyperthermic Intraperitoneal', 'Chemotherapy, Hot', 'Intraperitoneal Hyperthermic Chemotherapies', 'Intraperitoneal Chemotherapy, Hyperthermic', 'Hyperthermic Chemotherapy, Intraperitoneal', 'HIPEC', 'Intraperitoneal Hyperthermic Chemotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.'}, 'entity': {0: 'chemotherapy'}, 'text': {0: 'chemotherapy '}}",{},{},{},"  entity_group         value     score
0   Medication  chemotherapy  0.999848","[('chemotherapy', 'DRUG')]","{'keyword': {}, 'score': {}}"
1531,1531,1531,0.9470000267028807,27.0,(n=1486),UniversSB-Light,4,-0.2329999953508377,16777215,31,6,4,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1532,1532,1532,0.944000005722046,28.0,Primary endpoint,UniversSB-Bold,20,-0.2469999939203262,3355443,31,7,0,"{'concept_id': {0: 'C2349179'}, 'canonical_name': {0: 'End Point'}, 'aliases': {0: ['Endpoint', 'End Point', 'ENDPOINT', 'endpoints', 'endpoint', 'End-Point']}, 'types': {0: ['T080']}, 'definition': {0: 'A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.'}, 'entity': {0: 'Primary endpoint'}, 'text': {0: 'Primary endpoint'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  Primary endpoint  0.940143",[],"{'keyword': {0: 'primary endpoint'}, 'score': {0: 1.0}}"
1533,1533,1533,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,31,7,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1534,1534,1534,0.944000005722046,28.0,Secondary endpoints,UniversSB-Bold,20,-0.2469999939203262,3355443,31,8,0,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'Secondary endpoints'}}",{},"{'concept_id': {0: 'C1623508'}, 'canonical_name': {0: 'regulation of secondary metabolic process'}, 'aliases': {0: ['regulation of secondary metabolism']}, 'types': {0: ['T040']}, 'definition': {0: 'Any process that modulates the frequency, rate or extent of secondary metabolism, the chemical reactions and pathways involving compounds that are not necessarily required for growth and maintenance of cells, and are often unique to a taxon. [GOC:jl]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","{'concept_id': {0: 'C2981150'}, 'canonical_name': {0: 'Uranostaphyloschisis'}, 'aliases': {0: ['Cleft of hard and soft palate', 'Cleft of palate', 'Cleft hard and soft palate', 'Cleft palate', 'Cleft secondary palate', 'Palatoschisis', 'Cleft roof of mouth']}, 'types': {0: ['T019']}, 'definition': {0: 'Cleft palate is a developmental defect of the palate resulting from a failure of fusion of the palatine processes and manifesting as a separation of the roof of the mouth (soft and hard palate). [HPO:probinson]'}, 'entity': {0: 'Secondary'}, 'text': {0: 'Secondary endpoints'}}","           entity_group                value     score
0  Detailed_description  Secondary endpoints  0.811147",[],"{'keyword': {0: 'secondary endpoints'}, 'score': {0: 1.0}}"
1535,1535,1535,0.9470000267028807,27.0,Planned 10 years’ follow-up,UniversSB-Light,4,-0.2329999953508377,16777215,31,9,0,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'Planned 10 years’ follow-up'}}",{},{},{},"     entity_group      value     score
0        Duration   10 years  0.999410
1  Clinical_event  follow-up  0.993776",[],"{'keyword': {0: 'planned 10 years', 1: '10 years follow', 2: 'planned 10', 3: '10 years', 4: 'years follow'}, 'score': {0: 0.9349, 1: 0.8297, 2: 0.8114, 3: 0.7473, 4: 0.7286}}"
1536,1536,1536,0.944000005722046,27.0,Trastuzumab  ,UniversSB-Bold,20,-0.2469999939203262,16777215,31,10,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab  '}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999798","[('Trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
1537,1537,1537,0.944000005722046,27.0,6 mg/kg IV ,UniversSB-Bold,20,-0.2469999939203262,16777215,31,10,1,"{'concept_id': {0: 'C0439272'}, 'canonical_name': {0: 'ug/g'}, 'aliases': {0: ['Picogram per Microgram', 'Zeptogram per Femtogram', 'Yoctogram per Attogram', 'mg/kg', 'Milligram/kilogram', 'Microgram/gram', 'microgram/g', 'Femtogram per Nanogram', 'Nanogram per Milligram', 'Milligram/kilogram (qualifier value)', 'Microgram/gram (qualifier value)', 'mg kg', 'Microgram per Gram', 'Milligram/Kilogram', 'Milligram per Kilogram', 'Attogram per Picogram', 'microg/g']}, 'types': {0: ['T081']}, 'definition': {0: 'A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.'}, 'entity': {0: 'mg/kg IV'}, 'text': {0: '6 mg/kg IV '}}",{},{},{},{},"     entity_group    value     score
0          Dosage  6 mg/kg  0.909511
1  Administration       IV  0.990577","[('6 mg/kg', 'STRENGTH'), ('IV', 'ROUTE')]","{'keyword': {0: 'mg kg iv', 1: 'mg kg', 2: 'kg iv'}, 'score': {0: 0.7475, 1: 0.7458, 2: 0.6812}}"
1538,1538,1538,0.944000005722046,27.0,(n=743),UniversSB-Bold,20,-0.2469999939203262,16777215,31,10,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1539,1539,1539,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,31,11,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1540,1540,1540,0.9470000267028807,28.0,non-breast cancer as per the  ,UniversSB-Light,4,-0.2329999953508377,3355443,31,11,1,{},"{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'non-breast cancer'}, 'text': {0: 'non-breast cancer as per the  '}}",{},{},{},"       entity_group              value     score
0           History         non-breast  0.647748
1  Disease_disorder  non-breast cancer  0.972177",[],"{'keyword': {0: 'non breast cancer', 1: 'non breast', 2: 'breast cancer'}, 'score': {0: 0.9178, 1: 0.7301, 2: 0.6862}}"
1541,1541,1541,0.9470000267028807,28.0,STEEP definition,UniversSB-Light,4,-0.2329999953508377,3355443,31,11,2,"{'concept_id': {0: 'C3539107'}, 'canonical_name': {0: 'Definition (core metadata concept)'}, 'aliases': {0: ['Definition', 'Definition (core metadata concept)']}, 'types': {0: ['T170']}, 'definition': {0: None}, 'entity': {0: 'definition'}, 'text': {0: 'STEEP definition'}}",{},{},{},{},"           entity_group             value     score
0  Detailed_description  STEEP definition  0.998824",[],"{'keyword': {0: 'steep definition'}, 'score': {0: 1.0}}"
1542,1542,1542,0.9470000267028807,23.0,Anti-HER2 therapy for a total of 14 cycles. ,UniversSB-Light,4,-0.2329999953508377,3355443,31,12,0,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Anti-HER2 therapy for a total of 14 cycles. '}}",{},{},{},"  entity_group      value     score
0   Medication  Anti-HER2  0.606185
1  Coreference  Anti-HER2  0.565908
2   Medication    therapy  0.542007
3    Lab_value         14  0.923810",[],"{'keyword': {0: 'total 14 cycles', 1: 'therapy total 14', 2: 'anti her2 therapy', 3: 'her2 therapy total', 4: 'anti her2'}, 'score': {0: 0.8392, 1: 0.822, 2: 0.7728, 3: 0.7289, 4: 0.6897}}"
1543,1543,1543,0.9470000267028807,23.0,Radiation and endocrine therapy ,UniversSB-Light,4,-0.2329999953508377,3355443,31,12,1,"{'concept_id': {0: 'C1514396'}, 'canonical_name': {0: 'Preoperative Endocrine Therapy'}, 'aliases': {0: []}, 'types': {0: ['T061']}, 'definition': {0: 'Short term endocrine therapy, prior to surgery, to ""down-stage"" primary breast cancer in order to increase the rate of breast-conserving surgery. (from JMCC 7:557-562, 2000 via Medscape)'}, 'entity': {0: 'endocrine therapy'}, 'text': {0: 'Radiation and endocrine therapy '}}","{'concept_id': {0: 'C2607955'}, 'canonical_name': {0: 'Beta Radiation'}, 'aliases': {0: ['Rays, Beta', 'Ray, Beta', 'Beta Radiations', 'Beta Rays', 'Radiation, Beta', 'Beta Ray', 'Radiations, Beta']}, 'types': {0: ['T070']}, 'definition': {0: 'A stream of high energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus.'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy '}}",{},"{'concept_id': {0: 'C1154958'}, 'canonical_name': {0: 'response to electromagnetic radiation stimulus'}, 'aliases': {0: ['response to radiation stimulus', 'response to radiation']}, 'types': {0: ['T038']}, 'definition': {0: 'Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electromagnetic radiation stimulus. Electromagnetic radiation is a propagating wave in space with electric and magnetic components. These components oscillate at right angles to each other and to the direction of propagation. [GOC:jl, Wikipedia:Electromagnetic_radiation]'}, 'entity': {0: 'Radiation'}, 'text': {0: 'Radiation and endocrine therapy '}}",{},"            entity_group              value     score
0  Therapeutic_procedure          Radiation  0.994988
1  Therapeutic_procedure  endocrine therapy  0.948940",[],"{'keyword': {0: 'radiation endocrine therapy', 1: 'endocrine therapy', 2: 'radiation endocrine'}, 'score': {0: 0.843, 1: 0.824, 2: 0.8103}}"
1544,1544,1544,0.9470000267028807,23.0,administered according to institutional ,UniversSB-Light,4,-0.2329999953508377,3355443,31,12,2,"{'concept_id': {0: 'C1546848'}, 'canonical_name': {0: 'Living Arrangement - Institution'}, 'aliases': {0: ['Institution']}, 'types': {0: ['T033']}, 'definition': {0: '<p>Institution</p>'}, 'entity': {0: 'institutional'}, 'text': {0: 'administered according to institutional '}}","{'concept_id': {0: 'C5544477'}, 'canonical_name': {0: 'Systemic Racism'}, 'aliases': {0: ['Institutionalized Racisms', 'Racism, Systemic', 'Institutionalized Racism', 'Racism, Institutionalized', 'Structural Racisms', 'Racism, Structural', 'Racism, Institutional', 'Racisms, Systematic', 'Systematic Racisms', 'Racism, Systematic', 'Institutional Racism', 'Systematic Racism', 'Structural Racism']}, 'types': {0: ['T054']}, 'definition': {0: 'Processes of racism that are embedded in laws (local, state, and federal), policies, and practices of society and its institutions that provide advantages to racial groups deemed as superior, while differentially oppressing, disadvantaging, or otherwise neglecting racial groups viewed as inferior. Differential access to the goods, services, and opportunities of society by race. Institutionalized racism is normative, sometimes legalized, and often manifests as inherited disadvantage. It is structural, having been codified in our institutions of custom, practice, and law, so there need not be an identifiable perpetrator. (ttps://www.cdc.gov/chronicdisease/programs-impact/sdoh.htm)'}, 'entity': {0: 'institutional'}, 'text': {0: 'administered according to institutional '}}",{},{},{},"           entity_group                       value     score
0  Detailed_description  according to institutional  0.817311",[],"{'keyword': {0: 'administered according institutional', 1: 'according institutional', 2: 'administered according'}, 'score': {0: 0.9745, 1: 0.8839, 2: 0.8672}}"
1545,1545,1545,0.9470000267028807,23.0,standards and study protocol,UniversSB-Light,4,-0.2329999953508377,3355443,31,12,3,"{'concept_id': {0: 'C2985700'}, 'canonical_name': {0: 'Study Protocol Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic.'}, 'entity': {0: 'study protocol'}, 'text': {0: 'standards and study protocol'}}","{'concept_id': {0: 'C2936643'}, 'canonical_name': {0: 'Standard of Care'}, 'aliases': {0: ['Standards of Care', 'Care Standards', 'Care Standard']}, 'types': {0: ['T058']}, 'definition': {0: 'The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.'}, 'entity': {0: 'standards'}, 'text': {0: 'standards and study protocol'}}",{},{},{},"           entity_group           value     score
0  Diagnostic_procedure       standards  0.946151
1  Diagnostic_procedure  study protocol  0.709869",[],"{'keyword': {0: 'study protocol', 1: 'standards study protocol', 2: 'standards study'}, 'score': {0: 0.906, 1: 0.879, 2: 0.7344}}"
1546,1546,1546,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,31,13,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1547,1547,1547,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,31,13,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1548,1548,1548,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,31,13,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1549,1549,1549,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,31,13,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1550,1550,1550,0.9052734375,23.0,≥,ArialMT,0,-0.2119140625,3355443,31,14,0,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1551,1551,1551,0.9470000267028807,23.0,of treatment including ,UniversSB-Light,4,-0.2329999953508377,3355443,31,14,1,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'of treatment including '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'treatment including'}, 'score': {0: 0.9499}}"
1552,1552,1552,0.9052734375,22.65237236022949,≥,ArialMT,0,-0.2119140625,3355443,31,14,2,{},{},{},{},{},"           entity_group value     score
0  Quantitative_concept     ≥  0.182218",[],"{'keyword': {}, 'score': {}}"
1553,1553,1553,0.9470000267028807,23.0,therapy and ,UniversSB-Light,4,-0.2329999953508377,3355443,31,14,3,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: 'therapy and '}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  therapy  0.826489",[],"{'keyword': {}, 'score': {}}"
1554,1554,1554,0.9470000267028807,23.0,of trastuzumab therapy,UniversSB-Light,4,-0.2329999953508377,3355443,31,14,4,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},"{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab therapy'}, 'text': {0: 'of trastuzumab therapy'}}",{},{},"  entity_group                value     score
0   Medication          trastuzumab  0.999849
1   Medication  trastuzumab therapy  0.978093","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab therapy'}, 'score': {0: 0.9362}}"
1555,1555,1555,0.944000005722046,28.0,Stratification factors,UniversSB-Bold,20,-0.2469999939203262,3355443,31,15,0,"{'concept_id': {0: 'C1514983'}, 'canonical_name': {0: 'Stratification'}, 'aliases': {0: ['stratification']}, 'types': {0: ['T062']}, 'definition': {0: 'The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.'}, 'entity': {0: 'Stratification factors'}, 'text': {0: 'Stratification factors'}}",{},{},{},{},"           entity_group                   value     score
0  Diagnostic_procedure  Stratification factors  0.970758",[],"{'keyword': {0: 'stratification factors'}, 'score': {0: 1.0}}"
1556,1556,1556,0.9169999957084656,30.0,Reference:,ConduitITC-Bold,20,-0.2349999994039535,8194925,31,16,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1557,1557,1557,0.8830000162124634,22.0,1. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628. ,MyriadPro-Light,4,-0.25,3355443,31,16,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'et al', 4: 'engl med 2019'}, 'score': {0: 0.8031, 1: 0.7251, 2: 0.7194, 3: 0.6642, 4: 0.6422}}"
1558,1558,1558,0.944000005722046,21.0,Inclusion and  ,UniversSB-Bold,20,-0.2469999939203262,16777215,31,17,0,"{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Cellular Inclusion', 'Inclusion Body', 'inclusion bodies', 'Inclusion Bodies', 'inclusion body', 'body inclusion', 'Inclusions, Cellular', 'cellular inclusions', 'Bodies, Inclusion', 'Cellular Inclusions', 'Inclusions', 'cellular inclusion', 'Inclusion, Cellular', 'Body, Inclusion']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}","{'concept_id': {0: 'C0007637'}, 'canonical_name': {0: 'Inclusion Bodies'}, 'aliases': {0: ['Inclusions, Cellular', 'Inclusion, Cellular', 'Inclusion Body', 'Body, Inclusion', 'Cellular Inclusion', 'Bodies, Inclusion', 'Cellular Inclusions']}, 'types': {0: ['T026']}, 'definition': {0: 'A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"{'concept_id': {0: 'C0205708'}, 'canonical_name': {0: 'cytoplasmic inclusion'}, 'aliases': {0: []}, 'types': {0: ['T026']}, 'definition': {0: 'A stainable aggregation of protein, lipid or small molecules in the cytoplasm.'}, 'entity': {0: 'Inclusion'}, 'text': {0: 'Inclusion and  '}}",{},"  entity_group      value     score
0  Coreference  Inclusion  0.340508",[],"{'keyword': {}, 'score': {}}"
1559,1559,1559,0.944000005722046,21.0,exclusion criteria,UniversSB-Bold,20,-0.2469999939203262,16777215,31,17,1,"{'concept_id': {0: 'C2827032'}, 'canonical_name': {0: 'Trial Inclusion Exclusion Criteria Version'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A specific variant of the original trial inclusion exclusion criterion.'}, 'entity': {0: 'exclusion criteria'}, 'text': {0: 'exclusion criteria'}}",{},{},{},{},"           entity_group               value     score
0  Diagnostic_procedure  exclusion criteria  0.534692",[],"{'keyword': {0: 'exclusion criteria'}, 'score': {0: 1.0}}"
1560,1560,1560,0.944000005722046,21.0,Baseline characteristics  ,UniversSB-Bold,20,-0.2469999939203262,16777215,31,18,0,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'characteristics'}, 'text': {0: 'Baseline characteristics  '}}","           entity_group                     value     score
0  Diagnostic_procedure  Baseline characteristics  0.999933",[],"{'keyword': {0: 'baseline characteristics'}, 'score': {0: 1.0}}"
1561,1561,1561,0.944000005722046,21.0,were well-balanced,UniversSB-Bold,20,-0.2469999939203262,16777215,31,18,1,{},{},{},{},{},"  entity_group          value     score
0    Lab_value  well-balanced  0.999827",[],"{'keyword': {}, 'score': {}}"
1562,1562,1562,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,31,23,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1563,1563,1563,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,31,23,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1564,1564,1564,0.9470000267028807,28.0,• ,UniversSB-Light,4,-0.2329999953508377,16162586,31,23,2,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1565,1565,1565,0.9470000267028807,28.0,•  ,UniversSB-Light,4,-0.2329999953508377,16162586,31,23,3,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1566,1566,1566,0.9470000267028807,28.0,neoadjuvant therapy,UniversSB-Light,4,-0.2329999953508377,3355443,31,23,4,"{'concept_id': {0: 'C4744826'}, 'canonical_name': {0: 'Post Neoadjuvant Therapy Sample'}, 'aliases': {0: ['Post Neo-adjuvant Therapy Sample']}, 'types': {0: ['T031']}, 'definition': {0: 'A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}","{'concept_id': {0: 'C0242939'}, 'canonical_name': {0: 'Radiotherapy, Adjuvant'}, 'aliases': {0: ['Radiotherapies, Adjuvant', 'Adjuvant Radiotherapy', 'Adjuvant Radiotherapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.'}, 'entity': {0: 'neoadjuvant therapy'}, 'text': {0: 'neoadjuvant therapy'}}",{},{},{},"            entity_group                value     score
0  Therapeutic_procedure          neoadjuvant  0.652529
1  Therapeutic_procedure  neoadjuvant therapy  0.963288",[],"{'keyword': {0: 'neoadjuvant therapy'}, 'score': {0: 1.0}}"
1567,1567,1567,0.9470000267028807,19.0,*Dual neoadjuvant anti-HER2 therapy was also permitted.,UniversSB-Light,4,-0.2329999953508377,3355443,31,24,0,"{'concept_id': {0: 'C1363945'}, 'canonical_name': {0: 'Therapy Object (animal model)'}, 'aliases': {0: ['Therapy', 'Therapy Object']}, 'types': {0: ['T033']}, 'definition': {0: 'Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}","{'concept_id': {0: 'C1510538'}, 'canonical_name': {0: 'Distance Counseling'}, 'aliases': {0: ['E-Therapy', 'E Counseling', 'Counseling, Distance', 'E-Therapies', 'E Therapy', 'E-Counseling']}, 'types': {0: ['T061']}, 'definition': {0: 'Counseling conducted via electronic or other non-face-to-face interactions.'}, 'entity': {0: 'therapy'}, 'text': {0: '*Dual neoadjuvant anti-HER2 therapy was also permitted.'}}",{},{},{},"           entity_group              value     score
0  Detailed_description               Dual  0.999838
1  Detailed_description        neoadjuvant  0.999769
2            Medication        neoadjuvant  0.504794
3            Medication  anti-HER2 therapy  0.946504",[],"{'keyword': {0: 'her2 therapy permitted', 1: 'dual neoadjuvant', 2: 'her2 therapy', 3: 'anti her2', 4: 'neoadjuvant anti'}, 'score': {0: 0.8452, 1: 0.8024, 2: 0.7657, 3: 0.7064, 4: 0.6957}}"
1568,1568,1568,0.9470000267028807,19.0,"DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised ",UniversSB-Light,4,-0.2329999953508377,3355443,31,24,1,"{'concept_id': {0: 'C2828392'}, 'canonical_name': {0: 'Standard (document)'}, 'aliases': {0: ['Standard']}, 'types': {0: ['T170']}, 'definition': {0: 'A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.'}, 'entity': {0: 'standardised'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","{'concept_id': {0: 'C0007620'}, 'canonical_name': {0: 'Cell Survival'}, 'aliases': {0: ['Cell Viability', 'Survival, Cell', 'Viabilities, Cell', 'Cell Viabilities', 'Viability, Cell']}, 'types': {0: ['T043']}, 'definition': {0: 'The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.'}, 'entity': {0: 'overall survival'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}",{},"{'concept_id': {0: 'C3540443'}, 'canonical_name': {0: 'invasive filamentous growth'}, 'aliases': {0: ['invasive growth']}, 'types': {0: ['T043']}, 'definition': {0: 'The growth of colonies in filamentous chains of cells into a substrate. [GOC:di, PMID:22276126]'}, 'entity': {0: 'invasive'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'DFS, disease-free survival; eBC, early breast cancer; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; STEEP, standardised '}}","     entity_group        value     score
0  Administration  intravenous  0.999464","[('IV', 'ROUTE'), ('intravenous', 'ROUTE')]","{'keyword': {0: 'survival steep standardised', 1: 'cancer idfs invasive', 2: 'iv intravenous', 3: 'os overall', 4: 'breast cancer'}, 'score': {0: 0.3418, 1: 0.2671, 2: 0.1935, 3: 0.1796, 4: 0.1483}}"
1569,1569,1569,0.9470000267028807,19.0,definitions for efficacy endpoints.,UniversSB-Light,4,-0.2329999953508377,3355443,31,24,2,"{'concept_id': {0: 'C2347784'}, 'canonical_name': {0: 'Clinical Endpoint'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'definitions for efficacy endpoints.'}}","{'concept_id': {0: 'C0162488'}, 'canonical_name': {0: 'Surrogate Endpoints'}, 'aliases': {0: ['End Points, Surrogate', 'Endpoint, Surrogate', 'Surrogate End Points', 'Endpoints, Surrogate', 'Surrogate Endpoint', 'Surrogate End Point', 'End Point, Surrogate']}, 'types': {0: ['T080']}, 'definition': {0: 'A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.'}, 'entity': {0: 'endpoints'}, 'text': {0: 'definitions for efficacy endpoints.'}}",{},{},"{'concept_id': {0: 'C5209257'}, 'canonical_name': {0: 'Reduced drug efficacy'}, 'aliases': {0: ['Decreased drug efficacy']}, 'types': {0: ['T033']}, 'definition': {0: 'Decreased response to a drug intervention in comparison to the expected response. [ORCID:0000-0002-7440-8864, PMID:26178435]'}, 'entity': {0: 'efficacy'}, 'text': {0: 'definitions for efficacy endpoints.'}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'definitions efficacy endpoints', 1: 'definitions efficacy', 2: 'efficacy endpoints'}, 'score': {0: 0.8264, 1: 0.816, 2: 0.8015}}"
1570,1570,1570,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,31,25,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1571,1571,1571,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,31,25,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1572,1572,1572,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,31,25,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1573,1573,1573,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,31,25,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1574,1574,1574,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,31,26,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1575,1575,1575,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,31,26,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1576,1576,1576,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,31,26,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1577,1577,1577,0.75,98.0,Knowing what may lie ahead  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,32,1,0,{},{},{},{},{},"  entity_group  value     score
0         Date  ahead  0.362999",[],"{'keyword': {0: 'knowing lie', 1: 'knowing lie ahead', 2: 'lie ahead'}, 'score': {0: 0.8569, 1: 0.8339, 2: 0.7784}}"
1578,1578,1578,0.75,98.0,can give your patients a sense  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,32,1,1,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: 'can give your patients a sense  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'can give your patients a sense  '}}",{},{},{},"           entity_group  value     score
0  Diagnostic_procedure  sense  0.836095",[],"{'keyword': {0: 'patients sense'}, 'score': {0: 0.8771}}"
1579,1579,1579,0.75,98.0,of control,ConduitITC-Bold,20,-0.1700000017881393,8194925,32,1,2,"{'concept_id': {0: 'C0308718'}, 'canonical_name': {0: 'CONTROL veterinary product'}, 'aliases': {0: ['CONTROL [brand name]', 'CONTROL']}, 'types': {0: ['T121']}, 'definition': {0: 'brand of veterinary product'}, 'entity': {0: 'control'}, 'text': {0: 'of control'}}","{'concept_id': {0: 'C0031249'}, 'canonical_name': {0: 'Control, Pest'}, 'aliases': {0: ['Pest Management', 'Management, Pest', 'Pest Control']}, 'types': {0: ['T057']}, 'definition': {0: 'The reduction or regulation of the population of noxious, destructive, or dangerous plants, insects, or other animals. This includes control of plants that serve as habitats or food sources for animal pests.'}, 'entity': {0: 'control'}, 'text': {0: 'of control'}}",{},"{'concept_id': {0: 'C3544486'}, 'canonical_name': {0: 'cell cycle control'}, 'aliases': {0: ['regulation of cell cycle phase transition', 'regulation of cell cycle transition']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that modulates the frequency, rate or extent of cell cycle phase transition. [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:22841721]'}, 'entity': {0: 'control'}, 'text': {0: 'of control'}}",{},"           entity_group       value     score
0  Detailed_description  of control  0.495689",[],"{'keyword': {}, 'score': {}}"
1580,1580,1580,0.9470000267028807,32.0,The safety profile of adjuvant Kadcyla was consistent with previous studies,UniversSB-Light,4,-0.2329999953508377,3355443,32,2,0,"{'concept_id': {0: 'C0036745'}, 'canonical_name': {0: 'Study of serum'}, 'aliases': {0: ['serum studies', 'serology', 'serologies', 'Serology', 'study of serum']}, 'types': {0: ['T091']}, 'definition': {0: 'The study of serum, especially of antigen-antibody reactions in vitro.'}, 'entity': {0: 'studies'}, 'text': {0: 'The safety profile of adjuvant Kadcyla was consistent with previous studies'}}","{'concept_id': {0: 'C0023981'}, 'canonical_name': {0: 'Study, Longitudinal'}, 'aliases': {0: ['Longitudinal Studies', 'Studies, Longitudinal', 'Longitudinal Study']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which variables relating to an individual or group of individuals are assessed over a period of time.'}, 'entity': {0: 'studies'}, 'text': {0: 'The safety profile of adjuvant Kadcyla was consistent with previous studies'}}",{},{},{},"           entity_group             value     score
0  Detailed_description  adjuvant Kadcyla  0.904942
1           Coreference           Kadcyla  0.902791
2           Coreference           studies  0.382323","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'safety profile adjuvant', 1: 'consistent previous studies', 2: 'kadcyla consistent previous', 3: 'consistent previous', 4: 'previous studies'}, 'score': {0: 0.5878, 1: 0.5045, 2: 0.4769, 3: 0.4331, 4: 0.2592}}"
1581,1581,1581,0.9470000267028807,32.0,17.9% of patients discontinued  ,UniversSB-Light,4,-0.2329999953508377,16777215,32,3,0,"{'concept_id': {0: 'C0549178'}, 'canonical_name': {0: 'Continuous'}, 'aliases': {0: ['Continuous', 'Continuing', 'Continuous (qualifier value)', 'Continued', 'Continual', 'continuous', 'All of the time', 'Ongoing', 'Continue']}, 'types': {0: ['T078']}, 'definition': {0: 'Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.'}, 'entity': {0: 'discontinued'}, 'text': {0: '17.9% of patients discontinued  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: '17.9% of patients discontinued  '}}",{},{},{},"  entity_group         value     score
0    Lab_value        17.9 %  0.997940
1      History  discontinued  0.754478",[],"{'keyword': {0: '17 patients discontinued', 1: 'patients discontinued', 2: '17 patients'}, 'score': {0: 0.9369, 1: 0.8781, 2: 0.6724}}"
1582,1582,1582,0.9470000267028807,32.0,Kadcyla due to adverse events,UniversSB-Light,4,-0.2329999953508377,16777215,32,3,1,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'Kadcyla due to adverse events'}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'Kadcyla due to adverse events'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla due to adverse events'}}",{},{},"   entity_group           value     score
0   Coreference         Kadcyla  0.536706
1  Sign_symptom  adverse events  0.877486","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'adverse events', 1: 'kadcyla adverse events', 2: 'kadcyla adverse'}, 'score': {0: 0.8705, 1: 0.8159, 2: 0.7552}}"
1583,1583,1583,0.9470000267028807,32.0,98.8% of patients experienced  ,UniversSB-Light,4,-0.2329999953508377,16777215,32,4,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: '98.8% of patients experienced  '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: '98.8% of patients experienced  '}}",{},{},{},"  entity_group   value     score
0    Lab_value  98.8 %  0.999506",[],"{'keyword': {0: '98 patients experienced', 1: '98 patients', 2: 'patients experienced'}, 'score': {0: 0.9446, 1: 0.8177, 2: 0.7901}}"
1584,1584,1584,0.9470000267028807,32.0,adverse events with Kadcyla vs 93.3% ,UniversSB-Light,4,-0.2329999953508377,16777215,32,4,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'adverse events with Kadcyla vs 93.3% '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'adverse events with Kadcyla vs 93.3% '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'adverse events with Kadcyla vs 93.3% '}}",{},{},"   entity_group           value     score
0  Sign_symptom  adverse events  0.999666
1   Coreference         Kadcyla  0.773288
2     Lab_value          93.3 %  0.999897","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'adverse events', 1: 'adverse events kadcyla', 2: 'events kadcyla', 3: 'events kadcyla vs', 4: 'vs 93'}, 'score': {0: 0.863, 1: 0.8253, 2: 0.7671, 3: 0.7411, 4: 0.5291}}"
1585,1585,1585,0.9470000267028807,32.0,with trastuzumab,UniversSB-Light,4,-0.2329999953508377,16777215,32,4,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'with trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'with trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'with trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  trastuzumab  0.999832","[('trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
1586,1586,1586,0.9470000267028807,32.0,There was one grade 5  ,UniversSB-Light,4,-0.2329999953508377,16777215,32,9,0,{},{},{},{},{},"  entity_group    value     score
0    Lab_value      one  0.998139
1    Lab_value  grade 5  0.998042",[],"{'keyword': {}, 'score': {}}"
1587,1587,1587,0.9470000267028807,32.0,adverse event in a patient  ,UniversSB-Light,4,-0.2329999953508377,16777215,32,9,1,"{'concept_id': {0: 'C1578481'}, 'canonical_name': {0: 'Mail Claim Party - Patient'}, 'aliases': {0: ['Patient']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'patient'}, 'text': {0: 'adverse event in a patient  '}}","{'concept_id': {0: 'C4277550'}, 'canonical_name': {0: 'Patient Portals'}, 'aliases': {0: ['Patient Internet Portals', 'Web Portals, Patient', 'Web Portal, Patient', 'Patient Internet Portal', 'Portals, Patient Web', 'Portal, Patient Web', 'Portal, Patient Internet', 'Patient Web Portals', 'Internet Portal, Patient', 'Internet Portals, Patient', 'Patient Portal', 'Patient Web Portal', 'Portals, Patient Internet', 'Portal, Patient']}, 'types': {0: ['T170']}, 'definition': {0: 'A secure online website that provides patients convenient 24-hour access to personal health information via an Internet connection.'}, 'entity': {0: 'patient'}, 'text': {0: 'adverse event in a patient  '}}",{},{},{},"   entity_group          value     score
0  Sign_symptom  adverse event  0.998107",[],"{'keyword': {0: 'adverse event', 1: 'adverse event patient', 2: 'event patient'}, 'score': {0: 0.942, 1: 0.8598, 2: 0.7284}}"
1588,1588,1588,0.9470000267028807,32.0,treated with Kadcyla*,UniversSB-Light,4,-0.2329999953508377,16777215,32,9,2,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla*'}, 'text': {0: 'treated with Kadcyla*'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla*'}, 'text': {0: 'treated with Kadcyla*'}}",{},{},{},"           entity_group    value     score
0           Coreference  Kadcyla  0.934317
1  Detailed_description        *  0.725161","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'treated kadcyla'}, 'score': {0: 0.8732}}"
1589,1589,1589,0.9470000267028807,32.0,Serious adverse events occurred in ,UniversSB-Light,4,-0.2329999953508377,16777215,32,10,0,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'Serious adverse events occurred in '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'Serious adverse events occurred in '}}",{},{},{},"   entity_group           value     score
0      Severity         Serious  0.999734
1  Sign_symptom  adverse events  0.999859",[],"{'keyword': {0: 'adverse events occurred', 1: 'adverse events', 2: 'events occurred'}, 'score': {0: 0.9224, 1: 0.8859, 2: 0.824}}"
1590,1590,1590,0.9470000267028807,32.0,12.7% of patients treated with Kadcyla ,UniversSB-Light,4,-0.2329999953508377,16777215,32,10,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: '12.7% of patients treated with Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: '12.7% of patients treated with Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: '12.7% of patients treated with Kadcyla '}}",{},{},"  entity_group    value     score
0    Lab_value   12.7 %  0.999085
1   Medication  Kadcyla  0.767714","[('Kadcyla', 'DRUG')]","{'keyword': {0: '12 patients treated', 1: 'patients treated kadcyla', 2: '12 patients', 3: 'treated kadcyla', 4: 'patients treated'}, 'score': {0: 0.7839, 1: 0.7576, 2: 0.7565, 3: 0.7359, 4: 0.6994}}"
1591,1591,1591,0.9470000267028807,32.0,and 8.1% of patients treated with ,UniversSB-Light,4,-0.2329999953508377,16777215,32,10,2,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treated with'}, 'text': {0: 'and 8.1% of patients treated with '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: 'and 8.1% of patients treated with '}}",{},{},{},"  entity_group  value     score
0    Lab_value  8.1 %  0.998182",[],"{'keyword': {0: 'patients treated'}, 'score': {0: 0.6902}}"
1592,1592,1592,0.9470000267028807,32.0,trastuzumab,UniversSB-Light,4,-0.2329999953508377,16777215,32,10,3,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication  trastuzumab  0.999798","[('trastuzumab', 'DRUG')]","{'keyword': {}, 'score': {}}"
1593,1593,1593,0.9169999957084656,30.0,References:,ConduitITC-Bold,20,-0.2349999994039535,8194925,32,13,0,"{'concept_id': {0: 'C1561577'}, 'canonical_name': {0: 'Reference - MdfHmdMetSourceType'}, 'aliases': {0: ['Reference']}, 'types': {0: ['T170']}, 'definition': {0: '<p>This row represents a reference to a previously defined type. Such a reference means that, in a given message, the message element instance for the current row is identical to the message element instance that instantiates the referred row.</p>'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}","{'concept_id': {0: 'C0016483'}, 'canonical_name': {0: 'Food Preferences'}, 'aliases': {0: ['Food Preference', 'Preferences, Food', 'Preference, Food']}, 'types': {0: ['T080']}, 'definition': {0: 'The selection of one food over another.'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1594,1594,1594,0.8830000162124634,22.0,1. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628. ,MyriadPro-Light,4,-0.25,3355443,32,13,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'et al', 4: 'engl med 2019'}, 'score': {0: 0.8031, 1: 0.7251, 2: 0.7194, 3: 0.6642, 4: 0.6422}}"
1595,1595,1595,0.8830000162124634,22.0,2. Verma S et al. N Engl J Med. 2012;367(19):1783–1791.,MyriadPro-Light,4,-0.25,3355443,32,13,2,{},{},{},{},{},"           entity_group           value     score
0  Detailed_description           Verma  0.818863
1           Coreference           Verma  0.120926
2             Lab_value             367  0.923943
3             Lab_value  367 :1783–1791  0.497523",[],"{'keyword': {0: '2012 367 19', 1: 'verma et al', 2: 'al engl', 3: 'med 2012', 4: 'engl med 2012'}, 'score': {0: 0.8736, 1: 0.815, 2: 0.7844, 3: 0.7653, 4: 0.6619}}"
1596,1596,1596,0.9470000267028807,19.0,"*One patient with a platelet count of 55,000 mm",UniversSB-Light,4,-0.2329999953508377,3355443,32,14,0,"{'concept_id': {0: 'C5201036'}, 'canonical_name': {0: 'Low Platelet Count'}, 'aliases': {0: ['low platelet', 'low count platelet', 'low platelets', 'platelet count low', 'Low Platelet Count', 'low platelet count', 'platelet low', 'platelets low', 'Low platelet count']}, 'types': {0: ['T034']}, 'definition': {0: 'A lower than average level of platelets in a sample.'}, 'entity': {0: 'platelet count'}, 'text': {0: '*One patient with a platelet count of 55,000 mm'}}","{'concept_id': {0: 'C0005821'}, 'canonical_name': {0: 'Platelet'}, 'aliases': {0: ['Platelets', 'Platelets, Blood', 'Thrombocyte', 'Thrombocytes', 'Blood Platelet', 'Platelet, Blood', 'Blood Platelets']}, 'types': {0: ['T025']}, 'definition': {0: 'Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.'}, 'entity': {0: 'platelet count'}, 'text': {0: '*One patient with a platelet count of 55,000 mm'}}",{},{},"{'concept_id': {0: 'C0857460'}, 'canonical_name': {0: 'Increased platelet count'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'A higher than average level of platelets in a sample.'}, 'entity': {0: 'platelet count'}, 'text': {0: '*One patient with a platelet count of 55,000 mm'}}","           entity_group           value     score
0  Diagnostic_procedure  platelet count  0.999791
1             Lab_value       55,000 mm  0.999824",[],"{'keyword': {0: 'count 55 000', 1: 'patient platelet', 2: 'count 55', 3: 'platelet count', 4: '000 mm'}, 'score': {0: 0.6874, 1: 0.6818, 2: 0.6782, 3: 0.616, 4: 0.6147}}"
1597,1597,1597,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,32,15,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1598,1598,1598,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,32,15,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1599,1599,1599,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,32,15,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1600,1600,1600,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,32,15,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1601,1601,1601,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,32,16,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1602,1602,1602,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,32,16,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1603,1603,1603,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,32,16,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1604,1604,1604,0.9169999957084656,98.0,98.8% of patients experienced adverse events ,ConduitITC-Bold,20,-0.2349999994039535,8194925,33,1,0,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: '98.8% of patients experienced adverse events '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: '98.8% of patients experienced adverse events '}}",{},{},{},"   entity_group           value     score
0     Lab_value          98.8 %  0.999234
1  Sign_symptom  adverse events  0.999889",[],"{'keyword': {0: '98 patients experienced', 1: 'adverse events', 2: 'experienced adverse events', 3: 'patients experienced', 4: '98 patients'}, 'score': {0: 0.7907, 1: 0.788, 2: 0.7744, 3: 0.773, 4: 0.6827}}"
1605,1605,1605,0.9169999957084656,98.0,with Kadcyla vs 93.3% with trastuzumab,ConduitITC-Bold,20,-0.2349999994039535,8194925,33,1,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'with Kadcyla vs 93.3% with trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'with Kadcyla vs 93.3% with trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'with Kadcyla vs 93.3% with trastuzumab'}}",{},{},"  entity_group        value     score
0  Coreference      Kadcyla  0.761197
1    Lab_value       93.3 %  0.999871
2   Medication  trastuzumab  0.999862","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'kadcyla vs', 1: 'kadcyla vs 93', 2: 'vs 93 trastuzumab', 3: 'vs 93', 4: '93 trastuzumab'}, 'score': {0: 0.6757, 1: 0.6694, 2: 0.638, 3: 0.6234, 4: 0.591}}"
1606,1606,1606,0.9520000219345092,28.0,Trastuzumab (n=720),MyriadPro-Regular,4,-0.25,16777215,33,2,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=720)'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=720)'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=720)'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999842","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab 720'}, 'score': {0: 0.8957}}"
1607,1607,1607,0.9520000219345092,28.0,Kadcyla (n=740),MyriadPro-Regular,4,-0.25,16777215,33,2,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=740)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=740)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=740)'}}",{},{},"           entity_group    value    score
0  Diagnostic_procedure  Kadcyla  0.98247",[],"{'keyword': {0: 'kadcyla 740'}, 'score': {0: 0.8612}}"
1608,1608,1608,0.9520000219345092,26.0,"Patients, n (%)",MyriadPro-Regular,4,-0.25,16777215,33,3,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'Patients'}, 'text': {0: 'Patients, n (%)'}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'Patients'}, 'text': {0: 'Patients, n (%)'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1609,1609,1609,0.9520000219345092,26.0,All grades,MyriadPro-Regular,4,-0.25,16777215,33,3,1,"{'concept_id': {0: 'C3244287'}, 'canonical_name': {0: 'School Grade'}, 'aliases': {0: ['grade']}, 'types': {0: ['T033']}, 'definition': {0: '<b>Description:</b>The school grade or level the patient was in when immunized.'}, 'entity': {0: 'grades'}, 'text': {0: 'All grades'}}",{},{},{},{},"           entity_group   value     score
0  Detailed_description     All  0.846238
1  Diagnostic_procedure  grades  0.606837",[],"{'keyword': {}, 'score': {}}"
1610,1610,1610,0.9520000219345092,26.0,Grade 3*,MyriadPro-Regular,4,-0.25,16777215,33,3,2,{},{},{},{},{},"  entity_group      value    score
0    Lab_value  Grade 3 *  0.36618",[],"{'keyword': {}, 'score': {}}"
1611,1611,1611,0.9520000219345092,26.0,All grades,MyriadPro-Regular,4,-0.25,16777215,33,3,3,"{'concept_id': {0: 'C3244287'}, 'canonical_name': {0: 'School Grade'}, 'aliases': {0: ['grade']}, 'types': {0: ['T033']}, 'definition': {0: '<b>Description:</b>The school grade or level the patient was in when immunized.'}, 'entity': {0: 'grades'}, 'text': {0: 'All grades'}}",{},{},{},{},"           entity_group   value     score
0  Detailed_description     All  0.846238
1  Diagnostic_procedure  grades  0.606837",[],"{'keyword': {}, 'score': {}}"
1612,1612,1612,0.9520000219345092,26.0,Grade 3*,MyriadPro-Regular,4,-0.25,16777215,33,3,4,{},{},{},{},{},"  entity_group      value    score
0    Lab_value  Grade 3 *  0.36618",[],"{'keyword': {}, 'score': {}}"
1613,1613,1613,0.8830000162124634,26.0,Any adverse event,MyriadPro-Light,4,-0.25,5723991,33,4,0,"{'concept_id': {0: 'C5236149'}, 'canonical_name': {0: 'Adverse Event Term'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A term that refers to an adverse event, often taken from a list of standardized terms.'}, 'entity': {0: 'adverse event'}, 'text': {0: 'Any adverse event'}}","{'concept_id': {0: 'C0151735'}, 'canonical_name': {0: 'Injection Site Events'}, 'aliases': {0: ['Injection Site Event', 'Injection Site Adverse Event', 'Injection Site Reaction', 'Injection Site Reactions']}, 'types': {0: ['T046']}, 'definition': {0: 'Adverse reactions that occur initially at the site of injection or infusion. Milder type is confined to a local allergic flare reaction. A more severe reaction is caused by extravasation of VESICANTS from the blood vessel at the site of injection and can cause damage to the surrounding tissue. In tumor flare reaction symptoms involve well beyond the injection site such as an increase in the tumor size and tumor markers levels, bone pain, and HYPERCALCEMIA.'}, 'entity': {0: 'adverse event'}, 'text': {0: 'Any adverse event'}}",{},{},{},"   entity_group          value     score
0  Sign_symptom  adverse event  0.999895",[],"{'keyword': {0: 'adverse event'}, 'score': {0: 0.8962}}"
1614,1614,1614,0.8830000162124634,26.0,731 (98.8),MyriadPro-Light,4,-0.25,5723991,33,4,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   731  0.993434",[],"{'keyword': {0: '731 98'}, 'score': {0: 0.7557}}"
1615,1615,1615,0.8830000162124634,26.0,190 (25.7),MyriadPro-Light,4,-0.25,5723991,33,4,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value   190  0.999509",[],"{'keyword': {0: '190 25'}, 'score': {0: 0.7999}}"
1616,1616,1616,0.8830000162124634,26.0,672 (93.3),MyriadPro-Light,4,-0.25,5723991,33,4,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   672  0.981329",[],"{'keyword': {0: '672 93'}, 'score': {0: 0.7884}}"
1617,1617,1617,0.8830000162124634,26.0,111 (15.4),MyriadPro-Light,4,-0.25,5723991,33,4,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value   111  0.999389",[],"{'keyword': {0: '111 15'}, 'score': {0: 0.7994}}"
1618,1618,1618,0.8830000162124634,26.0,Fatigue,MyriadPro-Light,4,-0.25,5723991,33,5,0,"{'concept_id': {0: 'C4744662'}, 'canonical_name': {0: 'PROMIS Pediatric and Parent Proxy Physical Health Domain'}, 'aliases': {0: ['Ped Fatigue', 'PROMIS Ped Fatigue']}, 'types': {0: ['T170']}, 'definition': {0: 'The set of PROMIS measures that assess the physical health of pediatric subjects through self-report or parent proxy report.'}, 'entity': {0: 'Fatigue'}, 'text': {0: 'Fatigue'}}","{'concept_id': {0: 'C0004095'}, 'canonical_name': {0: 'Asthenopia'}, 'aliases': {0: ['Eyestrain', 'Fatigue, Visual', 'Visual Fatigue', 'Eye Fatigue', 'Fatigue, Eye']}, 'types': {0: ['T047']}, 'definition': {0: 'Term generally used to describe complaints related to refractive error, ocular muscle imbalance, including pain or aching around the eyes, burning and itchiness of the eyelids, ocular fatigue, and headaches.'}, 'entity': {0: 'Fatigue'}, 'text': {0: 'Fatigue'}}",{},"{'concept_id': {0: 'C2265886'}, 'canonical_name': {0: 'detection of muscle activity involved in regulation of muscle adaptation'}, 'aliases': {0: ['detection of fatigue']}, 'types': {0: ['T044']}, 'definition': {0: 'The series of events by which a muscle activity stimulus is received and converted into a molecular signal. This occurs as part of the regulation of muscle adaptation. [GOC:ef, GOC:mtg_muscle]'}, 'entity': {0: 'Fatigue'}, 'text': {0: 'Fatigue'}}","{'concept_id': {0: 'C5539444'}, 'canonical_name': {0: 'Cognitive fatigue'}, 'aliases': {0: ['Central fatigue']}, 'types': {0: ['T184']}, 'definition': {0: 'A failure to sustain attention that requires self-motivation to optimize performance. [PMID:21128132]'}, 'entity': {0: 'Fatigue'}, 'text': {0: 'Fatigue'}}","   entity_group    value     score
0  Sign_symptom  Fatigue  0.999914",[],"{'keyword': {}, 'score': {}}"
1619,1619,1619,0.8830000162124634,26.0,366 (49.5),MyriadPro-Light,4,-0.25,5723991,33,5,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   366  0.998327",[],"{'keyword': {0: '366 49'}, 'score': {0: 0.8512}}"
1620,1620,1620,0.8830000162124634,26.0,8 (1.1),MyriadPro-Light,4,-0.25,5723991,33,5,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     8  0.999834",[],"{'keyword': {}, 'score': {}}"
1621,1621,1621,0.8830000162124634,26.0,243 (33.8),MyriadPro-Light,4,-0.25,5723991,33,5,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   243  0.997947",[],"{'keyword': {0: '243 33'}, 'score': {0: 0.8392}}"
1622,1622,1622,0.8830000162124634,26.0,1 (0.1),MyriadPro-Light,4,-0.25,5723991,33,5,4,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1623,1623,1623,0.8830000162124634,26.0,Nausea,MyriadPro-Light,4,-0.25,5723991,33,6,0,"{'concept_id': {0: 'C1171206'}, 'canonical_name': {0: 'Nausea care'}, 'aliases': {0: ['Nausea Care', 'Nausea care (regime/therapy)', 'Nausea management']}, 'types': {0: ['T058']}, 'definition': {0: 'Actions performed to control the distaste for food and desire to vomit'}, 'entity': {0: 'Nausea'}, 'text': {0: 'Nausea'}}","{'concept_id': {0: 'C0027497'}, 'canonical_name': {0: 'Nausea'}, 'aliases': {0: []}, 'types': {0: ['T184']}, 'definition': {0: 'An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.'}, 'entity': {0: 'Nausea'}, 'text': {0: 'Nausea'}}",{},{},"{'concept_id': {0: 'C0027497'}, 'canonical_name': {0: 'Nausea'}, 'aliases': {0: []}, 'types': {0: ['T184']}, 'definition': {0: 'An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.'}, 'entity': {0: 'Nausea'}, 'text': {0: 'Nausea'}}","   entity_group   value     score
0  Sign_symptom  Nausea  0.999906",[],"{'keyword': {}, 'score': {}}"
1624,1624,1624,0.8830000162124634,26.0,308 (41.6),MyriadPro-Light,4,-0.25,5723991,33,6,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   308  0.999475",[],"{'keyword': {0: '308 41'}, 'score': {0: 0.8006}}"
1625,1625,1625,0.8830000162124634,26.0,4 (0.5),MyriadPro-Light,4,-0.25,5723991,33,6,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     4  0.999844",[],"{'keyword': {}, 'score': {}}"
1626,1626,1626,0.8830000162124634,26.0,94 (13.1),MyriadPro-Light,4,-0.25,5723991,33,6,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    94  0.999433",[],"{'keyword': {0: '94 13'}, 'score': {0: 0.8211}}"
1627,1627,1627,0.8830000162124634,26.0,2 (0.3),MyriadPro-Light,4,-0.25,5723991,33,6,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1628,1628,1628,0.8830000162124634,26.0,Decreased platelet count*,MyriadPro-Light,4,-0.25,5723991,33,7,0,"{'concept_id': {0: 'C0857460'}, 'canonical_name': {0: 'Increased number of platelets'}, 'aliases': {0: ['Platelet count above reference range (finding)', 'increased platelets', 'Elevated platelet count', 'PLATELETS INCREASED', 'high platelet count', 'increased platelet count', 'High Platelet Count', 'increased platelet', 'elevated platelet count', 'INCREASED PLATELET COUNT', 'Platelet count above reference range', 'platelets increased', 'Increased platelets', 'Increased platelet count']}, 'types': {0: ['T033']}, 'definition': {0: 'A higher than average level of platelets in a sample.'}, 'entity': {0: 'Decreased platelet count*'}, 'text': {0: 'Decreased platelet count*'}}","{'concept_id': {0: 'C0032181'}, 'canonical_name': {0: 'Platelet Count, Blood'}, 'aliases': {0: ['Platelet Numbers, Blood', 'Count, Blood Platelet', 'Platelet Numbers', 'Blood Platelet Numbers', 'Platelet Number', 'Number, Blood Platelet', 'Blood Platelet Counts', 'Counts, Blood Platelet', 'Blood Platelet Count', 'Platelet Count', 'Counts, Platelet', 'Number, Platelet', 'Count, Platelet', 'Platelet Number, Blood', 'Platelet Counts', 'Blood Platelet Number', 'Numbers, Blood Platelet', 'Platelet Counts, Blood', 'Numbers, Platelet']}, 'types': {0: ['T059']}, 'definition': {0: 'The number of PLATELETS per unit volume in a sample of venous BLOOD.'}, 'entity': {0: 'Decreased platelet count*'}, 'text': {0: 'Decreased platelet count*'}}",{},{},"{'concept_id': {0: 'C0580317'}, 'canonical_name': {0: 'Abnormal platelet count'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Abnormal number of platelets per volume of blood. In a healthy adult, a normal platelet count is between 150,000 and 450,000 per microliter of blood. [DDD:kfreson]'}, 'entity': {0: 'Decreased platelet count*'}, 'text': {0: 'Decreased platelet count*'}}","           entity_group           value     score
0             Lab_value       Decreased  0.999931
1  Diagnostic_procedure  platelet count  0.999942
2             Lab_value               *  0.998747",[],"{'keyword': {0: 'decreased platelet count', 1: 'decreased platelet', 2: 'platelet count'}, 'score': {0: 0.9814, 1: 0.9518, 2: 0.7469}}"
1629,1629,1629,0.8830000162124634,26.0,211 (28.5),MyriadPro-Light,4,-0.25,5723991,33,7,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   211  0.999028",[],"{'keyword': {0: '211 28'}, 'score': {0: 0.8389}}"
1630,1630,1630,0.8830000162124634,26.0,27 (3.6),MyriadPro-Light,4,-0.25,5723991,33,7,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    27  0.999653",[],"{'keyword': {}, 'score': {}}"
1631,1631,1631,0.8830000162124634,26.0,17 (2.4),MyriadPro-Light,4,-0.25,5723991,33,7,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    17  0.999571",[],"{'keyword': {}, 'score': {}}"
1632,1632,1632,0.8830000162124634,26.0,1 (0.1),MyriadPro-Light,4,-0.25,5723991,33,7,4,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1633,1633,1633,0.8830000162124634,26.0,Increased aspartate aminotransferase level,MyriadPro-Light,4,-0.25,5723991,33,8,0,"{'concept_id': {0: 'C1547707'}, 'canonical_name': {0: 'Floor - story of building'}, 'aliases': {0: ['Floor', 'Story', 'Level']}, 'types': {0: ['T083']}, 'definition': {0: 'A location comprising a single level of a multilevel building.'}, 'entity': {0: 'level'}, 'text': {0: 'Increased aspartate aminotransferase level'}}","{'concept_id': {0: 'C5197751'}, 'canonical_name': {0: 'Sea Level Rise'}, 'aliases': {0: ['Rising Sea Levels', 'Sea Level, Rising', 'Sea-Level Rise', 'Rising Sea Level', 'Sea Levels, Rising']}, 'types': {0: ['T067']}, 'definition': {0: 'An increase in the volume of the oceans and seas causing an elevation of the air-sea interface.'}, 'entity': {0: 'level'}, 'text': {0: 'Increased aspartate aminotransferase level'}}",{},"{'concept_id': {0: 'C2247344'}, 'canonical_name': {0: 'aspartate-prephenate aminotransferase activity'}, 'aliases': {0: ['prephenate aspartate aminotransferase activity', 'L-aspartate:prephenate aminotransferase activity', 'PAT', 'L-arogenate:oxaloacetate aminotransferase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: L-arogenate + oxaloacetate = prephenate + L-aspartate. [EC:2.6.1.78]'}, 'entity': {0: 'aspartate aminotransferase'}, 'text': {0: 'Increased aspartate aminotransferase level'}}","{'concept_id': {0: 'C4703556'}, 'canonical_name': {0: 'Abnormal hypoxanthine-guanine phosphoribosyltransferase level'}, 'aliases': {0: ['Abnormal GMP pyrophosphorylase level', 'Abnormal 6-hydroxypurine phosphoribosyltransferase level', 'Abnormal GPRT level']}, 'types': {0: ['T033']}, 'definition': {0: 'Altered level of the enzyme that catalyzes conversion of hypoxanthine to inosine monophosphate and guanine to guanosine monophosphate via transfer of the 5-phosphoribosyl group from 5-phosphoribosyl 1-pyrophosphate. [RGD:sjwang]'}, 'entity': {0: 'level'}, 'text': {0: 'Increased aspartate aminotransferase level'}}","           entity_group                             value     score
0             Lab_value                         Increased  0.999820
1  Diagnostic_procedure  aspartate aminotransferase level  0.997505",[],"{'keyword': {0: 'increased aspartate aminotransferase', 1: 'increased aspartate', 2: 'aspartate aminotransferase level', 3: 'aminotransferase level', 4: 'aspartate aminotransferase'}, 'score': {0: 0.9785, 1: 0.9394, 2: 0.8709, 3: 0.8362, 4: 0.7941}}"
1634,1634,1634,0.8830000162124634,26.0,210 (28.4),MyriadPro-Light,4,-0.25,5723991,33,8,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   210  0.999433",[],"{'keyword': {0: '210 28'}, 'score': {0: 0.9019}}"
1635,1635,1635,0.8830000162124634,26.0,4 (0.5),MyriadPro-Light,4,-0.25,5723991,33,8,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     4  0.999844",[],"{'keyword': {}, 'score': {}}"
1636,1636,1636,0.8830000162124634,26.0,40 (5.6),MyriadPro-Light,4,-0.25,5723991,33,8,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    40  0.999794",[],"{'keyword': {}, 'score': {}}"
1637,1637,1637,0.8830000162124634,26.0,2 (0.3),MyriadPro-Light,4,-0.25,5723991,33,8,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1638,1638,1638,0.8830000162124634,26.0,Headache,MyriadPro-Light,4,-0.25,5723991,33,9,0,"{'concept_id': {0: 'C0270697'}, 'canonical_name': {0: 'Post-Lumbar Puncture Headache'}, 'aliases': {0: ['Post-Lumbar Puncture Headache', 'Postspinal headache', 'Post-lumbar puncture headache', 'headache post spinal', 'post-lumbar puncture headache', 'post lumbar puncture headache', 'dural headache post puncture', 'post dural puncture headache', 'headache spinal', 'headaches spinal', 'headaches lumbar puncture', 'Spinal headache', 'headache post lumbar puncture', 'post spinal headache', 'dural headaches post puncture', 'Headache following lumbar puncture', 'headaches post spinal', 'Lumbar Puncture Headache', 'spinal headache', 'Headache following lumbar puncture (disorder)', 'lumbar puncture headache', 'Lumbar puncture headache']}, 'types': {0: ['T184']}, 'definition': {0: 'Headache in erect position, after lumbar puncture; due to lowering of intracranial pressure by leakage of cerebrospinal fluid through the needle tract.'}, 'entity': {0: 'Headache'}, 'text': {0: 'Headache'}}","{'concept_id': {0: 'C0393735'}, 'canonical_name': {0: 'Syndrome, Headache'}, 'aliases': {0: ['Headache Disorder', 'Headache Syndromes', 'Headache Disorders', 'Cephalgia Syndromes', 'Cephalgia Syndrome', 'Headache Syndrome']}, 'types': {0: ['T047']}, 'definition': {0: 'Various conditions with the symptom of HEADACHE. Headache disorders are classified into major groups, such as PRIMARY HEADACHE DISORDERS (based on characteristics of their headache symptoms) and SECONDARY HEADACHE DISORDERS (based on their etiologies). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)'}, 'entity': {0: 'Headache'}, 'text': {0: 'Headache'}}",{},{},"{'concept_id': {0: 'C0009088'}, 'canonical_name': {0: 'Cluster headache'}, 'aliases': {0: []}, 'types': {0: ['T047']}, 'definition': {0: 'A primary headache disorder that is characterized by severe, strictly unilateral PAIN which is orbital, supraorbital, temporal or in any combination of these sites, lasting 15-180 min. occurring 1 to 8 times a day. The attacks are associated with one or more of the following, all of which are ipsilateral: conjunctival injection, lacrimation, nasal congestion, rhinorrhea, facial SWEATING, eyelid EDEMA, and miosis. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)'}, 'entity': {0: 'Headache'}, 'text': {0: 'Headache'}}","   entity_group     value    score
0  Sign_symptom  Headache  0.99988",[],"{'keyword': {}, 'score': {}}"
1639,1639,1639,0.8830000162124634,26.0,210 (28.4),MyriadPro-Light,4,-0.25,5723991,33,9,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   210  0.999433",[],"{'keyword': {0: '210 28'}, 'score': {0: 0.9019}}"
1640,1640,1640,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,33,9,2,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1641,1641,1641,0.8830000162124634,26.0,122 (16.9),MyriadPro-Light,4,-0.25,5723991,33,9,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   122  0.999822",[],"{'keyword': {0: '122 16'}, 'score': {0: 0.7973}}"
1642,1642,1642,0.8830000162124634,26.0,1 (0.1),MyriadPro-Light,4,-0.25,5723991,33,9,4,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1643,1643,1643,0.8830000162124634,26.0,Arthralgia,MyriadPro-Light,4,-0.25,5723991,33,10,0,"{'concept_id': {0: 'C0221785'}, 'canonical_name': {0: 'Pain in wrist'}, 'aliases': {0: ['Wrist arthralgia', 'Wrist joint pain', 'pain in wrist', 'joint pain wrist', 'wrist pain', 'wrist joint pain', 'joint pain wrists', 'Wrist joint pain (finding)', 'pain wrist', 'WRIST PAIN', 'Arthralgia of wrist', 'Pain in wrist (finding)', 'pains wrist', 'Wrist pain', 'pain wrists', 'Pain in wrist']}, 'types': {0: ['T184']}, 'definition': {0: 'An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the wrist. [UToronto:chum]'}, 'entity': {0: 'Arthralgia'}, 'text': {0: 'Arthralgia'}}","{'concept_id': {0: 'C0003862'}, 'canonical_name': {0: 'Arthralgia'}, 'aliases': {0: ['Pains, Joint', 'Pain, Joint', 'Arthralgias', 'Joint Pain', 'Joint Pains']}, 'types': {0: ['T184']}, 'definition': {0: 'Pain in the joint.'}, 'entity': {0: 'Arthralgia'}, 'text': {0: 'Arthralgia'}}",{},{},"{'concept_id': {0: 'C0019559'}, 'canonical_name': {0: 'Hip joint pain'}, 'aliases': {0: ['Hip arthralgia', 'Arthralgia of the hip', 'Coxalgia']}, 'types': {0: ['T184']}, 'definition': {0: 'A sensation of discomfort emanating from the pelvis, its supporting structures, or its articulation with the femur (acetabulofemoral or femoroacetabular joint).'}, 'entity': {0: 'Arthralgia'}, 'text': {0: 'Arthralgia'}}","   entity_group       value     score
0  Sign_symptom  Arthralgia  0.997537",[],"{'keyword': {}, 'score': {}}"
1644,1644,1644,0.8830000162124634,26.0,192 (25.9),MyriadPro-Light,4,-0.25,5723991,33,10,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   192  0.999349",[],"{'keyword': {0: '192 25'}, 'score': {0: 0.86}}"
1645,1645,1645,0.8830000162124634,26.0,1 (0.1),MyriadPro-Light,4,-0.25,5723991,33,10,2,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1646,1646,1646,0.8830000162124634,26.0,148 (20.6),MyriadPro-Light,4,-0.25,5723991,33,10,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   148  0.999731",[],"{'keyword': {0: '148 20'}, 'score': {0: 0.8378}}"
1647,1647,1647,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,33,10,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1648,1648,1648,0.8830000162124634,26.0,Radiation-related skin injury,MyriadPro-Light,4,-0.25,5723991,33,11,0,{},"{'concept_id': {0: 'C0034530'}, 'canonical_name': {0: 'Radiation Injury'}, 'aliases': {0: ['Radiation Injuries', 'Injuries, Radiation', 'Injury, Radiation']}, 'types': {0: ['T037']}, 'definition': {0: 'Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES.'}, 'entity': {0: 'Radiation-related skin injury'}, 'text': {0: 'Radiation-related skin injury'}}",{},{},{},"       entity_group              value     score
0  Disease_disorder  Radiation-related  0.546773
1  Disease_disorder        skin injury  0.999186",[],"{'keyword': {0: 'radiation related skin', 1: 'skin injury', 2: 'radiation related', 3: 'related skin injury', 4: 'related skin'}, 'score': {0: 0.926, 1: 0.8893, 2: 0.8517, 3: 0.8357, 4: 0.7572}}"
1649,1649,1649,0.8830000162124634,26.0,188 (25.4),MyriadPro-Light,4,-0.25,5723991,33,11,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   188  0.999761",[],"{'keyword': {0: '188 25'}, 'score': {0: 0.8369}}"
1650,1650,1650,0.8830000162124634,26.0,10 (1.4),MyriadPro-Light,4,-0.25,5723991,33,11,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    10  0.999608",[],"{'keyword': {}, 'score': {}}"
1651,1651,1651,0.8830000162124634,26.0,199 (27.6),MyriadPro-Light,4,-0.25,5723991,33,11,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   199  0.999539",[],"{'keyword': {0: '199 27'}, 'score': {0: 0.8559}}"
1652,1652,1652,0.8830000162124634,26.0,7 (1.0),MyriadPro-Light,4,-0.25,5723991,33,11,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value     7  0.999803",[],"{'keyword': {}, 'score': {}}"
1653,1653,1653,0.8830000162124634,26.0,Increased alanine aminotransferase level,MyriadPro-Light,4,-0.25,5723991,33,12,0,"{'concept_id': {0: 'C3887708'}, 'canonical_name': {0: 'Alanine Aminotransferase 1, human'}, 'aliases': {0: ['ALT1', 'Alanine Aminotransferase', 'GPT', 'Glutamate Pyruvate Transaminase 1', 'Glutamic-Pyruvic Transaminase 1', 'Glutamic--Alanine Transaminase 1', 'Glutamic-Pyruvic Transaminase', 'Glutamic-Alanine Transaminase 1', 'GPT1', 'EC 2.6.1.2', 'Glutamic-Pyruvate Transaminase', 'Alanine Aminotransferase 1', 'AAT1', 'Glutamic--Pyruvic Transaminase 1', 'Glutamic-Alanine Transaminase', 'GPT 1']}, 'types': {0: ['T116', 'T126']}, 'definition': {0: 'Alanine aminotransferase 1 (496 aa, ~55 kDa) is encoded by the human GPT gene. This protein plays a role in both amino acid metabolism and pyruvate synthesis.'}, 'entity': {0: 'alanine aminotransferase'}, 'text': {0: 'Increased alanine aminotransferase level'}}","{'concept_id': {0: 'C0002594'}, 'canonical_name': {0: 'Aminotransferases'}, 'aliases': {0: ['Aminotransferase', 'Transaminases', 'Transaminase']}, 'types': {0: ['T116', 'T126']}, 'definition': {0: 'A subclass of enzymes of the transferase class that catalyze the transfer of an amino group from a donor (generally an amino acid) to an acceptor (generally a 2-keto acid). Most of these enzymes are pyridoxyl phosphate proteins. (Dorland, 28th ed) EC 2.6.1.'}, 'entity': {0: 'alanine aminotransferase'}, 'text': {0: 'Increased alanine aminotransferase level'}}",{},"{'concept_id': {0: 'C1152208'}, 'canonical_name': {0: 'aminotransferase activity'}, 'aliases': {0: ['transaminase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the transfer of an amino group to an acceptor, usually a 2-oxo acid. [ISBN:0198506732]'}, 'entity': {0: 'alanine aminotransferase'}, 'text': {0: 'Increased alanine aminotransferase level'}}","{'concept_id': {0: 'C0151905'}, 'canonical_name': {0: 'Alanine aminotransferase increased'}, 'aliases': {0: ['Elevated serum ALT', 'Elevated serum glutamic-pyruvic transaminase', 'Elevated serum alanine aminotransferase', 'Elevated circulating alanine aminotransferase concentration']}, 'types': {0: ['T033']}, 'definition': {0: 'An increase in the level of alanine aminotransferase in the blood.'}, 'entity': {0: 'alanine aminotransferase'}, 'text': {0: 'Increased alanine aminotransferase level'}}","           entity_group                           value     score
0             Lab_value                       Increased  0.999901
1  Diagnostic_procedure  alanine aminotransferase level  0.995934",[],"{'keyword': {0: 'increased alanine aminotransferase', 1: 'increased alanine', 2: 'alanine aminotransferase level', 3: 'aminotransferase level', 4: 'alanine aminotransferase'}, 'score': {0: 0.9807, 1: 0.9502, 2: 0.8665, 3: 0.8023, 4: 0.7287}}"
1654,1654,1654,0.8830000162124634,26.0,171 (23.1),MyriadPro-Light,4,-0.25,5723991,33,12,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   171  0.999359",[],"{'keyword': {0: '171 23'}, 'score': {0: 0.8545}}"
1655,1655,1655,0.8830000162124634,26.0,3 (0.4),MyriadPro-Light,4,-0.25,5723991,33,12,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     3  0.999773",[],"{'keyword': {}, 'score': {}}"
1656,1656,1656,0.8830000162124634,26.0,41 (5.7),MyriadPro-Light,4,-0.25,5723991,33,12,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    41  0.999779",[],"{'keyword': {}, 'score': {}}"
1657,1657,1657,0.8830000162124634,26.0,2 (0.3),MyriadPro-Light,4,-0.25,5723991,33,12,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1658,1658,1658,0.8830000162124634,26.0,Epistaxis,MyriadPro-Light,4,-0.25,5723991,33,13,0,"{'concept_id': {0: 'C0179204'}, 'canonical_name': {0: 'Nasal balloon'}, 'aliases': {0: ['Nasal balloon, device', 'Epistaxis Balloons', 'Nasal balloon, device (physical object)', 'BALLOON, EPISTAXIS', 'nasal balloon', 'Balloons, Nasal', 'balloons nasal', 'Balloons, Epistaxis', 'Nasal balloon', 'Nasal Balloons', 'Nosebleed Balloons']}, 'types': {0: ['T074']}, 'definition': {0: 'An epistaxis balloon is a device consisting of an inflatable balloon intended to control internal nasal bleeding by exerting pressure against the sphenopalatine artery.'}, 'entity': {0: 'Epistaxis'}, 'text': {0: 'Epistaxis'}}","{'concept_id': {0: 'C0014591'}, 'canonical_name': {0: 'Nasal Bleedings'}, 'aliases': {0: ['Nasal Bleeding', 'Epistaxis', 'Bleedings, Nasal', 'Nose Bleeds', 'Nosebleeds', 'Nose Bleed', 'Bleeding, Nasal', 'Nosebleed']}, 'types': {0: ['T046']}, 'definition': {0: 'Bleeding from the nose.'}, 'entity': {0: 'Epistaxis'}, 'text': {0: 'Epistaxis'}}",{},{},"{'concept_id': {0: 'C0014591'}, 'canonical_name': {0: 'Nosebleed'}, 'aliases': {0: ['Nose bleed', 'Nose bleeding', 'Nasal hemorrhage', 'Bloody nose', 'Epistaxis', 'Nasal haemorrhage']}, 'types': {0: ['T046']}, 'definition': {0: 'Bleeding from the nose.'}, 'entity': {0: 'Epistaxis'}, 'text': {0: 'Epistaxis'}}","   entity_group      value     score
0  Sign_symptom  Epistaxis  0.930277",[],"{'keyword': {}, 'score': {}}"
1659,1659,1659,0.8830000162124634,26.0,159 (21.5),MyriadPro-Light,4,-0.25,5723991,33,13,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   159  0.999667",[],"{'keyword': {0: '159 21'}, 'score': {0: 0.8008}}"
1660,1660,1660,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,33,13,2,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1661,1661,1661,0.8830000162124634,26.0,25 (3.5),MyriadPro-Light,4,-0.25,5723991,33,13,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    25  0.999666",[],"{'keyword': {}, 'score': {}}"
1662,1662,1662,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,33,13,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1663,1663,1663,0.8830000162124634,26.0,Peripheral sensory neuropathy,MyriadPro-Light,4,-0.25,5723991,33,14,0,"{'concept_id': {0: 'C0031117'}, 'canonical_name': {0: 'Peripheral Neuropathy'}, 'aliases': {0: ['PERIPHERAL NEUROPATHY', 'Peripheral Neuropathy', 'peripheral neuropathy', 'Peripheral nerve damage', 'Peripheral neuritis', 'Peripheral neuropathy']}, 'types': {0: ['T047']}, 'definition': {0: 'A disorder affecting the peripheral nervous system. It manifests with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs.'}, 'entity': {0: 'Peripheral sensory neuropathy'}, 'text': {0: 'Peripheral sensory neuropathy'}}","{'concept_id': {0: 'C0699739'}, 'canonical_name': {0: 'Congenital Sensory Neuropathies'}, 'aliases': {0: ['Neuropathies, Congenital Sensory', 'Sensory Neuropathies, Hereditary', 'Neuropathy, Hereditary Sensory', 'Sensory Neuropathies, Congenital', 'Neuropathies, Hereditary Sensory', 'Hereditary Sensory Neuropathy', 'Neurogenic Acroosteolysis', 'Neuropathy, Congenital Sensory', 'Hereditary Sensory Neuropathies', 'Congenital Sensory Neuropathy', 'Sensory Neuropathy, Congenital', 'Acroosteolysis, Neurogenic', 'Sensory Neuropathy, Hereditary', 'Neurogenic Acroosteolyses', 'Acroosteolyses, Neurogenic']}, 'types': {0: ['T047']}, 'definition': {0: 'group of peripheral nervous system hereditary disorders with varying course, symptoms, neuropathology, and genetics, but characterized by degeneration of peripheral nerves, and clinically by loss of sensation.'}, 'entity': {0: 'Peripheral sensory neuropathy'}, 'text': {0: 'Peripheral sensory neuropathy'}}",{},{},"{'concept_id': {0: 'C0031117'}, 'canonical_name': {0: 'Peripheral neuropathy'}, 'aliases': {0: ['Peripheral nerve damage', 'Peripheral neuritis']}, 'types': {0: ['T047']}, 'definition': {0: 'A disorder affecting the peripheral nervous system. It manifests with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs.'}, 'entity': {0: 'Peripheral sensory neuropathy'}, 'text': {0: 'Peripheral sensory neuropathy'}}","       entity_group                          value     score
0  Disease_disorder  Peripheral sensory neuropathy  0.999234",[],"{'keyword': {0: 'peripheral sensory neuropathy', 1: 'sensory neuropathy', 2: 'peripheral sensory'}, 'score': {0: 1.0, 1: 0.9812, 2: 0.8705}}"
1664,1664,1664,0.8830000162124634,26.0,138 (18.6),MyriadPro-Light,4,-0.25,5723991,33,14,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   138  0.999762",[],"{'keyword': {0: '138 18'}, 'score': {0: 0.8429}}"
1665,1665,1665,0.8830000162124634,26.0,10 (1.4),MyriadPro-Light,4,-0.25,5723991,33,14,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    10  0.999608",[],"{'keyword': {}, 'score': {}}"
1666,1666,1666,0.8830000162124634,26.0,50 (6.9),MyriadPro-Light,4,-0.25,5723991,33,14,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    50  0.999601",[],"{'keyword': {}, 'score': {}}"
1667,1667,1667,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,33,14,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1668,1668,1668,0.8830000162124634,26.0,Constipation,MyriadPro-Light,4,-0.25,5723991,33,15,0,"{'concept_id': {0: 'C3641755'}, 'canonical_name': {0: 'Have Constipation'}, 'aliases': {0: ['Have Constipation', 'Have Been Constipated']}, 'types': {0: ['T170']}, 'definition': {0: 'A question about whether an individual is or has been constipated.'}, 'entity': {0: 'Constipation'}, 'text': {0: 'Constipation'}}","{'concept_id': {0: 'C0009806'}, 'canonical_name': {0: 'Constipation'}, 'aliases': {0: []}, 'types': {0: ['T184']}, 'definition': {0: 'Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.'}, 'entity': {0: 'Constipation'}, 'text': {0: 'Constipation'}}",{},{},"{'concept_id': {0: 'C0401149'}, 'canonical_name': {0: 'Infrequent bowel movements'}, 'aliases': {0: ['Chronic constipation']}, 'types': {0: ['T184']}, 'definition': {0: 'Constipation for longer than three months with fewer than 3 bowel movements per week, straining, lumpy or hard stools, and a sensation of anorectal obstruction or incomplete defecation. [ORCID:0000-0001-5208-3432]'}, 'entity': {0: 'Constipation'}, 'text': {0: 'Constipation'}}","   entity_group         value     score
0  Sign_symptom  Constipation  0.999722",[],"{'keyword': {}, 'score': {}}"
1669,1669,1669,0.8830000162124634,26.0,126 (17.0),MyriadPro-Light,4,-0.25,5723991,33,15,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   126  0.999776",[],"{'keyword': {0: '126 17'}, 'score': {0: 0.694}}"
1670,1670,1670,0.8830000162124634,26.0,1 (0.1),MyriadPro-Light,4,-0.25,5723991,33,15,2,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1671,1671,1671,0.8830000162124634,26.0,59 (8.2),MyriadPro-Light,4,-0.25,5723991,33,15,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    59  0.999645",[],"{'keyword': {}, 'score': {}}"
1672,1672,1672,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,33,15,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1673,1673,1673,0.8830000162124634,26.0,Myalgia,MyriadPro-Light,4,-0.25,5723991,33,16,0,"{'concept_id': {0: 'C0032238'}, 'canonical_name': {0: 'Pleurodynia, Epidemic'}, 'aliases': {0: ['Epidemic myalgia', 'Epidemic, myositis', 'Myalgia, Epidemic', 'Epidemic Pleurodynia', 'Bornholm Disease', 'DABNEY GRIP', 'Epidemic myositis', 'MYALGIA, EPIDEMIC', 'Bornholm disease', 'devil grip', 'epidemic pleurodynia', 'BORNHOLM DISEASE', 'Epidemic Myalgias', 'epidemic myalgia', 'Epidemic Pleurodynias', 'DEVIL GRIP', 'Epidemic pleurodynia', 'Epidemic benign dry pleurisy', 'Pleurodynias, Epidemic', 'Epidemic, myalgia', 'Epidemic pleurodynia (disorder)', 'PLEURODYNIA, EPIDEMIC', 'Epidemic Myalgia', ""Devil's grip"", ""devil's grip"", 'SYLVEST SYNDROME', 'bornholms disease', 'devils grip', 'bornholm disease', 'Myalgias, Epidemic', 'Epidemic pleurisy']}, 'types': {0: ['T047']}, 'definition': {0: 'An acute, febrile, infectious disease generally occurring in epidemics. It is usually caused by coxsackieviruses B and sometimes by coxsackieviruses A; echoviruses; or other enteroviruses.'}, 'entity': {0: 'Myalgia'}, 'text': {0: 'Myalgia'}}","{'concept_id': {0: 'C0016053'}, 'canonical_name': {0: 'Fibromyalgia Fibromyositis Syndrome'}, 'aliases': {0: ['Diffuse Myofascial Pain Syndrome', 'Muscular Rheumatism', 'Myofascial Pain Syndrome, Diffuse', 'Syndrome, Fibromyositis-Fibromyalgia', 'Syndromes, Fibromyalgia-Fibromyositis', 'Fibromyositis Fibromyalgia Syndrome', 'Fibromyalgia-Fibromyositis Syndromes', 'Fibromyositis-Fibromyalgia Syndromes', 'Fibrositis', 'Fibromyositis-Fibromyalgia Syndrome', 'Fibromyalgias', 'Fibrositides', 'Syndromes, Fibromyositis-Fibromyalgia', 'Rheumatism, Muscular', 'Fibromyalgia', 'Fibromyalgia-Fibromyositis Syndrome', 'Syndrome, Fibromyalgia-Fibromyositis']}, 'types': {0: ['T047']}, 'definition': {0: 'A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95)'}, 'entity': {0: 'Myalgia'}, 'text': {0: 'Myalgia'}}",{},{},"{'concept_id': {0: 'C4732758'}, 'canonical_name': {0: 'Gastrocnemius myalgia'}, 'aliases': {0: ['Calf myalgia', 'Calf muscle pain']}, 'types': {0: ['T184']}, 'definition': {0: 'Pain of the gastrocnemius muscle. [PMID:29491286]'}, 'entity': {0: 'Myalgia'}, 'text': {0: 'Myalgia'}}","   entity_group    value     score
0  Sign_symptom  Myalgia  0.921871",[],"{'keyword': {}, 'score': {}}"
1674,1674,1674,0.8830000162124634,26.0,114 (15.4),MyriadPro-Light,4,-0.25,5723991,33,16,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value   114  0.99968",[],"{'keyword': {0: '114 15'}, 'score': {0: 0.7406}}"
1675,1675,1675,0.8830000162124634,26.0,3 (0.4),MyriadPro-Light,4,-0.25,5723991,33,16,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     3  0.999773",[],"{'keyword': {}, 'score': {}}"
1676,1676,1676,0.8830000162124634,26.0,80 (11.1),MyriadPro-Light,4,-0.25,5723991,33,16,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    80  0.999821",[],"{'keyword': {0: '80 11'}, 'score': {0: 0.8124}}"
1677,1677,1677,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,33,16,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1678,1678,1678,0.8830000162124634,26.0,Hot flushes,MyriadPro-Light,4,-0.25,5723991,33,17,0,"{'concept_id': {0: 'C0005874'}, 'canonical_name': {0: 'Blushing'}, 'aliases': {0: ['blushing', 'flushes', 'Blush', 'Blushing', 'Blushing, function (observable entity)', 'Blushing, function', 'Blushings', 'blush', 'Blushes']}, 'types': {0: ['T184']}, 'definition': {0: 'Involuntary reddening, especially of the face, associated with feelings of embarrassment, confusion or shame.'}, 'entity': {0: 'Hot flushes'}, 'text': {0: 'Hot flushes'}}",{},{},{},{},"   entity_group        value     score
0  Sign_symptom  Hot flushes  0.914683",[],"{'keyword': {0: 'hot flushes'}, 'score': {0: 1.0}}"
1679,1679,1679,0.8830000162124634,26.0,95 (12.8),MyriadPro-Light,4,-0.25,5723991,33,17,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value    95  0.99951",[],"{'keyword': {0: '95 12'}, 'score': {0: 0.884}}"
1680,1680,1680,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,33,17,2,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1681,1681,1681,0.8830000162124634,26.0,146 (20.3),MyriadPro-Light,4,-0.25,5723991,33,17,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   146  0.999759",[],"{'keyword': {0: '146 20'}, 'score': {0: 0.7477}}"
1682,1682,1682,0.8830000162124634,26.0,2 (0.3),MyriadPro-Light,4,-0.25,5723991,33,17,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1683,1683,1683,0.9520000219345092,19.0,Adverse events of any grade with an incidence ≥15% in either treatment group.,MyriadPro-Regular,4,-0.25,3355443,33,18,0,"{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Therapeutic procedure'}, 'aliases': {0: ['TX', 'therapies', 'treatments', 'Therapeutic', 'Therapeutic procedure', 'Therapeutic procedure, NOS', 'methods treatment', 'Therapies', 'therapeutic method', 'Therapy', 'Therapeutics', 'treatment', 'Treatment', 'Therapeutic Interventions', 'Therapy (regime/therapy)', 'Treatments', 'Therapeutic Technique', 'Therapeutic Procedure', 'Therapeutic procedure (procedure)', 'therapy', 'therapeutic procedure', 'Therapy, NOS', 'method treatment', 'treatment method', 'Therapeutic Method', 'therapeutics']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'treatment group'}, 'text': {0: 'Adverse events of any grade with an incidence ≥15% in either treatment group.'}}","{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Treatments'}, 'aliases': {0: ['Therapy', 'Treatment', 'Therapeutics', 'Therapeutic', 'Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'treatment group'}, 'text': {0: 'Adverse events of any grade with an incidence ≥15% in either treatment group.'}}",{},{},{},"           entity_group           value     score
0          Sign_symptom  Adverse events  0.999710
1  Detailed_description             any  0.803977
2             Lab_value           ≥15 %  0.996612",[],"{'keyword': {0: 'adverse events', 1: 'treatment group', 2: 'adverse events grade', 3: 'grade incidence', 4: '15 treatment group'}, 'score': {0: 0.8099, 1: 0.6087, 2: 0.5985, 3: 0.4106, 4: 0.3303}}"
1684,1684,1684,0.8830000162124634,19.0,Adapted from von Minckwitz et al. 2019.,MyriadPro-Light,4,-0.25,3355443,33,18,1,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
1685,1685,1685,0.8830000162124634,19.0,"*All listed adverse events are grade 3 except for decreased platelet count, which includes 2.0% of patients in the Kadcyla group ",MyriadPro-Light,4,-0.25,3355443,33,18,2,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: '*All listed adverse events are grade 3 except for decreased platelet count, which includes 2.0% of patients in the Kadcyla group '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: '*All listed adverse events are grade 3 except for decreased platelet count, which includes 2.0% of patients in the Kadcyla group '}}",{},{},"{'concept_id': {0: 'C0857460'}, 'canonical_name': {0: 'Increased platelet count'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'A higher than average level of platelets in a sample.'}, 'entity': {0: 'platelet count'}, 'text': {0: '*All listed adverse events are grade 3 except for decreased platelet count, which includes 2.0% of patients in the Kadcyla group '}}","            entity_group           value     score
0           Sign_symptom  adverse events  0.999881
1              Lab_value         grade 3  0.999442
2              Lab_value       decreased  0.996125
3   Diagnostic_procedure        platelet  0.982448
4              Lab_value           2.0 %  0.997067
5             Medication         Kadcyla  0.563766
6  Therapeutic_procedure           group  0.669253","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'adverse events grade', 1: 'patients kadcyla', 2: 'listed adverse events', 3: 'includes patients', 4: 'decreased platelet count'}, 'score': {0: 0.594, 1: 0.5714, 2: 0.4463, 3: 0.4313, 4: 0.2837}}"
1686,1686,1686,0.8830000162124634,19.0,and 0.1% of patients in the trastuzumab group who had a grade 4 decreased platelet count.,MyriadPro-Light,4,-0.25,3355443,33,18,3,"{'concept_id': {0: 'C5201036'}, 'canonical_name': {0: 'Low Platelet Count'}, 'aliases': {0: ['low platelet', 'low count platelet', 'low platelets', 'platelet count low', 'Low Platelet Count', 'low platelet count', 'platelet low', 'platelets low', 'Low platelet count']}, 'types': {0: ['T034']}, 'definition': {0: 'A lower than average level of platelets in a sample.'}, 'entity': {0: 'platelet count'}, 'text': {0: 'and 0.1% of patients in the trastuzumab group who had a grade 4 decreased platelet count.'}}","{'concept_id': {0: 'C0005821'}, 'canonical_name': {0: 'Platelet'}, 'aliases': {0: ['Platelets', 'Platelets, Blood', 'Thrombocyte', 'Thrombocytes', 'Blood Platelet', 'Platelet, Blood', 'Blood Platelets']}, 'types': {0: ['T025']}, 'definition': {0: 'Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.'}, 'entity': {0: 'platelet count'}, 'text': {0: 'and 0.1% of patients in the trastuzumab group who had a grade 4 decreased platelet count.'}}","{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab group'}, 'text': {0: 'and 0.1% of patients in the trastuzumab group who had a grade 4 decreased platelet count.'}}",{},"{'concept_id': {0: 'C0857460'}, 'canonical_name': {0: 'Increased platelet count'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'A higher than average level of platelets in a sample.'}, 'entity': {0: 'platelet count'}, 'text': {0: 'and 0.1% of patients in the trastuzumab group who had a grade 4 decreased platelet count.'}}","           entity_group        value     score
0             Lab_value        0.1 %  0.997264
1            Medication  trastuzumab  0.999858
2             Lab_value      grade 4  0.999789
3             Lab_value    decreased  0.999934
4  Diagnostic_procedure     platelet  0.999435","[('0.1', 'STRENGTH'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'grade decreased', 1: 'platelet count', 2: 'group grade', 3: 'trastuzumab group', 4: 'patients trastuzumab group'}, 'score': {0: 0.5369, 1: 0.4915, 2: 0.4701, 3: 0.436, 4: 0.4245}}"
1687,1687,1687,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,33,19,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1688,1688,1688,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,33,19,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1689,1689,1689,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,33,19,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1690,1690,1690,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,33,19,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1691,1691,1691,0.75,98.0,98.8% of patients experienced adverse events ,ConduitITC-Bold,20,-0.1700000017881393,8194925,34,1,0,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: '98.8% of patients experienced adverse events '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: '98.8% of patients experienced adverse events '}}",{},{},{},"   entity_group           value     score
0     Lab_value          98.8 %  0.999234
1  Sign_symptom  adverse events  0.999889",[],"{'keyword': {0: '98 patients experienced', 1: 'adverse events', 2: 'experienced adverse events', 3: 'patients experienced', 4: '98 patients'}, 'score': {0: 0.7907, 1: 0.788, 2: 0.7744, 3: 0.773, 4: 0.6827}}"
1692,1692,1692,0.75,98.0,with Kadcyla vs 93.3% with trastuzumab,ConduitITC-Bold,20,-0.1700000017881393,8194925,34,1,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'with Kadcyla vs 93.3% with trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'with Kadcyla vs 93.3% with trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'with Kadcyla vs 93.3% with trastuzumab'}}",{},{},"  entity_group        value     score
0  Coreference      Kadcyla  0.761197
1    Lab_value       93.3 %  0.999871
2   Medication  trastuzumab  0.999862","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'kadcyla vs', 1: 'kadcyla vs 93', 2: 'vs 93 trastuzumab', 3: 'vs 93', 4: '93 trastuzumab'}, 'score': {0: 0.6757, 1: 0.6694, 2: 0.638, 3: 0.6234, 4: 0.591}}"
1693,1693,1693,0.944000005722046,28.0,Trastuzumab (n=720),UniversSB-Medium,4,-0.2349999994039535,16777215,34,2,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=720)'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=720)'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=720)'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999842","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab 720'}, 'score': {0: 0.8957}}"
1694,1694,1694,0.944000005722046,28.0,Kadcyla (n=740),UniversSB-Medium,4,-0.2349999994039535,16777215,34,2,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=740)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=740)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=740)'}}",{},{},"           entity_group    value    score
0  Diagnostic_procedure  Kadcyla  0.98247",[],"{'keyword': {0: 'kadcyla 740'}, 'score': {0: 0.8612}}"
1695,1695,1695,0.944000005722046,26.0,"Patients, n (%)",UniversSB-Medium,4,-0.2349999994039535,16777215,34,3,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'Patients'}, 'text': {0: 'Patients, n (%)'}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'Patients'}, 'text': {0: 'Patients, n (%)'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1696,1696,1696,0.944000005722046,26.0,All grades,UniversSB-Medium,4,-0.2349999994039535,16777215,34,3,1,"{'concept_id': {0: 'C3244287'}, 'canonical_name': {0: 'School Grade'}, 'aliases': {0: ['grade']}, 'types': {0: ['T033']}, 'definition': {0: '<b>Description:</b>The school grade or level the patient was in when immunized.'}, 'entity': {0: 'grades'}, 'text': {0: 'All grades'}}",{},{},{},{},"           entity_group   value     score
0  Detailed_description     All  0.846238
1  Diagnostic_procedure  grades  0.606837",[],"{'keyword': {}, 'score': {}}"
1697,1697,1697,0.944000005722046,26.0,Grade 3*,UniversSB-Medium,4,-0.2349999994039535,16777215,34,3,2,{},{},{},{},{},"  entity_group      value    score
0    Lab_value  Grade 3 *  0.36618",[],"{'keyword': {}, 'score': {}}"
1698,1698,1698,0.944000005722046,26.0,All grades,UniversSB-Medium,4,-0.2349999994039535,16777215,34,3,3,"{'concept_id': {0: 'C3244287'}, 'canonical_name': {0: 'School Grade'}, 'aliases': {0: ['grade']}, 'types': {0: ['T033']}, 'definition': {0: '<b>Description:</b>The school grade or level the patient was in when immunized.'}, 'entity': {0: 'grades'}, 'text': {0: 'All grades'}}",{},{},{},{},"           entity_group   value     score
0  Detailed_description     All  0.846238
1  Diagnostic_procedure  grades  0.606837",[],"{'keyword': {}, 'score': {}}"
1699,1699,1699,0.944000005722046,26.0,Grade 3*,UniversSB-Medium,4,-0.2349999994039535,16777215,34,3,4,{},{},{},{},{},"  entity_group      value    score
0    Lab_value  Grade 3 *  0.36618",[],"{'keyword': {}, 'score': {}}"
1700,1700,1700,0.9470000267028807,26.0,Any adverse event,UniversSB-Light,4,-0.2329999953508377,5723991,34,4,0,"{'concept_id': {0: 'C5236149'}, 'canonical_name': {0: 'Adverse Event Term'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A term that refers to an adverse event, often taken from a list of standardized terms.'}, 'entity': {0: 'adverse event'}, 'text': {0: 'Any adverse event'}}","{'concept_id': {0: 'C0151735'}, 'canonical_name': {0: 'Injection Site Events'}, 'aliases': {0: ['Injection Site Event', 'Injection Site Adverse Event', 'Injection Site Reaction', 'Injection Site Reactions']}, 'types': {0: ['T046']}, 'definition': {0: 'Adverse reactions that occur initially at the site of injection or infusion. Milder type is confined to a local allergic flare reaction. A more severe reaction is caused by extravasation of VESICANTS from the blood vessel at the site of injection and can cause damage to the surrounding tissue. In tumor flare reaction symptoms involve well beyond the injection site such as an increase in the tumor size and tumor markers levels, bone pain, and HYPERCALCEMIA.'}, 'entity': {0: 'adverse event'}, 'text': {0: 'Any adverse event'}}",{},{},{},"   entity_group          value     score
0  Sign_symptom  adverse event  0.999895",[],"{'keyword': {0: 'adverse event'}, 'score': {0: 0.8962}}"
1701,1701,1701,0.9470000267028807,26.0,731 (98.8),UniversSB-Light,4,-0.2329999953508377,5723991,34,4,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   731  0.993434",[],"{'keyword': {0: '731 98'}, 'score': {0: 0.7557}}"
1702,1702,1702,0.9470000267028807,26.0,190 (25.7),UniversSB-Light,4,-0.2329999953508377,5723991,34,4,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value   190  0.999509",[],"{'keyword': {0: '190 25'}, 'score': {0: 0.7999}}"
1703,1703,1703,0.9470000267028807,26.0,672 (93.3),UniversSB-Light,4,-0.2329999953508377,5723991,34,4,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   672  0.981329",[],"{'keyword': {0: '672 93'}, 'score': {0: 0.7884}}"
1704,1704,1704,0.9470000267028807,26.0,111 (15.4),UniversSB-Light,4,-0.2329999953508377,5723991,34,4,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value   111  0.999389",[],"{'keyword': {0: '111 15'}, 'score': {0: 0.7994}}"
1705,1705,1705,0.9470000267028807,26.0,Fatigue,UniversSB-Light,4,-0.2329999953508377,5723991,34,5,0,"{'concept_id': {0: 'C4744662'}, 'canonical_name': {0: 'PROMIS Pediatric and Parent Proxy Physical Health Domain'}, 'aliases': {0: ['Ped Fatigue', 'PROMIS Ped Fatigue']}, 'types': {0: ['T170']}, 'definition': {0: 'The set of PROMIS measures that assess the physical health of pediatric subjects through self-report or parent proxy report.'}, 'entity': {0: 'Fatigue'}, 'text': {0: 'Fatigue'}}","{'concept_id': {0: 'C0004095'}, 'canonical_name': {0: 'Asthenopia'}, 'aliases': {0: ['Eyestrain', 'Fatigue, Visual', 'Visual Fatigue', 'Eye Fatigue', 'Fatigue, Eye']}, 'types': {0: ['T047']}, 'definition': {0: 'Term generally used to describe complaints related to refractive error, ocular muscle imbalance, including pain or aching around the eyes, burning and itchiness of the eyelids, ocular fatigue, and headaches.'}, 'entity': {0: 'Fatigue'}, 'text': {0: 'Fatigue'}}",{},"{'concept_id': {0: 'C2265886'}, 'canonical_name': {0: 'detection of muscle activity involved in regulation of muscle adaptation'}, 'aliases': {0: ['detection of fatigue']}, 'types': {0: ['T044']}, 'definition': {0: 'The series of events by which a muscle activity stimulus is received and converted into a molecular signal. This occurs as part of the regulation of muscle adaptation. [GOC:ef, GOC:mtg_muscle]'}, 'entity': {0: 'Fatigue'}, 'text': {0: 'Fatigue'}}","{'concept_id': {0: 'C5539444'}, 'canonical_name': {0: 'Cognitive fatigue'}, 'aliases': {0: ['Central fatigue']}, 'types': {0: ['T184']}, 'definition': {0: 'A failure to sustain attention that requires self-motivation to optimize performance. [PMID:21128132]'}, 'entity': {0: 'Fatigue'}, 'text': {0: 'Fatigue'}}","   entity_group    value     score
0  Sign_symptom  Fatigue  0.999914",[],"{'keyword': {}, 'score': {}}"
1706,1706,1706,0.9470000267028807,26.0,366 (49.5),UniversSB-Light,4,-0.2329999953508377,5723991,34,5,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   366  0.998327",[],"{'keyword': {0: '366 49'}, 'score': {0: 0.8512}}"
1707,1707,1707,0.9470000267028807,26.0,8 (1.1),UniversSB-Light,4,-0.2329999953508377,5723991,34,5,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     8  0.999834",[],"{'keyword': {}, 'score': {}}"
1708,1708,1708,0.9470000267028807,26.0,243 (33.8),UniversSB-Light,4,-0.2329999953508377,5723991,34,5,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   243  0.997947",[],"{'keyword': {0: '243 33'}, 'score': {0: 0.8392}}"
1709,1709,1709,0.9470000267028807,26.0,1 (0.1),UniversSB-Light,4,-0.2329999953508377,5723991,34,5,4,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1710,1710,1710,0.9470000267028807,26.0,Nausea,UniversSB-Light,4,-0.2329999953508377,5723991,34,6,0,"{'concept_id': {0: 'C1171206'}, 'canonical_name': {0: 'Nausea care'}, 'aliases': {0: ['Nausea Care', 'Nausea care (regime/therapy)', 'Nausea management']}, 'types': {0: ['T058']}, 'definition': {0: 'Actions performed to control the distaste for food and desire to vomit'}, 'entity': {0: 'Nausea'}, 'text': {0: 'Nausea'}}","{'concept_id': {0: 'C0027497'}, 'canonical_name': {0: 'Nausea'}, 'aliases': {0: []}, 'types': {0: ['T184']}, 'definition': {0: 'An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.'}, 'entity': {0: 'Nausea'}, 'text': {0: 'Nausea'}}",{},{},"{'concept_id': {0: 'C0027497'}, 'canonical_name': {0: 'Nausea'}, 'aliases': {0: []}, 'types': {0: ['T184']}, 'definition': {0: 'An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.'}, 'entity': {0: 'Nausea'}, 'text': {0: 'Nausea'}}","   entity_group   value     score
0  Sign_symptom  Nausea  0.999906",[],"{'keyword': {}, 'score': {}}"
1711,1711,1711,0.9470000267028807,26.0,308 (41.6),UniversSB-Light,4,-0.2329999953508377,5723991,34,6,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   308  0.999475",[],"{'keyword': {0: '308 41'}, 'score': {0: 0.8006}}"
1712,1712,1712,0.9470000267028807,26.0,4 (0.5),UniversSB-Light,4,-0.2329999953508377,5723991,34,6,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     4  0.999844",[],"{'keyword': {}, 'score': {}}"
1713,1713,1713,0.9470000267028807,26.0,94 (13.1),UniversSB-Light,4,-0.2329999953508377,5723991,34,6,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    94  0.999433",[],"{'keyword': {0: '94 13'}, 'score': {0: 0.8211}}"
1714,1714,1714,0.9470000267028807,26.0,2 (0.3),UniversSB-Light,4,-0.2329999953508377,5723991,34,6,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1715,1715,1715,0.9470000267028807,26.0,Decreased platelet count*,UniversSB-Light,4,-0.2329999953508377,5723991,34,7,0,"{'concept_id': {0: 'C0857460'}, 'canonical_name': {0: 'Increased number of platelets'}, 'aliases': {0: ['Platelet count above reference range (finding)', 'increased platelets', 'Elevated platelet count', 'PLATELETS INCREASED', 'high platelet count', 'increased platelet count', 'High Platelet Count', 'increased platelet', 'elevated platelet count', 'INCREASED PLATELET COUNT', 'Platelet count above reference range', 'platelets increased', 'Increased platelets', 'Increased platelet count']}, 'types': {0: ['T033']}, 'definition': {0: 'A higher than average level of platelets in a sample.'}, 'entity': {0: 'Decreased platelet count*'}, 'text': {0: 'Decreased platelet count*'}}","{'concept_id': {0: 'C0032181'}, 'canonical_name': {0: 'Platelet Count, Blood'}, 'aliases': {0: ['Platelet Numbers, Blood', 'Count, Blood Platelet', 'Platelet Numbers', 'Blood Platelet Numbers', 'Platelet Number', 'Number, Blood Platelet', 'Blood Platelet Counts', 'Counts, Blood Platelet', 'Blood Platelet Count', 'Platelet Count', 'Counts, Platelet', 'Number, Platelet', 'Count, Platelet', 'Platelet Number, Blood', 'Platelet Counts', 'Blood Platelet Number', 'Numbers, Blood Platelet', 'Platelet Counts, Blood', 'Numbers, Platelet']}, 'types': {0: ['T059']}, 'definition': {0: 'The number of PLATELETS per unit volume in a sample of venous BLOOD.'}, 'entity': {0: 'Decreased platelet count*'}, 'text': {0: 'Decreased platelet count*'}}",{},{},"{'concept_id': {0: 'C0580317'}, 'canonical_name': {0: 'Abnormal platelet count'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Abnormal number of platelets per volume of blood. In a healthy adult, a normal platelet count is between 150,000 and 450,000 per microliter of blood. [DDD:kfreson]'}, 'entity': {0: 'Decreased platelet count*'}, 'text': {0: 'Decreased platelet count*'}}","           entity_group           value     score
0             Lab_value       Decreased  0.999931
1  Diagnostic_procedure  platelet count  0.999942
2             Lab_value               *  0.998747",[],"{'keyword': {0: 'decreased platelet count', 1: 'decreased platelet', 2: 'platelet count'}, 'score': {0: 0.9814, 1: 0.9518, 2: 0.7469}}"
1716,1716,1716,0.9470000267028807,26.0,211 (28.5),UniversSB-Light,4,-0.2329999953508377,5723991,34,7,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   211  0.999028",[],"{'keyword': {0: '211 28'}, 'score': {0: 0.8389}}"
1717,1717,1717,0.9470000267028807,26.0,27 (3.6),UniversSB-Light,4,-0.2329999953508377,5723991,34,7,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    27  0.999653",[],"{'keyword': {}, 'score': {}}"
1718,1718,1718,0.9470000267028807,26.0,17 (2.4),UniversSB-Light,4,-0.2329999953508377,5723991,34,7,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    17  0.999571",[],"{'keyword': {}, 'score': {}}"
1719,1719,1719,0.9470000267028807,26.0,1 (0.1),UniversSB-Light,4,-0.2329999953508377,5723991,34,7,4,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1720,1720,1720,0.9470000267028807,26.0,Increased aspartate aminotransferase level,UniversSB-Light,4,-0.2329999953508377,5723991,34,8,0,"{'concept_id': {0: 'C1547707'}, 'canonical_name': {0: 'Floor - story of building'}, 'aliases': {0: ['Floor', 'Story', 'Level']}, 'types': {0: ['T083']}, 'definition': {0: 'A location comprising a single level of a multilevel building.'}, 'entity': {0: 'level'}, 'text': {0: 'Increased aspartate aminotransferase level'}}","{'concept_id': {0: 'C5197751'}, 'canonical_name': {0: 'Sea Level Rise'}, 'aliases': {0: ['Rising Sea Levels', 'Sea Level, Rising', 'Sea-Level Rise', 'Rising Sea Level', 'Sea Levels, Rising']}, 'types': {0: ['T067']}, 'definition': {0: 'An increase in the volume of the oceans and seas causing an elevation of the air-sea interface.'}, 'entity': {0: 'level'}, 'text': {0: 'Increased aspartate aminotransferase level'}}",{},"{'concept_id': {0: 'C2247344'}, 'canonical_name': {0: 'aspartate-prephenate aminotransferase activity'}, 'aliases': {0: ['prephenate aspartate aminotransferase activity', 'L-aspartate:prephenate aminotransferase activity', 'PAT', 'L-arogenate:oxaloacetate aminotransferase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: L-arogenate + oxaloacetate = prephenate + L-aspartate. [EC:2.6.1.78]'}, 'entity': {0: 'aspartate aminotransferase'}, 'text': {0: 'Increased aspartate aminotransferase level'}}","{'concept_id': {0: 'C4703556'}, 'canonical_name': {0: 'Abnormal hypoxanthine-guanine phosphoribosyltransferase level'}, 'aliases': {0: ['Abnormal GMP pyrophosphorylase level', 'Abnormal 6-hydroxypurine phosphoribosyltransferase level', 'Abnormal GPRT level']}, 'types': {0: ['T033']}, 'definition': {0: 'Altered level of the enzyme that catalyzes conversion of hypoxanthine to inosine monophosphate and guanine to guanosine monophosphate via transfer of the 5-phosphoribosyl group from 5-phosphoribosyl 1-pyrophosphate. [RGD:sjwang]'}, 'entity': {0: 'level'}, 'text': {0: 'Increased aspartate aminotransferase level'}}","           entity_group                             value     score
0             Lab_value                         Increased  0.999820
1  Diagnostic_procedure  aspartate aminotransferase level  0.997505",[],"{'keyword': {0: 'increased aspartate aminotransferase', 1: 'increased aspartate', 2: 'aspartate aminotransferase level', 3: 'aminotransferase level', 4: 'aspartate aminotransferase'}, 'score': {0: 0.9785, 1: 0.9394, 2: 0.8709, 3: 0.8362, 4: 0.7941}}"
1721,1721,1721,0.9470000267028807,26.0,210 (28.4),UniversSB-Light,4,-0.2329999953508377,5723991,34,8,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   210  0.999433",[],"{'keyword': {0: '210 28'}, 'score': {0: 0.9019}}"
1722,1722,1722,0.9470000267028807,26.0,4 (0.5),UniversSB-Light,4,-0.2329999953508377,5723991,34,8,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     4  0.999844",[],"{'keyword': {}, 'score': {}}"
1723,1723,1723,0.9470000267028807,26.0,40 (5.6),UniversSB-Light,4,-0.2329999953508377,5723991,34,8,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    40  0.999794",[],"{'keyword': {}, 'score': {}}"
1724,1724,1724,0.9470000267028807,26.0,2 (0.3),UniversSB-Light,4,-0.2329999953508377,5723991,34,8,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1725,1725,1725,0.9470000267028807,26.0,Headache,UniversSB-Light,4,-0.2329999953508377,5723991,34,9,0,"{'concept_id': {0: 'C0270697'}, 'canonical_name': {0: 'Post-Lumbar Puncture Headache'}, 'aliases': {0: ['Post-Lumbar Puncture Headache', 'Postspinal headache', 'Post-lumbar puncture headache', 'headache post spinal', 'post-lumbar puncture headache', 'post lumbar puncture headache', 'dural headache post puncture', 'post dural puncture headache', 'headache spinal', 'headaches spinal', 'headaches lumbar puncture', 'Spinal headache', 'headache post lumbar puncture', 'post spinal headache', 'dural headaches post puncture', 'Headache following lumbar puncture', 'headaches post spinal', 'Lumbar Puncture Headache', 'spinal headache', 'Headache following lumbar puncture (disorder)', 'lumbar puncture headache', 'Lumbar puncture headache']}, 'types': {0: ['T184']}, 'definition': {0: 'Headache in erect position, after lumbar puncture; due to lowering of intracranial pressure by leakage of cerebrospinal fluid through the needle tract.'}, 'entity': {0: 'Headache'}, 'text': {0: 'Headache'}}","{'concept_id': {0: 'C0393735'}, 'canonical_name': {0: 'Syndrome, Headache'}, 'aliases': {0: ['Headache Disorder', 'Headache Syndromes', 'Headache Disorders', 'Cephalgia Syndromes', 'Cephalgia Syndrome', 'Headache Syndrome']}, 'types': {0: ['T047']}, 'definition': {0: 'Various conditions with the symptom of HEADACHE. Headache disorders are classified into major groups, such as PRIMARY HEADACHE DISORDERS (based on characteristics of their headache symptoms) and SECONDARY HEADACHE DISORDERS (based on their etiologies). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)'}, 'entity': {0: 'Headache'}, 'text': {0: 'Headache'}}",{},{},"{'concept_id': {0: 'C0009088'}, 'canonical_name': {0: 'Cluster headache'}, 'aliases': {0: []}, 'types': {0: ['T047']}, 'definition': {0: 'A primary headache disorder that is characterized by severe, strictly unilateral PAIN which is orbital, supraorbital, temporal or in any combination of these sites, lasting 15-180 min. occurring 1 to 8 times a day. The attacks are associated with one or more of the following, all of which are ipsilateral: conjunctival injection, lacrimation, nasal congestion, rhinorrhea, facial SWEATING, eyelid EDEMA, and miosis. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)'}, 'entity': {0: 'Headache'}, 'text': {0: 'Headache'}}","   entity_group     value    score
0  Sign_symptom  Headache  0.99988",[],"{'keyword': {}, 'score': {}}"
1726,1726,1726,0.9470000267028807,26.0,210 (28.4),UniversSB-Light,4,-0.2329999953508377,5723991,34,9,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   210  0.999433",[],"{'keyword': {0: '210 28'}, 'score': {0: 0.9019}}"
1727,1727,1727,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,34,9,2,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1728,1728,1728,0.9470000267028807,26.0,122 (16.9),UniversSB-Light,4,-0.2329999953508377,5723991,34,9,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   122  0.999822",[],"{'keyword': {0: '122 16'}, 'score': {0: 0.7973}}"
1729,1729,1729,0.9470000267028807,26.0,1 (0.1),UniversSB-Light,4,-0.2329999953508377,5723991,34,9,4,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1730,1730,1730,0.9470000267028807,26.0,Arthralgia,UniversSB-Light,4,-0.2329999953508377,5723991,34,10,0,"{'concept_id': {0: 'C0221785'}, 'canonical_name': {0: 'Pain in wrist'}, 'aliases': {0: ['Wrist arthralgia', 'Wrist joint pain', 'pain in wrist', 'joint pain wrist', 'wrist pain', 'wrist joint pain', 'joint pain wrists', 'Wrist joint pain (finding)', 'pain wrist', 'WRIST PAIN', 'Arthralgia of wrist', 'Pain in wrist (finding)', 'pains wrist', 'Wrist pain', 'pain wrists', 'Pain in wrist']}, 'types': {0: ['T184']}, 'definition': {0: 'An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the wrist. [UToronto:chum]'}, 'entity': {0: 'Arthralgia'}, 'text': {0: 'Arthralgia'}}","{'concept_id': {0: 'C0003862'}, 'canonical_name': {0: 'Arthralgia'}, 'aliases': {0: ['Pains, Joint', 'Pain, Joint', 'Arthralgias', 'Joint Pain', 'Joint Pains']}, 'types': {0: ['T184']}, 'definition': {0: 'Pain in the joint.'}, 'entity': {0: 'Arthralgia'}, 'text': {0: 'Arthralgia'}}",{},{},"{'concept_id': {0: 'C0019559'}, 'canonical_name': {0: 'Hip joint pain'}, 'aliases': {0: ['Hip arthralgia', 'Arthralgia of the hip', 'Coxalgia']}, 'types': {0: ['T184']}, 'definition': {0: 'A sensation of discomfort emanating from the pelvis, its supporting structures, or its articulation with the femur (acetabulofemoral or femoroacetabular joint).'}, 'entity': {0: 'Arthralgia'}, 'text': {0: 'Arthralgia'}}","   entity_group       value     score
0  Sign_symptom  Arthralgia  0.997537",[],"{'keyword': {}, 'score': {}}"
1731,1731,1731,0.9470000267028807,26.0,192 (25.9),UniversSB-Light,4,-0.2329999953508377,5723991,34,10,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   192  0.999349",[],"{'keyword': {0: '192 25'}, 'score': {0: 0.86}}"
1732,1732,1732,0.9470000267028807,26.0,1 (0.1),UniversSB-Light,4,-0.2329999953508377,5723991,34,10,2,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1733,1733,1733,0.9470000267028807,26.0,148 (20.6),UniversSB-Light,4,-0.2329999953508377,5723991,34,10,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   148  0.999731",[],"{'keyword': {0: '148 20'}, 'score': {0: 0.8378}}"
1734,1734,1734,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,34,10,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1735,1735,1735,0.9470000267028807,26.0,Radiation-related skin injury,UniversSB-Light,4,-0.2329999953508377,5723991,34,11,0,{},"{'concept_id': {0: 'C0034530'}, 'canonical_name': {0: 'Radiation Injury'}, 'aliases': {0: ['Radiation Injuries', 'Injuries, Radiation', 'Injury, Radiation']}, 'types': {0: ['T037']}, 'definition': {0: 'Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES.'}, 'entity': {0: 'Radiation-related skin injury'}, 'text': {0: 'Radiation-related skin injury'}}",{},{},{},"       entity_group              value     score
0  Disease_disorder  Radiation-related  0.546773
1  Disease_disorder        skin injury  0.999186",[],"{'keyword': {0: 'radiation related skin', 1: 'skin injury', 2: 'radiation related', 3: 'related skin injury', 4: 'related skin'}, 'score': {0: 0.926, 1: 0.8893, 2: 0.8517, 3: 0.8357, 4: 0.7572}}"
1736,1736,1736,0.9470000267028807,26.0,188 (25.4),UniversSB-Light,4,-0.2329999953508377,5723991,34,11,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   188  0.999761",[],"{'keyword': {0: '188 25'}, 'score': {0: 0.8369}}"
1737,1737,1737,0.9470000267028807,26.0,10 (1.4),UniversSB-Light,4,-0.2329999953508377,5723991,34,11,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    10  0.999608",[],"{'keyword': {}, 'score': {}}"
1738,1738,1738,0.9470000267028807,26.0,199 (27.6),UniversSB-Light,4,-0.2329999953508377,5723991,34,11,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   199  0.999539",[],"{'keyword': {0: '199 27'}, 'score': {0: 0.8559}}"
1739,1739,1739,0.9470000267028807,26.0,7 (1.0),UniversSB-Light,4,-0.2329999953508377,5723991,34,11,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value     7  0.999803",[],"{'keyword': {}, 'score': {}}"
1740,1740,1740,0.9470000267028807,26.0,Increased alanine aminotransferase level,UniversSB-Light,4,-0.2329999953508377,5723991,34,12,0,"{'concept_id': {0: 'C3887708'}, 'canonical_name': {0: 'Alanine Aminotransferase 1, human'}, 'aliases': {0: ['ALT1', 'Alanine Aminotransferase', 'GPT', 'Glutamate Pyruvate Transaminase 1', 'Glutamic-Pyruvic Transaminase 1', 'Glutamic--Alanine Transaminase 1', 'Glutamic-Pyruvic Transaminase', 'Glutamic-Alanine Transaminase 1', 'GPT1', 'EC 2.6.1.2', 'Glutamic-Pyruvate Transaminase', 'Alanine Aminotransferase 1', 'AAT1', 'Glutamic--Pyruvic Transaminase 1', 'Glutamic-Alanine Transaminase', 'GPT 1']}, 'types': {0: ['T116', 'T126']}, 'definition': {0: 'Alanine aminotransferase 1 (496 aa, ~55 kDa) is encoded by the human GPT gene. This protein plays a role in both amino acid metabolism and pyruvate synthesis.'}, 'entity': {0: 'alanine aminotransferase'}, 'text': {0: 'Increased alanine aminotransferase level'}}","{'concept_id': {0: 'C0002594'}, 'canonical_name': {0: 'Aminotransferases'}, 'aliases': {0: ['Aminotransferase', 'Transaminases', 'Transaminase']}, 'types': {0: ['T116', 'T126']}, 'definition': {0: 'A subclass of enzymes of the transferase class that catalyze the transfer of an amino group from a donor (generally an amino acid) to an acceptor (generally a 2-keto acid). Most of these enzymes are pyridoxyl phosphate proteins. (Dorland, 28th ed) EC 2.6.1.'}, 'entity': {0: 'alanine aminotransferase'}, 'text': {0: 'Increased alanine aminotransferase level'}}",{},"{'concept_id': {0: 'C1152208'}, 'canonical_name': {0: 'aminotransferase activity'}, 'aliases': {0: ['transaminase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the transfer of an amino group to an acceptor, usually a 2-oxo acid. [ISBN:0198506732]'}, 'entity': {0: 'alanine aminotransferase'}, 'text': {0: 'Increased alanine aminotransferase level'}}","{'concept_id': {0: 'C0151905'}, 'canonical_name': {0: 'Alanine aminotransferase increased'}, 'aliases': {0: ['Elevated serum ALT', 'Elevated serum glutamic-pyruvic transaminase', 'Elevated serum alanine aminotransferase', 'Elevated circulating alanine aminotransferase concentration']}, 'types': {0: ['T033']}, 'definition': {0: 'An increase in the level of alanine aminotransferase in the blood.'}, 'entity': {0: 'alanine aminotransferase'}, 'text': {0: 'Increased alanine aminotransferase level'}}","           entity_group                           value     score
0             Lab_value                       Increased  0.999901
1  Diagnostic_procedure  alanine aminotransferase level  0.995934",[],"{'keyword': {0: 'increased alanine aminotransferase', 1: 'increased alanine', 2: 'alanine aminotransferase level', 3: 'aminotransferase level', 4: 'alanine aminotransferase'}, 'score': {0: 0.9807, 1: 0.9502, 2: 0.8665, 3: 0.8023, 4: 0.7287}}"
1741,1741,1741,0.9470000267028807,26.0,171 (23.1),UniversSB-Light,4,-0.2329999953508377,5723991,34,12,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   171  0.999359",[],"{'keyword': {0: '171 23'}, 'score': {0: 0.8545}}"
1742,1742,1742,0.9470000267028807,26.0,3 (0.4),UniversSB-Light,4,-0.2329999953508377,5723991,34,12,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     3  0.999773",[],"{'keyword': {}, 'score': {}}"
1743,1743,1743,0.9470000267028807,26.0,41 (5.7),UniversSB-Light,4,-0.2329999953508377,5723991,34,12,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    41  0.999779",[],"{'keyword': {}, 'score': {}}"
1744,1744,1744,0.9470000267028807,26.0,2 (0.3),UniversSB-Light,4,-0.2329999953508377,5723991,34,12,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1745,1745,1745,0.9470000267028807,26.0,Epistaxis,UniversSB-Light,4,-0.2329999953508377,5723991,34,13,0,"{'concept_id': {0: 'C0179204'}, 'canonical_name': {0: 'Nasal balloon'}, 'aliases': {0: ['Nasal balloon, device', 'Epistaxis Balloons', 'Nasal balloon, device (physical object)', 'BALLOON, EPISTAXIS', 'nasal balloon', 'Balloons, Nasal', 'balloons nasal', 'Balloons, Epistaxis', 'Nasal balloon', 'Nasal Balloons', 'Nosebleed Balloons']}, 'types': {0: ['T074']}, 'definition': {0: 'An epistaxis balloon is a device consisting of an inflatable balloon intended to control internal nasal bleeding by exerting pressure against the sphenopalatine artery.'}, 'entity': {0: 'Epistaxis'}, 'text': {0: 'Epistaxis'}}","{'concept_id': {0: 'C0014591'}, 'canonical_name': {0: 'Nasal Bleedings'}, 'aliases': {0: ['Nasal Bleeding', 'Epistaxis', 'Bleedings, Nasal', 'Nose Bleeds', 'Nosebleeds', 'Nose Bleed', 'Bleeding, Nasal', 'Nosebleed']}, 'types': {0: ['T046']}, 'definition': {0: 'Bleeding from the nose.'}, 'entity': {0: 'Epistaxis'}, 'text': {0: 'Epistaxis'}}",{},{},"{'concept_id': {0: 'C0014591'}, 'canonical_name': {0: 'Nosebleed'}, 'aliases': {0: ['Nose bleed', 'Nose bleeding', 'Nasal hemorrhage', 'Bloody nose', 'Epistaxis', 'Nasal haemorrhage']}, 'types': {0: ['T046']}, 'definition': {0: 'Bleeding from the nose.'}, 'entity': {0: 'Epistaxis'}, 'text': {0: 'Epistaxis'}}","   entity_group      value     score
0  Sign_symptom  Epistaxis  0.930277",[],"{'keyword': {}, 'score': {}}"
1746,1746,1746,0.9470000267028807,26.0,159 (21.5),UniversSB-Light,4,-0.2329999953508377,5723991,34,13,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   159  0.999667",[],"{'keyword': {0: '159 21'}, 'score': {0: 0.8008}}"
1747,1747,1747,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,34,13,2,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1748,1748,1748,0.9470000267028807,26.0,25 (3.5),UniversSB-Light,4,-0.2329999953508377,5723991,34,13,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    25  0.999666",[],"{'keyword': {}, 'score': {}}"
1749,1749,1749,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,34,13,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1750,1750,1750,0.9470000267028807,26.0,Peripheral sensory neuropathy,UniversSB-Light,4,-0.2329999953508377,5723991,34,14,0,"{'concept_id': {0: 'C0031117'}, 'canonical_name': {0: 'Peripheral Neuropathy'}, 'aliases': {0: ['PERIPHERAL NEUROPATHY', 'Peripheral Neuropathy', 'peripheral neuropathy', 'Peripheral nerve damage', 'Peripheral neuritis', 'Peripheral neuropathy']}, 'types': {0: ['T047']}, 'definition': {0: 'A disorder affecting the peripheral nervous system. It manifests with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs.'}, 'entity': {0: 'Peripheral sensory neuropathy'}, 'text': {0: 'Peripheral sensory neuropathy'}}","{'concept_id': {0: 'C0699739'}, 'canonical_name': {0: 'Congenital Sensory Neuropathies'}, 'aliases': {0: ['Neuropathies, Congenital Sensory', 'Sensory Neuropathies, Hereditary', 'Neuropathy, Hereditary Sensory', 'Sensory Neuropathies, Congenital', 'Neuropathies, Hereditary Sensory', 'Hereditary Sensory Neuropathy', 'Neurogenic Acroosteolysis', 'Neuropathy, Congenital Sensory', 'Hereditary Sensory Neuropathies', 'Congenital Sensory Neuropathy', 'Sensory Neuropathy, Congenital', 'Acroosteolysis, Neurogenic', 'Sensory Neuropathy, Hereditary', 'Neurogenic Acroosteolyses', 'Acroosteolyses, Neurogenic']}, 'types': {0: ['T047']}, 'definition': {0: 'group of peripheral nervous system hereditary disorders with varying course, symptoms, neuropathology, and genetics, but characterized by degeneration of peripheral nerves, and clinically by loss of sensation.'}, 'entity': {0: 'Peripheral sensory neuropathy'}, 'text': {0: 'Peripheral sensory neuropathy'}}",{},{},"{'concept_id': {0: 'C0031117'}, 'canonical_name': {0: 'Peripheral neuropathy'}, 'aliases': {0: ['Peripheral nerve damage', 'Peripheral neuritis']}, 'types': {0: ['T047']}, 'definition': {0: 'A disorder affecting the peripheral nervous system. It manifests with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs.'}, 'entity': {0: 'Peripheral sensory neuropathy'}, 'text': {0: 'Peripheral sensory neuropathy'}}","       entity_group                          value     score
0  Disease_disorder  Peripheral sensory neuropathy  0.999234",[],"{'keyword': {0: 'peripheral sensory neuropathy', 1: 'sensory neuropathy', 2: 'peripheral sensory'}, 'score': {0: 1.0, 1: 0.9812, 2: 0.8705}}"
1751,1751,1751,0.9470000267028807,26.0,138 (18.6),UniversSB-Light,4,-0.2329999953508377,5723991,34,14,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   138  0.999762",[],"{'keyword': {0: '138 18'}, 'score': {0: 0.8429}}"
1752,1752,1752,0.9470000267028807,26.0,10 (1.4),UniversSB-Light,4,-0.2329999953508377,5723991,34,14,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    10  0.999608",[],"{'keyword': {}, 'score': {}}"
1753,1753,1753,0.9470000267028807,26.0,50 (6.9),UniversSB-Light,4,-0.2329999953508377,5723991,34,14,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    50  0.999601",[],"{'keyword': {}, 'score': {}}"
1754,1754,1754,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,34,14,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1755,1755,1755,0.9470000267028807,26.0,Constipation,UniversSB-Light,4,-0.2329999953508377,5723991,34,15,0,"{'concept_id': {0: 'C3641755'}, 'canonical_name': {0: 'Have Constipation'}, 'aliases': {0: ['Have Constipation', 'Have Been Constipated']}, 'types': {0: ['T170']}, 'definition': {0: 'A question about whether an individual is or has been constipated.'}, 'entity': {0: 'Constipation'}, 'text': {0: 'Constipation'}}","{'concept_id': {0: 'C0009806'}, 'canonical_name': {0: 'Constipation'}, 'aliases': {0: []}, 'types': {0: ['T184']}, 'definition': {0: 'Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.'}, 'entity': {0: 'Constipation'}, 'text': {0: 'Constipation'}}",{},{},"{'concept_id': {0: 'C0401149'}, 'canonical_name': {0: 'Infrequent bowel movements'}, 'aliases': {0: ['Chronic constipation']}, 'types': {0: ['T184']}, 'definition': {0: 'Constipation for longer than three months with fewer than 3 bowel movements per week, straining, lumpy or hard stools, and a sensation of anorectal obstruction or incomplete defecation. [ORCID:0000-0001-5208-3432]'}, 'entity': {0: 'Constipation'}, 'text': {0: 'Constipation'}}","   entity_group         value     score
0  Sign_symptom  Constipation  0.999722",[],"{'keyword': {}, 'score': {}}"
1756,1756,1756,0.9470000267028807,26.0,126 (17.0),UniversSB-Light,4,-0.2329999953508377,5723991,34,15,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   126  0.999776",[],"{'keyword': {0: '126 17'}, 'score': {0: 0.694}}"
1757,1757,1757,0.9470000267028807,26.0,1 (0.1),UniversSB-Light,4,-0.2329999953508377,5723991,34,15,2,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1758,1758,1758,0.9470000267028807,26.0,59 (8.2),UniversSB-Light,4,-0.2329999953508377,5723991,34,15,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    59  0.999645",[],"{'keyword': {}, 'score': {}}"
1759,1759,1759,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,34,15,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1760,1760,1760,0.9169999957084656,30.0,Reference:,ConduitITC-Bold,20,-0.2349999994039535,8194925,34,16,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1761,1761,1761,0.8830000162124634,22.0,1. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628. ,MyriadPro-Light,4,-0.25,3355443,34,16,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'et al', 4: 'engl med 2019'}, 'score': {0: 0.8031, 1: 0.7251, 2: 0.7194, 3: 0.6642, 4: 0.6422}}"
1762,1762,1762,0.9470000267028807,26.0,Myalgia,UniversSB-Light,4,-0.2329999953508377,5723991,34,17,0,"{'concept_id': {0: 'C0032238'}, 'canonical_name': {0: 'Pleurodynia, Epidemic'}, 'aliases': {0: ['Epidemic myalgia', 'Epidemic, myositis', 'Myalgia, Epidemic', 'Epidemic Pleurodynia', 'Bornholm Disease', 'DABNEY GRIP', 'Epidemic myositis', 'MYALGIA, EPIDEMIC', 'Bornholm disease', 'devil grip', 'epidemic pleurodynia', 'BORNHOLM DISEASE', 'Epidemic Myalgias', 'epidemic myalgia', 'Epidemic Pleurodynias', 'DEVIL GRIP', 'Epidemic pleurodynia', 'Epidemic benign dry pleurisy', 'Pleurodynias, Epidemic', 'Epidemic, myalgia', 'Epidemic pleurodynia (disorder)', 'PLEURODYNIA, EPIDEMIC', 'Epidemic Myalgia', ""Devil's grip"", ""devil's grip"", 'SYLVEST SYNDROME', 'bornholms disease', 'devils grip', 'bornholm disease', 'Myalgias, Epidemic', 'Epidemic pleurisy']}, 'types': {0: ['T047']}, 'definition': {0: 'An acute, febrile, infectious disease generally occurring in epidemics. It is usually caused by coxsackieviruses B and sometimes by coxsackieviruses A; echoviruses; or other enteroviruses.'}, 'entity': {0: 'Myalgia'}, 'text': {0: 'Myalgia'}}","{'concept_id': {0: 'C0016053'}, 'canonical_name': {0: 'Fibromyalgia Fibromyositis Syndrome'}, 'aliases': {0: ['Diffuse Myofascial Pain Syndrome', 'Muscular Rheumatism', 'Myofascial Pain Syndrome, Diffuse', 'Syndrome, Fibromyositis-Fibromyalgia', 'Syndromes, Fibromyalgia-Fibromyositis', 'Fibromyositis Fibromyalgia Syndrome', 'Fibromyalgia-Fibromyositis Syndromes', 'Fibromyositis-Fibromyalgia Syndromes', 'Fibrositis', 'Fibromyositis-Fibromyalgia Syndrome', 'Fibromyalgias', 'Fibrositides', 'Syndromes, Fibromyositis-Fibromyalgia', 'Rheumatism, Muscular', 'Fibromyalgia', 'Fibromyalgia-Fibromyositis Syndrome', 'Syndrome, Fibromyalgia-Fibromyositis']}, 'types': {0: ['T047']}, 'definition': {0: 'A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95)'}, 'entity': {0: 'Myalgia'}, 'text': {0: 'Myalgia'}}",{},{},"{'concept_id': {0: 'C4732758'}, 'canonical_name': {0: 'Gastrocnemius myalgia'}, 'aliases': {0: ['Calf myalgia', 'Calf muscle pain']}, 'types': {0: ['T184']}, 'definition': {0: 'Pain of the gastrocnemius muscle. [PMID:29491286]'}, 'entity': {0: 'Myalgia'}, 'text': {0: 'Myalgia'}}","   entity_group    value     score
0  Sign_symptom  Myalgia  0.921871",[],"{'keyword': {}, 'score': {}}"
1763,1763,1763,0.9470000267028807,26.0,114 (15.4),UniversSB-Light,4,-0.2329999953508377,5723991,34,17,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value   114  0.99968",[],"{'keyword': {0: '114 15'}, 'score': {0: 0.7406}}"
1764,1764,1764,0.9470000267028807,26.0,3 (0.4),UniversSB-Light,4,-0.2329999953508377,5723991,34,17,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     3  0.999773",[],"{'keyword': {}, 'score': {}}"
1765,1765,1765,0.9470000267028807,26.0,80 (11.1),UniversSB-Light,4,-0.2329999953508377,5723991,34,17,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value    80  0.999821",[],"{'keyword': {0: '80 11'}, 'score': {0: 0.8124}}"
1766,1766,1766,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,34,17,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1767,1767,1767,0.9470000267028807,26.0,Hot flushes,UniversSB-Light,4,-0.2329999953508377,5723991,34,18,0,"{'concept_id': {0: 'C0005874'}, 'canonical_name': {0: 'Blushing'}, 'aliases': {0: ['blushing', 'flushes', 'Blush', 'Blushing', 'Blushing, function (observable entity)', 'Blushing, function', 'Blushings', 'blush', 'Blushes']}, 'types': {0: ['T184']}, 'definition': {0: 'Involuntary reddening, especially of the face, associated with feelings of embarrassment, confusion or shame.'}, 'entity': {0: 'Hot flushes'}, 'text': {0: 'Hot flushes'}}",{},{},{},{},"   entity_group        value     score
0  Sign_symptom  Hot flushes  0.914683",[],"{'keyword': {0: 'hot flushes'}, 'score': {0: 1.0}}"
1768,1768,1768,0.9470000267028807,26.0,95 (12.8),UniversSB-Light,4,-0.2329999953508377,5723991,34,18,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value    95  0.99951",[],"{'keyword': {0: '95 12'}, 'score': {0: 0.884}}"
1769,1769,1769,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,34,18,2,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1770,1770,1770,0.9470000267028807,26.0,146 (20.3),UniversSB-Light,4,-0.2329999953508377,5723991,34,18,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   146  0.999759",[],"{'keyword': {0: '146 20'}, 'score': {0: 0.7477}}"
1771,1771,1771,0.9470000267028807,26.0,2 (0.3),UniversSB-Light,4,-0.2329999953508377,5723991,34,18,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1772,1772,1772,0.944000005722046,19.0,Adverse events of any grade with an incidence ,UniversSB-Medium,4,-0.2349999994039535,3355443,34,19,0,"{'concept_id': {0: 'C1708485'}, 'canonical_name': {0: 'Incidence Rate'}, 'aliases': {0: ['Rate, Incidence', 'Incidence Rates', 'Person-time Rate', 'Person time Rate', 'Incidence Rate', 'Person-time Rates', 'Rate, Person-time']}, 'types': {0: ['T079']}, 'definition': {0: 'The frequency of new occurrences of an event during a specified time period.'}, 'entity': {0: 'incidence'}, 'text': {0: 'Adverse events of any grade with an incidence '}}","{'concept_id': {0: 'C1708485'}, 'canonical_name': {0: 'Incidence Rate'}, 'aliases': {0: ['Person-time Rates', 'Person-time Rate', 'Rate, Incidence', 'Rate, Person-time', 'Person time Rate', 'Incidence Rates']}, 'types': {0: ['T079']}, 'definition': {0: 'The frequency of new occurrences of an event during a specified time period.'}, 'entity': {0: 'incidence'}, 'text': {0: 'Adverse events of any grade with an incidence '}}",{},{},{},"   entity_group           value     score
0  Sign_symptom  Adverse events  0.999626
1     Lab_value             any  0.389230
2     Lab_value       incidence  0.703636",[],"{'keyword': {0: 'adverse events', 1: 'adverse events grade', 2: 'grade incidence', 3: 'events grade incidence', 4: 'events grade'}, 'score': {0: 0.8551, 1: 0.6639, 2: 0.522, 3: 0.4817, 4: 0.4187}}"
1773,1773,1773,0.9470000267028807,19.0,Adapted from von Minckwitz et al. 2019.,UniversSB-Light,4,-0.2329999953508377,3355443,34,19,1,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
1774,1774,1774,0.9470000267028807,19.0,"*All listed adverse events are grade 3 except for decreased platelet count, which includes 2.0% of patients in the ",UniversSB-Light,4,-0.2329999953508377,3355443,34,19,2,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'patients'}, 'text': {0: '*All listed adverse events are grade 3 except for decreased platelet count, which includes 2.0% of patients in the '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'patients'}, 'text': {0: '*All listed adverse events are grade 3 except for decreased platelet count, which includes 2.0% of patients in the '}}",{},{},"{'concept_id': {0: 'C0857460'}, 'canonical_name': {0: 'Increased platelet count'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'A higher than average level of platelets in a sample.'}, 'entity': {0: 'platelet count'}, 'text': {0: '*All listed adverse events are grade 3 except for decreased platelet count, which includes 2.0% of patients in the '}}","           entity_group           value     score
0             Lab_value               *  0.716691
1          Sign_symptom  adverse events  0.999860
2             Lab_value         grade 3  0.999039
3             Lab_value       decreased  0.998055
4  Diagnostic_procedure        platelet  0.997552
5             Lab_value           2.0 %  0.999041",[],"{'keyword': {0: 'events grade', 1: 'adverse events grade', 2: 'count includes patients', 3: 'listed adverse events', 4: 'decreased platelet count'}, 'score': {0: 0.6143, 1: 0.5981, 2: 0.5811, 3: 0.5527, 4: 0.2726}}"
1775,1775,1775,0.9470000267028807,19.0,Kadcyla group and 0.1% of patients in the trastuzumab group who had a grade 4 decreased platelet count.,UniversSB-Light,4,-0.2329999953508377,3355443,34,19,3,"{'concept_id': {0: 'C5201036'}, 'canonical_name': {0: 'Low Platelet Count'}, 'aliases': {0: ['low platelet', 'low count platelet', 'low platelets', 'platelet count low', 'Low Platelet Count', 'low platelet count', 'platelet low', 'platelets low', 'Low platelet count']}, 'types': {0: ['T034']}, 'definition': {0: 'A lower than average level of platelets in a sample.'}, 'entity': {0: 'platelet count'}, 'text': {0: 'Kadcyla group and 0.1% of patients in the trastuzumab group who had a grade 4 decreased platelet count.'}}","{'concept_id': {0: 'C0005821'}, 'canonical_name': {0: 'Platelet'}, 'aliases': {0: ['Platelets', 'Platelets, Blood', 'Thrombocyte', 'Thrombocytes', 'Blood Platelet', 'Platelet, Blood', 'Blood Platelets']}, 'types': {0: ['T025']}, 'definition': {0: 'Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.'}, 'entity': {0: 'platelet count'}, 'text': {0: 'Kadcyla group and 0.1% of patients in the trastuzumab group who had a grade 4 decreased platelet count.'}}","{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab group'}, 'text': {0: 'Kadcyla group and 0.1% of patients in the trastuzumab group who had a grade 4 decreased platelet count.'}}",{},"{'concept_id': {0: 'C0857460'}, 'canonical_name': {0: 'Increased platelet count'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'A higher than average level of platelets in a sample.'}, 'entity': {0: 'platelet count'}, 'text': {0: 'Kadcyla group and 0.1% of patients in the trastuzumab group who had a grade 4 decreased platelet count.'}}","           entity_group                value     score
0  Diagnostic_procedure  Kadcyla group group  0.996650
1             Lab_value                0.1 %  0.847481
2            Medication          trastuzumab  0.942004
3             Lab_value              grade 4  0.999605
4             Lab_value            decreased  0.999931
5  Diagnostic_procedure             platelet  0.999503","[('Kadcyla', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'group grade', 1: 'kadcyla group patients', 2: 'patients trastuzumab', 3: 'platelet count', 4: 'decreased platelet count'}, 'score': {0: 0.6118, 1: 0.5939, 2: 0.5635, 3: 0.5064, 4: 0.2763}}"
1776,1776,1776,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,34,20,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1777,1777,1777,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,34,20,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1778,1778,1778,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,34,20,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1779,1779,1779,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,34,20,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1780,1780,1780,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,34,21,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1781,1781,1781,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,34,21,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1782,1782,1782,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,34,21,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1783,1783,1783,0.9169999957084656,98.0,17.9% of patients discontinued Kadcyla  ,ConduitITC-Bold,20,-0.2349999994039535,8194925,35,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: '17.9% of patients discontinued Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: '17.9% of patients discontinued Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: '17.9% of patients discontinued Kadcyla  '}}",{},{},"            entity_group    value     score
0              Lab_value   17.9 %  0.998868
1  Therapeutic_procedure  Kadcyla  0.799513","[('Kadcyla', 'DRUG')]","{'keyword': {0: '17 patients discontinued', 1: 'patients discontinued kadcyla', 2: 'patients discontinued', 3: 'discontinued kadcyla', 4: '17 patients'}, 'score': {0: 0.903, 1: 0.8888, 2: 0.857, 3: 0.7705, 4: 0.6425}}"
1784,1784,1784,0.9169999957084656,98.0,due to adverse events,ConduitITC-Bold,20,-0.2349999994039535,8194925,35,1,1,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'due to adverse events'}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'due to adverse events'}}",{},{},{},"   entity_group           value     score
0  Sign_symptom  adverse events  0.929723",[],"{'keyword': {0: 'adverse events'}, 'score': {0: 0.8903}}"
1785,1785,1785,0.9520000219345092,28.0,Trastuzumab (n=743),MyriadPro-Regular,4,-0.25,16777215,35,2,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999833","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab 743'}, 'score': {0: 0.8631}}"
1786,1786,1786,0.9520000219345092,28.0,Kadcyla (n=743),MyriadPro-Regular,4,-0.25,16777215,35,2,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}",{},{},"           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.969694",[],"{'keyword': {0: 'kadcyla 743'}, 'score': {0: 0.8404}}"
1787,1787,1787,0.9520000219345092,26.0,"Patients, n (%)*",MyriadPro-Regular,4,-0.25,16777215,35,3,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'Patients'}, 'text': {0: 'Patients, n (%)*'}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'Patients'}, 'text': {0: 'Patients, n (%)*'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1788,1788,1788,0.8830000162124634,26.0,Completed planned 14 cycles of treatment,MyriadPro-Light,4,-0.25,5723991,35,4,0,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'Completed planned 14 cycles of treatment'}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'Completed planned 14 cycles of treatment'}}",{},{},{},"            entity_group      value     score
0                 Dosage         14  0.879466
1   Quantitative_concept     cycles  0.514736
2  Therapeutic_procedure  treatment  0.880838","[('14 cycles', 'DURATION')]","{'keyword': {0: 'completed planned 14', 1: '14 cycles treatment', 2: '14 cycles', 3: 'planned 14', 4: 'cycles treatment'}, 'score': {0: 0.7927, 1: 0.7282, 2: 0.7042, 3: 0.5975, 4: 0.4745}}"
1789,1789,1789,0.8830000162124634,26.0,527 (70.9),MyriadPro-Light,4,-0.25,5723991,35,4,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value   527  0.85979",[],"{'keyword': {0: '527 70'}, 'score': {0: 0.704}}"
1790,1790,1790,0.8830000162124634,26.0,585 (78.7),MyriadPro-Light,4,-0.25,5723991,35,4,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value   585  0.938519",[],"{'keyword': {0: '585 78'}, 'score': {0: 0.8025}}"
1791,1791,1791,0.8830000162124634,26.0,Discontinued study treatment,MyriadPro-Light,4,-0.25,5723991,35,5,0,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'Discontinued study treatment'}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'Discontinued study treatment'}}",{},{},{},"            entity_group               value     score
0   Detailed_description  Discontinued study  0.971361
1  Therapeutic_procedure           treatment  0.807373",[],"{'keyword': {0: 'discontinued study treatment', 1: 'discontinued study', 2: 'study treatment'}, 'score': {0: 1.0, 1: 0.9781, 2: 0.6535}}"
1792,1792,1792,0.8830000162124634,26.0,212 (28.5),MyriadPro-Light,4,-0.25,5723991,35,5,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   212  0.999161",[],"{'keyword': {0: '212 28'}, 'score': {0: 0.8399}}"
1793,1793,1793,0.8830000162124634,26.0,135 (18.2),MyriadPro-Light,4,-0.25,5723991,35,5,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value   135  0.999537",[],"{'keyword': {0: '135 18'}, 'score': {0: 0.8669}}"
1794,1794,1794,0.8830000162124634,32.0,The most common adverse events leading to ,MyriadPro-Light,4,-0.25,3355443,35,6,0,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'The most common adverse events leading to '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'The most common adverse events leading to '}}",{},{},{},"   entity_group           value     score
0  Sign_symptom  adverse events  0.998512",[],"{'keyword': {0: 'adverse events leading', 1: 'events leading', 2: 'common adverse', 3: 'adverse events', 4: 'common adverse events'}, 'score': {0: 0.856, 1: 0.8517, 2: 0.8494, 3: 0.8398, 4: 0.8329}}"
1795,1795,1795,0.8830000162124634,32.0,discontinuation in the Kadcyla group were:,MyriadPro-Light,4,-0.25,3355443,35,6,1,"{'concept_id': {0: 'C4288399'}, 'canonical_name': {0: 'Pharmacotherapy Discontinuation'}, 'aliases': {0: ['Medication Discontinuation']}, 'types': {0: ['T061']}, 'definition': {0: 'The discontinuation of treatment with a drug.'}, 'entity': {0: 'discontinuation'}, 'text': {0: 'discontinuation in the Kadcyla group were:'}}",{},{},{},{},"           entity_group          value     score
0           Coreference        Kadcyla  0.531292
1  Detailed_description        Kadcyla  0.565048
2           Coreference  Kadcyla group  0.742093","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'discontinuation kadcyla', 1: 'discontinuation kadcyla group', 2: 'kadcyla group'}, 'score': {0: 0.8533, 1: 0.7762, 2: 0.592}}"
1796,1796,1796,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,35,7,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1797,1797,1797,0.9890000224113464,24.0,Safety,MyriadPro-Bold,20,-0.25,3355443,35,8,0,"{'concept_id': {0: 'C1456533'}, 'canonical_name': {0: 'Fire Safety'}, 'aliases': {0: []}, 'types': {0: ['T089']}, 'definition': {0: ""<p>Preventing fires is an important part of fire safety. In the United States, cooking is the main cause of home fires. Cigarettes are a big risk too - they are the leading cause of fire deaths. Here are some fire prevention tips:</p> <ul> <li>Don't leave the stove or oven unattended when they are on</li> <li>Don't let children use kitchen appliances unsupervised</li> <li>Don't smoke in bed</li> <li>Make sure your electrical appliances and cords are in good condition</li> </ul> <p>It is also important to be prepared in case there is a fire. Make sure that you have working smoke detectors on every floor and in every bedroom. You should also have fire extinguishers on every floor and in your kitchen. Make and practice an escape plan in case the main exit is blocked.</p>""}, 'entity': {0: 'Safety'}, 'text': {0: 'Safety'}}","{'concept_id': {0: 'C1456535'}, 'canonical_name': {0: 'Food Safety'}, 'aliases': {0: ['Safety, Food']}, 'types': {0: ['T057']}, 'definition': {0: 'Activities involved in ensuring the safety of FOOD including avoidance of bacterial and other contamination.'}, 'entity': {0: 'Safety'}, 'text': {0: 'Safety'}}",{},{},{},"           entity_group   value     score
0  Diagnostic_procedure  Safety  0.973877",[],"{'keyword': {}, 'score': {}}"
1798,1798,1798,0.8830000162124634,26.0,Adverse event,MyriadPro-Light,4,-0.25,5723991,35,8,1,"{'concept_id': {0: 'C5236149'}, 'canonical_name': {0: 'Adverse Event Term'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A term that refers to an adverse event, often taken from a list of standardized terms.'}, 'entity': {0: 'Adverse event'}, 'text': {0: 'Adverse event'}}","{'concept_id': {0: 'C0151735'}, 'canonical_name': {0: 'Injection Site Events'}, 'aliases': {0: ['Injection Site Event', 'Injection Site Adverse Event', 'Injection Site Reaction', 'Injection Site Reactions']}, 'types': {0: ['T046']}, 'definition': {0: 'Adverse reactions that occur initially at the site of injection or infusion. Milder type is confined to a local allergic flare reaction. A more severe reaction is caused by extravasation of VESICANTS from the blood vessel at the site of injection and can cause damage to the surrounding tissue. In tumor flare reaction symptoms involve well beyond the injection site such as an increase in the tumor size and tumor markers levels, bone pain, and HYPERCALCEMIA.'}, 'entity': {0: 'Adverse event'}, 'text': {0: 'Adverse event'}}",{},{},{},"   entity_group          value     score
0  Sign_symptom  Adverse event  0.935574",[],"{'keyword': {0: 'adverse event'}, 'score': {0: 1.0}}"
1799,1799,1799,0.8830000162124634,26.0,Pregnancy,MyriadPro-Light,4,-0.25,5723991,35,8,2,"{'concept_id': {0: 'C3843692'}, 'canonical_name': {0: 'Pregnancy 1'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'Pregnancy'}, 'text': {0: 'Pregnancy'}}","{'concept_id': {0: 'C0032974'}, 'canonical_name': {0: 'Pregnancy Proteins'}, 'aliases': {0: ['Placental Proteins', 'Proteins, Pregnancy', 'Proteins, Placental']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'Proteins produced by organs of the mother or the PLACENTA during PREGNANCY. These proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.)'}, 'entity': {0: 'Pregnancy'}, 'text': {0: 'Pregnancy'}}",{},"{'concept_id': {0: 'C0032961'}, 'canonical_name': {0: 'female pregnancy'}, 'aliases': {0: ['gestation']}, 'types': {0: ['T040']}, 'definition': {0: 'The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.'}, 'entity': {0: 'Pregnancy'}, 'text': {0: 'Pregnancy'}}","{'concept_id': {0: 'C4551893'}, 'canonical_name': {0: 'Toxaemia of pregnancy'}, 'aliases': {0: ['Hypertensive disorder of pregnancy', 'Toxemia of pregnancy']}, 'types': {0: ['T047']}, 'definition': {0: 'A pregnancy induced hypertensive state that occurs after 20 weeks of gestation characterized by an increase in blood pressure, along with body swelling and proteinuria.'}, 'entity': {0: 'Pregnancy'}, 'text': {0: 'Pregnancy'}}","  entity_group      value     score
0      History  Pregnancy  0.250901",[],"{'keyword': {}, 'score': {}}"
1800,1800,1800,0.8830000162124634,26.0,133 (17.9),MyriadPro-Light,4,-0.25,5723991,35,8,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   133  0.999757",[],"{'keyword': {0: '133 17'}, 'score': {0: 0.7952}}"
1801,1801,1801,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,35,8,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1802,1802,1802,0.8830000162124634,26.0,15 (2.0),MyriadPro-Light,4,-0.25,5723991,35,8,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value    15  0.999696",[],"{'keyword': {}, 'score': {}}"
1803,1803,1803,0.8830000162124634,26.0,1 (0.1),MyriadPro-Light,4,-0.25,5723991,35,8,6,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1804,1804,1804,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,35,9,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1805,1805,1805,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,35,10,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1806,1806,1806,0.8830000162124634,32.0,(n=12) ,MyriadPro-Light,4,-0.25,3355443,35,10,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1807,1807,1807,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,35,11,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1808,1808,1808,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,35,12,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1809,1809,1809,0.9890000224113464,24.0,Non-safety,MyriadPro-Bold,20,-0.25,3355443,35,13,0,{},"{'concept_id': {0: 'C0036043'}, 'canonical_name': {0: 'Safeties'}, 'aliases': {0: ['Safety']}, 'types': {0: ['T068']}, 'definition': {0: 'Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.'}, 'entity': {0: 'Non-safety'}, 'text': {0: 'Non-safety'}}",{},{},{},"           entity_group       value     score
0             Lab_value  Non-safety  0.528131
1  Diagnostic_procedure  Non-safety  0.714398",[],"{'keyword': {0: 'non safety'}, 'score': {0: 0.9774}}"
1810,1810,1810,0.8830000162124634,26.0,Lost to follow-up,MyriadPro-Light,4,-0.25,5723991,35,13,1,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'Lost to follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'Lost to follow-up'}}",{},{},{},"           entity_group      value     score
0  Detailed_description  follow-up  0.875353",[],"{'keyword': {0: 'lost follow'}, 'score': {0: 0.9484}}"
1811,1811,1811,0.8830000162124634,26.0,Non-adherence with study drug,MyriadPro-Light,4,-0.25,5723991,35,13,2,"{'concept_id': {0: 'C1705923'}, 'canonical_name': {0: 'Study Object'}, 'aliases': {0: ['Study', 'Study Object']}, 'types': {0: ['T170']}, 'definition': {0: 'An abbreviated set of written procedures that describe how a previously collected biospecimen will be utilized. Note that biospecimens may be collected (and utilized) with one PROTOCOL and then later utilized by multiple different STUDIES. (caTISSUE)'}, 'entity': {0: 'study drug'}, 'text': {0: 'Non-adherence with study drug'}}","{'concept_id': {0: 'C0013175'}, 'canonical_name': {0: 'Study, Drug Evaluation'}, 'aliases': {0: ['Drug Evaluation', 'Studies, Drug Evaluation', 'Drug Evaluations', 'Drug Evaluation Studies', 'Evaluation, Drug', 'Drug Evaluation Study', 'Evaluation Study, Drug', 'Evaluation Studies, Drug', 'Evaluations, Drug']}, 'types': {0: ['T062']}, 'definition': {0: 'Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.'}, 'entity': {0: 'study drug'}, 'text': {0: 'Non-adherence with study drug'}}",{},{},{},"           entity_group          value     score
0          Sign_symptom  Non-adherence  0.441297
1  Detailed_description     study drug  0.956633",[],"{'keyword': {0: 'non adherence', 1: 'non adherence study', 2: 'study drug', 3: 'adherence study', 4: 'adherence study drug'}, 'score': {0: 0.9547, 1: 0.7804, 2: 0.7404, 3: 0.6583, 4: 0.6283}}"
1812,1812,1812,0.8830000162124634,26.0,Physician decision,MyriadPro-Light,4,-0.25,5723991,35,13,3,"{'concept_id': {0: 'C0011115'}, 'canonical_name': {0: 'Decision Trees'}, 'aliases': {0: ['Trees, Decision', 'decision trees', 'Decision trees', 'decision tree', 'Tree, Decision', 'Decision Tree']}, 'types': {0: ['T170']}, 'definition': {0: 'A graphic device used in decision analysis, series of decision options are represented as branches (hierarchical).'}, 'entity': {0: 'decision'}, 'text': {0: 'Physician decision'}}","{'concept_id': {0: 'C0011109'}, 'canonical_name': {0: 'Decision Making'}, 'aliases': {0: []}, 'types': {0: ['T041']}, 'definition': {0: 'The process of making a selective intellectual judgment when presented with several complex alternatives consisting of several variables, and usually defining a course of action or an idea.'}, 'entity': {0: 'decision'}, 'text': {0: 'Physician decision'}}",{},{},{},"           entity_group      value     score
0  Detailed_description  Physician  0.864781
1        Clinical_event   decision  0.297085",[],"{'keyword': {0: 'physician decision'}, 'score': {0: 1.0}}"
1813,1813,1813,0.8830000162124634,26.0,Protocol violation,MyriadPro-Light,4,-0.25,5723991,35,13,4,"{'concept_id': {0: 'C1709750'}, 'canonical_name': {0: 'Protocol Violation'}, 'aliases': {0: ['Protocol Violation']}, 'types': {0: ['T169']}, 'definition': {0: 'A significant departure from processes or procedures that were required by the protocol. Violations often result in data that are not deemed evaluable for a per-protocol analysis, and may require that the subject(s) who violate the protocol be discontinued from the study. Compare to protocol deviation. (CDISC Glossary)'}, 'entity': {0: 'violation'}, 'text': {0: 'Protocol violation'}}","{'concept_id': {0: 'C0330463'}, 'canonical_name': {0: 'Viola'}, 'aliases': {0: ['Pansy', 'Violet', 'Violets', 'Pansies', 'Violas']}, 'types': {0: ['T002']}, 'definition': {0: 'A plant genus of the family VIOLACEAE. Some species in this genus are called bouncing bet which is a common name more often used with SAPONARIA OFFICINALIS. Members contain macrocyclic peptides.'}, 'entity': {0: 'violation'}, 'text': {0: 'Protocol violation'}}",{},{},{},"       entity_group      value     score
0  Disease_disorder   Protocol  0.591606
1      Sign_symptom  violation  0.400792",[],"{'keyword': {0: 'protocol violation'}, 'score': {0: 1.0}}"
1814,1814,1814,0.8830000162124634,26.0,Disease recurrence,MyriadPro-Light,4,-0.25,5723991,35,13,5,"{'concept_id': {0: 'C5447866'}, 'canonical_name': {0: 'Disease Recurrence Evidence'}, 'aliases': {0: ['Disease Recurrence Evidence']}, 'types': {0: ['T033']}, 'definition': {0: 'Clinical or laboratory test results that are the basis for a recurrent disease finding.'}, 'entity': {0: 'Disease recurrence'}, 'text': {0: 'Disease recurrence'}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'Disease recurrence'}, 'text': {0: 'Disease recurrence'}}",{},{},{},"   entity_group       value     score
0  Sign_symptom  recurrence  0.980423",[],"{'keyword': {0: 'disease recurrence'}, 'score': {0: 1.0}}"
1815,1815,1815,0.8830000162124634,26.0,Withdrawal by subject,MyriadPro-Light,4,-0.25,5723991,35,13,6,"{'concept_id': {0: 'C1706203'}, 'canonical_name': {0: 'Subject - topic'}, 'aliases': {0: ['Subject']}, 'types': {0: ['T078']}, 'definition': {0: 'Some matter, situation, or event that is thought about, written about, or discussed.'}, 'entity': {0: 'subject'}, 'text': {0: 'Withdrawal by subject'}}","{'concept_id': {0: 'C1708335'}, 'canonical_name': {0: 'Healthy Volunteers'}, 'aliases': {0: ['Healthy Subject', 'Participant, Healthy', 'Participants, Healthy', 'Healthy Participants', 'Volunteer, Healthy', 'Healthy Subjects', 'Subjects, Healthy', 'Subject, Healthy', 'Healthy Volunteer', 'Healthy Participant']}, 'types': {0: ['T098']}, 'definition': {0: 'An individual who is or becomes a participant in a research study and has no significant health-related issues.'}, 'entity': {0: 'subject'}, 'text': {0: 'Withdrawal by subject'}}",{},{},{},"           entity_group       value     score
0        Clinical_event  Withdrawal  0.514607
1  Detailed_description     subject  0.438371",[],"{'keyword': {0: 'withdrawal subject'}, 'score': {0: 0.8699}}"
1816,1816,1816,0.8830000162124634,26.0,Other,MyriadPro-Light,4,-0.25,5723991,35,13,7,{},{},{},{},{},"           entity_group  value     score
0  Detailed_description  Other  0.997497",[],"{'keyword': {}, 'score': {}}"
1817,1817,1817,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,35,14,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1818,1818,1818,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,35,14,1,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1819,1819,1819,0.8830000162124634,26.0,11 (1.5),MyriadPro-Light,4,-0.25,5723991,35,14,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    11  0.999628",[],"{'keyword': {}, 'score': {}}"
1820,1820,1820,0.8830000162124634,26.0,2 (0.3),MyriadPro-Light,4,-0.25,5723991,35,14,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1821,1821,1821,0.8830000162124634,26.0,16 (2.2),MyriadPro-Light,4,-0.25,5723991,35,14,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    16  0.999747",[],"{'keyword': {}, 'score': {}}"
1822,1822,1822,0.8830000162124634,26.0,49 (6.6),MyriadPro-Light,4,-0.25,5723991,35,14,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value    49  0.998985",[],"{'keyword': {}, 'score': {}}"
1823,1823,1823,0.8830000162124634,26.0,1 (0.1),MyriadPro-Light,4,-0.25,5723991,35,14,6,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1824,1824,1824,0.8830000162124634,26.0,3 (0.4),MyriadPro-Light,4,-0.25,5723991,35,15,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     3  0.999773",[],"{'keyword': {}, 'score': {}}"
1825,1825,1825,0.8830000162124634,26.0,3 (0.4),MyriadPro-Light,4,-0.25,5723991,35,15,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value     3  0.999773",[],"{'keyword': {}, 'score': {}}"
1826,1826,1826,0.8830000162124634,26.0,15 (2.0),MyriadPro-Light,4,-0.25,5723991,35,15,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    15  0.999696",[],"{'keyword': {}, 'score': {}}"
1827,1827,1827,0.8830000162124634,26.0,0 (0.0),MyriadPro-Light,4,-0.25,5723991,35,15,3,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1828,1828,1828,0.8830000162124634,26.0,39 (5.2),MyriadPro-Light,4,-0.25,5723991,35,15,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    39  0.999578",[],"{'keyword': {}, 'score': {}}"
1829,1829,1829,0.8830000162124634,26.0,57 (7.7),MyriadPro-Light,4,-0.25,5723991,35,15,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value    57  0.999667",[],"{'keyword': {}, 'score': {}}"
1830,1830,1830,0.8830000162124634,26.0,2 (0.3),MyriadPro-Light,4,-0.25,5723991,35,15,6,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1831,1831,1831,0.8830000162124634,32.0,•   ,MyriadPro-Light,4,-0.25,16162586,35,16,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1832,1832,1832,0.8830000162124634,19.0,Adapted from von Minckwitz et al. 2019.,MyriadPro-Light,4,-0.25,3355443,35,17,0,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
1833,1833,1833,0.8830000162124634,19.0,"*Twenty-seven patient records are excluded from this table: twenty-six patients received no study medication, and one patient was re-randomised.",MyriadPro-Light,4,-0.25,3355443,35,18,0,"{'concept_id': {0: 'C1578481'}, 'canonical_name': {0: 'Mail Claim Party - Patient'}, 'aliases': {0: ['Patient']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'patient'}, 'text': {0: '*Twenty-seven patient records are excluded from this table: twenty-six patients received no study medication, and one patient was re-randomised.'}}","{'concept_id': {0: 'C4277550'}, 'canonical_name': {0: 'Patient Portals'}, 'aliases': {0: ['Patient Internet Portals', 'Web Portals, Patient', 'Web Portal, Patient', 'Patient Internet Portal', 'Portals, Patient Web', 'Portal, Patient Web', 'Portal, Patient Internet', 'Patient Web Portals', 'Internet Portal, Patient', 'Internet Portals, Patient', 'Patient Portal', 'Patient Web Portal', 'Portals, Patient Internet', 'Portal, Patient']}, 'types': {0: ['T170']}, 'definition': {0: 'A secure online website that provides patients convenient 24-hour access to personal health information via an Internet connection.'}, 'entity': {0: 'patient'}, 'text': {0: '*Twenty-seven patient records are excluded from this table: twenty-six patients received no study medication, and one patient was re-randomised.'}}",{},{},{},"  entity_group         value     score
0    Lab_value  Twenty-seven  0.999247
1    Lab_value    twenty-six  0.993228",[],"{'keyword': {0: 'seven patient records', 1: 'patient records excluded', 2: 'seven patient', 3: 'medication patient randomised', 4: 'patients received study'}, 'score': {0: 0.7483, 1: 0.7041, 2: 0.6639, 3: 0.587, 4: 0.5346}}"
1834,1834,1834,0.8830000162124634,19.0,†Two patients did not finish the entire 14 cycles of assigned treatment but are included in the trastuzumab arm due to the incorrect completion  ,MyriadPro-Light,4,-0.25,3355443,35,18,1,"{'concept_id': {0: 'C5236288'}, 'canonical_name': {0: 'Completion Date'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'The date on which the activity or entity is finished.'}, 'entity': {0: 'completion'}, 'text': {0: '†Two patients did not finish the entire 14 cycles of assigned treatment but are included in the trastuzumab arm due to the incorrect completion  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab arm'}, 'text': {0: '†Two patients did not finish the entire 14 cycles of assigned treatment but are included in the trastuzumab arm due to the incorrect completion  '}}","{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab arm'}, 'text': {0: '†Two patients did not finish the entire 14 cycles of assigned treatment but are included in the trastuzumab arm due to the incorrect completion  '}}",{},{},"           entity_group                  value     score
0  Detailed_description                   †Two  0.757777
1             Lab_value                   †Two  0.988398
2  Quantitative_concept                     14  0.567164
3             Frequency                 cycles  0.469734
4            Medication  treatment trastuzumab  0.999749
5            Medication            trastuzumab  0.917970
6             Lab_value              incorrect  0.988837
7  Detailed_description             completion  0.895595","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'cycles assigned', 1: 'entire 14 cycles', 2: 'trastuzumab arm', 3: 'finish entire 14', 4: 'arm incorrect completion'}, 'score': {0: 0.7568, 1: 0.7199, 2: 0.6613, 3: 0.6312, 4: 0.5038}}"
1835,1835,1835,0.8830000162124634,19.0,of drug administration forms. One patient completed only 11 cycles of trastuzumab and the other was administered 13 cycles of trastuzumab and  ,MyriadPro-Light,4,-0.25,3355443,35,18,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of drug administration forms. One patient completed only 11 cycles of trastuzumab and the other was administered 13 cycles of trastuzumab and  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of drug administration forms. One patient completed only 11 cycles of trastuzumab and the other was administered 13 cycles of trastuzumab and  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of drug administration forms. One patient completed only 11 cycles of trastuzumab and the other was administered 13 cycles of trastuzumab and  '}}",{},{},"     entity_group                    value     score
0  Clinical_event           administration  0.316268
1          Dosage         11 cycles cycles  0.985159
2      Medication  trastuzumab trastuzumab  0.984889
3          Dosage         13 cycles cycles  0.998932","[('11 cycles', 'DURATION'), ('trastuzumab', 'DRUG'), ('13 cycles', 'DURATION'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'completed 11 cycles', 1: 'administration forms patient', 2: 'drug administration', 3: 'forms patient completed', 4: 'cycles trastuzumab'}, 'score': {0: 0.6363, 1: 0.5096, 2: 0.4075, 3: 0.3365, 4: 0.3148}}"
1836,1836,1836,0.8830000162124634,19.0,1 cycle of Kadcyla.,MyriadPro-Light,4,-0.25,3355443,35,18,3,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: '1 cycle of Kadcyla.'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: '1 cycle of Kadcyla.'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: '1 cycle of Kadcyla.'}}",{},{},"           entity_group value     score
0  Quantitative_concept     1  0.651334","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'cycle kadcyla'}, 'score': {0: 0.7987}}"
1837,1837,1837,0.8830000162124634,19.0,‡Delay in treatment >42 days due to scheduling difficulties.,MyriadPro-Light,4,-0.25,3355443,35,18,4,"{'concept_id': {0: 'C1299586'}, 'canonical_name': {0: 'Has difficulty doing (qualifier value)'}, 'aliases': {0: ['Has difficulty doing', 'Able with difficulty', 'difficulty', 'Able with difficulty (qualifier value)', 'Difficulty', 'difficulties']}, 'types': {0: ['T033']}, 'definition': {0: 'Something not easily done, accomplished, comprehended, or solved.'}, 'entity': {0: 'scheduling difficulties'}, 'text': {0: '‡Delay in treatment >42 days due to scheduling difficulties.'}}","{'concept_id': {0: 'C0019843'}, 'canonical_name': {0: 'Holidays'}, 'aliases': {0: ['Holiday']}, 'types': {0: ['T051']}, 'definition': {0: 'Days commemorating events. Holidays also include vacation periods.'}, 'entity': {0: 'days'}, 'text': {0: '‡Delay in treatment >42 days due to scheduling difficulties.'}}",{},{},"{'concept_id': {0: 'C0239043'}, 'canonical_name': {0: 'Chewing difficulties'}, 'aliases': {0: ['Impaired mastication', 'Difficulty chewing', 'Chewing difficulty']}, 'types': {0: ['T033']}, 'definition': {0: 'Pain or discomfort with mastication, a symptom of underlying disease. Causes can include problems with the teeth, jaws or temporomandibular joint, mumps, cancer, or a neuromuscular disorder.'}, 'entity': {0: 'scheduling difficulties'}, 'text': {0: '‡Delay in treatment >42 days due to scheduling difficulties.'}}","  entity_group    value     score
0     Duration        >  0.895343
1     Duration  42 days  0.973658",[],"{'keyword': {0: 'days scheduling', 1: '42 days', 2: 'scheduling difficulties', 3: 'treatment 42', 4: 'delay treatment'}, 'score': {0: 0.8139, 1: 0.7137, 2: 0.704, 3: 0.6878, 4: 0.6176}}"
1838,1838,1838,0.8830000162124634,19.0,§Did not complete 14 total cycles due to a misunderstanding.,MyriadPro-Light,4,-0.25,3355443,35,18,5,"{'concept_id': {0: 'C0162340'}, 'canonical_name': {0: 'Comprehension'}, 'aliases': {0: ['understand', 'Understanding', 'understanding', 'Understood', 'Understanding, function', 'Understanding, function (observable entity)', 'Understanding, NOS', 'Understand', 'Comprehension', 'knowledge or comprehension', 'comprehension', 'UNDERSTANDS']}, 'types': {0: ['T041']}, 'definition': {0: 'The act or fact of grasping the meaning, nature, or importance of; understanding. (American Heritage Dictionary, 4th ed) Includes understanding by a patient or research subject of information disclosed orally or in writing.'}, 'entity': {0: 'misunderstanding'}, 'text': {0: '§Did not complete 14 total cycles due to a misunderstanding.'}}","{'concept_id': {0: 'C0162340'}, 'canonical_name': {0: 'Understanding'}, 'aliases': {0: ['Comprehension']}, 'types': {0: ['T041']}, 'definition': {0: 'The act or fact of grasping the meaning, nature, or importance of; understanding. (American Heritage Dictionary, 4th ed) Includes understanding by a patient or research subject of information disclosed orally or in writing.'}, 'entity': {0: 'misunderstanding'}, 'text': {0: '§Did not complete 14 total cycles due to a misunderstanding.'}}",{},{},{},"           entity_group   value     score
0             Lab_value      14  0.935609
1  Diagnostic_procedure   total  0.510689
2  Detailed_description  cycles  0.383750",[],"{'keyword': {0: 'cycles misunderstanding', 1: 'did complete', 2: '14 total', 3: 'total cycles', 4: 'complete 14'}, 'score': {0: 0.8642, 1: 0.7904, 2: 0.7365, 3: 0.6897, 4: 0.6474}}"
1839,1839,1839,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,35,19,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1840,1840,1840,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,35,19,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1841,1841,1841,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,35,19,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1842,1842,1842,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,35,19,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1843,1843,1843,0.75,98.0,17.9% of patients discontinued Kadcyla  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,36,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: '17.9% of patients discontinued Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: '17.9% of patients discontinued Kadcyla  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: '17.9% of patients discontinued Kadcyla  '}}",{},{},"            entity_group    value     score
0              Lab_value   17.9 %  0.998868
1  Therapeutic_procedure  Kadcyla  0.799513","[('Kadcyla', 'DRUG')]","{'keyword': {0: '17 patients discontinued', 1: 'patients discontinued kadcyla', 2: 'patients discontinued', 3: 'discontinued kadcyla', 4: '17 patients'}, 'score': {0: 0.903, 1: 0.8888, 2: 0.857, 3: 0.7705, 4: 0.6425}}"
1844,1844,1844,0.75,98.0,due to adverse events,ConduitITC-Bold,20,-0.1700000017881393,8194925,36,1,1,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'due to adverse events'}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'due to adverse events'}}",{},{},{},"   entity_group           value     score
0  Sign_symptom  adverse events  0.929723",[],"{'keyword': {0: 'adverse events'}, 'score': {0: 0.8903}}"
1845,1845,1845,0.944000005722046,28.0,Trastuzumab (n=743),UniversSB-Medium,4,-0.2349999994039535,16777215,36,2,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: 'Trastuzumab (n=743)'}}",{},{},"  entity_group        value     score
0   Medication  Trastuzumab  0.999833","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'trastuzumab 743'}, 'score': {0: 0.8631}}"
1846,1846,1846,0.944000005722046,28.0,Kadcyla (n=743),UniversSB-Medium,4,-0.2349999994039535,16777215,36,2,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (n=743)'}}",{},{},"           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.969694",[],"{'keyword': {0: 'kadcyla 743'}, 'score': {0: 0.8404}}"
1847,1847,1847,0.944000005722046,26.0,"Patients, n (%)*",UniversSB-Medium,4,-0.2349999994039535,16777215,36,3,0,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'Patients'}, 'text': {0: 'Patients, n (%)*'}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'Patients'}, 'text': {0: 'Patients, n (%)*'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1848,1848,1848,0.9470000267028807,26.0,Completed planned 14 cycles of treatment,UniversSB-Light,4,-0.2329999953508377,5723991,36,4,0,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'Completed planned 14 cycles of treatment'}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'Completed planned 14 cycles of treatment'}}",{},{},{},"            entity_group      value     score
0                 Dosage         14  0.879466
1   Quantitative_concept     cycles  0.514736
2  Therapeutic_procedure  treatment  0.880838","[('14 cycles', 'DURATION')]","{'keyword': {0: 'completed planned 14', 1: '14 cycles treatment', 2: '14 cycles', 3: 'planned 14', 4: 'cycles treatment'}, 'score': {0: 0.7927, 1: 0.7282, 2: 0.7042, 3: 0.5975, 4: 0.4745}}"
1849,1849,1849,0.9470000267028807,26.0,527 (70.9),UniversSB-Light,4,-0.2329999953508377,5723991,36,4,1,{},{},{},{},{},"  entity_group value    score
0    Lab_value   527  0.85979",[],"{'keyword': {0: '527 70'}, 'score': {0: 0.704}}"
1850,1850,1850,0.9470000267028807,26.0,585 (78.7),UniversSB-Light,4,-0.2329999953508377,5723991,36,4,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value   585  0.938519",[],"{'keyword': {0: '585 78'}, 'score': {0: 0.8025}}"
1851,1851,1851,0.9470000267028807,32.0,The most common adverse events ,UniversSB-Light,4,-0.2329999953508377,3355443,36,5,0,"{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Adverse reaction to drug'}, 'aliases': {0: ['Drug Events, Adverse', 'Drug Side Effects', 'medication side effects', 'Adverse drug effect', 'Reactions, Adverse Drug', 'Drug reaction (qualifier value)', 'Adverse reaction to drug', 'drug side effects', 'Adverse drug reaction', 'Adverse Drug Event', 'adverse drug effects', 'Adverse Drug Experience', 'Side Effects of Drugs', 'Drug-induced reaction', 'Drug, adverse effect', 'drug adverse reaction', 'Drug Reactions, Adverse', 'DRUG REACTION', 'ADR - Adverse drug reaction', 'Drug Reaction, Adverse', 'Adverse Drug Events', 'Drug reaction, NOS', 'Drug Event, Adverse', 'Effects, Drug Side', 'Drug Related Side Effects and Adverse Reaction', 'Adverse reaction to medication', 'adverse drug effect', 'Adverse Drug Reaction', 'Adverse drug effect, NOS', 'side effect (drug)', 'Drug Related Side Effects and Adverse Reactions', 'Adverse drug reaction, NOS', 'Drug-Related Side Effects and Adverse Reaction', 'medications reactions', 'Side Effects, Drug', 'Drug reaction', 'Toxic drug response', 'adverse drug reactions', 'Drug-Related Side Effects and Adverse Reactions', 'Adverse reaction caused by drug (disorder)', 'medication side-effect', 'drug adverse reactions', 'Drug Reactions', 'adverse drug event', 'medications reaction', 'drug reaction', 'Adverse drug response', 'medication side effect', 'reaction medication', 'Adverse reaction caused by drug', 'Side Effect, Drug', 'Adverse Drug Reactions', 'medication reaction', 'Drug Side Effect', 'Drug-induced response', 'medication reactions', 'adverse drug events', 'ADR', 'drug adverse effect', 'medication adverse effects', 'medications side effect', 'adverse drug reaction', 'drug side effect']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'The most common adverse events '}}","{'concept_id': {0: 'C0041755'}, 'canonical_name': {0: 'Effects, Drug Side'}, 'aliases': {0: ['Adverse Drug Reactions', 'Adverse Drug Events', 'Drug Event, Adverse', 'Side Effect, Drug', 'Drug Events, Adverse', 'Drug Reactions, Adverse', 'Side Effects, Drug', 'Drug-Related Side Effects and Adverse Reaction', 'Adverse Drug Event', 'Drug-Related Side Effects and Adverse Reactions', 'Drug Related Side Effects and Adverse Reaction', 'Drug Related Side Effects and Adverse Reactions', 'Drug Side Effect', 'Reactions, Adverse Drug', 'Adverse Drug Reaction', 'Drug Side Effects', 'Drug Reaction, Adverse', 'Side Effects of Drugs']}, 'types': {0: ['T046']}, 'definition': {0: 'Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.'}, 'entity': {0: 'adverse events'}, 'text': {0: 'The most common adverse events '}}",{},{},{},"   entity_group           value     score
0  Sign_symptom  adverse events  0.999607",[],"{'keyword': {0: 'common adverse', 1: 'adverse events', 2: 'common adverse events'}, 'score': {0: 0.8704, 1: 0.8643, 2: 0.8593}}"
1852,1852,1852,0.9470000267028807,32.0,leading to discontinuation in the Kadcyla ,UniversSB-Light,4,-0.2329999953508377,3355443,36,5,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'leading to discontinuation in the Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'leading to discontinuation in the Kadcyla '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'leading to discontinuation in the Kadcyla '}}",{},{},"           entity_group    value     score
0           Coreference  Kadcyla  0.642921
1  Biological_structure  Kadcyla  0.684150","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'leading discontinuation', 1: 'leading discontinuation kadcyla', 2: 'discontinuation kadcyla'}, 'score': {0: 0.9286, 1: 0.906, 2: 0.8308}}"
1853,1853,1853,0.9470000267028807,32.0,group were:,UniversSB-Light,4,-0.2329999953508377,3355443,36,5,2,"{'concept_id': {0: 'C1257890'}, 'canonical_name': {0: 'Population Group'}, 'aliases': {0: ['groups population', 'Subpopulation', 'Population group', 'Population Groups', 'population groups', 'Group, Population', '^Population', 'Groups, Population', 'population group', 'Population Group', 'Group', 'Group (social concept)', 'group populations', 'Population']}, 'types': {0: ['T098']}, 'definition': {0: 'Individuals classified according to their sex, racial origin, religion, common place of living, financial or social status, or some other cultural or behavioral attribute. (UMLS, 2003)'}, 'entity': {0: 'group'}, 'text': {0: 'group were:'}}","{'concept_id': {0: 'C0034510'}, 'canonical_name': {0: 'Groups, Racial'}, 'aliases': {0: ['Group, Racial', 'Racial Group', 'Racial Groups']}, 'types': {0: ['T098']}, 'definition': {0: 'Groups of individuals with similar physical appearances often reinforced by cultural, social and/or linguistic similarities.'}, 'entity': {0: 'group'}, 'text': {0: 'group were:'}}",{},{},"{'concept_id': {0: 'C0427624'}, 'canonical_name': {0: 'Blood group AB'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'A blood group indicating the presence on erythrocytes of both the A and B forms of the H Antigen.'}, 'entity': {0: 'group'}, 'text': {0: 'group were:'}}","  entity_group  value     score
0  Coreference  group  0.616377",[],"{'keyword': {}, 'score': {}}"
1854,1854,1854,0.9470000267028807,26.0,Discontinued study treatment,UniversSB-Light,4,-0.2329999953508377,5723991,36,6,0,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'treatment'}, 'text': {0: 'Discontinued study treatment'}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: 'Discontinued study treatment'}}",{},{},{},"            entity_group               value     score
0   Detailed_description  Discontinued study  0.971361
1  Therapeutic_procedure           treatment  0.807373",[],"{'keyword': {0: 'discontinued study treatment', 1: 'discontinued study', 2: 'study treatment'}, 'score': {0: 1.0, 1: 0.9781, 2: 0.6535}}"
1855,1855,1855,0.9470000267028807,26.0,212 (28.5),UniversSB-Light,4,-0.2329999953508377,5723991,36,6,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value   212  0.999161",[],"{'keyword': {0: '212 28'}, 'score': {0: 0.8399}}"
1856,1856,1856,0.9470000267028807,26.0,135 (18.2),UniversSB-Light,4,-0.2329999953508377,5723991,36,6,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value   135  0.999537",[],"{'keyword': {0: '135 18'}, 'score': {0: 0.8669}}"
1857,1857,1857,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,36,7,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1858,1858,1858,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,36,8,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1859,1859,1859,0.944000005722046,24.0,Safety,UniversSB-Bold,20,-0.2469999939203262,3355443,36,9,0,"{'concept_id': {0: 'C1456533'}, 'canonical_name': {0: 'Fire Safety'}, 'aliases': {0: []}, 'types': {0: ['T089']}, 'definition': {0: ""<p>Preventing fires is an important part of fire safety. In the United States, cooking is the main cause of home fires. Cigarettes are a big risk too - they are the leading cause of fire deaths. Here are some fire prevention tips:</p> <ul> <li>Don't leave the stove or oven unattended when they are on</li> <li>Don't let children use kitchen appliances unsupervised</li> <li>Don't smoke in bed</li> <li>Make sure your electrical appliances and cords are in good condition</li> </ul> <p>It is also important to be prepared in case there is a fire. Make sure that you have working smoke detectors on every floor and in every bedroom. You should also have fire extinguishers on every floor and in your kitchen. Make and practice an escape plan in case the main exit is blocked.</p>""}, 'entity': {0: 'Safety'}, 'text': {0: 'Safety'}}","{'concept_id': {0: 'C1456535'}, 'canonical_name': {0: 'Food Safety'}, 'aliases': {0: ['Safety, Food']}, 'types': {0: ['T057']}, 'definition': {0: 'Activities involved in ensuring the safety of FOOD including avoidance of bacterial and other contamination.'}, 'entity': {0: 'Safety'}, 'text': {0: 'Safety'}}",{},{},{},"           entity_group   value     score
0  Diagnostic_procedure  Safety  0.973877",[],"{'keyword': {}, 'score': {}}"
1860,1860,1860,0.9470000267028807,26.0,Adverse event,UniversSB-Light,4,-0.2329999953508377,5723991,36,9,1,"{'concept_id': {0: 'C5236149'}, 'canonical_name': {0: 'Adverse Event Term'}, 'aliases': {0: []}, 'types': {0: ['T170']}, 'definition': {0: 'A term that refers to an adverse event, often taken from a list of standardized terms.'}, 'entity': {0: 'Adverse event'}, 'text': {0: 'Adverse event'}}","{'concept_id': {0: 'C0151735'}, 'canonical_name': {0: 'Injection Site Events'}, 'aliases': {0: ['Injection Site Event', 'Injection Site Adverse Event', 'Injection Site Reaction', 'Injection Site Reactions']}, 'types': {0: ['T046']}, 'definition': {0: 'Adverse reactions that occur initially at the site of injection or infusion. Milder type is confined to a local allergic flare reaction. A more severe reaction is caused by extravasation of VESICANTS from the blood vessel at the site of injection and can cause damage to the surrounding tissue. In tumor flare reaction symptoms involve well beyond the injection site such as an increase in the tumor size and tumor markers levels, bone pain, and HYPERCALCEMIA.'}, 'entity': {0: 'Adverse event'}, 'text': {0: 'Adverse event'}}",{},{},{},"   entity_group          value     score
0  Sign_symptom  Adverse event  0.935574",[],"{'keyword': {0: 'adverse event'}, 'score': {0: 1.0}}"
1861,1861,1861,0.9470000267028807,26.0,Pregnancy,UniversSB-Light,4,-0.2329999953508377,5723991,36,9,2,"{'concept_id': {0: 'C3843692'}, 'canonical_name': {0: 'Pregnancy 1'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'Pregnancy'}, 'text': {0: 'Pregnancy'}}","{'concept_id': {0: 'C0032974'}, 'canonical_name': {0: 'Pregnancy Proteins'}, 'aliases': {0: ['Placental Proteins', 'Proteins, Pregnancy', 'Proteins, Placental']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'Proteins produced by organs of the mother or the PLACENTA during PREGNANCY. These proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.)'}, 'entity': {0: 'Pregnancy'}, 'text': {0: 'Pregnancy'}}",{},"{'concept_id': {0: 'C0032961'}, 'canonical_name': {0: 'female pregnancy'}, 'aliases': {0: ['gestation']}, 'types': {0: ['T040']}, 'definition': {0: 'The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.'}, 'entity': {0: 'Pregnancy'}, 'text': {0: 'Pregnancy'}}","{'concept_id': {0: 'C4551893'}, 'canonical_name': {0: 'Toxaemia of pregnancy'}, 'aliases': {0: ['Hypertensive disorder of pregnancy', 'Toxemia of pregnancy']}, 'types': {0: ['T047']}, 'definition': {0: 'A pregnancy induced hypertensive state that occurs after 20 weeks of gestation characterized by an increase in blood pressure, along with body swelling and proteinuria.'}, 'entity': {0: 'Pregnancy'}, 'text': {0: 'Pregnancy'}}","  entity_group      value     score
0      History  Pregnancy  0.250901",[],"{'keyword': {}, 'score': {}}"
1862,1862,1862,0.9470000267028807,26.0,133 (17.9),UniversSB-Light,4,-0.2329999953508377,5723991,36,9,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value   133  0.999757",[],"{'keyword': {0: '133 17'}, 'score': {0: 0.7952}}"
1863,1863,1863,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,36,9,4,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1864,1864,1864,0.9470000267028807,26.0,15 (2.0),UniversSB-Light,4,-0.2329999953508377,5723991,36,9,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value    15  0.999696",[],"{'keyword': {}, 'score': {}}"
1865,1865,1865,0.9470000267028807,26.0,1 (0.1),UniversSB-Light,4,-0.2329999953508377,5723991,36,9,6,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1866,1866,1866,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,36,10,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1867,1867,1867,0.9470000267028807,32.0,level (n=12) ,UniversSB-Light,4,-0.2329999953508377,3355443,36,10,1,"{'concept_id': {0: 'C1547707'}, 'canonical_name': {0: 'Floor - story of building'}, 'aliases': {0: ['Floor', 'Story', 'Level']}, 'types': {0: ['T083']}, 'definition': {0: 'A location comprising a single level of a multilevel building.'}, 'entity': {0: 'level'}, 'text': {0: 'level (n=12) '}}","{'concept_id': {0: 'C5197751'}, 'canonical_name': {0: 'Sea Level Rise'}, 'aliases': {0: ['Rising Sea Levels', 'Sea Level, Rising', 'Sea-Level Rise', 'Rising Sea Level', 'Sea Levels, Rising']}, 'types': {0: ['T067']}, 'definition': {0: 'An increase in the volume of the oceans and seas causing an elevation of the air-sea interface.'}, 'entity': {0: 'level'}, 'text': {0: 'level (n=12) '}}",{},{},"{'concept_id': {0: 'C4703556'}, 'canonical_name': {0: 'Abnormal hypoxanthine-guanine phosphoribosyltransferase level'}, 'aliases': {0: ['Abnormal GMP pyrophosphorylase level', 'Abnormal 6-hydroxypurine phosphoribosyltransferase level', 'Abnormal GPRT level']}, 'types': {0: ['T033']}, 'definition': {0: 'Altered level of the enzyme that catalyzes conversion of hypoxanthine to inosine monophosphate and guanine to guanosine monophosphate via transfer of the 5-phosphoribosyl group from 5-phosphoribosyl 1-pyrophosphate. [RGD:sjwang]'}, 'entity': {0: 'level'}, 'text': {0: 'level (n=12) '}}","           entity_group  value     score
0  Detailed_description  level  0.464486",[],"{'keyword': {0: 'level 12'}, 'score': {0: 0.7846}}"
1868,1868,1868,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,36,11,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1869,1869,1869,0.9470000267028807,32.0,(n=11) ,UniversSB-Light,4,-0.2329999953508377,3355443,36,11,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1870,1870,1870,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,36,12,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1871,1871,1871,0.944000005722046,24.0,Non-safety,UniversSB-Bold,20,-0.2469999939203262,3355443,36,13,0,{},"{'concept_id': {0: 'C0036043'}, 'canonical_name': {0: 'Safeties'}, 'aliases': {0: ['Safety']}, 'types': {0: ['T068']}, 'definition': {0: 'Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.'}, 'entity': {0: 'Non-safety'}, 'text': {0: 'Non-safety'}}",{},{},{},"           entity_group       value     score
0             Lab_value  Non-safety  0.528131
1  Diagnostic_procedure  Non-safety  0.714398",[],"{'keyword': {0: 'non safety'}, 'score': {0: 0.9774}}"
1872,1872,1872,0.9470000267028807,26.0,Lost to follow-up,UniversSB-Light,4,-0.2329999953508377,5723991,36,13,1,"{'concept_id': {0: 'C0420315'}, 'canonical_name': {0: 'no follow-up'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: None}, 'entity': {0: 'follow-up'}, 'text': {0: 'Lost to follow-up'}}","{'concept_id': {0: 'C0016441'}, 'canonical_name': {0: 'Follow-Up Studies'}, 'aliases': {0: ['Studies, Followup', 'Follow-Up Study', 'Study, Follow-Up', 'Followup Study', 'Study, Followup', 'Followup Studies', 'Follow Up Studies', 'Studies, Follow-Up']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.'}, 'entity': {0: 'follow-up'}, 'text': {0: 'Lost to follow-up'}}",{},{},{},"           entity_group      value     score
0  Detailed_description  follow-up  0.875353",[],"{'keyword': {0: 'lost follow'}, 'score': {0: 0.9484}}"
1873,1873,1873,0.9470000267028807,26.0,Non-adherence with study drug,UniversSB-Light,4,-0.2329999953508377,5723991,36,13,2,"{'concept_id': {0: 'C1705923'}, 'canonical_name': {0: 'Study Object'}, 'aliases': {0: ['Study', 'Study Object']}, 'types': {0: ['T170']}, 'definition': {0: 'An abbreviated set of written procedures that describe how a previously collected biospecimen will be utilized. Note that biospecimens may be collected (and utilized) with one PROTOCOL and then later utilized by multiple different STUDIES. (caTISSUE)'}, 'entity': {0: 'study drug'}, 'text': {0: 'Non-adherence with study drug'}}","{'concept_id': {0: 'C0013175'}, 'canonical_name': {0: 'Study, Drug Evaluation'}, 'aliases': {0: ['Drug Evaluation', 'Studies, Drug Evaluation', 'Drug Evaluations', 'Drug Evaluation Studies', 'Evaluation, Drug', 'Drug Evaluation Study', 'Evaluation Study, Drug', 'Evaluation Studies, Drug', 'Evaluations, Drug']}, 'types': {0: ['T062']}, 'definition': {0: 'Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.'}, 'entity': {0: 'study drug'}, 'text': {0: 'Non-adherence with study drug'}}",{},{},{},"           entity_group          value     score
0          Sign_symptom  Non-adherence  0.441297
1  Detailed_description     study drug  0.956633",[],"{'keyword': {0: 'non adherence', 1: 'non adherence study', 2: 'study drug', 3: 'adherence study', 4: 'adherence study drug'}, 'score': {0: 0.9547, 1: 0.7804, 2: 0.7404, 3: 0.6583, 4: 0.6283}}"
1874,1874,1874,0.9470000267028807,26.0,Physician decision,UniversSB-Light,4,-0.2329999953508377,5723991,36,13,3,"{'concept_id': {0: 'C0011115'}, 'canonical_name': {0: 'Decision Trees'}, 'aliases': {0: ['Trees, Decision', 'decision trees', 'Decision trees', 'decision tree', 'Tree, Decision', 'Decision Tree']}, 'types': {0: ['T170']}, 'definition': {0: 'A graphic device used in decision analysis, series of decision options are represented as branches (hierarchical).'}, 'entity': {0: 'decision'}, 'text': {0: 'Physician decision'}}","{'concept_id': {0: 'C0011109'}, 'canonical_name': {0: 'Decision Making'}, 'aliases': {0: []}, 'types': {0: ['T041']}, 'definition': {0: 'The process of making a selective intellectual judgment when presented with several complex alternatives consisting of several variables, and usually defining a course of action or an idea.'}, 'entity': {0: 'decision'}, 'text': {0: 'Physician decision'}}",{},{},{},"           entity_group      value     score
0  Detailed_description  Physician  0.864781
1        Clinical_event   decision  0.297085",[],"{'keyword': {0: 'physician decision'}, 'score': {0: 1.0}}"
1875,1875,1875,0.9470000267028807,26.0,Protocol violation,UniversSB-Light,4,-0.2329999953508377,5723991,36,13,4,"{'concept_id': {0: 'C1709750'}, 'canonical_name': {0: 'Protocol Violation'}, 'aliases': {0: ['Protocol Violation']}, 'types': {0: ['T169']}, 'definition': {0: 'A significant departure from processes or procedures that were required by the protocol. Violations often result in data that are not deemed evaluable for a per-protocol analysis, and may require that the subject(s) who violate the protocol be discontinued from the study. Compare to protocol deviation. (CDISC Glossary)'}, 'entity': {0: 'violation'}, 'text': {0: 'Protocol violation'}}","{'concept_id': {0: 'C0330463'}, 'canonical_name': {0: 'Viola'}, 'aliases': {0: ['Pansy', 'Violet', 'Violets', 'Pansies', 'Violas']}, 'types': {0: ['T002']}, 'definition': {0: 'A plant genus of the family VIOLACEAE. Some species in this genus are called bouncing bet which is a common name more often used with SAPONARIA OFFICINALIS. Members contain macrocyclic peptides.'}, 'entity': {0: 'violation'}, 'text': {0: 'Protocol violation'}}",{},{},{},"       entity_group      value     score
0  Disease_disorder   Protocol  0.591606
1      Sign_symptom  violation  0.400792",[],"{'keyword': {0: 'protocol violation'}, 'score': {0: 1.0}}"
1876,1876,1876,0.9470000267028807,26.0,Disease recurrence,UniversSB-Light,4,-0.2329999953508377,5723991,36,13,5,"{'concept_id': {0: 'C5447866'}, 'canonical_name': {0: 'Disease Recurrence Evidence'}, 'aliases': {0: ['Disease Recurrence Evidence']}, 'types': {0: ['T033']}, 'definition': {0: 'Clinical or laboratory test results that are the basis for a recurrent disease finding.'}, 'entity': {0: 'Disease recurrence'}, 'text': {0: 'Disease recurrence'}}","{'concept_id': {0: 'C2825055'}, 'canonical_name': {0: 'Recurrences'}, 'aliases': {0: ['Recurrence']}, 'types': {0: ['T046']}, 'definition': {0: 'The return of a sign, symptom, or disease after a remission.'}, 'entity': {0: 'Disease recurrence'}, 'text': {0: 'Disease recurrence'}}",{},{},{},"   entity_group       value     score
0  Sign_symptom  recurrence  0.980423",[],"{'keyword': {0: 'disease recurrence'}, 'score': {0: 1.0}}"
1877,1877,1877,0.9470000267028807,26.0,Withdrawal by subject,UniversSB-Light,4,-0.2329999953508377,5723991,36,13,6,"{'concept_id': {0: 'C1706203'}, 'canonical_name': {0: 'Subject - topic'}, 'aliases': {0: ['Subject']}, 'types': {0: ['T078']}, 'definition': {0: 'Some matter, situation, or event that is thought about, written about, or discussed.'}, 'entity': {0: 'subject'}, 'text': {0: 'Withdrawal by subject'}}","{'concept_id': {0: 'C1708335'}, 'canonical_name': {0: 'Healthy Volunteers'}, 'aliases': {0: ['Healthy Subject', 'Participant, Healthy', 'Participants, Healthy', 'Healthy Participants', 'Volunteer, Healthy', 'Healthy Subjects', 'Subjects, Healthy', 'Subject, Healthy', 'Healthy Volunteer', 'Healthy Participant']}, 'types': {0: ['T098']}, 'definition': {0: 'An individual who is or becomes a participant in a research study and has no significant health-related issues.'}, 'entity': {0: 'subject'}, 'text': {0: 'Withdrawal by subject'}}",{},{},{},"           entity_group       value     score
0        Clinical_event  Withdrawal  0.514607
1  Detailed_description     subject  0.438371",[],"{'keyword': {0: 'withdrawal subject'}, 'score': {0: 0.8699}}"
1878,1878,1878,0.9470000267028807,26.0,Other,UniversSB-Light,4,-0.2329999953508377,5723991,36,13,7,{},{},{},{},{},"           entity_group  value     score
0  Detailed_description  Other  0.997497",[],"{'keyword': {}, 'score': {}}"
1879,1879,1879,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,36,14,0,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1880,1880,1880,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,36,14,1,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1881,1881,1881,0.9470000267028807,26.0,11 (1.5),UniversSB-Light,4,-0.2329999953508377,5723991,36,14,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    11  0.999628",[],"{'keyword': {}, 'score': {}}"
1882,1882,1882,0.9470000267028807,26.0,2 (0.3),UniversSB-Light,4,-0.2329999953508377,5723991,36,14,3,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1883,1883,1883,0.9470000267028807,26.0,16 (2.2),UniversSB-Light,4,-0.2329999953508377,5723991,36,14,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    16  0.999747",[],"{'keyword': {}, 'score': {}}"
1884,1884,1884,0.9470000267028807,26.0,49 (6.6),UniversSB-Light,4,-0.2329999953508377,5723991,36,14,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value    49  0.998985",[],"{'keyword': {}, 'score': {}}"
1885,1885,1885,0.9470000267028807,26.0,1 (0.1),UniversSB-Light,4,-0.2329999953508377,5723991,36,14,6,{},{},{},{},{},"  entity_group  value    score
0    Lab_value  1 0.1  0.99781",[],"{'keyword': {}, 'score': {}}"
1886,1886,1886,0.9470000267028807,26.0,3 (0.4),UniversSB-Light,4,-0.2329999953508377,5723991,36,15,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     3  0.999773",[],"{'keyword': {}, 'score': {}}"
1887,1887,1887,0.9470000267028807,26.0,3 (0.4),UniversSB-Light,4,-0.2329999953508377,5723991,36,15,1,{},{},{},{},{},"  entity_group value     score
0    Lab_value     3  0.999773",[],"{'keyword': {}, 'score': {}}"
1888,1888,1888,0.9470000267028807,26.0,15 (2.0),UniversSB-Light,4,-0.2329999953508377,5723991,36,15,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value    15  0.999696",[],"{'keyword': {}, 'score': {}}"
1889,1889,1889,0.9470000267028807,26.0,0 (0.0),UniversSB-Light,4,-0.2329999953508377,5723991,36,15,3,{},{},{},{},{},"  entity_group  value     score
0    Lab_value  0 0.0  0.999869",[],"{'keyword': {}, 'score': {}}"
1890,1890,1890,0.9470000267028807,26.0,39 (5.2),UniversSB-Light,4,-0.2329999953508377,5723991,36,15,4,{},{},{},{},{},"  entity_group value     score
0    Lab_value    39  0.999578",[],"{'keyword': {}, 'score': {}}"
1891,1891,1891,0.9470000267028807,26.0,57 (7.7),UniversSB-Light,4,-0.2329999953508377,5723991,36,15,5,{},{},{},{},{},"  entity_group value     score
0    Lab_value    57  0.999667",[],"{'keyword': {}, 'score': {}}"
1892,1892,1892,0.9470000267028807,26.0,2 (0.3),UniversSB-Light,4,-0.2329999953508377,5723991,36,15,6,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.999736",[],"{'keyword': {}, 'score': {}}"
1893,1893,1893,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,36,16,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1894,1894,1894,0.9169999957084656,30.0,Reference:,ConduitITC-Bold,20,-0.2349999994039535,8194925,36,17,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1895,1895,1895,0.8830000162124634,22.0,1. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628. ,MyriadPro-Light,4,-0.25,3355443,36,17,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'et al', 4: 'engl med 2019'}, 'score': {0: 0.8031, 1: 0.7251, 2: 0.7194, 3: 0.6642, 4: 0.6422}}"
1896,1896,1896,0.9470000267028807,19.0,Adapted from von Minckwitz et al. 2019.,UniversSB-Light,4,-0.2329999953508377,3355443,36,18,0,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Minckwitz  0.812322",[],"{'keyword': {0: 'adapted von minckwitz', 1: 'minckwitz et al', 2: 'von minckwitz', 3: 'al 2019', 4: 'et al'}, 'score': {0: 0.8801, 1: 0.8458, 2: 0.8121, 3: 0.7621, 4: 0.736}}"
1897,1897,1897,0.9470000267028807,19.0,"*Twenty-seven patient records are excluded from this table: twenty-six patients received no study medication, and one patient was re-randomised.",UniversSB-Light,4,-0.2329999953508377,3355443,36,19,0,"{'concept_id': {0: 'C1578481'}, 'canonical_name': {0: 'Mail Claim Party - Patient'}, 'aliases': {0: ['Patient']}, 'types': {0: ['T078']}, 'definition': {0: None}, 'entity': {0: 'patient'}, 'text': {0: '*Twenty-seven patient records are excluded from this table: twenty-six patients received no study medication, and one patient was re-randomised.'}}","{'concept_id': {0: 'C4277550'}, 'canonical_name': {0: 'Patient Portals'}, 'aliases': {0: ['Patient Internet Portals', 'Web Portals, Patient', 'Web Portal, Patient', 'Patient Internet Portal', 'Portals, Patient Web', 'Portal, Patient Web', 'Portal, Patient Internet', 'Patient Web Portals', 'Internet Portal, Patient', 'Internet Portals, Patient', 'Patient Portal', 'Patient Web Portal', 'Portals, Patient Internet', 'Portal, Patient']}, 'types': {0: ['T170']}, 'definition': {0: 'A secure online website that provides patients convenient 24-hour access to personal health information via an Internet connection.'}, 'entity': {0: 'patient'}, 'text': {0: '*Twenty-seven patient records are excluded from this table: twenty-six patients received no study medication, and one patient was re-randomised.'}}",{},{},{},"  entity_group         value     score
0    Lab_value  Twenty-seven  0.999247
1    Lab_value    twenty-six  0.993228",[],"{'keyword': {0: 'seven patient records', 1: 'patient records excluded', 2: 'seven patient', 3: 'medication patient randomised', 4: 'patients received study'}, 'score': {0: 0.7483, 1: 0.7041, 2: 0.6639, 3: 0.587, 4: 0.5346}}"
1898,1898,1898,0.9470000267028807,19.0,†Two patients did not finish the entire 14 cycles of assigned treatment but are included in the trastuzumab arm due to the incorrect completion  ,UniversSB-Light,4,-0.2329999953508377,3355443,36,19,1,"{'concept_id': {0: 'C5236288'}, 'canonical_name': {0: 'Completion Date'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'The date on which the activity or entity is finished.'}, 'entity': {0: 'completion'}, 'text': {0: '†Two patients did not finish the entire 14 cycles of assigned treatment but are included in the trastuzumab arm due to the incorrect completion  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab arm'}, 'text': {0: '†Two patients did not finish the entire 14 cycles of assigned treatment but are included in the trastuzumab arm due to the incorrect completion  '}}","{'concept_id': {0: 'C0728747'}, 'canonical_name': {0: 'trastuzumab'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.'}, 'entity': {0: 'trastuzumab arm'}, 'text': {0: '†Two patients did not finish the entire 14 cycles of assigned treatment but are included in the trastuzumab arm due to the incorrect completion  '}}",{},{},"           entity_group                  value     score
0  Detailed_description                   †Two  0.757777
1             Lab_value                   †Two  0.988398
2  Quantitative_concept                     14  0.567164
3             Frequency                 cycles  0.469734
4            Medication  treatment trastuzumab  0.999749
5            Medication            trastuzumab  0.917970
6             Lab_value              incorrect  0.988837
7  Detailed_description             completion  0.895595","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'cycles assigned', 1: 'entire 14 cycles', 2: 'trastuzumab arm', 3: 'finish entire 14', 4: 'arm incorrect completion'}, 'score': {0: 0.7568, 1: 0.7199, 2: 0.6613, 3: 0.6312, 4: 0.5038}}"
1899,1899,1899,0.9470000267028807,19.0,of drug administration forms. One patient completed only 11 cycles of trastuzumab and the other was administered 13 cycles of trastuzumab and  ,UniversSB-Light,4,-0.2329999953508377,3355443,36,19,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of drug administration forms. One patient completed only 11 cycles of trastuzumab and the other was administered 13 cycles of trastuzumab and  '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of drug administration forms. One patient completed only 11 cycles of trastuzumab and the other was administered 13 cycles of trastuzumab and  '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'of drug administration forms. One patient completed only 11 cycles of trastuzumab and the other was administered 13 cycles of trastuzumab and  '}}",{},{},"     entity_group                    value     score
0  Clinical_event           administration  0.316268
1          Dosage         11 cycles cycles  0.985159
2      Medication  trastuzumab trastuzumab  0.984889
3          Dosage         13 cycles cycles  0.998932","[('11 cycles', 'DURATION'), ('trastuzumab', 'DRUG'), ('13 cycles', 'DURATION'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'completed 11 cycles', 1: 'administration forms patient', 2: 'drug administration', 3: 'forms patient completed', 4: 'cycles trastuzumab'}, 'score': {0: 0.6363, 1: 0.5096, 2: 0.4075, 3: 0.3365, 4: 0.3148}}"
1900,1900,1900,0.9470000267028807,19.0,1 cycle of Kadcyla.,UniversSB-Light,4,-0.2329999953508377,3355443,36,19,3,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: '1 cycle of Kadcyla.'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: '1 cycle of Kadcyla.'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: '1 cycle of Kadcyla.'}}",{},{},"           entity_group value     score
0  Quantitative_concept     1  0.651334","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'cycle kadcyla'}, 'score': {0: 0.7987}}"
1901,1901,1901,0.9470000267028807,19.0,‡Delay in treatment >42 days due to scheduling difficulties.,UniversSB-Light,4,-0.2329999953508377,3355443,36,19,4,"{'concept_id': {0: 'C1299586'}, 'canonical_name': {0: 'Has difficulty doing (qualifier value)'}, 'aliases': {0: ['Has difficulty doing', 'Able with difficulty', 'difficulty', 'Able with difficulty (qualifier value)', 'Difficulty', 'difficulties']}, 'types': {0: ['T033']}, 'definition': {0: 'Something not easily done, accomplished, comprehended, or solved.'}, 'entity': {0: 'scheduling difficulties'}, 'text': {0: '‡Delay in treatment >42 days due to scheduling difficulties.'}}","{'concept_id': {0: 'C0019843'}, 'canonical_name': {0: 'Holidays'}, 'aliases': {0: ['Holiday']}, 'types': {0: ['T051']}, 'definition': {0: 'Days commemorating events. Holidays also include vacation periods.'}, 'entity': {0: 'days'}, 'text': {0: '‡Delay in treatment >42 days due to scheduling difficulties.'}}",{},{},"{'concept_id': {0: 'C0239043'}, 'canonical_name': {0: 'Chewing difficulties'}, 'aliases': {0: ['Impaired mastication', 'Difficulty chewing', 'Chewing difficulty']}, 'types': {0: ['T033']}, 'definition': {0: 'Pain or discomfort with mastication, a symptom of underlying disease. Causes can include problems with the teeth, jaws or temporomandibular joint, mumps, cancer, or a neuromuscular disorder.'}, 'entity': {0: 'scheduling difficulties'}, 'text': {0: '‡Delay in treatment >42 days due to scheduling difficulties.'}}","  entity_group    value     score
0     Duration        >  0.895343
1     Duration  42 days  0.973658",[],"{'keyword': {0: 'days scheduling', 1: '42 days', 2: 'scheduling difficulties', 3: 'treatment 42', 4: 'delay treatment'}, 'score': {0: 0.8139, 1: 0.7137, 2: 0.704, 3: 0.6878, 4: 0.6176}}"
1902,1902,1902,0.9470000267028807,19.0,§Did not complete 14 total cycles due to a misunderstanding.,UniversSB-Light,4,-0.2329999953508377,3355443,36,19,5,"{'concept_id': {0: 'C0162340'}, 'canonical_name': {0: 'Comprehension'}, 'aliases': {0: ['understand', 'Understanding', 'understanding', 'Understood', 'Understanding, function', 'Understanding, function (observable entity)', 'Understanding, NOS', 'Understand', 'Comprehension', 'knowledge or comprehension', 'comprehension', 'UNDERSTANDS']}, 'types': {0: ['T041']}, 'definition': {0: 'The act or fact of grasping the meaning, nature, or importance of; understanding. (American Heritage Dictionary, 4th ed) Includes understanding by a patient or research subject of information disclosed orally or in writing.'}, 'entity': {0: 'misunderstanding'}, 'text': {0: '§Did not complete 14 total cycles due to a misunderstanding.'}}","{'concept_id': {0: 'C0162340'}, 'canonical_name': {0: 'Understanding'}, 'aliases': {0: ['Comprehension']}, 'types': {0: ['T041']}, 'definition': {0: 'The act or fact of grasping the meaning, nature, or importance of; understanding. (American Heritage Dictionary, 4th ed) Includes understanding by a patient or research subject of information disclosed orally or in writing.'}, 'entity': {0: 'misunderstanding'}, 'text': {0: '§Did not complete 14 total cycles due to a misunderstanding.'}}",{},{},{},"           entity_group   value     score
0             Lab_value      14  0.935609
1  Diagnostic_procedure   total  0.510689
2  Detailed_description  cycles  0.383750",[],"{'keyword': {0: 'cycles misunderstanding', 1: 'did complete', 2: '14 total', 3: 'total cycles', 4: 'complete 14'}, 'score': {0: 0.8642, 1: 0.7904, 2: 0.7365, 3: 0.6897, 4: 0.6474}}"
1903,1903,1903,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,36,20,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1904,1904,1904,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,36,20,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1905,1905,1905,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,36,20,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1906,1906,1906,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,36,20,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1907,1907,1907,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,36,21,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1908,1908,1908,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,36,21,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1909,1909,1909,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,36,21,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1910,1910,1910,0.75,98.0,When a different direction ,ConduitITC-Bold,20,-0.1700000017881393,8194925,37,1,0,"{'concept_id': {0: 'C1550715'}, 'canonical_name': {0: 'direction - AddressPartType'}, 'aliases': {0: ['direction']}, 'types': {0: ['T078']}, 'definition': {0: '<p>Direction (e.g., N, S, W, E)</p>'}, 'entity': {0: 'direction'}, 'text': {0: 'When a different direction '}}","{'concept_id': {0: 'C0700158'}, 'canonical_name': {0: 'Direction'}, 'aliases': {0: ['Direction compound']}, 'types': {0: ['T122']}, 'definition': {0: None}, 'entity': {0: 'direction'}, 'text': {0: 'When a different direction '}}",{},{},{},"  entity_group                value     score
0    Lab_value                    a  0.640453
1    Lab_value  different direction  0.997081",[],"{'keyword': {0: 'different direction'}, 'score': {0: 0.8296}}"
1911,1911,1911,0.75,98.0,"is vital, give them Kadcyla",ConduitITC-Bold,20,-0.1700000017881393,8194925,37,1,1,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'is vital, give them Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'is vital, give them Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'is vital, give them Kadcyla'}}",{},{},"           entity_group    value     score
0           Coreference     them  0.623846
1  Diagnostic_procedure  Kadcyla  0.918343","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'vital kadcyla'}, 'score': {0: 0.8823}}"
1912,1912,1912,0.9470000267028807,32.0, ,UniversSB-Light,4,-0.2329999953508377,16162586,37,2,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1913,1913,1913,0.9470000267028807,32.0,following trastuzumab-based neoadjuvant therapy:,UniversSB-Light,4,-0.2329999953508377,3355443,37,2,1,{},"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'trastuzumab-based neoadjuvant therapy'}, 'text': {0: 'following trastuzumab-based neoadjuvant therapy:'}}",{},{},{},"            entity_group              value     score
0             Medication  trastuzumab-based  0.999864
1  Therapeutic_procedure        neoadjuvant  0.857213","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'following trastuzumab based', 1: 'trastuzumab based neoadjuvant', 2: 'based neoadjuvant', 3: 'trastuzumab based', 4: 'neoadjuvant therapy'}, 'score': {0: 0.9085, 1: 0.9068, 2: 0.889, 3: 0.8773, 4: 0.8616}}"
1914,1914,1914,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,37,3,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1915,1915,1915,0.9470000267028807,32.0,absolute reduction; hazard ratio 0.50; 95% Cl 0.39–0.64; p<0.001),UniversSB-Light,4,-0.2329999953508377,3355443,37,3,1,"{'concept_id': {0: 'C0475212'}, 'canonical_name': {0: 'centiliter'}, 'aliases': {0: ['Centiliter (qualifier value)', 'centiliter (cL)', 'Centiliter', 'centilitre', 'cL', 'cl']}, 'types': {0: ['T081']}, 'definition': {0: 'The unit of volume equal to one hundredth of a liter or 10 milliliters. One centiliter is equivalent to 0.6102 cubic inch, or 0.338 U.S. fluid ounce.'}, 'entity': {0: 'Cl'}, 'text': {0: 'absolute reduction; hazard ratio 0.50; 95% Cl 0.39–0.64; p<0.001)'}}","{'concept_id': {0: 'C0679771'}, 'canonical_name': {0: 'Harm Reduction'}, 'aliases': {0: ['Minimization, Harm', 'Reduction, Harm', 'Harm Minimization']}, 'types': {0: ['T061']}, 'definition': {0: 'The application of methods designed to reduce the risk of harm associated with certain behaviors without reduction in frequency of those behaviors. The risk-associated behaviors include ongoing and active addictive behaviors.'}, 'entity': {0: 'reduction'}, 'text': {0: 'absolute reduction; hazard ratio 0.50; 95% Cl 0.39–0.64; p<0.001)'}}",{},"{'concept_id': {0: 'C1150758'}, 'canonical_name': {0: '4-coumarate-CoA synthetase activity'}, 'aliases': {0: ['hydroxycinnamoyl CoA synthetase activity', '4-coumarate:CoA ligase activity', '4CL', 'p-hydroxycinnamic acid:CoA ligase activity', '4-coumaroyl-CoA synthetase activity', 'caffeolyl coenzyme A synthetase activity', '4-coumaroyl-CoA synthase activity', 'sinapoyl coenzyme A synthetase activity', 'feruloyl CoA ligase activity', '4-coumarate:coenzyme A ligase activity', 'hydroxycinnamate:CoA ligase activity', 'p-coumaryl coenzyme A synthetase activity', 'feruloyl coenzyme A synthetase activity', 'p-coumaryl-CoA ligase activity', '4-coumarate-CoA ligase activity', 'p-coumaryl-CoA synthetase activity', '4-coumaryl-CoA synthetase activity', '4-coumarate:CoA ligase (AMP-forming)', 'p-hydroxycinnamoyl coenzyme A synthetase activity', 'p-coumaroyl CoA ligase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: ATP + 4-coumarate + CoA = AMP + diphosphate + 4-coumaroyl-CoA. [EC:6.2.1.12]'}, 'entity': {0: 'Cl'}, 'text': {0: 'absolute reduction; hazard ratio 0.50; 95% Cl 0.39–0.64; p<0.001)'}}",{},"           entity_group                 value     score
0  Diagnostic_procedure          hazard ratio  0.999798
1             Lab_value  0.50 0.39–0.64 0.001  0.990356
2             Lab_value                    95  0.999416
3  Diagnostic_procedure                    Cl  0.999064",[],"{'keyword': {0: 'absolute reduction', 1: 'absolute reduction hazard', 2: '95 cl', 3: 'hazard ratio', 4: 'ratio 50'}, 'score': {0: 0.7045, 1: 0.6654, 2: 0.6092, 3: 0.6086, 4: 0.582}}"
1916,1916,1916,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,37,4,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1917,1917,1917,0.9470000267028807,32.0,(unstratified hazard ratio 0.60; 95% Cl 0.45–0.79),UniversSB-Light,4,-0.2329999953508377,3355443,37,4,1,"{'concept_id': {0: 'C0597342'}, 'canonical_name': {0: 'radiation hazard'}, 'aliases': {0: ['hazards radiation', 'radiation hazard']}, 'types': {0: ['T038']}, 'definition': {0: 'health hazard arising from exposure to ionizing radiation.'}, 'entity': {0: 'hazard ratio'}, 'text': {0: '(unstratified hazard ratio 0.60; 95% Cl 0.45–0.79)'}}",{},{},{},{},"           entity_group                      value     score
0  Diagnostic_procedure               unstratified  0.999883
1  Diagnostic_procedure  unstratified hazard ratio  0.885978
2             Lab_value             0.60 0.45–0.79  0.999824
3             Lab_value                         95  0.999810
4  Diagnostic_procedure                         Cl  0.999488",[],"{'keyword': {0: 'unstratified hazard ratio', 1: 'ratio 60', 2: '60 95 cl', 3: '45 79', 4: 'hazard ratio'}, 'score': {0: 0.8029, 1: 0.7088, 2: 0.6799, 3: 0.5835, 4: 0.4992}}"
1918,1918,1918,0.9470000267028807,32.0,•   ,UniversSB-Light,4,-0.2329999953508377,16162586,37,5,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1919,1919,1919,0.9470000267028807,32.0,"trastuzumab, but this was consistent with its safety profile from ",UniversSB-Light,4,-0.2329999953508377,3355443,37,5,1,"{'concept_id': {0: 'C1456533'}, 'canonical_name': {0: 'Fire Safety'}, 'aliases': {0: []}, 'types': {0: ['T089']}, 'definition': {0: ""<p>Preventing fires is an important part of fire safety. In the United States, cooking is the main cause of home fires. Cigarettes are a big risk too - they are the leading cause of fire deaths. Here are some fire prevention tips:</p> <ul> <li>Don't leave the stove or oven unattended when they are on</li> <li>Don't let children use kitchen appliances unsupervised</li> <li>Don't smoke in bed</li> <li>Make sure your electrical appliances and cords are in good condition</li> </ul> <p>It is also important to be prepared in case there is a fire. Make sure that you have working smoke detectors on every floor and in every bedroom. You should also have fire extinguishers on every floor and in your kitchen. Make and practice an escape plan in case the main exit is blocked.</p>""}, 'entity': {0: 'safety'}, 'text': {0: 'trastuzumab, but this was consistent with its safety profile from '}}","{'concept_id': {0: 'C1456535'}, 'canonical_name': {0: 'Food Safety'}, 'aliases': {0: ['Safety, Food']}, 'types': {0: ['T057']}, 'definition': {0: 'Activities involved in ensuring the safety of FOOD including avoidance of bacterial and other contamination.'}, 'entity': {0: 'safety'}, 'text': {0: 'trastuzumab, but this was consistent with its safety profile from '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'trastuzumab, but this was consistent with its safety profile from '}}",{},{},"  entity_group        value     score
0   Medication  trastuzumab  0.999745","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'consistent safety profile', 1: 'trastuzumab consistent safety', 2: 'safety profile', 3: 'consistent safety', 4: 'trastuzumab consistent'}, 'score': {0: 0.8648, 1: 0.8018, 2: 0.7762, 3: 0.7491, 4: 0.6805}}"
1920,1920,1920,0.9470000267028807,32.0,previous studies,UniversSB-Light,4,-0.2329999953508377,3355443,37,5,2,"{'concept_id': {0: 'C0036745'}, 'canonical_name': {0: 'Study of serum'}, 'aliases': {0: ['serum studies', 'serology', 'serologies', 'Serology', 'study of serum']}, 'types': {0: ['T091']}, 'definition': {0: 'The study of serum, especially of antigen-antibody reactions in vitro.'}, 'entity': {0: 'studies'}, 'text': {0: 'previous studies'}}","{'concept_id': {0: 'C0023981'}, 'canonical_name': {0: 'Study, Longitudinal'}, 'aliases': {0: ['Longitudinal Studies', 'Studies, Longitudinal', 'Longitudinal Study']}, 'types': {0: ['T062']}, 'definition': {0: 'Studies in which variables relating to an individual or group of individuals are assessed over a period of time.'}, 'entity': {0: 'studies'}, 'text': {0: 'previous studies'}}",{},{},{},"  entity_group    value     score
0     Duration  studies  0.571146",[],"{'keyword': {0: 'previous studies'}, 'score': {0: 1.0}}"
1921,1921,1921,0.9169999957084656,30.0,References:,ConduitITC-Bold,20,-0.2349999994039535,8194925,37,6,0,"{'concept_id': {0: 'C1561577'}, 'canonical_name': {0: 'Reference - MdfHmdMetSourceType'}, 'aliases': {0: ['Reference']}, 'types': {0: ['T170']}, 'definition': {0: '<p>This row represents a reference to a previously defined type. Such a reference means that, in a given message, the message element instance for the current row is identical to the message element instance that instantiates the referred row.</p>'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}","{'concept_id': {0: 'C0016483'}, 'canonical_name': {0: 'Food Preferences'}, 'aliases': {0: ['Food Preference', 'Preferences, Food', 'Preference, Food']}, 'types': {0: ['T080']}, 'definition': {0: 'The selection of one food over another.'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1922,1922,1922,0.8830000162124634,22.0,1. von Minckwitz G et al. N Engl J Med. 2019;380(7):617–628. ,MyriadPro-Light,4,-0.25,3355443,37,6,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: '2019 380 617', 1: 'al engl med', 2: 'med 2019', 3: 'et al', 4: 'engl med 2019'}, 'score': {0: 0.8031, 1: 0.7251, 2: 0.7194, 3: 0.6642, 4: 0.6422}}"
1923,1923,1923,0.8830000162124634,22.0,2. Verma S et al. N Engl J Med. 2012;367(19):1783–1791.,MyriadPro-Light,4,-0.25,3355443,37,6,2,{},{},{},{},{},"           entity_group           value     score
0  Detailed_description           Verma  0.818863
1           Coreference           Verma  0.120926
2             Lab_value             367  0.923943
3             Lab_value  367 :1783–1791  0.497523",[],"{'keyword': {0: '2012 367 19', 1: 'verma et al', 2: 'al engl', 3: 'med 2012', 4: 'engl med 2012'}, 'score': {0: 0.8736, 1: 0.815, 2: 0.7844, 3: 0.7653, 4: 0.6619}}"
1924,1924,1924,0.9470000267028807,19.0,"CI, confidence interval; eBC, early breast cancer. ",UniversSB-Light,4,-0.2329999953508377,3355443,37,7,0,"{'concept_id': {0: 'C0598034'}, 'canonical_name': {0: 'BRCA2 gene'}, 'aliases': {0: ['BRCA2, DNA Repair Associated Gene', 'brca2', 'brca 2 gene', 'FACD', 'breast cancer 2', 'BRCA2 Genes', 'XRCC11', 'BRCA2 DNA repair associated', 'breast cancer 2, early onset', 'BRCC2', 'Fanconi anemia, complementation group D1', 'FANCD1 GENE', 'FAD1', 'BRCA1/BRCA2-containing complex, subunit 2', 'BRCA2 gene', 'FANCD1', 'brca2 gene', 'BRCA2 GENE', 'Breast Cancer 2, Early Onset Gene', 'FANCD', 'Genes, BRCA2', 'BRCA2', 'BRCA2 Gene', 'BRCA2 DNA REPAIR-ASSOCIATED PROTEIN', 'FAD', 'brca2 genes', 'Gene, BRCA2']}, 'types': {0: ['T028']}, 'definition': {0: 'A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'CI, confidence interval; eBC, early breast cancer. '}}","{'concept_id': {0: 'C0006142'}, 'canonical_name': {0: 'Breast Malignant Neoplasms'}, 'aliases': {0: ['Mammary Cancers', 'Cancer of Breast', 'Cancers, Mammary', 'Malignant Neoplasm of Breast', 'Breast Malignant Tumors', 'Breast Cancer', 'Breast Malignant Neoplasm', 'Malignant Tumor of Breast', 'Mammary Cancer', 'Cancer, Mammary', 'Breast Malignant Tumor', 'Cancer, Breast', 'Cancer of the Breast']}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'CI, confidence interval; eBC, early breast cancer. '}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'CI, confidence interval; eBC, early breast cancer. '}}","Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'ebc early breast', 1: 'breast cancer', 2: 'ebc early', 3: 'interval ebc', 4: 'ci confidence interval'}, 'score': {0: 0.8357, 1: 0.7051, 2: 0.6649, 3: 0.6073, 4: 0.3895}}"
1925,1925,1925,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,37,9,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1926,1926,1926,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,37,9,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1927,1927,1927,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,37,9,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1928,1928,1928,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,37,9,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1929,1929,1929,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,37,10,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1930,1930,1930,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,37,10,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1931,1931,1931,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,37,10,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1932,1932,1932,0.75,98.0,Consider the whole HER2-positive eBC treatment ,ConduitITC-Bold,20,-0.1700000017881393,8194925,38,1,0,"{'concept_id': {0: 'C1960398'}, 'canonical_name': {0: 'HER2-positive carcinoma of breast'}, 'aliases': {0: ['HER2+ breast cancer', 'HER2 Overexpressing Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast (disorder)', 'HER2-Positive Breast Carcinoma', 'HER2 Overexpressing Subtype of Breast Carcinoma', 'HER2-positive breast cancer', 'HER2/neu-positive breast cancer', 'ERBB2 Overexpressing Subtype of Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast', 'HER2 Positive Breast Carcinoma', 'HER2 Positive Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).'}, 'entity': {0: 'HER2-positive'}, 'text': {0: 'Consider the whole HER2-positive eBC treatment '}}","{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Treatments'}, 'aliases': {0: ['Therapy', 'Treatment', 'Therapeutics', 'Therapeutic', 'Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'eBC treatment'}, 'text': {0: 'Consider the whole HER2-positive eBC treatment '}}",{},{},{},"            entity_group                                           value  \
0              Lab_value                                   HER2-positive   
1  Therapeutic_procedure  Consider the whole HER2-positive eBC treatment   
2  Therapeutic_procedure                                       treatment   

      score  
0  0.803031  
1  0.537932  
2  0.767745  ",[],"{'keyword': {0: 'ebc treatment', 1: 'her2 positive ebc', 2: 'consider her2', 3: 'positive ebc treatment', 4: 'her2 positive'}, 'score': {0: 0.8257, 1: 0.8138, 2: 0.792, 3: 0.768, 4: 0.6419}}"
1933,1933,1933,0.75,98.0,journey today to optimise your patients’ outcomes,ConduitITC-Bold,20,-0.1700000017881393,8194925,38,1,1,"{'concept_id': {0: 'C0086749'}, 'canonical_name': {0: 'Outcome Measures'}, 'aliases': {0: ['measure outcomes', 'measures outcome', 'Measures, Outcome', 'outcome measures', 'outcome measure', 'Outcome Measure', 'Outcome Measures', 'Measure, Outcome', 'measures outcomes']}, 'types': {0: ['T081']}, 'definition': {0: '<p>**Description:**Operational activities conducted for the purposes of assessing the results of an activity, product, or service</p>'}, 'entity': {0: 'outcomes'}, 'text': {0: 'journey today to optimise your patients’ outcomes'}}","{'concept_id': {0: 'C0032972'}, 'canonical_name': {0: 'Pregnancy Outcome'}, 'aliases': {0: ['Pregnancy Outcomes', 'Outcome, Pregnancy', 'Outcomes, Pregnancy']}, 'types': {0: ['T033']}, 'definition': {0: 'Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO.'}, 'entity': {0: 'outcomes'}, 'text': {0: 'journey today to optimise your patients’ outcomes'}}",{},{},{},"           entity_group          value     score
0  Detailed_description  journey today  0.940791
1  Diagnostic_procedure       outcomes  0.483345",[],"{'keyword': {0: 'journey today', 1: 'today optimise patients', 2: 'patients outcomes', 3: 'today optimise', 4: 'optimise patients outcomes'}, 'score': {0: 0.9195, 1: 0.8752, 2: 0.8457, 3: 0.8444, 4: 0.8423}}"
1934,1934,1934,0.944000005722046,24.0,Disease characteristics,UniversSB-Medium,4,-0.2349999994039535,0,38,2,0,"{'concept_id': {0: 'C1705348'}, 'canonical_name': {0: 'Disease Characteristics Domain'}, 'aliases': {0: ['Disease Characteristics Domain']}, 'types': {0: ['T077']}, 'definition': {0: 'A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to disease characteristics.'}, 'entity': {0: 'Disease characteristics'}, 'text': {0: 'Disease characteristics'}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'Disease characteristics'}, 'text': {0: 'Disease characteristics'}}",{},{},{},"           entity_group                    value     score
0  Diagnostic_procedure  Disease characteristics  0.896728",[],"{'keyword': {0: 'disease characteristics'}, 'score': {0: 1.0}}"
1935,1935,1935,0.9470000267028807,24.0,Tumour stage ,UniversSB-Light,4,-0.2329999953508377,0,38,3,0,"{'concept_id': {0: 'C0475455'}, 'canonical_name': {0: 'T - Tumor stage'}, 'aliases': {0: ['T stage', 'T Category', 'T Classification', 'T - Tumour stage', 'T - Tumor stage', 'T - Tumor stage (attribute)', 'Tumour stages', 'Tumor stages', 'T - Tumor stages', 'tumor stages', 'T category (observable entity)', 'T - Tumour stages', 'T category']}, 'types': {0: ['T170']}, 'definition': {0: 'One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).'}, 'entity': {0: 'Tumour stage'}, 'text': {0: 'Tumour stage '}}",{},{},{},"{'concept_id': {0: 'C0027651'}, 'canonical_name': {0: 'Oncology'}, 'aliases': {0: ['Oncological abnormality', 'Neoplasia', 'Tumour', 'Neoplasm', 'Tumor']}, 'types': {0: ['T191']}, 'definition': {0: 'New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.'}, 'entity': {0: 'Tumour stage'}, 'text': {0: 'Tumour stage '}}","   entity_group         value     score
0  Sign_symptom  Tumour stage  0.768214",[],"{'keyword': {0: 'tumour stage'}, 'score': {0: 1.0}}"
1936,1936,1936,0.944000005722046,24.0,Neoadjuvant,UniversSB-Medium,4,-0.2349999994039535,0,38,4,0,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'Neoadjuvant'}, 'text': {0: 'Neoadjuvant'}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'Neoadjuvant'}, 'text': {0: 'Neoadjuvant'}}",{},{},{},"           entity_group        value     score
0  Detailed_description  Neoadjuvant  0.956138
1          Sign_symptom  Neoadjuvant  0.386592
2               History  Neoadjuvant  0.344678",[],"{'keyword': {}, 'score': {}}"
1937,1937,1937,0.9470000267028807,24.0,PHESGO,UniversSB-Light,4,-0.2329999953508377,0,38,4,1,"{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: ['Phesgo']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: 'PHESGO'}}",{},"{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: 'PHESGO'}}",{},{},"   entity_group   value     score
0  Sign_symptom  PHESGO  0.506898
1   Coreference  PHESGO  0.299037","[('PHESGO', 'DRUG')]","{'keyword': {}, 'score': {}}"
1938,1938,1938,0.9470000267028807,24.0, (pertuzumab/trastuzumab) SC plus chemotherapy (3–6 cycles),UniversSB-Light,4,-0.2329999953508377,0,38,4,2,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: ' (pertuzumab/trastuzumab) SC plus chemotherapy (3–6 cycles)'}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: ' (pertuzumab/trastuzumab) SC plus chemotherapy (3–6 cycles)'}}",{},{},{},"       entity_group                   value     score
0        Medication  pertuzumab/trastuzumab  0.999829
1  Disease_disorder                      SC  0.863019
2        Medication            chemotherapy  0.999876
3         Lab_value                     3–6  0.464376","[('trastuzumab', 'DRUG'), ('SC', 'ROUTE'), ('chemotherapy', 'DRUG'), ('3–6 cycles', 'DURATION')]","{'keyword': {0: 'plus chemotherapy cycles', 1: 'trastuzumab sc plus', 2: 'chemotherapy cycles', 3: 'trastuzumab sc', 4: 'pertuzumab trastuzumab'}, 'score': {0: 0.8387, 1: 0.8298, 2: 0.712, 3: 0.6578, 4: 0.3754}}"
1939,1939,1939,0.75,53.0,Kadcyla allows you to ,ConduitITC-Bold,20,-0.1700000017881393,16777215,38,5,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla allows you to '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla allows you to '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla allows you to '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.475378
1   Medication  Kadcyla  0.717254","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla allows'}, 'score': {0: 0.9278}}"
1940,1940,1940,0.75,53.0,adapt adjuvant therapy ,ConduitITC-Bold,20,-0.1700000017881393,16777215,38,5,1,"{'concept_id': {0: 'C0085533'}, 'canonical_name': {0: 'Chemotherapy, Adjuvant'}, 'aliases': {0: ['Adjuvant Drug Therapy', 'Adjuvant Chemotherapy', 'adjuvant chemotherapy', 'Drug Therapy, Adjuvant']}, 'types': {0: ['T061']}, 'definition': {0: 'Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.'}, 'entity': {0: 'adjuvant therapy'}, 'text': {0: 'adapt adjuvant therapy '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'adjuvant therapy'}, 'text': {0: 'adapt adjuvant therapy '}}",{},{},{},"            entity_group             value     score
0   Detailed_description             adapt  0.999687
1  Therapeutic_procedure  adjuvant therapy  0.969879",[],"{'keyword': {0: 'adapt adjuvant therapy', 1: 'adapt adjuvant', 2: 'adjuvant therapy'}, 'score': {0: 1.0, 1: 0.9287, 2: 0.8928}}"
1941,1941,1941,0.75,53.0,based on patients’ ,ConduitITC-Bold,20,-0.1700000017881393,16777215,38,5,2,"{'concept_id': {0: 'C1705908'}, 'canonical_name': {0: 'Veterinary Patient'}, 'aliases': {0: ['Veterinary Patient', 'Patient']}, 'types': {0: ['T001']}, 'definition': {0: 'A non-human animal that is a subject in a study.'}, 'entity': {0: 'patients’'}, 'text': {0: 'based on patients’ '}}","{'concept_id': {0: 'C0025360'}, 'canonical_name': {0: 'Mentally Ill Persons'}, 'aliases': {0: ['Mental Patients', 'Person, Mentally Ill', 'Ill, Mentally', 'Mentally Ill Person', 'Persons, Mentally Ill', 'Mentally Ill']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.'}, 'entity': {0: 'patients’'}, 'text': {0: 'based on patients’ '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'based patients'}, 'score': {0: 0.8565}}"
1942,1942,1942,0.75,53.0,neoadjuvant response,ConduitITC-Bold,20,-0.1700000017881393,16777215,38,5,3,"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Neoadjuvant Therapy'}, 'aliases': {0: ['Preoperative Therapy', 'Therapy, Neoadjuvant', 'neoadjuvant treatment', 'Neoadjuvant Treatment', 'Neoadjuvant Treatments', 'Neoadjuvant Therapies', 'Neoadjuvant', 'Induction Therapy', 'Neoadjuvant Therapy', 'induction therapy', 'Treatment, Neoadjuvant', 'neoadjuvant therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant response'}, 'text': {0: 'neoadjuvant response'}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant response'}, 'text': {0: 'neoadjuvant response'}}",{},{},{},"   entity_group                 value     score
0  Sign_symptom           neoadjuvant  0.998864
1  Sign_symptom  neoadjuvant response  0.993135",[],"{'keyword': {0: 'neoadjuvant response'}, 'score': {0: 1.0}}"
1943,1943,1943,0.944000005722046,24.0,Surgery,UniversSB-Medium,4,-0.2349999994039535,0,38,6,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  Surgery  0.998798",[],"{'keyword': {}, 'score': {}}"
1944,1944,1944,0.9470000267028807,24.0,Clinically,UniversSB-Light,4,-0.2329999953508377,0,38,8,0,"{'concept_id': {0: 'C0205210'}, 'canonical_name': {0: 'Clinical'}, 'aliases': {0: ['Clinical (qualifier value)', 'clinical', 'Clinical']}, 'types': {0: ['T080']}, 'definition': {0: 'Relating to the examination and treatment of patients dependent on direct observation. The term may also refer to the institution (clinic) providing this activity.'}, 'entity': {0: 'Clinically'}, 'text': {0: 'Clinically'}}",{},{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  Clinically  0.966238",[],"{'keyword': {}, 'score': {}}"
1945,1945,1945,0.8830000162124634,24.0,Clinically,MyriadPro-Light,4,-0.25,0,38,9,0,"{'concept_id': {0: 'C0205210'}, 'canonical_name': {0: 'Clinical'}, 'aliases': {0: ['Clinical (qualifier value)', 'clinical', 'Clinical']}, 'types': {0: ['T080']}, 'definition': {0: 'Relating to the examination and treatment of patients dependent on direct observation. The term may also refer to the institution (clinic) providing this activity.'}, 'entity': {0: 'Clinically'}, 'text': {0: 'Clinically'}}",{},{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  Clinically  0.966238",[],"{'keyword': {}, 'score': {}}"
1946,1946,1946,0.9520000219345092,26.0,or,MyriadPro-Regular,4,-0.25,0,38,10,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1947,1947,1947,0.9520000219345092,22.0,and,MyriadPro-Regular,4,-0.25,0,38,10,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1948,1948,1948,0.944000005722046,24.0,Evidence of nodal metastases at surgery,UniversSB-Medium,4,-0.2349999994039535,0,38,11,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'surgery'}, 'text': {0: 'Evidence of nodal metastases at surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'surgery'}, 'text': {0: 'Evidence of nodal metastases at surgery'}}",{},{},{},"           entity_group       value     score
0  Biological_structure       nodal  0.999766
1      Disease_disorder  metastases  0.927845
2           Coreference     surgery  0.592903",[],"{'keyword': {0: 'evidence nodal metastases', 1: 'evidence nodal', 2: 'nodal metastases', 3: 'nodal metastases surgery', 4: 'metastases surgery'}, 'score': {0: 0.9448, 1: 0.7767, 2: 0.6829, 3: 0.4733, 4: 0.4429}}"
1949,1949,1949,0.944000005722046,24.0,No evidence of nodal metastases at surgery,UniversSB-Medium,4,-0.2349999994039535,0,38,12,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'surgery'}, 'text': {0: 'No evidence of nodal metastases at surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'surgery'}, 'text': {0: 'No evidence of nodal metastases at surgery'}}",{},{},{},"           entity_group       value     score
0  Biological_structure       nodal  0.999686
1      Disease_disorder  metastases  0.975436
2           Coreference     surgery  0.547385",[],"{'keyword': {0: 'evidence nodal', 1: 'evidence nodal metastases', 2: 'nodal metastases', 3: 'nodal metastases surgery', 4: 'metastases surgery'}, 'score': {0: 0.7023, 1: 0.6408, 2: 0.6274, 3: 0.5605, 4: 0.5356}}"
1950,1950,1950,0.9470000267028807,22.894540786743164,pCR in breast and axilla,UniversSB-Light,4,-0.2329999953508377,0,38,13,0,"{'concept_id': {0: 'C0238729'}, 'canonical_name': {0: 'Mass of axilla'}, 'aliases': {0: ['Lump of axilla', 'Axillary Mass', 'Mass of axilla (finding)', 'axillary lumps', 'axillary lump', 'axilla mass', 'AXILLARY MASS', 'axilla lump', 'mass axilla', 'axillary mass']}, 'types': {0: ['T033']}, 'definition': {0: 'An abnormal growth in the axilla.'}, 'entity': {0: 'axilla'}, 'text': {0: 'pCR in breast and axilla'}}","{'concept_id': {0: 'C0024947'}, 'canonical_name': {0: 'Bone, Maxillary'}, 'aliases': {0: ['Bones, Maxillary', 'Maxillary Bones', 'Maxillae', 'Maxillas', 'Maxilla', 'Maxillary Bone']}, 'types': {0: ['T023']}, 'definition': {0: 'One of a pair of irregularly shaped bones that form the upper jaw. A maxillary bone provides tooth sockets for the superior teeth, forms part of the ORBIT, and contains the MAXILLARY SINUS.'}, 'entity': {0: 'axilla'}, 'text': {0: 'pCR in breast and axilla'}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast'}, 'text': {0: 'pCR in breast and axilla'}}","           entity_group   value     score
0  Diagnostic_procedure     pCR  0.999817
1  Biological_structure  breast  0.999936
2  Biological_structure  axilla  0.999896",[],"{'keyword': {0: 'pcr breast', 1: 'pcr breast axilla', 2: 'breast axilla'}, 'score': {0: 0.8547, 1: 0.8147, 2: 0.698}}"
1951,1951,1951,0.9470000267028807,22.894540786743164,Residual invasive disease in ,UniversSB-Light,4,-0.2329999953508377,0,38,13,1,"{'concept_id': {0: 'C4684759'}, 'canonical_name': {0: 'Residual Risk'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Risk that remains after risk control measures have been taken.'}, 'entity': {0: 'Residual'}, 'text': {0: 'Residual invasive disease in '}}","{'concept_id': {0: 'C0242740'}, 'canonical_name': {0: 'Gastric Stump'}, 'aliases': {0: ['Remnant Stomachs', 'Stomachs, Remnant', 'Remnant, Gastric', 'Gastric Stumps', 'Gastric Remnant', 'Residual Stomach', 'Residual Stomachs', 'Stomachs, Residual', 'Stomach, Residual', 'Stump, Gastric', 'Stumps, Gastric', 'Remnants, Gastric', 'Gastric Remnants', 'Stomach, Remnant', 'Remnant Stomach']}, 'types': {0: ['T023']}, 'definition': {0: 'That portion of the stomach remaining after gastric surgery, usually gastrectomy or gastroenterostomy for cancer of the stomach or peptic ulcer. It is a common site of cancer referred to as stump cancer or carcinoma of the gastric stump.'}, 'entity': {0: 'Residual'}, 'text': {0: 'Residual invasive disease in '}}",{},{},{},"           entity_group     value     score
0  Detailed_description  Residual  0.999950
1  Detailed_description  invasive  0.405941
2      Disease_disorder   disease  0.392131",[],"{'keyword': {0: 'residual invasive disease', 1: 'residual invasive', 2: 'invasive disease'}, 'score': {0: 0.975, 1: 0.944, 2: 0.8337}}"
1952,1952,1952,0.9470000267028807,22.894540786743164,breast (or axilla),UniversSB-Light,4,-0.2329999953508377,0,38,13,2,"{'concept_id': {0: 'C0238729'}, 'canonical_name': {0: 'Mass of axilla'}, 'aliases': {0: ['Lump of axilla', 'Axillary Mass', 'Mass of axilla (finding)', 'axillary lumps', 'axillary lump', 'axilla mass', 'AXILLARY MASS', 'axilla lump', 'mass axilla', 'axillary mass']}, 'types': {0: ['T033']}, 'definition': {0: 'An abnormal growth in the axilla.'}, 'entity': {0: 'axilla'}, 'text': {0: 'breast (or axilla)'}}","{'concept_id': {0: 'C0024947'}, 'canonical_name': {0: 'Bone, Maxillary'}, 'aliases': {0: ['Bones, Maxillary', 'Maxillary Bones', 'Maxillae', 'Maxillas', 'Maxilla', 'Maxillary Bone']}, 'types': {0: ['T023']}, 'definition': {0: 'One of a pair of irregularly shaped bones that form the upper jaw. A maxillary bone provides tooth sockets for the superior teeth, forms part of the ORBIT, and contains the MAXILLARY SINUS.'}, 'entity': {0: 'axilla'}, 'text': {0: 'breast (or axilla)'}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast'}, 'text': {0: 'breast (or axilla)'}}","           entity_group   value     score
0  Biological_structure  breast  0.999903
1  Biological_structure  axilla  0.904969",[],"{'keyword': {0: 'breast axilla'}, 'score': {0: 0.6956}}"
1953,1953,1953,0.9470000267028807,24.0,pCR in breast,UniversSB-Light,4,-0.2329999953508377,0,38,13,3,"{'concept_id': {0: 'C4050242'}, 'canonical_name': {0: 'Pathologic Complete Response'}, 'aliases': {0: ['Pathologic Complete Response', 'Pathological Complete Remission', 'pCR']}, 'types': {0: ['T033']}, 'definition': {0: 'The disappearance of all signs of cancer, supported by pathological examination.'}, 'entity': {0: 'pCR'}, 'text': {0: 'pCR in breast'}}","{'concept_id': {0: 'C1709846'}, 'canonical_name': {0: 'Real-Time Polymerase Chain Reaction'}, 'aliases': {0: ['Real Time PCR', 'Real-Time PCRs', 'PCRs, Real-Time', 'PCR, Real-Time', 'Real Time Polymerase Chain Reaction', 'Real-Time PCR']}, 'types': {0: ['T063']}, 'definition': {0: 'An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.'}, 'entity': {0: 'pCR'}, 'text': {0: 'pCR in breast'}}",{},{},{},"           entity_group   value     score
0  Diagnostic_procedure     pCR  0.999828
1  Biological_structure  breast  0.999899",[],"{'keyword': {0: 'pcr breast'}, 'score': {0: 0.906}}"
1954,1954,1954,0.944000005722046,19.0,Other treatment options are available. ,UniversSB-Medium,4,-0.2349999994039535,3355443,38,14,0,"{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Therapeutic procedure'}, 'aliases': {0: ['TX', 'therapies', 'treatments', 'Therapeutic', 'Therapeutic procedure', 'Therapeutic procedure, NOS', 'methods treatment', 'Therapies', 'therapeutic method', 'Therapy', 'Therapeutics', 'treatment', 'Treatment', 'Therapeutic Interventions', 'Therapy (regime/therapy)', 'Treatments', 'Therapeutic Technique', 'Therapeutic Procedure', 'Therapeutic procedure (procedure)', 'therapy', 'therapeutic procedure', 'Therapy, NOS', 'method treatment', 'treatment method', 'Therapeutic Method', 'therapeutics']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'treatment options'}, 'text': {0: 'Other treatment options are available. '}}","{'concept_id': {0: 'C0871549'}, 'canonical_name': {0: 'Withholding Treatment'}, 'aliases': {0: ['Treatment, Withholding', 'Treatment Cessations', 'Withholding Treatments', 'Cessation of Treatment', 'Treatment Cessation', 'Treatments, Withholding']}, 'types': {0: ['T058']}, 'definition': {0: ""Withholding or withdrawal of a particular treatment or treatments, often (but not necessarily) life-prolonging treatment, from a patient or from a research subject as part of a research protocol. The concept is differentiated from REFUSAL TO TREAT, where the emphasis is on the health professional's or health facility's refusal to treat a patient or group of patients when the patient or the patient's representative requests treatment. Withholding of life-prolonging treatment is usually indexed only with EUTHANASIA, PASSIVE, unless the distinction between withholding and withdrawing treatment, or the issue of withholding palliative rather than curative treatment, is discussed.""}, 'entity': {0: 'treatment options'}, 'text': {0: 'Other treatment options are available. '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'options available', 1: 'treatment options', 2: 'treatment options available'}, 'score': {0: 0.8093, 1: 0.8063, 2: 0.805}}"
1955,1955,1955,0.9470000267028807,19.0,"*In the adjuvant setting, PHESGO should be administered for a total of one ",UniversSB-Light,4,-0.2329999953508377,3355443,38,14,1,"{'concept_id': {0: 'C1621583'}, 'canonical_name': {0: 'Administer - dosing instruction imperative'}, 'aliases': {0: ['Administer - dosing instruction imperative', 'Administer', 'Administer - dosing instruction imperative (qualifier value)']}, 'types': {0: ['T169']}, 'definition': {0: 'To dispense, apply, or tender something to another, such as administering a medicine.'}, 'entity': {0: 'administered'}, 'text': {0: '*In the adjuvant setting, PHESGO should be administered for a total of one '}}",{},"{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: '*In the adjuvant setting, PHESGO should be administered for a total of one '}}",{},{},"  entity_group                  value     score
0   Medication  adjuvant administered  0.927768
1   Medication                 PHESGO  0.987906
2       Dosage                    one  0.813255","[('PHESGO', 'DRUG')]","{'keyword': {0: 'phesgo administered total', 1: 'setting phesgo administered', 2: 'phesgo administered', 3: 'adjuvant setting', 4: 'setting phesgo'}, 'score': {0: 0.7864, 1: 0.7272, 2: 0.7256, 3: 0.7201, 4: 0.6862}}"
1956,1956,1956,0.9470000267028807,19.0,"year (up to 18 cycles or until disease recurrence, or unmanageable toxicity, ",UniversSB-Light,4,-0.2329999953508377,3355443,38,14,2,"{'concept_id': {0: 'C0242890'}, 'canonical_name': {0: 'Toxicity Tests'}, 'aliases': {0: ['toxicity tests', 'testing toxicity', 'Test, Toxicity', 'Toxicity testing', 'Toxicity Testing', 'toxicity test', 'Toxicity Test', 'Tests, Toxicity']}, 'types': {0: ['T060']}, 'definition': {0: 'An array of tests used to determine the toxicity of a substance to living systems. These include tests on clinical drugs, foods, and environmental pollutants.'}, 'entity': {0: 'toxicity'}, 'text': {0: 'year (up to 18 cycles or until disease recurrence, or unmanageable toxicity, '}}","{'concept_id': {0: 'C0013221'}, 'canonical_name': {0: 'Toxicity, Drug'}, 'aliases': {0: ['Drug Toxicities', 'Drug Toxicity', 'Toxicities, Drug']}, 'types': {0: ['T037']}, 'definition': {0: 'An adverse effect of a drug used therapeutically or diagnostically.'}, 'entity': {0: 'toxicity'}, 'text': {0: 'year (up to 18 cycles or until disease recurrence, or unmanageable toxicity, '}}",{},{},{},"  entity_group value     score
0     Duration  year  0.687364
1     Duration    18  0.597262",[],"{'keyword': {0: 'year 18 cycles', 1: 'recurrence unmanageable toxicity', 2: '18 cycles disease', 3: '18 cycles', 4: 'disease recurrence'}, 'score': {0: 0.7403, 1: 0.7282, 2: 0.6866, 3: 0.6858, 4: 0.5958}}"
1957,1957,1957,0.9470000267028807,19.0,"whichever occurs first), as part of a complete regimen for early breast ",UniversSB-Light,4,-0.2329999953508377,3355443,38,14,3,"{'concept_id': {0: 'C1517886'}, 'canonical_name': {0: 'Limited stage (cancer stage)'}, 'aliases': {0: ['Limited Stage', 'Early-Stage Cancer', 'Early Stage', 'Limited Metastatic Disease']}, 'types': {0: ['T185']}, 'definition': {0: 'Cancer that is localized in its original site of growth, or involves adjacent lymph nodes but has not spread to other anatomic sites.'}, 'entity': {0: 'early'}, 'text': {0: 'whichever occurs first), as part of a complete regimen for early breast '}}","{'concept_id': {0: 'C3177188'}, 'canonical_name': {0: 'Early Therapy'}, 'aliases': {0: ['Therapies, Early', 'Therapy, Early', 'Early Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures undertaken to prevent or reduce the incidence or progression of disease, in individuals with EARLY DIAGNOSIS of disease, or known DISEASE SUSCEPTIBILITY.'}, 'entity': {0: 'early'}, 'text': {0: 'whichever occurs first), as part of a complete regimen for early breast '}}",{},"{'concept_id': {0: 'C1818858'}, 'canonical_name': {0: 'early phagosome'}, 'aliases': {0: ['early phagocytic vesicle']}, 'types': {0: ['T026']}, 'definition': {0: 'A membrane-bounded intracellular vesicle as initially formed upon the ingestion of particulate material by phagocytosis. [GOC:mah, PMID:12388753]'}, 'entity': {0: 'early'}, 'text': {0: 'whichever occurs first), as part of a complete regimen for early breast '}}",{},"           entity_group   value    score
0  Biological_structure  breast  0.99935",[],"{'keyword': {0: 'occurs complete regimen', 1: 'regimen early', 2: 'regimen early breast', 3: 'complete regimen early', 4: 'whichever occurs'}, 'score': {0: 0.8161, 1: 0.8086, 2: 0.739, 3: 0.7305, 4: 0.719}}"
1958,1958,1958,0.9470000267028807,19.0,cancer and regardless of the timing of surgery. Treatment should include ,UniversSB-Light,4,-0.2329999953508377,3355443,38,14,4,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'Treatment'}, 'text': {0: 'cancer and regardless of the timing of surgery. Treatment should include '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'Treatment'}, 'text': {0: 'cancer and regardless of the timing of surgery. Treatment should include '}}",{},{},"{'concept_id': {0: 'C0007114'}, 'canonical_name': {0: 'Skin cancer'}, 'aliases': {0: []}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the skin. Primary malignant skin neoplasms most often are carcinomas (either basal cell or squamous cell carcinomas) or melanomas. Metastatic malignant neoplasms to the skin include carcinomas and lymphomas.'}, 'entity': {0: 'cancer'}, 'text': {0: 'cancer and regardless of the timing of surgery. Treatment should include '}}","            entity_group      value     score
0  Therapeutic_procedure  Treatment  0.998497",[],"{'keyword': {0: 'treatment include', 1: 'surgery treatment include', 2: 'cancer regardless timing', 3: 'timing surgery treatment', 4: 'regardless timing surgery'}, 'score': {0: 0.8983, 1: 0.7686, 2: 0.715, 3: 0.5252, 4: 0.3419}}"
1959,1959,1959,0.9470000267028807,19.0,standard anthracycline- and/or taxane-based chemotherapy.,UniversSB-Light,4,-0.2329999953508377,3355443,38,14,5,"{'concept_id': {0: 'C2828392'}, 'canonical_name': {0: 'Standard (document)'}, 'aliases': {0: ['Standard']}, 'types': {0: ['T170']}, 'definition': {0: 'A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.'}, 'entity': {0: 'standard'}, 'text': {0: 'standard anthracycline- and/or taxane-based chemotherapy.'}}","{'concept_id': {0: 'C0038137'}, 'canonical_name': {0: 'standards'}, 'aliases': {0: []}, 'types': {0: ['T169']}, 'definition': {0: 'Used with facilities, personnel, and program headings for the development, testing, and application of standards of adequacy or acceptable performance and with chemicals and drugs for standards of identification, quality, and potency. It includes health or safety standards in industries and occupations.'}, 'entity': {0: 'standard'}, 'text': {0: 'standard anthracycline- and/or taxane-based chemotherapy.'}}",{},{},{},"           entity_group         value     score
0  Detailed_description  taxane-based  0.999916","[('anthracycline-', 'DRUG'), ('taxane', 'DRUG'), ('chemotherapy', 'DRUG')]","{'keyword': {0: 'standard anthracycline taxane', 1: 'standard anthracycline', 2: 'anthracycline taxane based', 3: 'taxane based chemotherapy', 4: 'based chemotherapy'}, 'score': {0: 0.8737, 1: 0.8285, 2: 0.8266, 3: 0.742, 4: 0.7055}}"
1960,1960,1960,0.944000005722046,24.0,Adjuvant* ,UniversSB-Medium,4,-0.2349999994039535,0,38,15,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'Adjuvant*'}, 'text': {0: 'Adjuvant* '}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'Adjuvant*'}, 'text': {0: 'Adjuvant* '}}",{},{},{},"           entity_group     value     score
0  Diagnostic_procedure  Adjuvant  0.582094
1  Detailed_description         *  0.614326",[],"{'keyword': {}, 'score': {}}"
1961,1961,1961,0.9470000267028807,22.894540786743164,PHESGO SC based regimen,UniversSB-Light,4,-0.2329999953508377,0,38,15,1,"{'concept_id': {0: 'C0392970'}, 'canonical_name': {0: 'Doxorubicin/Docetaxel Regimen'}, 'aliases': {0: ['Docetaxel/Doxorubicin', 'Doxorubicin-Docetaxel', 'Doxorubicin/Docetaxel Regimen', 'Docetaxel/Doxorubicin Regimen', 'Adriamycin-Taxotere Regimen', 'AT Regimen', 'Doxorubicin/Docetaxel', 'Adriamycin/Taxotere', 'DOX/TXT', 'docetaxel/doxorubicin', 'Docetaxel-Doxorubicin']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemotherapy regimen consisting of doxorubicin and docetaxel that may be used in the treatment of breast cancer.'}, 'entity': {0: 'regimen'}, 'text': {0: 'PHESGO SC based regimen'}}","{'concept_id': {0: 'C0912478'}, 'canonical_name': {0: 'TIC protocol'}, 'aliases': {0: ['TIC regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A regimen consisting of paclitaxel, ifosfamide, mesna and carboplatin used as salvage therapy for the treatment of advanced-stage testicular cancer; also used for the treatment of unresectable and recurrent squamous cell head and neck cancer.'}, 'entity': {0: 'regimen'}, 'text': {0: 'PHESGO SC based regimen'}}","{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: 'PHESGO SC based regimen'}}",{},{},"            entity_group   value     score
0  Therapeutic_procedure  PHESGO  0.801073","[('PHESGO', 'DRUG'), ('SC', 'ROUTE')]","{'keyword': {0: 'phesgo sc based', 1: 'phesgo sc', 2: 'sc based', 3: 'based regimen', 4: 'sc based regimen'}, 'score': {0: 0.9229, 1: 0.8759, 2: 0.8432, 3: 0.8229, 4: 0.7852}}"
1962,1962,1962,0.944000005722046,24.0,Adjuvant,UniversSB-Medium,4,-0.2349999994039535,0,38,16,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}",{},{},{},"           entity_group     value     score
0  Detailed_description  Adjuvant  0.584447
1               History  Adjuvant  0.588875",[],"{'keyword': {}, 'score': {}}"
1963,1963,1963,0.9470000267028807,22.894540786743164,Kadcyla (14 cycles),UniversSB-Light,4,-0.2329999953508377,0,38,16,1,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Kadcyla (14 cycles)'}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Kadcyla (14 cycles)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (14 cycles)'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.741233
1    Lab_value       14  0.586142","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla 14 cycles', 1: '14 cycles', 2: 'kadcyla 14'}, 'score': {0: 0.9513, 1: 0.8869, 2: 0.8491}}"
1964,1964,1964,0.944000005722046,24.0,Adjuvant,UniversSB-Medium,4,-0.2349999994039535,0,38,17,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}",{},{},{},"           entity_group     value     score
0  Detailed_description  Adjuvant  0.584447
1               History  Adjuvant  0.588875",[],"{'keyword': {}, 'score': {}}"
1965,1965,1965,0.9470000267028807,22.894540786743164,Herceptin,UniversSB-Light,4,-0.2329999953508377,0,38,17,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Herceptin'}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Herceptin'}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Herceptin'}}",{},{},"           entity_group      value     score
0  Diagnostic_procedure  Herceptin  0.985167","[('Herceptin', 'DRUG')]","{'keyword': {}, 'score': {}}"
1966,1966,1966,0.9470000267028807,22.894540786743164,   (up to 18 cycles),UniversSB-Light,4,-0.2329999953508377,0,38,17,2,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: '   (up to 18 cycles)'}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: '   (up to 18 cycles)'}}",{},{},{},"           entity_group value     score
0  Detailed_description    18  0.406117",[],"{'keyword': {0: '18 cycles'}, 'score': {0: 0.8319}}"
1967,1967,1967,0.9470000267028807,11.07699966430664,†,UniversSB-Light,4,-0.2329999953508377,3355443,38,18,0,{},{},{},{},{},"           entity_group value     score
0  Detailed_description     †  0.176692",[],"{'keyword': {}, 'score': {}}"
1968,1968,1968,0.9470000267028807,19.0,patients must be node-positive at diagnosis or node-negative at diagnosis ,UniversSB-Light,4,-0.2329999953508377,3355443,38,18,1,"{'concept_id': {0: 'C1546899'}, 'canonical_name': {0: 'Diagnosis Classification - Diagnosis'}, 'aliases': {0: ['Diagnosis']}, 'types': {0: ['T185']}, 'definition': {0: None}, 'entity': {0: 'diagnosis'}, 'text': {0: 'patients must be node-positive at diagnosis or node-negative at diagnosis '}}","{'concept_id': {0: 'C2718037'}, 'canonical_name': {0: 'Late Diagnosis'}, 'aliases': {0: ['Diagnosis, Late', 'Late Diagnoses']}, 'types': {0: ['T080']}, 'definition': {0: 'Excessive period of time between onset of disease and identification.'}, 'entity': {0: 'diagnosis'}, 'text': {0: 'patients must be node-positive at diagnosis or node-negative at diagnosis '}}",{},{},"{'concept_id': {0: 'C0001816'}, 'canonical_name': {0: 'Agnosia'}, 'aliases': {0: []}, 'types': {0: ['T048']}, 'definition': {0: 'Loss of the ability to comprehend the meaning or recognize the importance of various forms of stimulation that cannot be attributed to impairment of a primary sensory modality. Tactile agnosia is characterized by an inability to perceive the shape and nature of an object by touch alone, despite unimpaired sensation to light touch, position, and other primary sensory modalities.'}, 'entity': {0: 'diagnosis'}, 'text': {0: 'patients must be node-positive at diagnosis or node-negative at diagnosis '}}","  entity_group          value     score
0    Lab_value  node-positive  0.989704
1    Lab_value  node-negative  0.917429",[],"{'keyword': {0: 'node negative', 1: 'negative diagnosis', 2: 'diagnosis node negative', 3: 'positive diagnosis', 4: 'patients node'}, 'score': {0: 0.7794, 1: 0.7664, 2: 0.6322, 3: 0.6205, 4: 0.4963}}"
1969,1969,1969,0.9470000267028807,19.0,and upstaged following surgery.,UniversSB-Light,4,-0.2329999953508377,3355443,38,18,2,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'surgery'}, 'text': {0: 'and upstaged following surgery.'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'surgery'}, 'text': {0: 'and upstaged following surgery.'}}",{},{},{},"   entity_group     value     score
0  Sign_symptom  upstaged  0.998013",[],"{'keyword': {0: 'upstaged following surgery', 1: 'upstaged following', 2: 'following surgery'}, 'score': {0: 0.9655, 1: 0.9463, 2: 0.7547}}"
1970,1970,1970,0.9470000267028807,19.0,"eBC, early breast cancer; pCR, pathological complete response;  ",UniversSB-Light,4,-0.2329999953508377,3355443,38,18,3,"{'concept_id': {0: 'C4054467'}, 'canonical_name': {0: 'Morphologic Complete Response'}, 'aliases': {0: ['Morphologic CR']}, 'types': {0: ['T033']}, 'definition': {0: 'The disappearance of all signs of cancer, supported by morphological analysis.'}, 'entity': {0: 'pathological complete response'}, 'text': {0: 'eBC, early breast cancer; pCR, pathological complete response;  '}}","{'concept_id': {0: 'C1709846'}, 'canonical_name': {0: 'Real-Time Polymerase Chain Reaction'}, 'aliases': {0: ['Real Time PCR', 'Real-Time PCRs', 'PCRs, Real-Time', 'PCR, Real-Time', 'Real Time Polymerase Chain Reaction', 'Real-Time PCR']}, 'types': {0: ['T063']}, 'definition': {0: 'An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.'}, 'entity': {0: 'pCR'}, 'text': {0: 'eBC, early breast cancer; pCR, pathological complete response;  '}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer; pCR, pathological complete response;  '}}","           entity_group   value     score
0  Biological_structure  breast  0.998095",[],"{'keyword': {0: 'ebc early breast', 1: 'breast cancer', 2: 'breast cancer pcr', 3: 'pathological complete', 4: 'pathological complete response'}, 'score': {0: 0.852, 1: 0.7259, 2: 0.7254, 3: 0.6977, 4: 0.6234}}"
1971,1971,1971,0.9470000267028807,19.0,"SC, subcutaneous.",UniversSB-Light,4,-0.2329999953508377,3355443,38,18,4,"{'concept_id': {0: 'C0222331'}, 'canonical_name': {0: 'Subcutaneous Fat'}, 'aliases': {0: ['subcutaneous adipose tissue', 'Subcutaneous Fats', 'Subcutaneous adipose tissue', 'Panniculus adiposus', 'Panniculus adiposus telae subcutaneae', 'Subcutaneous fatty tissue', 'paniculus adiposus', 'Structure of subcutaneous fatty tissue', 'Fat, Subcutaneous', 'Subcutaneous fat', 'Paniculus adiposus', 'subcutaneous fat', 'Subcutaneous Fat', 'Subcutaneous Tissue', 'Structure of subcutaneous fatty tissue (body structure)', 'Panniculus adiposus (Tela subcutanea)', 'fat subcutaneous', 'Fatty layer of subcutaneous tissue', 'Subcutis', 'Fats, Subcutaneous', 'Subcutaneous Adipose Tissue', 'Fatty layer of superficial fascia', 'Adipose Tissue, Subcutaneous']}, 'types': {0: ['T024']}, 'definition': {0: 'Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'SC, subcutaneous.'}}","{'concept_id': {0: 'C0278403'}, 'canonical_name': {0: 'Tissues, Subcutaneous'}, 'aliases': {0: ['Subcutaneous Tissue', 'Fascia, Superficial', 'Superficial Fascia', 'Tela Subcutanea', 'Tissue, Subcutaneous', 'Subcutaneous Tissues', 'Hypodermis']}, 'types': {0: ['T024']}, 'definition': {0: 'Loose connective tissue lying under the DERMIS, which binds SKIN loosely to subjacent tissues. It may contain a pad of ADIPOCYTES, which vary in number according to the area of the body and vary in size according to the nutritional state.'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'SC, subcutaneous.'}}",{},{},"{'concept_id': {0: 'C1857657'}, 'canonical_name': {0: 'Reduced subcutaneous fat'}, 'aliases': {0: ['Reduced fat tissue below the skin', 'Reduced subcutaneous adipose tissue', 'Decreased subcutaneous fat', 'Decreased subcutaneous adipose tissue', 'Scanty adipose tissue']}, 'types': {0: ['T033']}, 'definition': {0: 'A reduced amount of fat tissue in the lowest layer of the integument. This feature can be appreciated by a reduced skinfold thickness. []'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'SC, subcutaneous.'}}","Empty DataFrame
Columns: []
Index: []","[('SC', 'ROUTE'), ('subcutaneous', 'ROUTE')]","{'keyword': {0: 'sc subcutaneous'}, 'score': {0: 0.8459}}"
1972,1972,1972,0.9169999957084656,30.0,References:,ConduitITC-Bold,20,-0.2349999994039535,8194925,38,19,0,"{'concept_id': {0: 'C1561577'}, 'canonical_name': {0: 'Reference - MdfHmdMetSourceType'}, 'aliases': {0: ['Reference']}, 'types': {0: ['T170']}, 'definition': {0: '<p>This row represents a reference to a previously defined type. Such a reference means that, in a given message, the message element instance for the current row is identical to the message element instance that instantiates the referred row.</p>'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}","{'concept_id': {0: 'C0016483'}, 'canonical_name': {0: 'Food Preferences'}, 'aliases': {0: ['Food Preference', 'Preferences, Food', 'Preference, Food']}, 'types': {0: ['T080']}, 'definition': {0: 'The selection of one food over another.'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
1973,1973,1973,0.8830000162124634,22.0,1. PHESGO Summary of Product Characteristics.,MyriadPro-Light,4,-0.25,3355443,38,19,1,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. PHESGO Summary of Product Characteristics.'}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. PHESGO Summary of Product Characteristics.'}}","{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: '1. PHESGO Summary of Product Characteristics.'}}",{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. PHESGO Summary of Product Characteristics.'}}","           entity_group   value     score
0  Diagnostic_procedure  PHESGO  0.828961",[],"{'keyword': {0: 'phesgo summary', 1: 'phesgo summary product', 2: 'summary product', 3: 'summary product characteristics', 4: 'product characteristics'}, 'score': {0: 0.8879, 1: 0.8812, 2: 0.8252, 3: 0.6915, 4: 0.6733}}"
1974,1974,1974,0.8830000162124634,22.0,2. Senkus E et al. Ann Oncol. 2015;26 Suppl 5:v8–30.,MyriadPro-Light,4,-0.25,3355443,38,19,2,{},{},{},{},{},"           entity_group   value     score
0  Detailed_description  Senkus  0.697720
1             Lab_value    2015  0.885578
2             Lab_value      26  0.999859
3  Diagnostic_procedure   Suppl  0.999946
4             Lab_value  2015 5  0.998968",[],"{'keyword': {0: '26 suppl v8', 1: 'v8 30', 2: 'ann oncol 2015', 3: 'al ann oncol', 4: 'et al'}, 'score': {0: 0.8717, 1: 0.8323, 2: 0.7641, 3: 0.7517, 4: 0.6848}}"
1975,1975,1975,0.8830000162124634,22.0,3. Kadcyla Summary of Product Characteristics.,MyriadPro-Light,4,-0.25,3355443,38,19,3,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'Characteristics'}, 'text': {0: '3. Kadcyla Summary of Product Characteristics.'}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'Characteristics'}, 'text': {0: '3. Kadcyla Summary of Product Characteristics.'}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'Characteristics'}, 'text': {0: '3. Kadcyla Summary of Product Characteristics.'}}","           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.796608","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla summary product', 1: 'summary product', 2: 'kadcyla summary', 3: 'summary product characteristics', 4: 'product characteristics'}, 'score': {0: 0.8884, 1: 0.8883, 2: 0.863, 3: 0.7817, 4: 0.7661}}"
1976,1976,1976,0.8830000162124634,22.0,4. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020.,MyriadPro-Light,4,-0.25,3355443,38,19,4,"{'concept_id': {0: 'C1960398'}, 'canonical_name': {0: 'HER2-positive carcinoma of breast'}, 'aliases': {0: ['HER2+ breast cancer', 'HER2 Overexpressing Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast (disorder)', 'HER2-Positive Breast Carcinoma', 'HER2 Overexpressing Subtype of Breast Carcinoma', 'HER2-positive breast cancer', 'HER2/neu-positive breast cancer', 'ERBB2 Overexpressing Subtype of Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast', 'HER2 Positive Breast Carcinoma', 'HER2 Positive Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).'}, 'entity': {0: 'HER2-positive'}, 'text': {0: '4. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020.'}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'treatment'}, 'text': {0: '4. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020.'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'Trastuzumab'}, 'text': {0: '4. National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020.'}}",{},{},"           entity_group                value     score
0            Medication          Trastuzumab  0.999841
1            Medication            emtansine  0.995490
2  Detailed_description             adjuvant  0.609343
3             Lab_value  HER2-positive TA632  0.996677
4             Lab_value        HER2-positive  0.734865
5  Detailed_description                early  0.694268
6  Biological_structure               breast  0.949489","[('Trastuzumab', 'DRUG')]","{'keyword': {0: 'emtansine adjuvant treatment', 1: 'health care excellence', 2: 'breast cancer', 3: 'national institute', 4: 'positive early'}, 'score': {0: 0.85, 1: 0.7941, 2: 0.6912, 3: 0.6556, 4: 0.5471}}"
1977,1977,1977,0.8830000162124634,22.0,5. Scottish Medicines Consortium. SMC2298. November 2020.,MyriadPro-Light,4,-0.25,3355443,38,19,5,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'medicines consortium smc2298', 1: 'consortium smc2298 november', 2: 'scottish medicines', 3: 'smc2298 november', 4: 'november 2020'}, 'score': {0: 0.9043, 1: 0.8859, 2: 0.8666, 3: 0.8427, 4: 0.8187}}"
1978,1978,1978,0.8830000162124634,22.0,6. Herceptin subcutaneous Summary of Product Characteristics.,MyriadPro-Light,4,-0.25,3355443,38,19,6,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'Characteristics'}, 'text': {0: '6. Herceptin subcutaneous Summary of Product Characteristics.'}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'Characteristics'}, 'text': {0: '6. Herceptin subcutaneous Summary of Product Characteristics.'}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'Characteristics'}, 'text': {0: '6. Herceptin subcutaneous Summary of Product Characteristics.'}}","  entity_group      value     score
0   Medication  Herceptin  0.880854","[('Herceptin', 'DRUG'), ('subcutaneous', 'ROUTE')]","{'keyword': {0: 'herceptin subcutaneous summary', 1: 'herceptin subcutaneous', 2: 'subcutaneous summary product', 3: 'summary product', 4: 'product characteristics'}, 'score': {0: 0.9008, 1: 0.8654, 2: 0.8533, 3: 0.8102, 4: 0.6386}}"
1979,1979,1979,0.8830000162124634,22.0,7. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management (NG101). July 2018.,MyriadPro-Light,4,-0.25,3355443,38,19,7,"{'concept_id': {0: 'C1273870'}, 'canonical_name': {0: 'Management procedure'}, 'aliases': {0: ['Supervision', 'Management procedure', 'Managing', 'Oversight', 'management procedures', 'Management', 'management procedure', 'Managed', 'Management procedure (procedure)']}, 'types': {0: ['T057']}, 'definition': {0: 'The act of conducting, controlling or supervising something.'}, 'entity': {0: 'management'}, 'text': {0: '7. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management (NG101). July 2018.'}}","{'concept_id': {0: 'C0031249'}, 'canonical_name': {0: 'Control, Pest'}, 'aliases': {0: ['Pest Management', 'Management, Pest', 'Pest Control']}, 'types': {0: ['T057']}, 'definition': {0: 'The reduction or regulation of the population of noxious, destructive, or dangerous plants, insects, or other animals. This includes control of plants that serve as habitats or food sources for animal pests.'}, 'entity': {0: 'management'}, 'text': {0: '7. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management (NG101). July 2018.'}}",{},"{'concept_id': {0: 'C1818858'}, 'canonical_name': {0: 'early phagosome'}, 'aliases': {0: ['early phagocytic vesicle']}, 'types': {0: ['T026']}, 'definition': {0: 'A membrane-bounded intracellular vesicle as initially formed upon the ingestion of particulate material by phagocytosis. [GOC:mah, PMID:12388753]'}, 'entity': {0: 'Early'}, 'text': {0: '7. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management (NG101). July 2018.'}}","{'concept_id': {0: 'C0001816'}, 'canonical_name': {0: 'Agnosia'}, 'aliases': {0: []}, 'types': {0: ['T048']}, 'definition': {0: 'Loss of the ability to comprehend the meaning or recognize the importance of various forms of stimulation that cannot be attributed to impairment of a primary sensory modality. Tactile agnosia is characterized by an inability to perceive the shape and nature of an object by touch alone, despite unimpaired sensation to light touch, position, and other primary sensory modalities.'}, 'entity': {0: 'diagnosis'}, 'text': {0: '7. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management (NG101). July 2018.'}}","           entity_group   value     score
0  Biological_structure  breast  0.999369",[],"{'keyword': {0: 'management ng101 july', 1: 'breast cancer', 2: 'cancer diagnosis', 3: 'national institute', 4: 'early locally advanced'}, 'score': {0: 0.8481, 1: 0.7306, 2: 0.6741, 3: 0.6652, 4: 0.6185}}"
1980,1980,1980,0.8830000162124634,22.0,8. Scottish Medicines Consortium. SMC928/13. January 2014.,MyriadPro-Light,4,-0.25,3355443,38,19,8,{},{},{},{},{},"           entity_group      value     score
0  Diagnostic_procedure  SMC928/13  0.997028
1                  Date       2014  0.903686",[],"{'keyword': {0: 'medicines consortium smc928', 1: 'scottish medicines', 2: 'smc928 13', 3: 'january 2014', 4: '13 january'}, 'score': {0: 0.8924, 1: 0.8587, 2: 0.8477, 3: 0.8308, 4: 0.7955}}"
1981,1981,1981,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,38,20,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1982,1982,1982,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,38,20,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1983,1983,1983,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,38,20,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
1984,1984,1984,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,38,20,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1985,1985,1985,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,38,21,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
1986,1986,1986,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,38,21,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
1987,1987,1987,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,38,21,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
1988,1988,1988,0.9169999957084656,98.0,Dosing and administration,ConduitITC-Bold,20,-0.2349999994039535,8194925,39,0,0,"{'concept_id': {0: 'C0001563'}, 'canonical_name': {0: 'Administration, Oral'}, 'aliases': {0: ['oral medication administration', 'oral administration', 'oral enteral administration', 'PO administration', 'Administrations, Oral', 'administration oral', 'Drug Administration, Oral', 'Medication administration: oral', 'Oral Administration', 'Oral Drug Administration', 'Oral Drug Administrations', 'Administration of drug or medicament via oral route (procedure)', 'Administrations, Oral Drug', 'per os administration', 'Oral Administrations', 'Administration of drug or medicament via oral route', 'Administration, Oral Drug', 'Drug Administrations, Oral']}, 'types': {0: ['T061']}, 'definition': {0: 'The giving of drugs, chemicals, or other substances by mouth.'}, 'entity': {0: 'administration'}, 'text': {0: 'Dosing and administration'}}","{'concept_id': {0: 'C4505223'}, 'canonical_name': {0: 'Mass Drug Administration'}, 'aliases': {0: ['Mass Administration', 'Drug Administration, Mass', 'Mass Drug Administrations', 'Mass Administrations']}, 'types': {0: ['T061']}, 'definition': {0: 'Administration of a medication to at-risk individuals in a population without individual diagnosis. It is often used in order to treat, control, and/or prevent spread of often endemic DISEASE OUTBREAKS such as NEGLECTED DISEASES in high disease burden areas.'}, 'entity': {0: 'administration'}, 'text': {0: 'Dosing and administration'}}",{},{},{},"     entity_group           value     score
0  Clinical_event          Dosing  0.814939
1  Clinical_event  administration  0.920820",[],"{'keyword': {0: 'dosing administration'}, 'score': {0: 0.8001}}"
1989,1989,1989,0.8830000162124634,28.0,• ,MyriadPro-Light,4,-0.25,16162586,39,1,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1990,1990,1990,0.8830000162124634,28.0,"In the adjuvant setting, Kadcyla should be administered for a total of 14, 3-week  ",MyriadPro-Light,4,-0.25,3355443,39,2,0,"{'concept_id': {0: 'C1621583'}, 'canonical_name': {0: 'Administer - dosing instruction imperative'}, 'aliases': {0: ['Administer - dosing instruction imperative', 'Administer', 'Administer - dosing instruction imperative (qualifier value)']}, 'types': {0: ['T169']}, 'definition': {0: 'To dispense, apply, or tender something to another, such as administering a medicine.'}, 'entity': {0: 'administered'}, 'text': {0: 'In the adjuvant setting, Kadcyla should be administered for a total of 14, 3-week  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'In the adjuvant setting, Kadcyla should be administered for a total of 14, 3-week  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'In the adjuvant setting, Kadcyla should be administered for a total of 14, 3-week  '}}",{},{},"  entity_group          value     score
0   Medication        Kadcyla  0.990637
1     Duration  14 , , 3-week  0.995443","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'total 14 week', 1: 'adjuvant setting', 2: 'kadcyla administered', 3: 'setting kadcyla', 4: 'administered total'}, 'score': {0: 0.8248, 1: 0.7342, 2: 0.7197, 3: 0.6872, 4: 0.5765}}"
1991,1991,1991,0.8830000162124634,28.0,"cycles, or until disease recurrence or unmanageable toxicity.",MyriadPro-Light,4,-0.25,3355443,39,2,1,"{'concept_id': {0: 'C0242890'}, 'canonical_name': {0: 'Toxicity Tests'}, 'aliases': {0: ['toxicity tests', 'testing toxicity', 'Test, Toxicity', 'Toxicity testing', 'Toxicity Testing', 'toxicity test', 'Toxicity Test', 'Tests, Toxicity']}, 'types': {0: ['T060']}, 'definition': {0: 'An array of tests used to determine the toxicity of a substance to living systems. These include tests on clinical drugs, foods, and environmental pollutants.'}, 'entity': {0: 'toxicity'}, 'text': {0: 'cycles, or until disease recurrence or unmanageable toxicity.'}}","{'concept_id': {0: 'C0013221'}, 'canonical_name': {0: 'Toxicity, Drug'}, 'aliases': {0: ['Drug Toxicities', 'Drug Toxicity', 'Toxicities, Drug']}, 'types': {0: ['T037']}, 'definition': {0: 'An adverse effect of a drug used therapeutically or diagnostically.'}, 'entity': {0: 'toxicity'}, 'text': {0: 'cycles, or until disease recurrence or unmanageable toxicity.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'recurrence unmanageable toxicity', 1: 'unmanageable toxicity', 2: 'recurrence unmanageable', 3: 'cycles disease', 4: 'cycles disease recurrence'}, 'score': {0: 0.8662, 1: 0.8486, 2: 0.8234, 3: 0.8177, 4: 0.7523}}"
1992,1992,1992,0.8830000162124634,25.0,First infusion,MyriadPro-Light,4,-0.25,5723991,39,3,0,"{'concept_id': {0: 'C1827465'}, 'canonical_name': {0: 'Infusion route'}, 'aliases': {0: ['Infusion Method of Administration', 'Infusion']}, 'types': {0: ['T169']}, 'definition': {0: 'The technique of administration of a pharmaceutical product, usually slowly and in larger volumes than for an injection, by introducing it into the body, usually after puncturing the skin; it is usually administered intravenously, but occasionally by other routes, e.g. subcutaneously.'}, 'entity': {0: 'First infusion'}, 'text': {0: 'First infusion'}}",{},{},{},{},"     entity_group     value     score
0  Administration  infusion  0.877367",[],"{'keyword': {}, 'score': {}}"
1993,1993,1993,0.8830000162124634,25.0,Every 3 weeks for  ,MyriadPro-Light,4,-0.25,5723991,39,3,1,"{'concept_id': {0: 'C4288440'}, 'canonical_name': {0: 'Past 2 Weeks'}, 'aliases': {0: ['Last 2 Weeks', 'Past Two Weeks', 'Last Two Weeks']}, 'types': {0: ['T079']}, 'definition': {0: 'A period of time consisting of the 14 days before the present.'}, 'entity': {0: 'weeks'}, 'text': {0: 'Every 3 weeks for  '}}","{'concept_id': {0: 'C0331595'}, 'canonical_name': {0: 'Leeks'}, 'aliases': {0: ['Leek']}, 'types': {0: ['T168']}, 'definition': {0: 'Onion like roots from Allium porrum.'}, 'entity': {0: 'weeks'}, 'text': {0: 'Every 3 weeks for  '}}",{},{},{},"  entity_group          value     score
0    Frequency  Every 3 weeks  0.998906
1    Frequency            for  0.853285",[],"{'keyword': {}, 'score': {}}"
1994,1994,1994,0.8830000162124634,25.0,up to 14 cycles,MyriadPro-Light,4,-0.25,5723991,39,3,2,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: 'up to 14 cycles'}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: 'up to 14 cycles'}}",{},{},{},"           entity_group   value     score
0             Lab_value      up  0.524413
1  Detailed_description   to 14  0.656414
2  Quantitative_concept  cycles  0.484756","[('up to 14 cycles', 'DURATION')]","{'keyword': {0: '14 cycles'}, 'score': {0: 0.7684}}"
1995,1995,1995,0.9520000219345092,28.0,Kadcyla,MyriadPro-Regular,4,-0.25,8194925,39,4,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.784572",[],"{'keyword': {}, 'score': {}}"
1996,1996,1996,0.8830000162124634,28.0,•,MyriadPro-Light,4,-0.25,16162586,39,5,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
1997,1997,1997,0.8830000162124634,28.0,and for at least 90 minutes following the initial ,MyriadPro-Light,4,-0.25,3355443,39,5,1,{},{},{},{},{},"           entity_group       value     score
0              Duration  90 minutes  0.992977
1  Detailed_description     initial  0.999756",[],"{'keyword': {0: '90 minutes following', 1: 'following initial', 2: '90 minutes', 3: 'minutes following initial', 4: 'minutes following'}, 'score': {0: 0.837, 1: 0.7988, 2: 0.7704, 3: 0.7606, 4: 0.7262}}"
1998,1998,1998,0.8830000162124634,28.0,"infusion for fever, chills, or other infusion-related ",MyriadPro-Light,4,-0.25,3355443,39,5,2,"{'concept_id': {0: 'C0948715'}, 'canonical_name': {0: 'Infusion-Related Reaction'}, 'aliases': {0: ['Infusion-Related Reaction', 'Infusion Related Reaction']}, 'types': {0: ['T046']}, 'definition': {0: 'A reaction to the infusion of pharmacological or biological substances. Symptoms may appear within minutes to hours following the infusion and may include pruritus, flushing, swelling, dyspnea, bronchospasm, and hypotension.'}, 'entity': {0: 'infusion-related'}, 'text': {0: 'infusion for fever, chills, or other infusion-related '}}","{'concept_id': {0: 'C0085593'}, 'canonical_name': {0: 'Chills'}, 'aliases': {0: []}, 'types': {0: ['T184']}, 'definition': {0: 'The sudden sensation of being cold. It may be accompanied by SHIVERING.'}, 'entity': {0: 'chills'}, 'text': {0: 'infusion for fever, chills, or other infusion-related '}}",{},"{'concept_id': {0: 'C3158581'}, 'canonical_name': {0: 'fever generation'}, 'aliases': {0: []}, 'types': {0: ['T046']}, 'definition': {0: 'The heat generation process that results in a rise in body temperature above the normal, often as a response to infection. [GOC:dph, GOC:jl]'}, 'entity': {0: 'fever'}, 'text': {0: 'infusion for fever, chills, or other infusion-related '}}","{'concept_id': {0: 'C0085593'}, 'canonical_name': {0: 'Chills'}, 'aliases': {0: []}, 'types': {0: ['T184']}, 'definition': {0: 'The sudden sensation of being cold. It may be accompanied by SHIVERING.'}, 'entity': {0: 'chills'}, 'text': {0: 'infusion for fever, chills, or other infusion-related '}}","           entity_group                      value     score
0        Administration  infusion infusion-related  0.997939
1          Sign_symptom                     chills  0.986109
2  Detailed_description           infusion-related  0.862600",[],"{'keyword': {0: 'infusion related', 1: 'chills infusion related', 2: 'chills infusion', 3: 'infusion fever', 4: 'fever chills'}, 'score': {0: 0.8786, 1: 0.8363, 2: 0.7522, 3: 0.704, 4: 0.5891}}"
1999,1999,1999,0.8830000162124634,28.0,reactions. The infusion site should be closely ,MyriadPro-Light,4,-0.25,3355443,39,5,3,"{'concept_id': {0: 'C1827465'}, 'canonical_name': {0: 'Infusion route'}, 'aliases': {0: ['Infusion Method of Administration', 'Infusion']}, 'types': {0: ['T169']}, 'definition': {0: 'The technique of administration of a pharmaceutical product, usually slowly and in larger volumes than for an injection, by introducing it into the body, usually after puncturing the skin; it is usually administered intravenously, but occasionally by other routes, e.g. subcutaneously.'}, 'entity': {0: 'infusion site'}, 'text': {0: 'reactions. The infusion site should be closely '}}",{},{},{},{},"            entity_group          value     score
0  Therapeutic_procedure       infusion  0.998410
1  Therapeutic_procedure  infusion site  0.980573
2   Detailed_description        closely  0.934629",[],"{'keyword': {0: 'reactions infusion', 1: 'site closely', 2: 'reactions infusion site', 3: 'infusion site closely', 4: 'infusion site'}, 'score': {0: 0.7971, 1: 0.789, 2: 0.7793, 3: 0.7053, 4: 0.6571}}"
2000,2000,2000,0.8830000162124634,28.0,monitored for possible SC infiltration during ,MyriadPro-Light,4,-0.25,3355443,39,5,4,"{'concept_id': {0: 'C1523986'}, 'canonical_name': {0: 'Infiltration Route of Drug Administration'}, 'aliases': {0: ['Infiltration', 'Infiltration Route of Administration']}, 'types': {0: ['T169']}, 'definition': {0: 'Route of drug administration that results in substances passing into tissue spaces or intracellularly.'}, 'entity': {0: 'infiltration'}, 'text': {0: 'monitored for possible SC infiltration during '}}","{'concept_id': {0: 'C0751982'}, 'canonical_name': {0: 'Neutrophil Infiltration'}, 'aliases': {0: ['Neutrophil Recruitment', 'Infiltration, Neutrophil', 'Recruitment, Neutrophil']}, 'types': {0: ['T039']}, 'definition': {0: 'The diffusion or accumulation of neutrophils in tissues or cells in response to a wide variety of substances released at the sites of inflammatory reactions.'}, 'entity': {0: 'infiltration'}, 'text': {0: 'monitored for possible SC infiltration during '}}",{},"{'concept_id': {0: 'C3269157'}, 'canonical_name': {0: 'renal filtration'}, 'aliases': {0: []}, 'types': {0: ['T039']}, 'definition': {0: 'A renal system process in which fluid circulating through the body is filtered through a barrier system. [GOC:pr, GOC:sart]'}, 'entity': {0: 'infiltration'}, 'text': {0: 'monitored for possible SC infiltration during '}}","{'concept_id': {0: 'C2711227'}, 'canonical_name': {0: 'Hepatic steatosis'}, 'aliases': {0: ['Liver steatosis', 'Steatosis', 'Fatty liver', 'Fatty infiltration of liver']}, 'types': {0: ['T047']}, 'definition': {0: 'Inflammation of the liver related to lipid accumulation in fatty liver.'}, 'entity': {0: 'infiltration'}, 'text': {0: 'monitored for possible SC infiltration during '}}","       entity_group value     score
0  Disease_disorder    SC  0.999756",[],"{'keyword': {0: 'monitored possible sc', 1: 'monitored possible', 2: 'possible sc infiltration', 3: 'sc infiltration', 4: 'possible sc'}, 'score': {0: 0.906, 1: 0.8901, 2: 0.7562, 3: 0.7407, 4: 0.7266}}"
2001,2001,2001,0.8830000162124634,28.0,administration,MyriadPro-Light,4,-0.25,3355443,39,5,5,"{'concept_id': {0: 'C0001563'}, 'canonical_name': {0: 'Administration, Oral'}, 'aliases': {0: ['oral medication administration', 'oral administration', 'oral enteral administration', 'PO administration', 'Administrations, Oral', 'administration oral', 'Drug Administration, Oral', 'Medication administration: oral', 'Oral Administration', 'Oral Drug Administration', 'Oral Drug Administrations', 'Administration of drug or medicament via oral route (procedure)', 'Administrations, Oral Drug', 'per os administration', 'Oral Administrations', 'Administration of drug or medicament via oral route', 'Administration, Oral Drug', 'Drug Administrations, Oral']}, 'types': {0: ['T061']}, 'definition': {0: 'The giving of drugs, chemicals, or other substances by mouth.'}, 'entity': {0: 'administration'}, 'text': {0: 'administration'}}","{'concept_id': {0: 'C4505223'}, 'canonical_name': {0: 'Mass Drug Administration'}, 'aliases': {0: ['Mass Administration', 'Drug Administration, Mass', 'Mass Drug Administrations', 'Mass Administrations']}, 'types': {0: ['T061']}, 'definition': {0: 'Administration of a medication to at-risk individuals in a population without individual diagnosis. It is often used in order to treat, control, and/or prevent spread of often endemic DISEASE OUTBREAKS such as NEGLECTED DISEASES in high disease burden areas.'}, 'entity': {0: 'administration'}, 'text': {0: 'administration'}}",{},{},{},"           entity_group           value     score
0  Diagnostic_procedure  administration  0.509965",[],"{'keyword': {}, 'score': {}}"
2002,2002,2002,0.9520000219345092,26.0,3.6 mg/kg bodyweight  ,MyriadPro-Regular,4,-0.25,16777215,39,6,0,{},{},{},{},{},"           entity_group       value     score
0             Lab_value   3.6 mg/kg  0.999857
1  Diagnostic_procedure  bodyweight  0.987930",[],"{'keyword': {0: 'mg kg', 1: 'mg kg bodyweight', 2: 'kg bodyweight'}, 'score': {0: 0.7497, 1: 0.7375, 2: 0.6374}}"
2003,2003,2003,0.9520000219345092,26.0,administered over 90 minutes,MyriadPro-Regular,4,-0.25,16777215,39,6,1,"{'concept_id': {0: 'C1282918'}, 'canonical_name': {0: 'Minute (diminutive)'}, 'aliases': {0: ['Minute', 'Minuscule (qualifier value)', 'Minuscule', 'minute', 'minutes']}, 'types': {0: ['T081']}, 'definition': {0: 'Extremely small in size or amount.'}, 'entity': {0: 'minutes'}, 'text': {0: 'administered over 90 minutes'}}",{},{},{},{},"  entity_group            value     score
0     Duration  over 90 minutes  0.990136","[('over 90 minutes', 'DURATION')]","{'keyword': {0: 'administered 90 minutes', 1: 'administered 90', 2: '90 minutes'}, 'score': {0: 0.9184, 1: 0.8819, 2: 0.6934}}"
2004,2004,2004,0.9520000219345092,26.0,3.6 mg/kg bodyweight  ,MyriadPro-Regular,4,-0.25,16777215,39,6,2,{},{},{},{},{},"           entity_group       value     score
0             Lab_value   3.6 mg/kg  0.999857
1  Diagnostic_procedure  bodyweight  0.987930",[],"{'keyword': {0: 'mg kg', 1: 'mg kg bodyweight', 2: 'kg bodyweight'}, 'score': {0: 0.7497, 1: 0.7375, 2: 0.6374}}"
2005,2005,2005,0.9520000219345092,26.0,administered over 30 minutes,MyriadPro-Regular,4,-0.25,16777215,39,6,3,"{'concept_id': {0: 'C1282918'}, 'canonical_name': {0: 'Minute (diminutive)'}, 'aliases': {0: ['Minute', 'Minuscule (qualifier value)', 'Minuscule', 'minute', 'minutes']}, 'types': {0: ['T081']}, 'definition': {0: 'Extremely small in size or amount.'}, 'entity': {0: 'minutes'}, 'text': {0: 'administered over 30 minutes'}}",{},{},{},{},"  entity_group            value     score
0     Duration  over 30 minutes  0.993062","[('over 30 minutes', 'DURATION')]","{'keyword': {0: 'administered 30 minutes', 1: 'administered 30', 2: '30 minutes'}, 'score': {0: 0.9077, 1: 0.8952, 2: 0.6641}}"
2006,2006,2006,0.8830000162124634,28.0,•,MyriadPro-Light,4,-0.25,16162586,39,7,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
2007,2007,2007,0.8830000162124634,28.0,doses of Kadcyla may be administered as ,MyriadPro-Light,4,-0.25,3355443,39,7,1,"{'concept_id': {0: 'C1621583'}, 'canonical_name': {0: 'Administer - dosing instruction imperative'}, 'aliases': {0: ['Administer - dosing instruction imperative', 'Administer', 'Administer - dosing instruction imperative (qualifier value)']}, 'types': {0: ['T169']}, 'definition': {0: 'To dispense, apply, or tender something to another, such as administering a medicine.'}, 'entity': {0: 'administered'}, 'text': {0: 'doses of Kadcyla may be administered as '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'doses of Kadcyla may be administered as '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'doses of Kadcyla may be administered as '}}",{},{},"  entity_group    value     score
0   Medication  Kadcyla  0.957851","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'doses kadcyla administered', 1: 'kadcyla administered', 2: 'doses kadcyla'}, 'score': {0: 0.7049, 1: 0.6491, 2: 0.6202}}"
2008,2008,2008,0.8830000162124634,28.0,30-minute infusions. Patients should be observed ,MyriadPro-Light,4,-0.25,3355443,39,7,2,"{'concept_id': {0: 'C0017313'}, 'canonical_name': {0: 'patient care'}, 'aliases': {0: ['caring patient', 'Patient Care', 'patient care', 'Care, Patient', 'Patient Care Delivery', 'caring patients']}, 'types': {0: ['T058']}, 'definition': {0: 'The services rendered by members of the health profession and non-professionals under their supervision.'}, 'entity': {0: 'Patients'}, 'text': {0: '30-minute infusions. Patients should be observed '}}","{'concept_id': {0: 'C0029921'}, 'canonical_name': {0: 'Outpatients'}, 'aliases': {0: ['Out-patients', 'Out-patient', 'Out patients', 'Outpatient']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.'}, 'entity': {0: 'Patients'}, 'text': {0: '30-minute infusions. Patients should be observed '}}",{},{},{},"           entity_group                value     score
0                Dosage            30-minute  0.909977
1        Administration  30-minute infusions  0.501553
2        Administration            infusions  0.934590
3  Diagnostic_procedure             observed  0.629627",[],"{'keyword': {0: 'patients observed', 1: 'infusions patients observed', 2: 'infusions patients', 3: '30 minute', 4: 'minute infusions'}, 'score': {0: 0.7958, 1: 0.76, 2: 0.5876, 3: 0.5262, 4: 0.4896}}"
2009,2009,2009,0.8830000162124634,28.0,during the infusion and for at least 30 minutes after ,MyriadPro-Light,4,-0.25,3355443,39,7,3,"{'concept_id': {0: 'C2964135'}, 'canonical_name': {0: 'Infusion Rate'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'The volume of a substance injected into a subject in a unit time.'}, 'entity': {0: 'infusion'}, 'text': {0: 'during the infusion and for at least 30 minutes after '}}","{'concept_id': {0: 'C1136122'}, 'canonical_name': {0: 'Infusions, Intralesional'}, 'aliases': {0: ['Infusion, Intralesional', 'Intralesional Infusion', 'Intralesional Infusions']}, 'types': {0: ['T061']}, 'definition': {0: 'The administration of medication or fluid directly into localized lesions, by means of gravity flow or INFUSION PUMPS.'}, 'entity': {0: 'infusion'}, 'text': {0: 'during the infusion and for at least 30 minutes after '}}",{},{},"{'concept_id': {0: 'C0009676'}, 'canonical_name': {0: 'Easily confused'}, 'aliases': {0: ['Confusion', 'Disorientation', 'Mental disorientation']}, 'types': {0: ['T048']}, 'definition': {0: 'A mental state characterized by bewilderment, emotional disturbance, lack of clear thinking, and perceptual disorientation.'}, 'entity': {0: 'infusion'}, 'text': {0: 'during the infusion and for at least 30 minutes after '}}","            entity_group                    value     score
0  Therapeutic_procedure  during infusion minutes  0.999351
1  Therapeutic_procedure                 infusion  0.739365
2               Duration               30 minutes  0.971139
3   Detailed_description                    after  0.491157",[],"{'keyword': {0: 'infusion 30 minutes', 1: '30 minutes', 2: 'infusion 30'}, 'score': {0: 0.8153, 1: 0.7444, 2: 0.6991}}"
2010,2010,2010,0.8830000162124634,28.0,infusion,MyriadPro-Light,4,-0.25,3355443,39,7,4,"{'concept_id': {0: 'C2964135'}, 'canonical_name': {0: 'Infusion Rate'}, 'aliases': {0: []}, 'types': {0: ['T079']}, 'definition': {0: 'The volume of a substance injected into a subject in a unit time.'}, 'entity': {0: 'infusion'}, 'text': {0: 'infusion'}}","{'concept_id': {0: 'C1136122'}, 'canonical_name': {0: 'Infusions, Intralesional'}, 'aliases': {0: ['Infusion, Intralesional', 'Intralesional Infusion', 'Intralesional Infusions']}, 'types': {0: ['T061']}, 'definition': {0: 'The administration of medication or fluid directly into localized lesions, by means of gravity flow or INFUSION PUMPS.'}, 'entity': {0: 'infusion'}, 'text': {0: 'infusion'}}",{},{},"{'concept_id': {0: 'C0009676'}, 'canonical_name': {0: 'Easily confused'}, 'aliases': {0: ['Confusion', 'Disorientation', 'Mental disorientation']}, 'types': {0: ['T048']}, 'definition': {0: 'A mental state characterized by bewilderment, emotional disturbance, lack of clear thinking, and perceptual disorientation.'}, 'entity': {0: 'infusion'}, 'text': {0: 'infusion'}}","     entity_group     value     score
0  Administration  infusion  0.998245",[],"{'keyword': {}, 'score': {}}"
2011,2011,2011,0.8830000162124634,28.0,•,MyriadPro-Light,4,-0.25,16162586,39,8,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
2012,2012,2012,0.8830000162124634,28.0,important to check the vial labels to ensure that the ,MyriadPro-Light,4,-0.25,3355443,39,8,1,"{'concept_id': {0: 'C0037914'}, 'canonical_name': {0: 'Spin Labels'}, 'aliases': {0: ['spin label', 'labeling spin', 'Spin Label', 'Spin labels', 'Label, Spin', 'spin labels', 'Labels, Spin']}, 'types': {0: ['T130']}, 'definition': {0: 'Molecules which contain an atom or a group of atoms exhibiting an unpaired electron spin that can be detected by electron spin resonance spectroscopy and can be bonded to another molecule. (McGraw-Hill Dictionary of Chemical and Technical Terms, 4th ed)'}, 'entity': {0: 'vial labels'}, 'text': {0: 'important to check the vial labels to ensure that the '}}",{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'check vial labels', 1: 'labels ensure', 2: 'important check', 3: 'important check vial', 4: 'vial labels'}, 'score': {0: 0.5439, 1: 0.5143, 2: 0.5137, 3: 0.474, 4: 0.3515}}"
2013,2013,2013,0.8830000162124634,28.0,medicinal product being prepared is trastuzumab ,MyriadPro-Light,4,-0.25,3355443,39,8,2,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'medicinal product being prepared is trastuzumab '}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'medicinal product being prepared is trastuzumab '}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'medicinal product being prepared is trastuzumab '}}",{},{},"  entity_group        value     score
0  Coreference      product  0.778501
1   Medication  trastuzumab  0.999902","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'medicinal product', 1: 'medicinal product prepared', 2: 'product prepared', 3: 'product prepared trastuzumab', 4: 'prepared trastuzumab'}, 'score': {0: 0.9164, 1: 0.8845, 2: 0.8811, 3: 0.8666, 4: 0.8315}}"
2014,2014,2014,0.8830000162124634,28.0,emtansine and not trastuzumab,MyriadPro-Light,4,-0.25,3355443,39,8,3,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'emtansine and not trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'emtansine and not trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'emtansine and not trastuzumab'}}",{},{},"  entity_group        value     score
0   Medication    emtansine  0.999263
1   Medication  trastuzumab  0.999742","[('emtansine', 'DRUG'), ('trastuzumab', 'DRUG')]","{'keyword': {0: 'emtansine trastuzumab'}, 'score': {0: 0.7507}}"
2015,2015,2015,0.8830000162124634,19.0,"IV, intravenous; SC, subcutaneous. ",MyriadPro-Light,4,-0.25,3355443,39,9,0,"{'concept_id': {0: 'C0222331'}, 'canonical_name': {0: 'Subcutaneous Fat'}, 'aliases': {0: ['subcutaneous adipose tissue', 'Subcutaneous Fats', 'Subcutaneous adipose tissue', 'Panniculus adiposus', 'Panniculus adiposus telae subcutaneae', 'Subcutaneous fatty tissue', 'paniculus adiposus', 'Structure of subcutaneous fatty tissue', 'Fat, Subcutaneous', 'Subcutaneous fat', 'Paniculus adiposus', 'subcutaneous fat', 'Subcutaneous Fat', 'Subcutaneous Tissue', 'Structure of subcutaneous fatty tissue (body structure)', 'Panniculus adiposus (Tela subcutanea)', 'fat subcutaneous', 'Fatty layer of subcutaneous tissue', 'Subcutis', 'Fats, Subcutaneous', 'Subcutaneous Adipose Tissue', 'Fatty layer of superficial fascia', 'Adipose Tissue, Subcutaneous']}, 'types': {0: ['T024']}, 'definition': {0: 'Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'IV, intravenous; SC, subcutaneous. '}}","{'concept_id': {0: 'C0278403'}, 'canonical_name': {0: 'Tissues, Subcutaneous'}, 'aliases': {0: ['Subcutaneous Tissue', 'Fascia, Superficial', 'Superficial Fascia', 'Tela Subcutanea', 'Tissue, Subcutaneous', 'Subcutaneous Tissues', 'Hypodermis']}, 'types': {0: ['T024']}, 'definition': {0: 'Loose connective tissue lying under the DERMIS, which binds SKIN loosely to subjacent tissues. It may contain a pad of ADIPOCYTES, which vary in number according to the area of the body and vary in size according to the nutritional state.'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'IV, intravenous; SC, subcutaneous. '}}",{},{},"{'concept_id': {0: 'C1857657'}, 'canonical_name': {0: 'Reduced subcutaneous fat'}, 'aliases': {0: ['Reduced fat tissue below the skin', 'Reduced subcutaneous adipose tissue', 'Decreased subcutaneous fat', 'Decreased subcutaneous adipose tissue', 'Scanty adipose tissue']}, 'types': {0: ['T033']}, 'definition': {0: 'A reduced amount of fat tissue in the lowest layer of the integument. This feature can be appreciated by a reduced skinfold thickness. []'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'IV, intravenous; SC, subcutaneous. '}}","     entity_group                     value     score
0  Administration               intravenous  0.999613
1  Administration  intravenous subcutaneous  0.884820","[('IV', 'ROUTE'), ('intravenous', 'ROUTE'), ('SC', 'ROUTE'), ('subcutaneous', 'ROUTE')]","{'keyword': {0: 'iv intravenous sc', 1: 'intravenous sc subcutaneous', 2: 'intravenous sc', 3: 'sc subcutaneous', 4: 'iv intravenous'}, 'score': {0: 0.8242, 1: 0.8017, 2: 0.7457, 3: 0.7346, 4: 0.5646}}"
2016,2016,2016,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,39,11,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
2017,2017,2017,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,39,11,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
2018,2018,2018,0.8830000162124634,35.0,MOA,MyriadPro-Light,4,-0.25,9211020,39,11,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
2019,2019,2019,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,39,11,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
2020,2020,2020,0.75,98.0,Consider the whole HER2-positive eBC treatment ,ConduitITC-Bold,20,-0.1700000017881393,8194925,40,1,0,"{'concept_id': {0: 'C1960398'}, 'canonical_name': {0: 'HER2-positive carcinoma of breast'}, 'aliases': {0: ['HER2+ breast cancer', 'HER2 Overexpressing Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast (disorder)', 'HER2-Positive Breast Carcinoma', 'HER2 Overexpressing Subtype of Breast Carcinoma', 'HER2-positive breast cancer', 'HER2/neu-positive breast cancer', 'ERBB2 Overexpressing Subtype of Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast', 'HER2 Positive Breast Carcinoma', 'HER2 Positive Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).'}, 'entity': {0: 'HER2-positive'}, 'text': {0: 'Consider the whole HER2-positive eBC treatment '}}","{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Treatments'}, 'aliases': {0: ['Therapy', 'Treatment', 'Therapeutics', 'Therapeutic', 'Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'eBC treatment'}, 'text': {0: 'Consider the whole HER2-positive eBC treatment '}}",{},{},{},"            entity_group                                           value  \
0              Lab_value                                   HER2-positive   
1  Therapeutic_procedure  Consider the whole HER2-positive eBC treatment   
2  Therapeutic_procedure                                       treatment   

      score  
0  0.803031  
1  0.537932  
2  0.767745  ",[],"{'keyword': {0: 'ebc treatment', 1: 'her2 positive ebc', 2: 'consider her2', 3: 'positive ebc treatment', 4: 'her2 positive'}, 'score': {0: 0.8257, 1: 0.8138, 2: 0.792, 3: 0.768, 4: 0.6419}}"
2021,2021,2021,0.75,98.0,journey today to optimise your patients’ outcomes,ConduitITC-Bold,20,-0.1700000017881393,8194925,40,1,1,"{'concept_id': {0: 'C0086749'}, 'canonical_name': {0: 'Outcome Measures'}, 'aliases': {0: ['measure outcomes', 'measures outcome', 'Measures, Outcome', 'outcome measures', 'outcome measure', 'Outcome Measure', 'Outcome Measures', 'Measure, Outcome', 'measures outcomes']}, 'types': {0: ['T081']}, 'definition': {0: '<p>**Description:**Operational activities conducted for the purposes of assessing the results of an activity, product, or service</p>'}, 'entity': {0: 'outcomes'}, 'text': {0: 'journey today to optimise your patients’ outcomes'}}","{'concept_id': {0: 'C0032972'}, 'canonical_name': {0: 'Pregnancy Outcome'}, 'aliases': {0: ['Pregnancy Outcomes', 'Outcome, Pregnancy', 'Outcomes, Pregnancy']}, 'types': {0: ['T033']}, 'definition': {0: 'Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO.'}, 'entity': {0: 'outcomes'}, 'text': {0: 'journey today to optimise your patients’ outcomes'}}",{},{},{},"           entity_group          value     score
0  Detailed_description  journey today  0.940791
1  Diagnostic_procedure       outcomes  0.483345",[],"{'keyword': {0: 'journey today', 1: 'today optimise patients', 2: 'patients outcomes', 3: 'today optimise', 4: 'optimise patients outcomes'}, 'score': {0: 0.9195, 1: 0.8752, 2: 0.8457, 3: 0.8444, 4: 0.8423}}"
2022,2022,2022,0.944000005722046,24.0,Disease characteristics,UniversSB-Medium,4,-0.2349999994039535,0,40,2,0,"{'concept_id': {0: 'C1705348'}, 'canonical_name': {0: 'Disease Characteristics Domain'}, 'aliases': {0: ['Disease Characteristics Domain']}, 'types': {0: ['T077']}, 'definition': {0: 'A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to disease characteristics.'}, 'entity': {0: 'Disease characteristics'}, 'text': {0: 'Disease characteristics'}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'Disease characteristics'}, 'text': {0: 'Disease characteristics'}}",{},{},{},"           entity_group                    value     score
0  Diagnostic_procedure  Disease characteristics  0.896728",[],"{'keyword': {0: 'disease characteristics'}, 'score': {0: 1.0}}"
2023,2023,2023,0.9470000267028807,24.0,Tumour stage ,UniversSB-Light,4,-0.2329999953508377,0,40,3,0,"{'concept_id': {0: 'C0475455'}, 'canonical_name': {0: 'T - Tumor stage'}, 'aliases': {0: ['T stage', 'T Category', 'T Classification', 'T - Tumour stage', 'T - Tumor stage', 'T - Tumor stage (attribute)', 'Tumour stages', 'Tumor stages', 'T - Tumor stages', 'tumor stages', 'T category (observable entity)', 'T - Tumour stages', 'T category']}, 'types': {0: ['T170']}, 'definition': {0: 'One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).'}, 'entity': {0: 'Tumour stage'}, 'text': {0: 'Tumour stage '}}",{},{},{},"{'concept_id': {0: 'C0027651'}, 'canonical_name': {0: 'Oncology'}, 'aliases': {0: ['Oncological abnormality', 'Neoplasia', 'Tumour', 'Neoplasm', 'Tumor']}, 'types': {0: ['T191']}, 'definition': {0: 'New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.'}, 'entity': {0: 'Tumour stage'}, 'text': {0: 'Tumour stage '}}","   entity_group         value     score
0  Sign_symptom  Tumour stage  0.768214",[],"{'keyword': {0: 'tumour stage'}, 'score': {0: 1.0}}"
2024,2024,2024,0.944000005722046,24.0,Neoadjuvant,UniversSB-Medium,4,-0.2349999994039535,0,40,4,0,"{'concept_id': {0: 'C0001552'}, 'canonical_name': {0: 'Pharmaceutical Adjuvants'}, 'aliases': {0: ['Adjuvants, Pharmaceutic', 'Adjuvant, Pharmaceutical', 'Adjuvant, Pharmaceutic', 'Pharmaceutic Adjuvants', 'Pharmaceutic Adjuvant', 'Adjuvants, Pharmaceutical', 'Pharmaceutical Adjuvant', 'Pharmaceutical Adjuvants', 'Adjuvant', 'ADJ']}, 'types': {0: ['T120']}, 'definition': {0: 'Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.'}, 'entity': {0: 'Neoadjuvant'}, 'text': {0: 'Neoadjuvant'}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'Neoadjuvant'}, 'text': {0: 'Neoadjuvant'}}",{},{},{},"           entity_group        value     score
0  Detailed_description  Neoadjuvant  0.956138
1          Sign_symptom  Neoadjuvant  0.386592
2               History  Neoadjuvant  0.344678",[],"{'keyword': {}, 'score': {}}"
2025,2025,2025,0.9470000267028807,24.0,PHESGO,UniversSB-Light,4,-0.2329999953508377,0,40,4,1,"{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: ['Phesgo']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: 'PHESGO'}}",{},"{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: 'PHESGO'}}",{},{},"   entity_group   value     score
0  Sign_symptom  PHESGO  0.506898
1   Coreference  PHESGO  0.299037","[('PHESGO', 'DRUG')]","{'keyword': {}, 'score': {}}"
2026,2026,2026,0.9470000267028807,24.0, (pertuzumab/trastuzumab) SC plus chemotherapy (3–6 cycles),UniversSB-Light,4,-0.2329999953508377,0,40,4,2,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: ' (pertuzumab/trastuzumab) SC plus chemotherapy (3–6 cycles)'}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: ' (pertuzumab/trastuzumab) SC plus chemotherapy (3–6 cycles)'}}",{},{},{},"       entity_group                   value     score
0        Medication  pertuzumab/trastuzumab  0.999829
1  Disease_disorder                      SC  0.863019
2        Medication            chemotherapy  0.999876
3         Lab_value                     3–6  0.464376","[('trastuzumab', 'DRUG'), ('SC', 'ROUTE'), ('chemotherapy', 'DRUG'), ('3–6 cycles', 'DURATION')]","{'keyword': {0: 'plus chemotherapy cycles', 1: 'trastuzumab sc plus', 2: 'chemotherapy cycles', 3: 'trastuzumab sc', 4: 'pertuzumab trastuzumab'}, 'score': {0: 0.8387, 1: 0.8298, 2: 0.712, 3: 0.6578, 4: 0.3754}}"
2027,2027,2027,0.75,53.0,Kadcyla allows you to ,ConduitITC-Bold,20,-0.1700000017881393,16777215,40,5,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla allows you to '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla allows you to '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla allows you to '}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.475378
1   Medication  Kadcyla  0.717254","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla allows'}, 'score': {0: 0.9278}}"
2028,2028,2028,0.75,53.0,adapt adjuvant therapy ,ConduitITC-Bold,20,-0.1700000017881393,16777215,40,5,1,"{'concept_id': {0: 'C0085533'}, 'canonical_name': {0: 'Chemotherapy, Adjuvant'}, 'aliases': {0: ['Adjuvant Drug Therapy', 'Adjuvant Chemotherapy', 'adjuvant chemotherapy', 'Drug Therapy, Adjuvant']}, 'types': {0: ['T061']}, 'definition': {0: 'Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.'}, 'entity': {0: 'adjuvant therapy'}, 'text': {0: 'adapt adjuvant therapy '}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'adjuvant therapy'}, 'text': {0: 'adapt adjuvant therapy '}}",{},{},{},"            entity_group             value     score
0   Detailed_description             adapt  0.999687
1  Therapeutic_procedure  adjuvant therapy  0.969879",[],"{'keyword': {0: 'adapt adjuvant therapy', 1: 'adapt adjuvant', 2: 'adjuvant therapy'}, 'score': {0: 1.0, 1: 0.9287, 2: 0.8928}}"
2029,2029,2029,0.75,53.0,based on patients’ ,ConduitITC-Bold,20,-0.1700000017881393,16777215,40,5,2,"{'concept_id': {0: 'C1705908'}, 'canonical_name': {0: 'Veterinary Patient'}, 'aliases': {0: ['Veterinary Patient', 'Patient']}, 'types': {0: ['T001']}, 'definition': {0: 'A non-human animal that is a subject in a study.'}, 'entity': {0: 'patients’'}, 'text': {0: 'based on patients’ '}}","{'concept_id': {0: 'C0025360'}, 'canonical_name': {0: 'Mentally Ill Persons'}, 'aliases': {0: ['Mental Patients', 'Person, Mentally Ill', 'Ill, Mentally', 'Mentally Ill Person', 'Persons, Mentally Ill', 'Mentally Ill']}, 'types': {0: ['T101']}, 'definition': {0: 'Persons with psychiatric illnesses or diseases, particularly psychotic and severe mood disorders.'}, 'entity': {0: 'patients’'}, 'text': {0: 'based on patients’ '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'based patients'}, 'score': {0: 0.8565}}"
2030,2030,2030,0.75,53.0,neoadjuvant response,ConduitITC-Bold,20,-0.1700000017881393,16777215,40,5,3,"{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Neoadjuvant Therapy'}, 'aliases': {0: ['Preoperative Therapy', 'Therapy, Neoadjuvant', 'neoadjuvant treatment', 'Neoadjuvant Treatment', 'Neoadjuvant Treatments', 'Neoadjuvant Therapies', 'Neoadjuvant', 'Induction Therapy', 'Neoadjuvant Therapy', 'induction therapy', 'Treatment, Neoadjuvant', 'neoadjuvant therapy']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant response'}, 'text': {0: 'neoadjuvant response'}}","{'concept_id': {0: 'C0600558'}, 'canonical_name': {0: 'Treatment, Neoadjuvant'}, 'aliases': {0: ['Therapy, Neoadjuvant', 'Neoadjuvant Therapy', 'Neoadjuvant Treatments', 'Neoadjuvant Treatment', 'Neoadjuvant Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy.'}, 'entity': {0: 'neoadjuvant response'}, 'text': {0: 'neoadjuvant response'}}",{},{},{},"   entity_group                 value     score
0  Sign_symptom           neoadjuvant  0.998864
1  Sign_symptom  neoadjuvant response  0.993135",[],"{'keyword': {0: 'neoadjuvant response'}, 'score': {0: 1.0}}"
2031,2031,2031,0.944000005722046,24.0,Surgery,UniversSB-Medium,4,-0.2349999994039535,0,40,6,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'Surgery'}, 'text': {0: 'Surgery'}}",{},{},{},"            entity_group    value     score
0  Therapeutic_procedure  Surgery  0.998798",[],"{'keyword': {}, 'score': {}}"
2032,2032,2032,0.9470000267028807,24.0,Clinically,UniversSB-Light,4,-0.2329999953508377,0,40,8,0,"{'concept_id': {0: 'C0205210'}, 'canonical_name': {0: 'Clinical'}, 'aliases': {0: ['Clinical (qualifier value)', 'clinical', 'Clinical']}, 'types': {0: ['T080']}, 'definition': {0: 'Relating to the examination and treatment of patients dependent on direct observation. The term may also refer to the institution (clinic) providing this activity.'}, 'entity': {0: 'Clinically'}, 'text': {0: 'Clinically'}}",{},{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  Clinically  0.966238",[],"{'keyword': {}, 'score': {}}"
2033,2033,2033,0.8830000162124634,24.0,Clinically,MyriadPro-Light,4,-0.25,0,40,9,0,"{'concept_id': {0: 'C0205210'}, 'canonical_name': {0: 'Clinical'}, 'aliases': {0: ['Clinical (qualifier value)', 'clinical', 'Clinical']}, 'types': {0: ['T080']}, 'definition': {0: 'Relating to the examination and treatment of patients dependent on direct observation. The term may also refer to the institution (clinic) providing this activity.'}, 'entity': {0: 'Clinically'}, 'text': {0: 'Clinically'}}",{},{},{},{},"           entity_group       value     score
0  Diagnostic_procedure  Clinically  0.966238",[],"{'keyword': {}, 'score': {}}"
2034,2034,2034,0.9520000219345092,26.0,or,MyriadPro-Regular,4,-0.25,0,40,10,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2035,2035,2035,0.9520000219345092,22.0,and,MyriadPro-Regular,4,-0.25,0,40,10,1,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2036,2036,2036,0.944000005722046,24.0,Evidence of nodal metastases at surgery,UniversSB-Medium,4,-0.2349999994039535,0,40,11,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'surgery'}, 'text': {0: 'Evidence of nodal metastases at surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'surgery'}, 'text': {0: 'Evidence of nodal metastases at surgery'}}",{},{},{},"           entity_group       value     score
0  Biological_structure       nodal  0.999766
1      Disease_disorder  metastases  0.927845
2           Coreference     surgery  0.592903",[],"{'keyword': {0: 'evidence nodal metastases', 1: 'evidence nodal', 2: 'nodal metastases', 3: 'nodal metastases surgery', 4: 'metastases surgery'}, 'score': {0: 0.9448, 1: 0.7767, 2: 0.6829, 3: 0.4733, 4: 0.4429}}"
2037,2037,2037,0.944000005722046,24.0,No evidence of nodal metastases at surgery,UniversSB-Medium,4,-0.2349999994039535,0,40,12,0,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'surgery'}, 'text': {0: 'No evidence of nodal metastases at surgery'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'surgery'}, 'text': {0: 'No evidence of nodal metastases at surgery'}}",{},{},{},"           entity_group       value     score
0  Biological_structure       nodal  0.999686
1      Disease_disorder  metastases  0.975436
2           Coreference     surgery  0.547385",[],"{'keyword': {0: 'evidence nodal', 1: 'evidence nodal metastases', 2: 'nodal metastases', 3: 'nodal metastases surgery', 4: 'metastases surgery'}, 'score': {0: 0.7023, 1: 0.6408, 2: 0.6274, 3: 0.5605, 4: 0.5356}}"
2038,2038,2038,0.9470000267028807,22.894540786743164,pCR in breast and axilla,UniversSB-Light,4,-0.2329999953508377,0,40,13,0,"{'concept_id': {0: 'C0238729'}, 'canonical_name': {0: 'Mass of axilla'}, 'aliases': {0: ['Lump of axilla', 'Axillary Mass', 'Mass of axilla (finding)', 'axillary lumps', 'axillary lump', 'axilla mass', 'AXILLARY MASS', 'axilla lump', 'mass axilla', 'axillary mass']}, 'types': {0: ['T033']}, 'definition': {0: 'An abnormal growth in the axilla.'}, 'entity': {0: 'axilla'}, 'text': {0: 'pCR in breast and axilla'}}","{'concept_id': {0: 'C0024947'}, 'canonical_name': {0: 'Bone, Maxillary'}, 'aliases': {0: ['Bones, Maxillary', 'Maxillary Bones', 'Maxillae', 'Maxillas', 'Maxilla', 'Maxillary Bone']}, 'types': {0: ['T023']}, 'definition': {0: 'One of a pair of irregularly shaped bones that form the upper jaw. A maxillary bone provides tooth sockets for the superior teeth, forms part of the ORBIT, and contains the MAXILLARY SINUS.'}, 'entity': {0: 'axilla'}, 'text': {0: 'pCR in breast and axilla'}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast'}, 'text': {0: 'pCR in breast and axilla'}}","           entity_group   value     score
0  Diagnostic_procedure     pCR  0.999817
1  Biological_structure  breast  0.999936
2  Biological_structure  axilla  0.999896",[],"{'keyword': {0: 'pcr breast', 1: 'pcr breast axilla', 2: 'breast axilla'}, 'score': {0: 0.8547, 1: 0.8147, 2: 0.698}}"
2039,2039,2039,0.9470000267028807,22.894540786743164,Residual invasive disease in ,UniversSB-Light,4,-0.2329999953508377,0,40,13,1,"{'concept_id': {0: 'C4684759'}, 'canonical_name': {0: 'Residual Risk'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Risk that remains after risk control measures have been taken.'}, 'entity': {0: 'Residual'}, 'text': {0: 'Residual invasive disease in '}}","{'concept_id': {0: 'C0242740'}, 'canonical_name': {0: 'Gastric Stump'}, 'aliases': {0: ['Remnant Stomachs', 'Stomachs, Remnant', 'Remnant, Gastric', 'Gastric Stumps', 'Gastric Remnant', 'Residual Stomach', 'Residual Stomachs', 'Stomachs, Residual', 'Stomach, Residual', 'Stump, Gastric', 'Stumps, Gastric', 'Remnants, Gastric', 'Gastric Remnants', 'Stomach, Remnant', 'Remnant Stomach']}, 'types': {0: ['T023']}, 'definition': {0: 'That portion of the stomach remaining after gastric surgery, usually gastrectomy or gastroenterostomy for cancer of the stomach or peptic ulcer. It is a common site of cancer referred to as stump cancer or carcinoma of the gastric stump.'}, 'entity': {0: 'Residual'}, 'text': {0: 'Residual invasive disease in '}}",{},{},{},"           entity_group     value     score
0  Detailed_description  Residual  0.999950
1  Detailed_description  invasive  0.405941
2      Disease_disorder   disease  0.392131",[],"{'keyword': {0: 'residual invasive disease', 1: 'residual invasive', 2: 'invasive disease'}, 'score': {0: 0.975, 1: 0.944, 2: 0.8337}}"
2040,2040,2040,0.9470000267028807,22.894540786743164,breast (or axilla),UniversSB-Light,4,-0.2329999953508377,0,40,13,2,"{'concept_id': {0: 'C0238729'}, 'canonical_name': {0: 'Mass of axilla'}, 'aliases': {0: ['Lump of axilla', 'Axillary Mass', 'Mass of axilla (finding)', 'axillary lumps', 'axillary lump', 'axilla mass', 'AXILLARY MASS', 'axilla lump', 'mass axilla', 'axillary mass']}, 'types': {0: ['T033']}, 'definition': {0: 'An abnormal growth in the axilla.'}, 'entity': {0: 'axilla'}, 'text': {0: 'breast (or axilla)'}}","{'concept_id': {0: 'C0024947'}, 'canonical_name': {0: 'Bone, Maxillary'}, 'aliases': {0: ['Bones, Maxillary', 'Maxillary Bones', 'Maxillae', 'Maxillas', 'Maxilla', 'Maxillary Bone']}, 'types': {0: ['T023']}, 'definition': {0: 'One of a pair of irregularly shaped bones that form the upper jaw. A maxillary bone provides tooth sockets for the superior teeth, forms part of the ORBIT, and contains the MAXILLARY SINUS.'}, 'entity': {0: 'axilla'}, 'text': {0: 'breast (or axilla)'}}",{},{},"{'concept_id': {0: 'C1458155'}, 'canonical_name': {0: 'Neoplasm of the breast'}, 'aliases': {0: ['Tumours of the breast', 'Breast tumor', 'Neoplasia of the breast', 'Breast tumour']}, 'types': {0: ['T191']}, 'definition': {0: 'Tumors or cancer of the human BREAST.'}, 'entity': {0: 'breast'}, 'text': {0: 'breast (or axilla)'}}","           entity_group   value     score
0  Biological_structure  breast  0.999903
1  Biological_structure  axilla  0.904969",[],"{'keyword': {0: 'breast axilla'}, 'score': {0: 0.6956}}"
2041,2041,2041,0.9470000267028807,24.0,pCR in breast,UniversSB-Light,4,-0.2329999953508377,0,40,13,3,"{'concept_id': {0: 'C4050242'}, 'canonical_name': {0: 'Pathologic Complete Response'}, 'aliases': {0: ['Pathologic Complete Response', 'Pathological Complete Remission', 'pCR']}, 'types': {0: ['T033']}, 'definition': {0: 'The disappearance of all signs of cancer, supported by pathological examination.'}, 'entity': {0: 'pCR'}, 'text': {0: 'pCR in breast'}}","{'concept_id': {0: 'C1709846'}, 'canonical_name': {0: 'Real-Time Polymerase Chain Reaction'}, 'aliases': {0: ['Real Time PCR', 'Real-Time PCRs', 'PCRs, Real-Time', 'PCR, Real-Time', 'Real Time Polymerase Chain Reaction', 'Real-Time PCR']}, 'types': {0: ['T063']}, 'definition': {0: 'An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.'}, 'entity': {0: 'pCR'}, 'text': {0: 'pCR in breast'}}",{},{},{},"           entity_group   value     score
0  Diagnostic_procedure     pCR  0.999828
1  Biological_structure  breast  0.999899",[],"{'keyword': {0: 'pcr breast'}, 'score': {0: 0.906}}"
2042,2042,2042,0.944000005722046,19.0,Other treatment options are available. ,UniversSB-Medium,4,-0.2349999994039535,3355443,40,14,0,"{'concept_id': {0: 'C0087111'}, 'canonical_name': {0: 'Therapeutic procedure'}, 'aliases': {0: ['TX', 'therapies', 'treatments', 'Therapeutic', 'Therapeutic procedure', 'Therapeutic procedure, NOS', 'methods treatment', 'Therapies', 'therapeutic method', 'Therapy', 'Therapeutics', 'treatment', 'Treatment', 'Therapeutic Interventions', 'Therapy (regime/therapy)', 'Treatments', 'Therapeutic Technique', 'Therapeutic Procedure', 'Therapeutic procedure (procedure)', 'therapy', 'therapeutic procedure', 'Therapy, NOS', 'method treatment', 'treatment method', 'Therapeutic Method', 'therapeutics']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures concerned with the remedial treatment or prevention of diseases.'}, 'entity': {0: 'treatment options'}, 'text': {0: 'Other treatment options are available. '}}","{'concept_id': {0: 'C0871549'}, 'canonical_name': {0: 'Withholding Treatment'}, 'aliases': {0: ['Treatment, Withholding', 'Treatment Cessations', 'Withholding Treatments', 'Cessation of Treatment', 'Treatment Cessation', 'Treatments, Withholding']}, 'types': {0: ['T058']}, 'definition': {0: ""Withholding or withdrawal of a particular treatment or treatments, often (but not necessarily) life-prolonging treatment, from a patient or from a research subject as part of a research protocol. The concept is differentiated from REFUSAL TO TREAT, where the emphasis is on the health professional's or health facility's refusal to treat a patient or group of patients when the patient or the patient's representative requests treatment. Withholding of life-prolonging treatment is usually indexed only with EUTHANASIA, PASSIVE, unless the distinction between withholding and withdrawing treatment, or the issue of withholding palliative rather than curative treatment, is discussed.""}, 'entity': {0: 'treatment options'}, 'text': {0: 'Other treatment options are available. '}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'options available', 1: 'treatment options', 2: 'treatment options available'}, 'score': {0: 0.8093, 1: 0.8063, 2: 0.805}}"
2043,2043,2043,0.9470000267028807,19.0,"*In the adjuvant setting, PHESGO should be administered for a total of one ",UniversSB-Light,4,-0.2329999953508377,3355443,40,14,1,"{'concept_id': {0: 'C1621583'}, 'canonical_name': {0: 'Administer - dosing instruction imperative'}, 'aliases': {0: ['Administer - dosing instruction imperative', 'Administer', 'Administer - dosing instruction imperative (qualifier value)']}, 'types': {0: ['T169']}, 'definition': {0: 'To dispense, apply, or tender something to another, such as administering a medicine.'}, 'entity': {0: 'administered'}, 'text': {0: '*In the adjuvant setting, PHESGO should be administered for a total of one '}}",{},"{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: '*In the adjuvant setting, PHESGO should be administered for a total of one '}}",{},{},"  entity_group                  value     score
0   Medication  adjuvant administered  0.927768
1   Medication                 PHESGO  0.987906
2       Dosage                    one  0.813255","[('PHESGO', 'DRUG')]","{'keyword': {0: 'phesgo administered total', 1: 'setting phesgo administered', 2: 'phesgo administered', 3: 'adjuvant setting', 4: 'setting phesgo'}, 'score': {0: 0.7864, 1: 0.7272, 2: 0.7256, 3: 0.7201, 4: 0.6862}}"
2044,2044,2044,0.9470000267028807,19.0,"year (up to 18 cycles or until disease recurrence, or unmanageable toxicity, ",UniversSB-Light,4,-0.2329999953508377,3355443,40,14,2,"{'concept_id': {0: 'C0242890'}, 'canonical_name': {0: 'Toxicity Tests'}, 'aliases': {0: ['toxicity tests', 'testing toxicity', 'Test, Toxicity', 'Toxicity testing', 'Toxicity Testing', 'toxicity test', 'Toxicity Test', 'Tests, Toxicity']}, 'types': {0: ['T060']}, 'definition': {0: 'An array of tests used to determine the toxicity of a substance to living systems. These include tests on clinical drugs, foods, and environmental pollutants.'}, 'entity': {0: 'toxicity'}, 'text': {0: 'year (up to 18 cycles or until disease recurrence, or unmanageable toxicity, '}}","{'concept_id': {0: 'C0013221'}, 'canonical_name': {0: 'Toxicity, Drug'}, 'aliases': {0: ['Drug Toxicities', 'Drug Toxicity', 'Toxicities, Drug']}, 'types': {0: ['T037']}, 'definition': {0: 'An adverse effect of a drug used therapeutically or diagnostically.'}, 'entity': {0: 'toxicity'}, 'text': {0: 'year (up to 18 cycles or until disease recurrence, or unmanageable toxicity, '}}",{},{},{},"  entity_group value     score
0     Duration  year  0.687364
1     Duration    18  0.597262",[],"{'keyword': {0: 'year 18 cycles', 1: 'recurrence unmanageable toxicity', 2: '18 cycles disease', 3: '18 cycles', 4: 'disease recurrence'}, 'score': {0: 0.7403, 1: 0.7282, 2: 0.6866, 3: 0.6858, 4: 0.5958}}"
2045,2045,2045,0.9470000267028807,19.0,"whichever occurs first), as part of a complete regimen for early breast ",UniversSB-Light,4,-0.2329999953508377,3355443,40,14,3,"{'concept_id': {0: 'C1517886'}, 'canonical_name': {0: 'Limited stage (cancer stage)'}, 'aliases': {0: ['Limited Stage', 'Early-Stage Cancer', 'Early Stage', 'Limited Metastatic Disease']}, 'types': {0: ['T185']}, 'definition': {0: 'Cancer that is localized in its original site of growth, or involves adjacent lymph nodes but has not spread to other anatomic sites.'}, 'entity': {0: 'early'}, 'text': {0: 'whichever occurs first), as part of a complete regimen for early breast '}}","{'concept_id': {0: 'C3177188'}, 'canonical_name': {0: 'Early Therapy'}, 'aliases': {0: ['Therapies, Early', 'Therapy, Early', 'Early Therapies']}, 'types': {0: ['T061']}, 'definition': {0: 'Procedures undertaken to prevent or reduce the incidence or progression of disease, in individuals with EARLY DIAGNOSIS of disease, or known DISEASE SUSCEPTIBILITY.'}, 'entity': {0: 'early'}, 'text': {0: 'whichever occurs first), as part of a complete regimen for early breast '}}",{},"{'concept_id': {0: 'C1818858'}, 'canonical_name': {0: 'early phagosome'}, 'aliases': {0: ['early phagocytic vesicle']}, 'types': {0: ['T026']}, 'definition': {0: 'A membrane-bounded intracellular vesicle as initially formed upon the ingestion of particulate material by phagocytosis. [GOC:mah, PMID:12388753]'}, 'entity': {0: 'early'}, 'text': {0: 'whichever occurs first), as part of a complete regimen for early breast '}}",{},"           entity_group   value    score
0  Biological_structure  breast  0.99935",[],"{'keyword': {0: 'occurs complete regimen', 1: 'regimen early', 2: 'regimen early breast', 3: 'complete regimen early', 4: 'whichever occurs'}, 'score': {0: 0.8161, 1: 0.8086, 2: 0.739, 3: 0.7305, 4: 0.719}}"
2046,2046,2046,0.9470000267028807,19.0,cancer and regardless of the timing of surgery. Treatment should include ,UniversSB-Light,4,-0.2329999953508377,3355443,40,14,4,"{'concept_id': {0: 'C1522326'}, 'canonical_name': {0: 'Treating'}, 'aliases': {0: ['Treat', 'Treatment', 'treated with', 'treating', 'Treated', 'Treating', 'treated']}, 'types': {0: ['T169']}, 'definition': {0: 'Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.'}, 'entity': {0: 'Treatment'}, 'text': {0: 'cancer and regardless of the timing of surgery. Treatment should include '}}","{'concept_id': {0: 'C0376495'}, 'canonical_name': {0: 'Retreatments'}, 'aliases': {0: ['Retreatment']}, 'types': {0: ['T061']}, 'definition': {0: 'The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.'}, 'entity': {0: 'Treatment'}, 'text': {0: 'cancer and regardless of the timing of surgery. Treatment should include '}}",{},{},"{'concept_id': {0: 'C0007114'}, 'canonical_name': {0: 'Skin cancer'}, 'aliases': {0: []}, 'types': {0: ['T191']}, 'definition': {0: 'A primary or metastatic malignant neoplasm involving the skin. Primary malignant skin neoplasms most often are carcinomas (either basal cell or squamous cell carcinomas) or melanomas. Metastatic malignant neoplasms to the skin include carcinomas and lymphomas.'}, 'entity': {0: 'cancer'}, 'text': {0: 'cancer and regardless of the timing of surgery. Treatment should include '}}","            entity_group      value     score
0  Therapeutic_procedure  Treatment  0.998497",[],"{'keyword': {0: 'treatment include', 1: 'surgery treatment include', 2: 'cancer regardless timing', 3: 'timing surgery treatment', 4: 'regardless timing surgery'}, 'score': {0: 0.8983, 1: 0.7686, 2: 0.715, 3: 0.5252, 4: 0.3419}}"
2047,2047,2047,0.9470000267028807,19.0,standard anthracycline- and/or taxane-based chemotherapy.,UniversSB-Light,4,-0.2329999953508377,3355443,40,14,5,"{'concept_id': {0: 'C2828392'}, 'canonical_name': {0: 'Standard (document)'}, 'aliases': {0: ['Standard']}, 'types': {0: ['T170']}, 'definition': {0: 'A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.'}, 'entity': {0: 'standard'}, 'text': {0: 'standard anthracycline- and/or taxane-based chemotherapy.'}}","{'concept_id': {0: 'C0038137'}, 'canonical_name': {0: 'standards'}, 'aliases': {0: []}, 'types': {0: ['T169']}, 'definition': {0: 'Used with facilities, personnel, and program headings for the development, testing, and application of standards of adequacy or acceptable performance and with chemicals and drugs for standards of identification, quality, and potency. It includes health or safety standards in industries and occupations.'}, 'entity': {0: 'standard'}, 'text': {0: 'standard anthracycline- and/or taxane-based chemotherapy.'}}",{},{},{},"           entity_group         value     score
0  Detailed_description  taxane-based  0.999916","[('anthracycline-', 'DRUG'), ('taxane', 'DRUG'), ('chemotherapy', 'DRUG')]","{'keyword': {0: 'standard anthracycline taxane', 1: 'standard anthracycline', 2: 'anthracycline taxane based', 3: 'taxane based chemotherapy', 4: 'based chemotherapy'}, 'score': {0: 0.8737, 1: 0.8285, 2: 0.8266, 3: 0.742, 4: 0.7055}}"
2048,2048,2048,0.9169999957084656,30.0,Reference:,ConduitITC-Bold,20,-0.2349999994039535,8194925,40,15,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2049,2049,2049,0.8830000162124634,22.0,1. Kadcyla Summary of Product Characteristics.,MyriadPro-Light,4,-0.25,3355443,40,15,1,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics.'}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics.'}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics.'}}","           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.796608","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla summary', 1: 'kadcyla summary product', 2: 'summary product', 3: 'summary product characteristics', 4: 'product characteristics'}, 'score': {0: 0.8868, 1: 0.8835, 2: 0.8533, 3: 0.7331, 4: 0.7046}}"
2050,2050,2050,0.944000005722046,24.0,Adjuvant* ,UniversSB-Medium,4,-0.2349999994039535,0,40,16,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'Adjuvant*'}, 'text': {0: 'Adjuvant* '}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'Adjuvant*'}, 'text': {0: 'Adjuvant* '}}",{},{},{},"           entity_group     value     score
0  Diagnostic_procedure  Adjuvant  0.582094
1  Detailed_description         *  0.614326",[],"{'keyword': {}, 'score': {}}"
2051,2051,2051,0.9470000267028807,22.894540786743164,PHESGO SC based regimen,UniversSB-Light,4,-0.2329999953508377,0,40,16,1,"{'concept_id': {0: 'C0392970'}, 'canonical_name': {0: 'Doxorubicin/Docetaxel Regimen'}, 'aliases': {0: ['Docetaxel/Doxorubicin', 'Doxorubicin-Docetaxel', 'Doxorubicin/Docetaxel Regimen', 'Docetaxel/Doxorubicin Regimen', 'Adriamycin-Taxotere Regimen', 'AT Regimen', 'Doxorubicin/Docetaxel', 'Adriamycin/Taxotere', 'DOX/TXT', 'docetaxel/doxorubicin', 'Docetaxel-Doxorubicin']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemotherapy regimen consisting of doxorubicin and docetaxel that may be used in the treatment of breast cancer.'}, 'entity': {0: 'regimen'}, 'text': {0: 'PHESGO SC based regimen'}}","{'concept_id': {0: 'C0912478'}, 'canonical_name': {0: 'TIC protocol'}, 'aliases': {0: ['TIC regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A regimen consisting of paclitaxel, ifosfamide, mesna and carboplatin used as salvage therapy for the treatment of advanced-stage testicular cancer; also used for the treatment of unresectable and recurrent squamous cell head and neck cancer.'}, 'entity': {0: 'regimen'}, 'text': {0: 'PHESGO SC based regimen'}}","{'concept_id': {0: 'C5239903'}, 'canonical_name': {0: 'Phesgo'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'PHESGO'}, 'text': {0: 'PHESGO SC based regimen'}}",{},{},"            entity_group   value     score
0  Therapeutic_procedure  PHESGO  0.801073","[('PHESGO', 'DRUG'), ('SC', 'ROUTE')]","{'keyword': {0: 'phesgo sc based', 1: 'phesgo sc', 2: 'sc based', 3: 'based regimen', 4: 'sc based regimen'}, 'score': {0: 0.9229, 1: 0.8759, 2: 0.8432, 3: 0.8229, 4: 0.7852}}"
2052,2052,2052,0.944000005722046,24.0,Adjuvant,UniversSB-Medium,4,-0.2349999994039535,0,40,17,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}",{},{},{},"           entity_group     value     score
0  Detailed_description  Adjuvant  0.584447
1               History  Adjuvant  0.588875",[],"{'keyword': {}, 'score': {}}"
2053,2053,2053,0.9470000267028807,22.894540786743164,Kadcyla (14 cycles),UniversSB-Light,4,-0.2329999953508377,0,40,17,1,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Kadcyla (14 cycles)'}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: 'Kadcyla (14 cycles)'}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla (14 cycles)'}}",{},{},"  entity_group    value     score
0  Coreference  Kadcyla  0.741233
1    Lab_value       14  0.586142","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla 14 cycles', 1: '14 cycles', 2: 'kadcyla 14'}, 'score': {0: 0.9513, 1: 0.8869, 2: 0.8491}}"
2054,2054,2054,0.944000005722046,24.0,Adjuvant,UniversSB-Medium,4,-0.2349999994039535,0,40,18,0,"{'concept_id': {0: 'C1522673'}, 'canonical_name': {0: 'Adjuvant'}, 'aliases': {0: ['Adjuvant Generic', 'adjuvant']}, 'types': {0: ['T169']}, 'definition': {0: 'Serving to aid or contribute; auxiliary.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}","{'concept_id': {0: 'C0003865'}, 'canonical_name': {0: 'Arthritis, Adjuvant-Induced'}, 'aliases': {0: ['Arthritis, Adjuvant', 'Adjuvant Arthritis']}, 'types': {0: ['T050']}, 'definition': {0: 'An experimental model of arthritis that is induced by injecting adjuvants. These adjuvants generally consists of a mixture of light paraffin oil, emulsifying agent, and infective agents or antigens, such as killed mycobacteria or bacterial lipopolysaccharides.'}, 'entity': {0: 'Adjuvant'}, 'text': {0: 'Adjuvant'}}",{},{},{},"           entity_group     value     score
0  Detailed_description  Adjuvant  0.584447
1               History  Adjuvant  0.588875",[],"{'keyword': {}, 'score': {}}"
2055,2055,2055,0.9470000267028807,22.894540786743164,Herceptin,UniversSB-Light,4,-0.2329999953508377,0,40,18,1,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Herceptin'}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Herceptin'}}","{'concept_id': {0: 'C0338204'}, 'canonical_name': {0: 'Herceptin'}, 'aliases': {0: []}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: None}, 'entity': {0: 'Herceptin'}, 'text': {0: 'Herceptin'}}",{},{},"           entity_group      value     score
0  Diagnostic_procedure  Herceptin  0.985167","[('Herceptin', 'DRUG')]","{'keyword': {}, 'score': {}}"
2056,2056,2056,0.9470000267028807,22.894540786743164,   (up to 18 cycles),UniversSB-Light,4,-0.2329999953508377,0,40,18,2,"{'concept_id': {0: 'C2718082'}, 'canonical_name': {0: 'Light Cycle'}, 'aliases': {0: ['Light-Dark Cycles', 'Cycle, Dark-Light', 'Light Cycles', 'Light Dark Cycle', 'Light-Dark Cycle', 'Cycle, Light', 'Cycles, Dark-Light', 'Dark Light Cycle', 'Cycles, Light-Dark', 'Cycle, Light-Dark', 'Light Cycle', 'Dark-Light Cycles', 'Dark-Light Cycle', 'Cycles, Light']}, 'types': {0: ['T079']}, 'definition': {0: 'The amount of ambient light/darkness to which a subject is exposed in a period of time.'}, 'entity': {0: 'cycles'}, 'text': {0: '   (up to 18 cycles)'}}","{'concept_id': {0: 'C2936387'}, 'canonical_name': {0: 'Water Cycle'}, 'aliases': {0: ['Cycle, Water', 'Cycles, Water', 'Hydrologic Cycle', 'Water Cycles', 'Cycles, Hydrologic', 'Cycle, Hydrologic', 'Hydrologic Cycles']}, 'types': {0: ['T067']}, 'definition': {0: 'Circulation of water among various ecological systems, in various states, on, above, and below the surface of the earth.'}, 'entity': {0: 'cycles'}, 'text': {0: '   (up to 18 cycles)'}}",{},{},{},"           entity_group value     score
0  Detailed_description    18  0.406117",[],"{'keyword': {0: '18 cycles'}, 'score': {0: 0.8319}}"
2057,2057,2057,0.9470000267028807,11.07699966430664,†,UniversSB-Light,4,-0.2329999953508377,3355443,40,19,0,{},{},{},{},{},"           entity_group value     score
0  Detailed_description     †  0.176692",[],"{'keyword': {}, 'score': {}}"
2058,2058,2058,0.9470000267028807,19.0,patients must be node-positive at diagnosis or node-negative at diagnosis ,UniversSB-Light,4,-0.2329999953508377,3355443,40,19,1,"{'concept_id': {0: 'C1546899'}, 'canonical_name': {0: 'Diagnosis Classification - Diagnosis'}, 'aliases': {0: ['Diagnosis']}, 'types': {0: ['T185']}, 'definition': {0: None}, 'entity': {0: 'diagnosis'}, 'text': {0: 'patients must be node-positive at diagnosis or node-negative at diagnosis '}}","{'concept_id': {0: 'C2718037'}, 'canonical_name': {0: 'Late Diagnosis'}, 'aliases': {0: ['Diagnosis, Late', 'Late Diagnoses']}, 'types': {0: ['T080']}, 'definition': {0: 'Excessive period of time between onset of disease and identification.'}, 'entity': {0: 'diagnosis'}, 'text': {0: 'patients must be node-positive at diagnosis or node-negative at diagnosis '}}",{},{},"{'concept_id': {0: 'C0001816'}, 'canonical_name': {0: 'Agnosia'}, 'aliases': {0: []}, 'types': {0: ['T048']}, 'definition': {0: 'Loss of the ability to comprehend the meaning or recognize the importance of various forms of stimulation that cannot be attributed to impairment of a primary sensory modality. Tactile agnosia is characterized by an inability to perceive the shape and nature of an object by touch alone, despite unimpaired sensation to light touch, position, and other primary sensory modalities.'}, 'entity': {0: 'diagnosis'}, 'text': {0: 'patients must be node-positive at diagnosis or node-negative at diagnosis '}}","  entity_group          value     score
0    Lab_value  node-positive  0.989704
1    Lab_value  node-negative  0.917429",[],"{'keyword': {0: 'node negative', 1: 'negative diagnosis', 2: 'diagnosis node negative', 3: 'positive diagnosis', 4: 'patients node'}, 'score': {0: 0.7794, 1: 0.7664, 2: 0.6322, 3: 0.6205, 4: 0.4963}}"
2059,2059,2059,0.9470000267028807,19.0,and upstaged following surgery.,UniversSB-Light,4,-0.2329999953508377,3355443,40,19,2,"{'concept_id': {0: 'C0543467'}, 'canonical_name': {0: 'Operative Surgical Procedures'}, 'aliases': {0: ['operative procedure', 'Operative Procedures', 'operation', 'surgical procedures', 'surgery', 'Surgery, NOS', 'Surgical Procedure', 'Surgical (qualifier value)', 'Surgical Interventions', 'Procedures, Surgical', 'Procedures, Operative Surgical', 'Surgically', 'Procedure, Operative Surgical', 'Operation, NOS', 'GENERIC OPERATIVE PROCEDURES', 'Surg', 'SURG', 'Operative Surgical Procedures', 'Surgery (qualifier value)', 'Surgery, Operative', 'surgical procedure', 'Surgery procedure', 'Surgical procedure, NOS', 'H&P.SURG PROC', 'surgeries', 'Procedure, Surgical', 'Surgical procedures history', 'GENERAL OPERATIVE PROCEDURES', 'surgical treatments', 'operation (surgery)', 'surgery procedure', 'Operative Surgical Procedure', 'Surgical Procedure, Operative', 'Operation', 'Surgical procedure', 'operative procedures', 'surgical treatment', 'Operative Procedure', 'Surgical Procedures', 'Operative procedure, NOS', 'Surgical Procedures, Operative', 'Operative procedure', 'Procedures, Operative', 'Surgical', 'Surgery', 'operative surgery', 'Surgical procedures', 'Surgical procedure (procedure)', 'Procedure, Operative']}, 'types': {0: ['T061']}, 'definition': {0: 'Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.).'}, 'entity': {0: 'surgery'}, 'text': {0: 'and upstaged following surgery.'}}","{'concept_id': {0: 'C0038908'}, 'canonical_name': {0: 'Oral Surgery'}, 'aliases': {0: ['Surgery, Oral', 'Surgery, Maxillofacial', 'Maxillofacial Surgery']}, 'types': {0: ['T091']}, 'definition': {0: 'A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.'}, 'entity': {0: 'surgery'}, 'text': {0: 'and upstaged following surgery.'}}",{},{},{},"   entity_group     value     score
0  Sign_symptom  upstaged  0.998013",[],"{'keyword': {0: 'upstaged following surgery', 1: 'upstaged following', 2: 'following surgery'}, 'score': {0: 0.9655, 1: 0.9463, 2: 0.7547}}"
2060,2060,2060,0.9470000267028807,19.0,"eBC, early breast cancer; pCR, pathological complete response;  ",UniversSB-Light,4,-0.2329999953508377,3355443,40,19,3,"{'concept_id': {0: 'C4054467'}, 'canonical_name': {0: 'Morphologic Complete Response'}, 'aliases': {0: ['Morphologic CR']}, 'types': {0: ['T033']}, 'definition': {0: 'The disappearance of all signs of cancer, supported by morphological analysis.'}, 'entity': {0: 'pathological complete response'}, 'text': {0: 'eBC, early breast cancer; pCR, pathological complete response;  '}}","{'concept_id': {0: 'C1709846'}, 'canonical_name': {0: 'Real-Time Polymerase Chain Reaction'}, 'aliases': {0: ['Real Time PCR', 'Real-Time PCRs', 'PCRs, Real-Time', 'PCR, Real-Time', 'Real Time Polymerase Chain Reaction', 'Real-Time PCR']}, 'types': {0: ['T063']}, 'definition': {0: 'An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.'}, 'entity': {0: 'pCR'}, 'text': {0: 'eBC, early breast cancer; pCR, pathological complete response;  '}}",{},{},"{'concept_id': {0: 'C0678222'}, 'canonical_name': {0: 'Breast cancer'}, 'aliases': {0: ['Breast carcinoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.'}, 'entity': {0: 'early breast cancer'}, 'text': {0: 'eBC, early breast cancer; pCR, pathological complete response;  '}}","           entity_group   value     score
0  Biological_structure  breast  0.998095",[],"{'keyword': {0: 'ebc early breast', 1: 'breast cancer', 2: 'breast cancer pcr', 3: 'pathological complete', 4: 'pathological complete response'}, 'score': {0: 0.852, 1: 0.7259, 2: 0.7254, 3: 0.6977, 4: 0.6234}}"
2061,2061,2061,0.9470000267028807,19.0,"SC, subcutaneous.",UniversSB-Light,4,-0.2329999953508377,3355443,40,19,4,"{'concept_id': {0: 'C0222331'}, 'canonical_name': {0: 'Subcutaneous Fat'}, 'aliases': {0: ['subcutaneous adipose tissue', 'Subcutaneous Fats', 'Subcutaneous adipose tissue', 'Panniculus adiposus', 'Panniculus adiposus telae subcutaneae', 'Subcutaneous fatty tissue', 'paniculus adiposus', 'Structure of subcutaneous fatty tissue', 'Fat, Subcutaneous', 'Subcutaneous fat', 'Paniculus adiposus', 'subcutaneous fat', 'Subcutaneous Fat', 'Subcutaneous Tissue', 'Structure of subcutaneous fatty tissue (body structure)', 'Panniculus adiposus (Tela subcutanea)', 'fat subcutaneous', 'Fatty layer of subcutaneous tissue', 'Subcutis', 'Fats, Subcutaneous', 'Subcutaneous Adipose Tissue', 'Fatty layer of superficial fascia', 'Adipose Tissue, Subcutaneous']}, 'types': {0: ['T024']}, 'definition': {0: 'Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'SC, subcutaneous.'}}","{'concept_id': {0: 'C0278403'}, 'canonical_name': {0: 'Tissues, Subcutaneous'}, 'aliases': {0: ['Subcutaneous Tissue', 'Fascia, Superficial', 'Superficial Fascia', 'Tela Subcutanea', 'Tissue, Subcutaneous', 'Subcutaneous Tissues', 'Hypodermis']}, 'types': {0: ['T024']}, 'definition': {0: 'Loose connective tissue lying under the DERMIS, which binds SKIN loosely to subjacent tissues. It may contain a pad of ADIPOCYTES, which vary in number according to the area of the body and vary in size according to the nutritional state.'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'SC, subcutaneous.'}}",{},{},"{'concept_id': {0: 'C1857657'}, 'canonical_name': {0: 'Reduced subcutaneous fat'}, 'aliases': {0: ['Reduced fat tissue below the skin', 'Reduced subcutaneous adipose tissue', 'Decreased subcutaneous fat', 'Decreased subcutaneous adipose tissue', 'Scanty adipose tissue']}, 'types': {0: ['T033']}, 'definition': {0: 'A reduced amount of fat tissue in the lowest layer of the integument. This feature can be appreciated by a reduced skinfold thickness. []'}, 'entity': {0: 'subcutaneous'}, 'text': {0: 'SC, subcutaneous.'}}","Empty DataFrame
Columns: []
Index: []","[('SC', 'ROUTE'), ('subcutaneous', 'ROUTE')]","{'keyword': {0: 'sc subcutaneous'}, 'score': {0: 0.8459}}"
2062,2062,2062,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,40,20,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
2063,2063,2063,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,40,20,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
2064,2064,2064,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,9211020,40,20,2,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
2065,2065,2065,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,40,20,3,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
2066,2066,2066,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,40,21,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
2067,2067,2067,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,40,21,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
2068,2068,2068,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,40,21,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
2069,2069,2069,0.75,98.0,Kadcyla offers dual antitumour activity  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,41,1,0,"{'concept_id': {0: 'C5204827'}, 'canonical_name': {0: 'Ado-trastuzumab Emtansine Regimen'}, 'aliases': {0: ['Kadcyla Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'A chemo/immunotherapy regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer.'}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla offers dual antitumour activity  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'Kadcyla'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla offers dual antitumour activity  '}}","{'concept_id': {0: 'C3537584'}, 'canonical_name': {0: 'KADCYLA'}, 'aliases': {0: []}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'Kadcyla'}, 'text': {0: 'Kadcyla offers dual antitumour activity  '}}",{},{},"           entity_group                value     score
0            Medication              Kadcyla  0.522079
1           Coreference              Kadcyla  0.340912
2  Detailed_description                 dual  0.995293
3  Diagnostic_procedure  antitumour activity  0.790299","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'dual antitumour activity', 1: 'offers dual antitumour', 2: 'antitumour activity', 3: 'kadcyla offers', 4: 'kadcyla offers dual'}, 'score': {0: 0.962, 1: 0.949, 2: 0.9012, 3: 0.8869, 4: 0.8405}}"
2070,2070,2070,0.75,98.0,with HER2 suppression and the release  ,ConduitITC-Bold,20,-0.1700000017881393,8194925,41,1,1,"{'concept_id': {0: 'C0680255'}, 'canonical_name': {0: 'Discharge (release)'}, 'aliases': {0: ['release', 'discharge (release)']}, 'types': {0: ['T058']}, 'definition': {0: None}, 'entity': {0: 'release'}, 'text': {0: 'with HER2 suppression and the release  '}}","{'concept_id': {0: 'C3850077'}, 'canonical_name': {0: 'Drug Liberation'}, 'aliases': {0: ['Release, Drug', 'Dissolution, Drug', 'Drug Dissolution', 'Liberation, Drug', 'Drug Release']}, 'types': {0: ['T070']}, 'definition': {0: 'Release of drugs from DOSAGE FORMS into solution.'}, 'entity': {0: 'release'}, 'text': {0: 'with HER2 suppression and the release  '}}",{},"{'concept_id': {0: 'C1160693'}, 'canonical_name': {0: 'virus exit from host cell'}, 'aliases': {0: ['viral exit', 'viral release', 'viral shedding', 'viral release from host cell', 'release of virus from host']}, 'types': {0: ['T043']}, 'definition': {0: 'The dissemination of mature viral particles from the host cell, e.g. by cell lysis or the budding of virus particles from the cell membrane. [GOC:jl]'}, 'entity': {0: 'release'}, 'text': {0: 'with HER2 suppression and the release  '}}",{},"  entity_group        value     score
0   Medication         HER2  0.852387
1  Coreference  suppression  0.554873
2   Medication      release  0.383429",[],"{'keyword': {0: 'her2 suppression release', 1: 'suppression release', 2: 'her2 suppression'}, 'score': {0: 0.9031, 1: 0.8856, 2: 0.7413}}"
2071,2071,2071,0.75,98.0,of DM1 inside HER2-targeted cells,ConduitITC-Bold,20,-0.1700000017881393,8194925,41,1,2,"{'concept_id': {0: 'C5235659'}, 'canonical_name': {0: 'HER2-targeting Agent'}, 'aliases': {0: ['ERBB2-Targeting Agent']}, 'types': {0: ['T121']}, 'definition': {0: 'Any agent that targets the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2/neu; HER-2; erbB-2).'}, 'entity': {0: 'HER2-targeted cells'}, 'text': {0: 'of DM1 inside HER2-targeted cells'}}",{},{},{},"{'concept_id': {0: 'C0221284'}, 'canonical_name': {0: 'Codocytes'}, 'aliases': {0: ['Target cells']}, 'types': {0: ['T025']}, 'definition': {0: 'Target cells (codocytes) have a centrally located disk of hemoglobin surrounded by an area of pallor with an outer rim of hemoglobin adjacent to the cell membrane giving the cell the appearance of a target. [PMID:27372866, PMID:32965812]'}, 'entity': {0: 'HER2-targeted cells'}, 'text': {0: 'of DM1 inside HER2-targeted cells'}}","           entity_group                value     score
0  Diagnostic_procedure                  DM1  0.999445
1  Biological_structure        HER2-targeted  0.751804
2  Detailed_description  HER2-targeted cells  0.822867",[],"{'keyword': {0: 'targeted cells', 1: 'inside her2', 2: 'dm1 inside her2', 3: 'dm1 inside', 4: 'her2 targeted'}, 'score': {0: 0.817, 1: 0.7905, 2: 0.7811, 3: 0.7668, 4: 0.7056}}"
2072,2072,2072,0.9470000267028807,32.0,This dual mechanism of action expands on the activity of trastuzumab,UniversSB-Light,4,-0.2329999953508377,3355443,41,2,0,"{'concept_id': {0: 'C5206964'}, 'canonical_name': {0: 'Trastuzumab Regimen'}, 'aliases': {0: ['Herceptin Regimen']}, 'types': {0: ['T061']}, 'definition': {0: 'An immunotherapy regimen consisting of trastuzumab that may be used in the treatment of breast cancer.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'This dual mechanism of action expands on the activity of trastuzumab'}}","{'concept_id': {0: 'C2983775'}, 'canonical_name': {0: 'zirconium-89-trastuzumab'}, 'aliases': {0: ['(89)Zr-trastuzumab', '89Zr-trastuzumab']}, 'types': {0: ['T116', 'T130']}, 'definition': {0: 'A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium Zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'This dual mechanism of action expands on the activity of trastuzumab'}}","{'concept_id': {0: 'C2935436'}, 'canonical_name': {0: 'trastuzumab emtansine'}, 'aliases': {0: ['ado-trastuzumab emtansine']}, 'types': {0: ['T116', 'T121', 'T129']}, 'definition': {0: 'An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.'}, 'entity': {0: 'trastuzumab'}, 'text': {0: 'This dual mechanism of action expands on the activity of trastuzumab'}}","{'concept_id': {0: 'C1151329'}, 'canonical_name': {0: 'chlorophyll a oxygenase activity'}, 'aliases': {0: ['chlorophyllide-a oxygenase activity', 'CAO activity', 'chlorophyllide a oxygenase activity', 'chlorophyllide a:oxygen 7-oxidoreductase activity']}, 'types': {0: ['T044']}, 'definition': {0: 'Catalysis of the reaction: chlorophyllide a + NADPH + O2 + 2 H+ = 7-hydroxychlorophyllide a + NADP+ + H2O. [EC:1.13.12.14, MetaCyc:RXN-7676]'}, 'entity': {0: 'activity'}, 'text': {0: 'This dual mechanism of action expands on the activity of trastuzumab'}}","{'concept_id': {0: 'C0424295'}, 'canonical_name': {0: 'Hyperactivity'}, 'aliases': {0: ['Hyperactive behavior', 'More active than typical', 'Hyperactive behaviour']}, 'types': {0: ['T048']}, 'definition': {0: 'Increased motor activity that is not goal directed.'}, 'entity': {0: 'activity'}, 'text': {0: 'This dual mechanism of action expands on the activity of trastuzumab'}}","  entity_group        value     score
0   Medication  trastuzumab  0.999828","[('trastuzumab', 'DRUG')]","{'keyword': {0: 'dual mechanism action', 1: 'expands activity', 2: 'activity trastuzumab', 3: 'mechanism action', 4: 'action expands'}, 'score': {0: 0.858, 1: 0.8561, 2: 0.8354, 3: 0.8204, 4: 0.7866}}"
2073,2073,2073,0.944000005722046,28.0,HER2+ antitumour activities,UniversSB-Medium,4,-0.2349999994039535,3355443,41,2,1,"{'concept_id': {0: 'C1960398'}, 'canonical_name': {0: 'HER2-positive carcinoma of breast'}, 'aliases': {0: ['HER2+ breast cancer', 'HER2 Overexpressing Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast (disorder)', 'HER2-Positive Breast Carcinoma', 'HER2 Overexpressing Subtype of Breast Carcinoma', 'HER2-positive breast cancer', 'HER2/neu-positive breast cancer', 'ERBB2 Overexpressing Subtype of Breast Carcinoma', 'Human epidermal growth factor 2 positive carcinoma of breast', 'HER2 Positive Breast Carcinoma', 'HER2 Positive Breast Cancer']}, 'types': {0: ['T191']}, 'definition': {0: 'A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).'}, 'entity': {0: 'HER2+'}, 'text': {0: 'HER2+ antitumour activities'}}",{},{},{},{},"           entity_group                  value     score
0  Diagnostic_procedure             antitumour  0.444132
1            Medication             antitumour  0.358042
2  Diagnostic_procedure  antitumour activities  0.608017",[],"{'keyword': {0: 'her2 antitumour activities', 1: 'antitumour activities', 2: 'her2 antitumour'}, 'score': {0: 0.9807, 1: 0.9304, 2: 0.9011}}"
2074,2074,2074,0.944000005722046,28.0,1.  ,UniversSB-Medium,4,-0.2349999994039535,16233287,41,3,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2075,2075,2075,0.9470000267028807,28.0,receptor at subdomain IV,UniversSB-Light,4,-0.2329999953508377,3355443,41,3,1,{},{},{},{},{},"           entity_group      value     score
0  Diagnostic_procedure   receptor  0.988074
1  Detailed_description  subdomain  0.588519
2  Biological_structure  subdomain  0.562773
3  Detailed_description         IV  0.569774",[],"{'keyword': {0: 'receptor subdomain iv', 1: 'receptor subdomain', 2: 'subdomain iv'}, 'score': {0: 0.9109, 1: 0.8745, 2: 0.8374}}"
2076,2076,2076,0.944000005722046,33.023399353027344,1,UniversSB-Medium,4,-0.2349999994039535,16777215,41,4,0,{},{},{},{},{},"  entity_group value     score
0       Dosage     1  0.686147",[],"{'keyword': {}, 'score': {}}"
2077,2077,2077,0.944000005722046,28.0,2. ,UniversSB-Medium,4,-0.2349999994039535,16233287,41,7,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2078,2078,2078,0.944000005722046,33.023399353027344,2,UniversSB-Medium,4,-0.2349999994039535,16777215,41,11,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     2  0.982709",[],"{'keyword': {}, 'score': {}}"
2079,2079,2079,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,41,15,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
2080,2080,2080,0.9470000267028807,28.0,(antiproliferative and apoptotic effects),UniversSB-Light,4,-0.2329999953508377,3355443,41,15,1,"{'concept_id': {0: 'C1280500'}, 'canonical_name': {0: 'Effect'}, 'aliases': {0: ['effects', 'Effect', 'Effect (qualifier value)', 'effect']}, 'types': {0: ['T080']}, 'definition': {0: 'A phenomenon that follows and is caused by some previous phenomenon.'}, 'entity': {0: 'apoptotic effects'}, 'text': {0: '(antiproliferative and apoptotic effects)'}}",{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'apoptotic effects', 1: 'antiproliferative apoptotic effects', 2: 'antiproliferative apoptotic'}, 'score': {0: 0.8326, 1: 0.8263, 2: 0.8136}}"
2081,2081,2081,0.944000005722046,33.023399353027344,3,UniversSB-Medium,4,-0.2349999994039535,16777215,41,18,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     3  0.991883",[],"{'keyword': {}, 'score': {}}"
2082,2082,2082,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,41,19,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
2083,2083,2083,0.9470000267028807,28.0,•,UniversSB-Light,4,-0.2329999953508377,16162586,41,22,0,{},{},{},{},{},"  entity_group value    score
0    Lab_value     •  0.56699",[],"{'keyword': {}, 'score': {}}"
2084,2084,2084,0.944000005722046,33.023399353027344,4,UniversSB-Medium,4,-0.2349999994039535,16777215,41,23,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     4  0.999388",[],"{'keyword': {}, 'score': {}}"
2085,2085,2085,0.944000005722046,28.0,DM1 cytotoxic activity*,UniversSB-Medium,4,-0.2349999994039535,3355443,41,29,0,"{'concept_id': {0: 'C4521706'}, 'canonical_name': {0: 'Cytotoxic (disposition)'}, 'aliases': {0: ['Cytotoxic (disposition)', 'Cytotoxic']}, 'types': {0: ['T080']}, 'definition': {0: 'A substance that destroys or impairs the function of living cells'}, 'entity': {0: 'cytotoxic activity*'}, 'text': {0: 'DM1 cytotoxic activity*'}}",{},{},{},{},"           entity_group               value     score
0  Diagnostic_procedure                 DM1  0.995482
1  Diagnostic_procedure  cytotoxic activity  0.994031",[],"{'keyword': {0: 'dm1 cytotoxic activity', 1: 'dm1 cytotoxic', 2: 'cytotoxic activity'}, 'score': {0: 0.9739, 1: 0.8992, 2: 0.8551}}"
2086,2086,2086,0.944000005722046,33.023399353027344,5,UniversSB-Medium,4,-0.2349999994039535,16777215,41,32,0,{},{},{},{},{},"  entity_group value     score
0    Lab_value     5  0.998987",[],"{'keyword': {}, 'score': {}}"
2087,2087,2087,0.944000005722046,28.0,3.  ,UniversSB-Medium,4,-0.2349999994039535,16233287,41,35,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2088,2088,2088,0.9470000267028807,28.0,HER2 receptor complex is internalised via ,UniversSB-Light,4,-0.2329999953508377,3355443,41,35,1,"{'concept_id': {0: 'C0525032'}, 'canonical_name': {0: 'International Normalized Ratio'}, 'aliases': {0: ['internationalised ratio', 'international normalized ratio (INR)', 'international normalized ratio', 'INR', 'international normalized ratios', 'INR (International normalized ratio)', 'Ratios, International Normalized', 'international normalising ratio', 'International Normalized Ratios', 'International normalized ratio (qualifier value)', 'INR - Internationalised ratio', 'international normalize ratio', 'International normalised ratio', 'Ratio, International Normalized', 'Internationalised ratio', 'INR (International normalised ratio)', 'international normalised ratio', 'bcr', 'International Normalized Ratio', 'international normalizing ratio', 'Normalized Ratios, International', 'International normalized ratio (observable entity)', 'International normalized ratio', 'Normalized Ratio, International']}, 'types': {0: ['T059']}, 'definition': {0: 'System established by the World Health Organization and the International Committee on Thrombosis and Hemostasis for monitoring and reporting blood coagulation tests. Under this system, results are standardized using the International Sensitivity Index for the particular test reagent/instrument combination used.'}, 'entity': {0: 'internalised'}, 'text': {0: 'HER2 receptor complex is internalised via '}}",{},{},{},{},"           entity_group                  value     score
0  Diagnostic_procedure                   HER2  0.987977
1  Diagnostic_procedure  HER2 receptor complex  0.908869",[],"{'keyword': {0: 'receptor complex internalised', 1: 'complex internalised', 2: 'her2 receptor complex', 3: 'her2 receptor', 4: 'receptor complex'}, 'score': {0: 0.8341, 1: 0.7937, 2: 0.7528, 3: 0.7434, 4: 0.6446}}"
2089,2089,2089,0.9470000267028807,28.0,endocytosis,UniversSB-Light,4,-0.2329999953508377,3355443,41,35,2,"{'concept_id': {0: 'C1159767'}, 'canonical_name': {0: 'regulation of endocytosis'}, 'aliases': {0: []}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that modulates the frequency, rate or extent of endocytosis. [GOC:go_curators]'}, 'entity': {0: 'endocytosis'}, 'text': {0: 'endocytosis'}}","{'concept_id': {0: 'C0014139'}, 'canonical_name': {0: 'Endocytoses'}, 'aliases': {0: ['Endocytosis']}, 'types': {0: ['T043']}, 'definition': {0: 'Cellular uptake of extracellular materials within membrane-limited vacuoles or microvesicles. ENDOSOMES play a central role in endocytosis.'}, 'entity': {0: 'endocytosis'}, 'text': {0: 'endocytosis'}}",{},"{'concept_id': {0: 'C1159769'}, 'canonical_name': {0: 'positive regulation of endocytosis'}, 'aliases': {0: ['up-regulation of endocytosis', 'upregulation of endocytosis', 'up regulation of endocytosis']}, 'types': {0: ['T043']}, 'definition': {0: 'Any process that activates or increases the frequency, rate or extent of endocytosis. [GOC:go_curators]'}, 'entity': {0: 'endocytosis'}, 'text': {0: 'endocytosis'}}",{},"   entity_group        value     score
0  Sign_symptom  endocytosis  0.977787",[],"{'keyword': {}, 'score': {}}"
2090,2090,2090,0.944000005722046,28.0,4.  ,UniversSB-Medium,4,-0.2349999994039535,16233287,41,54,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2091,2091,2091,0.9470000267028807,28.0,degradation inside the target cell and ,UniversSB-Light,4,-0.2329999953508377,3355443,41,54,1,"{'concept_id': {0: 'C1521840'}, 'canonical_name': {0: 'Target'}, 'aliases': {0: ['Destination', 'Targeted', 'Targeting', 'Target']}, 'types': {0: ['T169']}, 'definition': {0: 'An object fixed as a goal or point of examination; something to point at; a destination.'}, 'entity': {0: 'target cell'}, 'text': {0: 'degradation inside the target cell and '}}","{'concept_id': {0: 'C1257756'}, 'canonical_name': {0: 'Degradation, RNA'}, 'aliases': {0: ['RNA Degradation']}, 'types': {0: ['T045']}, 'definition': {0: ""The chemical reactions and pathways resulting in the breakdown of RNA, ribonucleic acid, one of the two main type of nucleic acid, consisting of a long, unbranched macromolecule formed from ribonucleotides joined in 3',5'-phosphodiester linkage. [ISBN:0198506732]""}, 'entity': {0: 'degradation'}, 'text': {0: 'degradation inside the target cell and '}}",{},"{'concept_id': {0: 'C1257756'}, 'canonical_name': {0: 'RNA catabolic process'}, 'aliases': {0: ['RNA catabolism', 'RNA breakdown', 'RNA degradation']}, 'types': {0: ['T045']}, 'definition': {0: ""The chemical reactions and pathways resulting in the breakdown of RNA, ribonucleic acid, one of the two main type of nucleic acid, consisting of a long, unbranched macromolecule formed from ribonucleotides joined in 3',5'-phosphodiester linkage. [ISBN:0198506732]""}, 'entity': {0: 'degradation'}, 'text': {0: 'degradation inside the target cell and '}}","{'concept_id': {0: 'C0221284'}, 'canonical_name': {0: 'Codocytes'}, 'aliases': {0: ['Target cells']}, 'types': {0: ['T025']}, 'definition': {0: 'Target cells (codocytes) have a centrally located disk of hemoglobin surrounded by an area of pallor with an outer rim of hemoglobin adjacent to the cell membrane giving the cell the appearance of a target. [PMID:27372866, PMID:32965812]'}, 'entity': {0: 'target cell'}, 'text': {0: 'degradation inside the target cell and '}}","           entity_group        value     score
0  Diagnostic_procedure  degradation  0.987409",[],"{'keyword': {0: 'degradation inside target', 1: 'degradation inside', 2: 'inside target cell', 3: 'target cell', 4: 'inside target'}, 'score': {0: 0.9458, 1: 0.9243, 2: 0.893, 3: 0.8478, 4: 0.8205}}"
2092,2092,2092,0.9470000267028807,28.0,"releases the active chemotherapy, DM1",UniversSB-Light,4,-0.2329999953508377,3355443,41,54,2,"{'concept_id': {0: 'C3250443'}, 'canonical_name': {0: 'MYOTONIC DYSTROPHY 1'}, 'aliases': {0: ['STEINERT DISEASE', 'DYSTROPHIA MYOTONICA', 'Steinert myotonic dystrophy syndrome (disorder)', 'Steinert syndrome', 'MYOTONIC DYSTROPHY 1', 'Steinert disease', 'Steinert myotonic dystrophy', 'DM1', 'DYSTROPHIA MYOTONICA 1', 'DM', 'Dystrophia Myotonica 1', 'Myotonic dystrophy type 1', 'Steinert myotonic dystrophy syndrome']}, 'types': {0: ['T047']}, 'definition': {0: 'A rare autosomal dominant disorder caused by mutations in the DMPK gene. It is characterized by myotonia, muscular dystrophy, hypogonadism, heart conduction defects and cataracts.'}, 'entity': {0: 'DM1'}, 'text': {0: 'releases the active chemotherapy, DM1'}}","{'concept_id': {0: 'C1868801'}, 'canonical_name': {0: 'Hyperthermic Intraperitoneal Chemotherapy'}, 'aliases': {0: ['Hot Chemotherapy', 'Chemotherapy, Intraperitoneal Hyperthermic', 'Chemotherapy, Hyperthermic Intraperitoneal', 'Chemotherapy, Hot', 'Intraperitoneal Hyperthermic Chemotherapies', 'Intraperitoneal Chemotherapy, Hyperthermic', 'Hyperthermic Chemotherapy, Intraperitoneal', 'HIPEC', 'Intraperitoneal Hyperthermic Chemotherapy']}, 'types': {0: ['T061']}, 'definition': {0: 'A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.'}, 'entity': {0: 'active chemotherapy'}, 'text': {0: 'releases the active chemotherapy, DM1'}}",{},{},{},"  entity_group         value     score
0   Medication  chemotherapy  0.973854
1   Medication           DM1  0.909766","[('chemotherapy', 'DRUG')]","{'keyword': {0: 'releases active chemotherapy', 1: 'active chemotherapy dm1', 2: 'releases active', 3: 'active chemotherapy', 4: 'chemotherapy dm1'}, 'score': {0: 0.9302, 1: 0.8273, 2: 0.804, 3: 0.7443, 4: 0.7285}}"
2093,2093,2093,0.944000005722046,24.76759910583496,Downstream ,UniversSB-Medium,4,-0.2349999994039535,0,41,55,0,"{'concept_id': {0: 'C1333245'}, 'canonical_name': {0: 'DOCK1 gene'}, 'aliases': {0: ['dedicator of cyto-kinesis 1', 'DOWNSTREAM OF CRK, 180-KD', 'DOCK1', 'DOCK180', 'DEDICATOR OF CYTOKINESIS 1', 'DOWNSTREAM OF CRK', 'DOCK1 Gene', 'CED5, C. ELEGANS, HOMOLOG OF', 'DOCK1 gene', 'ced5', 'DOwnstream of CrK', 'DOCK', 'dedicator of cytokinesis 1', 'Dedicator of Cytokinesis 1 Gene']}, 'types': {0: ['T028']}, 'definition': {0: 'This gene is involved in apoptosis, cell motility/migration and phagocytosis.'}, 'entity': {0: 'Downstream'}, 'text': {0: 'Downstream '}}",{},{},{},{},"           entity_group       value     score
0  Detailed_description  Downstream  0.999402",[],"{'keyword': {}, 'score': {}}"
2094,2094,2094,0.944000005722046,24.76759910583496,signalling pathways,UniversSB-Medium,4,-0.2349999994039535,0,41,55,1,"{'concept_id': {0: 'C4236748'}, 'canonical_name': {0: 'receptor signaling pathway via STAT'}, 'aliases': {0: ['kinase activated-STAT cascade', 'STAT signalling pathway', 'kinase-STAT cascade']}, 'types': {0: ['T044']}, 'definition': {0: 'An intracellular signal transduction process in which STAT proteins (Signal Transducers and Activators of Transcription) convey a signal to trigger a change in the activity or state of a cell. The STAT cascade begins with receptor activation followed by activation of STAT proteins by kinases. It proceeds through STA dimerization and subsequent nuclear translocation of STAT proteins, and ends with regulation of target gene expression by STAT proteins. [GOC:rjd, PMID:21534947, PMID:24587195]'}, 'entity': {0: 'signalling pathways'}, 'text': {0: 'signalling pathways'}}","{'concept_id': {0: 'C0086982'}, 'canonical_name': {0: 'Pathway, Signal Transduction'}, 'aliases': {0: ['Pathways, Signal Transduction', 'Signal Transduction Pathways', 'Signal Transduction Pathway']}, 'types': {0: ['T044']}, 'definition': {0: 'An elaboration of the known or inferred interactions involved in a signal transduction pathway.'}, 'entity': {0: 'signalling pathways'}, 'text': {0: 'signalling pathways'}}",{},"{'concept_id': {0: 'C1155452'}, 'canonical_name': {0: 'Notch-receptor signaling pathway'}, 'aliases': {0: ['Notch signalling pathway', 'N signaling pathway', 'N signalling pathway', 'Notch-receptor signalling pathway', 'Notch receptor signaling pathway', 'Notch signaling pathway', 'Notch receptor signalling pathway']}, 'types': {0: ['T044']}, 'definition': {0: 'The series of molecular signals initiated by an extracellular ligand binding to the receptor Notch on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:go_curators, GOC:signaling]'}, 'entity': {0: 'signalling pathways'}, 'text': {0: 'signalling pathways'}}",{},"           entity_group                value     score
0  Diagnostic_procedure  signalling pathways  0.999775",[],"{'keyword': {0: 'signalling pathways'}, 'score': {0: 1.0}}"
2095,2095,2095,0.9169999957084656,30.0,References:,ConduitITC-Bold,20,-0.2349999994039535,8194925,41,57,0,"{'concept_id': {0: 'C1561577'}, 'canonical_name': {0: 'Reference - MdfHmdMetSourceType'}, 'aliases': {0: ['Reference']}, 'types': {0: ['T170']}, 'definition': {0: '<p>This row represents a reference to a previously defined type. Such a reference means that, in a given message, the message element instance for the current row is identical to the message element instance that instantiates the referred row.</p>'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}","{'concept_id': {0: 'C0016483'}, 'canonical_name': {0: 'Food Preferences'}, 'aliases': {0: ['Food Preference', 'Preferences, Food', 'Preference, Food']}, 'types': {0: ['T080']}, 'definition': {0: 'The selection of one food over another.'}, 'entity': {0: 'References'}, 'text': {0: 'References:'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2096,2096,2096,0.8830000162124634,22.0,1. Kadcyla Summary of Product Characteristics. ,MyriadPro-Light,4,-0.25,3355443,41,57,1,"{'concept_id': {0: 'C0870672'}, 'canonical_name': {0: 'Human Characteristics'}, 'aliases': {0: ['Human Nature', 'human nature', 'Characteristics, Human', 'Nature, Human', 'human characteristics', 'Human Characteristic', 'Characteristic, Human']}, 'types': {0: ['T102']}, 'definition': {0: ""The fundamental dispositions and traits of humans. (Merriam-Webster's Collegiate Dictionary, 10th ed)""}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics. '}}","{'concept_id': {0: 'C0037401'}, 'canonical_name': {0: 'Social Characteristics'}, 'aliases': {0: ['Trait, Social', 'Social Attributes', 'Characteristics, Social', 'Social Traits', 'Sociological Characteristic', 'Characteristics, Sociological', 'Traits, Social', 'Social Attribute', 'Sociological Characteristics', 'Attribute, Social', 'Social Trait', 'Characteristic, Sociological', 'Attributes, Social']}, 'types': {0: ['T055']}, 'definition': {0: 'A trait or factor of an individual that is related to the way they socialize or present themselves to others.'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics. '}}",{},{},"{'concept_id': {0: 'C1286315'}, 'canonical_name': {0: 'Pain characteristic'}, 'aliases': {0: []}, 'types': {0: ['T201']}, 'definition': {0: 'A pain characteristic is defined as a subjective category or type of pain. []'}, 'entity': {0: 'Characteristics'}, 'text': {0: '1. Kadcyla Summary of Product Characteristics. '}}","           entity_group    value     score
0  Diagnostic_procedure  Kadcyla  0.796608","[('Kadcyla', 'DRUG')]","{'keyword': {0: 'kadcyla summary', 1: 'kadcyla summary product', 2: 'summary product', 3: 'summary product characteristics', 4: 'product characteristics'}, 'score': {0: 0.8868, 1: 0.8835, 2: 0.8533, 3: 0.7331, 4: 0.7046}}"
2097,2097,2097,0.8830000162124634,22.0,"2. Nahta R, et al. Cancer Lett. 2006;232(2):123–138. ",MyriadPro-Light,4,-0.25,3355443,41,57,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value   232  0.996301",[],"{'keyword': {0: '232 123 138', 1: 'nahta et al', 2: 'cancer lett 2006', 3: 'al cancer', 4: 'lett 2006'}, 'score': {0: 0.8822, 1: 0.8524, 2: 0.795, 3: 0.7189, 4: 0.6153}}"
2098,2098,2098,0.8830000162124634,22.0,3. Herceptin,MyriadPro-Light,4,-0.25,3355443,41,57,3,{},{},{},{},{},"           entity_group      value     score
0  Diagnostic_procedure  Herceptin  0.985167","[('Herceptin', 'DRUG')]","{'keyword': {}, 'score': {}}"
2099,2099,2099,0.944000005722046,28.0,5.  ,UniversSB-Medium,4,-0.2349999994039535,16233287,41,59,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2100,2100,2100,0.9470000267028807,28.0,"microtubules and inhibits their polymerisation, ",UniversSB-Light,4,-0.2329999953508377,3355443,41,59,1,"{'concept_id': {0: 'C1519613'}, 'canonical_name': {0: 'Translation Initiation'}, 'aliases': {0: ['biopolymerization', 'biopolymerisation', 'translational initiation', 'translation initiation']}, 'types': {0: ['T045']}, 'definition': {0: 'The process preceding formation of the peptide bond between the first two amino acids of a protein. This includes the formation of a complex of the ribosome, mRNA or circRNA, and an initiation complex that contains the first aminoacyl-tRNA. [ISBN:019879276X]'}, 'entity': {0: 'polymerisation'}, 'text': {0: 'microtubules and inhibits their polymerisation, '}}","{'concept_id': {0: 'C0026042'}, 'canonical_name': {0: 'Microtubule Proteins'}, 'aliases': {0: ['Proteins, Microtubule']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'Proteins found in the microtubules.'}, 'entity': {0: 'microtubules'}, 'text': {0: 'microtubules and inhibits their polymerisation, '}}",{},"{'concept_id': {0: 'C1519613'}, 'canonical_name': {0: 'biopolymerization'}, 'aliases': {0: ['biopolymerisation', 'translation initiation', 'translational initiation']}, 'types': {0: ['T045']}, 'definition': {0: 'The process preceding formation of the peptide bond between the first two amino acids of a protein. This includes the formation of a complex of the ribosome, mRNA or circRNA, and an initiation complex that contains the first aminoacyl-tRNA. [ISBN:019879276X]'}, 'entity': {0: 'polymerisation'}, 'text': {0: 'microtubules and inhibits their polymerisation, '}}","{'concept_id': {0: 'C0424296'}, 'canonical_name': {0: 'Disinhibition'}, 'aliases': {0: []}, 'types': {0: ['T048']}, 'definition': {0: 'Unrestrained behavior, often at odds with social norms.'}, 'entity': {0: 'inhibits'}, 'text': {0: 'microtubules and inhibits their polymerisation, '}}","           entity_group         value     score
0  Detailed_description  microtubules  0.486186",[],"{'keyword': {0: 'microtubules inhibits polymerisation', 1: 'microtubules inhibits', 2: 'inhibits polymerisation'}, 'score': {0: 0.915, 1: 0.8278, 2: 0.8107}}"
2101,2101,2101,0.9470000267028807,28.0,causing cell-cycle arrest and cell death,UniversSB-Light,4,-0.2329999953508377,3355443,41,59,2,"{'concept_id': {0: 'C2754100'}, 'canonical_name': {0: 'neuron death'}, 'aliases': {0: ['neuron cell death', 'neuronal cell death']}, 'types': {0: ['T043']}, 'definition': {0: 'The process of cell death in a neuron. [GOC:BHF, GOC:mah]'}, 'entity': {0: 'cell death'}, 'text': {0: 'causing cell-cycle arrest and cell death'}}","{'concept_id': {0: 'C3546446'}, 'canonical_name': {0: 'Regulated Cell Death'}, 'aliases': {0: ['Cell Death, Regulated']}, 'types': {0: ['T043']}, 'definition': {0: 'Genetically encoded mechanisms in multicellular and unicellular eukaryotes that function to eliminate cells that are superfluous either during development, or to maintain tissue and organism homeostasis; and cells that are irreversibly damaged, abnormal, and/or potentially harmful.'}, 'entity': {0: 'cell death'}, 'text': {0: 'causing cell-cycle arrest and cell death'}}",{},"{'concept_id': {0: 'C3546446'}, 'canonical_name': {0: 'regulated cell death'}, 'aliases': {0: []}, 'types': {0: ['T043']}, 'definition': {0: 'Genetically encoded mechanisms in multicellular and unicellular eukaryotes that function to eliminate cells that are superfluous either during development, or to maintain tissue and organism homeostasis; and cells that are irreversibly damaged, abnormal, and/or potentially harmful.'}, 'entity': {0: 'cell death'}, 'text': {0: 'causing cell-cycle arrest and cell death'}}",{},"       entity_group                  value     score
0  Disease_disorder      cell-cycle arrest  0.916239
1  Disease_disorder  cell-cycle cell death  0.915735",[],"{'keyword': {0: 'causing cell cycle', 1: 'arrest cell death', 2: 'cell cycle arrest', 3: 'cell death', 4: 'cell cycle'}, 'score': {0: 0.8972, 1: 0.8914, 2: 0.8841, 3: 0.8254, 4: 0.8046}}"
2102,2102,2102,0.9470000267028807,19.0,*Cytotoxic DM1-containing catabolites (primarily lysine-bound emtansine).,UniversSB-Light,4,-0.2329999953508377,3355443,41,60,0,"{'concept_id': {0: 'C4505403'}, 'canonical_name': {0: 'Maytansinoid DM1'}, 'aliases': {0: ['Emtansine', 'DM1, Maytansinoid', 'Mertansine']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'emtansine'}, 'text': {0: '*Cytotoxic DM1-containing catabolites (primarily lysine-bound emtansine).'}}","{'concept_id': {0: 'C4505403'}, 'canonical_name': {0: 'Maytansinoid DM1'}, 'aliases': {0: ['Emtansine', 'Mertansine', 'DM1, Maytansinoid']}, 'types': {0: ['T109', 'T121']}, 'definition': {0: None}, 'entity': {0: 'emtansine'}, 'text': {0: '*Cytotoxic DM1-containing catabolites (primarily lysine-bound emtansine).'}}",{},{},{},"           entity_group                               value     score
0  Diagnostic_procedure                           Cytotoxic  0.425934
1  Detailed_description                      DM1-containing  0.907907
2  Detailed_description  catabolites primarily lysine-bound  0.563882
3  Detailed_description              lysine-bound emtansine  0.697296","[('emtansine', 'DRUG')]","{'keyword': {0: 'dm1 containing catabolites', 1: 'cytotoxic dm1 containing', 2: 'primarily lysine', 3: 'cytotoxic dm1', 4: 'dm1 containing'}, 'score': {0: 0.9177, 1: 0.8341, 2: 0.758, 3: 0.7538, 4: 0.7417}}"
2103,2103,2103,0.9470000267028807,19.0,"DM1, derivative of maytansine; IV, intravenous.",UniversSB-Light,4,-0.2329999953508377,3355443,41,61,0,"{'concept_id': {0: 'C0455142'}, 'canonical_name': {0: 'Intravenous therapy'}, 'aliases': {0: ['care intravenous', 'Intravenous Care', 'Intravenous therapy (regime/therapy)', 'Intravenous (IV) Therapy', 'Intravenous therapy', 'intravenous therapy', 'Intravenous care']}, 'types': {0: ['T061']}, 'definition': {0: 'Actions performed to support the use of infusion equipment'}, 'entity': {0: 'intravenous'}, 'text': {0: 'DM1, derivative of maytansine; IV, intravenous.'}}","{'concept_id': {0: 'C0021440'}, 'canonical_name': {0: 'Infusion, Intravenous'}, 'aliases': {0: ['Intravenous Infusion', 'Intravenous Infusions', 'Infusions, Intravenous']}, 'types': {0: ['T061']}, 'definition': {0: 'The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.'}, 'entity': {0: 'intravenous'}, 'text': {0: 'DM1, derivative of maytansine; IV, intravenous.'}}",{},{},{},"     entity_group        value     score
0      Medication   maytansine  0.999303
1  Administration  intravenous  0.999469","[('maytansine', 'DRUG'), ('IV', 'ROUTE'), ('intravenous', 'ROUTE')]","{'keyword': {0: 'dm1 derivative maytansine', 1: 'maytansine iv', 2: 'maytansine iv intravenous', 3: 'dm1 derivative', 4: 'iv intravenous'}, 'score': {0: 0.8663, 1: 0.8395, 2: 0.8073, 3: 0.7113, 4: 0.6078}}"
2104,2104,2104,0.9470000267028807,35.0,PI,UniversSB-Light,4,-0.2329999953508377,9211020,41,62,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
2105,2105,2105,0.9470000267028807,35.0,REF,UniversSB-Light,4,-0.2329999953508377,9211020,41,62,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
2106,2106,2106,0.9470000267028807,47.0,i,UniversSB-Light,4,-0.2329999953508377,9211020,41,62,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
2107,2107,2107,0.9470000267028807,35.0,MOA,UniversSB-Light,4,-0.2329999953508377,16777215,41,62,3,"{'concept_id': {0: 'C0431108'}, 'canonical_name': {0: 'Anaplastic Oligoastrocytoma'}, 'aliases': {0: ['Anaplastic Oligoastrocytoma, Not Otherwise Specified', 'aMOA', 'Anaplastic Oligoastrocytoma', 'anaplastic oligoastrocytoma', 'WHO Grade 3 Mixed Glioma', 'Anaplastic Oligoastrocytoma, NOS', 'Anaplastic oligoastrocytoma (morphologic abnormality)', 'Anaplastic Mixed Glioma', 'WHO Grade III Mixed Glioma', 'Anaplastic oligoastrocytoma']}, 'types': {0: ['T191']}, 'definition': {0: 'A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.'}, 'entity': {0: 'MOA'}, 'text': {0: 'MOA'}}",{},{},{},{},"  entity_group value     score
0    Lab_value   MOA  0.626914",[],"{'keyword': {}, 'score': {}}"
2108,2108,2108,0.8830000162124634,35.0,PI,MyriadPro-Light,4,-0.25,9211020,41,63,0,"{'concept_id': {0: 'C0122626'}, 'canonical_name': {0: 'human pancreatic eicosapeptide'}, 'aliases': {0: ['Pancreatic Icosapeptide', 'PI', 'human pancreatic eicosapeptide']}, 'types': {0: ['T116']}, 'definition': {0: 'Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.'}, 'entity': {0: 'PI'}, 'text': {0: 'PI'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure    PI  0.992753","[('PI', 'DRUG')]","{'keyword': {}, 'score': {}}"
2109,2109,2109,0.8830000162124634,35.0,REF,MyriadPro-Light,4,-0.25,9211020,41,63,1,"{'concept_id': {0: 'C1425988'}, 'canonical_name': {0: 'ALYREF gene'}, 'aliases': {0: ['THO COMPLEX, SUBUNIT 4', 'ALYREF gene', 'Aly/REF export factor', 'ALY/REF EXPORT FACTOR', 'ALY', 'bZIP-ENHANCING FACTOR', 'BEF', 'ALYREF', 'REF', 'THOC4', 'ALY/REF', 'TRANSCRIPTIONAL COACTIVATOR ALY', 'THO complex 4']}, 'types': {0: ['T028']}, 'definition': {0: None}, 'entity': {0: 'REF'}, 'text': {0: 'REF'}}",{},{},{},{},"           entity_group value     score
0  Diagnostic_procedure   REF  0.181966",[],"{'keyword': {}, 'score': {}}"
2110,2110,2110,0.8830000162124634,47.0,i,MyriadPro-Light,4,-0.25,9211020,41,63,2,{},{},{},{},{},"  entity_group value     score
0  Coreference     i  0.093767",[],"{'keyword': {}, 'score': {}}"
2111,2111,2111,0.9052734375,18.0,Promotional Certification,ArialMT,0,-0.2119140625,0,42,1,0,"{'concept_id': {0: 'C0007836'}, 'canonical_name': {0: 'Certification'}, 'aliases': {0: ['certification', 'Certification', 'certifications', 'Certified', 'Certifications']}, 'types': {0: ['T064']}, 'definition': {0: 'Compliance with a set of standards defined by non-governmental organizations. Certification is applied for by individuals on a voluntary basis and represents a professional status when achieved, e.g., certification for a medical specialty.'}, 'entity': {0: 'Promotional Certification'}, 'text': {0: 'Promotional Certification'}}","{'concept_id': {0: 'C0007836'}, 'canonical_name': {0: 'Certification'}, 'aliases': {0: ['Certifications']}, 'types': {0: ['T064']}, 'definition': {0: 'Compliance with a set of standards defined by non-governmental organizations. Certification is applied for by individuals on a voluntary basis and represents a professional status when achieved, e.g., certification for a medical specialty.'}, 'entity': {0: 'Promotional Certification'}, 'text': {0: 'Promotional Certification'}}",{},{},{},"           entity_group                      value     score
0  Diagnostic_procedure  Promotional Certification  0.955142",[],"{'keyword': {0: 'promotional certification'}, 'score': {0: 1.0}}"
2112,2112,2112,0.9052734375,11.0,  Number:,ArialMT,0,-0.2119140625,0,42,2,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2113,2113,2113,0.9520000219345092,10.0,M-GB-00010642,MyriadPro-Regular,4,-0.25,0,42,2,1,{},{},{},{},{},"           entity_group          value     score
0  Detailed_description  M-GB-00010642  0.578235
1  Diagnostic_procedure  M-GB-00010642  0.510839
2             Lab_value  M-GB-00010642  0.562100",[],"{'keyword': {0: 'gb 00010642'}, 'score': {0: 0.9114}}"
2114,2114,2114,0.9052734375,11.0,  Version:,ArialMT,0,-0.2119140625,0,42,3,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2115,2115,2115,0.9052734375,11.0,1,ArialMT,0,-0.2119140625,0,42,3,1,{},{},{},{},{},"  entity_group value     score
0       Dosage     1  0.686147",[],"{'keyword': {}, 'score': {}}"
2116,2116,2116,0.9052734375,11.0,. 0,ArialMT,0,-0.2119140625,0,42,3,2,{},{},{},{},{},"  entity_group value     score
0    Lab_value     0  0.998937",[],"{'keyword': {}, 'score': {}}"
2117,2117,2117,0.9052734375,11.0,  Name:,ArialMT,0,-0.2119140625,0,42,4,0,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {}, 'score': {}}"
2118,2118,2118,0.9052734375,11.0,Breast Cancer_ Kadcyla EBC_ iPDF_ January 2023,ArialMT,0,-0.2119140625,0,42,4,1,"{'concept_id': {0: 'C3829466'}, 'canonical_name': {0: 'January'}, 'aliases': {0: []}, 'types': {0: ['T080']}, 'definition': {0: 'The first month of the year in the Gregorian calendar.'}, 'entity': {0: 'January'}, 'text': {0: 'Breast Cancer_ Kadcyla EBC_ iPDF_ January 2023'}}","{'concept_id': {0: 'C0294028'}, 'canonical_name': {0: 'Breast Cancer 2 Protein'}, 'aliases': {0: ['Fanconi Anemia Complementation Group D1 Protein', 'Fanconi Anemia Group D1 Protein', 'FANCD1 Protein', 'BRCA2 Protein', 'Fanconi Anemia Group D1 Complementing Protein', 'BRCA2 Gene Product', 'Breast Cancer 2 Gene Product']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)'}, 'entity': {0: 'Breast Cancer'}, 'text': {0: 'Breast Cancer_ Kadcyla EBC_ iPDF_ January 2023'}}",{},{},"{'concept_id': {0: 'C0006826'}, 'canonical_name': {0: 'Cancer'}, 'aliases': {0: []}, 'types': {0: ['T191']}, 'definition': {0: 'A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.'}, 'entity': {0: 'Breast Cancer'}, 'text': {0: 'Breast Cancer_ Kadcyla EBC_ iPDF_ January 2023'}}","           entity_group         value     score
0      Disease_disorder        Breast  0.551875
1  Diagnostic_procedure       Kadcyla  0.494787
2  Detailed_description          EBC_  0.593256
3                  Date  January 2023  0.988384",[],"{'keyword': {0: 'breast cancer_ kadcyla', 1: 'ebc_ ipdf_', 2: 'cancer_ kadcyla ebc_', 3: 'ebc_ ipdf_ january', 4: 'january 2023'}, 'score': {0: 0.9105, 1: 0.868, 2: 0.8636, 3: 0.8252, 4: 0.7883}}"
2119,2119,2119,0.9052734375,9.0,Certification Declaration:,ArialMT,0,-0.2119140625,0,42,5,0,"{'concept_id': {0: 'C0007836'}, 'canonical_name': {0: 'Certification'}, 'aliases': {0: ['certification', 'Certification', 'certifications', 'Certified', 'Certifications']}, 'types': {0: ['T064']}, 'definition': {0: 'Compliance with a set of standards defined by non-governmental organizations. Certification is applied for by individuals on a voluntary basis and represents a professional status when achieved, e.g., certification for a medical specialty.'}, 'entity': {0: 'Certification Declaration'}, 'text': {0: 'Certification Declaration:'}}","{'concept_id': {0: 'C0007836'}, 'canonical_name': {0: 'Certification'}, 'aliases': {0: ['Certifications']}, 'types': {0: ['T064']}, 'definition': {0: 'Compliance with a set of standards defined by non-governmental organizations. Certification is applied for by individuals on a voluntary basis and represents a professional status when achieved, e.g., certification for a medical specialty.'}, 'entity': {0: 'Certification Declaration'}, 'text': {0: 'Certification Declaration:'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'certification declaration'}, 'score': {0: 0.9528}}"
2120,2120,2120,0.9052734375,9.0,I certify that I have examined the final electronic version of this material and believe it to be in accordance with the,ArialMT,0,-0.2119140625,0,42,5,1,"{'concept_id': {0: 'C1880278'}, 'canonical_name': {0: 'Dent in Material'}, 'aliases': {0: []}, 'types': {0: ['T033']}, 'definition': {0: 'Problem associated with a undesired change in shape, characterized by the presence of a slight hollow (dent) in the device surface.'}, 'entity': {0: 'material'}, 'text': {0: 'I certify that I have examined the final electronic version of this material and believe it to be in accordance with the'}}","{'concept_id': {0: 'C0011379'}, 'canonical_name': {0: 'Dental Materials'}, 'aliases': {0: ['Dental Material', 'Material, Dental', 'Materials, Dental']}, 'types': {0: ['T122']}, 'definition': {0: 'Materials used in the production of dental bases, restorations, impressions, prostheses, etc.'}, 'entity': {0: 'material'}, 'text': {0: 'I certify that I have examined the final electronic version of this material and believe it to be in accordance with the'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'believe accordance', 1: 'version material', 2: 'electronic version material', 3: 'examined final', 4: 'final electronic'}, 'score': {0: 0.7854, 1: 0.5822, 2: 0.5583, 3: 0.5465, 4: 0.2847}}"
2121,2121,2121,0.9052734375,9.0,requirements of the relevant regulations relating to advertising; the ABPI Code of Practice; company policies and procedures;,ArialMT,0,-0.2119140625,0,42,5,2,"{'concept_id': {0: 'C2700391'}, 'canonical_name': {0: 'Procedure (set of actions)'}, 'aliases': {0: ['procedure', 'procedures', 'Procedure']}, 'types': {0: ['T169']}, 'definition': {0: 'Any stepwise set of actions.'}, 'entity': {0: 'procedures'}, 'text': {0: 'requirements of the relevant regulations relating to advertising; the ABPI Code of Practice; company policies and procedures;'}}","{'concept_id': {0: 'C1260336'}, 'canonical_name': {0: 'Maze Ablation'}, 'aliases': {0: ['Maze Ablations', 'Maze Surgery', 'Maze Procedures', 'Cox-Maze Operation', 'Maze Procedure', 'Maze Surgeries', 'Cox Maze Operation', 'Ablation, Maze', 'Cox-Maze Procedure', 'Cox Maze Procedure', 'Cox-Maze Operations']}, 'types': {0: ['T061']}, 'definition': {0: 'A surgical treatment in which heart tissue is scarred (cut-and-sew method), excised or otherwise destroyed in an open chest approach to direct electrical signals through a more controlled path via the ATRIOVENTRICULAR NODE. It is often used to restore normal rhythms in ATRIAL FIBRILLATION.'}, 'entity': {0: 'procedures'}, 'text': {0: 'requirements of the relevant regulations relating to advertising; the ABPI Code of Practice; company policies and procedures;'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'relevant regulations relating', 1: 'requirements relevant', 2: 'practice company', 3: 'abpi code', 4: 'practice company policies'}, 'score': {0: 0.6876, 1: 0.6129, 2: 0.5587, 3: 0.4497, 4: 0.0524}}"
2122,2122,2122,0.9052734375,9.0,is not inconsistent with the marketing authorisation and the summary of product characteristics and is a fair and truthful,ArialMT,0,-0.2119140625,0,42,5,3,"{'concept_id': {0: 'C2911689'}, 'canonical_name': {0: 'Fair (qualifier)'}, 'aliases': {0: ['Fair', 'Fair (qualifier value)']}, 'types': {0: ['T080']}, 'definition': {0: 'Having no exceptional quality or ability.'}, 'entity': {0: 'fair'}, 'text': {0: 'is not inconsistent with the marketing authorisation and the summary of product characteristics and is a fair and truthful'}}","{'concept_id': {0: 'C0018715'}, 'canonical_name': {0: 'Health Fairs'}, 'aliases': {0: ['Fairs, Health', 'Fair, Health', 'Health Fair']}, 'types': {0: ['T058']}, 'definition': {0: 'Community health education events focused on prevention of disease and promotion of health through audiovisual exhibits.'}, 'entity': {0: 'fair'}, 'text': {0: 'is not inconsistent with the marketing authorisation and the summary of product characteristics and is a fair and truthful'}}",{},{},"{'concept_id': {0: 'C1849221'}, 'canonical_name': {0: 'Light colored hair'}, 'aliases': {0: ['Flaxen hair color', 'Fair hair', 'Blond hair', 'Flaxen hair colour', 'Light coloured hair', 'Sandy hair colour', 'Fair hair colour', 'Towhead (hair color)', 'Straw colored hair', 'Sandy hair color', 'Straw coloured hair', 'Fair hair color']}, 'types': {0: ['T033']}, 'definition': {0: 'A human hair color characterized by low levels of eumelanin.'}, 'entity': {0: 'fair'}, 'text': {0: 'is not inconsistent with the marketing authorisation and the summary of product characteristics and is a fair and truthful'}}","  entity_group     value     score
0    Lab_value      fair  0.778180
1    Lab_value  truthful  0.657639",[],"{'keyword': {0: 'product characteristics fair', 1: 'characteristics fair truthful', 2: 'inconsistent marketing', 3: 'summary product characteristics', 4: 'authorisation summary'}, 'score': {0: 0.8226, 1: 0.7977, 2: 0.77, 3: 0.7643, 4: 0.4407}}"
2123,2123,2123,0.9052734375,9.0,presentation of the facts about the medicine.,ArialMT,0,-0.2119140625,0,42,5,4,"{'concept_id': {0: 'C0029167'}, 'canonical_name': {0: 'Oral Medicine'}, 'aliases': {0: ['medicine oral', 'Medicine, Oral', 'oral medicine', 'stomatology', 'Stomatology', 'Oral medicine', 'medicines oral']}, 'types': {0: ['T091']}, 'definition': {0: 'A branch of dentistry dealing with diseases of the oral and paraoral structures and the oral management of systemic diseases. (Hall, What is Oral Medicine, Anyway? Clinical Update: National Naval Dental Center, March 1991, p7-8)'}, 'entity': {0: 'medicine'}, 'text': {0: 'presentation of the facts about the medicine.'}}","{'concept_id': {0: 'C0038195'}, 'canonical_name': {0: 'State Medicine'}, 'aliases': {0: ['Socialized Medicine', 'Medicine, State', 'Medicine, Socialized']}, 'types': {0: ['T064']}, 'definition': {0: 'A system of medical care regulated, controlled and financed by the government, in which the government assumes responsibility for the health needs of the population.'}, 'entity': {0: 'medicine'}, 'text': {0: 'presentation of the facts about the medicine.'}}",{},"{'concept_id': {0: 'C0206431'}, 'canonical_name': {0: 'antigen processing and presentation'}, 'aliases': {0: ['antigen processing', 'antigen presentation']}, 'types': {0: ['T043']}, 'definition': {0: 'The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)'}, 'entity': {0: 'presentation'}, 'text': {0: 'presentation of the facts about the medicine.'}}",{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'presentation facts medicine', 1: 'presentation facts', 2: 'facts medicine'}, 'score': {0: 0.932, 1: 0.8656, 2: 0.8526}}"
2124,2124,2124,0.9052734375,9.0,"If this is certification of an international meeting, I certify that I have examined all the proposed arrangements for the meeting",ArialMT,0,-0.2119140625,0,42,6,0,"{'concept_id': {0: 'C0449830'}, 'canonical_name': {0: 'With configuration'}, 'aliases': {0: ['Configuration', 'configuration', 'Has configuration', 'configurations', 'With configuration (attribute)', 'Arrangement', 'With configuration']}, 'types': {0: ['T082']}, 'definition': {0: 'The spatial property of the way in which something is placed.'}, 'entity': {0: 'arrangements'}, 'text': {0: 'If this is certification of an international meeting, I certify that I have examined all the proposed arrangements for the meeting'}}","{'concept_id': {0: 'C0242487'}, 'canonical_name': {0: 'Living Arrangements'}, 'aliases': {0: ['Arrangement, Living', 'Arrangements, Living', 'Living Arrangement']}, 'types': {0: ['T078']}, 'definition': {0: 'A description of a personal residence and the relationship between the occupants that reside there.'}, 'entity': {0: 'arrangements'}, 'text': {0: 'If this is certification of an international meeting, I certify that I have examined all the proposed arrangements for the meeting'}}",{},{},{},"     entity_group            value     score
0  Clinical_event  meeting meeting  0.373439",[],"{'keyword': {0: 'certify examined proposed', 1: 'international meeting certify', 2: 'proposed arrangements', 3: 'international meeting', 4: 'certification international'}, 'score': {0: 0.7622, 1: 0.7304, 2: 0.7269, 3: 0.6631, 4: 0.6502}}"
2125,2125,2125,0.9052734375,9.0,"and in my belief the arrangements are in accordance with the requirements of the relevant regulations relating to advertising,",ArialMT,0,-0.2119140625,0,42,6,1,"{'concept_id': {0: 'C0001690'}, 'canonical_name': {0: 'Advertising (activity)'}, 'aliases': {0: ['Advertising', 'advertising', 'advertised', 'Advertising as Topic', 'Advertisings', 'Advertisement as Topic']}, 'types': {0: ['T057']}, 'definition': {0: 'Works about the act or practice of calling public attention to a product, service, need, etc., especially by paid announcements in newspapers, magazines, on radio, or on television. (Random House Unabridged Dictionary, 2d ed)'}, 'entity': {0: 'advertising'}, 'text': {0: 'and in my belief the arrangements are in accordance with the requirements of the relevant regulations relating to advertising,'}}","{'concept_id': {0: 'C0949214'}, 'canonical_name': {0: 'Advertisements'}, 'aliases': {0: ['Advertisement']}, 'types': {0: ['T170']}, 'definition': {0: 'An act, practice or form of communication used to encourage, persuade, or manipulate an audience to take or continue to take a certain action.'}, 'entity': {0: 'advertising'}, 'text': {0: 'and in my belief the arrangements are in accordance with the requirements of the relevant regulations relating to advertising,'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'accordance requirements relevant', 1: 'relating advertising', 2: 'regulations relating advertising', 3: 'arrangements accordance requirements', 4: 'belief arrangements'}, 'score': {0: 0.8691, 1: 0.7959, 2: 0.789, 3: 0.7547, 4: 0.6468}}"
2126,2126,2126,0.9052734375,9.0,the ABPI Code of Practice and company policies and procedures.,ArialMT,0,-0.2119140625,0,42,6,2,"{'concept_id': {0: 'C2700391'}, 'canonical_name': {0: 'Procedure (set of actions)'}, 'aliases': {0: ['procedure', 'procedures', 'Procedure']}, 'types': {0: ['T169']}, 'definition': {0: 'Any stepwise set of actions.'}, 'entity': {0: 'procedures'}, 'text': {0: 'the ABPI Code of Practice and company policies and procedures.'}}","{'concept_id': {0: 'C1260336'}, 'canonical_name': {0: 'Maze Ablation'}, 'aliases': {0: ['Maze Ablations', 'Maze Surgery', 'Maze Procedures', 'Cox-Maze Operation', 'Maze Procedure', 'Maze Surgeries', 'Cox Maze Operation', 'Ablation, Maze', 'Cox-Maze Procedure', 'Cox Maze Procedure', 'Cox-Maze Operations']}, 'types': {0: ['T061']}, 'definition': {0: 'A surgical treatment in which heart tissue is scarred (cut-and-sew method), excised or otherwise destroyed in an open chest approach to direct electrical signals through a more controlled path via the ATRIOVENTRICULAR NODE. It is often used to restore normal rhythms in ATRIAL FIBRILLATION.'}, 'entity': {0: 'procedures'}, 'text': {0: 'the ABPI Code of Practice and company policies and procedures.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'abpi code practice', 1: 'abpi code', 2: 'company policies', 3: 'policies procedures', 4: 'practice company'}, 'score': {0: 0.9027, 1: 0.8446, 2: 0.8199, 3: 0.8161, 4: 0.7696}}"
2127,2127,2127,0.9052734375,9.0,I certify that the correct certificate and process has been used for this item.,ArialMT,0,-0.2119140625,0,42,7,0,"{'concept_id': {0: 'C4684623'}, 'canonical_name': {0: 'Data Item'}, 'aliases': {0: ['Data Element Item']}, 'types': {0: ['T071']}, 'definition': {0: 'A named component of a data element, usually the smallest component. (ANSI)'}, 'entity': {0: 'item'}, 'text': {0: 'I certify that the correct certificate and process has been used for this item.'}}","{'concept_id': {0: 'C0007835'}, 'canonical_name': {0: 'Certificate of Need'}, 'aliases': {0: ['Need Certificates', 'Need Certificate']}, 'types': {0: ['T170']}, 'definition': {0: 'A certificate issued by a governmental body to an individual or organization proposing to construct or modify a health facility, or to offer a new or different service. The process of issuing the certificate is also included.'}, 'entity': {0: 'certificate'}, 'text': {0: 'I certify that the correct certificate and process has been used for this item.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'certify correct certificate', 1: 'correct certificate process', 2: 'used item', 3: 'certificate process', 4: 'process used'}, 'score': {0: 0.8436, 1: 0.7689, 2: 0.7122, 3: 0.6619, 4: 0.647}}"
2128,2128,2128,0.9052734375,9.0,"Final Form Declaration by Appropriately Qualified Person, if applicable:",ArialMT,0,-0.2119140625,0,42,8,0,"{'concept_id': {0: 'C2985652'}, 'canonical_name': {0: 'Qualified Person'}, 'aliases': {0: []}, 'types': {0: ['T097']}, 'definition': {0: 'A person that has been recognized as having certain training/experience or other characteristics that would make that person an appropriate performer for a certain activity.'}, 'entity': {0: 'Appropriately Qualified Person'}, 'text': {0: 'Final Form Declaration by Appropriately Qualified Person, if applicable:'}}","{'concept_id': {0: 'C0376315'}, 'canonical_name': {0: 'Form'}, 'aliases': {0: ['Forms']}, 'types': {0: ['T073']}, 'definition': {0: 'Document used for acquiring particular information or for presenting particular information in a prescribed sequence and format, often with blank spaces or lines or other methods to prompt for insertion of the requested information.'}, 'entity': {0: 'Final Form'}, 'text': {0: 'Final Form Declaration by Appropriately Qualified Person, if applicable:'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'final form declaration', 1: 'form declaration', 2: 'declaration appropriately', 3: 'declaration appropriately qualified', 4: 'qualified person'}, 'score': {0: 0.8885, 1: 0.8746, 2: 0.8376, 3: 0.7683, 4: 0.5662}}"
2129,2129,2129,0.9052734375,9.0,I have reviewed the final physical form of this material and believe it to be an accurate rendition of the final electronic version.,ArialMT,0,-0.2119140625,0,42,8,1,"{'concept_id': {0: 'C0013852'}, 'canonical_name': {0: 'Electrons'}, 'aliases': {0: ['Electron', 'Negatrons', 'negatron', 'Negative beta particle (physical force)', 'electrons', 'Electron (substance)', 'Negatron', 'Negative Beta Particle', 'Electrons', 'electron', 'Negative beta particle']}, 'types': {0: ['T196']}, 'definition': {0: 'Stable elementary particles having the smallest known negative charge, present in all elements; also called negatrons. Positively charged electrons are called positrons. The numbers, energies and arrangement of electrons around atomic nuclei determine the chemical identities of elements. Beams of electrons are called CATHODE RAYS.'}, 'entity': {0: 'electronic version'}, 'text': {0: 'I have reviewed the final physical form of this material and believe it to be an accurate rendition of the final electronic version.'}}","{'concept_id': {0: 'C4281784'}, 'canonical_name': {0: 'Electronic'}, 'aliases': {0: ['Electronics']}, 'types': {0: ['T090']}, 'definition': {0: 'The study, control, and application of the conduction of ELECTRICITY through gases or vacuum, or through semiconducting or conducting materials. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)'}, 'entity': {0: 'electronic version'}, 'text': {0: 'I have reviewed the final physical form of this material and believe it to be an accurate rendition of the final electronic version.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'accurate rendition final', 1: 'rendition final electronic', 2: 'physical form', 3: 'reviewed final', 4: 'electronic version'}, 'score': {0: 0.8172, 1: 0.7965, 2: 0.7327, 3: 0.706, 4: 0.7045}}"
2130,2130,2130,0.9052734375,14.0,Approvals,ArialMT,0,-0.2119140625,0,42,9,0,{},{},{},{},{},"           entity_group      value     score
0  Detailed_description  Approvals  0.197485",[],"{'keyword': {}, 'score': {}}"
2131,2131,2131,0.9520000219345092,10.0,Gemma Levett (levettg) - Non-Medical Final Signatory,MyriadPro-Regular,4,-0.25,0,42,10,0,{},{},{},{},{},"           entity_group        value     score
0  Detailed_description  Non-Medical  0.958355",[],"{'keyword': {0: 'final signatory', 1: 'levett levettg non', 2: 'levettg non medical', 3: 'gemma levett levettg', 4: 'non medical final'}, 'score': {0: 0.8574, 1: 0.8498, 2: 0.8385, 3: 0.8176, 4: 0.7983}}"
2132,2132,2132,0.9520000219345092,10.0,Declaration,MyriadPro-Regular,4,-0.25,0,42,10,1,{},{},{},{},{},"  entity_group        value     score
0  Coreference  Declaration  0.783362",[],"{'keyword': {}, 'score': {}}"
2133,2133,2133,0.9520000219345092,10.0,(levettg@roche.com),MyriadPro-Regular,4,-0.25,0,42,10,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'levettg roche com', 1: 'roche com', 2: 'levettg roche'}, 'score': {0: 0.8268, 1: 0.789, 2: 0.7271}}"
2134,2134,2134,0.9520000219345092,10.0,"Meaning: As the Non-Medical Final Signatory, I approve",MyriadPro-Regular,4,-0.25,0,42,11,0,"{'concept_id': {0: 'C2346846'}, 'canonical_name': {0: 'Approved Protocol - clinical study status'}, 'aliases': {0: ['Approved Protocol', 'Approved', 'Approved Clinical Study Protocol']}, 'types': {0: ['T169']}, 'definition': {0: 'Protocol is approved by the review board.'}, 'entity': {0: 'I approve'}, 'text': {0: 'Meaning: As the Non-Medical Final Signatory, I approve'}}",{},{},{},{},"  entity_group    value     score
0    Lab_value  approve  0.329056",[],"{'keyword': {0: 'signatory approve', 1: 'non medical', 2: 'non medical final', 3: 'meaning non medical', 4: 'medical final signatory'}, 'score': {0: 0.9099, 1: 0.7758, 2: 0.7703, 3: 0.7551, 4: 0.6013}}"
2135,2135,2135,0.9520000219345092,10.0,this document for use.,MyriadPro-Regular,4,-0.25,0,42,11,1,"{'concept_id': {0: 'C1563337'}, 'canonical_name': {0: 'ActClass - document'}, 'aliases': {0: ['ActClassDocument', 'document']}, 'types': {0: ['T170']}, 'definition': {0: '<p>Specialization of Act to add the characteristics unique to document management services.</p>'}, 'entity': {0: 'document'}, 'text': {0: 'this document for use.'}}","{'concept_id': {0: 'C5690896'}, 'canonical_name': {0: 'Document Analysis'}, 'aliases': {0: ['Analysis, Document', 'Document Analyses']}, 'types': {0: ['T062']}, 'definition': {0: 'A form of qualitative research that uses a systematic procedure to analyze documentary evidence and answer specific research questions.'}, 'entity': {0: 'document'}, 'text': {0: 'this document for use.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'document use'}, 'score': {0: 0.9136}}"
2136,2136,2136,0.9520000219345092,10.0,Date: 10-Jan-2023 13:52:39 GMT+0000,MyriadPro-Regular,4,-0.25,0,42,11,2,{},{},{},{},{},"  entity_group              value     score
0         Date        10-Jan-2023  0.996636
1         Time  13:52:39 GMT+0000  0.978002
2    Lab_value           GMT+0000  0.998654",[],"{'keyword': {0: '39 gmt 0000', 1: 'jan 2023 13', 2: '52 39', 3: '13 52', 4: 'date 10 jan'}, 'score': {0: 0.8662, 1: 0.8051, 2: 0.7961, 3: 0.7558, 4: 0.7462}}"
2137,2137,2137,0.9520000219345092,10.0,Michelle Swift (swiftm) - Medical Final Signatory,MyriadPro-Regular,4,-0.25,0,42,12,0,"{'concept_id': {0: 'C4288222'}, 'canonical_name': {0: 'Signed By'}, 'aliases': {0: ['Signer', 'Signatory']}, 'types': {0: ['T169']}, 'definition': {0: 'Indicates the person who has signed a document, physically or electronically (digital signature).'}, 'entity': {0: 'Medical Final Signatory'}, 'text': {0: 'Michelle Swift (swiftm) - Medical Final Signatory'}}","{'concept_id': {0: 'C1436935'}, 'canonical_name': {0: 'PAXIP1L protein, human'}, 'aliases': {0: ['PAXIP1 protein, human', 'PAX transcription activation domain interacting protein 1 like, human', 'swift protein, human', 'PTIP protein, human']}, 'types': {0: ['T116', 'T123']}, 'definition': {0: 'PAX-interacting protein 1 (1069 aa, ~121 kDa) is encoded by the human PAXIP1 gene. This protein is involved in both DNA damage responses and transcription regulation.'}, 'entity': {0: 'Michelle Swift (swiftm'}, 'text': {0: 'Michelle Swift (swiftm) - Medical Final Signatory'}}",{},{},{},"           entity_group   value     score
0  Detailed_description  swiftm  0.768072",[],"{'keyword': {0: 'final signatory', 1: 'medical final signatory', 2: 'medical final', 3: 'michelle swift swiftm', 4: 'swiftm medical'}, 'score': {0: 0.9092, 1: 0.9077, 2: 0.8799, 3: 0.8523, 4: 0.8464}}"
2138,2138,2138,0.9520000219345092,10.0,Declaration,MyriadPro-Regular,4,-0.25,0,42,12,1,{},{},{},{},{},"  entity_group        value     score
0  Coreference  Declaration  0.783362",[],"{'keyword': {}, 'score': {}}"
2139,2139,2139,0.9520000219345092,10.0,(swiftm@roche.com),MyriadPro-Regular,4,-0.25,0,42,12,2,{},{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'swiftm roche com', 1: 'roche com', 2: 'swiftm roche'}, 'score': {0: 0.8177, 1: 0.7849, 2: 0.7272}}"
2140,2140,2140,0.9520000219345092,10.0,"Meaning: As the Medical Final Signatory, I approve this",MyriadPro-Regular,4,-0.25,0,42,13,0,"{'concept_id': {0: 'C4288222'}, 'canonical_name': {0: 'Signed By'}, 'aliases': {0: ['Signer', 'Signatory']}, 'types': {0: ['T169']}, 'definition': {0: 'Indicates the person who has signed a document, physically or electronically (digital signature).'}, 'entity': {0: 'Medical Final Signatory'}, 'text': {0: 'Meaning: As the Medical Final Signatory, I approve this'}}",{},{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'signatory approve', 1: 'final signatory approve', 2: 'final signatory', 3: 'medical final', 4: 'meaning medical final'}, 'score': {0: 0.9078, 1: 0.8702, 2: 0.5873, 3: 0.5146, 4: 0.4656}}"
2141,2141,2141,0.9520000219345092,10.0,document for use.,MyriadPro-Regular,4,-0.25,0,42,13,1,"{'concept_id': {0: 'C1563337'}, 'canonical_name': {0: 'ActClass - document'}, 'aliases': {0: ['ActClassDocument', 'document']}, 'types': {0: ['T170']}, 'definition': {0: '<p>Specialization of Act to add the characteristics unique to document management services.</p>'}, 'entity': {0: 'document'}, 'text': {0: 'document for use.'}}","{'concept_id': {0: 'C5690896'}, 'canonical_name': {0: 'Document Analysis'}, 'aliases': {0: ['Analysis, Document', 'Document Analyses']}, 'types': {0: ['T062']}, 'definition': {0: 'A form of qualitative research that uses a systematic procedure to analyze documentary evidence and answer specific research questions.'}, 'entity': {0: 'document'}, 'text': {0: 'document for use.'}}",{},{},{},"Empty DataFrame
Columns: []
Index: []",[],"{'keyword': {0: 'document use'}, 'score': {0: 0.892}}"
2142,2142,2142,0.9520000219345092,10.0,Date: 12-Jan-2023 16:03:34 GMT+0000,MyriadPro-Regular,4,-0.25,0,42,13,2,{},{},{},{},{},"  entity_group                          value     score
0         Date                    12-Jan-2023  0.993456
1         Time              16:03:34 GMT+0000  0.981122
2    Lab_value                       GMT+0000  0.723668
3         Time  12-Jan-2023 16:03:34 GMT+0000  0.690307",[],"{'keyword': {0: '2023 16 03', 1: '34 gmt 0000', 2: 'date 12', 3: 'date 12 jan', 4: '03 34 gmt'}, 'score': {0: 0.8864, 1: 0.8575, 2: 0.7855, 3: 0.7778, 4: 0.7714}}"
